
<html lang="en"     class="pb-page"  data-request-id="25cfa06f-46f7-4681-a2ef-94deaf4e6194"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c01140;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities" /></meta><meta name="dc.Creator" content="Rolando  Cannalire" /></meta><meta name="dc.Creator" content="Carmen  Cerchia" /></meta><meta name="dc.Creator" content="Andrea R.  Beccari" /></meta><meta name="dc.Creator" content="Francesco Saverio  Di Leva" /></meta><meta name="dc.Creator" content="Vincenzo  Summa" /></meta><meta name="dc.Description" content="The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is an urgent global need..." /></meta><meta name="Description" content="The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is an urgent global need..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 13, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01140" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01140" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01140" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01140" /></link>
        
    
    

<title>Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01140" /></meta><meta property="og:title" content="Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0023.jpeg" /></meta><meta property="og:description" content="The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is an urgent global need, thus different strategies targeting either virus or host cell are still under investigation. Direct-acting agents, targeting protease and polymerase functionalities, represent a milestone in antiviral therapy. The 3C-like (or Main) protease (3CLpro) and the nsp12 RNA-dependent RNA-polymerase (RdRp) are the best characterized SARS-CoV-2 targets and show the highest degree of conservation across coronaviruses fostering the identification of broad-spectrum inhibitors. Coronaviruses also possess a papain-like protease, another essential enzyme, still poorly characterized and not equally conserved, limiting the identification of broad-spectrum agents. Herein, we provide an exhaustive comparative analysis of SARS-CoV-2 proteases and RdRp with respect to other coronavirus homologues. Moreover, we highlight the most promising inhibitors of these proteins reported so far, including the possible strategies for their further development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01140"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01140">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01140&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01140&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01140&amp;href=/doi/10.1021/acs.jmedchem.0c01140" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.0c02076" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Rolando Cannalire</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rolando Cannalire</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, University of Naples âFederico IIâ, via D. Montesano 49, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rolando++Cannalire">Rolando Cannalire</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Carmen Cerchia</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Cerchia</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, University of Naples âFederico IIâ, via D. Montesano 49, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Cerchia">Carmen Cerchia</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Andrea R. Beccari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea R. Beccari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">DompÃ© Farmaceutici SpA, via Campo di Pile, 67100 LâAquila, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea+R.++Beccari">Andrea R. Beccari</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Francesco Saverio Di Leva</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesco Saverio Di Leva</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, University of Naples âFederico IIâ, via D. Montesano 49, 80131 Napoli, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesco+Saverio++Di+Leva">Francesco Saverio Di Leva</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Vincenzo Summa</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vincenzo Summa</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy, University of Naples âFederico IIâ, via D. Montesano 49, 80131 Napoli, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +39 081-678656. Email: <a href="/cdn-cgi/l/email-protection#d9afb0b7babcb7a3b6f7aaacb4b4b899acb7b0b7b8f7b0ad"><span class="__cf_email__" data-cfemail="83f5eaede0e6edf9ecadf0f6eeeee2c3f6edeaede2adeaf7">[emailÂ protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vincenzo++Summa">Vincenzo Summa</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6288-2681" title="Orcid link">http://orcid.org/0000-0002-6288-2681</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01140&amp;href=/doi/10.1021%2Facs.jmedchem.0c01140" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 13, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>2 July 2020</li><li><span class="item_label"><b>Published</b> online</span>13 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01140" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01140</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01140"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">11875</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01140" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Rolando&quot;,&quot;last_name&quot;:&quot;Cannalire&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Cerchia&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;R. Beccari&quot;},{&quot;first_name&quot;:&quot;Francesco&quot;,&quot;last_name&quot;:&quot;Saverio Di Leva&quot;},{&quot;first_name&quot;:&quot;Vincenzo&quot;,&quot;last_name&quot;:&quot;Summa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01140&quot;},&quot;abstract&quot;:&quot;The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is an urgent global need, thus different strategies targeting either virus or host cell are still under investigation. Direct-acting agents, targeting protease and polymerase functionalities, represent a milestone in antiviral therapy. The 3C-like (or Main) protease (3CLpro) and the nsp12 RNA-dependent RNA-polymerase (RdRp) are the best characterized SARS-CoV-2 targets and show the highest degree of conservation across coronaviruses fostering the identification of broad-spectrum inhibitors. Coronaviruses also possess a papain-like protease, another essential enzyme, still poorly characterized and not equally conserved, limiting the identification of broad-spectrum agents. Herein, we provide an exhaustive comparative analysis of SARS-CoV-2 proteases and RdRp with respect to other coronavirus homologues. Moreover, we highlight the most promi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01140&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01140" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01140&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01140" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01140&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01140" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01140&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01140&amp;href=/doi/10.1021/acs.jmedchem.0c01140" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01140" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01140" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (20 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01140%26sid%3Dliteratum%253Aachs%26pmid%3D33186044%26genre%3Darticle%26aulast%3DCannalire%26date%3D2020%26atitle%3DTargeting%2BSARS-CoV-2%2BProteases%2Band%2BPolymerase%2Bfor%2BCOVID-19%2BTreatment%253A%2BState%2Bof%2Bthe%2BArt%2Band%2BFuture%2BOpportunities%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292644" title="SARS-CoV-2">SARS-CoV-2</a>,</li><li><a href="/action/doSearch?ConceptID=292641" title="SARS-CoV">SARS-CoV</a>,</li><li><a href="/action/doSearch?ConceptID=291362" title="Antimicrobial agents">Antimicrobial agents</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290831" title="Monomers">Monomers</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The newly emerged coronavirus, called SARS-CoV-2, is the causing pathogen of pandemic COVID-19. The identification of drugs to treat COVID-19 and other coronavirus diseases is an urgent global need, thus different strategies targeting either virus or host cell are still under investigation. Direct-acting agents, targeting protease and polymerase functionalities, represent a milestone in antiviral therapy. The 3C-like (or Main) protease (3CL<sup>pro</sup>) and the nsp12 RNA-dependent RNA-polymerase (RdRp) are the best characterized SARS-CoV-2 targets and show the highest degree of conservation across coronaviruses fostering the identification of broad-spectrum inhibitors. Coronaviruses also possess a papain-like protease, another essential enzyme, still poorly characterized and not equally conserved, limiting the identification of broad-spectrum agents. Herein, we provide an exhaustive comparative analysis of SARS-CoV-2 proteases and RdRp with respect to other coronavirus homologues. Moreover, we highlight the most promising inhibitors of these proteins reported so far, including the possible strategies for their further development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="specialIssueNotice" class="extra-info-sec articleNote"><h4>SPECIAL ISSUE</h4><p class="last">This article is part of the <a href="/toc/jmcmar"><issue-title>COVID-19</issue-title></a> special issue.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33462" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33462" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">RNA viruses represent a large and heterogeneous group of human pathogens that periodically jeopardize the public health because of apparent sudden epidemic outbreaks. In the recent years, the World Health Organization (WHO) prioritized the most threatening viral diseases worldwide including Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), Ebola, Zika, and Dengue<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> while advancing the theory of Disease X, a disease associated with pandemic risk caused by a still unknown pathogen.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Lastly, at the end of 2019, an outbreak of severe pneumonia with an uncertain etiopathology in China was indicated as the Disease X by WHO that soon after announced the identification of a new coronavirus (CoV), called 2019-nCoV, as the etiologic agent of COVID-19 disease.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Genomic sequence of 2019-nCoV has highlighted 79.5% identity to SARS-CoV genome and thereafter the new CoV is known as SARS-CoV-2. The infection has rapidly spread in many countries across Asia, Europe, and Americas, causing the pandemic COVID-19 disease, as announced by WHO on March 11 2020, that currently has caused almost 35 million cases, many hospitalizations and more than one million deaths.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The current scenario has highlighted major gaps in the abilities of most countries to face new virulent pathogens. In fact, the most effective procedure to control the spread of the infection is the social distancing: as a consequence, billions of peopleâs lives have been impacted following such countermeasures.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6â8)</a> Moreover, COVID-19 will likely burden on worldwide health systems and on the global economy due to the lock-down measures, and the damage will be uncountable if the spread of the virus is not effectively controlled.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> However, together with the social distancing and the lock-down, the availability of effective antiviral drugs would have an enormous beneficial impact on the control of the health emergency and the possibility to come back to normal life.</div><div class="NLM_p">In this context, drug repurposing offers the opportunity to quickly identify a drug to prevent, control or, hopefully, eradicate the SARS-CoV-2 virus, although a serious clinical validation is required.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> WHO has launched âSolidarityâ, one of the largest international clinical trials aimed at identifying successful treatments against COVID-19.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Among the drugs under investigation, Remdesivir was included. It is an intravenous (iv) monophosphoramidate nucleoside prodrug polymerase inhibitor with broad-spectrum activity against RNA viruses, originally under investigation as an Ebola virus disease (EVD) medication. On the basis of the clinical trials results, Remdesivir was granted an emergency use authorization (EUA) for the treatment of patients with severe COVID-19 symptoms being the only pathogen specific drug approved for treatment of the disease at the moment.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The authorization was granted in the U.S. first, and then in a growing number of countries, including Japan, India, EU, UK, Australia, and South Korea, based on the promising results from the National Institute of Allergy and Infectious Diseases (NIAID), the Gilead clinical trials, and from the compassionate use programs.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13â15)</a> The FDA subsequently broadened the scope of the existing EUA to include treatment of all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease. Remdesivir eventually received the approval from the FDA for the treatment of COVID-19 patients requiring hospitalization.</div><div class="NLM_p">Besides drug repurposing, which can offer the great advantage to translate safe-in-man drugs quickly into clinic with just little experimental evidence of antiviral activity, the rational design of new chemical entities to specifically act against key steps of viral replication, supported by appropriate biological and DMPK screening cascade, represents the main strategy to discover new potent and selective antiviral drugs.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16,17)</a> Immediately after the understanding of the potential pandemic spread of the SARS-CoV-2 infection, the whole scientific community collaborated to characterize the viral genome and viable therapeutic targets in order to rapidly identify provisional treatments and, as a longer-term goal, find a cure.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Many efforts have been made in molecular biology, biochemistry, and structural biology of SARS-CoV-2, thus biochemical assays and 3D-structures have been made public for different viral proteins, while it has been shown that different cell lines are permissive toward viral infection thus allowing easy phenotypic screenings to identify antiviral compounds. Moreover, anti-SARS-CoV-2 drug discovery can take advantage from the knowledge and the biology tools acquired on other human pathogenic CoVs such as SARS-CoV and MERS-CoV, to cite a few, that can be utilized as counter screenings to develop broad-spectrum CoV inhibitors to potentially protect also from emerging infection caused by the same virus family.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a></div><div class="NLM_p">Researchers all around the world are exploiting different strategies targeting both viral and host factors essential for the pathogen replication to block one or more steps of its life cycles, and their efforts have already produced a great amount of data and studies. Thus, COVID-19 drug discovery is an emerging, rapidly evolving, and intriguing research field for medicinal chemists.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p last">This Perspective will aim to critically describe some of the most promising approaches toward the identification of anti-CoVs agents, especially focusing on the best characterized virus targets and the state-of-the-art on the antiviral agents identified, providing an unbiased point-of-view on the gaps to be filled. The inhibition of viral protease and polymerase functionalities represents a milestone in antiviral drug discovery field and provided most of the effective antiviral drugs for the treatment of HIV and hepatitis C virus (HCV) infections and also allowed for the development of antiviral agents acting against different virus families. Indeed, viral protease and polymerase inhibitors are included in the WHO list of essential drugs. Therefore, an exhaustive comparative analysis of SARS-CoV-2 proteases and RdRp with respect to other human pathogenic CoVs homologues is provided. Moreover, the most interesting compounds targeting the SARS-CoV-2, 3-chymotrypsin-like (3CL), or Main (M) protease (pro), and the nsp12 RNA-dependent RNA polymerase (RdRp), are analyzed in detail, discussing biological activity <i>in vitro</i>/<i>in vivo</i>, DMPK and clinical data, when available. Possible strategies for further development of the inhibitors are also discussed providing an unbiased point-of-view on the gaps to be filled. Additionally, potential strategies targeting the less explored papain-like (PL) pro will be described.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Biochemistry and Replicative Cycle of SARS-CoV-2</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23336" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23336" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Belonging to the subfamily <i>Coronavirinae</i>, family <i>Coronavirdiae</i>, order <i>Nidovirales</i>, CoVs are single-stranded positive-sense (ss-(+)) RNA viruses, further clustered into four classes designated as alpha, beta, gamma, and delta.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Bats and rodents are the gene sources of most Î±-CoVs and Î²-CoVs, while avian species are those for most Î³- and Î´-CoVs, indeed, CoVs are able to cross species barriers, sometimes emerging as important human pathogens.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Before December 2019, six CoVs were known to infect humans, including Î±-CoVs, <i>i.e</i>., HCoV-229E and HCoV-NL63, and Î²-CoVs, such as HCoV-OC43, HCoV-HKU1, SARS-CoV, and MERS-CoV.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The Î²-CoV HCoV-OC43 and HCoV-HKU1 usually cause common cold disease, while SARS-CoV and MERS-CoV and the newly identified SARS-CoV-2, to different extents, may cause severe life-threatening conditions to lower respiratory tract such as pneumonia, but they may also affect the gastrointestinal system, heart, kidney, liver, and central nervous system, leading to multiple organ failure.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Moreover, SARS CoV-2, even if associated with a lower mortality rate, is more transmissible than SARS-CoV.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Genomic comparative analysis showed that SARS-CoV-2 sequence has identity of 79.5 and 96% to SARS-CoV and a bat CoV, SL-CoV-RaTG13, respectively; thus, its outbreak highlights the ability of viral spillover from animals to humans.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">CoVs share many morphological, biochemical, and functional aspects, which help in the understanding of SARS-CoV-2 biology and life cycle.<a onclick="showRef(event, 'ref4 ref20'); return false;" href="javascript:void(0);" class="ref ref4 ref20">(4,20)</a> CoVs are relatively big (50â200 nm) enveloped viruses containing an encapsidated (ss-(+))-RNA, which is the largest viral genome found so far, with SARS-CoV-2 made-up by 30 kb (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Similar to other CoVs, the SARS-CoV-2 viral membrane is studded with glycoprotein spikes (S), that give CoVs their crown-like appearance in electron microscope imaging.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The virion contains other three structural proteins, known as envelope (E), membrane (M), which form the viral envelope together with S, and nucleocapsid (N), a basic RNA-binding protein that complexes and protects the genome.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of SARS-CoV-2 virion, viral entry, genome translation, and polyprotein processing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The S protein mediates the virus attachment to the host cell membrane through subunit S1 interaction with the human angiotensin-converting enzyme 2 (ACE2), acting as the receptor for viral entry (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> The interactions between the two proteins have been fully elucidated with the support of several 3D structures of the S/ACE2 complex, highlighting the key residues involved in the recognitions process.<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27â29)</a></div><div class="NLM_p">The host proteins CatB/L, transmembrane protease serine 2 (TMPRSS2) have been shown to be involved in the entry process.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Thus, the identification of drugs targeting either the viral or the host factors could represent a valid strategy to inhibit viral entry.<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a></div><div class="NLM_p">Upon the entry, the uncoating by nucleocapsid degradation allows the release into the cytoplasm of the viral RNA, ready for translation. The genome contains a 5â² cap structure with a leader sequence along with a 3â² poly(A) tail that allows it acting as mRNA. The 5â²- and the 3â²-ends contain highly stem loop structured untranslated regions (UTRs) required for RNA replication and transcription.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The 5â²- and 3â²-UTRs flank the coding region with the two-thirds of the genome from the 5â²-end comprising two overlapping open reading frames (ORFs), ORF1a and ORF1b, that encode for polyproteins pp1a (4382 amino acids) and pp1ab (7073 amino acids), respectively. The autoproteolytically processing by 3CL<sup>pro</sup> and PL<sup>pro</sup> affords 16 nonstructural proteins (nsp1â16), which form the replicase/transcriptase complex (RTC) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). The terminal 10 kb toward the 3â²-poly(A) tail encodes instead for the structural S, E, M, and N, following this order (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Among the genes for structural proteins, there are those encoding for accessory proteins that show roles in viral pathogenesis and host immunity suppression, although they are not essential for <i>in vitro</i> replication, as found for other CoVs.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> SARS-CoV-2 and SARS-CoV display very similar genetic composition, sharing the Orf1ab encoding for the 16 nsps and the four typical CoV structural proteins. They differ in some accessory proteins, with SARS-CoV-2 Orf3b and Orf10 showing low homology to SARS-CoV and an intact Orf8 instead of the two subunits, Orf8a and Orf8b, expressed by the latter virus.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">The RTC includes different enzymes and cofactors involved in post-translational polyprotein processing, RNA synthesis, maturation, and virions assembly and egress, which therefore can constitute ideal viral targets for drug discovery, being essential for the virus life cycle and devoid of a close host homologue.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The nsps that exert enzymatic activities are the nsp3 PL<sup>pro</sup> that catalyzes cleavages at the nsp1/2, nsp2/3, and nsp3/4 sites of the polyprotein, and the nsp5 3CL<sup>pro</sup> (or M<sup>pro</sup>), which performs the remaining 11 proteolytic events.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> PL<sup>pro</sup> additionally cleaves post-translational modified host proteins involved in innate immune response, thus contributing to immune escape. Predominantly PL<sup>pro</sup> can recognize and hydrolyze the cellular proteins ubiquitin (Ub) and the Ub-like protein ISG15 from interferon (IFN) responsive factor 3 (IRF3), blocking its nuclear translocation, thus reducing type I IFN response.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> The nsp3, nsp4, and nsp6 have transmembrane domains and should serve as scaffold to anchor the RTC complex to intracellular membranes, a prerequisite for RNA virus replication. Then, the nsp7 nsp8 primase complex is able to synthesize short oligonucleotides, while the nsp12 RdRp is the elongating polymerase that, together with the nsp13 helicase/triphosphatase, the nsp14 exoribonuclease, the nsp15 endonuclease, and nsp10-N7- and nsp16â2â²O-methyltransferases, assembles in the RTC, thus creating the suitable environment for RNA synthesis and maturation.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Moreover, nsp1, nsp3 deubiquitinase and nsp16â2â²O-methyltransferase mediate suppression of the innate immune response.</div><div class="NLM_p">Genomic ss-(+)-RNA transcription proceeds through (â)-strand intermediates that serve as templates for the production of both genomic and subgenomic RNAs, which are capped and polyadenylated as the full genomic RNA. The subgenomic RNAs are then translated into the four structural and some accessory proteins. Hence, discontinuous transcription may favor CoV genome recombination, as observed in the murine CoV experimental model.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">Assembly of new viral particles takes place on intracellular membranes, where N protein binds to genomic RNA and the nucleocapsid associates to M protein, which is thought to cause membrane curvature and drive budding into ER/Golgi membranes. During this process, S and E are also acquired. In particular, E protein by acting as viroporin alters cell secretory pathways and promotes virion egress by exocytosis.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div><div class="NLM_p last">On the basis of the prominent roles in intracellular steps of viral life cycle, the amount of biochemical/structural data and the knowledge acquired on inhibitors of homologues proteins in other CoVs and other RNA viruses, the 3CL<sup>pro</sup> and the nsp12 RdRp are at moment the most relevant viral targets to identify specific anti-CoVs agents.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">The 3CL<sup>pro</sup> (or M<sup>pro</sup>): Structure and Function</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The 3CL<sup>pro</sup>, known also as M<sup>pro</sup>, is a 33.8 kDa cysteine protease able to process the polyprotein at no less than 11 conserved sites, starting with the autolytic cleavage from pp1a and pp1ab; thus, it is responsible for the release of most of the nsps CoV functional proteins. This pivotal role in the viral life cycle and the lack of homologous proteins in human cells make 3CL<sup>pro</sup> a very attractive target for the identification of anti-SARS-CoV-2 agents.</div><div class="NLM_p">A large number of crystal structures of 3CL<sup>pro</sup> from SARS-CoV-2 and other CoVs have been solved either in their apo forms or in complex with inhibitors, providing very important information about the folding, the assembly, and the catalytic mechanism of these proteins. In around seven months, between the end of February and the end of September 2020, already 192 3D-structures of the SARS-CoV-2 3CL<sup>pro</sup> have been released. Comparison of the apo structures of SARS-CoV-2 3CL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2E">6Y2E</a>)<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and SARS-CoV 3CL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BX4">2BX4</a>)<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> reveals analogous tridimensional features, consistent with the 96% sequence identity and the similar catalytic activity of the two enzymes. Indeed, similar to SARS-CoV 3CL<sup>pro</sup>,<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37â39)</a> the active form of SARS-CoV-2 3CL<sup>pro</sup> is a dimer, with an estimated dissociation constant in the low Î¼M range.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Each protomer is formed by three domains:<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> six antiparallel Î²-barrels form domains I and II (residues 10â99 and 100â182, respectively) and host the substrate-binding site, while domain III (residues 198â303) is a globular cluster of five helices that regulates protein dimerization. Arg4 and Glu290 from each protomer establish an ionic bond driving the formation of the dimer, which has contact interface between the perpendicularly oriented domain II of protomer A and domain III of protomer B (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). The N-terminal tail, called the âN-fingerâ, of molecule B is squeezed in between domains II and III of the parent monomer and domain II of the other one. This peculiar arrangement is stabilized by some key hydrogen bonds, particularly those formed by Ser1 and Glu166 from each unit. In each monomer, the substrate binding site is located in a wide cleft between domains I and II, hosting the Cys145-His41 catalytic dyad. With respect to these residues, a number of subpockets can be identified, namely S4, S3, S2, S1, and S1â², which are occupied, respectively, by the substrate P4, P3, P2, P1, and P1â² amino acids. Notably, dimerization of 3CL<sup>pro</sup> seems to help the shaping of the substrate-binding site, particularly of the S1 site, explaining why the enzyme is catalytically inactive in the monomeric form, as demonstrated for the SARS-CoV enzyme.<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37â39)</a> The substrates of CoVs 3CL<sup>pro</sup> display almost identical recognition motifs, which is consistent with the high structural similarity of the catalytic domains of these enzymes.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In particular, they all share the Leu-Gln-Ser (Ala, Gly) as preferred P2âP1âP1â² sequence, suggesting the possibility to identify very effective broad-spectrum inhibitors of the CoVs enzyme family. The substrate preferences of SARS-CoV and SARS-CoV-2 3CL proteases were recently compared by examining the hydrolytic rate of different peptides/peptidomimetics.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In particular, the catalytic performance of each enzyme was evaluated against a combinatorial library of fluorogenic substrates endowed with a glutamine at the P1 position, while displaying different natural and unnatural amino acids as P2, P3, and P4. Remarkably, this analysis showed that both SARS-CoV and SARS-CoV-2 3CL<sup>pro</sup> have substrate specificity in S2 with Leu as the best P2 residue, although other hydrophobic replacers are tolerated, such as 2-Abz, Phe(4-NO<sub>2</sub>), 3-Abz, Î²-Ala, Dht, hLeu, Met, and Ile. Several hydrophobic D and L but also basic amino acids are suitable as P3, but Tle, <span class="smallcaps smallerCapital">d</span>-Phe, <span class="smallcaps smallerCapital">d</span>-Tyr, Orn, hArg, Dab, Dht, Lys, <span class="smallcaps smallerCapital">d</span>-Phg, <span class="smallcaps smallerCapital">d</span>-Trp, Arg, and Met(O)<sub>2</sub> are mostly preferred.<a onclick="showRef(event, 'ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref40 ref41">(40,41)</a> Both enzymes have poor substrate specificity at the P4 position, with preference for small hydrophobic amino acids.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview of SARS-CoV-2 3CL<sup>pro</sup> architecture. The X-ray structure of SARS-CoV-2 3CLpro (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2G">6Y2G</a>) is shown as a ribbon model in two different orientations. For clarity, the bound inhibitor has been removed. Protomers A (light-blue) and B (light-orange) associate into a dimer stabilized by a salt bridge between Glu290 and Arg4, while the substrate binding site resides at the interface of domains I and II. The catalytic residues Cys145 and His41 are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The SARS-CoVs 3CL<sup>pro</sup> substrate affinity and specificity can be reasonably explained based on the shape and amino acid composition of the different subpockets of the cleavage site. In both SARS-CoVs 3CL<sup>pro</sup>, the S1 pocket is formed by the side chains of residues Phe140, Asn142, His163, Glu166, and His172 and the main chains of Phe140 and Leu141. Interestingly, the imidazole of His163 is located at the very bottom of the cleft, suitably positioned to donate a H-bond to the side chain carbonyl of substrate/inhibitor P1 Gln. The S2 subsite of SARS-CoVs 3CL<sup>pro</sup> is a buried hydrophobic pocket that can host bulky alkyl/aryl substituents as the substrate S1 Leu side chain. This cage is defined by a âlidâ comprising the 3<sub>10</sub> helix residues 46â51, particularly Met49, three walls defined by the main-chain of residues 186â188 and by the side chains of His41, Asp187, and Gln189 and a floor lined by Met165. Notably, the shape and the size of the S2 subsite of SARS-CoVs 3CL<sup>pro</sup> is highly similar to that of the MERS-CoV homologue. Indeed, only two conservative mutations can be found, specifically the replacement of Met49 and Arg188 in SARS-CoVs with Leu49 and Lys191 in MERS-CoV, respectively. On the other hand, the volume of the S2 subsite in SARS-CoVs 3CL<sup>pro</sup> (252 Ã<sup>3</sup>) is significantly larger than in other CoVsâ homologues of the Î±-genus, such as the HCoV-NL63 3CL<sup>pro</sup> (45 Ã<sup>3</sup>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Actually, this knowledge might be exploited to guide the structure-based drug design (SBDD) of either specific or broad spectrum inhibitors of CoVs 3CL<sup>pro</sup>. Compared to S1 and S2, the S4, S3, and the S1â² pockets of the SARS-CoVs 3CL<sup>pro</sup> are more shallow and exposed to the solvent and could accommodate groups of various size and nature. In particular, S3 and S4 are defined by the flexible loops connecting residues 165â168 and 189â192, which can rearrange upon ligand binding, while the S1â² cleft is characterized by a number of threonine residues (Thr24, Thr25, and Thr26), which can potentially form either hydrogen bonds or lipophilic contacts with the substrate/inhibitor P1â² group.</div><div class="NLM_p last">The structure of CoVs 3CL<sup>pro</sup> resembles that of the main proteases of enteroviruses (EVs), a family of small and naked (+)-<i>ss</i>-RNA viruses.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> In fact, in EVs genome the M<sup>pro</sup> is a cysteine protease encoded by the 3C region, hence the name 3C-like of CoVs protease. The EV 3C protein has a chymotrypsin-like fold with two catalytic domains similar in shape to domains I and II of CoVs 3CL. Contrary to CoVs 3CL<sup>pro</sup>, the EV 3C protease lacks a dimerization domain, and it works as a monomer. Also, the EV 3C protease displays, in addition to the catalytic Cys-His, an acidic (Asp/Glu) residue to form a reactive triad. A very important similarity between CoVs and EVs M<sup>pro</sup> is the peculiar almost absolute requirement for glutamine in the substrate P1. This represents an unknown specificity in human proteases that increases the appeal of these viral proteins as a target for safe and selective inhibitors. Indeed, Rupintrivir (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf" class="ext-link">Figure S1</a>), a potent peptidic inhibitor of EV 3C<sup>pro</sup>, successfully completed phase II trials for human rhinovirus (HRV) infection in 1999 without showing toxicity in common cold patients.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> This compound has inspired design of CoV 3CL<sup>pro</sup> inhibitors, although it shows very weak activity when tested against the CoV protease.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> A major difference between the 3C and the 3CL proteins is in the S2 subsite, which completely lacks the lid in the 3C protein. For instance, a comparison of SARS-CoV 3CL and EV Coxsackie B 3C highlighted that in EVs the S2 appears as an open hydrophobic channel lined by Arg39, Asn69, and Glu71, forming the back wall, residues 127â132 and His40 as the side walls, and Val162 constituting the floor.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Nonetheless, covalent peptidic inhibitors reported for both targets are able to broadly inhibit EVs and CoVs replication in cell cultures.<a onclick="showRef(event, 'ref43 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref45">(43,45)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Targeting SARS-CoV-2 3CL<sup>pro</sup></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30476" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30476" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The targeting of proteases represents a solid route for antiviral drug discovery as demonstrated by the therapeutic success of HIV and HCV proteases inhibitors. Inhibition of these enzymes can be achieved by different approaches; indeed, the design of reversible, covalent reversible, and irreversible binders has been exploited in different therapeutic areas including antivirals. The identification of potent noncovalent inhibitors generally requires much efforts and it is a time-consuming process, although it is the most favored strategy to obtain safe and efficacious drugs. On the other hand, the identification of irreversible inhibitors is an apparently simpler and attractive approach, but it suffers from a potential serious drawback due to lack of target selectivity that can lead to unpredictable severe toxicity. A similar but less risky approach is represented by the design of covalent reversible inhibitors that requires the knowledge of the catalytic mechanism and the substrate specificity, thus relying on natural substrate modifications. In general, such an approach consists of converting good substrates into good covalent reversible inhibitors. This can be achieved by replacing part of the protease substrate with a moiety, known as a âwarheadâ, that is an electrophilic reactive group able to form the covalent reversible bond with the catalytic machinery. Indeed, this strategy has afforded the FDA approved Î±-ketoamide inhibitors of HCV NS3/4A serine protease, Telaprevir<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and Boceprevir.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In fact, the reaction of these compounds with the enzyme affords stable hemiketals mimicking the tetrahedral transition state of the cleavage process. This approach also yielded human cysteine protease cathepsin K inhibitors, such as the clinical candidate Odanacatib,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> which features a nitrile warhead, for the treatment of osteoporosis and bone metastasis, even if the phase III clinical trial was discontinued in 2016. Similar to irreversible binders, covalent reversible inhibitors might suffer of lack of high selectivity; furthermore, they have generally less favorable pharmacokinetic properties that can lead to a suboptimal dosing regimen. However, because these drugs are designed based on the substrate sequences, they have higher specificity for target proteins, which reduces their potential side toxicity. In addition, considering that the length of COVID-19 patients treatment should be relatively short, this approach appears as a privileged route to discovery drugs targeting SARS-CoV-2 3CL<sup>pro</sup> with limited side effects compared to the use of covalent binders for chronic treatments, and the suboptimal dosing regimen can be tolerated. Homologous proteins of related CoVs such as SARS- and MERS-CoVs have represented the main targets for the identification of potent and selective inhibitors of these viruses.<a onclick="showRef(event, 'ref45 ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref45 ref49 ref50">(45,49,50)</a> Indeed, several compounds targeting the 3CL<sup>pro</sup> of different CoVs have been reported over the years, thus providing compounds and knowledge useful for the discovery of anti-SARS-CoV-2 agents.</div><div class="NLM_p">As introduced in the previous section, several crystal structures of ligands bound to 3CL<sup>pro</sup> have been released in the PDB, including complexes containing peptidic covalent reversible/irreversible inhibitors. These inhibitors act through a two-step mechanism: first, they bind to the active site, similar to a natural substrate, forming a noncovalent complex with the protease so that the C-terminal warhead comes in close proximity to the catalytic Cys145, to form, in the second step, a covalent bond with this residue by a nucleophilic attack. A number of academic groups have reported peptide covalent reversible inhibitors of SARS-CoV-2 3CL<sup>pro</sup>, biological activities, and their cocrystal structures with the target protein; in these compounds, the explored chemical warheads include Michael acceptors, Î±-ketoamides, aldehydes, and ketones. To efficiently compete with the natural substrates at the catalytic site, most of the inhibitors span from P1âP4 to establish a considerable number of specific interactions with the binding pockets (namely, the enzyme S1âS4 subsites), to facilitate the covalent reaction between the Cys145 and the warhead (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). This contributes not only to the affinity and potency, but, more importantly to the binding specificity, limiting the cross reactivity with other off targets that could lead to severe side effects. In addition, the reported inhibitors share similar peptide sequence organization in P1âP2 residues, while there are remarkable differences at P3/P4 positions and in the overall compound molecular size (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematization of the main features of 3CL<sup>pro</sup> inhibitors and protease subsite specificity. (A) General representation of peptidic covalent reversible inhibitors of SARS-CoV-2 3CL<sup>pro</sup> summarizing the chemical requirements and SAR of compounds so far reported in literature. (B) Surface representation of the active site pocket of SARS-CoV 3CL<sup>pro</sup> bound to a peptide aldehyde inhibitor (dark salmon sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SNE">3SNE</a>), chosen as a representative substrate-like inhibitor. The S1âS4 and S1â² subsites are indicated with red lines and labeled. The key residues forming the active site pocket are displayed as white sticks; the catalytic residues Cys145 and His41 are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the first released X-ray structure, SARS-CoV-2 3CL<sup>pro</sup> was in complex with the <i>N</i>-term isoxazole capped tetrapeptide <b>1</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LU7">6LU7</a>, superseded by <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BQY">7BQY</a>; <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a> and <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystallographic pose of compound <b>1</b> (violet sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BQY">7BQY</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks and labeled. H-bonds are depicted as dashed black lines. (B) Surface representation of the active site pocket with bound N3. The P1âP4 and P1â² moieties are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds <b>1</b>â<b>9</b> with biological activities. <sup>a</sup>Antiviral activity evaluated by viral plaque assay. <sup>b</sup>Data from ref <a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>. <sup>c</sup>Antiviral activity evaluated by viral RNA qRT-PCR quantification. <sup>d</sup>Antiviral activity evaluated by CPE reduction. <sup>e</sup>Values in bracket have been obtained in the presence of a P-gp inhibitor. The main structural differences, significant modifications, and warheads are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>1</b> is endowed with a vinyl carboxyl ester acting as the Michael acceptor warhead that traps the catalytic Cys145 through its nucleophilic attack at the vinyl Î²-carbon. This compound was previously identified by SBDD as inhibitor of 3CL proteases of different CoVs,<a onclick="showRef(event, 'ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref51 ref52">(51,52)</a> including SARS- and MERS-CoVs, showing in enzymatic assay a <i>K</i><sub>i</sub> = 9 Î¼M<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and an IC<sub>50</sub> = 0.3 Î¼M,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> respectively, however no data in the same assay were reported against SARS-CoV-2 3CL<sup>pro</sup>. Nonetheless, the high structure identity between this protein and its SARS-CoV homologue would suggest that <b>1</b> may reasonably inhibit also SARS-CoV-2 3CL<sup>pro</sup> with similar potency. This hypothesis is supported by cell-based assay data showing that <b>1</b> inhibits SARS-CoV-2 replication with an EC<sub>50</sub> = 16.77 Î¼M. As expected, <b>1</b> has modest selective index with respect to other CoVs (EC<sub>50</sub> = 4.0, 8.8, 2.7, and 3.4 Î¼M against HCoV-229E, FIPV, MHV-A59, and MHV, respectively), and most likely the variability depends on subtle differences in amino acids sequences in the different CoVs proteases and cellular assay conditions.</div><div class="NLM_p">Peptidomimetic Î±-ketoamides have been recently reported as broad-spectrum inhibitors of 3CL and 3C proteases active in cell-based assays against different CoVs and EVs, with derivative <b>2</b> showing the most promising activity.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Preliminary chemical optimization of <b>2</b> by SBDD led to derivatives <b>3</b> and <b>4</b>, the first SARS-CoV-2 3CL<sup>pro</sup> inhibitors designed <i>ad hoc</i> (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The X-ray structure solved for the complex <b>3</b>/SARS-CoV-2 3CL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2F">6Y2F</a>) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) confirmed the formation of a thiohemiketal obtained by the nucleophilic attack of the Cys145 over the Î±-carbonyl of the ketoamide warhead.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> The oxyanion group is stabilized by a H-bond with His41, while the amide oxygen of <b>3</b> accepts a H-bond from the main-chain amides of Gly143 and Cys145, which, together with Ser144, form the so-called âoxyanion holeâ typical of cysteine proteases. Ketoamide derivative <b>3</b> inhibits SARS-CoV-2 3CL<sup>pro</sup> in biochemical assay with an IC<sub>50</sub> = 0.67 Î¼M, showing similar potency against SARS- and MERS-CoVs M<sup>pro</sup>. <b>3</b> showed EC<sub>50</sub> â¼ 4â5 Î¼M against SARS-CoV-2 replication in human lung (Calu3) cells but, unfortunately, no data on cytotoxicity are provided (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Co-crystallographic pose of compound <b>3</b> (green sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2F">6Y2F</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks. H-bonds are depicted as dashed black lines. (B) Surface representation of the active site pocket with bound compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In another study, a SBDD strategy led to the identification of dipeptides <b>5</b> and <b>6</b> having an aldehyde as warhead and exhibiting excellent inhibitory activity against SARS-CoV-2 3CL<sup>pro</sup> in enzymatic assays, with IC<sub>50</sub> = 53 and 40 nM, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Notably, derivatives <b>5</b> and <b>6</b> are the smallest and most potent SARS-CoV-2 3CL<sup>pro</sup> inhibitors reported so far. More interestingly, both compounds potently inhibited SARS-CoV-2 infection in cell culture with sub-Î¼M potencies (EC<sub>50</sub> = 0.53 and 0.72 Î¼M for <b>5</b> and <b>6</b>, respectively), coupled with low toxicity (CC<sub>50</sub><i>s</i> > 100 Î¼M, SIs > 139) (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). As expected, both compounds bind to the protein with similar poses, as shown in cocrystal structures (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LZE">6LZE</a> for <b>5</b> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M0K">6M0K</a> for <b>6</b>), where the carbon of the aldehyde and the sulfur of Cys145 form the thiohemiacetal, the oxygen of the resulting tetrahedral adduct is stabilized by interaction with backbone of residue Cys145 and through a water bridge with the Thr26 side chain (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Co-crystallographic pose of compound <b>5</b> (yellow-orange sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LZE">6LZE</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the binding pocket are displayed as white sticks; water molecules are shown as red spheres. H-bonds are depicted as dashed black lines. (B) Overlay of <b>5</b> and <b>6</b> (raspberry sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M0K">6M0K</a>) co-crystallographic poses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Additional peptidic reversible covalent inhibitors have been identified through a biochemical screening based on enzymatic assay against SARS-CoV-2 3CL<sup>pro</sup> using a focused library of 68 known protease inhibitors, including approved and investigational drugs.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> An investigational veterinary drug (usually administered via a subcutaneous route) for feline infectious peritonitis (FIP),<a onclick="showRef(event, 'ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref57 ref58">(57,58)</a> compound <b>7</b> (GC376), is a Î±-hydroxy-bisulfite dipeptide able to potently inhibit SARS-CoV-2 3CL<sup>pro</sup> (IC<sub>50</sub> = 30 nM) and viral replication, even though with almost two orders lower potency (EC<sub>50</sub> = 3.37 Î¼M in CPE assay) and no cytotoxicity up to 100 Î¼M (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Thermal shift assay and kinetic enzymatic experiments supported specific binding and reversible covalent inhibition (<i>K</i><sub>i</sub> = 60 nM). This inhibitor is a prodrug, converted into the aldehyde form by the removal of the bisulfite group to alkylate the Cys145 of the 3CL<sup>pro</sup>. Derivative <b>7</b> was originally designed to target 3CL of feline CoV and shares several chemical features with the inhibitors described for SARS-CoV-2 3CL<sup>pro</sup>.<a onclick="showRef(event, 'ref43 ref57'); return false;" href="javascript:void(0);" class="ref ref43 ref57">(43,57)</a> It shows activity against multiple 3CL proteases (IC<sub>50Â FIPVÂ 3CL</sub> = 0.72 Î¼M, IC<sub>50Â TGEVÂ 3CL</sub> = 0.82 Î¼M, IC<sub>50Â SARS-CoVÂ 3CL</sub> = 4.35 Î¼M, IC<sub>50Â MERS-CoVÂ 3CL</sub> = 1.56 Î¼M) and against CoVs (TGEV, FIPV, MHV, 229E, and BCV) in cell lines with high nM potency.<a onclick="showRef(event, 'ref43 ref57 ref58'); return false;" href="javascript:void(0);" class="ref ref43 ref57 ref58">(43,57,58)</a><b>7</b> and two close previously reported analogues, differing only in the electrophilic warhead (<i>i.e.</i>, an aldehyde or an Î±-ketoamide), resulted also in potent inhibition of EV 3C and norovirus 3CL cysteine proteases and of the replication of several of these viruses, including HRVs.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Notably, <b>7</b> has been crystallized in complex with SARS-CoV-2 3CL<sup>pro</sup>, revealing an interaction mode similar to the aldehyde derivatives <b>5</b> and <b>6</b> (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR">7BRR</a>,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTJ">6WTJ</a>,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTT">6WTT</a>,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C8U">7C8U</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6U">7C6U</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBT">7CBT</a>) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). Recently, a small set of new analogues of compound <b>7</b>, differing for the N-terminal capping moieties, has been reported as inhibitors of 3CL<sup>pro</sup> from SARS-CoV-2, MERS-, and SARS-CoVs.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> The new compounds showed biological activities in the same range of parent compound <b>7</b>.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Co-crystallographic pose of compound <b>7</b> (teal sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR">7BRR</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks; water molecules are shown as red spheres. H-bonds are depicted as dashed black lines. (B) Overlay of <b>7</b> bound to SARS-CoV-2 3CL<sup>pro</sup> structures (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR">7BRR</a>, teal; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTJ">6WTJ</a>, wheat; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTT">6WTT</a>, salmon), showing the different conformations of the benzyloxycarbonyl group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Three further reversible covalent inhibitors of SARS-CoV-2 3CL<sup>pro</sup> have been identified by applying the same biological screening protocol as for compound <b>7</b>. The anti-HCV drug Boceprevir<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> shows low Î¼M potency against the isolated 3CL<sup>pro</sup> and the viral replication with no host cell toxicity up to 100 Î¼M. Note that Boceprevir, originally optimized as HCV NS3 serine protease inhibitor, was 100-fold more potent against this target in comparison to the activity against the 3CL<sup>pro</sup>. Calpain cysteine protease inhibitors (Calpain inhibitor II: (2<i>S</i>)-2-acetamido-4-methyl-<i>N</i>-[(2<i>S</i>)-4-methyl-1-[[(2<i>S</i>)-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxopentan-2-yl]pentanamide; Calpain inhibitor XII: benzyl <i>N</i>-[1-[[1,2-dioxo-1-(pyridin-2-ylmethylamino)hexan-3-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate) with aldehyde warheads are slightly more potent in enzymatic and antiviral assays. These three inhibitors are structurally unrelated and deviate from 3CL substrate sequence specificity. Nonetheless, Boceprevir has been recently cocrystallized with SARS-CoV-2 3CL<sup>pro</sup> (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRP">7BRP</a>,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WNP">6WNP</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6S">7C6S</a>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZRU">6ZRU</a>), providing hints to improve its enzyme inhibition (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Noted that none of the HIV protease inhibitors, including Lopinavir, have shown activity in this study, thus providing an explanation to the difficult interpretation of the clinical results for the use of these drugs to treat COVID-19. Indeed, the results published for a clinical trial evaluating LopinavirâRitonavir in hospitalized adult patients with severe COVID-19 have shown no benefit.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structure and biological activity of Boceprevir. <sup>a</sup>Antiviral activity evaluated by viral plaque assay. <sup>b</sup>Antiviral activity evaluated by CPE reduction. (B) Co-crystallographic pose of Boceprevir (purple sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WNP">6WNP</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the active site pocket are displayed as white sticks; water molecules are displayed as red spheres. H-bonds are depicted as dashed black lines. (C) Surface representation of the active site pocket with bound Boceprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In spite of their different warheads, compounds <b>1</b>, <b>3</b>, and <b>5</b>â<b>7</b> share a Gln mimetic Î³-lactam, replacing the substrate P1 Gln to specifically fill the S1 subsite of the SARS-CoV-2 3CL<sup>pro</sup> catalytic pocket. Indeed, the Î³-lactam here establishes key H-bonds with the Phe140 main chain and with the side chains of His163 and Glu166 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>â<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>). Notably, Glu166 is involved not only in substrate recognition but also in the substrate-induced dimerization of SARS CoVs 3CL proteases through the interaction with Ser1 from the other monomer;<a onclick="showRef(event, 'ref35 ref63'); return false;" href="javascript:void(0);" class="ref ref35 ref63">(35,63)</a> therefore, the interaction of the inhibitor Î³-lactam with this residue could stabilize the monomeric and inactive form of the enzyme. Literature data on 3CL<sup>pro</sup> inhibitors of related CoVs clearly indicate that the P1 Î³-lactam enhances the inhibitory potency up to 10-fold, probably because the higher rigidity reduces the loss of entropy upon binding if compared to the flexible Gln.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In Boceprevir, the Î³-lactam is replaced by a cyclobutyl ring that cannot form any hydrogen bond at the S1 subsite, and this is likely one of the reasons for the modest inhibitory 3CL<sup>pro</sup> activity of this compound. Nevertheless, the presence of a modified proline at the P2 position would suggest the possibility to synthesize proline-based analogues with higher affinity and specificity toward the target enzyme. Indeed, the P2 amino acids of the other reported inhibitors show that this position tolerates a wide variety of residues characterized by similar lipophilicity and size to the substrate Leu and thus able to occupy the S2 subsite. In particular, leucine occupies the P2 position in <b>1</b> and <b>7</b>, while it is replaced by a cyclopropyl alanine in <b>3</b> or by cyclohexyl- and <i>m</i>-F-phenyl alanine residues in <b>5</b> and <b>6</b>, respectively. Compared to the other cocrystallized compounds, a difference in the binding mode of <b>6</b> is observed. In fact, the <i>m</i>-F-phenyl of this ligand undergoes a downward rotation so that the fluorine atom can form a H-bond with Gln189 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). It is interesting to report that this residue can alternatively form a hydrogen bond with the backbone nitrogen of the inhibitor P2 residue, as observed in the case of <b>1</b>.</div><div class="NLM_p">As described in the previous paragraph, the S3 and S4 pockets of SARS-CoVs 3CL<sup>pro</sup> are less structured and indeed can rearrange upon the binding of distinct P3/P4 residues. Hence, these amino acids are generally modified to modulate both potency and drug-like properties of the inhibitors. For instance, in peptide <b>1</b> the P3 lipophilic Val is solvent exposed, although it can establish van der Waals contacts with P1 Î³-lactam to stabilize the inhibitor binding conformation, while the P4 <i>N</i>-capped Ala can form some lipophilic contacts with residues Met165, Leu167, and Gln192 in S4 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Remarkably, the P3 backbone of the inhibitor establishes two key hydrogen bonds with the main chain of Glu166. These interactions can also be formed by derivative <b>3</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>), in which the P2âP3 amide bond is masked by a <i>N</i>-Boc-aminopyridone, likely to prevent cellular proteases cleavage. Indeed, the pyridone CO donates a H-bond to Glu166, which in turn accepts another H-bond from the NH of the ligand carbamate. The analysis of the <b>3/</b>3CL<sup>pro</sup> complex shows that the terminal hydrophobic Boc group does not establish significant interactions at the S3/S4 enzyme subsites. However, this group is fundamental to gain cell activity, probably due to the improvement of membrane permeation; in fact, its deletion did not affect biochemical inhibition of the protease but completely abrogated antiviral activity in cell-based assay (compound <b>4</b> in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Nonetheless, in the <b>3</b>/3CL<sup>pro</sup> cocrystal structure, a DMSO molecule is found between the Gln189 side chain and the pyridone moiety, suggesting that there is space for larger and more functionalized groups (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Similar to <b>3</b>, in aldehydes <b>5</b> and <b>6</b>, the P3 is replaced by a more drug-like moiety, specifically a 2-indolic acid that caps the <i>N</i>-terminal of P2. In the enzyme-bound conformation, the indole ring is exposed to solvent and stabilized by H-bonds with the amide backbone Glu166 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>), as the pyridone of <b>3</b>. Also, in derivative <b>7</b>, the P2 Leu is capped by a benzyloxycarbonyl group which can alternatively extend toward the S3/S4 pockets or downward to form intramolecular contacts with the P1 Î³-lactam; in both cases, however, this moiety can form only one hydrogen bond with Glu166 with respect to the two formed by inhibitors <b>1</b>, <b>3</b>, <b>5</b>, and <b>6</b>. To conclude, the crystallographic complexes of SARS-CoV-2 3CL<sup>pro</sup> with <b>1</b> and <b>3</b> show that the P1â² benzyl group cannot form specific interactions at the S1â² site. In fact, the aldehydes <b>5</b> and <b>6</b>, which completely lack a P1â² moiety, display the highest inhibitory potency against the enzyme, indicating the role of this substituent needs to be further investigated. It is worth noting that some of the cocrystallized inhibitors, namely derivatives <b>1</b>, <b>7</b>, and Boceprevir, fold, bringing the P3 residue or the benzyloxycarbonyl cap close to the P1 Î³-lactam, thus suggesting that P1âP3 macrocyclization could be explored as optimization strategy. Indeed, macrocyclization has been widely employed as strategy to preorganize HCV NS3 protease inhibitors in their bioactive conformation, leading to BILN-2061<a onclick="showRef(event, 'ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref64 ref65">(64,65)</a> and the approved pan-genotypic drug Grazoprevir.<a onclick="showRef(event, 'ref66 ref67'); return false;" href="javascript:void(0);" class="ref ref66 ref67">(66,67)</a> Moreover, macrocyclization generally show additional advantages potentially leading to greater stability and improved PK properties.</div><div class="NLM_p">Compounds <b>3</b>, <b>5</b>, and <b>6</b> have been also evaluated for their <i>in vivo</i> PK properties in mice, and even if dosages, parameters, and administration routes are not fully aligned, it is worth comparing the collected data. Pyridone <b>3</b> upon sc administration (3 mg/kg) showed modest half-life (<i>T</i><sub>1/2</sub> < 2 h) and a rather low <i>C</i><sub>max</sub> (around 126 ng/mL), indicating a suboptimal PK profile and the need of further optimization.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> More interestingly, indole derivatives <b>5</b> and <b>6</b> were dosed via iv (5 mg/kg), and ip (5 and 20 mg/kg) administrations (single dose), resulting in a reasonable profile with <i>T</i><sub>1/2</sub> ranging from â¼2 to â¼5 h, depending on the administration route and the compounds, CL = 17 and 21 mL/min/kg, respectively, via iv, high <i>C</i><sub>max</sub> (>2390 ng/mL) and availability >85%.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Overall, by comparing PK profiles of both compounds after iv administration at 5 mg/kg, <b>5</b> resulted metabolically more stable than <b>6</b>, showing a <i>T</i><sub>1/2</sub> = 4.4 h and CL = 17 mL/min/kg with respect to <i>T</i><sub>1/2</sub> = 1.65 h and CL = 21 mL/min/kg, respectively. Compound <b>5</b> was further evaluated in rats (10 mg/kg, iv) and dogs (5 mg/kg, iv), showing good half-life values (rat, 7.6 h; dog, 5.5 h), low clearance (rat, 4.01 mL/min/kg; dogs, 5.8 mL/min/kg), and high AUCs (rat, 41â¯500 hÂ·ng/mL and dog, 14900 hÂ·ng/mL). The PK profile was considered good enough to proceed in acute and seven-day toxicity studies in rats and dogs. In particular, compound <b>5</b> was evaluated for acute toxicity in rats by iv administration at 24 mg/kg (1 rat), 40 mg/kg (10 rats), and 60 mg/kg (4 rats); one rat from the last group died. The seven-day studies were carried out in rats by administering via iv at 2, 6, 18 mg/kg of the compound to four rats per study; four dogs were dosed via iv at 10 mg/kg (the first day), 15 mg/kg (the second day), 20 mg/kg (the third day), 25 mg/kg (the fourth day), 25 mg/kg (the fifth to seventh days, randomly two dogs), 40 mg/kg (the fifth to seventh days, other two dogs). All animals were clinically observed during seven days for toxic signs, which include bodyweight, food intake, and hematology, and no anomalies were observed. Therefore, <b>5</b> was considered well tolerated after iv administration at different doses in rats and dogs. The plasma concentration and the concentration at trough unfortunately were not reported.</div><div class="NLM_p">In summary, although there are slight differences in biochemical experimental conditions, in cell-based assays, and in the PK <i>in vivo</i> evaluation, that complicate a rigorous head-to-head comparison between the above mentioned inhibitors, some conclusions can be drawn. Compound <b>5</b>, having the indole as P2 capping group and aldehyde as the warhead, resulted in the most potent 3CL<sup>pro</sup> inhibitor, with acceptable PK after iv administration and an acceptable safety profile in preclinical species. Remarkably, compound <b>5</b> is reminiscent of SARS-CoV 3CL<sup>pro</sup> inhibitors disclosed in two patents by Pfizer, following the SARS outbreak in 2002â2003.<a onclick="showRef(event, 'ref68 ref69'); return false;" href="javascript:void(0);" class="ref ref68 ref69">(68,69)</a> Moreover, the introduction of an indole or other heterocycles in P3 was already reported for peptidomimetic inhibitors of SARS-CoV 3CL<sup>pro</sup>.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Similarly, these compounds having an indole as P2 drug-like cap and either a ketone-based warheads showed nM potency against the isolated target in biochemical assays. The COVID-19 pandemic prompted Pfizer to investigate the efficacy of these compounds and of newly developed analogues against SARS-CoV-2, and the obtained data have been recently reported.<a onclick="showRef(event, 'ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref71 ref72">(71,72)</a> One of the most potent derivatives is compound <b>8</b> (PF-00835231), which exhibits as P3âP1 substituents, respectively, a 6-methoxyindole capping group, a leucine, and the canonical Gln mimetic residue. Interestingly, the latter is functionalized with a hydroxymethylketone, enabling reversible covalent chemistry. Compound <b>8</b> exerts very potent inhibitory activity against a wide panel of 3CL<sup>pro</sup> from Î±-, Î²-, and Î³-CoVs, with <i>K</i><sub>i</sub>/IC<sub>50</sub> ranging from the low-nM to pM range. Particularly, a <i>K</i><sub>i</sub> = 0.27 nM and an IC<sub>50</sub> = 6.9 nM against SARS-CoV-2 3CL<sup>pro</sup> and a <i>K</i><sub>i</sub> = 4 nM against SARS-CoV 3CL<sup>pro</sup> have been reported. On the other hand, <b>8</b> resulted as being inactive on HIV and HCV proteases as well as against a panel of human proteases. Therefore, this molecule can be considered a selective 3CL<sup>pro</sup> inhibitor with broad-spectrum activity against CoVs. The efficacy of <b>8</b> against SARS-CoV and SARS-CoV-2 was evaluated in Vero cells, showing EC<sub>50</sub> values of 4.8 and 39.7 Î¼M, respectively. However, <b>8</b> has been shown to be substrate of P-gp, which is indeed highly expressed in Vero cells. In fact, in the presence of a P-gp inhibitor, the antiviral activity of <b>8</b> was significantly increased, with EC<sub>50</sub> values of 0.23 and 0.76 Î¼M against SARS-CoV and SARS-CoV-2, respectively, coupled to low toxicity (CC<sub>50</sub> > 100 Î¼M). Interestingly, <b>8</b> exhibits additive/synergistic effect in combination with Remdesivir against SARS-CoV-2 in cell-based assays. X-ray structures of <b>8</b> bound to the 3CL<sup>pro</sup> of either SARS-CoVs have been solved (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHL">6XHL</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHM">6XHM</a>, respectively). As expected, the crystal poses in both structures are almost identical and are very similar to those reported for <b>5</b> and <b>6</b>. DMPK profiling of <b>8</b> highlighted promising results but limited aqueous solubility to enable iv administration.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> To increase the solubility, a prodrug strategy has been applied to compound <b>8</b> and its phosphate ester <b>9</b> (PF-07304814) has been reported as a suitable clinical candidate,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> even though projected effective dose (500 mg/day) is high. On 15 September 2020, Pfizer announced the initiation of a double-blind, placebo-controlled phase Ib clinical trial (NCT04535167) to evaluate the safety, tolerability, and pharmacokinetics of <b>9</b>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a></div><div class="NLM_p">Besides the X-ray structures of the 3CL<sup>pro</sup> with the peptidic covalent inhibitors, some other strategies are currently underway to identify reversible inhibitors of the enzyme. Few results have been published and are available in preprint manuscripts, in press release on organization websites, and some crystal structure have been released in the PDB.</div><div class="NLM_p">Baicalein, one of the main flavones of <i>Scutelarria baicalensis</i>, has been shown to inhibit the proteases of SARS-CoV-2 and SARS-CoV with IC<sub>50</sub>s of 0.94 and 1.1 Î¼M (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A), respectively; its glucuronide analogue Baicalin is still active but less potent (IC<sub>50Â SARS-CoV-2Â 3CL</sub> = 6.41 Î¼M).<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> These data are partly consistent with those reported in another study, where Baicalein was found to be active against SARS-CoV-2 3CL<sup>pro</sup> (IC<sub>50Â SARS-CoV-2Â 3CL</sub> = 0.34 Î¼M), while Baicalin was only a weaker inhibitor (40% inhibition at 50 Î¼M).<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Perhaps the hydrolysis of the glucuronide moiety in one sample can explain the difference in activity. However, Baicalein was shown to be more potent in both studies. The specific binding of the flavones Baicalein and Baicalin to the protein target has been characterized by ITC showing <i>K</i><sub>D</sub>s of 4.03 and 11.5 Î¼M, respectively, and consistently with the compound structures the ITC profiles were typical of reversible binders.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> In the same study, the X-ray structure of Baicalein noncovalently bound to the active site of the 3CL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M2N">6M2N</a>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B) has been solved, revealing that Baicalein mainly occupies the S1 pocket, with the three phenolic hydroxyl groups forming multiple H-bonds with the main chain of Leu141 and Gly143 and the side chains of Ser144 and His163 by water bridges.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> The catalytic Cys145 and His41 stabilize the flavone binding mode by SâÏ and ÏâÏ interactions, respectively, while the carbonyl accepts a H-bond by the Glu166 backbone amide. Finally, the C-2 phenyl ring extends toward the S2 subsite forming favorable contacts with residues such as His41, Met49, and Tyr54. Therefore, Baicalein fills the core of the substrate binding site including the catalytic dyad and the S1/S2 protein residues sharing several recognition elements with peptide substrates and inhibitors.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Structures and biological activities of flavones Baicalein and Baicalin. <sup>a</sup>Antiviral activity evaluated by viral RNA measurement by qRT-PCR. (B) Co-crystallographic pose of Baicalein (light-pink sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M2N">6M2N</a>) into the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the binding pocket are displayed as white sticks. The buried water molecule is displayed as a red sphere. H-bonds are depicted as dashed black lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, Baicalein also showed antiviral activity (EC<sub>50</sub> = 1.69 Î¼M) against SARS-CoV-2 in infected cells without toxicity (CC<sub>50</sub> > 200 Î¼M, SI > 118), while Baicalin was less potent in the same assay (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> It is worth noting that Baicalin tablets have been used as adjuvant therapy for the treatment of acute, chronic, or persistent hepatitis in China and were shown to be well tolerated up to the dose of 2.8 g.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Phase IIa clinical trials are currently ongoing to evaluate Baicalin in healthy adults with influenza fever (NCT03830684).</div><div class="NLM_p">The 3D coordinates of SARS-CoV-2 3CL<sup>pro</sup> bound to another noncovalent ligand <b>10</b> (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W63">6W63</a>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W79">6W79</a>) have been recently released, showing that this compound can extend from S1â² to S3 establishing H-bonds with the backbone of Gly143 and Glu166 as well as with the His163 side chain (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). However, the data on the activity of <b>10</b> in enzymatic and antiviral cell-based assays are still unknown. Similar compounds belonging to a Ugi library were previously reported as SARS-CoV3CL<sup>pro</sup> inhibitors, demonstrating Î¼M inhibitory potency against the isolated target and poor activity in cell lines.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structure of compound <b>10</b>. (B) Co-crystallographic pose of <b>10</b> (slate sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W63">6W63</a>) into the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the binding pocket are displayed as white sticks; water molecules are displayed as red spheres. H-bonds are depicted as dashed black lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Scientists from the Diamond Light Source, the UKâs national synchrotron, solved a new apo-structure of the SARS-CoV-2 3CL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YB7">6YB7</a>) and then carried out a large X-ray crystallographic fragment screening, which resulted in the identification of 22 noncovalent and 44 covalent active-site binders. The corresponding complexes were deposited in the PDB, providing opportunity for fragments growing and/or merging. Indeed, follow-up medicinal chemistry efforts are currently focusing on a group of fragments functionalized with chloroacetamide warheads, which were selected because they were not identified as hits in previous screens and could thus in principle be selective for 3CL<sup>pro</sup>.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></div><div class="NLM_p">Additional approaches are based on drug repositioning through performing virtual screenings of approved and investigational drugs libraries, followed by experimental validation against the target protein in biochemical experiments and/or in cell-based SARS-CoV-2 replication assays. A large collection of about 10â¯000 drugs and clinical candidates has been screened through this approach. Among the compounds identified (see chemical structures in Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf" class="ext-link">Figure S2</a>), Ebselen (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>),<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> a synthetic organoselenium molecule endowed with anti-inflammatory, antioxidant, and cytoprotective properties, turned out as a covalent inhibitor of the SARS-CoV-2 3CL<sup>pro</sup> displaying antiviral activity in cell line, but the overall results are not particularly encouraging.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures and biological activities of Ebselen and compounds <b>11</b>â<b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">The PL<sup>pro</sup> as Antiviral Target</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81628" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81628" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The CoV nsp3 multidomain protein is the largest replicase subunit (1922 aa).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> This macromolecule, having transmembrane domains, is likely to play an essential role during the formation of the replication complex by mediating intracellular membranes rearrangement and by multiple interactions with other nsps.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Several domains of nsp3 have been identified and are conserved in all CoVs.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Among these, the PL<sup>pro</sup> domain (residues 1602â1855) is a cysteine protease that cleaves the viral polyprotein in the nsp1/2, nsp2/3 and nsp3/4 cleavage sites. Additionally, PL<sup>pro</sup> can recognize and hydrolyze the cellular proteins Ub and UbL protein ISG15 from the lysine Îµ-amino group of ubiquitinated host proteins involved in innate antiviral response.<a onclick="showRef(event, 'ref33 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref33 ref84 ref85">(33,84,85)</a> The PL<sup>pro</sup> thus acts as a potent suppressor of Ub-dependent host immunity mechanisms, blocking the production of IFNÎ² and other cytokines as well as IRF3 and NF-ÎºB pathways. By exerting proteolytic activity on part of the immature viral polyprotein and on Ub-modified host cell proteins, inhibitors of PL<sup>pro</sup> can block CoV replication and potentiate antiviral host cell immunity. In contrast to SARS-CoV-2 3CL<sup>pro</sup>, which is already well characterized and for which several inhibitors have been described, PL<sup>pro</sup> has been not investigated in detail so far. However, this protein is quite similar to the SARS-CoV homologue PL<sup>pro</sup>, sharing 83â86% sequence identity while differing from MERS-CoV PL<sup>pro</sup> (33% identity).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Thus, a description based on the structural and functional data on the SARS-CoV PL<sup>pro</sup> is possible. SARS-CoV-2 PL<sup>pro</sup> has the classic catalytic triad of cysteine proteases made by Cys111-His272-Asp286 (corresponding to Cys112-His273-Asp287 in SARS-CoV PL<sup>pro</sup>) that specifically recognize the P1âP4 sequence GGXL conserved in all the nsp1/2, nsp2/3, and nsp3/4 cleavage sites of the viral polyprotein.<a onclick="showRef(event, 'ref33 ref85'); return false;" href="javascript:void(0);" class="ref ref33 ref85">(33,85)</a> As anticipated above, PL<sup>pro</sup> is also able to cleave Ub and the UbL protein ISG15, both showing the GGRL recognition motif at the C-term, from the Îµ-amino group of host proteins. Indeed, the PL<sup>pro</sup> overall architecture resembles that of human deubiquitinating enzymes of the Ub-specific protease family. This comprises a three-dimensional right-hand structure that hosts the catalytic triad at the interface of the thumb and the palm subdomains, an Ub binding motif at the N-term, and a fingers region containing an essential structural zinc ion tetrahedrally coordinated by four cysteines.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> The Trp106 residue (Trp107 in SARS-CoV PL) in the oxyanion hole of the PL<sup>pro</sup> is required for the enzymatic activity because it stabilizes the hemithioacetal substrate intermediate through a single H-bond established by its indole nitrogen.<a onclick="showRef(event, 'ref33 ref85'); return false;" href="javascript:void(0);" class="ref ref33 ref85">(33,85)</a> An additional key common feature between SARS-CoV and SARS-CoV-2 PL<sup>pro</sup> is the presence of the flexible BL2 loop containing a Tyr residue (Tyr268). It is found in an open conformation in the unliganded PL<sup>pro</sup>, while it is in the closed form upon inhibitor binding.</div><div class="NLM_p">Like for SARS-CoV-2 3CL<sup>pro</sup>, the substrate specificity profile of PL<sup>pro</sup> was evaluated by determining the hydrolytic rate of different substrates from a combinatorial library, in comparison with the SARS-CoV enzyme.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> This analysis has shown that both proteases are highly specific for Gly in P1âP2, while they can accept a wide panel of P3 residues, tolerating not only basic residues like Arg, Lys Orn Phe(guan), hArg Dap, Dab but also hydrophobic amino acids, such as hTyr, Phe(F5), Cha, Met, Met(O), and Met(O)<sub>2</sub>. On the other hand, these pockets cannot recognize <span class="smallcaps smallerCapital">d</span>-amino acids. The S4 subsite can host only hydrophobic residues, among natural amino acids, with a strong preference for Leu. Notably, SARS-CoV PL<sup>pro</sup> can bind two P4 unnatural residues, namely hTyr and hTyr(Me), with higher affinity than leucine. On the basis of these specificities, two tetrapeptides, <b>11</b> and <b>12</b>, displaying a GG-Dap-X as P1âP4 sequence and functionalized with a vinyl ester warhead, were designed as covalent inhibitors of the SARS-CoV-2 and SARS-CoV PL PRs. Their IC<sub>50</sub>s were not reported in the original manuscript but can be derived from the inhibition curve. Thus, IC<sub>50</sub> for both compounds can be approximately estimated to be around 10 Î¼M, however their antiviral activity in cell-based assay was not reported (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). As expected, the compounds were inactive against MERS-CoV-PL<sup>pro</sup>, significantly differing from the SARS homologues. The X-ray structures of compounds <b>11</b> or <b>12</b> covalently bound to SARS-CoV-2 PL<sup>pro</sup> (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WUU">6WUU</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WX4">6WX4</a>, respectively) have been released.</div><div class="NLM_p">Seleno-organic compounds have been described in two preprint papers as irreversible inhibitors of PL<sup>pro</sup> of both SARS-CoV and SARS-CoV-2, with Ebselen (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) showing IC<sub>50</sub>s of 8.35 and 2.26 Î¼M, respectively, after incubation (60 min) with each enzyme, whereas no activity was detected without incubation.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Later on, benzisoselenazol-3(2<i>H</i>)-one derivatives, differing from Ebselen in the N substituent, and 2,2â²-dicarbamoyldiaryl diselenides have been reported as inhibitors of PL<sup>pro</sup> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> In particular, <i>o</i>-hydroxy (<b>13</b>) and <i>o</i>-methoxy (<b>14</b>) <i>N</i>-phenyl substituted benzisoselenazol-3(2<i>H</i>)-ones are 10-fold more potent against SARS-CoV-2 PL<sup>pro</sup> than Ebselen, with IC<sub>50</sub>s of 0.24 and 0.26 Î¼M, respectively. Similarly, the corresponding 2,2â²-dicarbamoyldiaryl diselenide analogues <b>15</b> and <b>16</b> show inhibitory potency in the same range (IC<sub>50</sub> = 0.34 and 0.26 Î¼M). Antiviral activity in cell-based assays was not investigated for Ebselen and its analogues. However, Ebselen has been shown to covalently inhibit also SARS-CoV-2 3CL<sup>pro</sup><a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and a plethora of protein targets, while benzisoselenazol-3(2<i>H</i>)-one and 2,2â²-dicarbamoyldiaryl diselenide derivatives have been shown to also irreversibly inhibit human methionine aminopeptidase 2,<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> thus hinting at a nonspecific effect on a wide panel of proteins due to the high reactivity of Se atom.</div><div class="NLM_p">Noncovalent naphthalene-based SARS-CoV PL<sup>pro</sup> inhibitors have been previously identified through HTS approaches showing high-nM/low-Î¼M potency in biochemical assays and weak antiviral activity in cell lines, with the optimized derivative <b>17</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) displaying the best performance (IC<sub>50Â SARS-CoVÂ PL</sub> = 0.6 Î¼M, EC<sub>50Â SARS-CoV</sub> = 14.5 Î¼M, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> As demonstrated by enzymatic kinetic experiments, <b>17</b> is a reversible competitive inhibitor that in the X-ray complex with SARS-CoV PL<sup>pro</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E9S">3E9S</a>) is bound at the S3âS4 subsites in a cleft for the access to the active site.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Recent results show that <b>17</b> is able to inhibit SARS-CoV-2 PL<sup>pro</sup> (IC<sub>50</sub> = 2.4 Î¼M, EC<sub>50Â SARS-CoV</sub> = 27.6 Î¼M <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), while it is not able to inhibit MERS-CoV PL<sup>pro</sup> due to the replacement with a threonine of Tyr268, in the BL2 loop, that is present in both the SARS-CoV and SARS-CoV-2 enzymes where the residue mediates interactions with the inhibitors.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> However, compound <b>17</b> demonstrated weak antiviral activity in cell-based assays (EC<sub>50Â SARS-CoV-2</sub> = 27.6 Î¼M in plaque assay, in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p last">In summary, targeting PL<sup>pro</sup> may represent a promising approach to tackle SARS-CoV-2 replication and host immune escape. However, no potent and cell-based active covalent inhibitor is yet available, probably because the design of peptidic compounds, resembling the substrate sequence, is hampered by P1âP2 specificity for glycine. On the other hand, known reversible noncovalent inhibitors of SARS-CoV PL<sup>pro</sup> show only moderate and narrow antiviral activity, being not active against the related MERS-CoV homologue. Therefore, much work is needed to validate PL<sup>pro</sup> as a viral target for successful drug discovery.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">SARS-CoV-2 RdRp: Structure and Function</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08807" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08807" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">CoVs rely on a multisubunit machinery for the replication and transcription of the viral genome. This macromolecular assembly is made up of nonstructural proteins (nsp), which are cleavage products of the ORF1a and ORF1ab viral polyproteins.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In particular, RdRp activity resides in nsp12 and catalyzes the formation of a phosphodiester bond between nucleoside triphosphates (NTPs) in a primer-dependent manner. The NTP substrates involved in this reaction are coordinated by two metal ions, which are bound by the conserved Asp residues. Consistent with this conserved mechanism, strong amino acid conservation can be observed in regions that are directly involved in nucleotide selection or catalysis.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a></div><div class="NLM_p">Upon the formation of a complex with nsp7 and nsp8, nsp12 acquires processivity for the synthesis of large RNAs, a mechanism that in CoVs has evolved to control the viral RNA synthesis during infection.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> In addition, nsp8 has shown RNA primase activity, that is, the ability to synthesize an RNA primer,<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> enabling <i>de novo</i> RNA synthesis. The structural and functional features of the RdRps among CoV family are highly conserved; for example, the RdRp of SARS-CoV-2 has 96% amino acid identity to that of SARS-CoV.<a onclick="showRef(event, 'ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref98 ref99">(98,99)</a></div><div class="NLM_p">Recently, the structure of SARS-CoV-2 full-length RdRp, in complex with cofactors nsp7 and nsp8, was determined by cryoelectron microscopy (cryo-EM) at 2.90 Ã resolution (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M71">6M71</a>)<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> showing the typical right-hand architecture of the viral RdRps (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), constituted by the finger, palm, and thumb subdomains.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> The nsp12 RdRp domain is connected through an interface to the N-terminal region possessing nucleotidyltransferase activity, named NiRAN, whose exact role in the viral life-cycle remains elusive.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> SARS-CoV-2 RdRp cryo-EM structure revealed also an additional, unique N-terminal Î²-hairpin, which was previously not observed in SARS-CoV RdRp.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Architecture of SARS-CoV-2 nsp12. (A) Schematic diagram outlining the domain organization of SARS-CoV-2 nsp12. The domains are colored as: palm, cyan; fingers, yellow-orange; thumb, salmon. The N-terminal NiRAN domain, the interface and the Î²-hairpin are colored light-pink, wheat, and blue-white, respectively. The polymerase conserved motifs are colored as: motif A, lime green; motif B, violet; motif C, slate; motif D, olive; motif E, sand; motif F, deep-teal; motif G, ruby. (B) Structure of SARS-CoV-2 in two different orientations (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M71">6M71</a>). (left) Ribbon diagram of nsp12 showing the arrangement of palm, fingers, and thumb domains. Domains are colored as in (A). Nsp7 and nsp8 cofactors are shown as pale-green and raspberry ribbon models, respectively. (right) The palm, fingers, and thumb domains are shown as a molecular surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The RdRp active site is composed by seven conserved motifs (AâG) lining a central cavity where the template-directed RNA synthesis takes place (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). In particular, the incoming NTP binds within motif F, whereas the RNA template enters the active site through a channel formed by motifs F and G; motif E and the thumb subdomain sustain the primer strand. The product of RNA synthesis leaves the active site through an RNA exit path, situated at the front side of the polymerase.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Overview of SARS-CoV-2 nsp12 active site. For clarity, the RdRp core region is shown as a white ribbon model, whereas the polymerase conserved motifs (AâG) are colored according to the upper schematic diagram. The catalytic residues Asp760 and Asp761 are shown as white sticks. The template entry, NTP entry, product hybrid exits paths are indicated by orange arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Three other groups reported further cryo-EM structures of nsp12 catalytic subunit and nsp7-nsp8 cofactors. The nsp12-nsp7-nsp8 complex has been solved both in the apo form (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV1">7BV1</a>) and bound to the template-primer RNA and Remdesivir monophosphate (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>);<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> this latter is described in more detail below. Subsequently, another apo structure was reported (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BW4">7BW4</a>).<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> By using circular dichroism (CD) experiments, the authors pointed out that both the nsp8 and nsp12 subunits of SARS-CoV-2 have shown lower melting temperature values, as compared to the corresponding subunits of SARS-CoV, suggesting the poorer thermostability of SARS-CoV-2 proteins and a possible adaptation of SARS-CoV-2 toward humans with relatively lower body temperatures than the natural bat hosts. Then, the cryo-EM structure of the replicating SARS-CoV-2 RdRp (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT">6YYT</a>), comprising nsp12, nsp8, and nsp7, and over two turns of RNA template-product duplex was reported, adding another piece of useful structural information (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of SARS-CoV-2 replicating RdRp-RNA complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT">6YYT</a>). Nsp12 is shown as a molecular surface (color code as in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), whereas the cofactors nsp7 and nsp8 (protomers 1 and 2) are shown as pale-green and raspberry ribbon models, respectively. RNA turns are shown as an orange ribbon model. The positively charged nsp8 residues, proposed to interact with RNA, are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The active site cleft of nsp12 binds the first turn of RNA, whereas two subunits of nsp8 bind to opposite sides of the cleft, flanking the exiting RNA duplex with long Î±-helical extensions, called âsliding polesâ. These nsp8 extensions are rich in positively charged residues and form multiple RNA backbone interactions. Notably, this structure revealed large additional portions in nsp8 that become ordered upon RNA binding, while nsp8 nsp7 complexes are usually more flexible.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> The mutation of one of these positively charged residues, namely Arg58, with Ala, was previously reported as lethal in SARS-CoV because of the strong decrease of polymerase activity, leading to a nonviable phenotype (as evaluated by immunofluorescence microscopy and plaque assays).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Targeting SARS-CoV-2 RdRp</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The SARS-CoV-2 RdRp represents an ideal drug target due to its critical role in virus replication and the absence of an enzymatic counterpart in the host cell. In fact, viral polymerases inhibitors represent the cornerstone of antiviral therapeutics; indeed, most of the approved drugs for the treatment of viral infections, including HIV and HCV, belong to this class.</div><div class="NLM_p">Inhibitors of viral polymerases fall into two main categories, according to their mode of action and structure, with nucleoside inhibitors (NIs) acting at the substrate site and the non-nucleoside inhibitors (NNIs) interacting with allosteric binding sites.</div><div class="NLM_p">Therefore, building on the experience and achievements obtained in the past, these approaches might lead to strategies that effectively control SARS-CoV-2 infection. NIs represent an attractive avenue toward disrupting viral RNA replication because of the high degree of conservation of active sites of RdRp and relatively low mutation rate in these regions, thus allowing for a broad antiviral activity and a high barrier to resistance. To compete with the natural substrates for incorporation into the viral RNA, NIs requires activation to the pharmacologically active triphosphate form (NTP) by a multistep process, carried out by host kinases (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>, orange box). The first phosphorylation step is often the rate-limiting step in the activation.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> To overcome this drawback, the application of the ProTide strategy, based on the synthesis of ester phosphoramidate prodrug of monophosphate nucleotides, has been extensively explored in NIs to bypass the initial phosphorylation step. After cellular uptake, ProTide ester hydrolysis is mediated by host esterases (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), followed by spontaneous cyclization, phenol release, and phosphoroamidase cleavage to deliver the nucleotide monophosphate, which is then converted into the active NTP form.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Putative mechanism of ProTides <i>in vivo</i> metabolism. Upon diffusion into the cell, the amino acid ester of the ProTide is cleaved by intracellular esterases, then a cyclization occurs onto the phosphorus, with the release of the phenoxide moiety. The unstable cyclic intermediate is then hydrolyzed by water to the alanine metabolite, whose PâN bond is hydrolyzed by phosphoramidase-type enzymes to unmask the NI monophosphate form. The NI monophosphate is routed to further phosphorylation steps, yielding the active triphosphate form (NTP) and thus circumventing the endogenous phosphorylation pathway (orange box). X, aromatic substituents; Y, O, or CH<sub>2</sub>; R, ester substituents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The viral RdRp binds the drug in the form of NTP; then, the hydrolysis and release of a pyrophosphate group provides the energy source for nucleotide monophosphate incorporation into the nascent RNA chain, with consequent inhibition of strand elongation and viral replication. Antiviral NIs fall into three categories: obligate chain terminators, nonobligate chain terminators, and mutagenic.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Obligate chain terminators do not possess the 3â²-hydroxyl group at the riboside moiety of the molecule. Nonobligate chain terminators possess instead a natural base and a 3â²-hydroxyl on the sugar, but they display an additional substituent at the C-1â² or the C-2â² positions of the ribose ring, blocking the formation of the phosphodiester linkage with the incoming NTP.<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> The mechanism of lethal mutagenesis involves the inability to recognize the nucleoside analogues as regular nucleobases, thus inducing a mismatch in base pairing and an increase in mutations, ultimately leading to nonviable genomes.</div><div class="NLM_p">Despite the large amount of structural data produced for the SARS-CoV-2 RdRp, this protein may appear as a still underexplored antiviral target in comparison with the 3CL<sup>pro</sup> of CoVs. Indeed, no focused medicinal chemistry programs, aimed at identifying specifically designed inhibitors of CoV RdRp, have been reported so far. On the other hand, the few inhibitors identified derive from a large repurposing campaign on known broad spectrum, well characterized NIs which can be readily used in the clinic. In fact, Remdesivir (GS-5734, developed by Gilead Sciences) was recently granted EUA<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> for the treatment of SARS-CoV-2, following the encouraging results from the National Institute of Allergy and Infectious Diseases (NIAID) and Gilead clinical trials and from the compassionate use programs.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13â15)</a> Other attractive candidates include Favipiravir (T-705, Avigan), which was granted emergency use approval in Russia and India, Galidesivir (Galidisvir, BCX4430), and the compound Î²-<span class="smallcaps smallerCapital">d</span>-<i>N</i><sup>4</sup>-hydroxycytidine-5â²-isobutyrate ester <b>18</b> (EIDD-2801). These compounds can be grouped in adenine (Remdesivir and Galidesivir), guanine (Favipiravir), and cytosine (<b>18</b>) analogues (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Remdesivir and Galidesivir are C nucleosides obtained by introducing a C-glycosidic bond to link the sugar to the nucleobase, showing higher resistance to phosphorolysis mediated by intracellular phosphorylases.</div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of antiviral nucleoside analogues in clinical development. The parent bases are highlighted in light-blue (adenine), green (guanine), and orange (cytosine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Remdesivir is the Sp isomer ester monophosphoramidate prodrug of 1â²-cyano-substituted adenine C-nucleoside ribose analogue <b>19</b> (GS-441524, <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> It was designed to deliver the nucleoside monophosphate <b>21</b> into the cell, circumventing the rate-limiting first phosphorylation step and allowing for efficient formation of the active triphosphate form (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>).<a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a> This advantage is not present in Favipiravir, <b>18</b>, and Galidesivir. Structurally, the 1-cyano group of Remdesivir provides potency and selectivity toward viral RNA polymerases. The Sp isomer was selected because of the high potency across multiple cell lines and the crystalline nature of an Sp prodrug reagent that allowed rapid synthesis scale-up, a key element for the current request of active pharmaceutical ingredients (API).<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Schematization of Remdesivir metabolic conversion to the active triphosphate form. Remdesivir is first transformed into the intermediate alanine metabolite <b>20</b>, then to the monophosphate form <b>21</b> and finally to the triphosphate form <b>22</b>. The phosphoramidate prodrug moiety is shown in magenta. <b>19</b> (GS-441524) is the parent nucleoside of Remdesivir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cryo-EM structure of Remdesivir in complex with RdRp from SARS-CoV-2 and a 50-base template-primer RNA (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>) has been recently released.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> This structure, generated using the drugâs triphosphate metabolite <b>22</b>, shows the nucleotide analogue in its monophosphate form, covalently bound to the primer strand at the 3â²-end (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) to terminate the chain elongation.</div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Binding mode of Remdesivir into the SARS-CoV-2 nsp12 active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>). (left) nsp12 is shown as a molecular surface, colored according to the schematic diagram in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. For clarity, nsp7 and nsp8 cofactor have been removed. The template and primer RNA are shown as ribbon models and labeled. (right) Zoom-in of the nsp12 active site. The covalently bound monophosphate form of Remdesivir (slate) and the pyrophosphate group are shown as sticks. Magnesium ions are shown as green spheres. The RNA bases interacting with Remdesivir are shown as orange thin sticks, while protein residues are shown as white thick sticks. Hydrogen bonds are shown as black dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next to the covalently bound Remdesivir, there is the leaving pyrophosphate group; the two catalytic magnesium ions, coordinated by two aspartic acid residues Asp760 and Asp761, are also visible. Strikingly, nsp7 and nsp8 do not form interactions with RNA, although they are required for RNA binding by RdRp. Remdesivir is positioned at the center of the catalytic site, with the adenosine analogue forming stacking interactions with the upstream bases U-1 and A-1 of the primer and template strands. In addition, Remdesivir engages three strong H-bonds with the uridine bases Uâ1 and U+1, whereas the sugar 2â²-OH group forms a further H-bond with Asn691 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>A). The Asp623, Ser682, and Asn691 residues are involved in the recognition of the ribose hydroxyl groups of the incoming NTP and are responsible for the proper positioning of the ribose moiety. Such residues represent a conserved feature among viral RdRps.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Among them, Ser682, located on motif B, is considered a âfidelity checkpointâ because it is sensitive to the conformational changes of motif B upon binding of the NTP, which, in turn, triggers the active site closure.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> This structure shows for the first time a clear picture of how the template-primer RNA is recognized by the enzyme and how the covalently bound Remdesivir interacts with the active site residues.</div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. A close view of the covalently bound Remdesivir within the RdRp active site. (A) Remdesivir is incorporated into the primer strand and terminates chain elongation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>). (B) Remdesivir incorporation induces a mechanism of delayed-chain termination (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C2K">7C2K</a>). RNA is shown as orange ribbon model. For clarity, only key residues (thick white sticks) and bases (orange thin sticks) that interact with Remdesivir are shown. Hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A âdelayedâ chain termination has been proposed for Remdesivir, according to which the RNA synthesis is terminated after the addition of three more nucleotides (at position i+3, where i corresponds to the position of the first incorporated Remdesivir monophosphate);<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113,114)</a> this mechanism has been reported for SARS-CoV, MERS-CoV, and also SARS-CoV-2.<a onclick="showRef(event, 'ref111 ref115'); return false;" href="javascript:void(0);" class="ref ref111 ref115">(111,115)</a> This hypothesis is consistent with a recently released cryo-EM structure of the SARS-CoV-2 RdRp in complex with RNA, before and after RNA translocation (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C2K">7C2K</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BZF">7BZF</a>, respectively).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> In the pretranslocated catalytic complex structure, the incorporated Remdesivir has been translocated to the â1 position, whereas the 3â²-guanosine occupies the +1 position (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>B). Remdesivir engages four H-bonds, with the upstream G-2 base, the uridine base U-1, and with Ser759. The primer strand with the incorporated Remdesivir may translocate without obstruction to positions i+1, i+2, or i+3, allowing the incorporation of three subsequent nucleotides. However, at position i+4, a putative steric clash was postulated between the 1â²-CN substituent of Remdesivir and Ser861 along the RNA exit tunnel.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Ser861 is highly conserved among CoV RdRps, and its important role in Remdesivir induced RdRp inhibition was ultimately supported by mutagenesis studies, revealing that the Ser861Ala RdRp mutant yields a smaller fraction of i+3 termination compared with the wild-type RdRp, possibly supporting the steric clash hypothesis.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a></div><div class="NLM_p">The analysis of the pretranslocated complex cryo-EM maps revealed the two bound nsp8 protomers in two distinct states, named conformations I and II;<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> this latter resembles the previously observed âsliding polesâ (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT">6YYT</a>), whereas in conformation I, the nsp8 protomer, which lays on the fingers and interface domains, show an orientation change of about 45Â°. Taken together, the structural information reported so far suggest that, besides targeting nsp12, an alternative approach for RdRp inhibition would be the disruption of the polymerase complex integrity, for example, targeting the interaction between nsp8 and nsp12. Indeed, it would be interesting to explore the presence of âhot spotsâ, which are small areas of the proteinâprotein interface providing most of the binding energy. In fact, proteinâprotein interactions (PPIs) are today a validated target for drug discovery, and in this perspective, the structure of the replicating RdRp (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>) may offer hints for the development of peptidomimetics or small molecules capable of impairing the PPIs between nsp7-nsp8-nsp12. For instance, the recognition between the upper part of nsp8â1 and the fingers domain of nsp12 is mediated by a Î² sheet, suggesting the possibility to design small peptidomimetics capable of resembling a Î²-strand motif.</div><div class="NLM_p">Remdesivir was originally developed within antiviral research program against HCV and respiratory syncytial virus (RSV) but has shown a broad antiviral activity against other different viruses, including Dengue, parainfluenza type 3 virus (hPIV3), Ebola virus, and SARS-CoV with EC<sub>50</sub> in the sub-Î¼M range.<a onclick="showRef(event, 'ref108 ref117 ref118'); return false;" href="javascript:void(0);" class="ref ref108 ref117 ref118">(108,117,118)</a> Remdesivir showed efficacy in preclinical rhesus monkey models of Ebola virus infection;<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> it was evaluated in humans on a compassionate basis in some isolated cases of EVD<a onclick="showRef(event, 'ref119 ref120'); return false;" href="javascript:void(0);" class="ref ref119 ref120">(119,120)</a> and in a large-scale clinical trial for EVD conducted in Congo.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> Although the efficacy of Remdesivir was lower than the antibodies treatments tested, the survival rate was significantly higher than in the EVD outbreak.</div><div class="NLM_p">The efficacy of Remdesivir against CoVs was only recently reported.<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> In particular, it showed dose-dependent inhibition of SARS-CoV and MERS-CoV replication in primary human airway epithelial cell (HAE) cultures, with average EC<sub>50</sub> = 0.069 Î¼M (SARS-CoV) and 0.074 Î¼M (MERS-CoV).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> While typical chain terminators are excised by the viral exonuclease nsp14, Remdesivir seems to be able to escape the exonuclease activity. Two amino acid substitutions were found in the nsp12 polymerase providing low-level resistance to Remdesivir, corresponding to the SARS-CoV residues Phe480Leu and Val557Leu. Such residues are identical across CoVs and have been found to cause an impairing of fitness and virulence.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></div><div class="NLM_p">The possible structural and function implications of such resistance mutations have been recently analyzed.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> The two mutations do not have a direct impact on the catalytic site or substrate-binding pocket but rather cause minor structural alterations, which likely impact an NTP fidelity checkpoint performed by the polymerase before catalysis. Phe480 is located at the interface between the fingers and palm domains, facing a patch of hydrophobic residues that indirectly impact motif B. The mutation Phe480Leu likely reduces the interactions within the hydrophobic core, thereby reducing its structural rigidity. Therefore, one possible interpretation is that the phenylalanine to leucine mutation would have an impact on the positioning of the Ser682 of motif B, altering the fidelity checkpoint. On the other hand, Val557 is located at the end of motif F and forms a hydrophobic wall upon which the template base is stacked. The consequence of a valine to leucine mutation is a more extended hydrophobic side chain, possibly generating a steric hindrance with the template RNA. As a result, the RNA would be expected to be deviated from the groove, away from the serine of motif B. Remdesivir also showed potential to treat SARS-CoV-2 infections, with different studies reporting slightly different antiviral activities for this drug (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref125 ref126 ref127 ref128'); return false;" href="javascript:void(0);" class="ref ref125 ref126 ref127 ref128">(125â128)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Remdesivir Antiviral Activities against SARS-CoV-2 Measured in Different Cell Lines and Assays</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Â </th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">EC<sub>50</sub> (Î¼M)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center" char=".">plaque assay</th><th class="colsep0 rowsep0" align="center" char=".">genome copy number</th><th class="colsep0 rowsep0" align="center" char=".">log<sub>10</sub> TCID<sub>50</sub> (mL)</th><th class="colsep0 rowsep0" align="center" char=".">cytopathic effect (CPE)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vero E6</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.77<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">26.90<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">23.15<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">0.651<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Â </td><td class="colsep0 rowsep0" align="char" char=".">1.65<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">1.49<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">â¯â¯â¯â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Calu3 2B4</td><td class="colsep0 rowsep0" align="char" char=".">0.28<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">0.60<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5" align="left">â¯â¯â¯â¯â¯â¯â¯â¯</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HAE</td><td class="colsep0 rowsep0" align="char" char=".">0.010<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">Â </td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a>,</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a>,</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a>,</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">From ref <a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a>,</p></div></div></div><div class="NLM_p">The potency of Remdesivir is highly dependent on the intracellular concentration of the pharmacologically active triphosphate metabolite, which can vary in different cell systems. Indeed, such concentration is markedly higher in primary HAE cultures compared to human lung cells (Calu3 195 2B4) and monkey kidney cells (Vero E6). Therefore, the differences in EC<sub>50</sub> may be due to intrinsic differences of SARS-CoV-2 virus isolates, methods of quantification, and assay conditions. Because SARS-CoV-2 does not readily infect wild-type mice because of incompatibilities between virus spike and the murine orthologue of ACE2, which is needed for SARS-CoV-2 entry, a recombinant SARS-CoV-1 chimeric virus, encoding the SARS-CoV-2 RdRp, was engineered to rapidly assess the <i>in vivo</i> efficacy of Remdesivir in mice.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Remdesivir inhibited chimeric virus replication in a dose-dependent manner in human epatoma (Huh7) cells, with mean EC<sub>50</sub> = 3 nM. Moreover, Remdesivir treatment significantly ameliorated loss of pulmonary function in female C57Bl/6 Ces1câ/â (carboxyl esterase 1c deficient) mice administered 25 mg/kg Remdesivir subcutaneously 1 day postinfection (dpi) and BID thereafter. The transgenic mice model better recapitulates the DMPK profile of Remdesivir in humans. Indeed, carboxyl esterase 1c is a serum esterase which dramatically reduces half-life of Remdesivir and is absent in humans.<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> For instance, the plasma stability of Remdesivir was significantly improved in Ces1câ/â mice (<i>T</i><sub>1/2</sub> â¼ 25 min) with respect to wild-type mice (<i>T</i><sub>1/2</sub> < 5 min). <i>In vivo</i> experiments in mice infected with MERS-CoV proved the higher efficacy of Remdesivir than a combination of Lopinavir/Ritonavir and IFN-Î² in improving lung function.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Remdesivir <i>in vivo</i> efficacy against SARS-CoV-2 was gauged in rhesus macaques: therapeutic treatment started 12 h after inoculation with SARS-CoV-2 and continued once daily through 6 days post inoculation (dpi).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> One group of rhesus macaques was treated with a loading dose of 10 mg/kg Remdesivir, followed by a daily maintenance dose of 5 mg/kg, while the other group, serving as control, received a vehicle solution. Remdesivir was able to reduce virus titers in bronchoalveolar lavages already 12 h after the first treatment, also reducing clinical disease and damage to the lungs. The treatment resulted in reduced virus replication in the lower respiratory tract but not in the upper tract, suggesting the need to explore drug delivery strategies to improve Remdesivir distribution. Furthermore, the study suggested that treatment of patients with Remdesivir should be initiated early during infection.</div><div class="NLM_p">Remdesivir received the approval from the FDA for the treatment of hospitalized patients diagnosed with COVID-19.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></div><div class="NLM_p">The optimal duration of treatment is still under evaluation in clinical trials. Both 5-day and 10-day treatment durations are suggested, based on the severity of disease, with 200 mg iv on the first day, followed by 100 mg each day thereafter. The approval was granted on the basis of the available data from the Gileadâs SIMPLE trials (NCT04292899), the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by NIAID (NCT04280705), in patients with severe manifestations of COVID-19, and from the compassionate use program.</div><div class="NLM_p">The two SIMPLE trials evaluated the safety and efficacy of 5-day and 10-day dosing duration of Remdesivir in hospitalized patients with severe (first study) and moderate manifestations (second study) of COVID-19. The results from the first study showed that patients receiving a 10-day treatment course had a distribution in clinical status similar to those taking a 5-day treatment course.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Thus, priority should be given to a 5-day regimen for patients at the early stages of severe disease (patients receiving supplemental oxygen but not yet been intubated).<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> During the trial, the side effects were mild and, however, the absence of a placebo control group and the open-label design of this study did not permit an overall assessment of the benefit of Remdesivir. Another limitation is the lack of SARS-CoV-2 viral-load results during and after treatment due to the variability in local access to testing and practices across the global sites.</div><div class="NLM_p">The recently published results of the second SIMPLE trial study showed that among patients with moderate COVID-19, those randomized to a 5-day course of Remdesivir plus standard of care had higher odds of having an improvement in clinical status compared to those randomized to standard of care alone. Patients randomized to a 10-day course of Remdesivir did not show a statistically significant difference in clinical status compared to standard care at 11 days after initiation of treatment.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">The ACTT trial is a randomized, double-blind, placebo-controlled multicenter trial conducted in around 100 sites globally, evaluating the time to recovery of hospitalized adults diagnosed with COVID-19 up to day 29. The recently published results indicate that Remdesivir was superior to placebo in shortening the time to recovery; mortality was numerically lower in the Remdesivir group than in the placebo group (11.4% with Remdesivir and 15.2% with placebo by day 29).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> On the other hand, according to the published results of a trial carried out at 10 hospitals in Hubei, China, Remdesivir was not associated with statistically significant clinical benefits beyond those of standard of care treatment.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> However, the trial was underpowered because the study terminated earlier, before attaining the prespecified sample size, as there were no further patients meeting eligibility criteria.<a onclick="showRef(event, 'ref132 ref133'); return false;" href="javascript:void(0);" class="ref ref132 ref133">(132,133)</a></div><div class="NLM_p">It has to be noted how challenging it is provide robust findings when conducting trials during a pandemic: in this light, it is highly valuable to share results across multiple, even smaller, but high-quality studies. Some of the variation in results from the RCTs of Remdesivir could be due to differences in study design.<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> The overall results suggest that Remdesivir improves the recovery of patients hospitalized with COVID-19 and may prevent the progression to more severe respiratory disease.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">Moreover, there is room for further studies involving potential combination therapies with other antivirals and anti-inflammatory agents in appropriate regimen. In this regard, the ACTT3 trial (NCT04492475) will evaluate the combination of INF-Î²1a and Remdesivir compared to Remdesivir alone.</div><div class="NLM_p">Significant efforts are devoted to find an alternative route of administration to the currently iv used. Because the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection in early disease, an inhaled, nebulized formulation of Remdesivir is being seen as a valid noninvasive alternative. This should afford a more targeted administration with a lower systemic exposure, increasing the therapeutic index of the drug. Inhaled Remdesivir would be particularly suited for early stage COVID-19 patients who do not need to be hospitalized. Additional clinical trials (GS-US-553-9018 and NCT04539262) have thus been initiated to evaluate this inhaled formulation.</div><div class="NLM_p">Favipiravir contains a carboxamide moiety, reminiscent of guanine; it is mainly incorporated in the salvage pathways for purine nucleotides through the purine phosphoribosyltransferases, then it needs to be converted to its ribofuranosyl monophosphate <b>23</b> and to be further processed to the active triphosphate form <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Schematization of Favipiravir metabolic conversion. Favipiravir is first converted to its ribofuranosyl monophosphate derivative <b>23</b> and subsequently to the triphosphate active form <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This drug possesses a broad-spectrum activity toward RNA viruses.<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> High concentrations (EC<sub>50</sub> of 61.88 Î¼M) were required to reduce viral infection in Vero E6 cells infected with SARS-CoV-2.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Conversely, no apparent antiviral effect against SARS-CoV-2 was observed <i>in vitro</i> at concentrations under 100 Î¼M. Favipiravir is thought to act as chain terminator;<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> however, a putative mechanism of lethal mutagenesis has been proposed in the activity of this drug against influenza A (H1N1) viruses <i>in vitro</i>.<a onclick="showRef(event, 'ref136 ref137'); return false;" href="javascript:void(0);" class="ref ref136 ref137">(136,137)</a> Thus, antiviral nucleoside mechanisms of action may well vary from one virus to another. Favipiravir received approval in Japan for restricted use in uncomplicated influenza virus infections. The established dose for influenza in Japan is 1600 mg twice a day on day 1 followed by 600 mg twice a day for four days.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> An important feature of this drug is the apparent lack of resistant mutants in cell cultures, as well as in clinical trials. Some studies, however, found mutants of influenza A (H1N1)<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> and chikungunya virus<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> with reduced susceptibility to Favipiravir in cell cultures, suggesting the need to implement diagnostic approaches to control the emergence of Favipiravir resistance in clinical settings.</div><div class="NLM_p">Regarding the use of Favipiravir against COVID-19, to date, the only published clinical results appeared in a preprint, describing an open-label randomized trial carried out in China, comparing the efficacy and safety of Favipiravir (1600 mg BID first day, followed by 600 mg BID) and Arbidol (200 mg TID) to treat COVID-19 patients.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> The clinical recovery rate on day 7 did not significantly differ between the Favipiravir group and the Arbidol group; patients administered Favipiravir experienced faster resolution of fever and cough but similar rates of respiratory failure compared to the control group receiving Arbidol. On 1 June 2020, Russiaâs Ministry of Health temporarily approved a Favipiravir-based medication for use in patients with COVID-19. Favipiravir also received accelerated approval in India for the treatment of mild to moderate COVID-19 patients. Despite the quite fast approval, more robust data, coming from well-designed studies and possibly involving larger population, are needed to provide strong evidence about the clinical benefit of this drug.</div><div class="NLM_p">Galidesivirâs (Galidisvir, BCX4430) effect on the inhibition of RNA transcriptional activity was first assessed in a cell-free isolated HCV RdRp assay.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Galidesivir acts as a nonobligate RNA chain terminator; the switch from furanose to an azasugar is thought to alter the electrostatic interaction of the ring so that the viral RdRp is unable to add more than one or two further nucleotides.<a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a> Galidesivir was shown to possess weak antiviral activities against many RNA viruses, also including SARS-CoV (EC<sub>50</sub> = 57.7 Î¼M, measured by NR uptake assay) and MERS-CoV (EC<sub>50</sub> = 68.4 Î¼M assessed by high-content image analysis) and to protect nonhuman primates from lethal filovirus challenge.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> On the other hand, Galidesivir does not inhibit SARS-CoV-2 viral replication at concentrations below 100 Î¼M.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a> Notably, Galidesivir can be administered by both parenteral (im and ip) and oral routes.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> Galidesivir is efficiently taken up into cells and converted to the active triphosphate. In mouse, rat (both treated with 2 mg/kg), guinea pig (50 mg/kg), and cynomolgus macaque (20 mg/kg), Galidesivir DMPK is characterized by rapid clearance from the plasma with a <i>T</i><sub>1/2</sub> < 5 min. Conversely, the <i>T</i><sub>1/2</sub> of the active triphosphate form in the liver in rats (administered 30 mg/kg) is substantially longer at 6.2 h.<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> Despite the apparently weak anti-CoV activity, on 10 April 2020, the company BioCryst Pharmaceuticals, Inc. announced that a clinical trial will be conducted in Brazil to evaluate the antiviral efficacy of Galidesivir (administered (iv) in patients with SARS-CoV-2 infection (NCT03891420).</div><div class="NLM_p">The isobutyrate ester derivative <b>18</b> is the orally available prodrug of the ribonucleoside analogue <b>25</b> (Î²-<span class="smallcaps smallerCapital">d</span>-<i>N</i><sup>4</sup>-hydroxycytidine, NHC, EIDD-1931) (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>).</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of the prodrug <b>18</b> and its parent compound <b>25</b>. The isobutyrate ester prodrug moiety is shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>25</b> is a broad-spectrum antiviral agent with <i>in vitro</i> activity against multiple unrelated viruses, including influenza, RSV, chikungunya virus, Ebola, Venezuelan equine encephalitis virus, and Eastern equine encephalitis virus.<a onclick="showRef(event, 'ref98 ref143 ref144 ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref98 ref143 ref144 ref145 ref146">(98,143â146)</a> In a recent study, <b>25</b> displayed potent antiviral activity in two cell lines infected with SARS-CoV-2, namely Vero cells, with EC<sub>50</sub> = 0.3 Î¼M and low toxicity (CC<sub>50</sub> > 10 Î¼M), as well as Calu3 cells, with EC<sub>50</sub> = 0.08 Î¼M (plaque assay). Moreover, <b>25</b> turned out to be active against SARS-CoV (average EC<sub>50</sub> = 0.14 Î¼M), MERS-CoV (average EC<sub>50</sub> = 0.024 Î¼M), and SARS-CoV-2 in HAE cultures<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> and shows remarkable potency against a model CoV mouse hepatitis virus (MHV) bearing resistance mutations to Remdesivir.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Thus, the lack of cross-resistance suggests that <b>25</b> and Remdesivir may select for exclusive and mutually sensitizing resistance pathways.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a><b>25</b> was reported as a potent broad-spectrum inhibitor of respiratory viruses during a HTS campaign for influenza A virus (IAV) and RSV inhibitors. Derivative <b>25</b> was found to be active at concentrations in the nM to low-Î¼M range and selectivity indices (SIs) of â¥89 against a broad panel of RSV, IAV, and IBV laboratory strains and isolates.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> DMPK profiling for <b>25</b> demonstrated dose-dependent oral bioavailability of 56, 43, and 36% as well as <i>T</i><sub>1/2</sub> of 5.2, 3.2, and 2.7 h following oral administration of 50, 150, and 500 mg/kg, respectively. The dose dependency of prodrug exposure was consistently observed in lung tissue, however, the peak of <b>25</b> triphosphate concentrations saturated above the oral dose levels of approximately 150 mg/kg, suggesting an anabolism bottleneck of <b>25</b> in mouse respiratory tissue at higher prodrug levels. Lung tissue distribution assessment revealed sustained levels of the active triphosphate anabolite of approximately 10 nmol/g for over 8 h after administration of 150 and 500 mg/kg. Compound <b>25</b> was also well tolerated after extended dosing at 800 mg/kg of body weight/day. While PK properties were good in rodents, oral bioavailability of <b>25</b> in cynomolgus macaques was limited. This liability led to the development of the prodrug <b>18</b>, a 5â²-isobutyrate ester of <b>25</b>, which demonstrated good oral bioavailability in nonhuman primates. Upon intestinal absorption, <b>18</b> can be efficiently hydrolyzed to free <b>25</b>.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div><div class="NLM_p">Compound <b>18</b> has shown a significant reduction of the virus titer and ameliorated the pulmonary function in animal models of SARS-CoV and MERS-CoV infection.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> In prophylactic efficacy studies, mice were administered <b>18</b> at doses of 50, 150, or 500 mg/kg by oral gavage 2 h before infection with SARS-CoV and MERS-CoV, and then every 12 h. At the dose of 500 mg/kg, the most complete protection from disease was observed, therefore the same dose was used for therapeutic efficacy studies for both viruses, with treatment starting 2 h before infection or 12, 24, or 48 h post infection (hpi). The overall results showed that early treatment with <b>18</b> provides higher clinical benefit, highlighting a window of 24 to 48 h within which to treat emerging CoV infection in mice before peak replication. The decrease of MERS-CoV yields both <i>in vitro</i> and <i>in vivo</i> were correlated with an increase of the frequency of mutation in the viral RNA but not in the host RNA, highlighting a putative mechanism of lethal mutagenesis. The interesting preclinical results, suggesting that <b>25</b>/<b>18</b> might be a promising clinical candidate, prompted the FDA and the UK Medicines and Healthcare Products Regulatory Agency to quickly give approval to initiate human safety testing. Inhibitor <b>18</b> has been evaluated in a phase I trial, recently completed (NCT04392219), whereas in late May, two phase II randomized, double-blind, placebo-controlled trials were activated to evaluate the antiviral efficacy of <b>18</b> in adults diagnosed with COVID-19 (NCT04405570, NCT04405739). To this aim, the Drug Innovation Ventures at Emory (DRIVE) LLC, which developed the drug, partnered with the biotech company Ridgeback Biotherapeutics LP and with Merck to advance <b>18</b> through clinical development and to optimize the drugâs availability during the pandemic.</div><div class="NLM_p">The structural information on CoV viral proteins available to date, evolving at unprecedented speed, has prompted a number of <i>in silico</i> studies attempting to provide new lead compounds or to repurpose known drugs as possible antiviral agents against SARS-CoV-2.<a onclick="showRef(event, 'ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref149 ref150">(149,150)</a> However, experimental validation of the findings from such studies is still missing.</div><div class="NLM_p">So far, NIs reached the most advanced stages of development; even if the activity of the currently evaluated candidates could be improved by medicinal chemistry efforts, taking into account the wealth of structural information that become available. Conversely, NNIs have not yet been reported for SARS-CoV-2 and for other human pathogenic CoVs. NNIs generally show lower resistance barrier with respect to NI/NTP and are characterized by drug-like heterocyclic scaffold; thus, the identification of such agents may offer the advantage to handle molecules with higher optimization potential. However, no allosteric sites have been mapped on the RdRp protein surface for CoVs. Because viral RdRp shows the typical 3D right-hand shape, organized in palm, thumb, and fingers subdomains, the knowledge acquired on other RNA virus polymerase may allow similar considerations also for CoVs RdRp. In this regard, the best characterized viral RdRp is HCV NS5B that, despite working in absence of a primer in cell environment, shows four distinct binding sites for different classes of NNIs that are able to allosterically modulate the enzyme.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> A very large number of inhibitors, specifically binding one of these sites, have been reported, with some of them reaching late stages of clinical trials and also approval (for instance, Dasabuvir).</div><div class="NLM_p last">The integrated computational and experimental analysis of the nsp12 surface may point toward the discovery of potential allosteric sites. The functional replicase complex requires the tight association of nsp12 with cofactors nsp7 and nsp8, as shown by cryo-EM, therefore these interfaces could represent druggable sites to be explored.</div></div><div id="sec8" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Concluding Remarks</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47127" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47127" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Concurrent to the pandemic outbreak of the SARS-CoV-2 infection, the scientific community in collaboration with private and public funding organizations, started an unprecedented task force to find effective antiviral agents to stop the COVID-19 crisis. Impressive efforts in molecular biology, biochemistry, and structural biology of SARS-CoV-2 have indeed provided in a very short time a huge amount of data. Both biochemical assays and 3D structures have been made public for several viral and host proteins, whereas newly developed phenotypic screenings might allow rapid identification of alternative molecular targets and antiviral compounds.</div><div class="NLM_p">The knowledge acquired in the past years on other human pathogenic CoVs, such as SARS-CoV and MERS-CoV, to cite a few, can accelerate COVID-19 drug discovery. Considering the information available to date, 3CL<sup>pro</sup> and nsp12 RdRp are among the most characterized SARS-CoV-2 targets, from both a structural and biochemical perspective, prompting the discovery of specific inhibitors as promising anti-CoV agents. Moreover, 3CL<sup>pro</sup> and nsp12 RdRp show the highest degree of conservation across different CoVs, with 96% sequence identity between the SARS-CoV-2 and the SARS-CoV proteins, thus fostering the identification of broad-spectrum inhibitors.</div><div class="NLM_p">At a glance, NIs targeting the nsp12 RdRp appear to be the most advanced candidates in the therapeutic arsenal for COVID-19 treatment. Indeed, the broad-spectrum viral RdRp inhibitor Remdesivir has received EUA for the treatment of patients diagnosed with COVID-19, being approved as the first specific antiviral drug. Remdesivir is iv administered, and this can be considered a main drawback limiting a fast large-scale production and forcing its use in hospital setting. To overcome this hurdle, an inhalation formulation is currently under evaluation in phase I clinical trials. The second most advanced NI is the orally available derivative <b>18</b>, namely the 5-isobutyrate ester of <b>25</b>, acting as a broad RdRp inhibitor that could be administered outside of a clinical setting. Both <b>18</b> and <b>25</b> showed interesting preclinical results against CoVs in <i>in vitro</i>/<i>in vivo</i> models; thus, a phase I trial started in mid-April and two phase II randomized, double-blind, placebo-controlled trials launched in late May are currently ongoing. The findings collected from both clinical and preclinical studies highlight that these drugs should be administered as early as possible after infection, as they might not be as effective in the later stages of the disease. Notably, these are the most advanced compounds coming from repurposing of molecules already profiled for other viruses, indicating that there is still room for the identification and development of further CoV RdRp inhibitors. In fact, on the basis of the experience with other viral polymerases, an alternative route to NIs would be represented by the discovery of NNIs. Such an approach would require the identification of allosteric pockets, which, however, have not been validated so far, although many efforts are ongoing in this direction. The NNIs have several advantages comparable to the NIs, particularly the higher chemical diversity and likely po administration. A major drawback of these compounds could be instead the low genetic barrier for resistance and narrow-spectrum activity, as previously found for NNIs targeting other viruses such as HIV-1 and HCV.</div><div class="NLM_p">The second most studied essential viral target is the 3CL<sup>pro</sup>. This protease shows a unique substrate sequence specificity for Gln-Leu as P1âP2 and maintains an overall high degree of conservation across the CoV genus. Remarkably, the considerable amount of data generated on other human pathogenic CoVs together with the available structural data on SARS-CoV-2 3CL<sup>pro</sup> enable SBDD of novel inhibitors of this enzyme. In the initial effort to identify 3CL<sup>pro</sup> inhibitors, several research groups are mainly focusing on the development of peptidic covalent and covalent reversible inhibitors. However, the inhibitors reported so far do not significantly deviate from the sequence specificity, showing only small differences in P3/P4. The most relevant examples are the indole dipeptide derivatives with an aldehyde and ketone-based warheads, with compounds <b>5</b> and <b>8</b> resulting in the leading SARS-CoV-2 3CL<sup>pro</sup> inhibitors. Interestingly, these molecules are endowed with nM potency against the isolated target and in cell-based assays that are coupled to promising <i>in vivo</i> DMPK and safety properties. However, the efficacy of derivatives <b>5</b> and <b>8</b> in animal models are still unknown. It is worth noting that the prodrug of compound <b>8</b>, <i>i.e</i>., its phosphate ester <b>9</b>, has been reported as a suitable clinical candidate for iv administration, advanced into a phase Ib clinical trial. The additive/synergistic antiviral effect observed <i>in vitro</i> for the combination of <b>8</b> plus Remdesivir represents a promising result to plan possible multidrug regimen.</div><div class="NLM_p">Nonetheless, so far, there is no report describing peptidic inhibitors of CoVs 3CL<sup>pro</sup> that are orally available, an important feature required for the domestic management of a widespread infection such as COVID-19. Through additional approaches, such as fragment screenings and HTS of libraries of approved and investigational drugs, Bacalein, a flavone derivative widely employed in traditional Chinese medicine, has been described in a preprint as noncovalent active site inhibitor of 3CL<sup>pro</sup>, as shown by X-ray crystallography, able to selectively inhibit SARS-CoV-2 replication in cells. Due to the stage of the development of such molecules, it is, however, clear that current 3CL<sup>pro</sup> inhibitors cannot be considered a near-term strategy to tackle COVID-19, although they represent a suitable starting point for lead optimization programs.</div><div class="NLM_p">Finally, another putative emerging target is the PL<sup>pro</sup>, which is nevertheless a more challenging and underexplored protein for the identification of inhibitors. Furthermore, this protease is less conserved across the CoVs family, and for this reason it may be less attractive in view of possible future CoV outbreaks.</div><div class="NLM_p">A summary table reporting all inhibitors for each of the three targets, with references and the current stage of development, is provided (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. List of All the Compounds, Including Repurposed Drugs, Discussed in the Text</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">target</th><th class="colsep0 rowsep0" align="center">phase</th><th class="colsep0 rowsep0" align="center">clinical trial ID</th><th class="colsep0 rowsep0" align="center">refs</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref40 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref40 ref51 ref52">(40,51,52)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b> (GC376)</td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref43 ref56 ref57 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref43 ref56 ref57 ref59 ref60">(43,56,57,59,60)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">Ib</td><td class="colsep0 rowsep0" align="center">NCT04535167</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Boceprevir</td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref47 ref59'); return false;" href="javascript:void(0);" class="ref ref47 ref59">(47,59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Baicalein</td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Baicalin</td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center">Â </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ebselen</td><td class="colsep0 rowsep0" align="center">3CL<sup>pro</sup> PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref40 ref88'); return false;" href="javascript:void(0);" class="ref ref40 ref88">(40,88)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">PL<sup>pro</sup></td><td class="colsep0 rowsep0" align="center">preclinical</td><td class="colsep0 rowsep0" align="center">Â </td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Remdesivir</td><td class="colsep0 rowsep0" align="center">RdRp</td><td class="colsep0 rowsep0" align="center">FDAÂ approved<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a></td><td class="colsep0 rowsep0" align="center">NCT04292899, NCT04280705</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref109 ref110">(109,110)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Favipiravir</td><td class="colsep0 rowsep0" align="center">RdRp</td><td class="colsep0 rowsep0" align="center">III<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="center">ChiCTR2000030254</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Galidesivir</td><td class="colsep0 rowsep0" align="center">RdRp</td><td class="colsep0 rowsep0" align="center">I</td><td class="colsep0 rowsep0" align="center">NCT03891420</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref141 ref142'); return false;" href="javascript:void(0);" class="ref ref141 ref142">(141,142)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b> (EIDD-2801)</td><td class="colsep0 rowsep0" align="center">RdRp</td><td class="colsep0 rowsep0" align="center">II</td><td class="colsep0 rowsep0" align="center">NCT04405570, NCT04405739</td><td class="colsep0 rowsep0" align="center"><a onclick="showRef(event, 'ref98 ref143 ref144 ref145 ref146'); return false;" href="javascript:void(0);" class="ref ref98 ref143 ref144 ref145 ref146">(98,143â146)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Marketed for HCV.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Phase II for influenza fever (NCT03830684).</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Phase I as an ingredient of Moist Exposed Burn Ointment (MEBO) for the treatment of pain and re-epithelization (NCT03728244, NCT02737943).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Phase II for brain disorders.</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">Marketed for influenza virus infections.</p></div></div></div><div class="NLM_p">The current scenario has emphasized that CoV infection coming from the spillover such as MERS, SARS-CoV, and SARS-CoV-2 could benefit from broad-spectrum antivirals, which today is still an unmet necessity. Therefore, stimulating research efforts toward this direction is of pivotal importance in order to face potential future pandemics.</div><div class="NLM_p last">Looking at the current panorama, the drug repurposing approach identified one approved drug, Remdesivir, and a covalent inhibitor with the hydroxyl methylketone prodrug, which entered in phase I. Other compounds are under investigation but lagging behind in their development, and there is no certainty that they will conclude the process. Instead, the structural information acquired on the targets will be of great inspiration for the medicinal chemists that will design <i>ad hoc</i> molecules, especially for the proteases where this approach has been successful for other viral infections. The antiviral approach put in place for this emergency will also be very important for future pandemics.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12"><a href="/doi/suppl/10.1021/acs.jmedchem.0c01140" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c01140?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01140</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical structure of Rupintrivir; additional repurposed 3CL<sup>pro</sup> inhibitors reported in ref <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> of main text (<a href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf">jm0c01140_si_001.pdf (101.47 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01140" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vincenzo Summa</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, University of Naples âFederico
IIâ, via D. Montesano 49, 80131 Napoli, Italy</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6288-2681" title="Orcid link">http://orcid.org/0000-0002-6288-2681</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#582e31363b3d362237762b2d353539182d3631363976312c"><span class="__cf_email__" data-cfemail="9fe9f6f1fcfaf1e5f0b1eceaf2f2fedfeaf1f6f1feb1f6eb">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rolando Cannalire</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, University of Naples âFederico
IIâ, via D. Montesano 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Cerchia</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, University of Naples âFederico
IIâ, via D. Montesano 49, 80131 Napoli, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea R. Beccari</span> - <span class="hlFld-Affiliation affiliation">DompÃ©
Farmaceutici SpA, via Campo di Pile, 67100 LâAquila, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesco Saverio Di Leva</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy, University of Naples âFederico
IIâ, via D. Montesano 49, 80131 Napoli, Italy</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>R.C. and C.C. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18527" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18527" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Rolando Cannalire</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=bio1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Rolando Cannalire received his Ph.D. in Chemistry and Technology of Drug (curriculum Medicinal Chemistry) at the University of Perugia in 2016, under the supervision of Prof. V. Cecchetti. During his Ph.D. course, he spent research periods in the laboratories of Prof. M. Viveiros at Universidade Nova de Lisboa (Portugal) and of Prof. S. Otto at University of Groningen (Netherlands). From 2016 to mid-2019, he held Postdoctoral Fellowships at the Department of Pharmaceutical Sciences of the University of Perugia. Since May 2019, he has been appointed Assistant Professor at the Department of Pharmacy of the University of Naples Federico II. His main research interests concern the design and synthesis of antiviral (mainly RNA viruses) and antibacterial small molecules, antitumor agents, kinase inhibitors, and development of innovative synthetic methodologies.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Carmen Cerchia</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=bio2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Carmen Cerchia obtained the Ph.D. in Pharmaceutical Sciences in 2016 at the Department of Pharmacy, University of Naples Federico II, under the supervision of Prof. Antonio Lavecchia. She then joined the group of Prof. JÃ¼rgen Bajorath at the Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-UniversitÃ¤t, Bonn, for one year, as visiting researcher. She is currently a Postdoctoral Fellow at the Department of Pharmacy, University of Naples Federico II. Her research interests are in the field of drug discovery and computational chemistry, in particular, large-scale compound data mining and virtual screening methodologies applied to biological targets involved in cancer and metabolic diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Andrea R. Beccari</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=bio3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Andrea Beccari is currently responsible for the Business Unit EXSCALATE. He started his career as drug designer in a pharmaceutical company in The Netherlands. Back in Italy, first, he led the drug discovery programs and then also became responsible of the technological platform. He has developed, in the last 10 years, proprietary computational tools now all integrated in the EXSCALATE platform. He was promoter and coordinator of the Italian Drug Discovery Network and cofounder and member of the board of the Avicenna Alliance (Brussel). He was originator and chairman of the Computational Driven Drug Discovery series of meetings. He has co-organized several initiatives with the European commission and parliament promoting the use of in silico simulations to increase the awareness towards the potentiality of high performance computing in healthcare.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Francesco Saverio Di Leva</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=bio4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Francesco Saverio Di Leva received his Ph.D. in Drug Discovery from the Italian Institute of Technology in Genoa (Italy) under the Supervision of Prof. Andrea Cavalli. During his Ph.D. course, he spent 18 months in the laboratories of Prof. Michele Parrinello at USI Lugano (Switzerland). From 2014 to 2017, he held a Postdoctoral Fellowship at the Department of Pharmacy of the University of Naples Federico II, where he is Assistant Professor since December 2017. He has been awarded with the Medicinal Chemistry Division Prize 2020 of the Italian Chemical Society. His research interests focus on the identification, through bioinformatic methodologies and biosimulations, of either therapeutic or diagnostic agents for cancer and for the treatment of infectious and metabolic diseases.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Vincenzo Summa</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=bio5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last">Vincenzo Summa obtained the Ph.D. in Organic Chemistry from the University of Wuppertal. In 1996, he joined Merck Research LaboratoryâItaly (IRBM). He served as Director in the Medicinal Chemistry Department, leading the team that discovered Isentress, the first-in-class HIV integrase inhibitor (Galien Prize USA and Italy for the best pharmaceutical agentâ2008), and Grazoprevir, a pangenotype HCV protease inhibitor. For the discovery of Isentress and Grazoprevir, he was awarded as Hero of Chemistry from ACS in 2013 and 2017, respectively. In 2009, he became a cofounder of IRBM Science Park, the spinoff of Merck Research LaboratoryâItaly, and Vice President of Drug Discovery. Since 2019, he is full Professor of Medicinal Chemistry at the Department of Pharmacy, University of Naples Federico II. His research interests focus on identification of anti-infectious and anticancer agents.</p></figure></div><div class="ack" id="ACK-d7e3629-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21881" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21881" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">R.C. acknowledges MIUR-Ministero dellâIstruzione, dellâUniversitÃ  e della Ricerca (Italian Ministry of Education, University and Research), PON R&I 2014-2020-AIM (Attraction and International Mobility), project AIM1873131, Num. AttivitÃ  2, Linea 2.1. This research was conducted under the project âEXaSCale smArt pLatform Against paThogEns for Corona VirusâExscalate4CoVâ founded by the EUâs H2020-SC1-PHE-CORONAVIRUS-2020 call, grant no. 101003551.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">3CL<sup>pro</sup></td><td class="NLM_def"><p class="first last">3-chymotrypsin-like protease</p></td></tr><tr><td class="NLM_term">ACE2</td><td class="NLM_def"><p class="first last">angiotensin-converting enzyme II</p></td></tr><tr><td class="NLM_term">CatB/L</td><td class="NLM_def"><p class="first last">cathepsinsB/L</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">circular dichroism</p></td></tr><tr><td class="NLM_term">CoV</td><td class="NLM_def"><p class="first last">coronavirus</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease 2019</p></td></tr><tr><td class="NLM_term">CPE</td><td class="NLM_def"><p class="first last">cytopathic effect</p></td></tr><tr><td class="NLM_term">E</td><td class="NLM_def"><p class="first last">envelope protein</p></td></tr><tr><td class="NLM_term">EVD</td><td class="NLM_def"><p class="first last">Ebola virus disease</p></td></tr><tr><td class="NLM_term">EVs</td><td class="NLM_def"><p class="first last">enteroviruses</p></td></tr><tr><td class="NLM_term">FIP</td><td class="NLM_def"><p class="first last">feline infectious peritonitis</p></td></tr><tr><td class="NLM_term">HAE</td><td class="NLM_def"><p class="first last">human airway epithelial cells</p></td></tr><tr><td class="NLM_term">HCoV</td><td class="NLM_def"><p class="first last">human coronavirus</p></td></tr><tr><td class="NLM_term">HCV</td><td class="NLM_def"><p class="first last">hepatitis C virus</p></td></tr><tr><td class="NLM_term">HIV</td><td class="NLM_def"><p class="first last">human immune deficiency virus</p></td></tr><tr><td class="NLM_term">hpi</td><td class="NLM_def"><p class="first last">hours post infection</p></td></tr><tr><td class="NLM_term">hPIV3</td><td class="NLM_def"><p class="first last">parainfluenza type 3 virus</p></td></tr><tr><td class="NLM_term">HRV</td><td class="NLM_def"><p class="first last">human rhinovirus</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high-throughput screen</p></td></tr><tr><td class="NLM_term">IAV</td><td class="NLM_def"><p class="first last">influenza A virus</p></td></tr><tr><td class="NLM_term">MERS</td><td class="NLM_def"><p class="first last">Middle East respiratory syndrome</p></td></tr><tr><td class="NLM_term">SARS</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome</p></td></tr><tr><td class="NLM_term">MERS-CoV</td><td class="NLM_def"><p class="first last">Middle East respiratory syndrome coronavirus</p></td></tr><tr><td class="NLM_term">MHV</td><td class="NLM_def"><p class="first last">mouse hepatitis virus</p></td></tr><tr><td class="NLM_term">N</td><td class="NLM_def"><p class="first last">nucleocapsid protein</p></td></tr><tr><td class="NLM_term">NIAID</td><td class="NLM_def"><p class="first last">National Institute of Allergy and Infectious Diseases</p></td></tr><tr><td class="NLM_term">Nsp</td><td class="NLM_def"><p class="first last">nonstructural proteins</p></td></tr><tr><td class="NLM_term">ORF</td><td class="NLM_def"><p class="first last">open reading frame</p></td></tr><tr><td class="NLM_term">PL<sup>pro</sup></td><td class="NLM_def"><p class="first last">papain-like protease</p></td></tr><tr><td class="NLM_term">PPIs</td><td class="NLM_def"><p class="first last">proteinâprotein interactions</p></td></tr><tr><td class="NLM_term">RBD</td><td class="NLM_def"><p class="first last">receptor-binding domain</p></td></tr><tr><td class="NLM_term">RdRp</td><td class="NLM_def"><p class="first last">RNA-dependent RNA polymerase</p></td></tr><tr><td class="NLM_term">RSV</td><td class="NLM_def"><p class="first last">respiratory syncytial virus</p></td></tr><tr><td class="NLM_term">RTC</td><td class="NLM_def"><p class="first last">replicase/transcriptase complex</p></td></tr><tr><td class="NLM_term">S</td><td class="NLM_def"><p class="first last">spike protein</p></td></tr><tr><td class="NLM_term">SARS-CoV</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus</p></td></tr><tr><td class="NLM_term">SARS-CoV-2</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus 2</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">transmembrane domain</p></td></tr><tr><td class="NLM_term">TMPRSS2</td><td class="NLM_def"><p class="first last">transmembrane protease serine 2</p></td></tr><tr><td class="NLM_term">UTR</td><td class="NLM_def"><p class="first last">untranslated regions</p></td></tr><tr><td class="NLM_term">WHO</td><td class="NLM_def"><p class="first last">World Health Organization</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11646" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11646" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 151 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Ten Threats to Global Health
in 2019</i>; <span class="NLM_publisher-name">World
Health Organization</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/emergencies/ten-threats-to-global-health-in-2019" class="extLink">https://www.who.int/emergencies/ten-threats-to-global-health-in-2019</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Ten+Threats+to+Global+Health%0Ain+2019%3B+World%0AHealth+Organization%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Femergencies%2Ften-threats-to-global-health-in-2019+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTen%2520Threats%2520to%2520Global%2520Health%250Ain%25202019%26pub%3DWorld%250AHealth%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span> <i>Prioritizing Diseases for
Research and Development in Emergency Contexts</i>; <span class="NLM_publisher-name">World Health Organization</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-context" class="extLink">https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-context</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Prioritizing+Diseases+for%0AResearch+and+Development+in+Emergency+Contexts%3B+World+Health+Organization%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Factivities%2Fprioritizing-diseases-for-research-and-development-in-emergency-context+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPrioritizing%2520Diseases%2520for%250AResearch%2520and%2520Development%2520in%2520Emergency%2520Contexts%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span> <span> </span><span class="NLM_article-title">A New Coronavirus Associated with Human Respiratory Disease in China</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">265</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2008-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2008-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32015508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=265-269&author=F.+Wuauthor=S.+Zhaoauthor=B.+Yuauthor=Y.+M.+Chenauthor=W.+Wangauthor=Z.+G.+Songauthor=Y.+Huauthor=Z.+W.+Taoauthor=J.+H.+Tianauthor=Y.+Y.+Peiauthor=M.+L.+Yuanauthor=Y.+L.+Zhangauthor=F.+H.+Daiauthor=Y.+Liuauthor=Q.+M.+Wangauthor=J.+J.+Zhengauthor=L.+Xuauthor=E.+C.+Holmesauthor=Y.+Z.+Zhang&title=A+New+Coronavirus+Associated+with+Human+Respiratory+Disease+in+China&doi=10.1038%2Fs41586-020-2008-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A new coronavirus associated with human respiratory disease in China</span></div><div class="casAuthors">Wu, Fan; Zhao, Su; Yu, Bin; Chen, Yan-Mei; Wang, Wen; Song, Zhi-Gang; Hu, Yi; Tao, Zhao-Wu; Tian, Jun-Hua; Pei, Yuan-Yuan; Yuan, Ming-Li; Zhang, Yu-Ling; Dai, Fa-Hui; Liu, Yi; Wang, Qi-Min; Zheng, Jiao-Jiao; Xu, Lin; Holmes, Edward C.; Zhang, Yong-Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health.  Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty.  A severe respiratory disease was recently reported in Wuhan, Hubei province, China.  As of 25 Jan. 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 Dec. 2019.  Epidemiol. investigations have suggested that the outbreak was assocd. with a seafood market in Wuhan.  Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 Dec. 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough.  Metagenomic RNA sequencing of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV').  Phylogenetic anal. of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China.  This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5h_VHfuDuTbVg90H21EOLACvtfcHk0lg-jYdCSLGq1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D&md5=0163a684829e880a0c3347e19f0ce52a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2008-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2008-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DZ.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DZ.%2BW.%26aulast%3DTian%26aufirst%3DJ.%2BH.%26aulast%3DPei%26aufirst%3DY.%2BY.%26aulast%3DYuan%26aufirst%3DM.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DF.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26atitle%3DA%2520New%2520Coronavirus%2520Associated%2520with%2520Human%2520Respiratory%2520Disease%2520in%2520China%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D265%26epage%3D269%26doi%3D10.1038%2Fs41586-020-2008-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">A Novel Coronavirus from Patients with Pneumonia in China, 2019</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">733</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2001017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31978945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&author=N.+Zhuauthor=D.+Zhangauthor=W.+Wangauthor=X.+Liauthor=B.+Yangauthor=J.+Songauthor=X.+Zhaoauthor=B.+Huangauthor=W.+Shiauthor=R.+Luauthor=P.+Niuauthor=F.+Zhanauthor=X.+Maauthor=D.+Wangauthor=W.+Xuauthor=G.+Wuauthor=G.+F.+Gaoauthor=W.+Tan&title=A+Novel+Coronavirus+from+Patients+with+Pneumonia+in+China%2C+2019&doi=10.1056%2FNEJMoa2001017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A novel coronavirus from patients with pneumonia in China, 2019</span></div><div class="casAuthors">Zhu, Na; Zhang, Dingyu; Wang, Wenling; Li, Xingwang; Yang, Bo; Song, Jingdong; Zhao, Xiang; Huang, Baoying; Shi, Weifeng; Lu, Roujian; Niu, Peihua; Zhan, Faxian; Ma, Xuejun; Wang, Dayan; Xu, Wenbo; Wu, Guizhen; Gao, George F.; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In Dec. 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.  A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia.  Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily.  Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans.  Enhanced surveillance and further investigation are ongoing.  Complete genome sequences of the three novel coronaviruses were submitted to GISAID (BetaCoV/Wuhan/ IVDC-HB-01/2019, accession ID: EPI_ISL_402119; BetaCoV/Wuhan/IVDC-HB-04/2020, accession ID: EPI_ISL_402120; BetaCoV/Wuhan/IVDC-HB-05/2019, accession ID: EPI_ISL_402121).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoibbAn_VqfXbVg90H21EOLACvtfcHk0lg-jYdCSLGq1w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D&md5=73cc5c839e1e934da69b39537063b7b3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001017%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DA%2520Novel%2520Coronavirus%2520from%2520Patients%2520with%2520Pneumonia%2520in%2520China%252C%25202019%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D727%26epage%3D733%26doi%3D10.1056%2FNEJMoa2001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span> <i>Coronavirus (COVID-19) Events As They Happen</i>; <span class="NLM_publisher-name">World Health Organisation</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen" class="extLink">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Coronavirus+%28COVID-19%29+Events+As+They+Happen%3B+World+Health+Organisation%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Fevents-as-they-happen+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Events%2520As%2520They%2520Happen%26pub%3DWorld%2520Health%2520Organisation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riddle, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeching, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamer, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribble, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, C. D.</span></span> <span> </span><span class="NLM_article-title">2020 Hubei Lockdowns</span>. <i>J. Travel Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">S63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fjtm%2Ftax026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=S63&author=M.+S.+Riddleauthor=B.+A.+Connorauthor=N.+J.+Beechingauthor=H.+L.+DuPontauthor=D.+H.+Hamerauthor=P.+Kozarskyauthor=M.+Libmanauthor=R.+Steffenauthor=D.+Taylorauthor=D.+R.+Tribbleauthor=J.+Vilaauthor=P.+Zangerauthor=C.+D.+Ericsson&title=2020+Hubei+Lockdowns"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjtm%2Ftax026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjtm%252Ftax026%26sid%3Dliteratum%253Aachs%26aulast%3DRiddle%26aufirst%3DM.%2BS.%26aulast%3DConnor%26aufirst%3DB.%2BA.%26aulast%3DBeeching%26aufirst%3DN.%2BJ.%26aulast%3DDuPont%26aufirst%3DH.%2BL.%26aulast%3DHamer%26aufirst%3DD.%2BH.%26aulast%3DKozarsky%26aufirst%3DP.%26aulast%3DLibman%26aufirst%3DM.%26aulast%3DSteffen%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DTribble%26aufirst%3DD.%2BR.%26aulast%3DVila%26aufirst%3DJ.%26aulast%3DZanger%26aufirst%3DP.%26aulast%3DEricsson%26aufirst%3DC.%2BD.%26atitle%3D2020%2520Hubei%2520Lockdowns%26jtitle%3DJ.%2520Travel%2520Med.%26date%3D2020%26volume%3D24%26spage%3DS63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saglietto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAscenzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoccai, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ferrari, G. M.</span></span> <span> </span><span class="NLM_article-title">COVID-19 in Europe: The Italian Lesson</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1110</span>â <span class="NLM_lpage">1111</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30690-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2930690-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32220279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls12qsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1110-1111&author=A.+Sagliettoauthor=F.+D%E2%80%99Ascenzoauthor=G.+B.+Zoccaiauthor=G.+M.+De+Ferrari&title=COVID-19+in+Europe%3A+The+Italian+Lesson&doi=10.1016%2FS0140-6736%2820%2930690-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 in Europe: the Italian lesson</span></div><div class="casAuthors">Saglietto, Andrea; D'Ascenzo, Fabrizio; Zoccai, Giuseppe Biondi; De Ferrari, Gaetano Maria</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10230</span>),
    <span class="NLM_cas:pages">1110-1111</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An editorial regarding a lesson learned in Italy to control SARS-CoV-2 spread.  Italy's implementation of restrictive measures to slow virus spread resulted in a lowering of actual reported COVID-19 cases when compared to projections.  The authors suggest that all other European nations implement similar restrictions to slow the spread of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKrppshdFKPrVg90H21EOLACvtfcHk0liqLcsXr1qtAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls12qsLY%253D&md5=493d2752bf7ad2422b025c5c7ecdf4e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930690-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930690-5%26sid%3Dliteratum%253Aachs%26aulast%3DSaglietto%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Ascenzo%26aufirst%3DF.%26aulast%3DZoccai%26aufirst%3DG.%2BB.%26aulast%3DDe%2BFerrari%26aufirst%3DG.%2BM.%26atitle%3DCOVID-19%2520in%2520Europe%253A%2520The%2520Italian%2520Lesson%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1110%26epage%3D1111%26doi%3D10.1016%2FS0140-6736%2820%2930690-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remuzzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuzzi, G.</span></span> <span> </span><span class="NLM_article-title">COVID-19 and Italy: What Next?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1225</span>â <span class="NLM_lpage">1228</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30627-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2930627-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32178769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFeqsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1225-1228&author=A.+Remuzziauthor=G.+Remuzzi&title=COVID-19+and+Italy%3A+What+Next%3F&doi=10.1016%2FS0140-6736%2820%2930627-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 and Italy: what next?</span></div><div class="casAuthors">Remuzzi, Andrea; Remuzzi, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10231</span>),
    <span class="NLM_cas:pages">1225-1228</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting >100 countries in a matter of weeks.  A global response to prep. health systems worldwide is imperative.  Although containment measures in China have reduced new cases by >90%, this redn. is not the case elsewhere, and Italy has been particularly affected.  There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia.  The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been 9-11% of patients who are actively infected.  The no. of patients infected since Feb 21 in Italy closely follows an exponential trend.  If this trend continues for 1 more week, there will be 30,000 infected patients.  Intensive care units will then be at max. capacity; â¤4000 hospital beds will be needed by mid-Apr., 2020.  Our anal. might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks.  If the Italian outbreak follows a similar trend as in Hubei province, China, the no. of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend.  However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYR_x7MkYturVg90H21EOLACvtfcHk0liqLcsXr1qtAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFeqsLw%253D&md5=eae507202578d450558f59f712187e4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930627-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930627-9%26sid%3Dliteratum%253Aachs%26aulast%3DRemuzzi%26aufirst%3DA.%26aulast%3DRemuzzi%26aufirst%3DG.%26atitle%3DCOVID-19%2520and%2520Italy%253A%2520What%2520Next%253F%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1225%26epage%3D1228%26doi%3D10.1016%2FS0140-6736%2820%2930627-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewnard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, N. C.</span></span> <span> </span><span class="NLM_article-title">Scientific and Ethical Basis for Social-Distancing Interventions against COVID-19</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">631</span>â <span class="NLM_lpage">633</span>, <span class="refDoi">Â DOI: 10.1016/S1473-3099(20)30190-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS1473-3099%2820%2930190-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32213329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1Ggs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=631-633&author=J.+A.+Lewnardauthor=N.+C.+Lo&title=Scientific+and+Ethical+Basis+for+Social-Distancing+Interventions+against+COVID-19&doi=10.1016%2FS1473-3099%2820%2930190-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and ethical basis for social-distancing interventions against COVID-19</span></div><div class="casAuthors">Lewnard, Joseph A.; Lo, Nathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-633</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A correspondence on the article by Joel Koo et al (2020) describing the effects of social distancing to slow COVID-19 spread.  The authors review the socioeconomic effects that social distancing may have and the ethics of imposing such restrictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIUrokr5TVurVg90H21EOLACvtfcHk0lgiZVf8_SaFzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1Ggs7g%253D&md5=f13af04567cb6cc9851061044a1bcdf4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930190-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930190-0%26sid%3Dliteratum%253Aachs%26aulast%3DLewnard%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DN.%2BC.%26atitle%3DScientific%2520and%2520Ethical%2520Basis%2520for%2520Social-Distancing%2520Interventions%2520against%2520COVID-19%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D631%26epage%3D633%26doi%3D10.1016%2FS1473-3099%2820%2930190-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pushpakom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilliams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanseau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Drug Repurposing: Progress, Challenges and Recommendations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2018.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnrd.2018.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30310233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=41-58&author=S.+Pushpakomauthor=F.+Iorioauthor=P.+A.+Eyersauthor=K.+J.+Escottauthor=S.+Hopperauthor=A.+Wellsauthor=A.+Doigauthor=T.+Guilliamsauthor=J.+Latimerauthor=C.+McNameeauthor=A.+Norrisauthor=P.+Sanseauauthor=D.+Cavallaauthor=M.+Pirmohamed&title=Drug+Repurposing%3A+Progress%2C+Challenges+and+Recommendations&doi=10.1038%2Fnrd.2018.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing: progress, challenges and recommendations</span></div><div class="casAuthors">Pushpakom, Sudeep; Iorio, Francesco; Eyers, Patrick A.; Escott, K. Jane; Hopper, Shirley; Wells, Andrew; Doig, Andrew; Guilliams, Tim; Latimer, Joanna; McNamee, Christine; Norris, Alan; Sanseau, Philippe; Cavalla, David; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-58</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compds., with potentially lower overall development costs and shorter development timelines.  Various data-driven and exptl. approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technol. and regulatory challenges that need to be addressed.  In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUl_N5c2iDerVg90H21EOLACvtfcHk0lgiZVf8_SaFzA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I&md5=6bcc8f26828414de02564494fb4d3296</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.168%26sid%3Dliteratum%253Aachs%26aulast%3DPushpakom%26aufirst%3DS.%26aulast%3DIorio%26aufirst%3DF.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DEscott%26aufirst%3DK.%2BJ.%26aulast%3DHopper%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DDoig%26aufirst%3DA.%26aulast%3DGuilliams%26aufirst%3DT.%26aulast%3DLatimer%26aufirst%3DJ.%26aulast%3DMcNamee%26aufirst%3DC.%26aulast%3DNorris%26aufirst%3DA.%26aulast%3DSanseau%26aufirst%3DP.%26aulast%3DCavalla%26aufirst%3DD.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DDrug%2520Repurposing%253A%2520Progress%252C%2520Challenges%2520and%2520Recommendations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D41%26epage%3D58%26doi%3D10.1038%2Fnrd.2018.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alpern, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertner, E.</span></span> <span> </span><span class="NLM_article-title">Off-Label Therapies for COVID-19âAre We All In This Together?</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">182</span>â <span class="NLM_lpage">184</span>, <span class="refDoi">Â DOI: 10.1002/cpt.1862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fcpt.1862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32311763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWnu7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=182-184&author=J.+D.+Alpernauthor=E.+Gertner&title=Off-Label+Therapies+for+COVID-19%E2%80%94Are+We+All+In+This+Together%3F&doi=10.1002%2Fcpt.1862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Off-Label Therapies for COVID-19-Are We All In This Together?</span></div><div class="casAuthors">Alpern, Jonathan D.; Gertner, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">182-184</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) continues to spread rapidly outside of mainland China. As of Apr. 6, 2020, there are over 300,000 cases and 10,000 deaths in the United States.  Effective therapies for the novel coronavirus are urgently needed and over 200 clin. trials are now underway across the globe.  Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial - the SOLIDARITY trial - to study the effect of drugs that have been identified as promising based on in vitro data and the early clin. experience with coronavirus disease 2019 (COVID-19): remdesivir, lopinavir, and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine (Plaquenil).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXRMw42SUJbVg90H21EOLACvtfcHk0lgXkUIrHPo2rQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWnu7%252FK&md5=249302a89d30e1b2a171d60b826fd975</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1862%26sid%3Dliteratum%253Aachs%26aulast%3DAlpern%26aufirst%3DJ.%2BD.%26aulast%3DGertner%26aufirst%3DE.%26atitle%3DOff-Label%2520Therapies%2520for%2520COVID-19%25E2%2580%2594Are%2520We%2520All%2520In%2520This%2520Together%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D182%26epage%3D184%26doi%3D10.1002%2Fcpt.1862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span> <i>Remdesivir Emergency Use Authorization</i>; <span class="NLM_publisher-name">Gilead Sciences, Inc.</span>, <span class="NLM_year">2020</span>; <a href="https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fda-authorization-letter_01may2020-old.pdf?la=en&amp;hash=2AE25800C7C9612D2F67F28D3F3B9921" class="extLink">https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fda-authorization-letter_01may2020-old.pdf?la=en&hash=2AE25800C7C9612D2F67F28D3F3B9921</a> (accessed 2020-08-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Remdesivir+Emergency+Use+Authorization%3B+Gilead+Sciences%2C+Inc.%2C+2020%3B+https%3A%2F%2Fwww.gilead.com%2F-%2Fmedia%2Ffiles%2Fpdfs%2Fremdesivir%2Feua-fda-authorization-letter_01may2020-old.pdf%3Fla%3Den%26hash%3D2AE25800C7C9612D2F67F28D3F3B9921+%28accessed+2020-08-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRemdesivir%2520Emergency%2520Use%2520Authorization%26pub%3DGilead%2520Sciences%252C%2520Inc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, D. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montejano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahass, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SenGupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MuÃ±oz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for 5 or 10 Days in Patients with Severe Covid-19</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2015301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2015301" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+D.+Goldmanauthor=D.+C.+B.+Lyeauthor=D.+S.+Huiauthor=K.+M.+Marksauthor=R.+Brunoauthor=R.+Montejanoauthor=C.+D.+Spinnerauthor=M.+Galliauthor=M.-Y.+Ahnauthor=R.+G.+Nahassauthor=Y.-S.+Chenauthor=D.+SenGuptaauthor=R.+H.+Hylandauthor=A.+O.+Osinusiauthor=H.+Caoauthor=C.+Blairauthor=X.+Weiauthor=A.+Gaggarauthor=D.+M.+Brainardauthor=W.+J.+Townerauthor=J.+Mu%C3%B1ozauthor=K.+M.+Mullaneauthor=F.+M.+Martyauthor=K.+T.+Tashimaauthor=G.+Diazauthor=A.+Subramanian&title=Remdesivir+for+5+or+10+Days+in+Patients+with+Severe+Covid-19&doi=10.1056%2FNEJMoa2015301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2015301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2015301%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BD.%26aulast%3DLye%26aufirst%3DD.%2BC.%2BB.%26aulast%3DHui%26aufirst%3DD.%2BS.%26aulast%3DMarks%26aufirst%3DK.%2BM.%26aulast%3DBruno%26aufirst%3DR.%26aulast%3DMontejano%26aufirst%3DR.%26aulast%3DSpinner%26aufirst%3DC.%2BD.%26aulast%3DGalli%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DChen%26aufirst%3DY.-S.%26aulast%3DSenGupta%26aufirst%3DD.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DOsinusi%26aufirst%3DA.%2BO.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DJ.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DTashima%26aufirst%3DK.%2BT.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DSubramanian%26aufirst%3DA.%26atitle%3DRemdesivir%2520for%25205%2520or%252010%2520Days%2520in%2520Patients%2520with%2520Severe%2520Covid-19%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMoa2015301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, M. S.</span></span> <span> </span><span class="NLM_article-title">Remdesivir â An Important First Step</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe2018715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMe2018715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32459913" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Dolinauthor=M.+S.+Hirsch&title=Remdesivir+%E2%80%94+An+Important+First+Step&doi=10.1056%2FNEJMe2018715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMe2018715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe2018715%26sid%3Dliteratum%253Aachs%26aulast%3DDolin%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DM.%2BS.%26atitle%3DRemdesivir%2520%25E2%2580%2594%2520An%2520Important%2520First%2520Step%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMe2018715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomashek, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalil, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luetkemeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez de Castilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touloumi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmagari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Palacios, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benfield, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ¤tkenheuer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortepeter, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atmar, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for the Treatment of Covid-19 â Final Report</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2007764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2007764" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+H.+Beigelauthor=K.+M.+Tomashekauthor=L.+E.+Doddauthor=A.+K.+Mehtaauthor=B.+S.+Zingmanauthor=A.+C.+Kalilauthor=E.+Hohmannauthor=H.+Y.+Chuauthor=A.+Luetkemeyerauthor=S.+Klineauthor=D.+Lopez+de+Castillaauthor=R.+W.+Finbergauthor=K.+Dierbergauthor=V.+Tapsonauthor=L.+Hsiehauthor=T.+F.+Pattersonauthor=R.+Paredesauthor=D.+A.+Sweeneyauthor=W.+R.+Shortauthor=G.+Touloumiauthor=D.+C.+Lyeauthor=N.+Ohmagariauthor=M.+Ohauthor=G.+M.+Ruiz-Palaciosauthor=T.+Benfieldauthor=G.+F%C3%A4tkenheuerauthor=M.+G.+Kortepeterauthor=R.+L.+Atmarauthor=C.+B.+Creechauthor=J.+Lundgrenauthor=A.+G.+Babikerauthor=S.+Pettauthor=J.+D.+Neatonauthor=T.+H.+Burgessauthor=T.+Bonnettauthor=M.+Greenauthor=M.+Makowskiauthor=A.+Osinusiauthor=S.+Nayakauthor=H.+C.+Lane&title=Remdesivir+for+the+Treatment+of+Covid-19+%E2%80%94+Final+Report&doi=10.1056%2FNEJMoa2007764"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2007764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2007764%26sid%3Dliteratum%253Aachs%26aulast%3DBeigel%26aufirst%3DJ.%2BH.%26aulast%3DTomashek%26aufirst%3DK.%2BM.%26aulast%3DDodd%26aufirst%3DL.%2BE.%26aulast%3DMehta%26aufirst%3DA.%2BK.%26aulast%3DZingman%26aufirst%3DB.%2BS.%26aulast%3DKalil%26aufirst%3DA.%2BC.%26aulast%3DHohmann%26aufirst%3DE.%26aulast%3DChu%26aufirst%3DH.%2BY.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DKline%26aufirst%3DS.%26aulast%3DLopez%2Bde%2BCastilla%26aufirst%3DD.%26aulast%3DFinberg%26aufirst%3DR.%2BW.%26aulast%3DDierberg%26aufirst%3DK.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DHsieh%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DT.%2BF.%26aulast%3DParedes%26aufirst%3DR.%26aulast%3DSweeney%26aufirst%3DD.%2BA.%26aulast%3DShort%26aufirst%3DW.%2BR.%26aulast%3DTouloumi%26aufirst%3DG.%26aulast%3DLye%26aufirst%3DD.%2BC.%26aulast%3DOhmagari%26aufirst%3DN.%26aulast%3DOh%26aufirst%3DM.%26aulast%3DRuiz-Palacios%26aufirst%3DG.%2BM.%26aulast%3DBenfield%26aufirst%3DT.%26aulast%3DF%25C3%25A4tkenheuer%26aufirst%3DG.%26aulast%3DKortepeter%26aufirst%3DM.%2BG.%26aulast%3DAtmar%26aufirst%3DR.%2BL.%26aulast%3DCreech%26aufirst%3DC.%2BB.%26aulast%3DLundgren%26aufirst%3DJ.%26aulast%3DBabiker%26aufirst%3DA.%2BG.%26aulast%3DPett%26aufirst%3DS.%26aulast%3DNeaton%26aufirst%3DJ.%2BD.%26aulast%3DBurgess%26aufirst%3DT.%2BH.%26aulast%3DBonnett%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DMakowski%26aufirst%3DM.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%2BC.%26atitle%3DRemdesivir%2520for%2520the%2520Treatment%2520of%2520Covid-19%2520%25E2%2580%2594%2520Final%2520Report%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMoa2007764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Drug Discovery and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1019</span>â <span class="NLM_lpage">1019</span>, <span class="refDoi">Â DOI: 10.1038/nrd2483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnrd2483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOjs7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1019-1019&author=J.+Vacca&title=Antiviral+Drug+Discovery+and+Development&doi=10.1038%2Fnrd2483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral drug discovery and development</span></div><div class="casAuthors">Vacca, Joseph; Burger, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New drugs have transformed the treatment of viral infections - in particular, HIV - in the past two decades.  Our interviewees this month describe the rewards and challenges of their complementary roles in antiviral drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMYwaI47OmZLVg90H21EOLACvtfcHk0lhz3jt1zQjHgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOjs7nI&md5=8a3c09236a94aa93dc43036c01ef8592</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2483%26sid%3Dliteratum%253Aachs%26aulast%3DVacca%26aufirst%3DJ.%26atitle%3DAntiviral%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D1019%26epage%3D1019%26doi%3D10.1038%2Fnrd2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Everts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span> <span> </span><span class="NLM_article-title">Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">169</span>, <span class="refDoi">Â DOI: 10.1146/annurev-pharmtox-010716-104533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1146%2Fannurev-pharmtox-010716-104533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27483339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oku7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=155-169&author=M.+Evertsauthor=T.+Cihlarauthor=J.+R.+Bostwickauthor=R.+J.+Whitley&title=Accelerating+Drug+Development%3A+Antiviral+Therapies+for+Emerging+Viruses+as+a+Model&doi=10.1146%2Fannurev-pharmtox-010716-104533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model</span></div><div class="casAuthors">Everts, Maaike; Cihlar, Tomas; Bostwick, J. Robert; Whitley, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-169</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Drug discovery and development is a lengthy and expensive process.  Although no one, simple, single soln. can significantly accelerate this process, steps can be taken to avoid unnecessary delays.  Using the development of antiviral therapies as a model, we describe options for acceleration that cover target selection, assay development and high-throughput screening, hit confirmation, lead identification and development, animal model evaluations, toxicity studies, regulatory issues, and the general drug discovery and development infrastructure.  Together, these steps could result in accelerated timelines for bringing antiviral therapies to market so they can treat emerging infections and reduce human suffering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcCmni1QuYLVg90H21EOLACvtfcHk0lhz3jt1zQjHgQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oku7%252FO&md5=e1bbd0d7afaa00f17321ebdaba603814</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104533%26sid%3Dliteratum%253Aachs%26aulast%3DEverts%26aufirst%3DM.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBostwick%26aufirst%3DJ.%2BR.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26atitle%3DAccelerating%2520Drug%2520Development%253A%2520Antiviral%2520Therapies%2520for%2520Emerging%2520Viruses%2520as%2520a%2520Model%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D155%26epage%3D169%26doi%3D10.1146%2Fannurev-pharmtox-010716-104533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jervey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaiu, D.</span></span> <span> </span><span class="NLM_article-title">Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.0c00272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.0c00272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=315-331&author=C.+Liuauthor=Q.+Zhouauthor=Y.+Liauthor=L.+V.+Garnerauthor=S.+P.+Watkinsauthor=L.+J.+Carterauthor=J.+Smootauthor=A.+C.+Greggauthor=A.+D.+Danielsauthor=S.+Jerveyauthor=D.+Albaiu&title=Research+and+Development+on+Therapeutic+Agents+and+Vaccines+for+COVID-19+and+Related+Human+Coronavirus+Diseases&doi=10.1021%2Facscentsci.0c00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</span></div><div class="casAuthors">Liu, Cynthia; Zhou, Qiongqiong; Li, Yingzhu; Garner, Linda V.; Watkins, Steve P.; Carter, Linda J.; Smoot, Jeffrey; Gregg, Anne C.; Daniels, Angela D.; Jervey, Susan; Albaiu, Dana</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-331</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe.  Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiol. of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines.  To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection.  It highlights antiviral strategies involving small mols. and biologics targeting complex mol. interactions involved in coronavirus infection and replication.  The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV.  The patent anal. of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines.  More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19.  The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAA030tIyfebVg90H21EOLACvtfcHk0lgImUi6_dmYhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWrsbo%253D&md5=fa29fb4cc3353a140e3a6a74059a99b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.0c00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.0c00272%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGarner%26aufirst%3DL.%2BV.%26aulast%3DWatkins%26aufirst%3DS.%2BP.%26aulast%3DCarter%26aufirst%3DL.%2BJ.%26aulast%3DSmoot%26aufirst%3DJ.%26aulast%3DGregg%26aufirst%3DA.%2BC.%26aulast%3DDaniels%26aufirst%3DA.%2BD.%26aulast%3DJervey%26aufirst%3DS.%26aulast%3DAlbaiu%26aufirst%3DD.%26atitle%3DResearch%2520and%2520Development%2520on%2520Therapeutic%2520Agents%2520and%2520Vaccines%2520for%2520COVID-19%2520and%2520Related%2520Human%2520Coronavirus%2520Diseases%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2020%26volume%3D6%26spage%3D315%26epage%3D331%26doi%3D10.1021%2Facscentsci.0c00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginex, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrado-Gil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta-Geijo, M. Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urquiza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">COVID-19: Drug Targets and Potential Treatments</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Gilauthor=T.+Ginexauthor=I.+Maestroauthor=V.+Nozalauthor=L.+Barrado-Gilauthor=M.+%C3%81.+Cuesta-Geijoauthor=J.+Urquizaauthor=D.+Ram%C3%ADrezauthor=C.+Alonsoauthor=N.+E.+Campilloauthor=A.+Martinez&title=COVID-19%3A+Drug+Targets+and+Potential+Treatments&doi=10.1021%2Facs.jmedchem.0c00606"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00606%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DC.%26aulast%3DGinex%26aufirst%3DT.%26aulast%3DMaestro%26aufirst%3DI.%26aulast%3DNozal%26aufirst%3DV.%26aulast%3DBarrado-Gil%26aufirst%3DL.%26aulast%3DCuesta-Geijo%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DUrquiza%26aufirst%3DJ.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DCOVID-19%253A%2520Drug%2520Targets%2520and%2520Potential%2520Treatments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span> <span> </span><span class="NLM_article-title">Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">236</span>, <span class="refDoi">Â DOI: 10.1080/22221751.2020.1719902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1080%2F22221751.2020.1719902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31987001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=221-236&author=J.+F.+W.+Chanauthor=K.+H.+Kokauthor=Z.+Zhuauthor=H.+Chuauthor=K.+K.+W.+Toauthor=S.+Yuanauthor=K.+Y.+Yuen&title=Genomic+Characterization+of+the+2019+Novel+Human-Pathogenic+Coronavirus+Isolated+from+a+Patient+with+Atypical+Pneumonia+after+Visiting+Wuhan&doi=10.1080%2F22221751.2020.1719902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</span></div><div class="casAuthors">Chan, Jasper Fuk-Woo; Kok, Kin-Hang; Zhu, Zheng; Chu, Hin; To, Kelvin Kai-Wang; Yuan, Shuofeng; Yuen, Kwok-Yung</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Microbes & Infections</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">221-236</span>CODEN:
                <span class="NLM_cas:coden">EMIMC4</span>;
        ISSN:<span class="NLM_cas:issn">2222-1751</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China.  Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization.  We performed bioinformatics anal. on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes.  Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV.  The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses.  However, the external subdomain of Spike's receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses.  Remarkably, its orf3b encodes a completely novel short protein.  Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) contg. six strands.  Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus would be important for understanding the origin and evolution of this novel lineage B betacoronavirus.  These findings provide the basis for starting further studies on the pathogenesis, and optimizing the design of diagnostic, antiviral and vaccination strategies for this emerging infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2BxE9eKNpaLVg90H21EOLACvtfcHk0lgImUi6_dmYhw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFOktLg%253D&md5=1ff0b451da73344406c7485aa5018a45</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F22221751.2020.1719902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F22221751.2020.1719902%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BF.%2BW.%26aulast%3DKok%26aufirst%3DK.%2BH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26atitle%3DGenomic%2520Characterization%2520of%2520the%25202019%2520Novel%2520Human-Pathogenic%2520Coronavirus%2520Isolated%2520from%2520a%2520Patient%2520with%2520Atypical%2520Pneumonia%2520after%2520Visiting%2520Wuhan%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2020%26volume%3D9%26spage%3D221%26epage%3D236%26doi%3D10.1080%2F22221751.2020.1719902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. L.</span></span> <span> </span><span class="NLM_article-title">Origin and Evolution of Pathogenic Coronaviruses</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">192</span>, <span class="refDoi">Â DOI: 10.1038/s41579-018-0118-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41579-018-0118-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30531947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhtbnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=181-192&author=J.+Cuiauthor=F.+Liauthor=Z.+L.+Shi&title=Origin+and+Evolution+of+Pathogenic+Coronaviruses&doi=10.1038%2Fs41579-018-0118-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of pathogenic coronaviruses</span></div><div class="casAuthors">Cui, Jie; Li, Fang; Shi, Zheng-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-192</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic viruses that emerged in humans at the beginning of the 21st century.  Both viruses likely originated in bats, and genetically diverse coronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide.  In this Review, we summarize the current knowledge on the origin and evolution of these two pathogenic coronaviruses and discuss their receptor usage; we also highlight the diversity and potential of spillover of bat-borne coronaviruses, as evidenced by the recent spillover of swine acute diarrhoea syndrome coronavirus (SADS-CoV) to pigs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosxL8lhv4N5rVg90H21EOLACvtfcHk0li9U2ThOXm-7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhtbnL&md5=b2b2c40c0cdf30107d8c70f482fc4f63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41579-018-0118-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41579-018-0118-9%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DZ.%2BL.%26atitle%3DOrigin%2520and%2520Evolution%2520of%2520Pathogenic%2520Coronaviruses%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2019%26volume%3D17%26spage%3D181%26epage%3D192%26doi%3D10.1038%2Fs41579-018-0118-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Severson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengartner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, R.</span></span> <span> </span><span class="NLM_article-title">RESEARCH High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1470</span>â <span class="NLM_lpage">1477</span>, <span class="refDoi">Â DOI: 10.3201/eid2607.200282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3201%2Feid2607.200282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32255761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB38zhslOrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1470-1477&author=S.+Sancheauthor=Y.+T.+Linauthor=C.+Xuauthor=E.+Romero-Seversonauthor=N.+Hengartnerauthor=R.+Ke&title=RESEARCH+High+Contagiousness+and+Rapid+Spread+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+2&doi=10.3201%2Feid2607.200282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2</span></div><div class="casAuthors">Sanche Steven; Lin Yen Ting; Xu Chonggang; Romero-Severson Ethan; Hengartner Nick; Ke Ruian</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1470-1477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 is the causative agent of the ongoing coronavirus disease pandemic.  Initial estimates of the early dynamics of the outbreak in Wuhan, China, suggested a doubling time of the number of infected persons of 6-7 days and a basic reproductive number (R0) of 2.2-2.7.  We collected extensive individual case reports across China and estimated key epidemiologic parameters, including the incubation period (4.2 days).  We then designed 2 mathematical modeling approaches to infer the outbreak dynamics in Wuhan by using high-resolution domestic travel and infection data.  Results show that the doubling time early in the epidemic in Wuhan was 2.3-3.3 days.  Assuming a serial interval of 6-9 days, we calculated a median R0 value of 5.7 (95% CI 3.8-8.9).  We further show that active surveillance, contact tracing, quarantine, and early strong social distancing efforts are needed to stop transmission of the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1QLaeKXMGxHRxY89Cm6SyfW6udTcc2eZC0p6kc-giK7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zhslOrtA%253D%253D&md5=60d7c57b32b8a34c33362239e1d2c98e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3201%2Feid2607.200282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid2607.200282%26sid%3Dliteratum%253Aachs%26aulast%3DSanche%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRomero-Severson%26aufirst%3DE.%26aulast%3DHengartner%26aufirst%3DN.%26aulast%3DKe%26aufirst%3DR.%26atitle%3DRESEARCH%2520High%2520Contagiousness%2520and%2520Rapid%2520Spread%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25202%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2020%26volume%3D26%26spage%3D1470%26epage%3D1477%26doi%3D10.3201%2Feid2607.200282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shereen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddique, R.</span></span> <span> </span><span class="NLM_article-title">COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses</span>. <i>J. Adv. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">91</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/j.jare.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jare.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32257431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsl2ktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=91-98&author=M.+A.+Shereenauthor=S.+Khanauthor=A.+Kazmiauthor=N.+Bashirauthor=R.+Siddique&title=COVID-19+Infection%3A+Origin%2C+Transmission%2C+and+Characteristics+of+Human+Coronaviruses&doi=10.1016%2Fj.jare.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses</span></div><div class="casAuthors">Shereen, Muhammad Adnan; Khan, Suliman; Kazmi, Abeer; Bashir, Nadia; Siddique, Rabeea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">JAROES</span>;
        ISSN:<span class="NLM_cas:issn">2090-1224</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world.  Genomic anal. revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir.  The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely.  There is no clin. approved antiviral drug or vaccine available to be used against COVID-19.  However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clin. trials, resulted in clin. recovery.  In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV).  We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGortH4RKXf6eLVg90H21EOLACvtfcHk0li9U2ThOXm-7w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsl2ktbk%253D&md5=31106b4d9e5f3131fcd206caed6ebc80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jare.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jare.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DShereen%26aufirst%3DM.%2BA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DKazmi%26aufirst%3DA.%26aulast%3DBashir%26aufirst%3DN.%26aulast%3DSiddique%26aufirst%3DR.%26atitle%3DCOVID-19%2520Infection%253A%2520Origin%252C%2520Transmission%252C%2520and%2520Characteristics%2520of%2520Human%2520Coronaviruses%26jtitle%3DJ.%2520Adv.%2520Res.%26date%3D2020%26volume%3D24%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fj.jare.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, A. R.</span>; <span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">Coronaviruses: An Overview of Their Replication and Pathogenesis</span>. In  <i>Coronaviruses: Methods and Protocols</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">1282</span>, pp  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">23</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2F978-1-4939-2438-7_1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1-23&author=A.+R.+Fehr&author=S.+Perlman&title=Coronaviruses%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2438-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2438-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DFehr%26aufirst%3DA.%2BR.%26atitle%3DCoronaviruses%253A%2520An%2520Overview%2520of%2520Their%2520Replication%2520and%2520Pathogenesis%26btitle%3DCoronaviruses%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2015%26volume%3D1282%26spage%3D1%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loganathan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samavarchi-Tehrani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramek, D.</span></span> <span> </span><span class="NLM_article-title">Rare Driver Mutations in Head and Neck Squamous Cell Carcinomas Converge on NOTCH Signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1264</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1126/science.aax0902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.aax0902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32165588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFemt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1264-1269&author=S.+K.+Loganathanauthor=K.+Schleicherauthor=A.+Malikauthor=R.+Quevedoauthor=E.+Langilleauthor=K.+Tengauthor=R.+H.+Ohauthor=B.+Rathodauthor=R.+Tsaiauthor=P.+Samavarchi-Tehraniauthor=T.+J.+Pughauthor=A.+C.+Gingrasauthor=D.+Schramek&title=Rare+Driver+Mutations+in+Head+and+Neck+Squamous+Cell+Carcinomas+Converge+on+NOTCH+Signaling&doi=10.1126%2Fscience.aax0902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling</span></div><div class="casAuthors">Loganathan, Sampath K.; Schleicher, Krista; Malik, Ahmad; Quevedo, Rene; Langille, Ellen; Teng, Katie; Oh, Robin H.; Rathod, Bhavisha; Tsai, Ricky; Samavarchi-Tehrani, Payman; Pugh, Trevor J.; Gingras, Anne-Claude; Schramek, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">1264-1269</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In most human cancers, only a few genes are mutated at high frequencies; most are mutated at low frequencies.  The functional consequences of these recurrent but infrequent "long tail" mutations are often unknown.  We focused on 484 long tail genes in head and neck squamous cell carcinoma (HNSCC) and used in vivo CRISPR to screen for genes that, upon mutation, trigger tumor development in mice.  Of the 15 tumor-suppressor genes identified, ADAM10 and AJUBA suppressed HNSCC in a haploinsufficient manner by promoting NOTCH receptor signaling.  ADAM10 and AJUBA mutations or monoallelic loss occur in 28% of human HNSCC cases and are mutually exclusive with NOTCH receptor mutations.  Our results show that oncogenic mutations in 67% of human HNSCC cases converge onto the NOTCH signaling pathway, making NOTCH inactivation a hallmark of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTSwKJHSQZ2rVg90H21EOLACvtfcHk0ljuqM9YmyFhKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFemt7c%253D&md5=7974c2cb4fc78ca29ec267cdb01aef2d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscience.aax0902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aax0902%26sid%3Dliteratum%253Aachs%26aulast%3DLoganathan%26aufirst%3DS.%2BK.%26aulast%3DSchleicher%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DQuevedo%26aufirst%3DR.%26aulast%3DLangille%26aufirst%3DE.%26aulast%3DTeng%26aufirst%3DK.%26aulast%3DOh%26aufirst%3DR.%2BH.%26aulast%3DRathod%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DR.%26aulast%3DSamavarchi-Tehrani%26aufirst%3DP.%26aulast%3DPugh%26aufirst%3DT.%2BJ.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DSchramek%26aufirst%3DD.%26atitle%3DRare%2520Driver%2520Mutations%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinomas%2520Converge%2520on%2520NOTCH%2520Signaling%26jtitle%3DScience%26date%3D2020%26volume%3D367%26spage%3D1264%26epage%3D1269%26doi%3D10.1126%2Fscience.aax0902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine-Weber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiergens, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ¶hlmann, S.</span></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">280</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32142651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=271-280&author=M.+Hoffmannauthor=H.+Kleine-Weberauthor=S.+Schroederauthor=N.+Kr%C3%BCgerauthor=T.+Herrlerauthor=S.+Erichsenauthor=T.+S.+Schiergensauthor=G.+Herrlerauthor=N.+H.+Wuauthor=A.+Nitscheauthor=M.+A.+M%C3%BCllerauthor=C.+Drostenauthor=S.+P%C3%B6hlmann&title=SARS-CoV-2+Cell+Entry+Depends+on+ACE2+and+TMPRSS2+and+Is+Blocked+by+a+Clinically+Proven+Protease+Inhibitor&doi=10.1016%2Fj.cell.2020.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span></div><div class="casAuthors">Hoffmann, Markus; Kleine-Weber, Hannah; Schroeder, Simon; Krueger, Nadine; Herrler, Tanja; Erichsen, Sandra; Schiergens, Tobias S.; Herrler, Georg; Wu, Nai-Huei; Nitsche, Andreas; Mueller, Marcel A.; Drosten, Christian; Poehlmann, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280.e8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency.  Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases.  Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets.  Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.  A TMPRSS2 inhibitor approved for clin. use blocked entry and might constitute a treatment option.  Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry.  Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq92X1lVQaLirVg90H21EOLACvtfcHk0ljuqM9YmyFhKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D&md5=60aea5c939a2d4df034a91d6198fb3ef</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DKleine-Weber%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DKr%25C3%25BCger%26aufirst%3DN.%26aulast%3DHerrler%26aufirst%3DT.%26aulast%3DErichsen%26aufirst%3DS.%26aulast%3DSchiergens%26aufirst%3DT.%2BS.%26aulast%3DHerrler%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DN.%2BH.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BA.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DP%25C3%25B6hlmann%26aufirst%3DS.%26atitle%3DSARS-CoV-2%2520Cell%2520Entry%2520Depends%2520on%2520ACE2%2520and%2520TMPRSS2%2520and%2520Is%2520Blocked%2520by%2520a%2520Clinically%2520Proven%2520Protease%2520Inhibitor%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D271%26epage%3D280%26doi%3D10.1016%2Fj.cell.2020.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e8.</p></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrapp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiona, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1260</span>â <span class="NLM_lpage">1263</span>, <span class="refDoi">Â DOI: 10.1126/science.abb2507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb2507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32075877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFemt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1260-1263&author=D.+Wrappauthor=N.+Wangauthor=K.+S.+Corbettauthor=J.+A.+Goldsmithauthor=C.+L.+Hsiehauthor=O.+Abionaauthor=B.+S.+Grahamauthor=J.+S.+McLellan&title=Cryo-EM+Structure+of+the+2019-NCoV+Spike+in+the+Prefusion+Conformation&doi=10.1126%2Fscience.abb2507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</span></div><div class="casAuthors">Wrapp, Daniel; Wang, Nianshuang; Corbett, Kizzmekia S.; Goldsmith, Jory A.; Hsieh, Ching-Lin; Abiona, Olubukola; Graham, Barney S.; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">1260-1263</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern.  The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics.  To facilitate medical countermeasure development, we detd. a 3.5-angstrom-resoln. cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation.  The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation.  We also provide biophys. and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S.  Addnl., we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.  The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFmIhnTBqdt7Vg90H21EOLACvtfcHk0ljuqM9YmyFhKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFemt70%253D&md5=27d08cbb9a43d1da051a8a92a9f68aa5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb2507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb2507%26sid%3Dliteratum%253Aachs%26aulast%3DWrapp%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCorbett%26aufirst%3DK.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%2BA.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DAbiona%26aufirst%3DO.%26aulast%3DGraham%26aufirst%3DB.%2BS.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DCryo-EM%2520Structure%2520of%2520the%25202019-NCoV%2520Spike%2520in%2520the%2520Prefusion%2520Conformation%26jtitle%3DScience%26date%3D2020%26volume%3D367%26spage%3D1260%26epage%3D1263%26doi%3D10.1126%2Fscience.abb2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">904</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32275855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFGrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=894-904&author=Q.+Wangauthor=Y.+Zhangauthor=L.+Wuauthor=S.+Niuauthor=C.+Songauthor=Z.+Zhangauthor=G.+Luauthor=C.+Qiaoauthor=Y.+Huauthor=K.+Y.+Yuenauthor=Q.+Wangauthor=H.+Zhouauthor=J.+Yanauthor=J.+Qi&title=Structural+and+Functional+Basis+of+SARS-CoV-2+Entry+by+Using+Human+ACE2&doi=10.1016%2Fj.cell.2020.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</span></div><div class="casAuthors">Wang, Qihui; Zhang, Yanfang; Wu, Lili; Niu, Sheng; Song, Chunli; Zhang, Zengyuan; Lu, Guangwen; Qiao, Chengpeng; Hu, Yu; Yuen, Kwok-Yung; Wang, Qisheng; Zhou, Huan; Yan, Jinghua; Qi, Jianxun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-904.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns.  Recently, ACE2 was reported as an entry receptor for SARS-CoV-2.  In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that obsd. for SARS-CoV.  However, at. details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD.  Addnl., a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2.  These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKfOekHApZrVg90H21EOLACvtfcHk0li41e6k1hq89Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFGrur4%253D&md5=188108e44f104860d4a2b83707ce7230</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DQiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26atitle%3DStructural%2520and%2520Functional%2520Basis%2520of%2520SARS-CoV-2%2520Entry%2520by%2520Using%2520Human%2520ACE2%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D894%26epage%3D904%26doi%3D10.1016%2Fj.cell.2020.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e9.</p></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2180-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2180-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32225176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslOqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2020&pages=215-220&author=J.+Lanauthor=J.+Geauthor=J.+Yuauthor=S.+Shanauthor=H.+Zhouauthor=S.+Fanauthor=Q.+Zhangauthor=X.+Shiauthor=Q.+Wangauthor=L.+Zhangauthor=X.+Wang&title=Structure+of+the+SARS-CoV-2+Spike+Receptor-Binding+Domain+Bound+to+the+ACE2+Receptor&doi=10.1038%2Fs41586-020-2180-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</span></div><div class="casAuthors">Lan, Jun; Ge, Jiwan; Yu, Jinfang; Shan, Sisi; Zhou, Huan; Fan, Shilong; Zhang, Qi; Shi, Xuanling; Wang, Qisheng; Zhang, Linqi; Wang, Xinquan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">7807</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from Dec. 2019 that quickly spread nationwide and to other countries around the world1-3.  Here, to better understand the initial step of infection at an at. level, we detd. the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2.  The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor4.  Structural anal. identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD.  Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses1-3,5.  The epitopes of two SARS-CoV antibodies that target the RBD are also analyzed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXsiu14u7z5bVg90H21EOLACvtfcHk0li41e6k1hq89Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslOqtL8%253D&md5=279c60143e8e5eb505457e0778baa8ef</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2180-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2180-5%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DStructure%2520of%2520the%2520SARS-CoV-2%2520Spike%2520Receptor-Binding%2520Domain%2520Bound%2520to%2520the%2520ACE2%2520Receptor%26jtitle%3DNature%26date%3D2020%26volume%3D581%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fs41586-020-2180-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Xiuauthor=A.+Dickauthor=H.+Juauthor=S.+Mirzaieauthor=F.+Abdiauthor=S.+Cocklinauthor=P.+Zhanauthor=X.+Liu&title=Inhibitors+of+SARS-CoV-2+Entry%3A+Current+and+Future+Opportunities&doi=10.1021%2Facs.jmedchem.0c00502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00502%26sid%3Dliteratum%253Aachs%26aulast%3DXiu%26aufirst%3DS.%26aulast%3DDick%26aufirst%3DA.%26aulast%3DJu%26aufirst%3DH.%26aulast%3DMirzaie%26aufirst%3DS.%26aulast%3DAbdi%26aufirst%3DF.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DInhibitors%2520of%2520SARS-CoV-2%2520Entry%253A%2520Current%2520and%2520Future%2520Opportunities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannalire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelliccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">Sars-Cov-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5707</span>, <span class="refDoi">Â DOI: 10.3390/ijms21165707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fijms21165707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVChs7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5707&author=R.+Cannalireauthor=I.+Stefanelliauthor=C.+Cerchiaauthor=A.+R.+Beccariauthor=S.+Pellicciaauthor=V.+Summa&title=Sars-Cov-2+Entry+Inhibitors%3A+Small+Molecules+and+Peptides+Targeting+Virus+or+Host+Cells&doi=10.3390%2Fijms21165707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells</span></div><div class="casAuthors">Cannalire, Rolando; Stefanelli, Irina; Cerchia, Carmen; Beccari, Andrea R.; Pelliccia, Sveva; Summa, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5707</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to unprecedented efforts to explore all possible approaches against COVID-19.  In this context, targeting virus entry is a promising antiviral strategy for controlling viral infections.  The main strategies pursued to inhibit the viral entry are considering both the virus and the host factors involved in the process.  Primarily, direct-acting antivirals rely on inhibition of the interaction between ACE2 and the receptor binding domain (RBD) of the Spike (S) protein or targeting the more conserved heptad repeats (HRs), involved in the membrane fusion process.  The inhibition of host TMPRSS2 and cathepsins B/L may represent a complementary strategy to be investigated.  In this review, we discuss the development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB/L, which have been exploited so far against CoVs and other related viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMTb3-BDmGt7Vg90H21EOLACvtfcHk0li-N9k7zAUCag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVChs7rL&md5=7aafad1d4cdb83377df1734f81d2fa3b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fijms21165707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21165707%26sid%3Dliteratum%253Aachs%26aulast%3DCannalire%26aufirst%3DR.%26aulast%3DStefanelli%26aufirst%3DI.%26aulast%3DCerchia%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DA.%2BR.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DSumma%26aufirst%3DV.%26atitle%3DSars-Cov-2%2520Entry%2520Inhibitors%253A%2520Small%2520Molecules%2520and%2520Peptides%2520Targeting%2520Virus%2520or%2520Host%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5707%26doi%3D10.3390%2Fijms21165707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. R.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the Interferon-Induced OAS-RNase L Pathway by Murine Coronavirus Ns2 Protein Is Required for Virus Replication and Liver Pathology</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">607</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2012.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.chom.2012.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22704621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XosFCjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=607-616&author=L.+Zhaoauthor=B.+K.+Jhaauthor=A.+Wuauthor=R.+Elliottauthor=J.+Ziebuhrauthor=A.+E.+Gorbalenyaauthor=R.+H.+Silvermanauthor=S.+R.+Weiss&title=Antagonism+of+the+Interferon-Induced+OAS-RNase+L+Pathway+by+Murine+Coronavirus+Ns2+Protein+Is+Required+for+Virus+Replication+and+Liver+Pathology&doi=10.1016%2Fj.chom.2012.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the Interferon-Induced OAS-RNase L Pathway by Murine Coronavirus ns2 Protein Is Required for Virus Replication and Liver Pathology</span></div><div class="casAuthors">Zhao, Ling; Jha, Babal K.; Wu, Ashley; Elliott, Ruth; Ziebuhr, John; Gorbalenya, Alexander E.; Silverman, Robert H.; Weiss, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">607-616</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many viruses induce hepatitis in humans, highlighting the need to understand the underlying mechanisms of virus-induced liver pathol.  The murine coronavirus known as mouse hepatitis virus (MHV) causes acute hepatitis in its natural host and provides a useful model for understanding virus interaction with liver cells.  The MHV accessory protein, ns2, antagonizes the type I interferon response and promotes hepatitis.  We show that ns2 has 2',5'-phosphodiesterase activity, which blocks the interferon inducible 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway to facilitate hepatitis development.  Ns2 cleaves 2',5'-oligoadenylate, the product of OAS, to prevent activation of the cellular endoribonuclease RNase L and consequently block viral RNA degrdn.  An ns2 mutant virus was unable to replicate in the liver or induce hepatitis in wild-type mice, but was highly pathogenic in RNase L deficient mice.  Thus, RNase L is a crit. cellular factor for protection against viral infection of the liver and the resulting hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZE4VGIhUHLVg90H21EOLACvtfcHk0li-N9k7zAUCag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosFCjuro%253D&md5=7417b0b387719d0d3d0ada997e695abf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJha%26aufirst%3DB.%2BK.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DSilverman%26aufirst%3DR.%2BH.%26aulast%3DWeiss%26aufirst%3DS.%2BR.%26atitle%3DAntagonism%2520of%2520the%2520Interferon-Induced%2520OAS-RNase%2520L%2520Pathway%2520by%2520Murine%2520Coronavirus%2520Ns2%2520Protein%2520Is%2520Required%2520for%2520Virus%2520Replication%2520and%2520Liver%2520Pathology%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D11%26spage%3D607%26epage%3D616%26doi%3D10.1016%2Fj.chom.2012.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freitas, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durie, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S. D.</span></span> <span> </span><span class="NLM_article-title">Characterization and Noncovalent Inhibition of the Deubiquitinase and DeISGylase Activity of SARS-CoV-2 Papain-Like Protease</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2099</span>â <span class="NLM_lpage">2109</span>, <span class="refDoi">Â DOI: 10.1021/acsinfecdis.0c00168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.0c00168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslylsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=2099-2109&author=B.+T.+Freitasauthor=I.+A.+Durieauthor=J.+Murrayauthor=J.+E.+Longoauthor=H.+C.+Millerauthor=D.+Crichauthor=R.+J.+Hoganauthor=R.+A.+Trippauthor=S.+D.+Pegan&title=Characterization+and+Noncovalent+Inhibition+of+the+Deubiquitinase+and+DeISGylase+Activity+of+SARS-CoV-2+Papain-Like+Protease&doi=10.1021%2Facsinfecdis.0c00168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease</span></div><div class="casAuthors">Freitas, Brendan T.; Durie, Ian A.; Murray, Jackelyn; Longo, Jaron E.; Miller, Holden C.; Crich, David; Hogan, Robert Jeff; Tripp, Ralph A.; Pegan, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2099-2109</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, is a novel human betacoronavirus that is rapidly spreading worldwide.  The outbreak currently includes over 3.7 million cases and 260,000 fatalities.  As a betacoronavirus, SARS-CoV-2 encodes for a papain-like protease (PLpro) that is likely responsible for cleavage of the coronavirus (CoV) viral polypeptide.  The PLpro is also responsible for suppression of host innate immune responses by virtue of its ability to reverse host ubiquitination and ISGylation events.  Here, the biochem. activity of SARS-CoV-2 PLpro against ubiquitin (Ub) and interferon-stimulated gene product 15 (ISG15) substrates is evaluated, revealing that the protease has a marked redn. in its ability to process K48 linked Ub substrates compared to its counterpart in SARS-CoV.  Addnl., its substrate activity more closely mirrors that of the PLpro from the Middle East respiratory syndrome coronavirus and prefers ISG15s from certain species including humans.  Addnl., naphthalene based PLpro inhibitors are shown to be effective at halting SARS-CoV-2 PLpro activity as well as SARS-CoV-2 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrtEvK1olMlrVg90H21EOLACvtfcHk0li-N9k7zAUCag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslylsbs%253D&md5=314ea59a92d60345f982e78e31e5b569</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.0c00168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.0c00168%26sid%3Dliteratum%253Aachs%26aulast%3DFreitas%26aufirst%3DB.%2BT.%26aulast%3DDurie%26aufirst%3DI.%2BA.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DLongo%26aufirst%3DJ.%2BE.%26aulast%3DMiller%26aufirst%3DH.%2BC.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DHogan%26aufirst%3DR.%2BJ.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DPegan%26aufirst%3DS.%2BD.%26atitle%3DCharacterization%2520and%2520Noncovalent%2520Inhibition%2520of%2520the%2520Deubiquitinase%2520and%2520DeISGylase%2520Activity%2520of%2520SARS-CoV-2%2520Papain-Like%2520Protease%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D2099%26epage%3D2109%26doi%3D10.1021%2Facsinfecdis.0c00168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span>; <span class="NLM_string-name">Lokugamage, K. G.</span>; <span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Viral and Cellular MRNA Translation in Coronavirus-Infected Cells</span>. In  <i>Advances in Virus Research</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">96</span>, pp  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">192</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=165-192&author=K.+Nakagawa&author=K.+G.+Lokugamage&author=S.+Makino&title=Advances+in+Virus+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DViral%2520and%2520Cellular%2520MRNA%2520Translation%2520in%2520Coronavirus-Infected%2520Cells%26btitle%3DAdvances%2520in%2520Virus%2520Research%26pub%3DAcademic%2520Press%26date%3D2016%26volume%3D96%26spage%3D165%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curth, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerhering, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved a-Ketoamide Inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">412</span>, <span class="refDoi">Â DOI: 10.1126/science.abb3405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb3405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32198291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslKrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=409-412&author=L.+Zhangauthor=D.+Linauthor=X.+Sunauthor=U.+Curthauthor=C.+Drostenauthor=L.+Sauerheringauthor=S.+Beckerauthor=K.+Roxauthor=R.+Hilgenfeld&title=Crystal+Structure+of+SARS-CoV-2+Main+Protease+Provides+a+Basis+for+Design+of+Improved+a-Ketoamide+Inhibitors&doi=10.1126%2Fscience.abb3405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors</span></div><div class="casAuthors">Zhang, Linlin; Lin, Daizong; Sun, Xinyuanyuan; Curth, Ute; Drosten, Christian; Sauerhering, Lucie; Becker, Stephan; Rox, Katharina; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6489</span>),
    <span class="NLM_cas:pages">409-412</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency.  An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA.  We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an Î±-ketoamide inhibitor.  This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compd. in plasma.  On the basis of the unliganded structure, we developed the lead compd. into a potent inhibitor of the SARS-CoV-2 Mpro.  The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT531N47m4BbVg90H21EOLACvtfcHk0lj6cTwv_FfoWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslKrtL8%253D&md5=9ac417c20f54c3327f9de9088b512d52</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb3405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb3405%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DCurth%26aufirst%3DU.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DSauerhering%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DRox%26aufirst%3DK.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520SARS-CoV-2%2520Main%2520Protease%2520Provides%2520a%2520Basis%2520for%2520Design%2520of%2520Improved%2520a-Ketoamide%2520Inhibitors%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D409%26epage%3D412%26doi%3D10.1126%2Fscience.abb3405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschueren, K. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigalke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesters, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">PH-Dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-Ray Structure Analyses</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">40</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jmb.2005.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16242152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2005&pages=25-40&author=J.+Tanauthor=K.+H.+G.+Verschuerenauthor=K.+Anandauthor=J.+Shenauthor=M.+Yangauthor=Y.+Xuauthor=Z.+Raoauthor=J.+Bigalkeauthor=B.+Heisenauthor=J.+R.+Mestersauthor=K.+Chenauthor=X.+Shenauthor=H.+Jiangauthor=R.+Hilgenfeld&title=PH-Dependent+Conformational+Flexibility+of+the+SARS-CoV+Main+Proteinase+%28Mpro%29+Dimer%3A+Molecular+Dynamics+Simulations+and+Multiple+X-Ray+Structure+Analyses&doi=10.1016%2Fj.jmb.2005.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses</span></div><div class="casAuthors">Tan, Jinzhi; Verschueren, Koen H. G.; Anand, Kanchan; Shen, Jianhua; Yang, Maojun; Xu, Yechun; Rao, Zihe; Bigalke, Janna; Heisen, Burkhard; Mesters, Jeroen R.; Chen, Kaixian; Shen, Xu; Jiang, Hualiang; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SARS coronavirus main proteinase (Mpro) is a key enzyme in the processing of the viral polyproteins and thus an attractive target for the discovery of drugs directed against SARS.  The enzyme has been shown by x-ray crystallog. to undergo significant pH-dependent conformational changes.  Here, we assess the conformational flexibility of the Mpro by anal. of multiple crystal structures (including two new crystal forms) and by mol. dynamics (MD) calcns.  The MD simulations take into account the different protonation states of two histidine residues in the substrate-binding site and explain the pH-activity profile of the enzyme.  The low enzymic activity of the Mpro monomer and the need for dimerization are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5RJ00EWJ7bVg90H21EOLACvtfcHk0lj6cTwv_FfoWg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsL7I&md5=38db21c716511e9322d97efb85c52a0e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DVerschueren%26aufirst%3DK.%2BH.%2BG.%26aulast%3DAnand%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DBigalke%26aufirst%3DJ.%26aulast%3DHeisen%26aufirst%3DB.%26aulast%3DMesters%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DPH-Dependent%2520Conformational%2520Flexibility%2520of%2520the%2520SARS-CoV%2520Main%2520Proteinase%2520%2528Mpro%2529%2520Dimer%253A%2520Molecular%2520Dynamics%2520Simulations%2520and%2520Multiple%2520X-Ray%2520Structure%2520Analyses%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D354%26spage%3D25%26epage%3D40%26doi%3D10.1016%2Fj.jmb.2005.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">1637</span>â <span class="NLM_lpage">1642</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M310875200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.M310875200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14561748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisF2gsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=1637-1642&author=K.+Fanauthor=P.+Weiauthor=Q.+Fengauthor=S.+Chenauthor=C.+Huangauthor=L.+Maauthor=B.+Laiauthor=J.+Peiauthor=Y.+Liuauthor=J.+Chenauthor=L.+Lai&title=Biosynthesis%2C+Purification%2C+and+Substrate+Specificity+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+3C-like+Proteinase&doi=10.1074%2Fjbc.M310875200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase</span></div><div class="casAuthors">Fan, Keqiang; Wei, Ping; Feng, Qian; Chen, Sidi; Huang, Changkang; Ma, Liang; Lai, Bing; Pei, Jianfeng; Liu, Ying; Chen, Jianguo; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1637-1642</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS.  In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase.  Analytic gel filtration shows a mixt. of monomer and dimer at a protein concn. of 4 mg/mL and mostly monomer at 0.2 mg/mL, which correspond to the concn. used in the enzyme assays.  The linear decrease of the enzymic-specific activity with the decrease of enzyme concn. revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase.  By using a high pressure liq. chromatog. assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency.  The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1' positions react slower.  The P2 position of the substrates seems to favor large hydrophobic residues.  Secondary structure studies for the peptide substrates revealed that substrates with more Î²-sheetlike structure tend to react fast.  This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM1N-CzXh2trVg90H21EOLACvtfcHk0lhTWxE4hVTzmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisF2gsQ%253D%253D&md5=ead84667c200117a64213a6baac25214</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310875200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310875200%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DB.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DBiosynthesis%252C%2520Purification%252C%2520and%2520Substrate%2520Specificity%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25203C-like%2520Proteinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D1637%26epage%3D1642%26doi%3D10.1074%2Fjbc.M310875200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme. Defining the Extra Domain as a New Target for Design of Highly Specific Protease Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">24765</span>â <span class="NLM_lpage">24773</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M311744200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.M311744200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=15037623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksV2iu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=24765-24773&author=J.+Shiauthor=Z.+Weiauthor=J.+Song&title=Dissection+Study+on+the+Severe+Acute+Respiratory+Syndrome+3C-like+Protease+Reveals+the+Critical+Role+of+the+Extra+Domain+in+Dimerization+of+the+Enzyme.+Defining+the+Extra+Domain+as+a+New+Target+for+Design+of+Highly+Specific+Protease+Inhibitors&doi=10.1074%2Fjbc.M311744200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme: Defining the extra domain as a new target for design of highly specific protease inhibitors</span></div><div class="casAuthors">Shi, Jiahai; Wei, Zheng; Song, Jianxing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">24765-24773</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome (SARS) 3C-like protease consists of two distinct folds, namely the N-terminal chymotrypsin fold contg. the domains I and II hosting the complete catalytic machinery and the C-terminal extra helical domain III unique for the coronavirus 3CL proteases.  Previously the functional role of this extra domain has been completely unknown, and it was believed that the coronavirus 3CL proteases share the same enzymic mechanism with picornavirus 3C proteases, which contain the chymotrypsin fold but have no extra domain.  To understand the functional role of the extra domain and to characterize the enzyme-substrate interactions by use of the dynamic light scattering, CD, and NMR spectroscopy, we (1) dissected the full-length SARS 3CL protease into two distinct folds and subsequently investigated their structural and dimerization properties and (2) studied the structural and binding interactions of three substrate peptides with the entire enzyme and its two dissected folds.  The results lead to several findings; (1) although two dissected parts folded into the native-like structures, the chymotrypsin fold only had weak activity as compared with the entire enzyme, and (2) although the chymotrypsin fold remained a monomer within a wide range of protein concns., the extra domain existed as a stable dimer even at a very low concn.  This observation strongly indicates that the extra domain contributes to the dimerization of the SARS 3CL protease, thus, switching the enzyme from the inactive form (monomer) to the active form (dimer).  This discovery not only separates the coronavirus 3CL protease from the picornavirus 3C protease in terms of the enzymic mechanism but also defines the dimerization interface on the extra helical domain as a new target for design of the specific protease inhibitors.  Furthermore, the detn. of the preferred soln. conformation of the substrate peptide S1 together with the NMR differential line-broadening and transferred nuclear Overhauser enhancement study allows us to pinpoint the bound structure of the S1 peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUDKFqysiYzLVg90H21EOLACvtfcHk0lhTWxE4hVTzmg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksV2iu7o%253D&md5=84829ea4faca1439c26815246f22528b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311744200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311744200%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DDissection%2520Study%2520on%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%25203C-like%2520Protease%2520Reveals%2520the%2520Critical%2520Role%2520of%2520the%2520Extra%2520Domain%2520in%2520Dimerization%2520of%2520the%2520Enzyme.%2520Defining%2520the%2520Extra%2520Domain%2520as%2520a%2520New%2520Target%2520for%2520Design%2520of%2520Highly%2520Specific%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D24765%26epage%3D24773%26doi%3D10.1074%2Fjbc.M311744200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3â²- Digallate (TF3)</span>. <i>Evidence-based Complement. Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">209</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1093/ecam/neh081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fecam%2Fneh081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=15937562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC2sbotVGjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=209-215&author=C.+N.+Chenauthor=C.+P.+C.+Linauthor=K.+K.+Huangauthor=W.+C.+Chenauthor=H.+P.+Hsiehauthor=P.+H.+Liangauthor=J.+T.+A.+Hsu&title=Inhibition+of+SARS-CoV+3C-like+Protease+Activity+by+Theaflavin-3%2C3%E2%80%B2-+Digallate+%28TF3%29&doi=10.1093%2Fecam%2Fneh081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)</span></div><div class="casAuthors">Chen Chia-Nan; Lin Coney P C; Huang Kuo-Kuei; Chen Wei-Cheng; Hsieh Hsin-Pang; Liang Po-Huang; Hsu John T-A</div><div class="citationInfo"><span class="NLM_cas:title">Evidence-based complementary and alternative medicine : eCAM</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-215</span>
        ISSN:<span class="NLM_cas:issn">1741-427X</span>.
    </div><div class="casAbstract">SARS-CoV is the causative agent of severe acute respiratory syndrome (SARS).  The virally encoded 3C-like protease (3CL(Pro)) has been presumed critical for the viral replication of SARS-CoV in infected host cells.  In this study, we screened a natural product library consisting of 720 compounds for inhibitory activity against 3CL(Pro).  Two compounds in the library were found to be inhibitive: tannic acid (IC(50) = 3 microM) and 3-isotheaflavin-3-gallate (TF2B) (IC(50) = 7 microM).  These two compounds belong to a group of natural polyphenols found in tea.  We further investigated the 3CL(Pro)-inhibitory activity of extracts from several different types of teas, including green tea, oolong tea, Puer tea and black tea.  Our results indicated that extracts from Puer and black tea were more potent than that from green or oolong teas in their inhibitory activities against 3CL(Pro).  Several other known compositions in teas were also evaluated for their activities in inhibiting 3CL(Pro).  We found that caffeine, (-)-epigallocatechin gallte (EGCg), epicatechin (EC), theophylline (TP), catechin (C), epicatechin gallate (ECg) and epigallocatechin (EGC) did not inhibit 3CL(Pro) activity.  Only theaflavin-3,3'-digallate (TF3) was found to be a 3CL(Pro) inhibitor.  This study has resulted in the identification of new compounds that are effective 3CL(Pro) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReGZlkwH5z_Awxfk_AGB-EfW6udTcc2eb3o-USxlDL8rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbotVGjtg%253D%253D&md5=308c27b8dec804c91fde2ed84dd39478</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fecam%2Fneh081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecam%252Fneh081%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BN.%26aulast%3DLin%26aufirst%3DC.%2BP.%2BC.%26aulast%3DHuang%26aufirst%3DK.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DLiang%26aufirst%3DP.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26atitle%3DInhibition%2520of%2520SARS-CoV%25203C-like%2520Protease%2520Activity%2520by%2520Theaflavin-3%252C3%25E2%2580%25B2-%2520Digallate%2520%2528TF3%2529%26jtitle%3DEvidence-based%2520Complement.%2520Altern.%2520Med.%26date%3D2005%26volume%3D2%26spage%3D209%26epage%3D215%26doi%3D10.1093%2Fecam%2Fneh081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">293</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2223-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2223-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2020&pages=289-293&author=Z.+Jinauthor=X.+Duauthor=Y.+Xuauthor=Y.+Dengauthor=M.+Liuauthor=Y.+Zhaoauthor=B.+Zhangauthor=X.+Liauthor=L.+Zhangauthor=C.+Pengauthor=Y.+Duanauthor=J.+Yuauthor=L.+Wangauthor=K.+Yangauthor=F.+Liuauthor=R.+Jiangauthor=X.+Yangauthor=T.+Youauthor=X.+Liuauthor=X.+Yangauthor=F.+Baiauthor=H.+Liuauthor=X.+Liuauthor=L.+W.+Guddatauthor=W.+Xuauthor=G.+Xiaoauthor=C.+Qinauthor=Z.+Shiauthor=H.+Jiangauthor=Z.+Raoauthor=H.+Yang&title=Structure+of+Mpro+from+SARS-CoV-2+and+Discovery+of+Its+Inhibitors&doi=10.1038%2Fs41586-020-2223-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</span></div><div class="casAuthors">Jin, Zhenming; Du, Xiaoyu; Xu, Yechun; Deng, Yongqiang; Liu, Meiqin; Zhao, Yao; Zhang, Bing; Li, Xiaofeng; Zhang, Leike; Peng, Chao; Duan, Yinkai; Yu, Jing; Wang, Lin; Yang, Kailin; Liu, Fengjiang; Jiang, Rendi; Yang, Xinglou; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Liu, Hong; Liu, Xiang; Guddat, Luke W.; Xu, Wenqing; Xiao, Gengfu; Qin, Chengfeng; Shi, Zhengli; Jiang, Hualiang; Rao, Zihe; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">7811</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the etiol. agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19).  Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited.  Here, we describe the results of a program that aimed to rapidly discover lead compds. for clin. use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening.  This program focused on identifying drug leads that target main protease (Mpro) of SARS-CoV-2: Mpro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2.  We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then detd. the crystal structure of Mpro of SARS-CoV-2 in complex with this compd.  Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compds.-including approved drugs, drug candidates in clin. trials and other pharmacol. active compds.-as inhibitors of Mpro.  Six of these compds. inhibited Mpro, showing half-maximal inhibitory concn. values that ranged from 0.67 to 21.4Î¼M.  One of these compds. (ebselen) also exhibited promising antiviral activity in cell-based assays.  Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clin. potential in response to new infectious diseases for which no specific drugs or vaccines are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFupuh6WIyW7Vg90H21EOLACvtfcHk0lg2IwFalsrjaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO&md5=b84f350fe9ce1109485df6caf814ba82</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2223-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2223-y%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520Mpro%2520from%2520SARS-CoV-2%2520and%2520Discovery%2520of%2520Its%2520Inhibitors%26jtitle%3DNature%26date%3D2020%26volume%3D582%26spage%3D289%26epage%3D293%26doi%3D10.1038%2Fs41586-020-2223-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rut, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groborz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmudzinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drag, M.</span></span> <span> </span><span class="NLM_article-title">Substrate Specificity Profiling of SARS-CoV-2 Mpro Protease Provides Basis for Anti-COVID-19 Drug Design</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.03.07.981928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.03.07.981928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32511411" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+Rutauthor=K.+Groborzauthor=L.+Zhangauthor=X.+Sunauthor=M.+Zmudzinskiauthor=R.+Hilgenfeldauthor=M.+Drag&title=Substrate+Specificity+Profiling+of+SARS-CoV-2+Mpro+Protease+Provides+Basis+for+Anti-COVID-19+Drug+Design&doi=10.1101%2F2020.03.07.981928"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2F2020.03.07.981928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.03.07.981928%26sid%3Dliteratum%253Aachs%26aulast%3DRut%26aufirst%3DW.%26aulast%3DGroborz%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZmudzinski%26aufirst%3DM.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DDrag%26aufirst%3DM.%26atitle%3DSubstrate%2520Specificity%2520Profiling%2520of%2520SARS-CoV-2%2520Mpro%2520Protease%2520Provides%2520Basis%2520for%2520Anti-COVID-19%2520Drug%2520Design%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.03.07.981928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Brunn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wilde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4562</span>â <span class="NLM_lpage">4578</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXivValt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4562-4578&author=L.+Zhangauthor=D.+Linauthor=Y.+Kusovauthor=Y.+Nianauthor=Q.+Maauthor=J.+Wangauthor=A.+Von+Brunnauthor=P.+Leyssenauthor=K.+Lankoauthor=J.+Neytsauthor=A.+De+Wildeauthor=E.+J.+Snijderauthor=H.+Liuauthor=R.+Hilgenfeld&title=%CE%B1-Ketoamides+as+Broad-Spectrum+Inhibitors+of+Coronavirus+and+Enterovirus+Replication%3A+Structure-Based+Design%2C+Synthesis%2C+and+Activity+Assessment&doi=10.1021%2Facs.jmedchem.9b01828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment</span></div><div class="casAuthors">Zhang, Linlin; Lin, Daizong; Kusov, Yuri; Nian, Yong; Ma, Qingjun; Wang, Jiang; von Brunn, Albrecht; Leyssen, Pieter; Lanko, Kristina; Neyts, Johan; de Wilde, Adriaan; Snijder, Eric J.; Liu, Hong; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4562-4578</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The main protease of coronaviruses and the 3C protease of enteroviruses share a similar active-site architecture and a unique requirement for glutamine in the P1 position of the substrate.  Because of their unique specificity and essential role in viral polyprotein processing, these proteases are suitable targets for the development of antiviral drugs.  In order to obtain near-equipotent, broad-spectrum antivirals against alphacoronaviruses, betacoronaviruses, and enteroviruses, we pursued structure-based design of peptidomimetic Î±-ketoamides as inhibitors of main and 3C proteases.  Six crystal structures of protease:inhibitor complexes were detd. as part of this study.  Compds. synthesized were tested against the recombinant proteases as well as in viral replicons and virus-infected cell cultures; most of them were not cell-toxic.  Optimization of the P2 substituent of the Î±-ketoamides proved crucial for achieving near-equipotency against the three virus genera.  The best near-equipotent inhibitors, (I) [R1 = cyclopentylmethyl (P2) and R1 = cyclohexylmethyl (P2)], display low-micromolar EC50 values against enteroviruses, alphacoronaviruses, and betacoronaviruses in cell cultures.  In Huh7 cells, I [R1 = cyclohexylmethyl (P2)] exhibits three-digit picomolar activity against Middle East Respiratory Syndrome coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWpcfl4wTRLLVg90H21EOLACvtfcHk0lg2IwFalsrjaA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXivValt7o%253D&md5=60d91a8ecf916856a844d835ecf84d5f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01828%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DKusov%26aufirst%3DY.%26aulast%3DNian%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVon%2BBrunn%26aufirst%3DA.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DLanko%26aufirst%3DK.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe%2BWilde%26aufirst%3DA.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3D%25CE%25B1-Ketoamides%2520as%2520Broad-Spectrum%2520Inhibitors%2520of%2520Coronavirus%2520and%2520Enterovirus%2520Replication%253A%2520Structure-Based%2520Design%252C%2520Synthesis%252C%2520and%2520Activity%2520Assessment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4562%26epage%3D4578%26doi%3D10.1021%2Facs.jmedchem.9b01828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiew, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandadapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alliston, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-O.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">11754</span>â <span class="NLM_lpage">11762</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01348-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01348-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22915796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCmur3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=11754-11762&author=Y.+Kimauthor=S.+Lovellauthor=K.-C.+Tiewauthor=S.+R.+Mandadapuauthor=K.+R.+Allistonauthor=K.+P.+Battaileauthor=W.+C.+Groutasauthor=K.-O.+Chang&title=Broad-Spectrum+Antivirals+against+3C+or+3C-Like+Proteases+of+Picornaviruses%2C+Noroviruses%2C+and+Coronaviruses&doi=10.1128%2FJVI.01348-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses</span></div><div class="casAuthors">Kim, Yunjeong; Lovell, Scott; Tiew, Kok-Chuan; Mandadapu, Sivakoteswara Rao; Alliston, Kevin R.; Battaile, Kevin P.; Groutas, William C.; Chang, Kyeong-Ok</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11754-11762</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Phylogenetic anal. has demonstrated that some pos.-sense RNA viruses can be classified into the picornavirus-like super-cluster, which includes picornaviruses, caliciviruses, and coronaviruses.  These viruses possess 3C or 3C-like proteases (3Cpro or 3CLpro, resp.), which contain a typical chymotrypsin-like fold and a catalytic triad (or dyad) with a Cys residue as a nucleophile.  The conserved key sites of 3Cpro or 3CLpro may serve as attractive targets for the design of broad-spectrum antivirals for multiple viruses in the supercluster.  We previously reported the structure-based design and synthesis of potent protease inhibitors of Norwalk virus (NV), a member of the Caliciviridae family.  We report herein the broad-spectrum antiviral activities of three compds. possessing a common dipeptidyl residue with different warheads, i.e., an aldehyde (GC373), a bisulfite adduct (GC376), and an Î±-ketoamide (GC375), against viruses that belong to the supercluster.  All compds. were highly effective against the majority of tested viruses, with half-maximal inhibitory concns. in the high nanomolar or low micromolar range in enzyme- and/or cell-based assays and with high therapeutic indexes.  We also report the high-resoln. X-ray cocrystal structures of NV 3CLpro-, poliovirus 3Cpro-, and transmissible gastroenteritis virus 3CLpro- GC376 inhibitor complexes, which show the compd. covalently bound to a nucleophilic Cys residue in the catalytic site of the corresponding protease.  We conclude that these compds. have the potential to be developed as antiviral therapeutics aimed at a single virus or multiple viruses in the picornavirus-like supercluster by targeting 3Cpro or 3CLpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDn4MUH7bIlLVg90H21EOLACvtfcHk0lgAJjwPfAi_AA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCmur3M&md5=c7fe984b52490199a2c2ef333c22fb98</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FJVI.01348-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01348-12%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DTiew%26aufirst%3DK.-C.%26aulast%3DMandadapu%26aufirst%3DS.%2BR.%26aulast%3DAlliston%26aufirst%3DK.%2BR.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.-O.%26atitle%3DBroad-Spectrum%2520Antivirals%2520against%25203C%2520or%25203C-Like%2520Proteases%2520of%2520Picornaviruses%252C%2520Noroviruses%252C%2520and%2520Coronaviruses%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D11754%26epage%3D11762%26doi%3D10.1128%2FJVI.01348-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwaltney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi-Burris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsyu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patick, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalman, L. S.</span></span> <span> </span><span class="NLM_article-title">Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3907</span>â <span class="NLM_lpage">3916</span>, <span class="refDoi">Â DOI: 10.1128/AAC.47.12.3907-3916.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.47.12.3907-3916.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14638501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsV2nu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=3907-3916&author=F.+G.+Haydenauthor=R.+B.+Turnerauthor=J.+M.+Gwaltneyauthor=K.+Chi-Burrisauthor=M.+Gerstenauthor=P.+Hsyuauthor=A.+K.+Patickauthor=G.+J.+Smithauthor=L.+S.+Zalman&title=Phase+II%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Studies+of+Ruprintrivir+Nasal+Spray+2-Percent+Suspension+for+Prevention+and+Treatment+of+Experimentally+Induced+Rhinovirus+Colds+in+Healthy+Volunteers&doi=10.1128%2FAAC.47.12.3907-3916.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2% suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers</span></div><div class="casAuthors">Hayden, Frederick G.; Turner, Ronald B.; Gwaltney, Jack M.; Chi-burris, Kathy; Gersten, Merril; Hsyu, Poe; Patick, Amy K.; Smith, George J., III; Zalman, Leora S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3907-3916</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human rhinovirus (HRV) infections are usually self-limited but may be assocd. with serious consequences, particularly in those with asthma and chronic respiratory disease.  Effective antiviral agents are needed for preventing and treating HRV illnesses.  Ruprintrivir (Agouron Pharmaceuticals, Inc., San Diego, Calif.) selectively inhibits HRV 3C protease and shows potent, broad-spectrum anti-HRV activity in vitro.  We conducted three double-blind, placebo-controlled clin. trials in 202 healthy volunteers to assess the activity of ruprintrivir in exptl. HRV infection.  Subjects were randomized to receive intranasal ruprintrivir (8 mg) or placebo sprays as prophylaxis (two or five times daily [2Ã/day or 5Ã/day] for 5 days) starting 6 h before infection or as treatment (5Ã/day for 4 days) starting 24 h after infection.  Ruprintrivir prophylaxis reduced the proportion of subjects with pos. viral cultures (for 5Ã/day dosing groups, 44% for ruprintrivir treatment group vs. 70% for placebo treatment group [P = 0.03]; for 2Ã/day dosing groups, 60% for ruprintrivir group vs. 92% for placebo group [P = 0.004]) and viral titers but did not decrease the frequency of colds.  Ruprintrivir treatment reduced the mean total daily symptom score (2.2 for ruprintrivir treatment group and 3.3 for the placebo treatment group [P = 0.014]) by 33%.  Secondary endpoints, including viral titers, individual symptom scores, and nasal discharge wts., were also reduced by ruprintrivir treatment.  Overall, ruprintrivir was well tolerated; blood-tinged mucus and nasal passage irritation were the most common adverse effects reported.  Pharmacokinetic anal. of plasma and nasal ruprintrivir concns. revealed intranasal drug residence with minimal systemic absorption.  Results from these studies in exptl. rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoudaxRiBJLg7Vg90H21EOLACvtfcHk0lgAJjwPfAi_AA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsV2nu7w%253D&md5=6d6c33f56af0c4f45145b291ace2dba1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.12.3907-3916.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.12.3907-3916.2003%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DTurner%26aufirst%3DR.%2BB.%26aulast%3DGwaltney%26aufirst%3DJ.%2BM.%26aulast%3DChi-Burris%26aufirst%3DK.%26aulast%3DGersten%26aufirst%3DM.%26aulast%3DHsyu%26aufirst%3DP.%26aulast%3DPatick%26aufirst%3DA.%2BK.%26aulast%3DSmith%26aufirst%3DG.%2BJ.%26aulast%3DZalman%26aufirst%3DL.%2BS.%26atitle%3DPhase%2520II%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Studies%2520of%2520Ruprintrivir%2520Nasal%2520Spray%25202-Percent%2520Suspension%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Experimentally%2520Induced%2520Rhinovirus%2520Colds%2520in%2520Healthy%2520Volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D3907%26epage%3D3916%26doi%3D10.1128%2FAAC.47.12.3907-3916.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6595</span>â <span class="NLM_lpage">6628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01461</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01461" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6595-6628&author=T.+Pillaiyarauthor=M.+Manickamauthor=V.+Namasivayamauthor=Y.+Hayashiauthor=S.+H.+Jung&title=An+Overview+of+Severe+Acute+Respiratory+Syndrome-Coronavirus+%28SARS-CoV%29+3CL+Protease+Inhibitors%3A+Peptidomimetics+and+Small+Molecule+Chemotherapy&doi=10.1021%2Facs.jmedchem.5b01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6595-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003.  The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CLpro, has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection.  Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications).  This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003-2015) from all sources, including lab. synthetic methods, natural products, and virtual screening.  We describe here mainly peptidomimetic and small mol. inhibitors of SARS-CoV 3CLpro.  Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB_JCXe-m0RLVg90H21EOLACvtfcHk0lgAJjwPfAi_AA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D&md5=6ce37076204280f64a7f362633fcee1a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01461%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DAn%2520Overview%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome-Coronavirus%2520%2528SARS-CoV%2529%25203CL%2520Protease%2520Inhibitors%253A%2520Peptidomimetics%2520and%2520Small%2520Molecule%2520Chemotherapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6595%26epage%3D6628%26doi%3D10.1021%2Facs.jmedchem.5b01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Telaprevir: An NS3â4A Protease Inhibitor for Treating Genotype 1 Chronic Hepatitis C Virus</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+Development+of+Telaprevir%3A+An+NS3%E2%80%934A+Protease+Inhibitor+for+Treating+Genotype+1+Chronic+Hepatitis+C+Virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) Î± and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lhYby-SVWDc2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Telaprevir%253A%2520An%2520NS3%25E2%2580%25934A%2520Protease%2520Inhibitor%2520for%2520Treating%2520Genotype%25201%2520Chronic%2520Hepatitis%2520C%2520Virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibulbhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butkiewicz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingravallo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichardo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroudy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfmacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanowich-Knipp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-Amino-1-(Cyclobutylmethyl)-2,3-Dioxopropyl]-3- [2(S)-[[[(1,1-Dimethylethyl)Amino]Carbonyl]Amino]-3,3-Dimethyl-1-Oxobutyl]-6, 6-Dimethyl-3-Azabicyclo[3.1.0]Hexan-2(S)-Carboxamide (SCH 503034), a Selective, Potent, Orally Bioavaila</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6074</span>â <span class="NLM_lpage">6086</span>, <span class="refDoi">Â DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.+T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.+C.+Chengauthor=Y.+Hsiehauthor=J.+M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-Amino-1-%28Cyclobutylmethyl%29-2%2C3-Dioxopropyl%5D-3-+%5B2%28S%29-%5B%5B%5B%281%2C1-Dimethylethyl%29Amino%5DCarbonyl%5DAmino%5D-3%2C3-Dimethyl-1-Oxobutyl%5D-6%2C+6-Dimethyl-3-Azabicyclo%5B3.1.0%5DHexan-2%28S%29-Carboxamide+%28SCH+503034%29%2C+a+Selective%2C+Potent%2C+Orally+Bioavaila&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-Î± or polyethylene glycol (PEG)-interferon-Î± alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0lhYby-SVWDc2w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.%2BM.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-Amino-1-%2528Cyclobutylmethyl%2529-2%252C3-Dioxopropyl%255D-3-%2520%255B2%2528S%2529-%255B%255B%255B%25281%252C1-Dimethylethyl%2529Amino%255DCarbonyl%255DAmino%255D-3%252C3-Dimethyl-1-Oxobutyl%255D-6%252C%25206-Dimethyl-3-Azabicyclo%255B3.1.0%255DHexan-2%2528S%2529-Carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520Selective%252C%2520Potent%252C%2520Orally%2520Bioavaila%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boggild, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajic-Veljanoski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald-Blumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridout, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tile, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. M.</span></span> <span> </span><span class="NLM_article-title">Odanacatib for the Treatment of Osteoporosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1717</span>â <span class="NLM_lpage">1726</span>, <span class="refDoi">Â DOI: 10.1517/14656566.2015.1064897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1517%2F14656566.2015.1064897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26149759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyru7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1717-1726&author=M.+K.+Boggildauthor=O.+Gajic-Veljanoskiauthor=H.+McDonald-Blumerauthor=R.+Ridoutauthor=L.+Tileauthor=R.+Josseauthor=A.+M.+Cheung&title=Odanacatib+for+the+Treatment+of+Osteoporosis&doi=10.1517%2F14656566.2015.1064897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Odanacatib for the treatment of osteoporosis</span></div><div class="casAuthors">Boggild, Miranda K.; Gajic-Veljanoski, Olga; McDonald-Blumer, Heather; Ridout, Rowena; Tile, Lianne; Josse, Robert; Cheung, Angela M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1717-1726</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Osteoporosis and fragility fractures are important public health concerns.  Cathepsin K inhibitors, including odanacatib, are a novel class of medications for osteoporosis whose mechanism of action is to directly inhibit bone resorption without killing osteoclasts, thereby permitting the complex coupling between bone resorption and formation to continue.  Areas covered: The physiol. basis for the mechanism of action of cathepsin K inhibitors is covered in addn. to a review of the preclin., Phase I, Phase II and preliminary Phase III trial data of odanacatib.  Expert opinion: Evidence suggests that odanacatib has similar efficacy to bisphosphonates at increasing bone mineral d. and decreasing risk of fragility fractures.  Although odanacatib may preferentially inhibit bone resorption more than formation, the clin. significance of this difference in mechanism of action is not yet known.  A careful anal. of the Phase III trial data is needed with specific attention to adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsg4VWIxbTXLVg90H21EOLACvtfcHk0lhcuLMD1Jb9eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyru7jM&md5=44c4eda645f2550e5b62e42d9984e879</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1064897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1064897%26sid%3Dliteratum%253Aachs%26aulast%3DBoggild%26aufirst%3DM.%2BK.%26aulast%3DGajic-Veljanoski%26aufirst%3DO.%26aulast%3DMcDonald-Blumer%26aufirst%3DH.%26aulast%3DRidout%26aufirst%3DR.%26aulast%3DTile%26aufirst%3DL.%26aulast%3DJosse%26aufirst%3DR.%26aulast%3DCheung%26aufirst%3DA.%2BM.%26atitle%3DOdanacatib%2520for%2520the%2520Treatment%2520of%2520Osteoporosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1717%26epage%3D1726%26doi%3D10.1517%2F14656566.2015.1064897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span> <span> </span><span class="NLM_article-title">Development of Small-Molecule MERS-CoV Inhibitors</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">721</span>, <span class="refDoi">Â DOI: 10.3390/v10120721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fv10120721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=721&author=R.+Liangauthor=L.+Wangauthor=N.+Zhangauthor=X.+Dengauthor=M.+Suauthor=Y.+Suauthor=L.+Huauthor=C.+Heauthor=T.+Yingauthor=S.+Jiangauthor=F.+Yu&title=Development+of+Small-Molecule+MERS-CoV+Inhibitors&doi=10.3390%2Fv10120721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small-molecule MERS-CoV inhibitors</span></div><div class="casAuthors">Liang, Ruiying; Wang, Lili; Zhang, Naru; Deng, Xiaoqian; Su, Meng; Su, Yudan; Hu, Lanfang; He, Chen; Ying, Tianlei; Jiang, Shibo; Yu, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">721</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Middle East respiratory syndrome coronavirus (MERS-CoV) with potential to cause global pandemics remains a threat to the public health, security, and economy.  In this review, we focus on advances in the research and development of small-mol. MERS-CoV inhibitors targeting different stages of the MERS-CoV life cycle, aiming to prevent or treat MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqctTvasJSAE7Vg90H21EOLACvtfcHk0lhcuLMD1Jb9eg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrnK&md5=9250f51075255474d07a53bf2cf71bfb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fv10120721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10120721%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYing%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520Small-Molecule%2520MERS-CoV%2520Inhibitors%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D721%26doi%3D10.3390%2Fv10120721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">From SARS to MERS: Crystallographic Studies on Coronaviral Proteases Enable Antiviral Drug Design</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">4085</span>â <span class="NLM_lpage">4096</span>, <span class="refDoi">Â DOI: 10.1111/febs.12936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1111%2Ffebs.12936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25039866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2014&pages=4085-4096&author=R.+Hilgenfeld&title=From+SARS+to+MERS%3A+Crystallographic+Studies+on+Coronaviral+Proteases+Enable+Antiviral+Drug+Design&doi=10.1111%2Ffebs.12936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design</span></div><div class="casAuthors">Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4085-4096</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Here, the author focuses on the important contributions that macromol. crystallog. has made over the past 12 yr to elucidating structures and mechanisms of the essential proteases of coronaviruses, the main protease (Mpro) and the papain-like protease (PLpro).  The role of x-ray crystallog. in structure-assisted drug discovery against these targets is discussed.  Aspects dealt with in this review include the emergence of the SARS coronavirus in 2002-2003 and of the MERS coronavirus 10 yr later and the origins of these viruses.  The crystal structure of the free SARS coronavirus Mpro and its dependence on pH is discussed, as are efforts to design inhibitors on the basis of these structures.  The mechanism of maturation of the enzyme from the viral polyprotein is still a matter of debate.  The crystal structure of the SARS coronavirus PLpro and its complex with ubiquitin is also discussed, as is its ortholog from MERS coronavirus.  Efforts at predictive structure-based inhibitor development for bat coronavirus Mpros to increase the preparedness against zoonotic transmission to man are described as well.  The paper closes with a brief discussion of structure-based discovery of antivirals in an academic setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy_Y5ir6KZ8LVg90H21EOLACvtfcHk0lhrCXXQNemYoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbI&md5=6a9330976a5c3a13dd4bf7bed14665ce</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12936%26sid%3Dliteratum%253Aachs%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DFrom%2520SARS%2520to%2520MERS%253A%2520Crystallographic%2520Studies%2520on%2520Coronaviral%2520Proteases%2520Enable%2520Antiviral%2520Drug%2520Design%26jtitle%3DFEBS%2520J.%26date%3D2014%26volume%3D281%26spage%3D4085%26epage%3D4096%26doi%3D10.1111%2Ffebs.12936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">22677</span>, <span class="refDoi">Â DOI: 10.1038/srep22677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsrep22677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26948040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslGrtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=22677&author=F.+Wangauthor=C.+Chenauthor=W.+Tanauthor=K.+Yangauthor=H.+Yang&title=Structure+of+Main+Protease+from+Human+Coronavirus+NL63%3A+Insights+for+Wide+Spectrum+Anti-Coronavirus+Drug+Design&doi=10.1038%2Fsrep22677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design</span></div><div class="casAuthors">Wang, Fenghua; Chen, Cheng; Tan, Wenjie; Yang, Kailin; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22677</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">First identified in The Netherlands in 2004, human coronavirus NL63 (HCoV-NL63) was found to cause worldwide infections.  Patients infected by HCoV-NL63 are typically young children with upper and lower respiratory tract infection, presenting with symptoms including croup, bronchiolitis, and pneumonia.  Unfortunately, there are currently no effective antiviral therapy to contain HCoV-NL63 infection.  CoV genomes encode an integral viral component, main protease (Mpro), which is essential for viral replication through proteolytic processing of RNA replicase machinery.  Due to the sequence and structural conservation among all CoVs, Mpro has been recognized as an attractive mol. target for rational anti-CoV drug design.  Here we present the crystal structure of HCoV-NL63 Mpro in complex with a Michael acceptor inhibitor N3.  Structural anal., consistent with biochem. inhibition results, reveals the mol. mechanism of enzyme inhibition at the highly conservative substrate-recognition pocket.  We show such mol. target remains unchanged across 30 clin. isolates of HCoV-NL63 strains.  Through comparative study with Mpros from other human CoVs (including the deadly SARS-CoV and MERS-CoV) and their related zoonotic CoVs, our structure of HCoV-NL63 Mpro provides crit. insight into rational development of wide spectrum antiviral therapeutics to treat infections caused by human CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLT78CqKCbcLVg90H21EOLACvtfcHk0lhrCXXQNemYoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslGrtLg%253D&md5=b756a48075e0f5551871a9569a99c8c0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsrep22677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep22677%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520Main%2520Protease%2520from%2520Human%2520Coronavirus%2520NL63%253A%2520Insights%2520for%2520Wide%2520Spectrum%2520Anti-Coronavirus%2520Drug%2520Design%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D22677%26doi%3D10.1038%2Fsrep22677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">The Newly Emerged SARS-Like Coronavirus HCoV-EMC Also Has an âAchillesââ Heelâ³: Current Effective Inhibitor Targeting a 3C-like Protease.</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">250</span>, <span class="refDoi">Â DOI: 10.1007/s13238-013-2841-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2Fs13238-013-2841-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23549610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC3srhslWqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=248-250&author=Z.+Renauthor=L.+Yanauthor=N.+Zhangauthor=Y.+Guoauthor=C.+Yangauthor=Z.+Louauthor=Z.+Rao&title=The+Newly+Emerged+SARS-Like+Coronavirus+HCoV-EMC+Also+Has+an+%E2%80%9CAchilles%E2%80%99%E2%80%99+Heel%E2%80%B3%3A+Current+Effective+Inhibitor+Targeting+a+3C-like+Protease.&doi=10.1007%2Fs13238-013-2841-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease</span></div><div class="casAuthors">Ren Zhilin; Yan Liming; Zhang Ning; Guo Yu; Yang Cheng; Lou Zhiyong; Rao Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Protein & cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">248-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_LY3nQVW-IS-bLEOO4dYpfW6udTcc2eaCrSBJNussHLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srhslWqtg%253D%253D&md5=d785b3818d939e5ca1a9b7f6572291e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs13238-013-2841-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-013-2841-3%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DThe%2520Newly%2520Emerged%2520SARS-Like%2520Coronavirus%2520HCoV-EMC%2520Also%2520Has%2520an%2520%25E2%2580%259CAchilles%25E2%2580%2599%25E2%2580%2599%2520Heel%25E2%2580%25B3%253A%2520Current%2520Effective%2520Inhibitor%2520Targeting%2520a%25203C-like%2520Protease.%26jtitle%3DProtein%2520Cell%26date%3D2013%26volume%3D4%26spage%3D248%26epage%3D250%26doi%3D10.1007%2Fs13238-013-2841-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">2515</span>â <span class="NLM_lpage">2527</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02114-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02114-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18094151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlyhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=2515-2527&author=X.+Xueauthor=H.+Yuauthor=H.+Yangauthor=F.+Xueauthor=Z.+Wuauthor=W.+Shenauthor=J.+Liauthor=Z.+Zhouauthor=Y.+Dingauthor=Q.+Zhaoauthor=X.+C.+Zhangauthor=M.+Liaoauthor=M.+Bartlamauthor=Z.+Rao&title=Structures+of+Two+Coronavirus+Main+Proteases%3A+Implications+for+Substrate+Binding+and+Antiviral+Drug+Design&doi=10.1128%2FJVI.02114-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design</span></div><div class="casAuthors">Xue, Xiaoyu; Yu, Hongwei; Yang, Haitao; Xue, Fei; Wu, Zhixin; Shen, Wei; Li, Jun; Zhou, Zhe; Ding, Yi; Zhao, Qi; Zhang, Xuejun C.; Liao, Ming; Bartlam, Mark; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2515-2527</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses (CoVs) can infect humans and multiple species of animals, causing a wide spectrum of diseases.  The coronavirus main protease (Mpro), which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design.  In this study, the crystal structures of infectious bronchitis virus (IBV) Mpro and a severe acute respiratory syndrome CoV (SARS-CoV) Mpro mutant (H41A), in complex with an N-terminal autocleavage substrate, were individually detd. to elucidate the structural flexibility and substrate binding of Mpro.  A monomeric form of IBV Mpro was identified for the first time in CoV Mpro structures.  A comparison of these two structures to other available Mpro structures provides new insights for the design of substrate-based inhibitors targeting CoV Mpros.  Furthermore, a Michael acceptor inhibitor (named N3) was cocrystd. with IBV Mpro and was found to demonstrate in vitro inactivation of IBV Mpro and potent antiviral activity against IBV in chicken embryos.  This provides a feasible animal model for designing wide-spectrum inhibitors against CoV-assocd. diseases.  The structure-based optimization of N3 has yielded two more efficacious lead compds., N27 and H16, with potent inhibition against SARS-CoV Mpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9WfRbvyd-w7Vg90H21EOLACvtfcHk0lgyjr5OZqmVNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlyhu70%253D&md5=7407ae587531f95fe6372ffa88e6393d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1128%2FJVI.02114-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02114-07%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructures%2520of%2520Two%2520Coronavirus%2520Main%2520Proteases%253A%2520Implications%2520for%2520Substrate%2520Binding%2520and%2520Antiviral%2520Drug%2520Design%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D2515%26epage%3D2527%26doi%3D10.1128%2FJVI.02114-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e324</span>, <span class="refDoi">Â DOI: 10.1371/journal.pbio.0030324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.pbio.0030324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16128623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BD2MrjtlWksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=e324&author=H.+Yangauthor=W.+Xieauthor=X.+Xueauthor=K.+Yangauthor=J.+Maauthor=W.+Liangauthor=Q.+Zhaoauthor=Z.+Zhouauthor=D.+Peiauthor=J.+Ziebuhrauthor=R.+Hilgenfeldauthor=K.+Y.+Yuenauthor=L.+Wongauthor=G.+Gaoauthor=S.+Chenauthor=Z.+Chenauthor=D.+Maauthor=M.+Bartlamauthor=Z.+Rao&title=Design+of+Wide-Spectrum+Inhibitors+Targeting+Coronavirus+Main+Proteases&doi=10.1371%2Fjournal.pbio.0030324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design of wide-spectrum inhibitors targeting coronavirus main proteases</span></div><div class="casAuthors">Yang Haitao; Xie Weiqing; Xue Xiaoyu; Yang Kailin; Ma Jing; Liang Wenxue; Zhao Qi; Zhou Zhe; Pei Duanqing; Ziebuhr John; Hilgenfeld Rolf; Yuen Kwok Yung; Wong Luet; Gao Guangxia; Chen Saijuan; Chen Zhu; Ma Dawei; Bartlam Mark; Rao Zihe</div><div class="citationInfo"><span class="NLM_cas:title">PLoS biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing highly prevalent diseases and often severe or fatal in humans and animals.  No licensed specific drugs are available to prevent their infection.  Different host receptors for cellular entry, poorly conserved structural proteins (antigens), and the high mutation and recombination rates of CoVs pose a significant problem in the development of wide-spectrum anti-CoV drugs and vaccines.  CoV main proteases (M(pro)s), which are key enzymes in viral gene expression and replication, were revealed to share a highly conservative substrate-recognition pocket by comparison of four crystal structures and a homology model representing all three genetic clusters of the genus Coronavirus.  This conclusion was further supported by enzyme activity assays.  Mechanism-based irreversible inhibitors were designed, based on this conserved structural region, and a uniform inhibition mechanism was elucidated from the structures of Mpro-inhibitor complexes from severe acute respiratory syndrome-CoV and porcine transmissible gastroenteritis virus.  A structure-assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV M(pro)s, potent antiviral activity, and extremely low cellular toxicity in cell-based assays.  Further modification could rapidly lead to the discovery of a single agent with clinical potential against existing and possible future emerging CoV-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTmeuy-d3hP7HHuJhbyicZfW6udTcc2eYjkc_ohfDQhbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrjtlWksA%253D%253D&md5=e71de1aa88f5c33517694e746325c6e8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0030324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0030324%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DDesign%2520of%2520Wide-Spectrum%2520Inhibitors%2520Targeting%2520Coronavirus%2520Main%2520Proteases%26jtitle%3DPLoS%2520Biol.%26date%3D2005%26volume%3D3%26spage%3De324%26doi%3D10.1371%2Fjournal.pbio.0030324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1331</span>â <span class="NLM_lpage">1335</span>, <span class="refDoi">Â DOI: 10.1126/science.abb4489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32321856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1alsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1331-1335&author=W.+Daiauthor=B.+Zhangauthor=X.+M.+Jiangauthor=H.+Suauthor=J.+Liauthor=Y.+Zhaoauthor=X.+Xieauthor=Z.+Jinauthor=J.+Pengauthor=F.+Liuauthor=C.+Liauthor=Y.+Liauthor=F.+Baiauthor=H.+Wangauthor=X.+Chengauthor=X.+Cenauthor=S.+Huauthor=X.+Yangauthor=J.+Wangauthor=X.+Liuauthor=G.+Xiaoauthor=H.+Jiangauthor=Z.+Raoauthor=L.+K.+Zhangauthor=Y.+Xuauthor=H.+Yangauthor=H.+Liu&title=Structure-Based+Design+of+Antiviral+Drug+Candidates+Targeting+the+SARS-CoV-2+Main+Protease&doi=10.1126%2Fscience.abb4489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease</span></div><div class="casAuthors">Dai, Wenhao; Zhang, Bing; Jiang, Xia-Ming; Su, Haixia; Li, Jian; Zhao, Yao; Xie, Xiong; Jin, Zhenming; Peng, Jingjing; Liu, Fengjiang; Li, Chunpu; Li, You; Bai, Fang; Wang, Haofeng; Cheng, Xi; Cen, Xiaobo; Hu, Shulei; Yang, Xiuna; Wang, Jiang; Liu, Xiang; Xiao, Gengfu; Jiang, Hualiang; Rao, Zihe; Zhang, Lei-Ke; Xu, Yechun; Yang, Haitao; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6497</span>),
    <span class="NLM_cas:pages">1331-1335</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiol. agent responsible for the global COVID-19 (coronavirus disease 2019) outbreak.  The main protease of SARS-CoV-2, Mpro, is a key enzyme that plays a pivotal role in mediating viral replication and transcription.  We designed and synthesized two lead compds. (11a and 11b) targeting Mpro.  Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity.  The x-ray crystal structures of SARS-CoV-2 Mpro in complex with 11a or 11b, both detd. at a resoln. of 1.5 angstroms, showed that the aldehyde groups of 11a and 11b are covalently bound to cysteine 145 of Mpro.  Both compds. showed good pharmacokinetic properties in vivo, and 11a also exhibited low toxicity, which suggests that these compds. are promising drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFFvzOwCOpZrVg90H21EOLACvtfcHk0lhKa2n_kx-MDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1alsrzL&md5=ec87c340410edb919d2584a2b4d33e1a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb4489%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DX.%2BM.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DCen%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DStructure-Based%2520Design%2520of%2520Antiviral%2520Drug%2520Candidates%2520Targeting%2520the%2520SARS-CoV-2%2520Main%2520Protease%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1331%26epage%3D1335%26doi%3D10.1126%2Fscience.abb4489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Boceprevir, GC-376, and Calpain Inhibitors II, XII Inhibit SARS-CoV-2 Viral Replication by Targeting the Viral Main Protease</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">678</span>â <span class="NLM_lpage">692</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41422-020-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32541865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WmsL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=678-692&author=C.+Maauthor=M.+D.+Saccoauthor=B.+Hurstauthor=J.+A.+Townsendauthor=Y.+Huauthor=T.+Szetoauthor=X.+Zhangauthor=B.+Tarbetauthor=M.+T.+Martyauthor=Y.+Chenauthor=J.+Wang&title=Boceprevir%2C+GC-376%2C+and+Calpain+Inhibitors+II%2C+XII+Inhibit+SARS-CoV-2+Viral+Replication+by+Targeting+the+Viral+Main+Protease&doi=10.1038%2Fs41422-020-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</span></div><div class="casAuthors">Ma, Chunlong; Sacco, Michael Dominic; Hurst, Brett; Townsend, Julia Alma; Hu, Yanmei; Szeto, Tommy; Zhang, Xiujun; Tarbet, Bart; Marty, Michael Thomas; Chen, Yu; Wang, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">678-692</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around Dec. 2019, and it is now widespread as a global pandemic.  The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.35% as of May 26, 2020.  There is no vaccine or antiviral available for SARS-CoV-2.  We report our discovery of inhibitors targeting the SARS-CoV-2 main protease (Mpro).  Using the FRET-based enzymic assay, several inhibitors including boceprevir, GC-376, and calpain inhibitors II and XII were identified to have potent activity with single-digit to submicromolar IC50 values in the enzymic assay.  The mechanism of action of the hits was further characterized using enzyme kinetic studies, thermal shift binding assays, and native mass spectrometry.  Significantly, 4 compds. (boceprevir, GC-376, and calpain inhibitors II and XII) inhibit SARS-CoV-2 viral replication in cell culture with EC50 values ranging 0.49-3.37Î¼M.  Notably, boceprevir and calpain inhibitors II and XII represent novel chemotypes that are distinct from known substrate-based peptidomimetic Mpro inhibitors.  A complex crystal structure of SARS-CoV-2 Mpro with GC-376, detd. at 2.15 Ã resoln. with 3 protomers per asym. unit, revealed 2 unique binding configurations, shedding light on the mol. interactions and protein conformational flexibility underlying substrate and inhibitor binding by Mpro.  Overall, the compds. identified provide promising starting points for the further development of SARS-CoV-2 therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVnFC-t0uFW7Vg90H21EOLACvtfcHk0lhKa2n_kx-MDw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WmsL%252FL&md5=225d518c313474cdfbcfe678d35e26a4</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26aulast%3DSacco%26aufirst%3DM.%2BD.%26aulast%3DHurst%26aufirst%3DB.%26aulast%3DTownsend%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSzeto%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTarbet%26aufirst%3DB.%26aulast%3DMarty%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DBoceprevir%252C%2520GC-376%252C%2520and%2520Calpain%2520Inhibitors%2520II%252C%2520XII%2520Inhibit%2520SARS-CoV-2%2520Viral%2520Replication%2520by%2520Targeting%2520the%2520Viral%2520Main%2520Protease%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D678%26epage%3D692%26doi%3D10.1038%2Fs41422-020-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasiti
Kankanamalage, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasekara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, N. C.</span></span> <span> </span><span class="NLM_article-title">Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1005531</span>, <span class="refDoi">Â DOI: 10.1371/journal.ppat.1005531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.ppat.1005531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27027316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGru7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1005531&author=Y.+Kimauthor=H.+Liuauthor=A.+C.+Galasiti%0AKankanamalageauthor=S.+Weerasekaraauthor=D.+H.+Huaauthor=W.+C.+Groutasauthor=K.+O.+Changauthor=N.+C.+Pedersen&title=Reversal+of+the+Progression+of+Fatal+Coronavirus+Infection+in+Cats+by+a+Broad-Spectrum+Coronavirus+Protease+Inhibitor&doi=10.1371%2Fjournal.ppat.1005531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor</span></div><div class="casAuthors">Kim, Yunjeong; Liu, Hongwei; Kankanamalage, Anushka C. Galasiti; Weerasekara, Sahani; Hua, Duy H.; Groutas, William C.; Chang, Kyeong-Ok; Pedersen, Niels C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1005531/1-e1005531/18</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Coronaviruses infect animals and humans causing a wide range of diseases.  The diversity of coronaviruses in many mammalian species is contributed by relatively high mutation and recombination rates during replication.  This dynamic nature of coronaviruses may facilitate cross-species transmission and shifts in tissue or cell tropism in a host, resulting in substantial change in virulence.  Feline enteric coronavirus (FECV) causes inapparent or mild enteritis in cats, but a highly fatal disease, called feline infectious peritonitis (FIP), can arise through mutation of FECV to FIP virus (FIPV).  The pathogenesis of FIP is intimately assocd. with immune responses and involves depletion of T cells, features shared by some other coronaviruses like Severe Acute Respiratory Syndrome Coronavirus.  The increasing risks of highly virulent coronavirus infections in humans or animals call for effective antiviral drugs, but no such measures are yet available.  Previously, we have reported the inhibitors that target 3C-like protease (3CLpro) with broad-spectrum activity against important human and animal coronaviruses.  Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in lab. cats with FIP.  Exptl. FIP is 100% fatal once certain clin. and lab. signs become apparent.We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated.  Antiviral treatment was assocd. with a rapid improvement in fever, ascites, lymphopenia and gross signs of illness and cats returned to normal health within 20 days or less of treatment.  Significant redn. in viral titers was also obsd. in cats.  These results indicate that continuous virus replication is required for progression of immune-mediated inflammatory disease of FIP.  These findings may provide important insights into devising therapeutic strategies and selection of antiviral compds. for further development for important coronaviruses in animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSH3BnhFwZLVg90H21EOLACvtfcHk0lgs5s0uqJ3Ypg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGru7fN&md5=7900b2718caeaf528f10f553e0e8fa16</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005531%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGalasiti%2BKankanamalage%26aufirst%3DA.%2BC.%26aulast%3DWeerasekara%26aufirst%3DS.%26aulast%3DHua%26aufirst%3DD.%2BH.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.%2BO.%26aulast%3DPedersen%26aufirst%3DN.%2BC.%26atitle%3DReversal%2520of%2520the%2520Progression%2520of%2520Fatal%2520Coronavirus%2520Infection%2520in%2520Cats%2520by%2520a%2520Broad-Spectrum%2520Coronavirus%2520Protease%2520Inhibitor%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3D1005531%26doi%3D10.1371%2Fjournal.ppat.1005531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasiti Kankanamalage, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. O.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a 3C-like Protease Inhibitor in Treating Various Forms of Acquired Feline Infectious Peritonitis</span>. <i>J. Feline Med. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">378</span>â <span class="NLM_lpage">392</span>, <span class="refDoi">Â DOI: 10.1177/1098612X17729626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1177%2F1098612X17729626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28901812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1cbns12gsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=378-392&author=N.+C.+Pedersenauthor=Y.+Kimauthor=H.+Liuauthor=A.+C.+Galasiti+Kankanamalageauthor=C.+Eckstrandauthor=W.+C.+Groutasauthor=M.+Bannaschauthor=J.+M.+Meadowsauthor=K.+O.+Chang&title=Efficacy+of+a+3C-like+Protease+Inhibitor+in+Treating+Various+Forms+of+Acquired+Feline+Infectious+Peritonitis&doi=10.1177%2F1098612X17729626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis</span></div><div class="casAuthors">Pedersen Niels C; Liu Hongwei; Bannasch Michael; Kim Yunjeong; Chang Kyeong-Ok; Galasiti Kankanamalage Anushka C; Groutas William C; Eckstrand Chrissy; Meadows Juliana M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of feline medicine and surgery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-392</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP).  Methods Twenty cats from 3.3-82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial.  Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP.  GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg.  Cats with neurologic signs were excluded from the study.  Results Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment.  However, disease signs recurred 1-7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks.  Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1-7 weeks of initial or repeat treatment(s).  Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions.  At the time of writing, seven cats were in disease remission.  Five kittens aged 3.3-4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5-14 months (mean 11.2 months).  A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376.  The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period.  Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss.  There was retarded development and abnormal eruption of permanent teeth in cats treated before 16-18 weeks of age.  Conclusions and relevance GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFFwhHX-Ibonqj_yg7twvpfW6udTcc2ebdaWv0AVwjtrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbns12gsg%253D%253D&md5=69b4ebebb24b351bfb0f409e275b3153</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1177%2F1098612X17729626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1098612X17729626%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DN.%2BC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGalasiti%2BKankanamalage%26aufirst%3DA.%2BC.%26aulast%3DEckstrand%26aufirst%3DC.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DBannasch%26aufirst%3DM.%26aulast%3DMeadows%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DK.%2BO.%26atitle%3DEfficacy%2520of%2520a%25203C-like%2520Protease%2520Inhibitor%2520in%2520Treating%2520Various%2520Forms%2520of%2520Acquired%2520Feline%2520Infectious%2520Peritonitis%26jtitle%3DJ.%2520Feline%2520Med.%2520Surg.%26date%3D2018%26volume%3D20%26spage%3D378%26epage%3D392%26doi%3D10.1177%2F1098612X17729626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span> <span> </span><span class="NLM_article-title">Both Boceprevir and GC376 Efficaciously Inhibit SARS-CoV-2 by Targeting Its Main Protease</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4417</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-18233-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-020-18233-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32887884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4417&author=L.+Fuauthor=F.+Yeauthor=Y.+Fengauthor=F.+Yuauthor=Q.+Wangauthor=Y.+Wuauthor=C.+Zhaoauthor=H.+Sunauthor=B.+Huangauthor=P.+Niuauthor=H.+Songauthor=Y.+Shiauthor=X.+Liauthor=W.+Tanauthor=J.+Qiauthor=G.+F.+Gao&title=Both+Boceprevir+and+GC376+Efficaciously+Inhibit+SARS-CoV-2+by+Targeting+Its+Main+Protease&doi=10.1038%2Fs41467-020-18233-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease</span></div><div class="casAuthors">Fu, Lifeng; Ye, Fei; Feng, Yong; Yu, Feng; Wang, Qisheng; Wu, Yan; Zhao, Cheng; Sun, Huan; Huang, Baoying; Niu, Peihua; Song, Hao; Shi, Yi; Li, Xuebing; Tan, Wenjie; Qi, Jianxun; Gao, George Fu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4417</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health.  The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target.  Here we show that a clin. approved anti-HCV drug, Boceprevir, and a pre-clin. inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro.  Moreover, combined application of GC376 with Remdesivir, a nucleotide analog that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect.  Further structural anal. reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition.  Our findings may provide crit. information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt43KcNqLbkLVg90H21EOLACvtfcHk0li40NURrJ2Ghg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsr3F&md5=273b11d16241499f15103885be398b23</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18233-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18233-x%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%2BF.%26atitle%3DBoth%2520Boceprevir%2520and%2520GC376%2520Efficaciously%2520Inhibit%2520SARS-CoV-2%2520by%2520Targeting%2520Its%2520Main%2520Protease%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4417%26doi%3D10.1038%2Fs41467-020-18233-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arutyunova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Belkum, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vederas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, M. J.</span></span> <span> </span><span class="NLM_article-title">Feline Coronavirus Drug Inhibits the Main Protease of SARS-CoV-2 and Blocks Virus Replication</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4282</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-18096-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-020-18096-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32855413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWqtbzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4282&author=W.+Vuongauthor=M.+B.+Khanauthor=C.+Fischerauthor=E.+Arutyunovaauthor=T.+Lamerauthor=J.+Shieldsauthor=H.+A.+Saffranauthor=R.+T.+McKayauthor=M.+J.+van+Belkumauthor=M.+A.+Joyceauthor=H.+S.+Youngauthor=D.+L.+Tyrrellauthor=J.+C.+Vederasauthor=M.+J.+Lemieux&title=Feline+Coronavirus+Drug+Inhibits+the+Main+Protease+of+SARS-CoV-2+and+Blocks+Virus+Replication&doi=10.1038%2Fs41467-020-18096-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication</span></div><div class="casAuthors">Vuong, Wayne; Khan, Muhammad Bashir; Fischer, Conrad; Arutyunova, Elena; Lamer, Tess; Shields, Justin; Saffran, Holly A.; McKay, Ryan T.; van Belkum, Marco J.; Joyce, Michael A.; Young, Howard S.; Tyrrell, D. Lorne; Vederas, John C.; Lemieux, M. Joanne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4282</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The main protease, Mpro (or 3CLpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide.  Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor.  We show the prodrug and its parent GC373, are effective inhibitors of the Mpro from both SARS-CoV and SARS-CoV-2 with IC50 values in the nanomolar range.  Crystal structures of SARS-CoV-2 Mpro with these inhibitors have a covalent modification of the nucleophilic Cys145.  NMR anal. reveals that inhibition proceeds via reversible formation of a hemithioacetal.  GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture.  They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals.  The work here lays the framework for their use in human trials for the treatment of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMA7W4XtRQrbVg90H21EOLACvtfcHk0li40NURrJ2Ghg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWqtbzN&md5=c06d2dc9a65ae289505fe120d41d8885</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18096-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18096-2%26sid%3Dliteratum%253Aachs%26aulast%3DVuong%26aufirst%3DW.%26aulast%3DKhan%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DArutyunova%26aufirst%3DE.%26aulast%3DLamer%26aufirst%3DT.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DSaffran%26aufirst%3DH.%2BA.%26aulast%3DMcKay%26aufirst%3DR.%2BT.%26aulast%3Dvan%2BBelkum%26aufirst%3DM.%2BJ.%26aulast%3DJoyce%26aufirst%3DM.%2BA.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26aulast%3DVederas%26aufirst%3DJ.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BJ.%26atitle%3DFeline%2520Coronavirus%2520Drug%2520Inhibits%2520the%2520Main%2520Protease%2520of%2520SARS-CoV-2%2520and%2520Blocks%2520Virus%2520Replication%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4282%26doi%3D10.1038%2Fs41467-020-18096-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathnayake, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashipathy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-O.</span></span> <span> </span><span class="NLM_article-title">3C-like Protease Inhibitors Block Coronavirus Replication in Vitro and Improve Survival in MERS-CoVâInfected Mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eabc5332</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.abc5332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.abc5332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32747425" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabc5332&author=A.+D.+Rathnayakeauthor=J.+Zhengauthor=Y.+Kimauthor=K.+D.+Pereraauthor=S.+Mackinauthor=D.+K.+Meyerholzauthor=M.+M.+Kashipathyauthor=K.+P.+Battaileauthor=S.+Lovellauthor=S.+Perlmanauthor=W.+C.+Groutasauthor=K.-O.+Chang&title=3C-like+Protease+Inhibitors+Block+Coronavirus+Replication+in+Vitro+and+Improve+Survival+in+MERS-CoV%E2%80%93Infected+Mice&doi=10.1126%2Fscitranslmed.abc5332"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abc5332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abc5332%26sid%3Dliteratum%253Aachs%26aulast%3DRathnayake%26aufirst%3DA.%2BD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPerera%26aufirst%3DK.%2BD.%26aulast%3DMackin%26aufirst%3DS.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DKashipathy%26aufirst%3DM.%2BM.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.-O.%26atitle%3D3C-like%2520Protease%2520Inhibitors%2520Block%2520Coronavirus%2520Replication%2520in%2520Vitro%2520and%2520Improve%2520Survival%2520in%2520MERS-CoV%25E2%2580%2593Infected%2520Mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deabc5332%26doi%3D10.1126%2Fscitranslmed.abc5332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">A Trial of LopinavirâRitonavir in Adults Hospitalized with Severe Covid-19</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">1787</span>â <span class="NLM_lpage">1799</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2001282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32187464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB383kvFOjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1787-1799&author=B.+Caoauthor=Y.+Wangauthor=D.+Wenauthor=W.+Liuauthor=J.+Wangauthor=G.+Fanauthor=L.+Ruanauthor=B.+Songauthor=Y.+Caiauthor=M.+Weiauthor=X.+Liauthor=J.+Xiaauthor=N.+Chenauthor=J.+Xiangauthor=T.+Yuauthor=T.+Baiauthor=X.+Xieauthor=L.+Zhangauthor=C.+Liauthor=Y.+Yuanauthor=H.+Chenauthor=H.+Liauthor=H.+Huangauthor=S.+Tuauthor=F.+Gongauthor=Y.+Liuauthor=Y.+Weiauthor=C.+Dongauthor=F.+Zhouauthor=X.+Guauthor=J.+Xuauthor=Z.+Liuauthor=Y.+Zhangauthor=H.+Liauthor=L.+Shangauthor=K.+Wangauthor=K.+Liauthor=X.+Zhouauthor=X.+Dongauthor=Z.+Quauthor=S.+Luauthor=X.+Huauthor=S.+Ruanauthor=S.+Luoauthor=J.+Wuauthor=L.+Pengauthor=F.+Chengauthor=L.+Panauthor=J.+Zouauthor=C.+Jiaauthor=J.+Wangauthor=X.+Liuauthor=S.+Wangauthor=X.+Wuauthor=Q.+Geauthor=J.+Heauthor=H.+Zhanauthor=F.+Qiuauthor=L.+Guoauthor=C.+Huangauthor=T.+Jakiauthor=F.+G.+Haydenauthor=P.+W.+Horbyauthor=D.+Zhangauthor=C.+Wang&title=A+Trial+of+Lopinavir%E2%80%93Ritonavir+in+Adults+Hospitalized+with+Severe+Covid-19&doi=10.1056%2FNEJMoa2001282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</span></div><div class="casAuthors">Cao Bin; Wang Yeming; Wen Danning; Liu Wen; Wang Jingli; Fan Guohui; Ruan Lianguo; Song Bin; Cai Yanping; Wei Ming; Li Xingwang; Xia Jiaan; Chen Nanshan; Xiang Jie; Yu Ting; Bai Tao; Xie Xuelei; Zhang Li; Li Caihong; Yuan Ye; Chen Hua; Li Huadong; Huang Hanping; Tu Shengjing; Gong Fengyun; Liu Ying; Wei Yuan; Dong Chongya; Zhou Fei; Gu Xiaoying; Xu Jiuyang; Liu Zhibo; Zhang Yi; Li Hui; Shang Lianhan; Wang Ke; Li Kunxia; Zhou Xia; Dong Xuan; Qu Zhaohui; Lu Sixia; Hu Xujuan; Ruan Shunan; Luo Shanshan; Wu Jing; Peng Lu; Cheng Fang; Pan Lihong; Zou Jun; Jia Chunmin; Wang Juan; Liu Xia; Wang Shuzhen; Wu Xudong; Ge Qin; He Jing; Zhan Haiyan; Qiu Fang; Guo Li; Huang Chaolin; Jaki Thomas; Hayden Frederick G; Horby Peter W; Zhang Dingyu; Wang Chen</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1787-1799</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.  METHODS:  We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg.  Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone.  The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.  RESULTS:  A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group.  Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80).  Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7).  The percentages of patients with detectable viral RNA at various time points were similar.  In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91).  Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group.  Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.  CONCLUSIONS:  In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care.  Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLXU2_2H1oIv6BottYdIAWfW6udTcc2eZCjSoEaLbE0rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383kvFOjtQ%253D%253D&md5=affdbe91481a3ada1a2fed29e2ad17f9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001282%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DRuan%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DBai%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DTu%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGe%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DHorby%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DA%2520Trial%2520of%2520Lopinavir%25E2%2580%2593Ritonavir%2520in%2520Adults%2520Hospitalized%2520with%2520Severe%2520Covid-19%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D1787%26epage%3D1799%26doi%3D10.1056%2FNEJMoa2001282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. Y.</span></span> <span> </span><span class="NLM_article-title">Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1327</span>â <span class="NLM_lpage">1336</span>, <span class="refDoi">Â DOI: 10.1016/j.bpj.2009.12.4272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bpj.2009.12.4272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=20371333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKnsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=1327-1336&author=S.+C.+Chengauthor=G.+G.+Changauthor=C.+Y.+Chou&title=Mutation+of+Glu-166+Blocks+the+Substrate-Induced+Dimerization+of+SARS+Coronavirus+Main+Protease&doi=10.1016%2Fj.bpj.2009.12.4272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease</span></div><div class="casAuthors">Cheng, Shu-Chun; Chang, Gu-Gang; Chou, Chi-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1327-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The maturation of SARS coronavirus involves the autocleavage of polyproteins 1a and 1ab by the main protease (Mpro) and a papain-like protease; these represent attractive targets for the development of anti-SARS drugs.  The functional unit of Mpro is a homodimer, and each subunit has a His-41Â·Â·Â·Cys-145 catalytic dyad.  Current thinking in this area is that Mpro dimerization is essential for catalysis; although, the influence of the substrate binding on the dimer formation has never been explored.  Here, we delineate the contributions of the peptide substrate to Mpro dimerization.  Enzyme kinetic assays indicate that the monomeric mutant R298A/L exhibits lower activity but in a cooperative manner.  Anal. ultracentrifugation analyses indicate that in the presence of substrates, the major species of R298A/L shows a significant size shift toward the dimeric form and the monomer-dimer dissocn. const. of R298A/L decreases by 12- to 17-fold, approaching that for wild-type.  Furthermore, this substrate-induced dimerization was found to be reversible after substrates were removed.  Based on the crystal structures, a key residue, Glu-166, which is responsible for recognizing the Gln-P1 of the substrate and binding to Ser-1 of another promoter, will interact with Asn-142 and block the S1 subsite entrance in the monomer.  Our studies indicate that mutation of Glu-166 in the R298A mutant indeed blocks the substrate-induced dimerization.  This demonstrates that Glu-166 plays a pivotal role in connecting the substrate binding site with the dimer interface.  We conclude that protein-ligand and protein-protein interactions are closely correlated in Mpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9okYa5bCE7Vg90H21EOLACvtfcHk0lh40nW0RigJTQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKnsLw%253D&md5=e553f8131ded8f8a5ef07181ad0819c8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2009.12.4272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2009.12.4272%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DG.%2BG.%26aulast%3DChou%26aufirst%3DC.%2BY.%26atitle%3DMutation%2520of%2520Glu-166%2520Blocks%2520the%2520Substrate-Induced%2520Dimerization%2520of%2520SARS%2520Coronavirus%2520Main%2520Protease%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D1327%26epage%3D1336%26doi%3D10.1016%2Fj.bpj.2009.12.4272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶s, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordingley, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LagacÃ©, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupart, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sentjens, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St George, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoneau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibeault, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LlinÃ s-Brunet, M.</span></span> <span> </span><span class="NLM_article-title">An NS3 Protease Inhibitor with Antiviral Effects in Humans Infected with Hepatitis C Virus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">189</span>, <span class="refDoi">Â DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagac%C3%A9author=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+Protease+Inhibitor+with+Antiviral+Effects+in+Humans+Infected+with+Hepatitis+C+Virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0lgqbhaOkwbn_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520Protease%2520Inhibitor%2520with%2520Antiviral%2520Effects%2520in%2520Humans%2520Infected%2520with%2520Hepatitis%2520C%2520Virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LlinÃ s-Brunet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garneau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand-MaÃ®tre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapeyre-Paquette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RhÃ©aume, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, D.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1605</span>â <span class="NLM_lpage">1608</span>, <span class="refDoi">Â DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.+M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-Activity+Study+on+a+Novel+Series+of+Macrocyclic+Inhibitors+of+the+Hepatitis+C+Virus+NS3+Protease+Leading+to+the+Discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0lgqbhaOkwbn_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-Activity%2520Study%2520on%2520a%2520Novel%2520Series%2520of%2520Macrocyclic%2520Inhibitors%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%2520Leading%2520to%2520the%2520Discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claudio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span> <span> </span><span class="NLM_article-title">MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4161</span>â <span class="NLM_lpage">4167</span>, <span class="refDoi">Â DOI: 10.1128/AAC.00324-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+Selective+Inhibitor+of+Hepatitis+C+Virus+NS3%2F4a+Protease+with+Broad+Activity+across+Genotypes+and+Resistant+Variants&doi=10.1128%2FAAC.00324-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0likXxWaatdMTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520with%2520Broad%2520Activity%2520across%2520Genotypes%2520and%2520Resistant%2520Variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167%26doi%3D10.1128%2FAAC.00324-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">332</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+Dimuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+Macrocyclic+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lgSFw2Cz-MYjQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDimuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Mitchell, L. J.,  Jr.</span>; <span class="NLM_string-name">Nieman, J. A.</span></span> <span> </span><span class="NLM_article-title">Anticoronaviral Compounds and Compositions, Their Pharmaceutical Uses and Materials for Their Synthesis</span>. <span class="NLM_patent">WO2005113580A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+S.+Kania&author=L.+J.+Mitchell&author=J.+A.+Nieman&title=Anticoronaviral+Compounds+and+Compositions%2C+Their+Pharmaceutical+Uses+and+Materials+for+Their+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DAnticoronaviral%2520Compounds%2520and%2520Compositions%252C%2520Their%2520Pharmaceutical%2520Uses%2520and%2520Materials%2520for%2520Their%2520Synthesis%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Mitchell, L. J.,  Jr.</span>; <span class="NLM_string-name">Nieman, J. A.</span></span> <span> </span><span class="NLM_article-title">Anticoronaviral Compounds and Compositions, Their Pharmaceutical Uses and Materials for Their Synthesis</span>. <span class="NLM_patent">WO2006061714A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+S.+Kania&author=L.+J.+Mitchell&author=J.+A.+Nieman&title=Anticoronaviral+Compounds+and+Compositions%2C+Their+Pharmaceutical+Uses+and+Materials+for+Their+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DAnticoronaviral%2520Compounds%2520and%2520Compositions%252C%2520Their%2520Pharmaceutical%2520Uses%2520and%2520Materials%2520for%2520Their%2520Synthesis%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thanigaimalai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koiwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushiji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naser-Tavakolian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶n, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Development of Potent Dipeptide-Type SARS-CoV 3CL Protease Inhibitors with Novel P3 Scaffolds: Design, Synthesis, Biological Evaluation, and Docking Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">372</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.ejmech.2013.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23994330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=372-384&author=P.+Thanigaimalaiauthor=S.+Konnoauthor=T.+Yamamotoauthor=Y.+Koiwaiauthor=A.+Taguchiauthor=K.+Takayamaauthor=F.+Yakushijiauthor=K.+Akajiauthor=S.+E.+Chenauthor=A.+Naser-Tavakolianauthor=A.+Sch%C3%B6nauthor=E.+Freireauthor=Y.+Hayashi&title=Development+of+Potent+Dipeptide-Type+SARS-CoV+3CL+Protease+Inhibitors+with+Novel+P3+Scaffolds%3A+Design%2C+Synthesis%2C+Biological+Evaluation%2C+and+Docking+Studies&doi=10.1016%2Fj.ejmech.2013.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies</span></div><div class="casAuthors">Thanigaimalai, Pillaiyar; Konno, Sho; Yamamoto, Takehito; Koiwai, Yuji; Taguchi, Akihiro; Takayama, Kentaro; Yakushiji, Fumika; Akaji, Kenichi; Chen, Shen-En; Naser-Tavakolian, Aurash; Schon, Arne; Freire, Ernesto; Hayashi, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro.  A docking study involving binding between the dipeptidic lead compd. (I) and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in I.  The modifications led to the identification of several potent derivs. with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range.  Compd. (II) , in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 Î¼M.  This potency was 65-fold higher than the potency of the lead compd. I (Ki = 0.39 Î¼M).  In addn., the Ki value of II was in very good agreement with the binding affinity (16 nM) obsd. in isothermal titrn. calorimetry (ITC).  A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (III).  Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJOG03zeobLVg90H21EOLACvtfcHk0lg9FOhzPUBnVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrzL&md5=28055f45719f5220358fac55d015d2ff</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DThanigaimalai%26aufirst%3DP.%26aulast%3DKonno%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DKoiwai%26aufirst%3DY.%26aulast%3DTaguchi%26aufirst%3DA.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DAkaji%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%2BE.%26aulast%3DNaser-Tavakolian%26aufirst%3DA.%26aulast%3DSch%25C3%25B6n%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520Potent%2520Dipeptide-Type%2520SARS-CoV%25203CL%2520Protease%2520Inhibitors%2520with%2520Novel%2520P3%2520Scaffolds%253A%2520Design%252C%2520Synthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Docking%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D372%26epage%3D384%26doi%3D10.1016%2Fj.ejmech.2013.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozminski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+L.+Hoffmanauthor=R.+S.+Kaniaauthor=M.+A.+Brothersauthor=J.+F.+Daviesauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+Heauthor=R.+J.+Hoganauthor=K.+Kozminskiauthor=L.+Y.+Liauthor=J.+W.+Locknerauthor=J.+Louauthor=M.+T.+Marraauthor=L.+J.+Mitchellauthor=B.+W.+Murrayauthor=J.+A.+Niemanauthor=S.+Noellauthor=S.+P.+Plankenauthor=T.+Roweauthor=K.+Ryanauthor=G.+J.+Smithauthor=J.+E.+Solowiejauthor=C.+M.+Steppanauthor=B.+Taggart&title=Discovery+of+Ketone-Based+Covalent+Inhibitors+of+Coronavirus+3CL+Proteases+for+the+Potential+Therapeutic+Treatment+of+COVID-19&doi=10.1021%2Facs.jmedchem.0c01063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01063%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DBrothers%26aufirst%3DM.%2BA.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHogan%26aufirst%3DR.%2BJ.%26aulast%3DKozminski%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLockner%26aufirst%3DJ.%2BW.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DMarra%26aufirst%3DM.%2BT.%26aulast%3DMitchell%26aufirst%3DL.%2BJ.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DNieman%26aufirst%3DJ.%2BA.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DPlanken%26aufirst%3DS.%2BP.%26aulast%3DRowe%26aufirst%3DT.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DG.%2BJ.%26aulast%3DSolowiej%26aufirst%3DJ.%2BE.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DTaggart%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520Ketone-Based%2520Covalent%2520Inhibitors%2520of%2520Coronavirus%25203CL%2520Proteases%2520for%2520the%2520Potential%2520Therapeutic%2520Treatment%2520of%2520COVID-19%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c01063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boras, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschenbrenner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakowski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadar, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendy, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oâ Brien, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossulek, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticehurst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Updyke, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.09.12.293498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.09.12.293498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32935104" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Borasauthor=R.+M.+Jonesauthor=B.+J.+Ansonauthor=D.+Arensonauthor=L.+Aschenbrennerauthor=M.+A.+Bakowskiauthor=N.+Beutlerauthor=J.+Binderauthor=E.+Chenauthor=H.+Engauthor=J.+Hammondauthor=R.+Hoffmanauthor=E.+P.+Kadarauthor=R.+Kaniaauthor=E.+Kimotoauthor=M.+G.+Kirkpatrickauthor=L.+Lanyonauthor=E.+K.+Lendyauthor=J.+R.+Lillisauthor=S.+A.+Luthraauthor=C.+Maauthor=S.+Noellauthor=R.+S.+Obachauthor=M.+N.+O%E2%80%99+Brienauthor=R.+O%E2%80%99Connorauthor=K.+Ogilvieauthor=D.+Owenauthor=M.+Petterssonauthor=M.+R.+Reeseauthor=T.+F.+Rogersauthor=M.+I.+Rossulekauthor=J.+G.+Sathishauthor=C.+Steppanauthor=M.+Ticehurstauthor=L.+W.+Updykeauthor=Y.+Zhuauthor=J.+Wangauthor=A.+K.+Chatterjeeauthor=A.+D.+Mesecarauthor=A.+S.+Andersonauthor=C.+Allerton&title=Discovery+of+a+Novel+Inhibitor+of+Coronavirus+3CL+Protease+as+a+Clinical+Candidate+for+the+Potential+Treatment+of+COVID-19&doi=10.1101%2F2020.09.12.293498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1101%2F2020.09.12.293498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.09.12.293498%26sid%3Dliteratum%253Aachs%26aulast%3DBoras%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DAnson%26aufirst%3DB.%2BJ.%26aulast%3DArenson%26aufirst%3DD.%26aulast%3DAschenbrenner%26aufirst%3DL.%26aulast%3DBakowski%26aufirst%3DM.%2BA.%26aulast%3DBeutler%26aufirst%3DN.%26aulast%3DBinder%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DHammond%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DKadar%26aufirst%3DE.%2BP.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKimoto%26aufirst%3DE.%26aulast%3DKirkpatrick%26aufirst%3DM.%2BG.%26aulast%3DLanyon%26aufirst%3DL.%26aulast%3DLendy%26aufirst%3DE.%2BK.%26aulast%3DLillis%26aufirst%3DJ.%2BR.%26aulast%3DLuthra%26aufirst%3DS.%2BA.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599%2BBrien%26aufirst%3DM.%2BN.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DReese%26aufirst%3DM.%2BR.%26aulast%3DRogers%26aufirst%3DT.%2BF.%26aulast%3DRossulek%26aufirst%3DM.%2BI.%26aulast%3DSathish%26aufirst%3DJ.%2BG.%26aulast%3DSteppan%26aufirst%3DC.%26aulast%3DTicehurst%26aufirst%3DM.%26aulast%3DUpdyke%26aufirst%3DL.%2BW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DAnderson%26aufirst%3DA.%2BS.%26aulast%3DAllerton%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520Coronavirus%25203CL%2520Protease%2520as%2520a%2520Clinical%2520Candidate%2520for%2520the%2520Potential%2520Treatment%2520of%2520COVID-19%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.09.12.293498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span> <i>Pfizer Investor
Day Features Significant Number of Pipeline Advances
for COVID-19 Programs and Across Numerous Therapeutic Areas</i>; <span class="NLM_publisher-name">Pfizer</span>, <span class="NLM_year">2020</span>;<a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline" class="extLink">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline</a> (accessed 2020-09-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pfizer+Investor%0ADay+Features+Significant+Number+of+Pipeline+Advances%0Afor+COVID-19+Programs+and+Across+Numerous+Therapeutic+Areas%3B+Pfizer%2C+2020%3Bhttps%3A%2F%2Fwww.pfizer.com%2Fnews%2Fpress-release%2Fpress-release-detail%2Fpfizer-investor-day-features-significant-number-pipeline+%28accessed+2020-09-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPfizer%2520Investor%250ADay%2520Features%2520Significant%2520Number%2520of%2520Pipeline%2520Advances%250Afor%2520COVID-19%2520Programs%2520and%2520Across%2520Numerous%2520Therapeutic%2520Areas%26pub%3DPfizer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, W.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-c.</span></span> <span> </span><span class="NLM_article-title">Anti-SARS-CoV-2 Activities in Vitro of Shuanghuanglian Preparations and Bioactive Ingredients</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1177</span>, <span class="refDoi">Â DOI: 10.1038/s41401-020-0483-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41401-020-0483-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32737471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFShu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=1167-1177&author=H.-x.+Suauthor=S.+Yaoauthor=W.-f.+Zhaoauthor=M.-j.+Liauthor=J.+Liuauthor=W.-j.+Shangauthor=H.+Xieauthor=C.-q.+Keauthor=H.-c.+Huauthor=M.-n.+Gaoauthor=K.-q.+Yuauthor=H.+Liuauthor=J.-s.+Shenauthor=W.+Tangauthor=L.-k.+Zhangauthor=G.-f.+Xiaoauthor=L.+Niauthor=D.-w.+Wangauthor=J.-p.+Zuoauthor=H.-l.+Jiangauthor=F.+Baiauthor=Y.+Wuauthor=Y.+Yeauthor=Y.-c.+Xu&title=Anti-SARS-CoV-2+Activities+in+Vitro+of+Shuanghuanglian+Preparations+and+Bioactive+Ingredients&doi=10.1038%2Fs41401-020-0483-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients</span></div><div class="casAuthors">Su, Hai-xia; Yao, Sheng; Zhao, Wen-feng; Li, Min-jun; Liu, Jia; Shang, Wei-juan; Xie, Hang; Ke, Chang-qiang; Hu, Hang-chen; Gao, Mei-na; Yu, Kun-qian; Liu, Hong; Shen, Jing-shan; Tang, Wei; Zhang, Lei-ke; Xiao, Geng-fu; Ni, Li; Wang, Dao-wen; Zuo, Jian-ping; Jiang, Hua-liang; Bai, Fang; Wu, Yan; Ye, Yang; Xu, Ye-chun</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1167-1177</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and there is no cure currently.  The 3CL protease (3CLpro) is a highly conserved protease which is indispensable for CoVs replication, and is a promising target for development of broad-spectrum antiviral drugs.  In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian prepn., a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.  We showed that either the oral liq. of Shuanghuanglian, the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-2 3CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.  Baicalin and baicalein, two ingredients of Shuanghuanglian, were characterized as the first noncovalent, nonpeptidomimetic inhibitors of SARS-CoV-2 3CLpro and exhibited potent antiviral activities in a cell-based system.  Remarkably, the binding mode of baicalein with SARS-CoV-2 3CLpro detd. by X-ray protein crystallog. was distinctly different from those of known 3CLpro inhibitors.  Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues, the crucial S1/S2 subsites and the oxyanion loop, acting as a "shield" in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.  Overall, this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target, and gains evidence supporting the in vivo studies of Shuanghuanglian oral liq. as well as two natural products for COVID-19 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE-aZrrHwqZrVg90H21EOLACvtfcHk0lgGbbudZ1BJrQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFShu7vI&md5=8560cc7a979d67e0fa0cf17eee71ef00</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fs41401-020-0483-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-020-0483-6%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.-x.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.-f.%26aulast%3DLi%26aufirst%3DM.-j.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DW.-j.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DC.-q.%26aulast%3DHu%26aufirst%3DH.-c.%26aulast%3DGao%26aufirst%3DM.-n.%26aulast%3DYu%26aufirst%3DK.-q.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.-s.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.-k.%26aulast%3DXiao%26aufirst%3DG.-f.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.-w.%26aulast%3DZuo%26aufirst%3DJ.-p.%26aulast%3DJiang%26aufirst%3DH.-l.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.-c.%26atitle%3DAnti-SARS-CoV-2%2520Activities%2520in%2520Vitro%2520of%2520Shuanghuanglian%2520Preparations%2520and%2520Bioactive%2520Ingredients%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2020%26volume%3D41%26spage%3D1167%26epage%3D1177%26doi%3D10.1038%2Fs41401-020-0483-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Scutellaria Baicalensis Extract and Baicalein Inhibit Replication of SARS-CoV-2 and Its 3C-like Protease in Vitro</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.10.035824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.10.035824" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Liuauthor=F.+Yeauthor=Q.+Sunauthor=H.+Liangauthor=C.+Liauthor=R.+Luauthor=B.+Huangauthor=W.+Tanauthor=L.+Lai&title=Scutellaria+Baicalensis+Extract+and+Baicalein+Inhibit+Replication+of+SARS-CoV-2+and+Its+3C-like+Protease+in+Vitro&doi=10.1101%2F2020.04.10.035824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1101%2F2020.04.10.035824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.10.035824%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DScutellaria%2520Baicalensis%2520Extract%2520and%2520Baicalein%2520Inhibit%2520Replication%2520of%2520SARS-CoV-2%2520and%2520Its%25203C-like%2520Protease%2520in%2520Vitro%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.10.035824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Baicalin and Baicalein as Novel, Natural Product Inhibitors of SARS-CoV-2 3CL Protease in Vitro</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.13.038687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.13.038687" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Suauthor=S.+Yaoauthor=W.+Zhaoauthor=M.+Liauthor=J.+Liuauthor=W.+Shangauthor=H.+Xieauthor=C.+Keauthor=M.+Gaoauthor=K.+Yuauthor=H.+Liuauthor=J.+Shenauthor=W.+Tangauthor=L.+Zhangauthor=J.+Zuoauthor=H.+Jiangauthor=F.+Baiauthor=Y.+Wuauthor=Y.+Yeauthor=Y.+Xu&title=Discovery+of+Baicalin+and+Baicalein+as+Novel%2C+Natural+Product+Inhibitors+of+SARS-CoV-2+3CL+Protease+in+Vitro&doi=10.1101%2F2020.04.13.038687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1101%2F2020.04.13.038687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.13.038687%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Baicalin%2520and%2520Baicalein%2520as%2520Novel%252C%2520Natural%2520Product%2520Inhibitors%2520of%2520SARS-CoV-2%25203CL%2520Protease%2520in%2520Vitro%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.13.038687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of Baicalein Chewable Tablets in Healthy Subjects</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">210</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1016/j.jep.2014.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jep.2014.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25219601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGlurrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2014&pages=210-215&author=M.+Liauthor=A.+Shiauthor=H.+Pangauthor=W.+Xueauthor=Y.+Liauthor=G.+Caoauthor=B.+Yanauthor=F.+Dongauthor=K.+Liauthor=W.+Xiaoauthor=G.+Heauthor=G.+Duauthor=X.+Hu&title=Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+a+Single+Ascending+Dose+of+Baicalein+Chewable+Tablets+in+Healthy+Subjects&doi=10.1016%2Fj.jep.2014.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects</span></div><div class="casAuthors">Li, Min; Shi, Aixin; Pang, Hongxian; Xue, Wei; Li, Yang; Cao, Guoying; Yan, Bei; Dong, Fan; Li, Kexin; Xiao, Wei; He, Guorong; Du, Guanhua; Hu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The root of Scutellaria baicalensis Georgi has been used extensively in traditional Chinese medicine for the treatment of inflammation, fever, cough, dysentery, and hypertension.  Baicalein is a flavonoid isolated from the root of Scutellaria baicalensis Georgi and is a novel neuroprotective agent under development for the treatment of Parkinson's disease.  We aimed to investigate the pharmacokinetic (PK) properties of baicalein and its main metabolite, bacalin, after single-dose administration in healthy Chinese subjects.  The safety and tolerability of baicalein were also assessed.This was a Phase I, randomized, double-blind, single-dose trial of baicalein (100-2800 mg) in 72 healthy adults.  Samples of blood, urine and feces were collected at regular intervals up to 48 h after administration of the study drug.  Baicalein and baicalin were then analyzed using liq. chromatog.-tandem mass spectrometry (LC/MS/MS).  The max. concn. that the drug achieved after dosing (Cmax), time to Cmax (Tmax), terminal half-life (t1/2), area under the curve from time zero to time of last quantifiable concn. (AUC(0, t)), area under the curve from time zero to infinity (AUC(0, â)), apparent total plasma clearance (CL/F), and apparent total vol. of distribution (V/F) were detd. using non-compartmental models.  Dose proportion was tested using a method combining the equivalence criterion and power model.  Phys. examns., vital signs, ECG findings, hematol., and urinalysis were monitored before and at regular intervals after administration of the study drug.  The PK profile of baicelein and baicelin was characterized by a median Tmax of 0.75-3.5 h and 0.5-3 h, resp., followed by a multiphasic profile with a t1/2 of 1.90-15.01 h and 4.22-10.80 h, resp.  The ests. of the proportionality coeff. (90% CI) for Cmax, AUC0-t and AUC0-â were 0.83 (0.70-0.96), 0.91 (0.81-1.00) and 0.92 (0.82-1.02), resp.  All values overlapped within the pre-specified range of (0.89-1.11), (0.93-1.07), and (0.93-1.07), resp.  Dose proportionality was inconclusive for a baicalein dose range of 100-2800 mg.  The total urinary clearance of baicalein and baicalin was <1%.  Approx. 27% of baicalein was eliminated as unchanged drug in feces.  Baicalein was well tolerated.  Eleven treatment-related adverse events were obsd., and all were rated as "mild" and resolved without further treatment.  No serious adverse events occurred.Single oral doses of 100-2800 mg of baicalein were safe and well tolerated by healthy subjects.  Clin. lab. assessments showed no signs of toxicity in the liver or kidney.  The favorable safety profile and PK properties warrant further clin. studies for baicalein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozaMGqrPx7VbVg90H21EOLACvtfcHk0li8r9TRRGeSFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGlurrJ&md5=4904b8921908f1f6618188f132763d7f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2014.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2014.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DSafety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520a%2520Single%2520Ascending%2520Dose%2520of%2520Baicalein%2520Chewable%2520Tablets%2520in%2520Healthy%2520Subjects%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2014%26volume%3D156%26spage%3D210%26epage%3D215%26doi%3D10.1016%2Fj.jep.2014.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldanha, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielech, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Structure-Based Optimization of a Series of N -(Tert -Butyl)-2-(N -Arylamido)-2-(Pyridin-3-Yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">534</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1021/jm301580n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301580n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=534-546&author=J.+Jacobsauthor=V.+Grum-Tokarsauthor=Y.+Zhouauthor=M.+Turlingtonauthor=S.+A.+Saldanhaauthor=P.+Chaseauthor=A.+Egglerauthor=E.+S.+Dawsonauthor=Y.+M.+Baez-Santosauthor=S.+Tomarauthor=A.+M.+Mielechauthor=S.+C.+Bakerauthor=C.+W.+Lindsleyauthor=P.+Hodderauthor=A.+Mesecarauthor=S.+R.+Stauffer&title=Discovery%2C+Synthesis%2C+and+Structure-Based+Optimization+of+a+Series+of+N+-%28Tert+-Butyl%29-2-%28N+-Arylamido%29-2-%28Pyridin-3-Yl%29+Acetamides+%28ML188%29+as+Potent+Noncovalent+Small+Molecule+Inhibitors+of+the+Severe+Acute+Respiratory+Syndrome+Coronavirus+%28SARS-CoV%29+3CL&doi=10.1021%2Fjm301580n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease</span></div><div class="casAuthors">Jacobs, Jon; Grum-Tokars, Valerie; Zhou, Ya; Turlington, Mark; Saldanha, S. Adrian; Chase, Peter; Eggler, Aimee; Dawson, Eric S.; Baez-Santos, Yahira M.; Tomar, Sakshi; Mielech, Anna M.; Baker, Susan C.; Lindsley, Craig W.; Hodder, Peter; Mesecar, Andrew; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A high-throughput screen of the NIH mol. libraries sample collection and subsequent optimization of a lead dipeptide-like series of severe acute respiratory syndrome (SARS) main protease (3CLpro) inhibitors led to the identification of probe compd. ML188 (I), [(R)-N-(4-(tert-butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide, Pubchem CID: 46897844].  Unlike the majority of reported coronavirus 3CLpro inhibitors that act via covalent modification of the enzyme, I is a noncovalent SARS-CoV 3CLpro inhibitor with moderate MW and good enzyme and antiviral inhibitory activity.  A multicomponent Ugi reaction was utilized to rapidly explore structure-activity relationships within S1', S1, and S2 enzyme binding pockets.  The X-ray structure of SARS-CoV 3CLpro bound with I was instrumental in guiding subsequent rounds of chem. optimization.  I provides an excellent starting point for the further design and refinement of 3CLpro inhibitors that act by a noncovalent mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_0gMuIcLErVg90H21EOLACvtfcHk0ljirQUPKulPOA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FE&md5=6f619d5642a8d29bdb9eee0b28a80247</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm301580n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301580n%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DJ.%26aulast%3DGrum-Tokars%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTurlington%26aufirst%3DM.%26aulast%3DSaldanha%26aufirst%3DS.%2BA.%26aulast%3DChase%26aufirst%3DP.%26aulast%3DEggler%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DBaez-Santos%26aufirst%3DY.%2BM.%26aulast%3DTomar%26aufirst%3DS.%26aulast%3DMielech%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMesecar%26aufirst%3DA.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Structure-Based%2520Optimization%2520of%2520a%2520Series%2520of%2520N%2520-%2528Tert%2520-Butyl%2529-2-%2528N%2520-Arylamido%2529-2-%2528Pyridin-3-Yl%2529%2520Acetamides%2520%2528ML188%2529%2520as%2520Potent%2520Noncovalent%2520Small%2520Molecule%2520Inhibitors%2520of%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520%2528SARS-CoV%2529%25203CL%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D534%26epage%3D546%26doi%3D10.1021%2Fjm301580n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span> <i>COVID-19, Main Protease
Structure and XChem Fragment Screen</i>; <span class="NLM_publisher-name">Diamond
Light Source</span>, <span class="NLM_year">2020</span>; <a href="https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html" class="extLink">hhttps://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html</a> (accessed 2020-06-).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+COVID-19%2C+Main+Protease%0AStructure+and+XChem+Fragment+Screen%3B+Diamond%0ALight+Source%2C+2020%3B+hhttps%3A%2F%2Fwww.diamond.ac.uk%2Fcovid-19%2Ffor-scientists%2FMain-protease-structure-and-XChem.html+%28accessed+2020-06-%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCOVID-19%252C%2520Main%2520Protease%250AStructure%2520and%2520XChem%2520Fragment%2520Screen%26pub%3DDiamond%250ALight%2520Source%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parnham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sies, H.</span></span> <span> </span><span class="NLM_article-title">Ebselen: Prospective Therapy for Cerebral Ischaemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">607</span>â <span class="NLM_lpage">619</span>, <span class="refDoi">Â DOI: 10.1517/13543784.9.3.607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1517%2F13543784.9.3.607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=11060699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslKnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=607-619&author=M.+Parnhamauthor=H.+Sies&title=Ebselen%3A+Prospective+Therapy+for+Cerebral+Ischaemia&doi=10.1517%2F13543784.9.3.607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Ebselen: prospective therapy for cerebral ischaemia</span></div><div class="casAuthors">Parnham, Michael; Sies, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">607-619</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 82 refs.  Stroke occurs due to hemorrhage or occlusive injury and results in ischemia and reperfusion injury.  A variety of destructive mechanisms are involved including oxygen radical generation, calcium overload, cytotoxicity and apoptosis as well as the generation of inflammatory mediators.  Ebselen, 2-phenyl-1,2-benzisoselenazol-3(2H)-one (PZ 51, DR3305), is a mimic of GSH peroxidase which also reacts with peroxynitrite and can inhibit enzymes such as lipoxygenases, NO synthases, NADPH oxidase, protein kinase C and H+/K+-ATPase.  Ebselen is in a late stage of development for the treatment of stroke.  The mol. actions of ebselen contribute to its anti-inflammatory and anti-oxidant properties, which have been demonstrated in a variety of in vivo models.  Numerous in vitro expts. using isolated LDL, liposomes, microsomes, isolated cells and organs have established that ebselen protects against oxidative challenge.  Unlike many inorg. and aliph. selenium compds., ebselen has low toxicity as metab. of the compd. does not liberate the selenium moiety, which remains within the ring structure.  Subsequent metab. involves methylation, glucuronidation and hydroxylation.  Exptl. studies in rats and dogs have revealed that ebselen is able to inhibit both vasospasm and tissue damage in stroke models, which correlates with its inhibitory effects on oxidative processes.  Results from randomized, placebo-controlled, double-blind clin. studies on the neurol. consequences of acute ischemic stroke, subarachnoid hemorrhage and acute middle cerebral artery occlusion, have revealed that ebselen significantly enhances outcome in patients who have experienced occlusive cerebral ischemia of limited duration.  The benefit achieved with ebselen is closely related to the rapidity with which the treatment is initiated, following the onset of the stroke attack.  Safety and tolerability are good and no adverse effects have become apparent.  Ebselen is currently at the pre-registration stage for subarachnoid hemorrhage and stroke in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGRNMF1u9z8rVg90H21EOLACvtfcHk0lhNebkXJGNK9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslKnsbs%253D&md5=4f5cd68b3073784362ce3b43ce474a7d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1517%2F13543784.9.3.607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.9.3.607%26sid%3Dliteratum%253Aachs%26aulast%3DParnham%26aufirst%3DM.%26aulast%3DSies%26aufirst%3DH.%26atitle%3DEbselen%253A%2520Prospective%2520Therapy%2520for%2520Cerebral%2520Ischaemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D9%26spage%3D607%26epage%3D619%26doi%3D10.1517%2F13543784.9.3.607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bredenbeek, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, L. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaan, W. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span> <span> </span><span class="NLM_article-title">Unique and Conserved Features of Genome and Proteome of SARS-Coronavirus, an Early Split-off from the Coronavirus Group 2 Lineage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">991</span>â <span class="NLM_lpage">1004</span>, <span class="refDoi">Â DOI: 10.1016/S0022-2836(03)00865-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0022-2836%2803%2900865-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=12927536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCls7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2003&pages=991-1004&author=E.+J.+Snijderauthor=P.+J.+Bredenbeekauthor=J.+C.+Dobbeauthor=V.+Thielauthor=J.+Ziebuhrauthor=L.+L.+M.+Poonauthor=Y.+Guanauthor=M.+Rozanovauthor=W.+J.+M.+Spaanauthor=A.+E.+Gorbalenya&title=Unique+and+Conserved+Features+of+Genome+and+Proteome+of+SARS-Coronavirus%2C+an+Early+Split-off+from+the+Coronavirus+Group+2+Lineage&doi=10.1016%2FS0022-2836%2803%2900865-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage</span></div><div class="casAuthors">Snijder, Eric J.; Bredenbeek, Peter J.; Dobbe, Jessika C.; Thiel, Volker; Ziebuhr, John; Poon, Leo L. M.; Guan, Yi; Rozanov, Mikhail; Spaan, Willy J. M.; Gorbalenya, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-1004</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The genome organization and expression strategy of the newly identified severe acute respiratory syndrome coronavirus (SARS-CoV) were predicted using recently published genome sequences.  Fourteen putative open reading frames were identified, 12 of which were predicted to be expressed from a nested set of eight subgenomic mRNAs.  The synthesis of these mRNAs in SARS-CoV-infected cells was confirmed exptl.  The 4382- and 7073 amino acid residue SARS-CoV replicase polyproteins are predicted to be cleaved into 16 subunits by two viral proteinases (bringing the total no. of SARS-CoV proteins to 28).  A phylogenetic anal. of the replicase gene, using a distantly related torovirus as an outgroup, demonstrated that, despite a no. of unique features, SARS-CoV is most closely related to group 2 coronaviruses.  Distant homologs of cellular RNA processing enzymes were identified in group 2 coronaviruses, with four of them being conserved in SARS-CoV.  These newly recognized viral enzymes place the mechanism of coronavirus RNA synthesis in a completely new perspective.  Furthermore, together with previously described viral enzymes, they will be important targets for the design of antiviral strategies aimed at controlling the further spread of SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm1drrDFEB-7Vg90H21EOLACvtfcHk0lhNebkXJGNK9A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCls7w%253D&md5=ae66a6495dfa0c753d589f91e3f9a23c</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900865-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900865-9%26sid%3Dliteratum%253Aachs%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DBredenbeek%26aufirst%3DP.%2BJ.%26aulast%3DDobbe%26aufirst%3DJ.%2BC.%26aulast%3DThiel%26aufirst%3DV.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DL.%2BL.%2BM.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DRozanov%26aufirst%3DM.%26aulast%3DSpaan%26aufirst%3DW.%2BJ.%2BM.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26atitle%3DUnique%2520and%2520Conserved%2520Features%2520of%2520Genome%2520and%2520Proteome%2520of%2520SARS-Coronavirus%252C%2520an%2520Early%2520Split-off%2520from%2520the%2520Coronavirus%2520Group%25202%2520Lineage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D331%26spage%3D991%26epage%3D1004%26doi%3D10.1016%2FS0022-2836%2803%2900865-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©cine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">The SARS-Coronavirus PLnc Domain of Nsp3 as a Replication/Transcription Scaffolding Protein</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2007.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.virusres.2007.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18255185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=136-148&author=I.+Imbertauthor=E.+J.+Snijderauthor=M.+Dimitrovaauthor=J.+C.+Guillemotauthor=P.+L%C3%A9cineauthor=B.+Canard&title=The+SARS-Coronavirus+PLnc+Domain+of+Nsp3+as+a+Replication%2FTranscription+Scaffolding+Protein&doi=10.1016%2Fj.virusres.2007.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein</span></div><div class="casAuthors">Imbert, Isabelle; Snijder, Eric J.; Dimitrova, Maria; Guillemot, Jean-Claude; Lecine, Patrick; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-148</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Many genetic and mechanistic features distinguish the coronavirus replication machinery from that encoded by most other RNA viruses.  The coronavirus replication/transcription complex is an assembly of viral and, most probably, cellular proteins that mediate the synthesis of both the unusually large (â¼30 kb) RNA genome and an extensive set of subgenomic mRNAs.  The viral components of the complex are encoded by the giant replicase gene, which is expressed in the form of two polyproteins (pp1a and pp1ab) that are processed into 16 cleavage products (nonstructural proteins 1-16).  Using the combination of yeast two-hybrid screening and GST pull-down assays, the authors have now analyzed all potential interactions between SARS-Coronavirus nonstructural proteins, which may contribute to the structure and/or function of the viral replication/transcription complex.  The authors demonstrate the existence of a complex network of interactions involving all 16 nonstructural proteins.  These results both confirmed previously described assocns. and identified novel heterodimerizations.  The interaction map thus provides a sum of the interactions that may occur at some point during coronavirus RNA synthesis and provides a framework for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhK3gRYNU_7Vg90H21EOLACvtfcHk0liiFfbmbxyz-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKlu7c%253D&md5=e91af89368fcb6d9b1e0f5aca95b86c8</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2007.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2007.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DImbert%26aufirst%3DI.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DDimitrova%26aufirst%3DM.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DL%25C3%25A9cine%26aufirst%3DP.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DThe%2520SARS-Coronavirus%2520PLnc%2520Domain%2520of%2520Nsp3%2520as%2520a%2520Replication%252FTranscription%2520Scaffolding%2520Protein%26jtitle%3DVirus%2520Res.%26date%3D2008%26volume%3D133%26spage%3D136%26epage%3D148%26doi%3D10.1016%2Fj.virusres.2007.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neuman, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¼thrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmeier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span> <span> </span><span class="NLM_article-title">Proteomics Analysis Unravels the Functional Repertoire of Coronavirus Nonstructural Protein 3</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">5279</span>â <span class="NLM_lpage">5294</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02631-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02631-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18367524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Slsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=5279-5294&author=B.+W.+Neumanauthor=J.+S.+Josephauthor=K.+S.+Saikatenduauthor=P.+Serranoauthor=A.+Chatterjeeauthor=M.+A.+Johnsonauthor=L.+Liaoauthor=J.+P.+Klausauthor=J.+R.+Yatesauthor=K.+W%C3%BCthrichauthor=R.+C.+Stevensauthor=M.+J.+Buchmeierauthor=P.+Kuhn&title=Proteomics+Analysis+Unravels+the+Functional+Repertoire+of+Coronavirus+Nonstructural+Protein+3&doi=10.1128%2FJVI.02631-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3</span></div><div class="casAuthors">Neuman, Benjamin W.; Joseph, Jeremiah S.; Saikatendu, Kumar S.; Serrano, Pedro; Chatterjee, Amarnath; Johnson, Margaret A.; Liao, Lujian; Klaus, Joseph P.; Yates, John R., III; Wuthrich, Kurt; Stevens, Raymond C.; Buchmeier, Michael J.; Kuhn, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5279-5294</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) coronavirus infection and growth are dependent on initiating signaling and enzyme actions upon viral entry into the host cell.  Proteins packaged during virus assembly may subsequently form the first line of attack and host manipulation upon infection.  A complete characterization of virion components is therefore important to understanding the dynamics of early stages of infection.  Mass spectrometry and kinase profiling techniques identified nearly 200 incorporated host and viral proteins.  We used published interaction data to identify hubs of connectivity with potential significance for virion formation.  Surprisingly, the hub with the most potential connections was not the viral M protein but the nonstructural protein 3 (nsp3), which is one of the novel virion components identified by mass spectrometry.  Based on new exptl. data and a bioinformatics anal. across the Coronaviridae, we propose a higher-resoln. functional domain architecture for nsp3 that dets. the interaction capacity of this protein.  Using recombinant protein domains expressed in Escherichia coli, we identified two addnl. RNA-binding domains of nsp3.  One of these domains is located within the previously described SARS-unique domain, and there is a nucleic acid chaperone-like domain located immediately downstream of the papain-like proteinase domain.  We also identified a novel cysteine-coordinated metal ion-binding domain.  Analyses of interdomain interactions and provisional functional annotation of the remaining, so-far-uncharacterized domains are presented.  Overall, the ensemble of data surveyed here paint a more complete picture of nsp3 as a conserved component of the viral protein processing machinery, which is intimately assocd. with viral RNA in its role as a virion component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIKSoeNFXMf7Vg90H21EOLACvtfcHk0liiFfbmbxyz-A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Slsrw%253D&md5=a82c5530f2f91b00f90989e240a40597</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FJVI.02631-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02631-07%26sid%3Dliteratum%253Aachs%26aulast%3DNeuman%26aufirst%3DB.%2BW.%26aulast%3DJoseph%26aufirst%3DJ.%2BS.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DSerrano%26aufirst%3DP.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DKlaus%26aufirst%3DJ.%2BP.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DBuchmeier%26aufirst%3DM.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26atitle%3DProteomics%2520Analysis%2520Unravels%2520the%2520Functional%2520Repertoire%2520of%2520Coronavirus%2520Nonstructural%2520Protein%25203%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D5279%26epage%3D5294%26doi%3D10.1128%2FJVI.02631-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotouhi-Ardakani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytvyn, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulea, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ©nard, R.</span></span> <span> </span><span class="NLM_article-title">The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">15199</span>â <span class="NLM_lpage">15208</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.24.15199-15208.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.79.24.15199-15208.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16306591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslOitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=15199-15208&author=H.+A.+Lindnerauthor=N.+Fotouhi-Ardakaniauthor=V.+Lytvynauthor=P.+Lachanceauthor=T.+Suleaauthor=R.+M%C3%A9nard&title=The+Papain-Like+Protease+from+the+Severe+Acute+Respiratory+Syndrome+Coronavirus+Is+a+Deubiquitinating+Enzyme&doi=10.1128%2FJVI.79.24.15199-15208.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme</span></div><div class="casAuthors">Lindner, Holger A.; Fotouhi-Ardakani, Nasser; Lytvyn, Viktoria; Lachance, Paule; Sulea, Traian; Menard, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15199-15208</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome coronavirus papain-like protease (SARS-CoV PLpro) is involved in the processing of the viral polyprotein and, thereby, contributes to the biogenesis of the virus replication complex.  Structural bioinformatics has revealed a relationship for the SARS-CoV PLpro to herpesvirus-assocd. ubiquitin-specific protease (HAUSP), a ubiquitin-specific protease, indicating potential deubiquitinating activity in addn. to its function in polyprotein processing.  In order to confirm this prediction, we overexpressed and purified SARS-CoV PLpro (amino acids [aa]1507 to 1858) from Escherichia coli.  The purified enzyme hydrolyzed ubiquitin-7-amino-4-methylcoumarin (Ub-AMC), a general deubiquitinating enzyme substrate, with a catalytic efficiency of 13,100 M-1 s-1, 220-fold more efficiently than the small synthetic peptide substrate Z-LRGG-AMC, which incorporates the C-terminal four residues of ubiquitin.  In addn., SARS-CoV PLpro was inhibited by the specific deubiquitinating enzyme inhibitor ubiquitin aldehyde, with an inhibition const. of 210 nM.  The purified SARS-CoV PLpro disassembles branched polyubiquitin chains with lengths of two to seven (Ub2-7) or four (Ub4) units, which involves isopeptide bond cleavage.  SARS-CoV PLpro processing activity was also detected against a protein fused to the C terminus of the ubiquitin-like modifier ISG15, both in vitro using the purified enzyme and in HeLa cells by coexpression with SARS-CoV PLpro (aa 1198 to 2009).  These results clearly establish that SARS-CoV PLpro is a deubiquitinating enzyme, thereby confirming our earlier prediction.  This unexpected activity for a coronavirus papain-like protease suggests a novel viral strategy to modulate the host cell ubiquitination machinery to its advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1m1bqW9GpybVg90H21EOLACvtfcHk0lgkviZVbW0tsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslOitw%253D%253D&md5=dff5e5e3d3b2fc8838413a8551480383</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.24.15199-15208.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.24.15199-15208.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DH.%2BA.%26aulast%3DFotouhi-Ardakani%26aufirst%3DN.%26aulast%3DLytvyn%26aufirst%3DV.%26aulast%3DLachance%26aufirst%3DP.%26aulast%3DSulea%26aufirst%3DT.%26aulast%3DM%25C3%25A9nard%26aufirst%3DR.%26atitle%3DThe%2520Papain-Like%2520Protease%2520from%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Is%2520a%2520Deubiquitinating%2520Enzyme%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D15199%26epage%3D15208%26doi%3D10.1128%2FJVI.79.24.15199-15208.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡ez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">The SARS-Coronavirus Papain-like Protease: Structure, Function and Inhibition by Designed Antiviral Compounds</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25554382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVOnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=21-38&author=Y.+M.+B%C3%A1ez-Santosauthor=S.+E.+St+Johnauthor=A.+D.+Mesecar&title=The+SARS-Coronavirus+Papain-like+Protease%3A+Structure%2C+Function+and+Inhibition+by+Designed+Antiviral+Compounds&doi=10.1016%2Fj.antiviral.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds</span></div><div class="casAuthors">Baez-Santos, Yahira M.; St. John, Sarah E.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over 10 years have passed since the deadly human coronavirus that causes severe acute respiratory syndrome (SARS-CoV) emerged from the Guangdong Province of China.  Despite the fact that the SARS-CoV pandemic infected over 8500 individuals, claimed over 800 lives and cost billions of dollars in economic loss worldwide, there still are no clin. approved antiviral drugs, vaccines or monoclonal antibody therapies to treat SARS-CoV infections.  The recent emergence of the deadly human coronavirus that causes Middle East respiratory syndrome (MERS-CoV) is a sobering reminder that new and deadly coronaviruses can emerge at any time with the potential to become pandemics.  Therefore, the continued development of therapeutic and prophylactic countermeasures to potentially deadly coronaviruses is warranted.  The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication.  Although the primary function of PLpro and 3CLpro are to process the viral polyprotein in a coordinated manner, PLpro has the addnl. function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses.  Therefore, targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells.  This review provides an up-to-date discussion on the SARS-CoV papain-like protease including a brief overview of the SARS-CoV genome and replication followed by a more in-depth discussion on the structure and catalytic mechanism of SARS-CoV PLpro, the multiple cellular functions of SARS-CoV PLpro, the inhibition of SARS-CoV PLpro by small mol. inhibitors, and the prospect of inhibiting papain-like protease from other coronaviruses.  This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkf_6BE2QqbVg90H21EOLACvtfcHk0lgkviZVbW0tsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVOnsw%253D%253D&md5=fcdde62e05b499546c73f3014ea521ad</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1ez-Santos%26aufirst%3DY.%2BM.%26aulast%3DSt%2BJohn%26aufirst%3DS.%2BE.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DThe%2520SARS-Coronavirus%2520Papain-like%2520Protease%253A%2520Structure%252C%2520Function%2520and%2520Inhibition%2520by%2520Designed%2520Antiviral%2520Compounds%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D115%26spage%3D21%26epage%3D38%26doi%3D10.1016%2Fj.antiviral.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarsiero, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Respiratory Syndrome Coronavirus Papain-like-Protease: Structure of a Viral Deubiquitinating Enzyme</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">5717</span>â <span class="NLM_lpage">5722</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0510851103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.0510851103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16581910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFaisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5717-5722&author=K.+Ratiaauthor=K.+S.+Saikatenduauthor=B.+D.+Santarsieroauthor=N.+Barrettoauthor=S.+C.+Bakerauthor=R.+C.+Stevensauthor=A.+D.+Mesecar&title=Severe+Acute+Respiratory+Syndrome+Coronavirus+Papain-like-Protease%3A+Structure+of+a+Viral+Deubiquitinating+Enzyme&doi=10.1073%2Fpnas.0510851103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme</span></div><div class="casAuthors">Ratia, Kiira; Saikatendu, Kumar Singh; Santarsiero, Bernard D.; Barretto, Naina; Baker, Susan C.; Stevens, Raymond C.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5717-5722</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro).  These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality assocd. with outbreaks of SARS-CoV.  In this work, we describe the 1.85-Ã crystal structure of the catalytic core of SARS-CoV PLpro and show that the overall architecture adopts a fold closely resembling that of known deubiquitinating enzymes (DUBs).  Key features, however, distinguish PLpro from characterized deubiquitinating enzymes, including an intact zinc-binding motif, an unobstructed catalytically competent active site, and the presence of an intriguing, ubiquitin-like (Ubl) N-terminal domain.  To gain insight into the active-site recognition of the C-terminal tail of ubiquitin and the related LXGG motif, we propose a model of PLpro in complex with ubiquitin-aldehyde that reveals well defined sites within the catalytic cleft that help to account for strict substrate-recognition motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2x9rmNLlYbVg90H21EOLACvtfcHk0lhdl_k4rg71ng"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFaisLc%253D&md5=a8531cf47993390ebeb194f71acf0ae4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510851103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510851103%26sid%3Dliteratum%253Aachs%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DSantarsiero%26aufirst%3DB.%2BD.%26aulast%3DBarretto%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DSevere%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Papain-like-Protease%253A%2520Structure%2520of%2520a%2520Viral%2520Deubiquitinating%2520Enzyme%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D5717%26epage%3D5722%26doi%3D10.1073%2Fpnas.0510851103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rut, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmudzinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snipas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Oualid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Activity Profiling and Structures of Inhibitor-Bound SARS-CoV-2-PLpro Protease Provides a Framework for Anti-COVID-19 Drug Design</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.29.068890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.29.068890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32511411" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+Rutauthor=Z.+Lvauthor=M.+Zmudzinskiauthor=S.+Patchettauthor=D.+Nayakauthor=S.+J.+Snipasauthor=F.+El+Oualidauthor=T.+T.+Huangauthor=M.+Bekesauthor=M.+Dragauthor=S.+K.+Olsen&title=Activity+Profiling+and+Structures+of+Inhibitor-Bound+SARS-CoV-2-PLpro+Protease+Provides+a+Framework+for+Anti-COVID-19+Drug+Design&doi=10.1101%2F2020.04.29.068890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1101%2F2020.04.29.068890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.29.068890%26sid%3Dliteratum%253Aachs%26aulast%3DRut%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DZmudzinski%26aufirst%3DM.%26aulast%3DPatchett%26aufirst%3DS.%26aulast%3DNayak%26aufirst%3DD.%26aulast%3DSnipas%26aufirst%3DS.%2BJ.%26aulast%3DEl%2BOualid%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DBekes%26aufirst%3DM.%26aulast%3DDrag%26aufirst%3DM.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DActivity%2520Profiling%2520and%2520Structures%2520of%2520Inhibitor-Bound%2520SARS-CoV-2-PLpro%2520Protease%2520Provides%2520a%2520Framework%2520for%2520Anti-COVID-19%2520Drug%2520Design%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.29.068890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÄglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brul, S.</span></span> <span> </span><span class="NLM_article-title">Ebselen as a Highly Active Inhibitor of PLProCoV2</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.05.17.100768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.05.17.100768" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+W%C4%99glarz-Tomczakauthor=J.+M.+Tomczakauthor=M.+Talmaauthor=S.+Brul&title=Ebselen+as+a+Highly+Active+Inhibitor+of+PLProCoV2&doi=10.1101%2F2020.05.17.100768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1101%2F2020.05.17.100768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.17.100768%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C4%2599glarz-Tomczak%26aufirst%3DE.%26aulast%3DTomczak%26aufirst%3DJ.%2BM.%26aulast%3DTalma%26aufirst%3DM.%26aulast%3DBrul%26aufirst%3DS.%26atitle%3DEbselen%2520as%2520a%2520Highly%2520Active%2520Inhibitor%2520of%2520PLProCoV2%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.17.100768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burda-Grabowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brul, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Inhibitors of PLproCoV2 by Screening Libraries of Selenium-Containing Compounds</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.05.20.107052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.05.20.107052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Weglarz-Tomczakauthor=J.+M.+Tomczakauthor=M.+Giurgauthor=M.+Burda-Grabowskaauthor=S.+Brul&title=Discovery+of+Potent+Inhibitors+of+PLproCoV2+by+Screening+Libraries+of+Selenium-Containing+Compounds&doi=10.1101%2F2020.05.20.107052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1101%2F2020.05.20.107052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.20.107052%26sid%3Dliteratum%253Aachs%26aulast%3DWeglarz-Tomczak%26aufirst%3DE.%26aulast%3DTomczak%26aufirst%3DJ.%2BM.%26aulast%3DGiurg%26aufirst%3DM.%26aulast%3DBurda-Grabowska%26aufirst%3DM.%26aulast%3DBrul%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Potent%2520Inhibitors%2520of%2520PLproCoV2%2520by%2520Screening%2520Libraries%2520of%2520Selenium-Containing%2520Compounds%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.20.107052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÄglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burda-Grabowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucha, A.</span></span> <span> </span><span class="NLM_article-title">Identification of Methionine Aminopeptidase 2 as a Molecular Target of the Organoselenium Drug Ebselen and Its Derivatives/Analogues: Synthesis, Inhibitory Activity and Molecular Modeling Study</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5254</span>â <span class="NLM_lpage">5259</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bmcl.2016.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27692546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFymtrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5254-5259&author=E.+W%C4%99glarz-Tomczakauthor=M.+Burda-Grabowskaauthor=M.+Giurgauthor=A.+Mucha&title=Identification+of+Methionine+Aminopeptidase+2+as+a+Molecular+Target+of+the+Organoselenium+Drug+Ebselen+and+Its+Derivatives%2FAnalogues%3A+Synthesis%2C+Inhibitory+Activity+and+Molecular+Modeling+Study&doi=10.1016%2Fj.bmcl.2016.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study</span></div><div class="casAuthors">Weglarz-Tomczak, Ewelina; Burda-Grabowska, Malgorzata; Giurg, Miroslaw; Mucha, Artur</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5254-5259</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A collection of twenty-six organoselenium compds., ebselen and its structural analogs, provided a novel approach for inhibiting the activity of human methionine aminopeptidase 2 (MetAP2).  This metalloprotease, being responsible for the removal of the amino-terminal methionine from newly synthesized proteins, plays a key role in angiogenesis, which is essential for the progression of diseases, including solid tumor cancers.  In this work, we discovered that ebselen, a synthetic organoselenium drug mol. with anti-inflammatory, anti-oxidant and cytoprotective activity, inhibits one of the main enzymes in the tumor progression pathway.  Using three-step synthesis, we obtained twenty-five ebselen derivs./analogs, e.g. I, ten of which are new, and tested their inhibitory activity toward three neutral aminopeptidases (MetAP2, alanine and leucine aminopeptidases).  All of the tested compds. proved to be selective, slow-binding inhibitors of MetAP2.  Similarly to ebselen, most of its analogs exhibited a moderate potency (IC50 = 1-12 Î¼M).  Moreover, we identified three strong inhibitors that bind favorably to the enzyme with the half maximal inhibitory concn. in the submicromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBrtF35eyEPbVg90H21EOLACvtfcHk0lioPYDd9WcOSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFymtrbN&md5=060229972f89968d856375356318d19f</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C4%2599glarz-Tomczak%26aufirst%3DE.%26aulast%3DBurda-Grabowska%26aufirst%3DM.%26aulast%3DGiurg%26aufirst%3DM.%26aulast%3DMucha%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Methionine%2520Aminopeptidase%25202%2520as%2520a%2520Molecular%2520Target%2520of%2520the%2520Organoselenium%2520Drug%2520Ebselen%2520and%2520Its%2520Derivatives%252FAnalogues%253A%2520Synthesis%252C%2520Inhibitory%2520Activity%2520and%2520Molecular%2520Modeling%2520Study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5254%26epage%3D5259%26doi%3D10.1016%2Fj.bmcl.2016.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baliji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">A Noncovalent Class of Papain-like Protease/Deubiquitinase Inhibitors Blocks SARS Virus Replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">16119</span>â <span class="NLM_lpage">16124</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0805240105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.0805240105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18852458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSju7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=16119-16124&author=K.+Ratiaauthor=S.+Peganauthor=J.+Takayamaauthor=K.+Sleemanauthor=M.+Coughlinauthor=S.+Balijiauthor=R.+Chaudhuriauthor=W.+Fuauthor=B.+S.+Prabhakarauthor=M.+E.+Johnsonauthor=S.+C.+Bakerauthor=A.+K.+Ghoshauthor=A.+D.+Mesecar&title=A+Noncovalent+Class+of+Papain-like+Protease%2FDeubiquitinase+Inhibitors+Blocks+SARS+Virus+Replication&doi=10.1073%2Fpnas.0805240105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication</span></div><div class="casAuthors">Ratia, Kiira; Pegan, Scott; Takayama, Jun; Sleeman, Katrina; Coughlin, Melissa; Baliji, Surendranath; Chaudhuri, Rima; Fu, Wentao; Prabhakar, Bellur S.; Johnson, Michael E.; Baker, Susan C.; Ghosh, Arun K.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16119-16124</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report the discovery and optimization of a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV).  This unique protease is not only responsible for processing the viral polyprotein into its functional units but is also capable of cleaving ubiquitin and ISG15 conjugates and plays a significant role in helping SARS-CoV evade the human immune system.  We screened a structurally diverse library of 50,080 compds. for inhibitors of PLpro and discovered a noncovalent lead inhibitor with an IC50 value of 20 Î¼M, which was improved to 600 nM via synthetic optimization.  The resulting compd., GRL0617, inhibited SARS-CoV viral replication in Vero E6 cells with an EC50 of 15 Î¼M and had no assocd. cytotoxicity.  The X-ray structure of PLpro in complex with GRL0617 indicates that the compd. has a unique mode of inhibition whereby it binds within the 54-53 subsites of the enzyme and induces a loop closure that shuts down catalysis at the active site.  These findings provide proof-of-principle that PLpro is a viable target for development of antivirals directed against SARS-CoV, and that potent noncovalent cysteine protease inhibitors can be developed with specificity directed toward pathogenic deubiquitinating enzymes without inhibiting host DUBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHkOorXemIEbVg90H21EOLACvtfcHk0lgPwbLtz4KpDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSju7rN&md5=c842f5d8458e7c091cbdef1fd94a8c87</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805240105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805240105%26sid%3Dliteratum%253Aachs%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DPegan%26aufirst%3DS.%26aulast%3DTakayama%26aufirst%3DJ.%26aulast%3DSleeman%26aufirst%3DK.%26aulast%3DCoughlin%26aufirst%3DM.%26aulast%3DBaliji%26aufirst%3DS.%26aulast%3DChaudhuri%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DPrabhakar%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DA%2520Noncovalent%2520Class%2520of%2520Papain-like%2520Protease%252FDeubiquitinase%2520Inhibitors%2520Blocks%2520SARS%2520Virus%2520Replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D16119%26epage%3D16124%26doi%3D10.1073%2Fpnas.0805240105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome - Coronavirus Papain-like Protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5228</span>â <span class="NLM_lpage">5240</span>, <span class="refDoi">Â DOI: 10.1021/jm900611t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900611t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlSnt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5228-5240&author=A.+K.+Ghoshauthor=J.+Takayamaauthor=Y.+Aubinauthor=K.+Ratiaauthor=R.+Chaudhuriauthor=Y.+Baezauthor=K.+Sleemanauthor=M.+Coughlinauthor=D.+B.+Nicholsauthor=D.+C.+Mulhearnauthor=B.+S.+Prabhakarauthor=S.+C.+Bakerauthor=M.+E.+Johnsonauthor=A.+D.+Mesecar&title=Structure-Based+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+a+Series+of+Novel+and+Reversible+Inhibitors+for+the+Severe+Acute+Respiratory+Syndrome+-+Coronavirus+Papain-like+Protease&doi=10.1021%2Fjm900611t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease</span></div><div class="casAuthors">Ghosh, Arun K.; Takayama, Jun; Aubin, Yoann; Ratia, Kiira; Chaudhuri, Rima; Baez, Yahira; Sleeman, Katrina; Coughlin, Melissa; Nichols, Daniel B.; Mulhearn, Debbie C.; Prabhakar, Bellur S.; Baker, Susan C.; Johnson, Michael E.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5228-5240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here the design, synthesis, mol. modeling, and biol. evaluation of a series of small mol., nonpeptide inhibitors of SARS-CoV PLpro.  Our initial lead compd. was identified via high-throughput screening of a diverse chem. library.  We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells.  Upon the basis of the X-ray crystal structure of inhibitor (III)-bound to SARS-CoV PLpro, a drug design template was created.  Our structure-based modification led to the design of a more potent inhibitor, (I) (enzyme IC50 = 0.46 Î¼M; antiviral EC50 = 6 Î¼M).  Interestingly, its methylamine deriv., (II), displayed good enzyme inhibitory potency (IC50 = 1.3 Î¼M) and the most potent SARS antiviral activity (EC50 = 5.2 Î¼M) in the series.  We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJF7Pn_WVnyrVg90H21EOLACvtfcHk0lgPwbLtz4KpDg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlSnt7o%253D&md5=6de7ca3e3417238331a8901ddaf84da9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm900611t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900611t%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DTakayama%26aufirst%3DJ.%26aulast%3DAubin%26aufirst%3DY.%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DChaudhuri%26aufirst%3DR.%26aulast%3DBaez%26aufirst%3DY.%26aulast%3DSleeman%26aufirst%3DK.%26aulast%3DCoughlin%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BB.%26aulast%3DMulhearn%26aufirst%3DD.%2BC.%26aulast%3DPrabhakar%26aufirst%3DB.%2BS.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DStructure-Based%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Series%2520of%2520Novel%2520and%2520Reversible%2520Inhibitors%2520for%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520-%2520Coronavirus%2520Papain-like%2520Protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5228%26epage%3D5240%26doi%3D10.1021%2Fjm900611t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡ez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraza, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agius, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielech, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">X-Ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2393</span>â <span class="NLM_lpage">2412</span>, <span class="refDoi">Â DOI: 10.1021/jm401712t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401712t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2393-2412&author=Y.+M.+B%C3%A1ez-Santosauthor=S.+J.+Barrazaauthor=M.+W.+Wilsonauthor=M.+P.+Agiusauthor=A.+M.+Mielechauthor=N.+M.+Davisauthor=S.+C.+Bakerauthor=S.+D.+Larsenauthor=A.+D.+Mesecar&title=X-Ray+Structural+and+Biological+Evaluation+of+a+Series+of+Potent+and+Highly+Selective+Inhibitors+of+Human+Coronavirus+Papain-like+Proteases&doi=10.1021%2Fjm401712t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases</span></div><div class="casAuthors">Baez-Santos, Yahira M.; Barraza, Scott J.; Wilson, Michael W.; Agius, Michael P.; Mielech, Anna M.; Davis, Nicole M.; Baker, Susan C.; Larsen, Scott D.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2393-2412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV).  A no. of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63.  Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is obsd.  X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead I and the most potent analogs II [X = 3-F, 4-F], featuring a monofluoro substitution at para and meta positions of the benzyl ring, resp.  Finally, the less lipophilic bis(amide) and methoxypyridine exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcS8tGH7OabVg90H21EOLACvtfcHk0lhGivtI2MqXKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqtLk%253D&md5=1c478c6345bc13e67d233f1815e867a4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm401712t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401712t%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1ez-Santos%26aufirst%3DY.%2BM.%26aulast%3DBarraza%26aufirst%3DS.%2BJ.%26aulast%3DWilson%26aufirst%3DM.%2BW.%26aulast%3DAgius%26aufirst%3DM.%2BP.%26aulast%3DMielech%26aufirst%3DA.%2BM.%26aulast%3DDavis%26aufirst%3DN.%2BM.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DX-Ray%2520Structural%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Series%2520of%2520Potent%2520and%2520Highly%2520Selective%2520Inhibitors%2520of%2520Human%2520Coronavirus%2520Papain-like%2520Proteases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2393%26epage%3D2412%26doi%3D10.1021%2Fjm401712t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">The Coronavirus Replicase</span>. In  <i>Current Topics in Microbiology and Immunology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2005</span>; Vol.  <span class="NLM_volume">287</span>, pp  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">94</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=57-94&author=J.+Ziebuhrauthor=L.+Enjuanes&title=Current+Topics+in+Microbiology+and+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DThe%2520Coronavirus%2520Replicase%26btitle%3DCurrent%2520Topics%2520in%2520Microbiology%2520and%2520Immunology%26aulast%3DEnjuanes%26aufirst%3DL.%26pub%3DSpringer%26date%3D2005%26volume%3D287%26spage%3D57%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Te
Velthuis, A. J. W.</span></span> <span> </span><span class="NLM_article-title">Common and Unique Features of Viral RNA-Dependent Polymerases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>â <span class="NLM_lpage">4420</span>, <span class="refDoi">Â DOI: 10.1007/s00018-014-1695-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2Fs00018-014-1695-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25080879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GntbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=4403-4420&author=A.+J.+W.+Te%0AVelthuis&title=Common+and+Unique+Features+of+Viral+RNA-Dependent+Polymerases&doi=10.1007%2Fs00018-014-1695-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Common and unique features of viral RNA-dependent polymerases</span></div><div class="casAuthors">te Velthuis, Aartjan J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4403-4420</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Eukaryotes and bacteria can be infected with a wide variety of RNA viruses.  On av., these pathogens share little sequence similarity and use different replication and transcription strategies.  Nevertheless, the members of nearly all RNA virus families depend on the activity of a virally encoded RNA-dependent polymerase for the condensation of nucleotide triphosphates.  This review provides an overview of our current understanding of the viral RNA-dependent polymerase structure and the biochem. and biophysics that is involved in replicating and transcribing the genetic material of RNA viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxoxM9xeapFrVg90H21EOLACvtfcHk0lhGivtI2MqXKQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GntbrN&md5=4ebf3c7985543f3069cfdc94485a2c7b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1695-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1695-z%26sid%3Dliteratum%253Aachs%26aulast%3DTe%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26atitle%3DCommon%2520and%2520Unique%2520Features%2520of%2520Viral%2520RNA-Dependent%2520Polymerases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2014%26volume%3D71%26spage%3D4403%26epage%3D4420%26doi%3D10.1007%2Fs00018-014-1695-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subissi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posthuma, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven-Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span> <span> </span><span class="NLM_article-title">One Severe Acute Respiratory Syndrome Coronavirus Protein Complex Integrates Processive RNA Polymerase and Exonuclease Activities</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E3900</span>â <span class="NLM_lpage">E3909</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1323705111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.1323705111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25197083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGntb3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E3900-E3909&author=L.+Subissiauthor=C.+C.+Posthumaauthor=A.+Colletauthor=J.+C.+Zevenhoven-Dobbeauthor=A.+E.+Gorbalenyaauthor=E.+Decrolyauthor=E.+J.+Snijderauthor=B.+Canardauthor=I.+Imbert&title=One+Severe+Acute+Respiratory+Syndrome+Coronavirus+Protein+Complex+Integrates+Processive+RNA+Polymerase+and+Exonuclease+Activities&doi=10.1073%2Fpnas.1323705111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities</span></div><div class="casAuthors">Subissi, Lorenzo; Posthuma, Clara C.; Collet, Axelle; Zevenhoven-Dobbe, Jessika C.; Gorbalenya, Alexander E.; Decroly, Etienne; Snijder, Eric J.; Canard, Bruno; Imbert, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">E3900-E3909</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In addn. to members causing milder human infections, the Coronaviridae family includes potentially lethal zoonotic agents causing severe acute respiratory syndrome (SARS) and the recently emerged Middle East respiratory syndrome.  The â¼30-kb pos.-stranded RNA genome of coronaviruses encodes a replication/transcription machinery that is unusually complex and composed of 16 nonstructural proteins (nsps).  SARS-CoV nsp12, the canonical RNA-dependent RNA polymerase (RdRp), exhibits poorly processive RNA synthesis in vitro, at odds with the efficient replication of a very large RNA genome in vivo.  Here, we report that SARS-CoV nsp7 and nsp8 activate and confer processivity to the RNA-synthesizing activity of nsp12.  Using biochem. assays and reverse genetics, the importance of conserved nsp7 and nsp8 residues was probed.  Whereas several nsp7 mutations affected virus replication to a limited extent, the replacement of two nsp8 residues (P183 and R190) essential for interaction with nsp12 and a third (K58) crit. for the interaction of the polymerase complex with RNA were all lethal to the virus.  Without a loss of processivity, the nsp7/nsp8/nsp12 complex can assoc. with nsp14, a bifunctional enzyme bearing 3'-5' exoribonuclease and RNA cap N7-guanine methyltransferase activities involved in replication fidelity and 5'-RNA capping, resp.  The identification of this tripartite polymerase complex that in turn assocs. with the nsp14 proofreading enzyme sheds light on how coronaviruses assemble an RNA-synthesizing machinery to replicate the largest known RNA genomes.  This protein complex is a fascinating example of the functional integration of RNA polymerase, capping, and proofreading activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodG7yPmFowK7Vg90H21EOLACvtfcHk0lgu_2GQWpZ3eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGntb3M&md5=ed2d7e8787ddd0d8a5e4565932cc54ef</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1323705111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1323705111%26sid%3Dliteratum%253Aachs%26aulast%3DSubissi%26aufirst%3DL.%26aulast%3DPosthuma%26aufirst%3DC.%2BC.%26aulast%3DCollet%26aufirst%3DA.%26aulast%3DZevenhoven-Dobbe%26aufirst%3DJ.%2BC.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DDecroly%26aufirst%3DE.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DCanard%26aufirst%3DB.%26aulast%3DImbert%26aufirst%3DI.%26atitle%3DOne%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Protein%2520Complex%2520Integrates%2520Processive%2520RNA%2520Polymerase%2520and%2520Exonuclease%2520Activities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE3900%26epage%3DE3909%26doi%3D10.1073%2Fpnas.1323705111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussetta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egloff, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">A Second, Non-Canonical RNA-Dependent RNA Polymerase in SARS Coronavirus</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4933</span>â <span class="NLM_lpage">4942</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsj.emboj.7601368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=17024178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyktb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=4933-4942&author=I.+Imbertauthor=J.+C.+Guillemotauthor=J.+M.+Bourhisauthor=C.+Bussettaauthor=B.+Coutardauthor=M.+P.+Egloffauthor=F.+Ferronauthor=A.+E.+Gorbalenyaauthor=B.+Canard&title=A+Second%2C+Non-Canonical+RNA-Dependent+RNA+Polymerase+in+SARS+Coronavirus&doi=10.1038%2Fsj.emboj.7601368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A second, non-canonical RNA-dependent RNA polymerase in SARS Coronavirus</span></div><div class="casAuthors">Imbert, Isabelle; Guillemot, Jean-Claude; Bourhis, Jean-Marie; Bussetta, Cecile; Coutard, Bruno; Egloff, Marie-Pierre; Ferron, Francois; Gorbalenya, Alexander E.; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4933-4942</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In (+) RNA coronaviruses, replication and transcription of the giant â¼30 kb genome to produce genome- and subgenome-size RNAs of both polarities are mediated by a cognate membrane-bound enzymic complex.  Its RNA-dependent RNA polymerase (RdRp) activity appears to be supplied by non-structural protein 12 (nsp12) that includes an RdRp domain conserved in all RNA viruses.  Using SARS coronavirus, we now show that coronaviruses uniquely encode a second RdRp residing in nsp8.  This protein strongly prefers the internal 5'-(G/U)CC-3' trinucleotides on RNA templates to initiate the synthesis of complementary oligonucleotides of <6 residues in a reaction whose fidelity is relatively low.  Distant structural homol. between the C-terminal domain of nsp8 and the catalytic palm subdomain of RdRps of RNA viruses suggests a common origin of the two coronavirus RdRps, which however may have evolved different sets of catalytic residues.  A parallel between the nsp8 RdRp and cellular DNA-dependent RNA primases is drawn to propose that the nsp8 RdRp produces primers utilized by the primer-dependent nsp12 RdRp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5dpY0uvoWbVg90H21EOLACvtfcHk0lgu_2GQWpZ3eQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyktb%252FJ&md5=d41d31d46aeed39c3a2fe105f7b1ee8c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601368%26sid%3Dliteratum%253Aachs%26aulast%3DImbert%26aufirst%3DI.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DBourhis%26aufirst%3DJ.%2BM.%26aulast%3DBussetta%26aufirst%3DC.%26aulast%3DCoutard%26aufirst%3DB.%26aulast%3DEgloff%26aufirst%3DM.%2BP.%26aulast%3DFerron%26aufirst%3DF.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DA%2520Second%252C%2520Non-Canonical%2520RNA-Dependent%2520RNA%2520Polymerase%2520in%2520SARS%2520Coronavirus%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D4933%26epage%3D4942%26doi%3D10.1038%2Fsj.emboj.7601368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saindane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harcourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornburg, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eabb5883</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.abb5883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.abb5883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32253226" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabb5883&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=S.+Zhouauthor=R.+L.+Grahamauthor=A.+J.+Pruijssersauthor=M.+L.+Agostiniauthor=S.+R.+Leistauthor=A.+Sch%C3%A4ferauthor=K.+H.+Dinnonauthor=L.+J.+Stevensauthor=J.+D.+Chappellauthor=X.+Luauthor=T.+M.+Hughesauthor=A.+S.+Georgeauthor=C.+S.+Hillauthor=S.+A.+Montgomeryauthor=A.+J.+Brownauthor=G.+R.+Bluemlingauthor=M.+G.+Natchusauthor=M.+Saindaneauthor=A.+A.+Kolykhalovauthor=G.+Painterauthor=J.+Harcourtauthor=A.+Taminauthor=N.+J.+Thornburgauthor=R.+Swanstromauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=An+Orally+Bioavailable+Broad-Spectrum+Antiviral+Inhibits+SARS-CoV-2+in+Human+Airway+Epithelial+Cell+Cultures+and+Multiple+Coronaviruses+in+Mice&doi=10.1126%2Fscitranslmed.abb5883"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abb5883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abb5883%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DStevens%26aufirst%3DL.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHughes%26aufirst%3DT.%2BM.%26aulast%3DGeorge%26aufirst%3DA.%2BS.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DSaindane%26aufirst%3DM.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DHarcourt%26aufirst%3DJ.%26aulast%3DTamin%26aufirst%3DA.%26aulast%3DThornburg%26aufirst%3DN.%2BJ.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DAn%2520Orally%2520Bioavailable%2520Broad-Spectrum%2520Antiviral%2520Inhibits%2520SARS-CoV-2%2520in%2520Human%2520Airway%2520Epithelial%2520Cell%2520Cultures%2520and%2520Multiple%2520Coronaviruses%2520in%2520Mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deabb5883%26doi%3D10.1126%2Fscitranslmed.abb5883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchdoerfer, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. B.</span></span> <span> </span><span class="NLM_article-title">Structure of the SARS-CoV Nsp12 Polymerase Bound to Nsp7 and Nsp8 Co-Factors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2342</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-10280-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-019-10280-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31138817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gslGnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2342&author=R.+N.+Kirchdoerferauthor=A.+B.+Ward&title=Structure+of+the+SARS-CoV+Nsp12+Polymerase+Bound+to+Nsp7+and+Nsp8+Co-Factors&doi=10.1038%2Fs41467-019-10280-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors</span></div><div class="casAuthors">Kirchdoerfer Robert N; Ward Andrew B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2342</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent history is punctuated by the emergence of highly pathogenic coronaviruses such as SARS- and MERS-CoV into human circulation.  Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome.  Here, we present the 3.1 ÃA resolution structure of the SARS-CoV nsp12 polymerase bound to its essential co-factors, nsp7 and nsp8, using single particle cryo-electron microscopy. nsp12 possesses an architecture common to all viral polymerases as well as a large N-terminal extension containing a kinase-like fold and is bound by two nsp8 co-factors.  This structure illuminates the assembly of the coronavirus core RNA-synthesis machinery, provides key insights into nsp12 polymerase catalysis and fidelity and acts as a template for the design of novel antiviral therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHhQTFTUGoc7HHuJhbyicZfW6udTcc2eZsoiVv_NbtO7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gslGnsg%253D%253D&md5=71c144c86c8cef5df8bd02905d93d6dc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10280-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10280-3%26sid%3Dliteratum%253Aachs%26aulast%3DKirchdoerfer%26aufirst%3DR.%2BN.%26aulast%3DWard%26aufirst%3DA.%2BB.%26atitle%3DStructure%2520of%2520the%2520SARS-CoV%2520Nsp12%2520Polymerase%2520Bound%2520to%2520Nsp7%2520and%2520Nsp8%2520Co-Factors%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2342%26doi%3D10.1038%2Fs41467-019-10280-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structure of the RNA-Dependent RNA Polymerase from COVID-19 Virus</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">782</span>, <span class="refDoi">Â DOI: 10.1126/science.abb7498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb7498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32277040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVyrsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=779-782&author=Y.+Gaoauthor=L.+Yanauthor=Y.+Huangauthor=F.+Liuauthor=Y.+Zhaoauthor=L.+Caoauthor=T.+Wangauthor=Q.+Sunauthor=Z.+Mingauthor=L.+Zhangauthor=J.+Geauthor=L.+Zhengauthor=Y.+Zhangauthor=H.+Wangauthor=Y.+Zhuauthor=C.+Zhuauthor=T.+Huauthor=T.+Huaauthor=B.+Zhangauthor=X.+Yangauthor=J.+Liauthor=H.+Yangauthor=Z.+Liuauthor=W.+Xuauthor=L.+W.+Guddatauthor=Q.+Wangauthor=Z.+Louauthor=Z.+Rao&title=Structure+of+the+RNA-Dependent+RNA+Polymerase+from+COVID-19+Virus&doi=10.1126%2Fscience.abb7498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the RNA-dependent RNA polymerase from COVID-19 virus</span></div><div class="casAuthors">Gao, Yan; Yan, Liming; Huang, Yucen; Liu, Fengjiang; Zhao, Yao; Cao, Lin; Wang, Tao; Sun, Qianqian; Ming, Zhenhua; Zhang, Lianqi; Ge, Ji; Zheng, Litao; Zhang, Ying; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Hua, Tian; Zhang, Bing; Yang, Xiuna; Li, Jun; Yang, Haitao; Liu, Zhijie; Xu, Wenqing; Guddat, Luke W.; Wang, Quan; Lou, Zhiyong; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6492</span>),
    <span class="NLM_cas:pages">779-782</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A novel coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] outbreak has caused a global coronavirus disease 2019 (COVID-19) pandemic, resulting in tens of thousands of infections and thousands of deaths worldwide.  The RNA-dependent RNA polymerase [(RdRp), also named nsp12] is the central component of coronaviral replication and transcription machinery, and it appears to be a primary target for the antiviral drug remdesivir.  We report the cryoelectron microscopy structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-angstrom resoln.  In addn. to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified Î²-hairpin domain at its N terminus.  A comparative anal. model shows how remdesivir binds to this polymerase.  The structure provides a basis for the design of new antiviral therapeutics that target viral RdRp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbDgKUj7ZIg7Vg90H21EOLACvtfcHk0lg-947b_wmi_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVyrsr4%253D&md5=07c9ca12ca757e52c2db2e4b4dcbf55b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb7498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb7498%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DMing%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructure%2520of%2520the%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520COVID-19%2520Virus%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D779%26epage%3D782%26doi%3D10.1126%2Fscience.abb7498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonald, S. M.</span></span> <span> </span><span class="NLM_article-title">RNA Synthetic Mechanisms Employed by Diverse Families of RNA Viruses</span>. <i>Wiley Interdiscip. Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">367</span>, <span class="refDoi">Â DOI: 10.1002/wrna.1164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fwrna.1164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23606593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=351-367&author=S.+M.+Mcdonald&title=RNA+Synthetic+Mechanisms+Employed+by+Diverse+Families+of+RNA+Viruses&doi=10.1002%2Fwrna.1164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">RNA synthetic mechanisms employed by diverse families of RNA viruses</span></div><div class="casAuthors">McDonald, Sarah M.</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: RNA</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-367</span>CODEN:
                <span class="NLM_cas:coden">WIRRCU</span>;
        ISSN:<span class="NLM_cas:issn">1757-7012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  RNA viruses are ubiquitous in nature, infecting every known organism on the planet.  These viruses can also be notorious human pathogens with significant medical and economic burdens.  Central to the lifecycle of an RNA virus is the synthesis of new RNA mols., a process that is mediated by specialized virally encoded enzymes called RNA-dependent RNA polymerases (RdRps).  RdRps directly catalyze phosphodiester bond formation between nucleoside triphosphates in an RNA-templated manner.  These enzymes are strikingly conserved in their structural and functional features, even among diverse RNA viruses belonging to different families.  During host cell infection, the activities of viral RdRps are often regulated by viral cofactor proteins.  Cofactors can modulate the type and timing of RNA synthesis by directly engaging the RdRp and/or by indirectly affecting its capacity to recognize template RNA.  High-resoln. structures of RdRps as apoenzymes, bound to RNA templates, in the midst of catalysis, and/or interacting with regulatory cofactor proteins, have dramatically increased our understanding of viral RNA synthetic mechanisms.  Combined with elegant biochem. studies, such structures are providing a scientific platform for the rational design of antiviral agents aimed at preventing and treating RNA virus-induced diseases.  WIREs RNA 2013, 4:351-367. doi: 10.1002/wrna.1164 Conflict of interest: The author has declared no conflicts of interest for this article.  For further resources related to this article, please visit the WIREs website.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6St7RlbCxJ7Vg90H21EOLACvtfcHk0lg-947b_wmi_A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCgurw%253D&md5=d376dde615f98162f3cb480b68782b38</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1164%26sid%3Dliteratum%253Aachs%26aulast%3DMcdonald%26aufirst%3DS.%2BM.%26atitle%3DRNA%2520Synthetic%2520Mechanisms%2520Employed%2520by%2520Diverse%2520Families%2520of%2520RNA%2520Viruses%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%2520RNA%26date%3D2013%26volume%3D4%26spage%3D351%26epage%3D367%26doi%3D10.1002%2Fwrna.1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyaeva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven-Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, G. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veelen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samborskiy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leontovich, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidorov, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posthuma, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Essential Nucleotidylating Activity Associated with a Newly Delineated Conserved Domain in the RNA Polymerase-Containing Protein of All Nidoviruses</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">8416</span>â <span class="NLM_lpage">8434</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkv838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fnar%2Fgkv838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26304538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGqs7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=8416-8434&author=K.+C.+Lehmannauthor=A.+Gulyaevaauthor=J.+C.+Zevenhoven-Dobbeauthor=G.+M.+C.+Janssenauthor=M.+Rubenauthor=H.+S.+Overkleeftauthor=P.+A.+Van+Veelenauthor=D.+V.+Samborskiyauthor=A.+A.+Kravchenkoauthor=A.+M.+Leontovichauthor=I.+A.+Sidorovauthor=E.+J.+Snijderauthor=C.+C.+Posthumaauthor=A.+E.+Gorbalenya&title=Discovery+of+an+Essential+Nucleotidylating+Activity+Associated+with+a+Newly+Delineated+Conserved+Domain+in+the+RNA+Polymerase-Containing+Protein+of+All+Nidoviruses&doi=10.1093%2Fnar%2Fgkv838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses</span></div><div class="casAuthors">Lehmann, Kathleen C.; Gulyaeva, Anastasia; Zevenhoven-Dobbe, Jessika C.; Janssen, George M. C.; Ruben, Mark; Overkleeft, Hermen S.; van Veelen, Peter A.; Samborskiy, Dmitry V.; Kravchenko, Alexander A.; Leontovich, Andrey M.; Sidorov, Igor A.; Snijder, Eric J.; Posthuma, Clara C.; Gorbalenya, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8416-8434</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">RNA viruses encode an RNA-dependent RNA polymerase (RdRp) that catalyzes the synthesis of their RNA(s).  In the case of pos.-stranded RNA viruses belonging to the order Nidovirales, the RdRp resides in a replicase subunit that is unusually large.  Bioinformatics anal. of this non-structural protein has now revealed a nidoviral signature domain (genetic marker) that is N-terminally adjacent to the RdRp and has no apparent homologs elsewhere.  Based on its conservation profile, this domain is proposed to have nucleotidylation activity.  We used recombinant non-structural protein 9 of the arterivirus equine arteritis virus (EAV) and different biochem. assays, including irreversible labeling with a GTP analog followed by a proteomics anal., to demonstrate the manganese-dependent covalent binding of guanosine and uridine phosphates to a lysine/histidine residue.  Most likely this was the invariant lysine of the newly identified domain, named nidovirus RdRp-assocd. nucleotidyltransferase (NiRAN), whose substitution with alanine severely diminished the described binding.  Furthermore, this mutation crippled EAV and prevented the replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture, indicating that NiRAN is essential for nidoviruses.  Potential functions supported by NiRAN may include nucleic acid ligation, mRNA capping and protein-primed RNA synthesis, possibilities that remain to be explored in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptC0dNyfEUh7Vg90H21EOLACvtfcHk0lhKiFc-Ss_28A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGqs7jK&md5=007b4fc844862dca2e4bb01f09ff88fc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv838%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DK.%2BC.%26aulast%3DGulyaeva%26aufirst%3DA.%26aulast%3DZevenhoven-Dobbe%26aufirst%3DJ.%2BC.%26aulast%3DJanssen%26aufirst%3DG.%2BM.%2BC.%26aulast%3DRuben%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DVan%2BVeelen%26aufirst%3DP.%2BA.%26aulast%3DSamborskiy%26aufirst%3DD.%2BV.%26aulast%3DKravchenko%26aufirst%3DA.%2BA.%26aulast%3DLeontovich%26aufirst%3DA.%2BM.%26aulast%3DSidorov%26aufirst%3DI.%2BA.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DPosthuma%26aufirst%3DC.%2BC.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520an%2520Essential%2520Nucleotidylating%2520Activity%2520Associated%2520with%2520a%2520Newly%2520Delineated%2520Conserved%2520Domain%2520in%2520the%2520RNA%2520Polymerase-Containing%2520Protein%2520of%2520All%2520Nidoviruses%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D8416%26epage%3D8434%26doi%3D10.1093%2Fnar%2Fgkv838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1499</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1126/science.abc1560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abc1560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32358203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CltLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1499-1504&author=W.+Yinauthor=C.+Maoauthor=X.+Luanauthor=D.-D.+Shenauthor=Q.+Shenauthor=H.+Suauthor=X.+Wangauthor=F.+Zhouauthor=W.+Zhaoauthor=M.+Gaoauthor=S.+Changauthor=Y.-C.+Xieauthor=G.+Tianauthor=H.-W.+Jiangauthor=S.-C.+Taoauthor=J.+Shenauthor=Y.+Jiangauthor=H.+Jiangauthor=Y.+Xuauthor=S.+Zhangauthor=Y.+Zhangauthor=H.+E.+Xu&title=Structural+Basis+for+the+Inhibition+of+the+RNA-Dependent+RNA+Polymerase+from+SARS-CoV-2+by+Remdesivir&doi=10.1126%2Fscience.abc1560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</span></div><div class="casAuthors">Yin, Wanchao; Mao, Chunyou; Luan, Xiaodong; Shen, Dan-Dan; Shen, Qingya; Su, Haixia; Wang, Xiaoxi; Zhou, Fulai; Zhao, Wenfeng; Gao, Minqi; Chang, Shenghai; Xie, Yuan-Chao; Tian, Guanghui; Jiang, He-Wei; Tao, Sheng-Ce; Shen, Jingshan; Jiang, Yi; Jiang, Hualiang; Xu, Yechun; Zhang, Shuyang; Zhang, Yan; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6498</span>),
    <span class="NLM_cas:pages">1499-1504</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global crisis.  Replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp) enzyme, a target of the antiviral drug remdesivir.  Here, we report the cryo-electron microscopy structure of the SARS-CoV-2 RdRp, both in the apo form at 2.8-angstrom resoln. and in complex with a 50-base template-primer RNA and remdesivir at 2.5-angstrom resoln.  The complex structure reveals that the partial double-stranded RNA template is inserted into the central channel of the RdRp, where remdesivir is covalently incorporated into the primer strand at the first replicated base pair, and terminates chain elongation.  Our structures provide insights into the mechanism of viral RNA replication and a rational template for drug design to combat the viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlizem_f4e1LVg90H21EOLACvtfcHk0lhQoSZ-I4NzGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CltLfK&md5=e5d7c8a1c27a02fdbfa9381482a0c3e8</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1126%2Fscience.abc1560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abc1560%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DD.-D.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.-C.%26aulast%3DTian%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.-W.%26aulast%3DTao%26aufirst%3DS.-C.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Inhibition%2520of%2520the%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520SARS-CoV-2%2520by%2520Remdesivir%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1499%26epage%3D1504%26doi%3D10.1126%2Fscience.abc1560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural and Biochemical Characterization of the Nsp12-Nsp7-Nsp8 Core Polymerase Complex from SARS-CoV-2</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">107774</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.107774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.celrep.2020.107774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32531208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGhs7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=107774&author=Q.+Pengauthor=R.+Pengauthor=B.+Yuanauthor=J.+Zhaoauthor=M.+Wangauthor=X.+Wangauthor=Q.+Wangauthor=Y.+Sunauthor=Z.+Fanauthor=J.+Qiauthor=G.+F.+Gaoauthor=Y.+Shi&title=Structural+and+Biochemical+Characterization+of+the+Nsp12-Nsp7-Nsp8+Core+Polymerase+Complex+from+SARS-CoV-2&doi=10.1016%2Fj.celrep.2020.107774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2</span></div><div class="casAuthors">Peng, Qi; Peng, Ruchao; Yuan, Bin; Zhao, Jingru; Wang, Min; Wang, Xixi; Wang, Qian; Sun, Yan; Fan, Zheng; Qi, Jianxun; Gao, George F.; Shi, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">107774</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has caused a huge no. of human deaths.  Currently, there are no specific drugs or vaccines available for this virus (SARS-CoV-2).  The viral polymerase is a promising antiviral target.  Here, the authors describe the near-at.-resoln. structure of the SARS-CoV-2 polymerase complex consisting of the nsp12 catalytic subunit and nsp7-nsp8 cofactors.  This structure highly resembles the counterpart of SARS-CoV with conserved motifs for all viral RNA-dependent RNA polymerases and suggests a mechanism of activation by cofactors.  Biochem. studies reveal reduced activity of the core polymerase complex and lower thermostability of individual subunits of SARS-CoV-2 compared with SARS-CoV.  These findings provide important insights into RNA synthesis by coronavirus polymerase and indicate adaptation of SARS-CoV-2 toward humans with a relatively lower body temp. than the natural bat hosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiKzBMRKFv-7Vg90H21EOLACvtfcHk0lhQoSZ-I4NzGw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGhs7jJ&md5=ffd9ec806cb1735c829f49cb2f34bdbe</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.107774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.107774%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520and%2520Biochemical%2520Characterization%2520of%2520the%2520Nsp12-Nsp7-Nsp8%2520Core%2520Polymerase%2520Complex%2520from%2520SARS-CoV-2%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D31%26spage%3D107774%26doi%3D10.1016%2Fj.celrep.2020.107774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegunov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span> <span> </span><span class="NLM_article-title">Structure of Replicating SARS-CoV-2 Polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">156</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2368-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2368-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32438371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2020&pages=154-156&author=H.+S.+Hillenauthor=G.+Kokicauthor=L.+Farnungauthor=C.+Dienemannauthor=D.+Tegunovauthor=P.+Cramer&title=Structure+of+Replicating+SARS-CoV-2+Polymerase&doi=10.1038%2Fs41586-020-2368-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of replicating SARS-CoV-2 polymerase</span></div><div class="casAuthors">Hillen, Hauke S.; Kokic, Goran; Farnung, Lucas; Dienemann, Christian; Tegunov, Dimitry; Cramer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7819</span>),
    <span class="NLM_cas:pages">154-156</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes1-3.  Here we present a cryo-electron microscopy structure of the SARS-CoV-2 RdRp in an active form that mimics the replicating enzyme.  The structure comprises the viral proteins non-structural protein 12 (nsp12), nsp8 and nsp7, and more than two turns of RNA template-product duplex.  The active-site cleft of nsp12 binds to the first turn of RNA and mediates RdRp activity with conserved residues.  Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA.  Long helical extensions in nsp8 protrude along exiting RNA, forming pos. charged 'sliding poles'.  These sliding poles can account for the known processivity of RdRp that is required for replicating the long genome of coronaviruses3.  Our results enable a detailed anal. of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvV9anYxFpbVg90H21EOLACvtfcHk0lhWHKo3K710AQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLjN&md5=a6c1595799a31219d6a54228f5df82c9</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2368-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2368-8%26sid%3Dliteratum%253Aachs%26aulast%3DHillen%26aufirst%3DH.%2BS.%26aulast%3DKokic%26aufirst%3DG.%26aulast%3DFarnung%26aufirst%3DL.%26aulast%3DDienemann%26aufirst%3DC.%26aulast%3DTegunov%26aufirst%3DD.%26aulast%3DCramer%26aufirst%3DP.%26atitle%3DStructure%2520of%2520Replicating%2520SARS-CoV-2%2520Polymerase%26jtitle%3DNature%26date%3D2020%26volume%3D584%26spage%3D154%26epage%3D156%26doi%3D10.1038%2Fs41586-020-2368-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The ProTide Prodrug Technology: From the Concept to the Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2211</span>â <span class="NLM_lpage">2226</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2211-2226&author=Y.+Mehellouauthor=H.+S.+Rattanauthor=J.+Balzarini&title=The+ProTide+Prodrug+Technology%3A+From+the+Concept+to+the+Clinic&doi=10.1021%2Facs.jmedchem.7b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The ProTide Prodrug Technology: From the Concept to the Clinic</span></div><div class="casAuthors">Mehellou, Youcef; Rattan, Hardeep S.; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2211-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ProTide technol. is a prodrug approach developed for the efficient intracellular delivery of nucleoside analog monophosphates and monophosphonates.  In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an arom. group and an amino acid ester moiety, which are enzymically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species.  Structurally, this represents the current end-point of an extensive medicinal chem. endeavor that spans almost three decades.  It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today.  This technol. has been extensively employed in drug discovery, and it has already led to the discovery of two FDA-approved (antiviral) ProTides.  In this work, we will review the development of the ProTide technol., its application in drug discovery, and its role in the improvement of drug delivery and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJFaQn4HwrVg90H21EOLACvtfcHk0lhWHKo3K710AQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P&md5=ab9f5805c3c9d2d80fbdd82a3ad86c73</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00734%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DRattan%26aufirst%3DH.%2BS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520ProTide%2520Prodrug%2520Technology%253A%2520From%2520the%2520Concept%2520to%2520the%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2211%26epage%3D2226%26doi%3D10.1021%2Facs.jmedchem.7b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span>; <span class="NLM_string-name">Neyts, J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Agents Acting as DNA or RNA Chain Terminators</span>. In  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¤usslich, H.-G.</span>, <span class="NLM_string-name">Bartenschlager, R.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2009</span>; Vol.  <span class="NLM_volume">189</span>, pp  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">84</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=53-84&author=E.+De+Clercq&author=J.+Neytsauthor=H.-G.+Kr%C3%A4usslich&author=R.+Bartenschlager&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAntiviral%2520Agents%2520Acting%2520as%2520DNA%2520or%2520RNA%2520Chain%2520Terminators%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DKr%25C3%25A4usslich%26aufirst%3DH.-G.%26pub%3DSpringer%26date%3D2009%26volume%3D189%26spage%3D53%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antiviral Activity of a Series of 1â²-Substituted 4-Aza-7,9-Dideazaadenosine C-Nucleosides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2705</span>â <span class="NLM_lpage">2707</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.02.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bmcl.2012.02.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22446091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGqt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2705-2707&author=A.+Choauthor=O.+L.+Saundersauthor=T.+Butlerauthor=L.+Zhangauthor=J.+Xuauthor=J.+E.+Velaauthor=J.+Y.+Fengauthor=A.+S.+Rayauthor=C.+U.+Kim&title=Synthesis+and+Antiviral+Activity+of+a+Series+of+1%E2%80%B2-Substituted+4-Aza-7%2C9-Dideazaadenosine+C-Nucleosides&doi=10.1016%2Fj.bmcl.2012.02.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides</span></div><div class="casAuthors">Cho, Aesop; Saunders, Oliver L.; Butler, Thomas; Zhang, Lijun; Xu, Jie; Vela, Jennifer E.; Feng, Joy Y.; Ray, Adrian S.; Kim, Choung U.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2705-2707</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1'-substituted analogs of 4-aza-7,9-dideazaadenosine C-nucleoside, e.g. I, were prepd. and evaluated for the potential as antiviral agents.  These compds. showed a broad range of inhibitory activity against various RNA viruses.  In particular, the whole cell potency against HCV when R = CN was attributed to inhibition of HCV NS5B polymerase and intracellular concn. of the corresponding nucleoside triphosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAj_ComFGJ9LVg90H21EOLACvtfcHk0lgw_30aU7lUiw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGqt7Y%253D&md5=b7576da7b34ae7b3862d80b52645465a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.105%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DA.%26aulast%3DSaunders%26aufirst%3DO.%2BL.%26aulast%3DButler%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DVela%26aufirst%3DJ.%2BE.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BU.%26atitle%3DSynthesis%2520and%2520Antiviral%2520Activity%2520of%2520a%2520Series%2520of%25201%25E2%2580%25B2-Substituted%25204-Aza-7%252C9-Dideazaadenosine%2520C-Nucleosides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2705%26epage%3D2707%26doi%3D10.1016%2Fj.bmcl.2012.02.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuthman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tongeren, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garza, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shurtleff, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retterer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharaibeh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelmsen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugelman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerffler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trancheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayers, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">381</span>â <span class="NLM_lpage">385</span>, <span class="refDoi">Â DOI: 10.1038/nature17180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature17180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26934220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGnu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2016&pages=381-385&author=T.+K.+Warrenauthor=R.+Jordanauthor=M.+K.+Loauthor=A.+S.+Rayauthor=R.+L.+Mackmanauthor=V.+Solovevaauthor=D.+Siegelauthor=M.+Perronauthor=R.+Bannisterauthor=H.+C.+Huiauthor=N.+Larsonauthor=R.+Strickleyauthor=J.+Wellsauthor=K.+S.+Stuthmanauthor=S.+A.+Van+Tongerenauthor=N.+L.+Garzaauthor=G.+Donnellyauthor=A.+C.+Shurtleffauthor=C.+J.+Rettererauthor=D.+Gharaibehauthor=R.+Zamaniauthor=T.+Kennyauthor=B.+P.+Eatonauthor=E.+Grimesauthor=L.+S.+Welchauthor=L.+Gombaauthor=C.+L.+Wilhelmsenauthor=D.+K.+Nicholsauthor=J.+E.+Nussauthor=E.+R.+Nagleauthor=J.+R.+Kugelmanauthor=G.+Palaciosauthor=E.+Doerfflerauthor=S.+Nevilleauthor=E.+Carraauthor=M.+O.+Clarkeauthor=L.+Zhangauthor=W.+Lewauthor=B.+Rossauthor=Q.+Wangauthor=K.+Chunauthor=L.+Wolfeauthor=D.+Babusisauthor=Y.+Parkauthor=K.+M.+Strayauthor=I.+Tranchevaauthor=J.+Y.+Fengauthor=O.+Barauskasauthor=Y.+Xuauthor=P.+Wongauthor=M.+R.+Braunauthor=M.+Flintauthor=L.+K.+McMullanauthor=S.+S.+Chenauthor=R.+Fearnsauthor=S.+Swaminathanauthor=D.+L.+Mayersauthor=C.+F.+Spiropoulouauthor=W.+A.+Leeauthor=S.+T.+Nicholauthor=T.+Cihlarauthor=S.+Bavari&title=Therapeutic+Efficacy+of+the+Small+Molecule+GS-5734+against+Ebola+Virus+in+Rhesus+Monkeys&doi=10.1038%2Fnature17180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</span></div><div class="casAuthors">Warren, Travis K.; Jordan, Robert; Lo, Michael K.; Ray, Adrian S.; Mackman, Richard L.; Soloveva, Veronica; Siegel, Dustin; Perron, Michel; Bannister, Roy; Hui, Hon C.; Larson, Nate; Strickley, Robert; Wells, Jay; Stuthman, Kelly S.; Van Tongeren, Sean A.; Garza, Nicole L.; Donnelly, Ginger; Shurtleff, Amy C.; Retterer, Cary J.; Gharaibeh, Dima; Zamani, Rouzbeh; Kenny, Tara; Eaton, Brett P.; Grimes, Elizabeth; Welch, Lisa S.; Gomba, Laura; Wilhelmsen, Catherine L.; Nichols, Donald K.; Nuss, Jonathan E.; Nagle, Elyse R.; Kugelman, Jeffrey R.; Palacios, Gustavo; Doerffler, Edward; Neville, Sean; Carra, Ernest; Clarke, Michael O.; Zhang, Lijun; Lew, Willard; Ross, Bruce; Wang, Queenie; Chun, Kwon; Wolfe, Lydia; Babusis, Darius; Park, Yeojin; Stray, Kirsten M.; Trancheva, Iva; Feng, Joy Y.; Barauskas, Ona; Xu, Yili; Wong, Pamela; Braun, Molly R.; Flint, Mike; McMullan, Laura K.; Chen, Shan-Shan; Fearns, Rachel; Swaminathan, Swami; Mayers, Douglas L.; Spiropoulou, Christina F.; Lee, William A.; Nichol, Stuart T.; Cihlar, Tomas; Bavari, Sina</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">7594</span>),
    <span class="NLM_cas:pages">381-385</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most recent Ebola virus outbreak in West Africa, which was unprecedented in the no. of cases and fatalities, geog. distribution, and no. of nations affected, highlights the need for safe, effective, and readily available antiviral agents for treatment and prevention of acute Ebola virus (EBOV) disease (EVD) or sequelae.  No antiviral therapeutics have yet received regulatory approval or demonstrated clin. efficacy.  Here we report the discovery of a novel small mol. GS-5734, a monophosphoramidate prodrug of an adenosine analog, with antiviral activity against EBOV.  GS-5734 exhibits antiviral activity against multiple variants of EBOV and other filoviruses in cell-based assays.  The pharmacol. active nucleoside triphosphate (NTP) is efficiently formed in multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as an alternative substrate and RNA-chain terminator in primer-extension assays using a surrogate respiratory syncytial virus RNA polymerase.  I.v. administration of GS-5734 to nonhuman primates resulted in persistent NTP levels in peripheral blood mononuclear cells (half-life, 14 h) and distribution to sanctuary sites for viral replication including testes, eyes, and brain.  In a rhesus monkey model of EVD, once-daily i.v. administration of 10 mg kg-1 GS-5734 for 12 days resulted in profound suppression of EBOV replication and protected 100% of EBOV-infected animals against lethal disease, ameliorating clin. disease signs and pathophysiol. markers, even when treatments were initiated three days after virus exposure when systemic viral RNA was detected in two out of six treated animals.  These results show the first substantive post-exposure protection by a small-mol. antiviral compd. against EBOV in nonhuman primates.  The broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenaviruses, and coronaviruses, suggests the potential for wider medical use.  GS-5734 is amenable to large-scale manufg., and clin. studies investigating the drug safety and pharmacokinetics are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX4QsyLVjgHLVg90H21EOLACvtfcHk0lhaYlYkADS03A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGnu70%253D&md5=ab121d827ac0a40cc1fed3dd1df905b6</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnature17180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17180%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DLarson%26aufirst%3DN.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DStuthman%26aufirst%3DK.%2BS.%26aulast%3DVan%2BTongeren%26aufirst%3DS.%2BA.%26aulast%3DGarza%26aufirst%3DN.%2BL.%26aulast%3DDonnelly%26aufirst%3DG.%26aulast%3DShurtleff%26aufirst%3DA.%2BC.%26aulast%3DRetterer%26aufirst%3DC.%2BJ.%26aulast%3DGharaibeh%26aufirst%3DD.%26aulast%3DZamani%26aufirst%3DR.%26aulast%3DKenny%26aufirst%3DT.%26aulast%3DEaton%26aufirst%3DB.%2BP.%26aulast%3DGrimes%26aufirst%3DE.%26aulast%3DWelch%26aufirst%3DL.%2BS.%26aulast%3DGomba%26aufirst%3DL.%26aulast%3DWilhelmsen%26aufirst%3DC.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BK.%26aulast%3DNuss%26aufirst%3DJ.%2BE.%26aulast%3DNagle%26aufirst%3DE.%2BR.%26aulast%3DKugelman%26aufirst%3DJ.%2BR.%26aulast%3DPalacios%26aufirst%3DG.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DNeville%26aufirst%3DS.%26aulast%3DCarra%26aufirst%3DE.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLew%26aufirst%3DW.%26aulast%3DRoss%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DWolfe%26aufirst%3DL.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DTrancheva%26aufirst%3DI.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DBraun%26aufirst%3DM.%2BR.%26aulast%3DFlint%26aufirst%3DM.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMayers%26aufirst%3DD.%2BL.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBavari%26aufirst%3DS.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520the%2520Small%2520Molecule%2520GS-5734%2520against%2520Ebola%2520Virus%2520in%2520Rhesus%2520Monkeys%26jtitle%3DNature%26date%3D2016%26volume%3D531%26spage%3D381%26epage%3D385%26doi%3D10.1038%2Fnature17180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerffler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][Triazin-4-Amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1648</span>â <span class="NLM_lpage">1661</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Gjsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1648-1661&author=D.+Siegelauthor=H.+C.+Huiauthor=E.+Doerfflerauthor=M.+O.+Clarkeauthor=K.+Chunauthor=L.+Zhangauthor=S.+Nevilleauthor=E.+Carraauthor=W.+Lewauthor=B.+Rossauthor=Q.+Wangauthor=L.+Wolfeauthor=R.+Jordanauthor=V.+Solovevaauthor=J.+Knoxauthor=J.+Perryauthor=M.+Perronauthor=K.+M.+Strayauthor=O.+Barauskasauthor=J.+Y.+Fengauthor=Y.+Xuauthor=G.+Leeauthor=A.+L.+Rheingoldauthor=A.+S.+Rayauthor=R.+Bannisterauthor=R.+Strickleyauthor=S.+Swaminathanauthor=W.+A.+Leeauthor=S.+Bavariauthor=T.+Cihlarauthor=M.+K.+Loauthor=T.+K.+Warrenauthor=R.+L.+Mackman&title=Discovery+and+Synthesis+of+a+Phosphoramidate+Prodrug+of+a+Pyrrolo%5B2%2C1-f%5D%5BTriazin-4-Amino%5D+Adenine+C-Nucleoside+%28GS-5734%29+for+the+Treatment+of+Ebola+and+Emerging+Viruses&doi=10.1021%2Facs.jmedchem.6b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses</span></div><div class="casAuthors">Siegel, Dustin; Hui, Hon C.; Doerffler, Edward; Clarke, Michael O.; Chun, Kwon; Zhang, Lijun; Neville, Sean; Carra, Ernest; Lew, Willard; Ross, Bruce; Wang, Queenie; Wolfe, Lydia; Jordan, Robert; Soloveva, Veronica; Knox, John; Perry, Jason; Perron, Michel; Stray, Kirsten M.; Barauskas, Ona; Feng, Joy Y.; Xu, Yili; Lee, Gary; Rheingold, Arnold L.; Ray, Adrian S.; Bannister, Roy; Strickley, Robert; Swaminathan, Swami; Lee, William A.; Bavari, Sina; Cihlar, Tomas; Lo, Michael K.; Warren, Travis K.; Mackman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1648-1661</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent Ebola virus (EBOV) outbreak in West Africa was the largest recorded in history with over 28,000 cases, resulting in >11,000 deaths including >500 healthcare workers.  A focused screening and lead optimization effort identified 4b (GS-5734) with anti-EBOV EC50 = 86 nM in macrophages as the clin. candidate.  Structure activity relationships established that the 1'-CN group and C-linked nucleobase were crit. for optimal anti-EBOV potency and selectivity against host polymerases.  A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclin. efficacy in a non-human-primate EBOV challenge model.  Once-daily 10 mg/kg iv treatment on days 3-14 postinfection had a significant effect on viremia and mortality, resulting in 100% survival of infected treated animals [ Nature 2016, 531, 381-385].  A phase 2 study (PREVAIL IV) is currently enrolling and will evaluate the effect of 4b on viral shedding from sanctuary sites in EBOV survivors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWkPjn__gILVg90H21EOLACvtfcHk0lhaYlYkADS03A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Gjsb4%253D&md5=b2a05cfeb4fd30fbca0d1d584ddcc220</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01594%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNeville%26aufirst%3DS.%26aulast%3DCarra%26aufirst%3DE.%26aulast%3DLew%26aufirst%3DW.%26aulast%3DRoss%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWolfe%26aufirst%3DL.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DKnox%26aufirst%3DJ.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DRheingold%26aufirst%3DA.%2BL.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26atitle%3DDiscovery%2520and%2520Synthesis%2520of%2520a%2520Phosphoramidate%2520Prodrug%2520of%2520a%2520Pyrrolo%255B2%252C1-f%255D%255BTriazin-4-Amino%255D%2520Adenine%2520C-Nucleoside%2520%2528GS-5734%2529%2520for%2520the%2520Treatment%2520of%2520Ebola%2520and%2520Emerging%2520Viruses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1648%26epage%3D1661%26doi%3D10.1021%2Facs.jmedchem.6b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">Remdesivir Is a Direct-Acting Antiviral That Inhibits RNA-Dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">6785</span>â <span class="NLM_lpage">6797</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA120.013679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.RA120.013679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32284326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=6785-6797&author=C.+J.+Gordonauthor=E.+P.+Tchesnokovauthor=E.+Woolnerauthor=J.+K.+Perryauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=Remdesivir+Is+a+Direct-Acting+Antiviral+That+Inhibits+RNA-Dependent+RNA+Polymerase+from+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+with+High+Potency&doi=10.1074%2Fjbc.RA120.013679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</span></div><div class="casAuthors">Gordon, Calvin J.; Tchesnokov, Egor P.; Woolner, Emma; Perry, Jason K.; Feng, Joy Y.; Porter, Danielle P.; Gotte, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6785-6797</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analog remdesivir (RDV).  RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action.  Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12.  Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA.  Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i + 3.  We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps.  A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP.  In this regard, the triphosphate forms of 2'-C-methylated compds., including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits.  Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not obsd.  These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analog as a direct-acting antiviral.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgHbFv_ESm2rVg90H21EOLACvtfcHk0ljlGXGXnDubJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7bN&md5=10cbcacce46953727591712e0edebed8</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA120.013679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA120.013679%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DC.%2BJ.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DWoolner%26aufirst%3DE.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DRemdesivir%2520Is%2520a%2520Direct-Acting%2520Antiviral%2520That%2520Inhibits%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25202%2520with%2520High%2520Potency%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D6785%26epage%3D6797%26doi%3D10.1074%2Fjbc.RA120.013679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, N. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selisko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eydoux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peersen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and SARS-CoV-2: Structural Requirements at Both Nsp12 RdRp and Nsp14 Exonuclease Active-Sites</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104793</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2020.104793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32283108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSrt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104793&author=A.+Shannonauthor=N.+T.+T.+Leauthor=B.+Seliskoauthor=C.+Eydouxauthor=K.+Alvarezauthor=J.+C.+Guillemotauthor=E.+Decrolyauthor=O.+Peersenauthor=F.+Ferronauthor=B.+Canard&title=Remdesivir+and+SARS-CoV-2%3A+Structural+Requirements+at+Both+Nsp12+RdRp+and+Nsp14+Exonuclease+Active-Sites&doi=10.1016%2Fj.antiviral.2020.104793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites</span></div><div class="casAuthors">Shannon, Ashleigh; Le, Nhung Thi-Tuyet; Selisko, Barbara; Eydoux, Cecilia; Alvarez, Karine; Guillemot, Jean-Claude; Decroly, Etienne; Peersen, Olve; Ferron, Francois; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104793</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals.  Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation.  To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogs (NAs), with over 25 approved for the treatment of several medically important viral diseases.  However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals.  Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes.  We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision.  Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogs.  Addnl., we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir.  This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotbZG0obWWsrVg90H21EOLACvtfcHk0ljlGXGXnDubJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSrt70%253D&md5=e7eb04df547768ddd50c875c11f7ccb5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104793%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DN.%2BT.%2BT.%26aulast%3DSelisko%26aufirst%3DB.%26aulast%3DEydoux%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DK.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DDecroly%26aufirst%3DE.%26aulast%3DPeersen%26aufirst%3DO.%26aulast%3DFerron%26aufirst%3DF.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DRemdesivir%2520and%2520SARS-CoV-2%253A%2520Structural%2520Requirements%2520at%2520Both%2520Nsp12%2520RdRp%2520and%2520Nsp14%2520Exonuclease%2520Active-Sites%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104793%26doi%3D10.1016%2Fj.antiviral.2020.104793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">326</span>, <span class="refDoi">Â DOI: 10.3390/v11040326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fv11040326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymt7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=326&author=E.+P.+Tchesnokovauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=Mechanism+of+Inhibition+of+Ebola+Virus+RNA-Dependent+RNA+Polymerase+by+Remdesivir&doi=10.3390%2Fv11040326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir</span></div><div class="casAuthors">Tchesnokov, Egor P.; Feng, Joy Y.; Porter, Danielle P.; Goette, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Remdesivir (GS-5734) is a 1'-cyano-substituted adenosine nucleotide analog prodrug that shows broad-spectrum antiviral activity against several RNA viruses.  This compd. is currently under clin. development for the treatment of Ebola virus disease (EVD).  While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated.  The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochem. studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target.  In this study, we confirmed that remdesivir-TP is able to compete for incorporation with ATP (ATP).  Enzyme kinetics revealed that EBOV RdRp and Respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies.  The selectivity of ATP against remdesivir-TP is â¼4 for EBOV RdRp and â¼3 for RSV RdRp.  In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of â¼500-fold.  For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1.  For RSV RdRp, we measured a â¼6-fold inhibition at position i+1 although RNA synthesis was not terminated.  Chain termination was in both cases delayed and was seen predominantly at position i+5.  This pattern is specific to remdesivir-TP and its 1'-cyano modification.  Compds. with modifications at the 2'-position show different patterns of inhibition.  While 2'-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1.  Taken together, our biochem. data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination.  The long distance of five residues between the incorporated nucleotide analog and its inhibitory effect warrant further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc37XlGxWUUbVg90H21EOLACvtfcHk0ljPDiwhHkLiSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymt7fJ&md5=1193e2fa405b0298678db0a005aa292e</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.3390%2Fv11040326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11040326%26sid%3Dliteratum%253Aachs%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520Inhibition%2520of%2520Ebola%2520Virus%2520RNA-Dependent%2520RNA%2520Polymerase%2520by%2520Remdesivir%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D326%26doi%3D10.3390%2Fv11040326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Initiation, Extension, and Termination of RNA Synthesis by a Paramyxovirus Polymerase</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e1006889</span>, <span class="refDoi">Â DOI: 10.1371/journal.ppat.1006889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.ppat.1006889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29425244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsleltrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e1006889&author=P.+C.+Jordanauthor=C.+Liuauthor=P.+Raynaudauthor=M.+K.+Loauthor=C.+F.+Spiropoulouauthor=J.+A.+Symonsauthor=L.+Beigelmanauthor=J.+Deval&title=Initiation%2C+Extension%2C+and+Termination+of+RNA+Synthesis+by+a+Paramyxovirus+Polymerase&doi=10.1371%2Fjournal.ppat.1006889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase</span></div><div class="casAuthors">Jordan, Paul C.; Liu, Cheng; Raynaud, Pauline; Lo, Michael K.; Spiropoulou, Christina F.; Symons, Julian A.; Beigelman, Leo; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1006889/1-e1006889/23</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Paramyxoviruses represent a family of RNA viruses causing significant human diseases.  These include measles virus, the most infectious virus ever reported, in addn. to parainfluenza virus, and other emerging viruses.  Paramyxoviruses likely share common replication machinery but their mechanisms of RNA biosynthesis activities and details of their complex polymerase structures are unknown.  Mechanistic and functional details of a paramyxovirus polymerase would have sweeping implications for understanding RNA virus replication and for the development of new antiviral medicines.  To study paramyxovirus polymerase structure and function, we expressed an active recombinant Nipah virus (NiV) polymerase complex assembled from the multifunctional NiV L protein bound to its phosphoprotein cofactor.  NiV is an emerging highly pathogenic virus that causes severe encephalitis and has been declared a global public health concern due to its high mortality rate.  Using neg.-stain electron microscopy, we demonstrated NiV polymerase forms ring-like particles resembling related RNA polymerases.  We identified conserved sequence elements driving recognition of the 3'- terminal genomic promoter by NiV polymerase, and leading to initiation of RNA synthesis, primer extension, and transition to elongation mode.  Polyadenylation resulting from NiV polymerase stuttering provides a mechanistic basis for transcription termination.  It also suggests a divergent adaptation in promoter recognition between pneumo- and paramyxoviruses.  The lack of available antiviral therapy for NiV prompted us to identify the triphosphate forms of R1479 and GS-5734, two clin. relevant nucleotide analogs, as substrates and inhibitors of NiV polymerase activity by delayed chain termination.  Overall, these findings provide low-resoln. structural details and the mechanism of an RNA polymerase from a previously uncharacterized virus family.  This work illustrates important functional differences yet remarkable similarities between the polymerases of nonsegmented neg.-strand RNA viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SobNcmdy9rVg90H21EOLACvtfcHk0ljPDiwhHkLiSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsleltrvM&md5=c4e11dad7faf0fb43d2dfff9f3dc202a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006889%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DP.%2BC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DRaynaud%26aufirst%3DP.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DInitiation%252C%2520Extension%252C%2520and%2520Termination%2520of%2520RNA%2520Synthesis%2520by%2520a%2520Paramyxovirus%2520Polymerase%26jtitle%3DPLoS%2520Pathog.%26date%3D2018%26volume%3D14%26spage%3De1006889%26doi%3D10.1371%2Fjournal.ppat.1006889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">The Antiviral Compound Remdesivir Potently Inhibits RNAdependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">4773</span>â <span class="NLM_lpage">4779</span>, <span class="refDoi">Â DOI: 10.1074/jbc.AC120.013056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.AC120.013056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32094225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVelsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=4773-4779&author=C.+J.+Gordonauthor=E.+P.+Tchesnokovauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=The+Antiviral+Compound+Remdesivir+Potently+Inhibits+RNAdependent+RNA+Polymerase+from+Middle+East+Respiratory+Syndrome+Coronavirus&doi=10.1074%2Fjbc.AC120.013056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</span></div><div class="casAuthors">Gordon, Calvin J.; Tchesnokov, Egor P.; Feng, Joy Y.; Porter, Danielle P.; Gotte, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4773-4779</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at contg. the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2).  Remdesivir (RDV) is an investigational compd. with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV).  RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps).  Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV.  We initially demonstrated that nsp8 and nsp12 form an active complex.  The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP.  Of note, the selectivity value for RDV-TP obtained with a steady-state approach suggests that it is more efficiently incorporated than ATP and 2 other nucleotide analogs.  Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3.  Hence, the likely mechanism of action is delayed RNA chain termination.  The addnl. 3 nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity.  Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbDEbqkrS27Vg90H21EOLACvtfcHk0ljPDiwhHkLiSQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVelsrg%253D&md5=e47890519ac94b27e3185224db05c225</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.AC120.013056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.AC120.013056%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DC.%2BJ.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DThe%2520Antiviral%2520Compound%2520Remdesivir%2520Potently%2520Inhibits%2520RNAdependent%2520RNA%2520Polymerase%2520from%2520Middle%2520East%2520Respiratory%2520Syndrome%2520Coronavirus%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D4773%26epage%3D4779%26doi%3D10.1074%2Fjbc.AC120.013056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32526208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGhtrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=417-428&author=Q.+Wangauthor=J.+Wuauthor=H.+Wangauthor=Y.+Gaoauthor=Q.+Liuauthor=A.+Muauthor=W.+Jiauthor=L.+Yanauthor=Y.+Zhuauthor=C.+Zhuauthor=X.+Fangauthor=X.+Yangauthor=Y.+Huangauthor=H.+Gaoauthor=F.+Liuauthor=J.+Geauthor=Q.+Sunauthor=X.+Yangauthor=W.+Xuauthor=Z.+Liuauthor=H.+Yangauthor=Z.+Louauthor=B.+Jiangauthor=L.+W.+Guddatauthor=P.+Gongauthor=Z.+Rao&title=Structural+Basis+for+RNA+Replication+by+the+SARS-CoV-2+Polymerase&doi=10.1016%2Fj.cell.2020.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase</span></div><div class="casAuthors">Wang, Quan; Wu, Jiqin; Wang, Haofeng; Gao, Yan; Liu, Qiaojie; Mu, An; Ji, Wenxin; Yan, Liming; Zhu, Yan; Zhu, Chen; Fang, Xiang; Yang, Xiaobao; Huang, Yucen; Gao, Hailong; Liu, Fengjiang; Ge, Ji; Sun, Qianqian; Yang, Xiuna; Xu, Wenqing; Liu, Zhijie; Yang, Haitao; Lou, Zhiyong; Jiang, Biao; Guddat, Luke W.; Gong, Peng; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417-428.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clin. studies for COVID-19 treatment, this despite an incomplete mechanistic understanding of the viral RNA-dependent RNA polymerase nsp12 drug interactions.  We examine the mol. basis of SARS-CoV-2 RNA replication by detg. the cryo-EM structures of the stalled pre- and post- translocated polymerase complexes.  Compared with the apo complex, the structures show notable structural rearrangements happening to nsp12 and its co-factors nsp7 and nsp8 to accommodate the nucleic acid, whereas there are highly conserved residues in nsp12, positioning the template and primer for an in-line attack on the incoming nucleotide.  Furthermore, we investigate the inhibition mechanism of the triphosphate metabolite of remdesivir through structural and kinetic analyses.  A transition model from the nsp7-nsp8 hexadecameric primase complex to the nsp12-nsp7-nsp8 polymerase complex is also proposed to provide clues for the understanding of the coronavirus transcription and replication machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr24LizT9ajcbVg90H21EOLACvtfcHk0lgqGbiDnRd1jg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGhtrjN&md5=ae9117fd346b577d85d37088b1999fb9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMu%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructural%2520Basis%2520for%2520RNA%2520Replication%2520by%2520the%2520SARS-CoV-2%2520Polymerase%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D417%26epage%3D428%26doi%3D10.1016%2Fj.cell.2020.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e13.</p></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava-Ranjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotard, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span> <span> </span><span class="NLM_article-title">GS-5734 and Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">43395</span>, <span class="refDoi">Â DOI: 10.1038/srep43395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsrep43395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28262699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1czjtFaltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=43395&author=M.+K.+Loauthor=R.+Jordanauthor=A.+Arveyauthor=J.+Sudhamsuauthor=P.+Shrivastava-Ranjanauthor=A.+L.+Hotardauthor=M.+Flintauthor=L.+K.+McMullanauthor=D.+Siegelauthor=M.+O.+Clarkeauthor=R.+L.+Mackmanauthor=H.+C.+Huiauthor=M.+Perronauthor=A.+S.+Rayauthor=T.+Cihlarauthor=S.+T.+Nicholauthor=C.+F.+Spiropoulou&title=GS-5734+and+Its+Parent+Nucleoside+Analog+Inhibit+Filo-%2C+Pneumo-%2C+and+Paramyxoviruses&doi=10.1038%2Fsrep43395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses</span></div><div class="casAuthors">Lo Michael K; Shrivastava-Ranjan Punya; Hotard Anne L; Flint Mike; McMullan Laura K; Nichol Stuart T; Spiropoulou Christina F; Jordan Robert; Arvey Aaron; Sudhamsu Jawahar; Siegel Dustin; Clarke Michael O; Mackman Richard L; Hui Hon C; Perron Michel; Ray Adrian S; Cihlar Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43395</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">GS-5734 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a non-human primate model of Ebola virus infection.  It has been administered under compassionate use to two Ebola patients, both of whom survived, and is currently in Phase 2 clinical development for treatment of Ebola virus disease.  Here we report the antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, providing evidence to support new indications for this compound against human viruses of significant public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTe-gGPhesmNRpyrDyM_m9cfW6udTcc2eYkXbi9tyPr07ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjtFaltg%253D%253D&md5=23a17a6f59bbe3e7b3f2f8770858a0c1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fsrep43395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep43395%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DArvey%26aufirst%3DA.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DShrivastava-Ranjan%26aufirst%3DP.%26aulast%3DHotard%26aufirst%3DA.%2BL.%26aulast%3DFlint%26aufirst%3DM.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26atitle%3DGS-5734%2520and%2520Its%2520Parent%2520Nucleoside%2520Analog%2520Inhibit%2520Filo-%252C%2520Pneumo-%252C%2520and%2520Paramyxoviruses%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D43395%26doi%3D10.1038%2Fsrep43395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klena, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaki, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, E.</span></span> <span> </span><span class="NLM_article-title">Remdesivir (GS-5734) Protects African Green Monkeys from Nipah Virus Challenge</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaau9242</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aau9242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aau9242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31142680" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaau9242&author=M.+K.+Loauthor=F.+Feldmannauthor=J.+M.+Garyauthor=R.+Jordanauthor=R.+Bannisterauthor=J.+Croninauthor=N.+R.+Patelauthor=J.+D.+Klenaauthor=S.+T.+Nicholauthor=T.+Cihlarauthor=S.+R.+Zakiauthor=H.+Feldmannauthor=C.+F.+Spiropoulouauthor=E.+de+Wit&title=Remdesivir+%28GS-5734%29+Protects+African+Green+Monkeys+from+Nipah+Virus+Challenge&doi=10.1126%2Fscitranslmed.aau9242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau9242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau9242%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DFeldmann%26aufirst%3DF.%26aulast%3DGary%26aufirst%3DJ.%2BM.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DCronin%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%2BR.%26aulast%3DKlena%26aufirst%3DJ.%2BD.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DZaki%26aufirst%3DS.%2BR.%26aulast%3DFeldmann%26aufirst%3DH.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3Dde%2BWit%26aufirst%3DE.%26atitle%3DRemdesivir%2520%2528GS-5734%2529%2520Protects%2520African%2520Green%2520Monkeys%2520from%2520Nipah%2520Virus%2520Challenge%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaau9242%26doi%3D10.1126%2Fscitranslmed.aau9242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ¶rnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprecher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Herp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoliÃ©, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosifiva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caluwaerts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antierens, A.</span></span> <span> </span><span class="NLM_article-title">First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1093/infdis/jiw493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Finfdis%2Fjiw493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28073857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ktlyltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2017&pages=171-174&author=J.+D%C3%B6rnemannauthor=C.+Burzioauthor=A.+Ronsseauthor=A.+Sprecherauthor=H.+De+Clerckauthor=M.+Van+Herpauthor=M.-C.+Koli%C3%A9author=V.+Yosifivaauthor=S.+Caluwaertsauthor=A.+K.+McElroyauthor=A.+Antierens&title=First+Newborn+Baby+to+Receive+Experimental+Therapies+Survives+Ebola+Virus+Disease&doi=10.1093%2Finfdis%2Fjiw493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease</span></div><div class="casAuthors">Dornemann Jenny; Burzio Chiara; Ronsse Axelle; Sprecher Armand; De Clerck Hilde; Van Herp Michel; Yosifiva Vesselina; Caluwaerts Severine; Antierens Annick; Kolie Marie-Claire; Caluwaerts Severine; McElroy Anita K; McElroy Anita K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A neonate born to an Ebola virus-positive woman was diagnosed with Ebola virus infection on her first day of life.  The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734.  On day 20, a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polymerase chain reaction.  The patient was discharged in good health on day 33 of life.  Further follow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months.  This patient is the first neonate documented to have survived congenital infection with Ebola virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVSdx4lvJNFrZpSb_XWfMrfW6udTcc2eYuFkPDfFp-Xbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ktlyltA%253D%253D&md5=6bd13c191096d2273beb5cc05306ccc7</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiw493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiw493%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6rnemann%26aufirst%3DJ.%26aulast%3DBurzio%26aufirst%3DC.%26aulast%3DRonsse%26aufirst%3DA.%26aulast%3DSprecher%26aufirst%3DA.%26aulast%3DDe%2BClerck%26aufirst%3DH.%26aulast%3DVan%2BHerp%26aufirst%3DM.%26aulast%3DKoli%25C3%25A9%26aufirst%3DM.-C.%26aulast%3DYosifiva%26aufirst%3DV.%26aulast%3DCaluwaerts%26aufirst%3DS.%26aulast%3DMcElroy%26aufirst%3DA.%2BK.%26aulast%3DAntierens%26aufirst%3DA.%26atitle%3DFirst%2520Newborn%2520Baby%2520to%2520Receive%2520Experimental%2520Therapies%2520Survives%2520Ebola%2520Virus%2520Disease%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D215%26spage%3D171%26epage%3D174%26doi%3D10.1093%2Finfdis%2Fjiw493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cropley, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabeen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karageorgopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackenby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConnachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahungu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mepham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenu, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, E. C.</span></span> <span> </span><span class="NLM_article-title">Late Ebola Virus Relapse Causing Meningoencephalitis: A Case Report</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">498</span>â <span class="NLM_lpage">503</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(16)30386-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2816%2930386-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27209148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FitV2ksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=498-503&author=M.+Jacobsauthor=A.+Rodgerauthor=D.+J.+Bellauthor=S.+Bhaganiauthor=I.+Cropleyauthor=A.+Filipeauthor=R.+J.+Giffordauthor=S.+Hopkinsauthor=J.+Hughesauthor=F.+Jabeenauthor=I.+Johannessenauthor=D.+Karageorgopoulosauthor=A.+Lackenbyauthor=R.+Lesterauthor=R.+S.+N.+Liuauthor=A.+MacConnachieauthor=T.+Mahunguauthor=D.+Martinauthor=N.+Marshallauthor=S.+Mephamauthor=R.+Ortonauthor=M.+Palmariniauthor=M.+Patelauthor=C.+Perryauthor=S.+E.+Petersauthor=D.+Porterauthor=D.+Ritchieauthor=N.+D.+Ritchieauthor=R.+A.+Seatonauthor=V.+B.+Sreenuauthor=K.+Templetonauthor=S.+Warrenauthor=G.+S.+Wilkieauthor=M.+Zambonauthor=R.+Gopalauthor=E.+C.+Thomson&title=Late+Ebola+Virus+Relapse+Causing+Meningoencephalitis%3A+A+Case+Report&doi=10.1016%2FS0140-6736%2816%2930386-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Late Ebola virus relapse causing meningoencephalitis: a case report</span></div><div class="casAuthors">Jacobs Michael; Rodger Alison; Bell David J; MacConnachie Alisdair; Perry Colin; Peters S Erica; Porter Duncan; Ritchie David; Ritchie Neil D; Seaton R Andrew; Bhagani Sanjay; Cropley Ian; Hopkins Susan; Karageorgopoulos Drosos; Lester Rebecca; Mahungu Tabitha; Mepham Stephen; Warren Simon; Filipe Ana; Gifford Robert J; Hughes Joseph; Orton Richard; Palmarini Massimo; Sreenu Vattipally B; Wilkie Gavin S; Jabeen Farrah; Johannessen Ingolfur; Templeton Kate; Lackenby Angie; Zambon Maria; Liu Rebecca S N; Martin Daniel; Marshall Neal; Patel Monika; Gopal Robin; Thomson Emma C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10043</span>),
    <span class="NLM_cas:pages">498-503</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There are thousands of survivors of the 2014 Ebola outbreak in west Africa.  Ebola virus can persist in survivors for months in immune-privileged sites; however, viral relapse causing life-threatening and potentially transmissible disease has not been described.  We report a case of late relapse in a patient who had been treated for severe Ebola virus disease with high viral load (peak cycle threshold value 13.2).  METHODS:  A 39-year-old female nurse from Scotland, who had assisted the humanitarian effort in Sierra Leone, had received intensive supportive treatment and experimental antiviral therapies, and had been discharged with undetectable Ebola virus RNA in peripheral blood.  The patient was readmitted to hospital 9 months after discharge with symptoms of acute meningitis, and was found to have Ebola virus in cerebrospinal fluid (CSF).  She was treated with supportive therapy and experimental antiviral drug GS-5734 (Gilead Sciences, San Francisco, Foster City, CA, USA).  We monitored Ebola virus RNA in CSF and plasma, and sequenced the viral genome using an unbiased metagenomic approach.  FINDINGS:  On admission, reverse transcriptase PCR identified Ebola virus RNA at a higher level in CSF (cycle threshold value 23.7) than plasma (31.3); infectious virus was only recovered from CSF.  The patient developed progressive meningoencephalitis with cranial neuropathies and radiculopathy.  Clinical recovery was associated with addition of high-dose corticosteroids during GS-5734 treatment.  CSF Ebola virus RNA slowly declined and was undetectable following 14 days of treatment with GS-5734.  Sequencing of plasma and CSF viral genome revealed only two non-coding changes compared with the original infecting virus.  INTERPRETATION:  Our report shows that previously unanticipated, late, severe relapses of Ebola virus can occur, in this case in the CNS.  This finding fundamentally redefines what is known about the natural history of Ebola virus infection.  Vigilance should be maintained in the thousands of Ebola survivors for cases of relapsed infection.  The potential for these cases to initiate new transmission chains is a serious public health concern.  FUNDING:  Royal Free London NHS Foundation Trust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYRsrOSKHcwJQHPYJuLg8TfW6udTcc2eYuFkPDfFp-Xbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FitV2ksg%253D%253D&md5=c2cb4099c19a6603874e120d53a7c8b4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2930386-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252930386-5%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DRodger%26aufirst%3DA.%26aulast%3DBell%26aufirst%3DD.%2BJ.%26aulast%3DBhagani%26aufirst%3DS.%26aulast%3DCropley%26aufirst%3DI.%26aulast%3DFilipe%26aufirst%3DA.%26aulast%3DGifford%26aufirst%3DR.%2BJ.%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DJabeen%26aufirst%3DF.%26aulast%3DJohannessen%26aufirst%3DI.%26aulast%3DKarageorgopoulos%26aufirst%3DD.%26aulast%3DLackenby%26aufirst%3DA.%26aulast%3DLester%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%2BS.%2BN.%26aulast%3DMacConnachie%26aufirst%3DA.%26aulast%3DMahungu%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DMarshall%26aufirst%3DN.%26aulast%3DMepham%26aufirst%3DS.%26aulast%3DOrton%26aufirst%3DR.%26aulast%3DPalmarini%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DC.%26aulast%3DPeters%26aufirst%3DS.%2BE.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DN.%2BD.%26aulast%3DSeaton%26aufirst%3DR.%2BA.%26aulast%3DSreenu%26aufirst%3DV.%2BB.%26aulast%3DTempleton%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DS.%26aulast%3DWilkie%26aufirst%3DG.%2BS.%26aulast%3DZambon%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DR.%26aulast%3DThomson%26aufirst%3DE.%2BC.%26atitle%3DLate%2520Ebola%2520Virus%2520Relapse%2520Causing%2520Meningoencephalitis%253A%2520A%2520Case%2520Report%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D498%26epage%3D503%26doi%3D10.1016%2FS0140-6736%2816%2930386-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulangu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshiani
Mbaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lusakibanza
Manzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nzolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshomba Oloma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyembe-Tamfum, J.-J.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">2293</span>â <span class="NLM_lpage">2303</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1910993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa1910993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31774950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2293-2303&author=S.+Mulanguauthor=L.+E.+Doddauthor=R.+T.+Daveyauthor=O.+Tshiani%0AMbayaauthor=M.+Proschanauthor=D.+Mukadiauthor=M.+Lusakibanza%0AManzoauthor=D.+Nzoloauthor=A.+Tshomba+Olomaauthor=A.+Ibandaauthor=R.+Aliauthor=S.+Coulibalyauthor=A.+C.+Levineauthor=R.+Graisauthor=J.+Diazauthor=H.+C.+Laneauthor=J.-J.+Muyembe-Tamfum&title=A+Randomized%2C+Controlled+Trial+of+Ebola+Virus+Disease+Therapeutics&doi=10.1056%2FNEJMoa1910993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, controlled trial of ebola virus disease therapeutics</span></div><div class="casAuthors">Mulangu, Sabue; Dodd, Lori E.; Davey, Richard T., Jr.; Mbaya, Olivier Tshiani; Proschan, Michael; Mukadi, Daniel; Manzo, Mariano Lusakibanza; Nzolo, Didier; Oloma, Antoine Tshomba; Ibanda, Augustin; Ali, Rosine; Coulibaly, Sinare; Levine, Adam C.; Grais, Rebecca; Diaz, Janet; Lane, H. Clifford; Muyembe-Tamfum, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2293-2303</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Although several exptl. therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial. methods We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018.  Patients of any age who had a pos. result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrolled.  All patients received std. care and were randomly assigned in a 1:1:1:1 ratio to i.v. administration of the triple monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3.  The REGN-EB3 group was added in a later version of the protocol, so data from these patients were compared with those of patients in the ZMapp group who were enrolled at or after the time the REGN-EB3 group was added (the ZMapp subgroup).  The primary end point was death at 28 days. results A total of 681 patients were enrolled from Nov. 20, 2018, to August 9, 2019, at which time the data and safety monitoring board recommended that patients be assigned only to the MAb114 and REGN-EB3 groups for the remainder of the trial; the recommendation was based on the results of an interim anal. that showed superiority of these groups to ZMapp and remdesivir with respect to mortality.  At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P = 0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P = 0.002).  A shorter duration of symptoms before admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated with improved survival.  Four serious adverse events were judged to be potentially related to the trial drugs. conclusions Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD.  Scientifically and ethically sound clin. research can be conducted during disease outbreaks and can help inform the outbreak response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsF31fomvTPrVg90H21EOLACvtfcHk0ljtS1rW4-dUjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsLzP&md5=ace616255b8372f99aef8dee4864d38f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1910993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1910993%26sid%3Dliteratum%253Aachs%26aulast%3DMulangu%26aufirst%3DS.%26aulast%3DDodd%26aufirst%3DL.%2BE.%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DTshiani%2BMbaya%26aufirst%3DO.%26aulast%3DProschan%26aufirst%3DM.%26aulast%3DMukadi%26aufirst%3DD.%26aulast%3DLusakibanza%2BManzo%26aufirst%3DM.%26aulast%3DNzolo%26aufirst%3DD.%26aulast%3DTshomba%2BOloma%26aufirst%3DA.%26aulast%3DIbanda%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DR.%26aulast%3DCoulibaly%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DA.%2BC.%26aulast%3DGrais%26aufirst%3DR.%26aulast%3DDiaz%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DH.%2BC.%26aulast%3DMuyembe-Tamfum%26aufirst%3DJ.-J.%26atitle%3DA%2520Randomized%252C%2520Controlled%2520Trial%2520of%2520Ebola%2520Virus%2520Disease%2520Therapeutics%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D2293%26epage%3D2303%26doi%3D10.1056%2FNEJMoa1910993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menachery, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralinski, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trantcheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmiotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaal3653</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aal3653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aal3653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28659436" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaal3653&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=R.+L.+Grahamauthor=V.+D.+Menacheryauthor=L.+E.+Gralinskiauthor=J.+B.+Caseauthor=S.+R.+Leistauthor=K.+Pyrcauthor=J.+Y.+Fengauthor=I.+Trantchevaauthor=R.+Bannisterauthor=Y.+Parkauthor=D.+Babusisauthor=M.+O.+Clarkeauthor=R.+L.+MacKmanauthor=J.+E.+Spahnauthor=C.+A.+Palmiottiauthor=D.+Siegelauthor=A.+S.+Rayauthor=T.+Cihlarauthor=R.+Jordanauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=Broad-Spectrum+Antiviral+GS-5734+Inhibits+Both+Epidemic+and+Zoonotic+Coronaviruses&doi=10.1126%2Fscitranslmed.aal3653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aal3653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aal3653%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DMenachery%26aufirst%3DV.%2BD.%26aulast%3DGralinski%26aufirst%3DL.%2BE.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DTrantcheva%26aufirst%3DI.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DMacKman%26aufirst%3DR.%2BL.%26aulast%3DSpahn%26aufirst%3DJ.%2BE.%26aulast%3DPalmiotti%26aufirst%3DC.%2BA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DBroad-Spectrum%2520Antiviral%2520GS-5734%2520Inhibits%2520Both%2520Epidemic%2520and%2520Zoonotic%2520Coronaviruses%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaal3653%26doi%3D10.1126%2Fscitranslmed.aal3653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span> <span> </span><span class="NLM_article-title">Broad Spectrum Antiviral Remdesivir Inhibits Human Endemic and Zoonotic Deltacoronaviruses with a Highly Divergent RNA Dependent RNA Polymerase</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">104541</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2019.104541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2019.104541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31233808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Git7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=104541&author=A.+J.+Brownauthor=J.+J.+Wonauthor=R.+L.+Grahamauthor=K.+H.+Dinnonauthor=A.+C.+Simsauthor=J.+Y.+Fengauthor=T.+Cihlarauthor=M.+R.+Denisonauthor=R.+S.+Baricauthor=T.+P.+Sheahan&title=Broad+Spectrum+Antiviral+Remdesivir+Inhibits+Human+Endemic+and+Zoonotic+Deltacoronaviruses+with+a+Highly+Divergent+RNA+Dependent+RNA+Polymerase&doi=10.1016%2Fj.antiviral.2019.104541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase</span></div><div class="casAuthors">Brown, Ariane J.; Won, John J.; Graham, Rachel L.; Dinnon, Kenneth H., III; Sims, Amy C.; Feng, Joy Y.; Cihlar, Tomas; Denison, Mark R.; Baric, Ralph S.; Sheahan, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104541</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The genetically diverse Orthocoronavirinae (CoV) family is prone to cross species transmission and disease emergence in both humans and livestock.  Viruses similar to known epidemic strains circulating in wild and domestic animals further increase the probability of emergence in the future.  Currently, there are no approved therapeutics for any human CoV presenting a clear unmet medical need.  Remdesivir (RDV, GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).  We developed multiple assays to further define the breadth of RDV antiviral activity against the CoV family.  Here, we show potent antiviral activity of RDV against endemic human CoVs OC43 (HCoV-OC43) and 229E (HCoV-229E) with submicromolar EC50 values.  Of known CoVs, the members of the deltacoronavirus genus have the most divergent RdRp as compared to SARS- and MERS-CoV and both avian and porcine members harbor a native residue in the RdRp that confers resistance in beta-CoVs.  Nevertheless, RDV is highly efficacious against porcine deltacoronavirus (PDCoV).  These data further extend the known breadth and antiviral activity of RDV to include both contemporary human and highly divergent zoonotic CoV and potentially enhance our ability to fight future emerging CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtZuP2J4qyxbVg90H21EOLACvtfcHk0ljtS1rW4-dUjA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Git7zI&md5=83a831806f8e8520713283d35de2bd7e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104541%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DWon%26aufirst%3DJ.%2BJ.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26atitle%3DBroad%2520Spectrum%2520Antiviral%2520Remdesivir%2520Inhibits%2520Human%2520Endemic%2520and%2520Zoonotic%2520Deltacoronaviruses%2520with%2520a%2520Highly%2520Divergent%2520RNA%2520Dependent%2520RNA%2520Polymerase%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D169%26spage%3D104541%26doi%3D10.1016%2Fj.antiviral.2019.104541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span> <span> </span><span class="NLM_article-title">Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e00221</span>, <span class="refDoi">Â DOI: 10.1128/mBio.00221-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FmBio.00221-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29511076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cktbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e00221&author=M.+L.+Agostiniauthor=E.+L.+Andresauthor=A.+C.+Simsauthor=R.+L.+Grahamauthor=T.+P.+Sheahanauthor=X.+Luauthor=E.+C.+Smithauthor=J.+B.+Caseauthor=J.+Y.+Fengauthor=R.+Jordanauthor=A.+S.+Rayauthor=T.+Cihlarauthor=D.+Siegelauthor=R.+L.+Mackmanauthor=M.+O.+Clarkeauthor=R.+S.+Baricauthor=M.+R.+Denison&title=Coronavirus+Susceptibility+to+the+Antiviral+Remdesivir+%28GS-5734%29+Is+Mediated+by+the+Viral+Polymerase+and+the+Proofreading+Exoribonuclease&doi=10.1128%2FmBio.00221-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</span></div><div class="casAuthors">Agostini, Maria L.; Andres, Erica L.; Sims, Amy C.; Graham, Rachel L.; Sheahan, Timothy P.; Lu, Xiaotao; Smith, Everett Clinton; Case, James Brett; Feng, Joy Y.; Jordan, Robert; Ray, Adrian S.; Cihlar, Tomas; Siege, Dustin; Mackman, Richard L.; Clarke, Michael O.; Baric, Ralph S.; Denison, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00221-18/1-e00221-18/15</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available.  The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity.  We recently reported that the nucleoside analog GS-5734 (remdesivir) potently inhibits human and zoonotic CoVs in vitro and in a severe acute respiratory syndrome coronavirus (SARS-CoV) mouse model.  However, studies with GS-5734 have not reported resistance assocd. with GS-5734, nor do we understand the action of GS-5734 in wild-type (WT) proofreading CoVs.  Here, we show that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concn. values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).  Passage of WT MHV in the presence of the GS-5734 parent nucleoside selected two mutations in the nsp12 polymerase at residues conserved across all CoVs that conferred up to 5.6-fold resistance to GS-5734, as detd. by EC50.  The resistant viruses were unable to compete with WT in direct coinfection passage in the absence of GS-5734.  Introduction of the MHV resistance mutations into SARS-CoV resulted in the same in vitro resistance phenotype and attenuated SARS-CoV pathogenesis in a mouse model.  Finally, we demonstrate that an MHV mutant lacking ExoN proofreading was significantly more sensitive to GS-5734.  Combined, the results indicate that GS-5734 interferes with the nsp12 polymerase even in the setting of intact ExoN proofreading activity and that resistance can be overcome with increased, nontoxic concns. of GS-5734, further supporting the development of GS-5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMg1wWYLfeubVg90H21EOLACvtfcHk0lgs8lAZIQsj3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cktbo%253D&md5=5b2ce6ee0d21ac1143bf3e2837a21167</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1128%2FmBio.00221-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00221-18%26sid%3Dliteratum%253Aachs%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DAndres%26aufirst%3DE.%2BL.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DE.%2BC.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26atitle%3DCoronavirus%2520Susceptibility%2520to%2520the%2520Antiviral%2520Remdesivir%2520%2528GS-5734%2529%2520Is%2520Mediated%2520by%2520the%2520Viral%2520Polymerase%2520and%2520the%2520Proofreading%2520Exoribonuclease%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De00221%26doi%3D10.1128%2FmBio.00221-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-0282-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41422-020-0282-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32020029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=269-271&author=M.+Wangauthor=R.+Caoauthor=L.+Zhangauthor=X.+Yangauthor=J.+Liuauthor=M.+Xuauthor=Z.+Shiauthor=Z.+Huauthor=W.+Zhongauthor=G.+Xiao&title=Remdesivir+and+Chloroquine+Effectively+Inhibit+the+Recently+Emerged+Novel+Coronavirus+%282019-NCoV%29+in+Vitro&doi=10.1038%2Fs41422-020-0282-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span></div><div class="casAuthors">Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China.  The initial cases were linked to exposures in a seafood market in Wuhan.  The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to severe acute respiratory syndrome CoV (SARS-CoV).  Currently, there is no specific treatment against the new virus.  Therefore, identifying effective antiviral agents to combat the disease is urgently needed.  In this study, we evaluated the antiviral efficiency of FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and favipiravir (T-705) against a clin. isolate of 2019-nCoV in vitro.  Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.  Since these compds. have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnj2tW4TeD7Vg90H21EOLACvtfcHk0lgs8lAZIQsj3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D&md5=bdf16b352ebc06bc148ed5c513b7d414</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0282-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0282-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26atitle%3DRemdesivir%2520and%2520Chloroquine%2520Effectively%2520Inhibit%2520the%2520Recently%2520Emerged%2520Novel%2520Coronavirus%2520%25282019-NCoV%2529%2520in%2520Vitro%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D269%26epage%3D271%26doi%3D10.1038%2Fs41422-020-0282-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewpreedee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, P. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, H. L.</span></span> <span> </span><span class="NLM_article-title">Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104786</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2020.104786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32251767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVOhtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104786&author=K.+T.+Choyauthor=A.+Y.+L.+Wongauthor=P.+Kaewpreedeeauthor=S.+F.+Siaauthor=D.+Chenauthor=K.+P.+Y.+Huiauthor=D.+K.+W.+Chuauthor=M.+C.+W.+Chanauthor=P.+P.+H.+Cheungauthor=X.+Huangauthor=M.+Peirisauthor=H.+L.+Yen&title=Remdesivir%2C+Lopinavir%2C+Emetine%2C+and+Homoharringtonine+Inhibit+SARS-CoV-2+Replication+in+Vitro&doi=10.1016%2Fj.antiviral.2020.104786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</span></div><div class="casAuthors">Choy, Ka-Tim; Wong, Alvina Yin-Lam; Kaewpreedee, Prathanporn; Sia, Sin Fun; Chen, Dongdong; Hui, Kenrie Pui Yan; Chu, Daniel Ka Wing; Chan, Michael Chi Wai; Cheung, Peter Pak-Hang; Huang, Xuhui; Peiris, Malik; Yen, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104786</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed.  We evaluated the in vitro antiviral effect of compds. that were previously reported to inhibit coronavirus replication and compds. that are currently under evaluation in clin. trials for SARS-CoV-2 patients.  We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estd. 50% effective concn. at 23.15Î¼M, 26.63Î¼M, 2.55Î¼M and 0.46Î¼M, resp.  Ribavirin or favipiravir that are currently evaluated under clin. trials showed no inhibition at 100Î¼M.  Synergy between remdesivir and emetine was obsd., and remdesivir at 6.25Î¼M in combination with emetine at 0.195Î¼M may achieve 64.9% inhibition in viral yield.  Combinational therapy may help to reduce the effective concn. of compds. below the therapeutic plasma concns. and provide better clin. benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3CI4nCzzgaLVg90H21EOLACvtfcHk0lgs8lAZIQsj3g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVOhtLw%253D&md5=d7907993ced412826670970df3fabd5a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104786%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DK.%2BT.%26aulast%3DWong%26aufirst%3DA.%2BY.%2BL.%26aulast%3DKaewpreedee%26aufirst%3DP.%26aulast%3DSia%26aufirst%3DS.%2BF.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DK.%2BP.%2BY.%26aulast%3DChu%26aufirst%3DD.%2BK.%2BW.%26aulast%3DChan%26aufirst%3DM.%2BC.%2BW.%26aulast%3DCheung%26aufirst%3DP.%2BP.%2BH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPeiris%26aufirst%3DM.%26aulast%3DYen%26aufirst%3DH.%2BL.%26atitle%3DRemdesivir%252C%2520Lopinavir%252C%2520Emetine%252C%2520and%2520Homoharringtonine%2520Inhibit%2520SARS-CoV-2%2520Replication%2520in%2520Vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104786%26doi%3D10.1016%2Fj.antiviral.2020.104786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runfeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunlong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jicheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiqi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qinhai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yongxia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chufang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhenhua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiming, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuxiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaobo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaotao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanshan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifeng, Y.</span></span> <span> </span><span class="NLM_article-title">Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity against Novel Coronavirus (SARS-CoV-2)</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">104761</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.phrs.2020.104761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32205232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFartrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2020&pages=104761&author=L.+Runfengauthor=H.+Yunlongauthor=H.+Jichengauthor=P.+Weiqiauthor=M.+Qinhaiauthor=S.+Yongxiaauthor=L.+Chufangauthor=Z.+Jinauthor=J.+Zhenhuaauthor=J.+Haimingauthor=Z.+Kuiauthor=H.+Shuxiangauthor=D.+Junauthor=L.+Xiaoboauthor=H.+Xiaotaoauthor=W.+Linauthor=Z.+Nanshanauthor=Y.+Zifeng&title=Lianhuaqingwen+Exerts+Anti-Viral+and+Anti-Inflammatory+Activity+against+Novel+Coronavirus+%28SARS-CoV-2%29&doi=10.1016%2Fj.phrs.2020.104761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)</span></div><div class="casAuthors">Runfeng, Li; Yunlong, Hou; Jicheng, Huang; Weiqi, Pan; Qinhai, Ma; Yongxia, Shi; Chufang, Li; Jin, Zhao; Zhenhua, Jia; Haiming, Jiang; Kui, Zheng; Shuxiang, Huang; Jun, Dai; Xiaobo, Li; Xiaotao, Hou; Lin, Wang; Nanshan, Zhong; Zifeng, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104761</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017).  The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response.  The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque redn. assay.  The effect of LH on virion morphol. was visualized under transmission electron microscope.  Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quant. PCR assays.  LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-Î±, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) prodn. at the mRNA levels.  Furthermore, LH treatment resulted in abnormal particle morphol. of virion in cells.  LH significantly inhibits the SARS-COV-2 replication, affects virus morphol. and exerts anti-inflammatory activity in vitro.  These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXIWE0RcS6LVg90H21EOLACvtfcHk0liKyzzH5km8Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFartrs%253D&md5=e1fddba011a2e62fd7ed0c3c557b410f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104761%26sid%3Dliteratum%253Aachs%26aulast%3DRunfeng%26aufirst%3DL.%26aulast%3DYunlong%26aufirst%3DH.%26aulast%3DJicheng%26aufirst%3DH.%26aulast%3DWeiqi%26aufirst%3DP.%26aulast%3DQinhai%26aufirst%3DM.%26aulast%3DYongxia%26aufirst%3DS.%26aulast%3DChufang%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DZhenhua%26aufirst%3DJ.%26aulast%3DHaiming%26aufirst%3DJ.%26aulast%3DKui%26aufirst%3DZ.%26aulast%3DShuxiang%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DXiaobo%26aufirst%3DL.%26aulast%3DXiaotao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DNanshan%26aufirst%3DZ.%26aulast%3DZifeng%26aufirst%3DY.%26atitle%3DLianhuaqingwen%2520Exerts%2520Anti-Viral%2520and%2520Anti-Inflammatory%2520Activity%2520against%2520Novel%2520Coronavirus%2520%2528SARS-CoV-2%2529%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D156%26spage%3D104761%26doi%3D10.1016%2Fj.phrs.2020.104761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralinksi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yount, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gully, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Pont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilello, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span> <span> </span><span class="NLM_article-title">Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">107940</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.107940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.celrep.2020.107940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32668216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2isrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2020&pages=107940&author=A.+J.+Pruijssersauthor=A.+S.+Georgeauthor=A.+Sch%C3%A4ferauthor=S.+R.+Leistauthor=L.+E.+Gralinksiauthor=K.+H.+Dinnonauthor=B.+L.+Yountauthor=M.+L.+Agostiniauthor=L.+J.+Stevensauthor=J.+D.+Chappellauthor=X.+Luauthor=T.+M.+Hughesauthor=K.+Gullyauthor=D.+R.+Martinezauthor=A.+J.+Brownauthor=R.+L.+Grahamauthor=J.+K.+Perryauthor=V.+Du+Pontauthor=J.+Pittsauthor=B.+Maauthor=D.+Babusisauthor=E.+Murakamiauthor=J.+Y.+Fengauthor=J.+P.+Bilelloauthor=D.+P.+Porterauthor=T.+Cihlarauthor=R.+S.+Baricauthor=M.+R.+Denisonauthor=T.+P.+Sheahan&title=Remdesivir+Inhibits+SARS-CoV-2+in+Human+Lung+Cells+and+Chimeric+SARS-CoV+Expressing+the+SARS-CoV-2+RNA+Polymerase+in+Mice&doi=10.1016%2Fj.celrep.2020.107940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</span></div><div class="casAuthors">Pruijssers, Andrea J.; George, Amelia S.; Schafer, Alexandra; Leist, Sarah R.; Gralinksi, Lisa E.; Dinnon, Kenneth H.; Yount, Boyd L.; Agostini, Maria L.; Stevens, Laura J.; Chappell, James D.; Lu, Xiaotao; Hughes, Tia M.; Gully, Kendra; Martinez, David R.; Brown, Ariane J.; Graham, Rachel L.; Perry, Jason K.; Du Pont, Venice; Pitts, Jared; Ma, Bin; Babusis, Darius; Murakami, Eisuke; Feng, Joy Y.; Bilello, John P.; Porter, Danielle P.; Cihlar, Tomas; Baric, Ralph S.; Denison, Mark R.; Sheahan, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107940</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19.  With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs.  We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 Î¼M).  Weaker activity is obsd. in Vero E6 cells (EC50 = 1.65 Î¼M) because of their low capacity to metabolize RDV.  To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase of SARS-CoV-2.  In mice infected with the chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function compared with vehicle-treated animals.  These data demonstrate that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clin. testing for treatment of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUzmxM5ARME7Vg90H21EOLACvtfcHk0liKyzzH5km8Rg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2isrzL&md5=d869e7d9f406848283f0a92d14e8f9ed</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.107940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.107940%26sid%3Dliteratum%253Aachs%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DGeorge%26aufirst%3DA.%2BS.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DGralinksi%26aufirst%3DL.%2BE.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DYount%26aufirst%3DB.%2BL.%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DStevens%26aufirst%3DL.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHughes%26aufirst%3DT.%2BM.%26aulast%3DGully%26aufirst%3DK.%26aulast%3DMartinez%26aufirst%3DD.%2BR.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DDu%2BPont%26aufirst%3DV.%26aulast%3DPitts%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DBilello%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26atitle%3DRemdesivir%2520Inhibits%2520SARS-CoV-2%2520in%2520Human%2520Lung%2520Cells%2520and%2520Chimeric%2520SARS-CoV%2520Expressing%2520the%2520SARS-CoV-2%2520RNA%2520Polymerase%2520in%2520Mice%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D32%26spage%3D107940%26doi%3D10.1016%2Fj.celrep.2020.107940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">222</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-13940-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-019-13940-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31924756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=222&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=S.+R.+Leistauthor=A.+Sch%C3%A4ferauthor=J.+Wonauthor=A.+J.+Brownauthor=S.+A.+Montgomeryauthor=A.+Hoggauthor=D.+Babusisauthor=M.+O.+Clarkeauthor=J.+E.+Spahnauthor=L.+Bauerauthor=S.+Sellersauthor=D.+Porterauthor=J.+Y.+Fengauthor=T.+Cihlarauthor=R.+Jordanauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=Comparative+Therapeutic+Efficacy+of+Remdesivir+and+Combination+Lopinavir%2C+Ritonavir%2C+and+Interferon+Beta+against+MERS-CoV&doi=10.1038%2Fs41467-019-13940-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</span></div><div class="casAuthors">Sheahan, Timothy P.; Sims, Amy C.; Leist, Sarah R.; Schafer, Alexandra; Won, John; Brown, Ariane J.; Montgomery, Stephanie A.; Hogg, Alison; Babusis, Darius; Clarke, Michael O.; Spahn, Jamie E.; Bauer, Laura; Sellers, Scott; Porter, Danielle; Feng, Joy Y.; Cihlar, Tomas; Jordan, Robert; Denison, Mark R.; Baric, Ralph S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease assocd. with more than 2468 human infections and over 851 deaths in 27 countries since 2012.  There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia.  Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro.  In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathol.  In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting other disease parameters.  Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathol.  Thus, we provide in vivo evidence of the potential for RDV to treat MERS-CoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9TF1JefverVg90H21EOLACvtfcHk0li1IQaYPcHaVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeisr0%253D&md5=6c0c2f8833068cf1c9bdef9847c31054</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13940-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13940-6%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DWon%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DHogg%26aufirst%3DA.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DSpahn%26aufirst%3DJ.%2BE.%26aulast%3DBauer%26aufirst%3DL.%26aulast%3DSellers%26aufirst%3DS.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DComparative%2520Therapeutic%2520Efficacy%2520of%2520Remdesivir%2520and%2520Combination%2520Lopinavir%252C%2520Ritonavir%252C%2520and%2520Interferon%2520Beta%2520against%2520MERS-CoV%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D222%26doi%3D10.1038%2Fs41467-019-13940-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade-White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doremalen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yinda, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-PÃ©rez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovaglio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, E.</span></span> <span> </span><span class="NLM_article-title">Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2423-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2423-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32516797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslelu7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2020&pages=273-276&author=B.+N.+Williamsonauthor=F.+Feldmannauthor=B.+Schwarzauthor=K.+Meade-Whiteauthor=D.+P.+Porterauthor=J.+Schulzauthor=N.+van+Doremalenauthor=I.+Leightonauthor=C.+K.+Yindaauthor=L.+P%C3%A9rez-P%C3%A9rezauthor=A.+Okumuraauthor=J.+Lovaglioauthor=P.+W.+Hanleyauthor=G.+Saturdayauthor=C.+M.+Bosioauthor=S.+Anzickauthor=K.+Barbianauthor=T.+Cihlarauthor=C.+Martensauthor=D.+P.+Scottauthor=V.+J.+Munsterauthor=E.+de+Wit&title=Clinical+Benefit+of+Remdesivir+in+Rhesus+Macaques+Infected+with+SARS-CoV-2&doi=10.1038%2Fs41586-020-2423-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2</span></div><div class="casAuthors">Williamson, Brandi N.; Feldmann, Friederike; Schwarz, Benjamin; Meade-White, Kimberly; Porter, Danielle P.; Schulz, Jonathan; van Doremalen, Neeltje; Leighton, Ian; Yinda, Claude Kwe; Perez-Perez, Lizzette; Okumura, Atsushi; Lovaglio, Jamie; Hanley, Patrick W.; Saturday, Greg; Bosio, Catharine M.; Anzick, Sarah; Barbian, Kent; Cihlar, Tomas; Martens, Craig; Scott, Dana P.; Munster, Vincent J.; de Wit, Emmie</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">7824</span>),
    <span class="NLM_cas:pages">273-276</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed.  While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclin. data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo.  Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2 that is currently being investigated in COVID-19 clin. trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4.  In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)2,5,6.  In vitro, remdesivir inhibited replication of SARS-CoV-27,8.  Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection9.  Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages twelve hours after the first dose.  Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.  At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage.  Thus, treatment with remdesivir initiated early during infection had a clin. benefit in rhesus macaques infected with SARS-CoV-2.  Although the rhesus macaque model does not represent the severe disease obsd. in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6fZodXTdabLVg90H21EOLACvtfcHk0li1IQaYPcHaVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslelu7rJ&md5=68d6cbbababc8d7b3d005285528b896e</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2423-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2423-5%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DB.%2BN.%26aulast%3DFeldmann%26aufirst%3DF.%26aulast%3DSchwarz%26aufirst%3DB.%26aulast%3DMeade-White%26aufirst%3DK.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DSchulz%26aufirst%3DJ.%26aulast%3Dvan%2BDoremalen%26aufirst%3DN.%26aulast%3DLeighton%26aufirst%3DI.%26aulast%3DYinda%26aufirst%3DC.%2BK.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DL.%26aulast%3DOkumura%26aufirst%3DA.%26aulast%3DLovaglio%26aufirst%3DJ.%26aulast%3DHanley%26aufirst%3DP.%2BW.%26aulast%3DSaturday%26aufirst%3DG.%26aulast%3DBosio%26aufirst%3DC.%2BM.%26aulast%3DAnzick%26aufirst%3DS.%26aulast%3DBarbian%26aufirst%3DK.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BP.%26aulast%3DMunster%26aufirst%3DV.%2BJ.%26aulast%3Dde%2BWit%26aufirst%3DE.%26atitle%3DClinical%2520Benefit%2520of%2520Remdesivir%2520in%2520Rhesus%2520Macaques%2520Infected%2520with%2520SARS-CoV-2%26jtitle%3DNature%26date%3D2020%26volume%3D585%26spage%3D273%26epage%3D276%26doi%3D10.1038%2Fs41586-020-2423-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas
LÃ³pez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattelan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano Viladomiu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbuagu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, L. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roestenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, O. T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Turnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span> <span> </span><span class="NLM_article-title">Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial</span>. <i>JAMA - J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1048</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1001/jama.2020.16349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1001%2Fjama.2020.16349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32821939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2020&pages=1048-1057&author=C.+D.+Spinnerauthor=R.+L.+Gottliebauthor=G.+J.+Crinerauthor=J.+R.+Arribas%0AL%C3%B3pezauthor=A.+M.+Cattelanauthor=A.+Soriano+Viladomiuauthor=O.+Ogbuaguauthor=P.+Malhotraauthor=K.+M.+Mullaneauthor=A.+Castagnaauthor=L.+Y.+A.+Chaiauthor=M.+Roestenbergauthor=O.+T.+Y.+Tsangauthor=E.+Bernasconiauthor=P.+Le+Turnierauthor=S.+C.+Changauthor=D.+Senguptaauthor=R.+H.+Hylandauthor=A.+O.+Osinusiauthor=H.+Caoauthor=C.+Blairauthor=H.+Wangauthor=A.+Gaggarauthor=D.+M.+Brainardauthor=M.+J.+McPhailauthor=S.+Bhaganiauthor=M.+Y.+Ahnauthor=A.+J.+Sanyalauthor=G.+Huhnauthor=F.+M.+Marty&title=Effect+of+Remdesivir+vs+Standard+Care+on+Clinical+Status+at+11+Days+in+Patients+with+Moderate+COVID-19%3A+A+Randomized+Clinical+Trial&doi=10.1001%2Fjama.2020.16349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial</span></div><div class="casAuthors">Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Lopez, Jose Ramon Arribas; Cattelan, Anna Maria; Viladomiu, Alex Soriano; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann; Roestenberg, Meta; Tsang, Owen Tak Yin; Bernasconi, Enos; Le Turnier, Paul; Chang, Shan-Chwen; SenGupta, Devi; Hyland, Robert H.; Osinusi, Anu O.; Cao, Huyen; Blair, Christiana; Wang, Hongyuan; Gaggar, Anuj; Brainard, Diana M.; McPhail, Mark J.; Bhagani, Sanjay; Ahn, Mi Young; Sanyal, Arun J.; Huhn, Gregory; Marty, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1048-1057</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Remdesivir demonstrated clin. benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.  To det. the efficacy of 5 or 10 days of remdesivir treatment compared with std. care on clin. status on day 11 after initiation of treatment.  Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen satn. >94%) enrolled from March 15 through Apr. 18, 2020, at 105 hospitals in the United States, Europe, and Asia.  The date of final follow-up was May 20, 2020.  Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or std. care (n = 200).  Remdesivir was dosed i.v. at 200 mg on day 1 followed by 100 mg/d. main outcomes and measures The primary end point was clin. status on day 11 on a 7-point ordinal scale ranging from death (category 1) to discharged (category 7).  Differences between remdesivir treatment groups and std. care were calcd. using proportional odds models and expressed as odds ratios.  An odds ratio greater than 1 indicates difference in clin. status distribution toward category 7 for the remdesivir group vs the std. care group. results Among 596 patients who were randomized, 584 began the study and received remdesivir or continued std. care (median age, 57 [interquartile range, 46-66] years; 227 [39%] women; 56% had cardiovascular disease, 42% hypertension, and 40% diabetes), and 533 (91%) completed the trial.  Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group.  On day 11, patients in the 5-day remdesivir group had statistically significantly higher odds of a better clin. status distribution than those receiving std. care (odds ratio, 1.65; 95% CI, 1.09-2.48; P = .02).  The clin. status distribution on day 11 between the 10-day remdesivir and std. care groups was not significantly different (P = .18 by Wilcoxon rank sum test).  By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and 4 (2%) in the std. care group.  Nausea (10% vs 3%), hypokalemia (6% vs 2%), and headache (5% vs 3%) were more frequent among remdesivir-treated patients compared with std. care.  Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clin. status compared with std. care at 11 days after initiation of treatment.  Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clin. status compared with std. care, but the difference was of uncertain clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgn63W-yBN1bVg90H21EOLACvtfcHk0lhQh-T1yk0VLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrnN&md5=d4a70d73dd4e543ba457938cd017bd16</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1001%2Fjama.2020.16349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2020.16349%26sid%3Dliteratum%253Aachs%26aulast%3DSpinner%26aufirst%3DC.%2BD.%26aulast%3DGottlieb%26aufirst%3DR.%2BL.%26aulast%3DCriner%26aufirst%3DG.%2BJ.%26aulast%3DArribas%2BL%25C3%25B3pez%26aufirst%3DJ.%2BR.%26aulast%3DCattelan%26aufirst%3DA.%2BM.%26aulast%3DSoriano%2BViladomiu%26aufirst%3DA.%26aulast%3DOgbuagu%26aufirst%3DO.%26aulast%3DMalhotra%26aufirst%3DP.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DCastagna%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DL.%2BY.%2BA.%26aulast%3DRoestenberg%26aufirst%3DM.%26aulast%3DTsang%26aufirst%3DO.%2BT.%2BY.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DLe%2BTurnier%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DOsinusi%26aufirst%3DA.%2BO.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcPhail%26aufirst%3DM.%2BJ.%26aulast%3DBhagani%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DM.%2BY.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26aulast%3DHuhn%26aufirst%3DG.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26atitle%3DEffect%2520of%2520Remdesivir%2520vs%2520Standard%2520Care%2520on%2520Clinical%2520Status%2520at%252011%2520Days%2520in%2520Patients%2520with%2520Moderate%2520COVID-19%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%2520-%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2020%26volume%3D324%26spage%3D1048%26epage%3D1057%26doi%3D10.1001%2Fjama.2020.16349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1569</span>â <span class="NLM_lpage">1578</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)31022-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2931022-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32423584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1569-1578&author=Y.+Wangauthor=D.+Zhangauthor=G.+Duauthor=R.+Duauthor=J.+Zhaoauthor=Y.+Jinauthor=S.+Fuauthor=L.+Gaoauthor=Z.+Chengauthor=Q.+Luauthor=Y.+Huauthor=G.+Luoauthor=K.+Wangauthor=Y.+Luauthor=H.+Liauthor=S.+Wangauthor=S.+Ruanauthor=C.+Yangauthor=C.+Meiauthor=Y.+Wangauthor=D.+Dingauthor=F.+Wuauthor=X.+Tangauthor=X.+Yeauthor=Y.+Yeauthor=B.+Liuauthor=J.+Yangauthor=W.+Yinauthor=A.+Wangauthor=G.+Fanauthor=F.+Zhouauthor=Z.+Liuauthor=X.+Guauthor=J.+Xuauthor=L.+Shangauthor=Y.+Zhangauthor=L.+Caoauthor=T.+Guoauthor=Y.+Wanauthor=H.+Qinauthor=Y.+Jiangauthor=T.+Jakiauthor=F.+G.+Haydenauthor=P.+W.+Horbyauthor=B.+Caoauthor=C.+Wang&title=Remdesivir+in+Adults+with+Severe+COVID-19%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Multicentre+Trial&doi=10.1016%2FS0140-6736%2820%2931022-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</span></div><div class="casAuthors">Wang, Yeming; Zhang, Dingyu; Du, Guanhua; Du, Ronghui; Zhao, Jianping; Jin, Yang; Fu, Shouzhi; Gao, Ling; Cheng, Zhenshun; Lu, Qiaofa; Hu, Yi; Luo, Guangwei; Wang, Ke; Lu, Yang; Li, Huadong; Wang, Shuzhen; Ruan, Shunan; Yang, Chengqing; Mei, Chunlin; Wang, Yi; Ding, Dan; Wu, Feng; Tang, Xin; Ye, Xianzhi; Ye, Yingchun; Liu, Bing; Yang, Jie; Yin, Wen; Wang, Aili; Fan, Guohui; Zhou, Fei; Liu, Zhibo; Gu, Xiaoying; Xu, Jiuyang; Shang, Lianhan; Zhang, Yi; Cao, Lianjun; Guo, Tingting; Wan, Yan; Qin, Hong; Jiang, Yushen; Jaki, Thomas; Hayden, Frederick G.; Horby, Peter W.; Cao, Bin; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10236</span>),
    <span class="NLM_cas:pages">1569-1578</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19).  Remdesivir (GS-5734), a nucleoside analog prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.  We did a randomized, double-blind, placebo-controlled, multicenter trial at ten hospitals in Hubei, China.  Eligible patients were adults (aged â¥18 years) admitted to hospital with lab.-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrollment of 12 days or less, oxygen satn. of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiol. confirmed pneumonia.  Patients were randomly assigned in a 2:1 ratio to i.v. remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same vol. of placebo infusions for 10 days.  Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids.  The primary endpoint was time to clin. improvement up to day 28, defined as the time (in days) from randomization to the point of a decline of two levels on a six-point ordinal scale of clin. status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first.  Primary anal. was done in the intention-to-treat (ITT) population and safety anal. was done in all patients who started their assigned treatment.  This trial is registered with ClinicalTrials.gov, NCT04257656.  Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomization was not included in the ITT population.  Remdesivir use was not assocd. with a difference in time to clin. improvement (hazard ratio 1Â·23 [95% CI 0Â·87-1Â·75]).  Although not statistically significant, patients receiving remdesivir had a numerically faster time to clin. improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1Â·52 [0Â·95-2Â·43]).  Adverse events were reported in 102 (66%) of 155 remdesivir recipients vs. 50 (64%) of 78 placebo recipients.  Remdesivir was stopped early because of adverse events in 18 (12%) patients vs. four (5%) patients who stopped placebo early.  In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not assocd. with statistically significant clin. benefits.  However, the numerical redn. in time to clin. improvement in those treated earlier requires confirmation in larger studies.  Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technol. Project.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmNUsjDSS-z7Vg90H21EOLACvtfcHk0lhQh-T1yk0VLw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D&md5=160af7f665ed7fe089e9c07b3bec1acd</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252931022-9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DHorby%26aufirst%3DP.%2BW.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRemdesivir%2520in%2520Adults%2520with%2520Severe%2520COVID-19%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Multicentre%2520Trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1569%26epage%3D1578%26doi%3D10.1016%2FS0140-6736%2820%2931022-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrie, J. D.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for COVID-19: Challenges of Underpowered Studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1525</span>â <span class="NLM_lpage">1527</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)31023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2931023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32423580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVWlurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1525-1527&author=J.+D.+Norrie&title=Remdesivir+for+COVID-19%3A+Challenges+of+Underpowered+Studies&doi=10.1016%2FS0140-6736%2820%2931023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir for COVID-19: challenges of underpowered studies</span></div><div class="casAuthors">Norrie, John David</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10236</span>),
    <span class="NLM_cas:pages">1525-1527</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review of a study reported by Wang Y. et al. (Lancet 2020; published online Apr. 29. https://doi.org/10.1016/S0140-6736(20)31022-9.) with commentary.  Wang et al. reported on a randomized, double-blind, placebo-controlled, multicenter trial of remdesivir in adults with severe COVID-19.  This trial posited 453 patients but was stopped after 237 because there were no further patients meeting the eligibility criteria.  Because the study was stopped early, it is underpowered and as such, no statistically significant conclusions could been drawn.  The authors conclude that during a pandemic, each individual study is at heightened risk of being incomplete.  They suggest that pooling data across possibly several underpowered but high-quality studies looks like our best way to obtain robust insights into what works, safely, and on whom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCz4NS5z3PcrVg90H21EOLACvtfcHk0lhyXZEd68wztQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurg%253D&md5=77c0e20b4f96d86e7df2764bb9c66402</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2931023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252931023-0%26sid%3Dliteratum%253Aachs%26aulast%3DNorrie%26aufirst%3DJ.%2BD.%26atitle%3DRemdesivir%2520for%2520COVID-19%253A%2520Challenges%2520of%2520Underpowered%2520Studies%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1525%26epage%3D1527%26doi%3D10.1016%2FS0140-6736%2820%2931023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, D. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Remdesivir in COVID-19</span>. <i>JAMA - J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1041</span>â <span class="NLM_lpage">1042</span>, <span class="refDoi">Â DOI: 10.1001/jama.2020.16337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1001%2Fjama.2020.16337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32821934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2020&pages=1041-1042&author=E.+K.+McCrearyauthor=D.+C.+Angus&title=Efficacy+of+Remdesivir+in+COVID-19&doi=10.1001%2Fjama.2020.16337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of remdesivir in COVID-19</span></div><div class="casAuthors">McCreary, Erin K.; Angus, Derek C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1041-1042</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">This article discusses the remdesivir in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-PwtDbtNXDLVg90H21EOLACvtfcHk0lhyXZEd68wztQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrbE&md5=5179ba768ea574dacb1c6f21275395a6</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1001%2Fjama.2020.16337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2020.16337%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DE.%2BK.%26aulast%3DAngus%26aufirst%3DD.%2BC.%26atitle%3DEfficacy%2520of%2520Remdesivir%2520in%2520COVID-19%26jtitle%3DJAMA%2520-%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2020%26volume%3D324%26spage%3D1041%26epage%3D1042%26doi%3D10.1001%2Fjama.2020.16337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiraki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daikoku, T.</span></span> <span> </span><span class="NLM_article-title">Favipiravir, an Anti-Influenza Drug against Life-Threatening RNA Virus Infections</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">107512</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2020.107512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.pharmthera.2020.107512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32097670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1WmsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2020&pages=107512&author=K.+Shirakiauthor=T.+Daikoku&title=Favipiravir%2C+an+Anti-Influenza+Drug+against+Life-Threatening+RNA+Virus+Infections&doi=10.1016%2Fj.pharmthera.2020.107512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</span></div><div class="casAuthors">Shiraki, Kimiyasu; Daikoku, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107512</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan.  Addnl., favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains.  This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduces the viral load.  Favipiravir cures all mice in a lethal influenza infection model, while oseltamivir fails to cure the animals.  Thus, favipiravir contributes to curing animals with lethal infection.  In addn. to influenza, favipiravir has a broad spectrum of anti-RNA virus activities in vitro and efficacies in animal models with lethal RNA viruses and has been used for treatment of human infection with life-threatening Ebola virus, Lassa virus, rabies, and severe fever with thrombocytopenia syndrome.  The best feature of favipiravir as an antiviral agent is the apparent lack of generation of favipiravir-resistant viruses.  Favipiravir alone maintains its therapeutic efficacy from the first to the last patient in an influenza pandemic or an epidemic lethal RNA virus infection.  Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which std. treatments are not available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEwOO4h_byl7Vg90H21EOLACvtfcHk0lhyXZEd68wztQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1WmsLc%253D&md5=8bec285689767cfdb14ee5b4735dc25c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2020.107512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2020.107512%26sid%3Dliteratum%253Aachs%26aulast%3DShiraki%26aufirst%3DK.%26aulast%3DDaikoku%26aufirst%3DT.%26atitle%3DFavipiravir%252C%2520an%2520Anti-Influenza%2520Drug%2520against%2520Life-Threatening%2520RNA%2520Virus%2520Infections%26jtitle%3DPharmacol.%2520Ther.%26date%3D2020%26volume%3D209%26spage%3D107512%26doi%3D10.1016%2Fj.pharmthera.2020.107512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3962</span>â <span class="NLM_lpage">3968</span>, <span class="refDoi">Â DOI: 10.1002/asia.201900841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fasia.201900841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31389664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFChsLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=3962-3968&author=E.+De+Clercq&title=New+Nucleoside+Analogues+for+the+Treatment+of+Hemorrhagic+Fever+Virus+Infections&doi=10.1002%2Fasia.201900841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3962-3968</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Eight different compds., all nucleoside analogs, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections.  They can be considered as either (i) adenine analogs (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogs contg. the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir).  All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine.  Four out of the eight compds. (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part.  The C-nucleoside and phosphoramidate (and for the adenine analogs the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRhK_m16Ho7Vg90H21EOLACvtfcHk0ljafccQnSjfSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFChsLnJ&md5=d28d163157c152c7fe1bb83ac7ffb928</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fasia.201900841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201900841%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNew%2520Nucleoside%2520Analogues%2520for%2520the%2520Treatment%2520of%2520Hemorrhagic%2520Fever%2520Virus%2520Infections%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2019%26volume%3D14%26spage%3D3962%26epage%3D3968%26doi%3D10.1002%2Fasia.201900841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baranovich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marjuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webby, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govorkova, E. A.</span></span> <span> </span><span class="NLM_article-title">T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3741</span>â <span class="NLM_lpage">3751</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02346-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02346-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23325689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlymsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=3741-3751&author=T.+Baranovichauthor=S.-S.+Wongauthor=J.+Armstrongauthor=H.+Marjukiauthor=R.+J.+Webbyauthor=R.+G.+Websterauthor=E.+A.+Govorkova&title=T-705+%28Favipiravir%29+Induces+Lethal+Mutagenesis+in+Influenza+A+H1N1+Viruses+In+Vitro&doi=10.1128%2FJVI.02346-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro</span></div><div class="casAuthors">Baranovich, Tatiana; Wong, Sook-San; Armstrong, Jianling; Marjuki, Henju; Webby, Richard J.; Webster, Robert G.; Govorkova, Elena A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3741-3751</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Several novel anti-influenza compds. are in various phases of clin. development.  One of these, T-705 (favipiravir), has a mechanism of action that is not fully understood but is suggested to target influenza virus RNA-dependent RNA polymerase.  We investigated the mechanism of T-705 activity against influenza A (H1N1) viruses by applying selective drug pressure over multiple sequential passage in MDCK cells.  We found that T-705 treatment did not select specific mutations in potential target proteins, including PB1, PB2, PA, and NP.  Phenotypic assays based on cell viability confirmed that no T-705-resistant variants were selected.  In the presence of T-705, titers of infectious virus decreased significantly (P < 0.0001) during serial passage in MDCK cells inoculated with seasonal influenza A (H1N1) viruses at a low multiplicity of infection (MOI; 0.0001 PFU/cell) or with 2009 pandemic H1N1 viruses at a high MOI (10 PFU/cell).  There was no corresponding decrease in the no. of viral RNA copies; therefore, specific virus infectivity (the ratio of infectious virus yield to viral RNA copy no.) was reduced.  Sequence anal. showed enrichment of GâA and CâT transversion mutations, increased mutation frequency, and a shift of the nucleotide profiles of individual NP gene clones under drug selection pressure.  Our results demonstrate that T-705 induces a high rate of mutation that generates a nonviable viral phenotype and that lethal mutagenesis is a key antiviral mechanism of T-705.  Our findings also explain the broad spectrum of activity of T-705 against viruses of multiple families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfot-qo_X4gLVg90H21EOLACvtfcHk0ljafccQnSjfSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlymsLc%253D&md5=330bcd116c6e434828555ea4d57d208d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1128%2FJVI.02346-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02346-12%26sid%3Dliteratum%253Aachs%26aulast%3DBaranovich%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DS.-S.%26aulast%3DArmstrong%26aufirst%3DJ.%26aulast%3DMarjuki%26aufirst%3DH.%26aulast%3DWebby%26aufirst%3DR.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%2BG.%26aulast%3DGovorkova%26aufirst%3DE.%2BA.%26atitle%3DT-705%2520%2528Favipiravir%2529%2520Induces%2520Lethal%2520Mutagenesis%2520in%2520Influenza%2520A%2520H1N1%2520Viruses%2520In%2520Vitro%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D3741%26epage%3D3751%26doi%3D10.1128%2FJVI.02346-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldhill, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Velthuis, A. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackenby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W. S.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Resistance to Favipiravir in Influenza</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">11613</span>â <span class="NLM_lpage">11618</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1811345115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.1811345115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30352857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSjs77O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=11613-11618&author=D.+H.+Goldhillauthor=A.+J.+W.+Te+Velthuisauthor=R.+A.+Fletcherauthor=P.+Langatauthor=M.+Zambonauthor=A.+Lackenbyauthor=W.+S.+Barclay&title=The+Mechanism+of+Resistance+to+Favipiravir+in+Influenza&doi=10.1073%2Fpnas.1811345115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of resistance to favipiravir in influenza</span></div><div class="casAuthors">Goldhill, Daniel H.; te Velthuis, Aartjan J. W.; Fletcher, Robert A.; Langat, Pinky; Zambon, Maria; Lackenby, Angie; Barclay, Wendy S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11613-11618</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections.  While emergence of resistance has been obsd. for many antiinfluenza drugs, to date, clin. trials and lab. studies of favipiravir have not yielded resistant viruses.  Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a lab. setting.  We found that two mutations were required for robust resistance to favipiravir.  We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture.  This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase.  K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F.  The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6syCwojqRlrVg90H21EOLACvtfcHk0ljafccQnSjfSw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSjs77O&md5=c0f0e26951bf79cf2ccca5bc67facaed</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811345115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811345115%26sid%3Dliteratum%253Aachs%26aulast%3DGoldhill%26aufirst%3DD.%2BH.%26aulast%3DTe%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26aulast%3DFletcher%26aufirst%3DR.%2BA.%26aulast%3DLangat%26aufirst%3DP.%26aulast%3DZambon%26aufirst%3DM.%26aulast%3DLackenby%26aufirst%3DA.%26aulast%3DBarclay%26aufirst%3DW.%2BS.%26atitle%3DThe%2520Mechanism%2520of%2520Resistance%2520to%2520Favipiravir%2520in%2520Influenza%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D11613%26epage%3D11618%26doi%3D10.1073%2Fpnas.1811345115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">QuÃ©rat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochmans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lamballerie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hemert, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span> <span> </span><span class="NLM_article-title">Mutations in the Chikungunya Virus Non-Structural Proteins Cause Resistance to Favipiravir (T-705), a Broad-Spectrum Antiviral</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2770</span>â <span class="NLM_lpage">2784</span>, <span class="refDoi">Â DOI: 10.1093/jac/dku209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fjac%2Fdku209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=24951535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Chsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=2770-2784&author=L.+Delangauthor=N.+Segura+Guerreroauthor=A.+Tasauthor=G.+Qu%C3%A9ratauthor=B.+Pastorinoauthor=M.+Froeyenauthor=K.+Dallmeierauthor=D.+Jochmansauthor=P.+Herdewijnauthor=F.+Belloauthor=E.+J.+Snijderauthor=X.+de+Lamballerieauthor=B.+Martinaauthor=J.+Neytsauthor=M.+J.+van+Hemertauthor=P.+Leyssen&title=Mutations+in+the+Chikungunya+Virus+Non-Structural+Proteins+Cause+Resistance+to+Favipiravir+%28T-705%29%2C+a+Broad-Spectrum+Antiviral&doi=10.1093%2Fjac%2Fdku209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the Chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral</span></div><div class="casAuthors">Delang, Leen; Guerrero, Nidya Segura; Tas, Ali; Querat, Gilles; Pastorino, Boris; Froeyen, Mathy; Dallmeier, Kai; Jochmans, Dirk; Herdewijn, Piet; Bello, Felio; Snijder, Eric J.; de Lamballerie, Xavier; Martina, Byron; Neyts, Johan; van Hemert, Martijn J.; Leyssen, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2770-2784</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: T-705, also known as favipiravir, is a small-mol. inhibitor that is currently in clin. development for the treatment of influenza virus infections.  This mol. also inhibits the replication of a broad spectrum of other RNA viruses.  The objective of this study was to investigate the antiviral effect of favipiravir on Cchikungunya virus (CHIKV) replication and to contribute to unravelling the mol. mechanism of action against this virus.  Methods: The anti-CHIKV effect of favipiravir was examd. in cell culture and in a mouse model of lethal infection.  A five-step protocol was used to select for CHIKV variants with reduced susceptibility to favipiravir.  The resistant phenotype was confirmed in cell culture and the whole genome was sequenced.  The identified mutations were reverse-engineered into an infectious clone to confirm their impact on the antiviral efficacy of favipiravir.  Results: Favipiravir inhibits the replication of lab. strains and clin. isolates of CHIKV, as well as of a panel of other alphaviruses.  Several favipiravir-resistant CHIKV variants were independently selected and all of them in particular acquired the unique K291R mutation in the RNA-dependent RNA polymerase (RdRp).  Reverse-engineering of this K291R mutation into an infectious clone of CHIKV confirmed the link between the mutant genotype and the resistant phenotype.  Interestingly, this particular lysine is also highly conserved in the RdRp of pos.-stranded RNA viruses in general.  Conclusions: This study provides an important insight into the precise mol. mechanism by which favipiravir exerts its antiviral activity against (alpha)viruses, which may be of help in designing other potent broad-spectrum antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLD2hrwuw29bVg90H21EOLACvtfcHk0liIUag9uY6mMg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Chsro%253D&md5=4b6a403c5bbd440308f0e35b0b9a722a</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdku209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdku209%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DSegura%2BGuerrero%26aufirst%3DN.%26aulast%3DTas%26aufirst%3DA.%26aulast%3DQu%25C3%25A9rat%26aufirst%3DG.%26aulast%3DPastorino%26aufirst%3DB.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DDallmeier%26aufirst%3DK.%26aulast%3DJochmans%26aufirst%3DD.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DBello%26aufirst%3DF.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3Dde%2BLamballerie%26aufirst%3DX.%26aulast%3DMartina%26aufirst%3DB.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3Dvan%2BHemert%26aufirst%3DM.%2BJ.%26aulast%3DLeyssen%26aufirst%3DP.%26atitle%3DMutations%2520in%2520the%2520Chikungunya%2520Virus%2520Non-Structural%2520Proteins%2520Cause%2520Resistance%2520to%2520Favipiravir%2520%2528T-705%2529%252C%2520a%2520Broad-Spectrum%2520Antiviral%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26spage%3D2770%26epage%3D2784%26doi%3D10.1093%2Fjac%2Fdku209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial</span>. <i>medRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.03.17.20037432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.03.17.20037432" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Chenauthor=Y.+Zhangauthor=J.+Huangauthor=P.+Yinauthor=Z.+Chengauthor=J.+Wuauthor=S.+Chenauthor=Y.+Zhangauthor=B.+Chenauthor=M.+Luauthor=Y.+Luoauthor=L.+Juauthor=J.+Zhangauthor=X.+Wang&title=Favipiravir+versus+Arbidol+for+COVID-19%3A+A+Randomized+Clinical+Trial&doi=10.1101%2F2020.03.17.20037432"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1101%2F2020.03.17.20037432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.03.17.20037432%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DFavipiravir%2520versus%2520Arbidol%2520for%2520COVID-19%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DmedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.03.17.20037432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuthman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garza, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tongeren, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retterer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegoraro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honnold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taubenheim, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minning, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span> <span> </span><span class="NLM_article-title">Protection against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">405</span>, <span class="refDoi">Â DOI: 10.1038/nature13027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature13027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=24590073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWhu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=402-405&author=T.+K.+Warrenauthor=J.+Wellsauthor=R.+G.+Panchalauthor=K.+S.+Stuthmanauthor=N.+L.+Garzaauthor=S.+A.+Van+Tongerenauthor=L.+Dongauthor=C.+J.+Rettererauthor=B.+P.+Eatonauthor=G.+Pegoraroauthor=S.+Honnoldauthor=S.+Bantiaauthor=P.+Kotianauthor=X.+Chenauthor=B.+R.+Taubenheimauthor=L.+S.+Welchauthor=D.+M.+Minningauthor=Y.+S.+Babuauthor=W.+P.+Sheridanauthor=S.+Bavari&title=Protection+against+Filovirus+Diseases+by+a+Novel+Broad-Spectrum+Nucleoside+Analogue+BCX4430&doi=10.1038%2Fnature13027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</span></div><div class="casAuthors">Warren, Travis K.; Wells, Jay; Panchal, Rekha G.; Stuthman, Kelly S.; Garza, Nicole L.; Van Tongeren, Sean A.; Dong, Lian; Retterer, Cary J.; Eaton, Brett P.; Pegoraro, Gianluca; Honnold, Shelley; Bantia, Shanta; Kotian, Pravin; Chen, Xilin; Taubenheim, Brian R.; Welch, Lisa S.; Minning, Dena M.; Babu, Yarlagadda S.; Sheridan, William P.; Bavari, Sina</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7496</span>),
    <span class="NLM_cas:pages">402-405</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever.  Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1).  Licensed therapeutic or vaccine products are not available to treat filovirus diseases.  Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential.  Here we show that BCX4430, a novel synthetic adenosine analog, inhibits infection of distinct filoviruses in human cells.  Biochem., reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator.  Post-exposure i.m. administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models.  Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 h after infection.  In addn., BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.  This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small mol.  We provide addnl. pharmacol. characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpev8c7g-X43rVg90H21EOLACvtfcHk0ljM3rKJabORLg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWhu7w%253D&md5=dc7d390055ecf253e4b21c95b4e9e1a2</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnature13027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13027%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DR.%2BG.%26aulast%3DStuthman%26aufirst%3DK.%2BS.%26aulast%3DGarza%26aufirst%3DN.%2BL.%26aulast%3DVan%2BTongeren%26aufirst%3DS.%2BA.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DRetterer%26aufirst%3DC.%2BJ.%26aulast%3DEaton%26aufirst%3DB.%2BP.%26aulast%3DPegoraro%26aufirst%3DG.%26aulast%3DHonnold%26aufirst%3DS.%26aulast%3DBantia%26aufirst%3DS.%26aulast%3DKotian%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DTaubenheim%26aufirst%3DB.%2BR.%26aulast%3DWelch%26aufirst%3DL.%2BS.%26aulast%3DMinning%26aufirst%3DD.%2BM.%26aulast%3DBabu%26aufirst%3DY.%2BS.%26aulast%3DSheridan%26aufirst%3DW.%2BP.%26aulast%3DBavari%26aufirst%3DS.%26atitle%3DProtection%2520against%2520Filovirus%2520Diseases%2520by%2520a%2520Novel%2520Broad-Spectrum%2520Nucleoside%2520Analogue%2520BCX4430%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D402%26epage%3D405%26doi%3D10.1038%2Fnature13027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taubenheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, W. P.</span></span> <span> </span><span class="NLM_article-title">BCX4430 - A Broad-Spectrum Antiviral Adenosine Nucleoside Analog under Development for the Treatment of Ebola Virus Disease</span>. <i>J. Infect. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">220</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1016/j.jiph.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jiph.2016.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27095300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsFamsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=220-226&author=R.+Taylorauthor=P.+Kotianauthor=T.+Warrenauthor=R.+Panchalauthor=S.+Bavariauthor=J.+Julanderauthor=S.+Doboauthor=A.+Roseauthor=Y.+El-Kattanauthor=B.+Taubenheimauthor=Y.+Babuauthor=W.+P.+Sheridan&title=BCX4430+-+A+Broad-Spectrum+Antiviral+Adenosine+Nucleoside+Analog+under+Development+for+the+Treatment+of+Ebola+Virus+Disease&doi=10.1016%2Fj.jiph.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease</span></div><div class="casAuthors">Taylor Raymond; Sheridan William P; Kotian Pravin; Dobo Sylvia; Rose Angela; El-Kattan Yahya; Babu Yarlagadda; Warren Travis; Panchal Rekha; Bavari Sina; Julander Justin; Taubenheim Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of infection and public health</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The adenosine nucleoside analog BCX4430 is a direct-acting antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses, such as the Ebola virus.  Cellular kinases phosphorylate BCX4430 to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination.  BCX4430 is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV and SARS-CoV.  In vivo, BCX4430 is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections.  In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, BCX4430 has demonstrated pronounced efficacy.  In experiments conducted in several models, both a reduction in the viral load and an improvement in survival were found to be related to the dose of BCX4430.  A Phase 1 clinical trial of intramuscular administration of BCX4430 in healthy subjects is currently ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL6Iq5eC6xuq__Jf7-eMvJfW6udTcc2eb1svwTVBrBFLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsFamsg%253D%253D&md5=acafc4b0a98b418c3ce361faf012a229</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.jiph.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jiph.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DKotian%26aufirst%3DP.%26aulast%3DWarren%26aufirst%3DT.%26aulast%3DPanchal%26aufirst%3DR.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DJulander%26aufirst%3DJ.%26aulast%3DDobo%26aufirst%3DS.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DEl-Kattan%26aufirst%3DY.%26aulast%3DTaubenheim%26aufirst%3DB.%26aulast%3DBabu%26aufirst%3DY.%26aulast%3DSheridan%26aufirst%3DW.%2BP.%26atitle%3DBCX4430%2520-%2520A%2520Broad-Spectrum%2520Antiviral%2520Adenosine%2520Nucleoside%2520Analog%2520under%2520Development%2520for%2520the%2520Treatment%2520of%2520Ebola%2520Virus%2520Disease%26jtitle%3DJ.%2520Infect.%2520Public%2520Health%26date%3D2016%26volume%3D9%26spage%3D220%26epage%3D226%26doi%3D10.1016%2Fj.jiph.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urakova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crossman, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokratian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolov, I.</span></span> <span> </span><span class="NLM_article-title">Î²-D-N-4-Hydroxycytidine Is a Potent Anti-Alphavirus Compound That Induces a High Level of Mutations in the Viral Genome</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">e019650-17</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01965-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01965-17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2017&pages=e019650-17&author=N.+Urakovaauthor=V.+Kuznetsovaauthor=D.+K.+Crossmanauthor=A.+Sokratianauthor=D.+B.+Guthrieauthor=A.+A.+Kolykhalovauthor=M.+A.+Lockwoodauthor=M.+G.+Natchusauthor=M.+R.+Crowleyauthor=G.+R.+Painterauthor=E.+I.+Frolovaauthor=I.+Frolov&title=%CE%B2-D-N-4-Hydroxycytidine+Is+a+Potent+Anti-Alphavirus+Compound+That+Induces+a+High+Level+of+Mutations+in+the+Viral+Genome&doi=10.1128%2FJVI.01965-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FJVI.01965-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01965-17%26sid%3Dliteratum%253Aachs%26aulast%3DUrakova%26aufirst%3DN.%26aulast%3DKuznetsova%26aufirst%3DV.%26aulast%3DCrossman%26aufirst%3DD.%2BK.%26aulast%3DSokratian%26aufirst%3DA.%26aulast%3DGuthrie%26aufirst%3DD.%2BB.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DCrowley%26aufirst%3DM.%2BR.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DFrolova%26aufirst%3DE.%2BI.%26aulast%3DFrolov%26aufirst%3DI.%26atitle%3D%25CE%25B2-D-N-4-Hydroxycytidine%2520Is%2520a%2520Potent%2520Anti-Alphavirus%2520Compound%2520That%2520Induces%2520a%2520High%2520Level%2520of%2520Mutations%2520in%2520the%2520Viral%2520Genome%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D92%26spage%3De019650-17%26doi%3D10.1128%2FJVI.01965-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhsous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrena, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shean, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Orally Efficacious Influenza Drug with High Resistance Barrier in Ferrets and Human Airway Epithelia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaax5866</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aax5866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aax5866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31645453" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaax5866&author=M.+Tootsauthor=J.+J.+Yoonauthor=R.+M.+Coxauthor=M.+Hartauthor=Z.+M.+Sticherauthor=N.+Makhsousauthor=R.+Pleskerauthor=A.+H.+Barrenaauthor=P.+G.+Reddyauthor=D.+G.+Mitchellauthor=R.+C.+Sheanauthor=G.+R.+Bluemlingauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+G.+Natchusauthor=G.+R.+Painterauthor=R.+K.+Plemper&title=Characterization+of+Orally+Efficacious+Influenza+Drug+with+High+Resistance+Barrier+in+Ferrets+and+Human+Airway+Epithelia&doi=10.1126%2Fscitranslmed.aax5866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5866%26sid%3Dliteratum%253Aachs%26aulast%3DToots%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DJ.%2BJ.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DHart%26aufirst%3DM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DMakhsous%26aufirst%3DN.%26aulast%3DPlesker%26aufirst%3DR.%26aulast%3DBarrena%26aufirst%3DA.%2BH.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DShean%26aufirst%3DR.%2BC.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DCharacterization%2520of%2520Orally%2520Efficacious%2520Influenza%2520Drug%2520with%2520High%2520Resistance%2520Barrier%2520in%2520Ferrets%2520and%2520Human%2520Airway%2520Epithelia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaax5866%26doi%3D10.1126%2Fscitranslmed.aax5866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saindane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Antiviral Î²-D-N-4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">e01348-19</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01348-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01348-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31578288" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=e01348-19&author=M.+L.+Agostiniauthor=A.+J.+Pruijssersauthor=J.+D.+Chappellauthor=J.+Gribbleauthor=X.+Luauthor=E.+L.+Andresauthor=G.+R.+Bluemlingauthor=M.+A.+Lockwoodauthor=T.+P.+Sheahanauthor=A.+C.+Simsauthor=M.+G.+Natchusauthor=M.+Saindaneauthor=A.+A.+Kolykhalovauthor=G.+R.+Painterauthor=R.+S.+Baricauthor=M.+R.+Denison&title=Small-Molecule+Antiviral+%CE%B2-D-N-4-Hydroxycytidine+Inhibits+a+Proofreading-Intact+Coronavirus+with+a+High+Genetic+Barrier+to+Resistance&doi=10.1128%2FJVI.01348-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FJVI.01348-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01348-19%26sid%3Dliteratum%253Aachs%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DGribble%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAndres%26aufirst%3DE.%2BL.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DSaindane%26aufirst%3DM.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26atitle%3DSmall-Molecule%2520Antiviral%2520%25CE%25B2-D-N-4-Hydroxycytidine%2520Inhibits%2520a%2520Proofreading-Intact%2520Coronavirus%2520with%2520a%2520High%2520Genetic%2520Barrier%2520to%2520Resistance%26jtitle%3DJ.%2520Virol.%26date%3D2019%26volume%3D93%26spage%3De01348-19%26doi%3D10.1128%2FJVI.01348-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehteshami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merits, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of Î²-D-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e023950-16</span>, <span class="refDoi">Â DOI: 10.1128/AAC.02395-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.02395-16" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e023950-16&author=M.+Ehteshamiauthor=S.+Taoauthor=K.+Zandiauthor=H.+M.+Hsiaoauthor=Y.+Jiangauthor=E.+Hammondauthor=F.+Amblardauthor=O.+O.+Russellauthor=A.+Meritsauthor=R.+F.+Schinazi&title=Characterization+of+%CE%B2-D-N4-Hydroxycytidine+as+a+Novel+Inhibitor+of+Chikungunya+Virus&doi=10.1128%2FAAC.02395-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1128%2FAAC.02395-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02395-16%26sid%3Dliteratum%253Aachs%26aulast%3DEhteshami%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DZandi%26aufirst%3DK.%26aulast%3DHsiao%26aufirst%3DH.%2BM.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHammond%26aufirst%3DE.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DMerits%26aufirst%3DA.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DCharacterization%2520of%2520%25CE%25B2-D-N4-Hydroxycytidine%2520as%2520a%2520Novel%2520Inhibitor%2520of%2520Chikungunya%2520Virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De023950-16%26doi%3D10.1128%2FAAC.02395-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludeke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luczo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e00766-18</span>, <span class="refDoi">Â DOI: 10.1128/AAC.00766-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.00766-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29891600" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00766-18&author=J.-J.+Yoonauthor=M.+Tootsauthor=S.+Leeauthor=M.-E.+Leeauthor=B.+Ludekeauthor=J.+M.+Luczoauthor=K.+Gantiauthor=R.+M.+Coxauthor=Z.+M.+Sticherauthor=V.+Edupugantiauthor=D.+G.+Mitchellauthor=M.+A.+Lockwoodauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+L.+Mooreauthor=G.+R.+Painterauthor=A.+C.+Lowenauthor=S.+M.+Tompkinsauthor=R.+Fearnsauthor=M.+G.+Natchusauthor=R.+K.+Plemper&title=Orally+Efficacious+Broad-Spectrum+Ribonucleoside+Analog+Inhibitor+of+Influenza+and+Respiratory+Syncytial+Viruses&doi=10.1128%2FAAC.00766-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.00766-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00766-18%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DJ.-J.%26aulast%3DToots%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-E.%26aulast%3DLudeke%26aufirst%3DB.%26aulast%3DLuczo%26aufirst%3DJ.%2BM.%26aulast%3DGanti%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DEdupuganti%26aufirst%3DV.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DLowen%26aufirst%3DA.%2BC.%26aulast%3DTompkins%26aufirst%3DS.%2BM.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DOrally%2520Efficacious%2520Broad-Spectrum%2520Ribonucleoside%2520Analog%2520Inhibitor%2520of%2520Influenza%2520and%2520Respiratory%2520Syncytial%2520Viruses%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De00766-18%26doi%3D10.1128%2FAAC.00766-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhsous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrena, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shean, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Orally Efficacious Influenza Drug with High Resistance Barrier in Ferrets and Human Airway Epithelia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaax5866</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aax5866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aax5866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31645453" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaax5866&author=M.+Tootsauthor=J.-J.+Yoonauthor=R.+M.+Coxauthor=M.+Hartauthor=Z.+M.+Sticherauthor=N.+Makhsousauthor=R.+Pleskerauthor=A.+H.+Barrenaauthor=P.+G.+Reddyauthor=D.+G.+Mitchellauthor=R.+C.+Sheanauthor=G.+R.+Bluemlingauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+G.+Natchusauthor=G.+R.+Painterauthor=R.+K.+Plemper&title=Characterization+of+Orally+Efficacious+Influenza+Drug+with+High+Resistance+Barrier+in+Ferrets+and+Human+Airway+Epithelia&doi=10.1126%2Fscitranslmed.aax5866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5866%26sid%3Dliteratum%253Aachs%26aulast%3DToots%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DJ.-J.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DHart%26aufirst%3DM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DMakhsous%26aufirst%3DN.%26aulast%3DPlesker%26aufirst%3DR.%26aulast%3DBarrena%26aufirst%3DA.%2BH.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DShean%26aufirst%3DR.%2BC.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DCharacterization%2520of%2520Orally%2520Efficacious%2520Influenza%2520Drug%2520with%2520High%2520Resistance%2520Barrier%2520in%2520Ferrets%2520and%2520Human%2520Airway%2520Epithelia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaax5866%26doi%3D10.1126%2Fscitranslmed.aax5866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">766</span>â <span class="NLM_lpage">788</span>, <span class="refDoi">Â DOI: 10.1016/j.apsb.2020.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.apsb.2020.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32292689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=766-788&author=C.+Wuauthor=Y.+Liuauthor=Y.+Yangauthor=P.+Zhangauthor=W.+Zhongauthor=Y.+Wangauthor=Q.+Wangauthor=Y.+Xuauthor=M.+Liauthor=X.+Liauthor=M.+Zhengauthor=L.+Chenauthor=H.+Li&title=Analysis+of+Therapeutic+Targets+for+SARS-CoV-2+and+Discovery+of+Potential+Drugs+by+Computational+Methods&doi=10.1016%2Fj.apsb.2020.02.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DAnalysis%2520of%2520Therapeutic%2520Targets%2520for%2520SARS-CoV-2%2520and%2520Discovery%2520of%2520Potential%2520Drugs%2520by%2520Computational%2520Methods%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D766%26epage%3D788%26doi%3D10.1016%2Fj.apsb.2020.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elfiky, A. A.</span></span> <span> </span><span class="NLM_article-title">Anti-HCV, Nucleotide Inhibitors, Repurposing against COVID-19</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">117477</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2020.117477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.lfs.2020.117477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32119961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=2020&pages=117477&author=A.+A.+Elfiky&title=Anti-HCV%2C+Nucleotide+Inhibitors%2C+Repurposing+against+COVID-19&doi=10.1016%2Fj.lfs.2020.117477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</span></div><div class="casAuthors">Elfiky, Abdo A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117477</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19).  Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries.  Human to human transmission is confirmed for COVID-19 by China a month ago.  Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths.  Addnl., MERS HCoV is responsible for 858 deaths out of about 2500 reported cases.  The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).  In this study, sequence anal., modeling, and docking are used to build a model for Wuhan COVID-19 RdRp.  Addnl., the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.  The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.  The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs.  Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosW2yKnGd-SrVg90H21EOLACvtfcHk0lheGMF9Jfr7mw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeisLo%253D&md5=39ac1e1c2df2a282c1240267850ba35b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2020.117477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2020.117477%26sid%3Dliteratum%253Aachs%26aulast%3DElfiky%26aufirst%3DA.%2BA.%26atitle%3DAnti-HCV%252C%2520Nucleotide%2520Inhibitors%252C%2520Repurposing%2520against%2520COVID-19%26jtitle%3DLife%2520Sci.%26date%3D2020%26volume%3D248%26spage%3D117477%26doi%3D10.1016%2Fj.lfs.2020.117477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span> <span> </span><span class="NLM_article-title">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2481</span>â <span class="NLM_lpage">2531</span>, <span class="refDoi">Â DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+Nucleotide%2C+and+Non-Nucleoside+Inhibitors+of+Hepatitis+C+Virus+NS5B+RNA-Dependent+RNA-Polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0ljuL2xHCQhzAw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520Nucleotide%252C%2520and%2520Non-Nucleoside%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%2520NS5B%2520RNA-Dependent%2520RNA-Polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Chamandi S. Dampalla, Yunjeong Kim, Naemi Bickmeier, Athri D. Rathnayake, Harry Nhat Nguyen, Jian Zheng, Maithri M. Kashipathy, Matthew A. Baird, Kevin P. Battaile, Scott Lovell, Stanley Perlman, Kyeong-Ok Chang, <span class="NLM_string-name hlFld-ContribAuthor">William C. Groutas</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Design of Conformationally Constrained Cyclohexane Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 3CL Protease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (14)
                                     , 10047-10058. <a href="https://doi.org/10.1021/acs.jmedchem.1c00319" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00319</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00319%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDesign%252Bof%252BConformationally%252BConstrained%252BCyclohexane%252BInhibitors%252Bof%252BSevere%252BAcute%252BRespiratory%252BSyndrome%252BCoronavirus-2%252B3CL%252BProtease%26aulast%3DDampalla%26aufirst%3DChamandi%2BS.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D20022021%26date%3D02072021%26volume%3D64%26issue%3D14%26spage%3D10047%26epage%3D10058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bing Bai, Alexandr Belovodskiy, Mostofa Hena, Appan Srinivas Kandadai, Michael A. Joyce, Holly A. Saffran, Justin A. Shields, Muhammad Bashir Khan, Elena Arutyunova, Jimmy Lu, Sardeev K. Bajwa, Darren Hockman, Conrad Fischer, Tess Lamer, Wayne Vuong, Marco J. van Belkum, Zhengxian Gu, Fusen Lin, Yanhua Du, Jia Xu, Mohammad Rahim, Howard S. Young, John C. Vederas, D. Lorne Tyrrell, M. Joanne Lemieux, <span class="NLM_string-name hlFld-ContribAuthor">James A. Nieman</span>. </span><span class="cited-content_cbyCitation_article-title">Peptidomimetic Î±-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00616&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00616%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPeptidomimetic%252B%2525CE%2525B1-Acyloxymethylketone%252BWarheads%252Bwith%252BSix-Membered%252BLactam%252BP1%252BGlutamine%252BMimic%25253A%252BSARS-CoV-2%252B3CL%252BProtease%252BInhibition%25252C%252BCoronavirus%252BAntiviral%252BActivity%25252C%252Band%252Bin%252BVitro%252BBiological%252BStability%26aulast%3DBai%26aufirst%3DBing%26date%3D2021%26date%3D2021%26date%3D04042021%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Eunice Cho, Margarida Rosa, Ruhi Anjum, Saman Mehmood, Mariya Soban, Moniza Mujtaba, Khair Bux, Syed T. Moin, Mohammad Tanweer, Sarath Dantu, Alessandro Pandini, Junqi Yin, Heng Ma, Arvind Ramanathan, Barira Islam, Antonia S. J. S. Mey, Debsindhu Bhowmik, <span class="NLM_string-name hlFld-ContribAuthor">Shozeb Haider</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamic Profiling of Î²-Coronavirus 3CL Mpro Protease Ligand-Binding Sites. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2021,</strong> <em>61 </em>
                                    (6)
                                     , 3058-3073. <a href="https://doi.org/10.1021/acs.jcim.1c00449" title="DOI URL">https://doi.org/10.1021/acs.jcim.1c00449</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.1c00449&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.1c00449%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DDynamic%252BProfiling%252Bof%252B%2525CE%2525B2-Coronavirus%252B3CL%252BMpro%252BProtease%252BLigand-Binding%252BSites%26aulast%3DCho%26aufirst%3DEunice%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D19042021%26date%3D14062021%26volume%3D61%26issue%3D6%26spage%3D3058%26epage%3D3073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, <span class="NLM_string-name hlFld-ContribAuthor">Andrea Zaliani</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen. </span><span class="cited-content_cbyCitation_journal-name">ACS Pharmacology & Translational Science</span><span> <strong>2021,</strong> <em>4 </em>
                                    (3)
                                     , 1096-1110. <a href="https://doi.org/10.1021/acsptsci.0c00216" title="DOI URL">https://doi.org/10.1021/acsptsci.0c00216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsptsci.0c00216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsptsci.0c00216%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Pharmacology%2520%2526%2520Translational%2520Science%26atitle%3DIdentification%252Bof%252BInhibitors%252Bof%252BSARS-CoV-2%252B3CL-Pro%252BEnzymatic%252BActivity%252BUsing%252Ba%252BSmall%252BMolecule%252Bin%252BVitro%252BRepurposing%252BScreen%26aulast%3DKuzikov%26aufirst%3DMaria%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D17122020%26date%3D11032021%26volume%3D4%26issue%3D3%26spage%3D1096%26epage%3D1110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Schematic representation of SARS-CoV-2 virion, viral entry, genome translation, and polyprotein processing.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Overview of SARS-CoV-2 3CL<sup>pro</sup> architecture. The X-ray structure of SARS-CoV-2 3CLpro (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2G">6Y2G</a>) is shown as a ribbon model in two different orientations. For clarity, the bound inhibitor has been removed. Protomers A (light-blue) and B (light-orange) associate into a dimer stabilized by a salt bridge between Glu290 and Arg4, while the substrate binding site resides at the interface of domains I and II. The catalytic residues Cys145 and His41 are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Schematization of the main features of 3CL<sup>pro</sup> inhibitors and protease subsite specificity. (A) General representation of peptidic covalent reversible inhibitors of SARS-CoV-2 3CL<sup>pro</sup> summarizing the chemical requirements and SAR of compounds so far reported in literature. (B) Surface representation of the active site pocket of SARS-CoV 3CL<sup>pro</sup> bound to a peptide aldehyde inhibitor (dark salmon sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SNE">3SNE</a>), chosen as a representative substrate-like inhibitor. The S1âS4 and S1â² subsites are indicated with red lines and labeled. The key residues forming the active site pocket are displayed as white sticks; the catalytic residues Cys145 and His41 are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Co-crystallographic pose of compound <b>1</b> (violet sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BQY">7BQY</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks and labeled. H-bonds are depicted as dashed black lines. (B) Surface representation of the active site pocket with bound N3. The P1âP4 and P1â² moieties are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Compounds <b>1</b>â<b>9</b> with biological activities. <sup>a</sup>Antiviral activity evaluated by viral plaque assay. <sup>b</sup>Data from ref <a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a>. <sup>c</sup>Antiviral activity evaluated by viral RNA qRT-PCR quantification. <sup>d</sup>Antiviral activity evaluated by CPE reduction. <sup>e</sup>Values in bracket have been obtained in the presence of a P-gp inhibitor. The main structural differences, significant modifications, and warheads are highlighted.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Co-crystallographic pose of compound <b>3</b> (green sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2F">6Y2F</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks. H-bonds are depicted as dashed black lines. (B) Surface representation of the active site pocket with bound compound <b>3</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Co-crystallographic pose of compound <b>5</b> (yellow-orange sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LZE">6LZE</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the binding pocket are displayed as white sticks; water molecules are shown as red spheres. H-bonds are depicted as dashed black lines. (B) Overlay of <b>5</b> and <b>6</b> (raspberry sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M0K">6M0K</a>) co-crystallographic poses.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Co-crystallographic pose of compound <b>7</b> (teal sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR">7BRR</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. (A) The key residues forming the active site pocket are displayed as white sticks; water molecules are shown as red spheres. H-bonds are depicted as dashed black lines. (B) Overlay of <b>7</b> bound to SARS-CoV-2 3CL<sup>pro</sup> structures (PDBs: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR">7BRR</a>, teal; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTJ">6WTJ</a>, wheat; <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTT">6WTT</a>, salmon), showing the different conformations of the benzyloxycarbonyl group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Structure and biological activity of Boceprevir. <sup>a</sup>Antiviral activity evaluated by viral plaque assay. <sup>b</sup>Antiviral activity evaluated by CPE reduction. (B) Co-crystallographic pose of Boceprevir (purple sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WNP">6WNP</a>) covalently bound to the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the active site pocket are displayed as white sticks; water molecules are displayed as red spheres. H-bonds are depicted as dashed black lines. (C) Surface representation of the active site pocket with bound Boceprevir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. (A) Structures and biological activities of flavones Baicalein and Baicalin. <sup>a</sup>Antiviral activity evaluated by viral RNA measurement by qRT-PCR. (B) Co-crystallographic pose of Baicalein (light-pink sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M2N">6M2N</a>) into the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the binding pocket are displayed as white sticks. The buried water molecule is displayed as a red sphere. H-bonds are depicted as dashed black lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (A) Chemical structure of compound <b>10</b>. (B) Co-crystallographic pose of <b>10</b> (slate sticks, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W63">6W63</a>) into the active site of SARS-CoV-2 3CL<sup>pro</sup>. The key residues forming the binding pocket are displayed as white sticks; water molecules are displayed as red spheres. H-bonds are depicted as dashed black lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Chemical structures and biological activities of Ebselen and compounds <b>11</b>â<b>17</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Architecture of SARS-CoV-2 nsp12. (A) Schematic diagram outlining the domain organization of SARS-CoV-2 nsp12. The domains are colored as: palm, cyan; fingers, yellow-orange; thumb, salmon. The N-terminal NiRAN domain, the interface and the Î²-hairpin are colored light-pink, wheat, and blue-white, respectively. The polymerase conserved motifs are colored as: motif A, lime green; motif B, violet; motif C, slate; motif D, olive; motif E, sand; motif F, deep-teal; motif G, ruby. (B) Structure of SARS-CoV-2 in two different orientations (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M71">6M71</a>). (left) Ribbon diagram of nsp12 showing the arrangement of palm, fingers, and thumb domains. Domains are colored as in (A). Nsp7 and nsp8 cofactors are shown as pale-green and raspberry ribbon models, respectively. (right) The palm, fingers, and thumb domains are shown as a molecular surface.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Overview of SARS-CoV-2 nsp12 active site. For clarity, the RdRp core region is shown as a white ribbon model, whereas the polymerase conserved motifs (AâG) are colored according to the upper schematic diagram. The catalytic residues Asp760 and Asp761 are shown as white sticks. The template entry, NTP entry, product hybrid exits paths are indicated by orange arrows.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Structure of SARS-CoV-2 replicating RdRp-RNA complex (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT">6YYT</a>). Nsp12 is shown as a molecular surface (color code as in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), whereas the cofactors nsp7 and nsp8 (protomers 1 and 2) are shown as pale-green and raspberry ribbon models, respectively. RNA turns are shown as an orange ribbon model. The positively charged nsp8 residues, proposed to interact with RNA, are shown as sticks.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Putative mechanism of ProTides <i>in vivo</i> metabolism. Upon diffusion into the cell, the amino acid ester of the ProTide is cleaved by intracellular esterases, then a cyclization occurs onto the phosphorus, with the release of the phenoxide moiety. The unstable cyclic intermediate is then hydrolyzed by water to the alanine metabolite, whose PâN bond is hydrolyzed by phosphoramidase-type enzymes to unmask the NI monophosphate form. The NI monophosphate is routed to further phosphorylation steps, yielding the active triphosphate form (NTP) and thus circumventing the endogenous phosphorylation pathway (orange box). X, aromatic substituents; Y, O, or CH<sub>2</sub>; R, ester substituents.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Chemical structures of antiviral nucleoside analogues in clinical development. The parent bases are highlighted in light-blue (adenine), green (guanine), and orange (cytosine).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Schematization of Remdesivir metabolic conversion to the active triphosphate form. Remdesivir is first transformed into the intermediate alanine metabolite <b>20</b>, then to the monophosphate form <b>21</b> and finally to the triphosphate form <b>22</b>. The phosphoramidate prodrug moiety is shown in magenta. <b>19</b> (GS-441524) is the parent nucleoside of Remdesivir.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Binding mode of Remdesivir into the SARS-CoV-2 nsp12 active site (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>). (left) nsp12 is shown as a molecular surface, colored according to the schematic diagram in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. For clarity, nsp7 and nsp8 cofactor have been removed. The template and primer RNA are shown as ribbon models and labeled. (right) Zoom-in of the nsp12 active site. The covalently bound monophosphate form of Remdesivir (slate) and the pyrophosphate group are shown as sticks. Magnesium ions are shown as green spheres. The RNA bases interacting with Remdesivir are shown as orange thin sticks, while protein residues are shown as white thick sticks. Hydrogen bonds are shown as black dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. A close view of the covalently bound Remdesivir within the RdRp active site. (A) Remdesivir is incorporated into the primer strand and terminates chain elongation (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2">7BV2</a>). (B) Remdesivir incorporation induces a mechanism of delayed-chain termination (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C2K">7C2K</a>). RNA is shown as orange ribbon model. For clarity, only key residues (thick white sticks) and bases (orange thin sticks) that interact with Remdesivir are shown. Hydrogen bonds are shown as dashed lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. Schematization of Favipiravir metabolic conversion. Favipiravir is first converted to its ribofuranosyl monophosphate derivative <b>23</b> and subsequently to the triphosphate active form <b>24</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/medium/jm0c01140_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Chemical structures of the prodrug <b>18</b> and its parent compound <b>25</b>. The isobutyrate ester prodrug moiety is shown in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.0c01140/20201113/images/large/jm0c01140_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01140&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i21">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27550" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27550" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 151 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Ten Threats to Global Health
in 2019</i>; <span class="NLM_publisher-name">World
Health Organization</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/emergencies/ten-threats-to-global-health-in-2019" class="extLink">https://www.who.int/emergencies/ten-threats-to-global-health-in-2019</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Ten+Threats+to+Global+Health%0Ain+2019%3B+World%0AHealth+Organization%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Femergencies%2Ften-threats-to-global-health-in-2019+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DTen%2520Threats%2520to%2520Global%2520Health%250Ain%25202019%26pub%3DWorld%250AHealth%2520Organization%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span> <i>Prioritizing Diseases for
Research and Development in Emergency Contexts</i>; <span class="NLM_publisher-name">World Health Organization</span>, <span class="NLM_year">2020</span>; <a href="https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-context" class="extLink">https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-context</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Prioritizing+Diseases+for%0AResearch+and+Development+in+Emergency+Contexts%3B+World+Health+Organization%2C+2020%3B+https%3A%2F%2Fwww.who.int%2Factivities%2Fprioritizing-diseases-for-research-and-development-in-emergency-context+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPrioritizing%2520Diseases%2520for%250AResearch%2520and%2520Development%2520in%2520Emergency%2520Contexts%26pub%3DWorld%2520Health%2520Organization%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Z. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Z.</span></span> <span> </span><span class="NLM_article-title">A New Coronavirus Associated with Human Respiratory Disease in China</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>579</i></span>,  <span class="NLM_fpage">265</span>â <span class="NLM_lpage">269</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2008-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2008-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32015508" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=579&publication_year=2020&pages=265-269&author=F.+Wuauthor=S.+Zhaoauthor=B.+Yuauthor=Y.+M.+Chenauthor=W.+Wangauthor=Z.+G.+Songauthor=Y.+Huauthor=Z.+W.+Taoauthor=J.+H.+Tianauthor=Y.+Y.+Peiauthor=M.+L.+Yuanauthor=Y.+L.+Zhangauthor=F.+H.+Daiauthor=Y.+Liuauthor=Q.+M.+Wangauthor=J.+J.+Zhengauthor=L.+Xuauthor=E.+C.+Holmesauthor=Y.+Z.+Zhang&title=A+New+Coronavirus+Associated+with+Human+Respiratory+Disease+in+China&doi=10.1038%2Fs41586-020-2008-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A new coronavirus associated with human respiratory disease in China</span></div><div class="casAuthors">Wu, Fan; Zhao, Su; Yu, Bin; Chen, Yan-Mei; Wang, Wen; Song, Zhi-Gang; Hu, Yi; Tao, Zhao-Wu; Tian, Jun-Hua; Pei, Yuan-Yuan; Yuan, Ming-Li; Zhang, Yu-Ling; Dai, Fa-Hui; Liu, Yi; Wang, Qi-Min; Zheng, Jiao-Jiao; Xu, Lin; Holmes, Edward C.; Zhang, Yong-Zhen</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">579</span>
        (<span class="NLM_cas:issue">7798</span>),
    <span class="NLM_cas:pages">265-269</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Emerging infectious diseases, such as severe acute respiratory syndrome (SARS) and Zika virus disease, present a major threat to public health.  Despite intense research efforts, how, when and where new diseases appear are still a source of considerable uncertainty.  A severe respiratory disease was recently reported in Wuhan, Hubei province, China.  As of 25 Jan. 2020, at least 1,975 cases had been reported since the first patient was hospitalized on 12 Dec. 2019.  Epidemiol. investigations have suggested that the outbreak was assocd. with a seafood market in Wuhan.  Here we study a single patient who was a worker at the market and who was admitted to the Central Hospital of Wuhan on 26 Dec. 2019 while experiencing a severe respiratory syndrome that included fever, dizziness and a cough.  Metagenomic RNA sequencing of a sample of bronchoalveolar lavage fluid from the patient identified a new RNA virus strain from the family Coronaviridae, which is designated here 'WH-Human 1' coronavirus (and has also been referred to as '2019-nCoV').  Phylogenetic anal. of the complete viral genome (29,903 nucleotides) revealed that the virus was most closely related (89.1% nucleotide similarity) to a group of SARS-like coronaviruses (genus Betacoronavirus, subgenus Sarbecovirus) that had previously been found in bats in China.  This outbreak highlights the ongoing ability of viral spill-over from animals to cause severe disease in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5h_VHfuDuTbVg90H21EOLACvtfcHk0lglfwhGDGDW8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFKlsLc%253D&md5=0163a684829e880a0c3347e19f0ce52a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2008-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2008-3%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DY.%2BM.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DZ.%2BG.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTao%26aufirst%3DZ.%2BW.%26aulast%3DTian%26aufirst%3DJ.%2BH.%26aulast%3DPei%26aufirst%3DY.%2BY.%26aulast%3DYuan%26aufirst%3DM.%2BL.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DDai%26aufirst%3DF.%2BH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%2BM.%26aulast%3DZheng%26aufirst%3DJ.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26atitle%3DA%2520New%2520Coronavirus%2520Associated%2520with%2520Human%2520Respiratory%2520Disease%2520in%2520China%26jtitle%3DNature%26date%3D2020%26volume%3D579%26spage%3D265%26epage%3D269%26doi%3D10.1038%2Fs41586-020-2008-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">A Novel Coronavirus from Patients with Pneumonia in China, 2019</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">727</span>â <span class="NLM_lpage">733</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2001017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31978945" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=727-733&author=N.+Zhuauthor=D.+Zhangauthor=W.+Wangauthor=X.+Liauthor=B.+Yangauthor=J.+Songauthor=X.+Zhaoauthor=B.+Huangauthor=W.+Shiauthor=R.+Luauthor=P.+Niuauthor=F.+Zhanauthor=X.+Maauthor=D.+Wangauthor=W.+Xuauthor=G.+Wuauthor=G.+F.+Gaoauthor=W.+Tan&title=A+Novel+Coronavirus+from+Patients+with+Pneumonia+in+China%2C+2019&doi=10.1056%2FNEJMoa2001017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A novel coronavirus from patients with pneumonia in China, 2019</span></div><div class="casAuthors">Zhu, Na; Zhang, Dingyu; Wang, Wenling; Li, Xingwang; Yang, Bo; Song, Jingdong; Zhao, Xiang; Huang, Baoying; Shi, Weifeng; Lu, Roujian; Niu, Peihua; Zhan, Faxian; Ma, Xuejun; Wang, Dayan; Xu, Wenbo; Wu, Guizhen; Gao, George F.; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">727-733</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In Dec. 2019, a cluster of patients with pneumonia of unknown cause was linked to a seafood wholesale market in Wuhan, China.  A previously unknown betacoronavirus was discovered through the use of unbiased sequencing in samples from patients with pneumonia.  Human airway epithelial cells were used to isolate a novel coronavirus, named 2019-nCoV, which formed a clade within the subgenus sarbecovirus, Orthocoronavirinae subfamily.  Different from both MERS-CoV and SARS-CoV, 2019-nCoV is the seventh member of the family of coronaviruses that infect humans.  Enhanced surveillance and further investigation are ongoing.  Complete genome sequences of the three novel coronaviruses were submitted to GISAID (BetaCoV/Wuhan/ IVDC-HB-01/2019, accession ID: EPI_ISL_402119; BetaCoV/Wuhan/IVDC-HB-04/2020, accession ID: EPI_ISL_402120; BetaCoV/Wuhan/IVDC-HB-05/2019, accession ID: EPI_ISL_402121).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoibbAn_VqfXbVg90H21EOLACvtfcHk0lglfwhGDGDW8Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjslGmsrc%253D&md5=73cc5c839e1e934da69b39537063b7b3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001017%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DA%2520Novel%2520Coronavirus%2520from%2520Patients%2520with%2520Pneumonia%2520in%2520China%252C%25202019%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D727%26epage%3D733%26doi%3D10.1056%2FNEJMoa2001017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span> <i>Coronavirus (COVID-19) Events As They Happen</i>; <span class="NLM_publisher-name">World Health Organisation</span>, <span class="NLM_year">2019</span>; <a href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen" class="extLink">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen</a> (accessed 2020-09-28).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Coronavirus+%28COVID-19%29+Events+As+They+Happen%3B+World+Health+Organisation%2C+2019%3B+https%3A%2F%2Fwww.who.int%2Femergencies%2Fdiseases%2Fnovel-coronavirus-2019%2Fevents-as-they-happen+%28accessed+2020-09-28%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCoronavirus%2520%2528COVID-19%2529%2520Events%2520As%2520They%2520Happen%26pub%3DWorld%2520Health%2520Organisation%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riddle, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeching, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DuPont, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamer, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozarsky, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Libman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tribble, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vila, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ericsson, C. D.</span></span> <span> </span><span class="NLM_article-title">2020 Hubei Lockdowns</span>. <i>J. Travel Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">S63</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fjtm%2Ftax026" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=S63&author=M.+S.+Riddleauthor=B.+A.+Connorauthor=N.+J.+Beechingauthor=H.+L.+DuPontauthor=D.+H.+Hamerauthor=P.+Kozarskyauthor=M.+Libmanauthor=R.+Steffenauthor=D.+Taylorauthor=D.+R.+Tribbleauthor=J.+Vilaauthor=P.+Zangerauthor=C.+D.+Ericsson&title=2020+Hubei+Lockdowns"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1093%2Fjtm%2Ftax026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjtm%252Ftax026%26sid%3Dliteratum%253Aachs%26aulast%3DRiddle%26aufirst%3DM.%2BS.%26aulast%3DConnor%26aufirst%3DB.%2BA.%26aulast%3DBeeching%26aufirst%3DN.%2BJ.%26aulast%3DDuPont%26aufirst%3DH.%2BL.%26aulast%3DHamer%26aufirst%3DD.%2BH.%26aulast%3DKozarsky%26aufirst%3DP.%26aulast%3DLibman%26aufirst%3DM.%26aulast%3DSteffen%26aufirst%3DR.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DTribble%26aufirst%3DD.%2BR.%26aulast%3DVila%26aufirst%3DJ.%26aulast%3DZanger%26aufirst%3DP.%26aulast%3DEricsson%26aufirst%3DC.%2BD.%26atitle%3D2020%2520Hubei%2520Lockdowns%26jtitle%3DJ.%2520Travel%2520Med.%26date%3D2020%26volume%3D24%26spage%3DS63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saglietto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DâAscenzo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zoccai, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Ferrari, G. M.</span></span> <span> </span><span class="NLM_article-title">COVID-19 in Europe: The Italian Lesson</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1110</span>â <span class="NLM_lpage">1111</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30690-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2930690-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32220279" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls12qsLY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1110-1111&author=A.+Sagliettoauthor=F.+D%E2%80%99Ascenzoauthor=G.+B.+Zoccaiauthor=G.+M.+De+Ferrari&title=COVID-19+in+Europe%3A+The+Italian+Lesson&doi=10.1016%2FS0140-6736%2820%2930690-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 in Europe: the Italian lesson</span></div><div class="casAuthors">Saglietto, Andrea; D'Ascenzo, Fabrizio; Zoccai, Giuseppe Biondi; De Ferrari, Gaetano Maria</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10230</span>),
    <span class="NLM_cas:pages">1110-1111</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">An editorial regarding a lesson learned in Italy to control SARS-CoV-2 spread.  Italy's implementation of restrictive measures to slow virus spread resulted in a lowering of actual reported COVID-19 cases when compared to projections.  The authors suggest that all other European nations implement similar restrictions to slow the spread of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKrppshdFKPrVg90H21EOLACvtfcHk0ljBCwKKZlRGyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls12qsLY%253D&md5=493d2752bf7ad2422b025c5c7ecdf4e8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930690-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930690-5%26sid%3Dliteratum%253Aachs%26aulast%3DSaglietto%26aufirst%3DA.%26aulast%3DD%25E2%2580%2599Ascenzo%26aufirst%3DF.%26aulast%3DZoccai%26aufirst%3DG.%2BB.%26aulast%3DDe%2BFerrari%26aufirst%3DG.%2BM.%26atitle%3DCOVID-19%2520in%2520Europe%253A%2520The%2520Italian%2520Lesson%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1110%26epage%3D1111%26doi%3D10.1016%2FS0140-6736%2820%2930690-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Remuzzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remuzzi, G.</span></span> <span> </span><span class="NLM_article-title">COVID-19 and Italy: What Next?</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1225</span>â <span class="NLM_lpage">1228</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)30627-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2930627-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32178769" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltFeqsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1225-1228&author=A.+Remuzziauthor=G.+Remuzzi&title=COVID-19+and+Italy%3A+What+Next%3F&doi=10.1016%2FS0140-6736%2820%2930627-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 and Italy: what next?</span></div><div class="casAuthors">Remuzzi, Andrea; Remuzzi, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10231</span>),
    <span class="NLM_cas:pages">1225-1228</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already taken on pandemic proportions, affecting >100 countries in a matter of weeks.  A global response to prep. health systems worldwide is imperative.  Although containment measures in China have reduced new cases by >90%, this redn. is not the case elsewhere, and Italy has been particularly affected.  There is now grave concern regarding the Italian national health system's capacity to effectively respond to the needs of patients who are infected and require intensive care for SARS-CoV-2 pneumonia.  The percentage of patients in intensive care reported daily in Italy between March 1 and March 11, 2020, has consistently been 9-11% of patients who are actively infected.  The no. of patients infected since Feb 21 in Italy closely follows an exponential trend.  If this trend continues for 1 more week, there will be 30,000 infected patients.  Intensive care units will then be at max. capacity; â¤4000 hospital beds will be needed by mid-Apr., 2020.  Our anal. might help political leaders and health authorities to allocate enough resources, including personnel, beds, and intensive care facilities, to manage the situation in the next few days and weeks.  If the Italian outbreak follows a similar trend as in Hubei province, China, the no. of newly infected patients could start to decrease within 3-4 days, departing from the exponential trend.  However, this cannot currently be predicted because of differences between social distancing measures and the capacity to quickly build dedicated facilities in China.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYR_x7MkYturVg90H21EOLACvtfcHk0ljBCwKKZlRGyQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltFeqsLw%253D&md5=eae507202578d450558f59f712187e4a</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930627-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930627-9%26sid%3Dliteratum%253Aachs%26aulast%3DRemuzzi%26aufirst%3DA.%26aulast%3DRemuzzi%26aufirst%3DG.%26atitle%3DCOVID-19%2520and%2520Italy%253A%2520What%2520Next%253F%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1225%26epage%3D1228%26doi%3D10.1016%2FS0140-6736%2820%2930627-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lewnard, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, N. C.</span></span> <span> </span><span class="NLM_article-title">Scientific and Ethical Basis for Social-Distancing Interventions against COVID-19</span>. <i>Lancet Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">631</span>â <span class="NLM_lpage">633</span>, <span class="refDoi">Â DOI: 10.1016/S1473-3099(20)30190-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS1473-3099%2820%2930190-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32213329" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXls1Ggs7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2020&pages=631-633&author=J.+A.+Lewnardauthor=N.+C.+Lo&title=Scientific+and+Ethical+Basis+for+Social-Distancing+Interventions+against+COVID-19&doi=10.1016%2FS1473-3099%2820%2930190-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Scientific and ethical basis for social-distancing interventions against COVID-19</span></div><div class="casAuthors">Lewnard, Joseph A.; Lo, Nathan C.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">631-633</span>CODEN:
                <span class="NLM_cas:coden">LIDABP</span>;
        ISSN:<span class="NLM_cas:issn">1473-3099</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A correspondence on the article by Joel Koo et al (2020) describing the effects of social distancing to slow COVID-19 spread.  The authors review the socioeconomic effects that social distancing may have and the ethics of imposing such restrictions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIUrokr5TVurVg90H21EOLACvtfcHk0lhwgwWtIiHgPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXls1Ggs7g%253D&md5=f13af04567cb6cc9851061044a1bcdf4</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1473-3099%2820%2930190-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1473-3099%252820%252930190-0%26sid%3Dliteratum%253Aachs%26aulast%3DLewnard%26aufirst%3DJ.%2BA.%26aulast%3DLo%26aufirst%3DN.%2BC.%26atitle%3DScientific%2520and%2520Ethical%2520Basis%2520for%2520Social-Distancing%2520Interventions%2520against%2520COVID-19%26jtitle%3DLancet%2520Infect.%2520Dis.%26date%3D2020%26volume%3D20%26spage%3D631%26epage%3D633%26doi%3D10.1016%2FS1473-3099%2820%2930190-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pushpakom, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iorio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eyers, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guilliams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latimer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Norris, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanseau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirmohamed, M.</span></span> <span> </span><span class="NLM_article-title">Drug Repurposing: Progress, Challenges and Recommendations</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">41</span>â <span class="NLM_lpage">58</span>, <span class="refDoi">Â DOI: 10.1038/nrd.2018.168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnrd.2018.168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30310233" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=41-58&author=S.+Pushpakomauthor=F.+Iorioauthor=P.+A.+Eyersauthor=K.+J.+Escottauthor=S.+Hopperauthor=A.+Wellsauthor=A.+Doigauthor=T.+Guilliamsauthor=J.+Latimerauthor=C.+McNameeauthor=A.+Norrisauthor=P.+Sanseauauthor=D.+Cavallaauthor=M.+Pirmohamed&title=Drug+Repurposing%3A+Progress%2C+Challenges+and+Recommendations&doi=10.1038%2Fnrd.2018.168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Drug repurposing: progress, challenges and recommendations</span></div><div class="casAuthors">Pushpakom, Sudeep; Iorio, Francesco; Eyers, Patrick A.; Escott, K. Jane; Hopper, Shirley; Wells, Andrew; Doig, Andrew; Guilliams, Tim; Latimer, Joanna; McNamee, Christine; Norris, Alan; Sanseau, Philippe; Cavalla, David; Pirmohamed, Munir</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-58</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Given the high attrition rates, substantial costs and slow pace of new drug discovery and development, repurposing of 'old' drugs to treat both common and rare diseases is increasingly becoming an attractive proposition because it involves the use of de-risked compds., with potentially lower overall development costs and shorter development timelines.  Various data-driven and exptl. approaches have been suggested for the identification of repurposable drug candidates; however, there are also major technol. and regulatory challenges that need to be addressed.  In this Review, we present approaches used for drug repurposing (also known as drug repositioning), discuss the challenges faced by the repurposing community and recommend innovative ways by which these challenges could be addressed to help realize the full potential of drug repurposing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUl_N5c2iDerVg90H21EOLACvtfcHk0lhwgwWtIiHgPA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvV2gtr7I&md5=6bcc8f26828414de02564494fb4d3296</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2018.168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2018.168%26sid%3Dliteratum%253Aachs%26aulast%3DPushpakom%26aufirst%3DS.%26aulast%3DIorio%26aufirst%3DF.%26aulast%3DEyers%26aufirst%3DP.%2BA.%26aulast%3DEscott%26aufirst%3DK.%2BJ.%26aulast%3DHopper%26aufirst%3DS.%26aulast%3DWells%26aufirst%3DA.%26aulast%3DDoig%26aufirst%3DA.%26aulast%3DGuilliams%26aufirst%3DT.%26aulast%3DLatimer%26aufirst%3DJ.%26aulast%3DMcNamee%26aufirst%3DC.%26aulast%3DNorris%26aufirst%3DA.%26aulast%3DSanseau%26aufirst%3DP.%26aulast%3DCavalla%26aufirst%3DD.%26aulast%3DPirmohamed%26aufirst%3DM.%26atitle%3DDrug%2520Repurposing%253A%2520Progress%252C%2520Challenges%2520and%2520Recommendations%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2019%26volume%3D18%26spage%3D41%26epage%3D58%26doi%3D10.1038%2Fnrd.2018.168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alpern, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertner, E.</span></span> <span> </span><span class="NLM_article-title">Off-Label Therapies for COVID-19âAre We All In This Together?</span>. <i>Clin. Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">182</span>â <span class="NLM_lpage">184</span>, <span class="refDoi">Â DOI: 10.1002/cpt.1862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fcpt.1862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32311763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVWnu7%252FK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2020&pages=182-184&author=J.+D.+Alpernauthor=E.+Gertner&title=Off-Label+Therapies+for+COVID-19%E2%80%94Are+We+All+In+This+Together%3F&doi=10.1002%2Fcpt.1862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Off-Label Therapies for COVID-19-Are We All In This Together?</span></div><div class="casAuthors">Alpern, Jonathan D.; Gertner, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">182-184</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) continues to spread rapidly outside of mainland China. As of Apr. 6, 2020, there are over 300,000 cases and 10,000 deaths in the United States.  Effective therapies for the novel coronavirus are urgently needed and over 200 clin. trials are now underway across the globe.  Recognizing the need for robust randomized control trials, the World Health Organization (WHO) recently organized a multinational randomized trial - the SOLIDARITY trial - to study the effect of drugs that have been identified as promising based on in vitro data and the early clin. experience with coronavirus disease 2019 (COVID-19): remdesivir, lopinavir, and ritonavir; lopinavir and ritonavir + interferon; and chloroquine or hydroxychloroquine (Plaquenil).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIXRMw42SUJbVg90H21EOLACvtfcHk0lgDKCoTcyWmsw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVWnu7%252FK&md5=249302a89d30e1b2a171d60b826fd975</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1002%2Fcpt.1862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcpt.1862%26sid%3Dliteratum%253Aachs%26aulast%3DAlpern%26aufirst%3DJ.%2BD.%26aulast%3DGertner%26aufirst%3DE.%26atitle%3DOff-Label%2520Therapies%2520for%2520COVID-19%25E2%2580%2594Are%2520We%2520All%2520In%2520This%2520Together%253F%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2020%26volume%3D108%26spage%3D182%26epage%3D184%26doi%3D10.1002%2Fcpt.1862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span> <i>Remdesivir Emergency Use Authorization</i>; <span class="NLM_publisher-name">Gilead Sciences, Inc.</span>, <span class="NLM_year">2020</span>; <a href="https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fda-authorization-letter_01may2020-old.pdf?la=en&amp;hash=2AE25800C7C9612D2F67F28D3F3B9921" class="extLink">https://www.gilead.com/-/media/files/pdfs/remdesivir/eua-fda-authorization-letter_01may2020-old.pdf?la=en&hash=2AE25800C7C9612D2F67F28D3F3B9921</a> (accessed 2020-08-09).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Remdesivir+Emergency+Use+Authorization%3B+Gilead+Sciences%2C+Inc.%2C+2020%3B+https%3A%2F%2Fwww.gilead.com%2F-%2Fmedia%2Ffiles%2Fpdfs%2Fremdesivir%2Feua-fda-authorization-letter_01may2020-old.pdf%3Fla%3Den%26hash%3D2AE25800C7C9612D2F67F28D3F3B9921+%28accessed+2020-08-09%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DRemdesivir%2520Emergency%2520Use%2520Authorization%26pub%3DGilead%2520Sciences%252C%2520Inc%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldman, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, D. C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montejano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spinner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nahass, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SenGupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Towner, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MuÃ±oz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tashima, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for 5 or 10 Days in Patients with Severe Covid-19</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2015301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2015301" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+D.+Goldmanauthor=D.+C.+B.+Lyeauthor=D.+S.+Huiauthor=K.+M.+Marksauthor=R.+Brunoauthor=R.+Montejanoauthor=C.+D.+Spinnerauthor=M.+Galliauthor=M.-Y.+Ahnauthor=R.+G.+Nahassauthor=Y.-S.+Chenauthor=D.+SenGuptaauthor=R.+H.+Hylandauthor=A.+O.+Osinusiauthor=H.+Caoauthor=C.+Blairauthor=X.+Weiauthor=A.+Gaggarauthor=D.+M.+Brainardauthor=W.+J.+Townerauthor=J.+Mu%C3%B1ozauthor=K.+M.+Mullaneauthor=F.+M.+Martyauthor=K.+T.+Tashimaauthor=G.+Diazauthor=A.+Subramanian&title=Remdesivir+for+5+or+10+Days+in+Patients+with+Severe+Covid-19&doi=10.1056%2FNEJMoa2015301"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2015301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2015301%26sid%3Dliteratum%253Aachs%26aulast%3DGoldman%26aufirst%3DJ.%2BD.%26aulast%3DLye%26aufirst%3DD.%2BC.%2BB.%26aulast%3DHui%26aufirst%3DD.%2BS.%26aulast%3DMarks%26aufirst%3DK.%2BM.%26aulast%3DBruno%26aufirst%3DR.%26aulast%3DMontejano%26aufirst%3DR.%26aulast%3DSpinner%26aufirst%3DC.%2BD.%26aulast%3DGalli%26aufirst%3DM.%26aulast%3DAhn%26aufirst%3DM.-Y.%26aulast%3DNahass%26aufirst%3DR.%2BG.%26aulast%3DChen%26aufirst%3DY.-S.%26aulast%3DSenGupta%26aufirst%3DD.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DOsinusi%26aufirst%3DA.%2BO.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DTowner%26aufirst%3DW.%2BJ.%26aulast%3DMu%25C3%25B1oz%26aufirst%3DJ.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26aulast%3DTashima%26aufirst%3DK.%2BT.%26aulast%3DDiaz%26aufirst%3DG.%26aulast%3DSubramanian%26aufirst%3DA.%26atitle%3DRemdesivir%2520for%25205%2520or%252010%2520Days%2520in%2520Patients%2520with%2520Severe%2520Covid-19%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMoa2015301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, M. S.</span></span> <span> </span><span class="NLM_article-title">Remdesivir â An Important First Step</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMe2018715</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMe2018715" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32459913" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+Dolinauthor=M.+S.+Hirsch&title=Remdesivir+%E2%80%94+An+Important+First+Step&doi=10.1056%2FNEJMe2018715"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1056%2FNEJMe2018715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMe2018715%26sid%3Dliteratum%253Aachs%26aulast%3DDolin%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DM.%2BS.%26atitle%3DRemdesivir%2520%25E2%2580%2594%2520An%2520Important%2520First%2520Step%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMe2018715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beigel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomashek, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zingman, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalil, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luetkemeyer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez de Castilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finberg, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dierberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapson, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paredes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Short, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Touloumi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lye, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohmagari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Palacios, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benfield, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">FÃ¤tkenheuer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortepeter, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atmar, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creech, C. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundgren, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babiker, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neaton, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgess, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonnett, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for the Treatment of Covid-19 â Final Report</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2007764</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2007764" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+H.+Beigelauthor=K.+M.+Tomashekauthor=L.+E.+Doddauthor=A.+K.+Mehtaauthor=B.+S.+Zingmanauthor=A.+C.+Kalilauthor=E.+Hohmannauthor=H.+Y.+Chuauthor=A.+Luetkemeyerauthor=S.+Klineauthor=D.+Lopez+de+Castillaauthor=R.+W.+Finbergauthor=K.+Dierbergauthor=V.+Tapsonauthor=L.+Hsiehauthor=T.+F.+Pattersonauthor=R.+Paredesauthor=D.+A.+Sweeneyauthor=W.+R.+Shortauthor=G.+Touloumiauthor=D.+C.+Lyeauthor=N.+Ohmagariauthor=M.+Ohauthor=G.+M.+Ruiz-Palaciosauthor=T.+Benfieldauthor=G.+F%C3%A4tkenheuerauthor=M.+G.+Kortepeterauthor=R.+L.+Atmarauthor=C.+B.+Creechauthor=J.+Lundgrenauthor=A.+G.+Babikerauthor=S.+Pettauthor=J.+D.+Neatonauthor=T.+H.+Burgessauthor=T.+Bonnettauthor=M.+Greenauthor=M.+Makowskiauthor=A.+Osinusiauthor=S.+Nayakauthor=H.+C.+Lane&title=Remdesivir+for+the+Treatment+of+Covid-19+%E2%80%94+Final+Report&doi=10.1056%2FNEJMoa2007764"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2007764&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2007764%26sid%3Dliteratum%253Aachs%26aulast%3DBeigel%26aufirst%3DJ.%2BH.%26aulast%3DTomashek%26aufirst%3DK.%2BM.%26aulast%3DDodd%26aufirst%3DL.%2BE.%26aulast%3DMehta%26aufirst%3DA.%2BK.%26aulast%3DZingman%26aufirst%3DB.%2BS.%26aulast%3DKalil%26aufirst%3DA.%2BC.%26aulast%3DHohmann%26aufirst%3DE.%26aulast%3DChu%26aufirst%3DH.%2BY.%26aulast%3DLuetkemeyer%26aufirst%3DA.%26aulast%3DKline%26aufirst%3DS.%26aulast%3DLopez%2Bde%2BCastilla%26aufirst%3DD.%26aulast%3DFinberg%26aufirst%3DR.%2BW.%26aulast%3DDierberg%26aufirst%3DK.%26aulast%3DTapson%26aufirst%3DV.%26aulast%3DHsieh%26aufirst%3DL.%26aulast%3DPatterson%26aufirst%3DT.%2BF.%26aulast%3DParedes%26aufirst%3DR.%26aulast%3DSweeney%26aufirst%3DD.%2BA.%26aulast%3DShort%26aufirst%3DW.%2BR.%26aulast%3DTouloumi%26aufirst%3DG.%26aulast%3DLye%26aufirst%3DD.%2BC.%26aulast%3DOhmagari%26aufirst%3DN.%26aulast%3DOh%26aufirst%3DM.%26aulast%3DRuiz-Palacios%26aufirst%3DG.%2BM.%26aulast%3DBenfield%26aufirst%3DT.%26aulast%3DF%25C3%25A4tkenheuer%26aufirst%3DG.%26aulast%3DKortepeter%26aufirst%3DM.%2BG.%26aulast%3DAtmar%26aufirst%3DR.%2BL.%26aulast%3DCreech%26aufirst%3DC.%2BB.%26aulast%3DLundgren%26aufirst%3DJ.%26aulast%3DBabiker%26aufirst%3DA.%2BG.%26aulast%3DPett%26aufirst%3DS.%26aulast%3DNeaton%26aufirst%3DJ.%2BD.%26aulast%3DBurgess%26aufirst%3DT.%2BH.%26aulast%3DBonnett%26aufirst%3DT.%26aulast%3DGreen%26aufirst%3DM.%26aulast%3DMakowski%26aufirst%3DM.%26aulast%3DOsinusi%26aufirst%3DA.%26aulast%3DNayak%26aufirst%3DS.%26aulast%3DLane%26aufirst%3DH.%2BC.%26atitle%3DRemdesivir%2520for%2520the%2520Treatment%2520of%2520Covid-19%2520%25E2%2580%2594%2520Final%2520Report%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26doi%3D10.1056%2FNEJMoa2007764" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Drug Discovery and Development</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1019</span>â <span class="NLM_lpage">1019</span>, <span class="refDoi">Â DOI: 10.1038/nrd2483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnrd2483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOjs7nI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1019-1019&author=J.+Vacca&title=Antiviral+Drug+Discovery+and+Development&doi=10.1038%2Fnrd2483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Antiviral drug discovery and development</span></div><div class="casAuthors">Vacca, Joseph; Burger, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1019</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New drugs have transformed the treatment of viral infections - in particular, HIV - in the past two decades.  Our interviewees this month describe the rewards and challenges of their complementary roles in antiviral drug discovery and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMYwaI47OmZLVg90H21EOLACvtfcHk0lhg2F4H6MkAHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOjs7nI&md5=8a3c09236a94aa93dc43036c01ef8592</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2483%26sid%3Dliteratum%253Aachs%26aulast%3DVacca%26aufirst%3DJ.%26atitle%3DAntiviral%2520Drug%2520Discovery%2520and%2520Development%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D1019%26epage%3D1019%26doi%3D10.1038%2Fnrd2483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Everts, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bostwick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitley, R. J.</span></span> <span> </span><span class="NLM_article-title">Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model</span>. <i>Annu. Rev. Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">155</span>â <span class="NLM_lpage">169</span>, <span class="refDoi">Â DOI: 10.1146/annurev-pharmtox-010716-104533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1146%2Fannurev-pharmtox-010716-104533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27483339" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oku7%252FO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=155-169&author=M.+Evertsauthor=T.+Cihlarauthor=J.+R.+Bostwickauthor=R.+J.+Whitley&title=Accelerating+Drug+Development%3A+Antiviral+Therapies+for+Emerging+Viruses+as+a+Model&doi=10.1146%2Fannurev-pharmtox-010716-104533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model</span></div><div class="casAuthors">Everts, Maaike; Cihlar, Tomas; Bostwick, J. Robert; Whitley, Richard J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">155-169</span>CODEN:
                <span class="NLM_cas:coden">ARPTDI</span>;
        ISSN:<span class="NLM_cas:issn">0362-1642</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews</span>)
        </div><div class="casAbstract">Drug discovery and development is a lengthy and expensive process.  Although no one, simple, single soln. can significantly accelerate this process, steps can be taken to avoid unnecessary delays.  Using the development of antiviral therapies as a model, we describe options for acceleration that cover target selection, assay development and high-throughput screening, hit confirmation, lead identification and development, animal model evaluations, toxicity studies, regulatory issues, and the general drug discovery and development infrastructure.  Together, these steps could result in accelerated timelines for bringing antiviral therapies to market so they can treat emerging infections and reduce human suffering.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDcCmni1QuYLVg90H21EOLACvtfcHk0lhg2F4H6MkAHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oku7%252FO&md5=e1bbd0d7afaa00f17321ebdaba603814</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-pharmtox-010716-104533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-pharmtox-010716-104533%26sid%3Dliteratum%253Aachs%26aulast%3DEverts%26aufirst%3DM.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBostwick%26aufirst%3DJ.%2BR.%26aulast%3DWhitley%26aufirst%3DR.%2BJ.%26atitle%3DAccelerating%2520Drug%2520Development%253A%2520Antiviral%2520Therapies%2520for%2520Emerging%2520Viruses%2520as%2520a%2520Model%26jtitle%3DAnnu.%2520Rev.%2520Pharmacol.%2520Toxicol.%26date%3D2017%26volume%3D57%26spage%3D155%26epage%3D169%26doi%3D10.1146%2Fannurev-pharmtox-010716-104533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garner, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smoot, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gregg, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daniels, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jervey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albaiu, D.</span></span> <span> </span><span class="NLM_article-title">Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">315</span>â <span class="NLM_lpage">331</span>, <span class="refDoi">Â DOI: 10.1021/acscentsci.0c00272</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.0c00272" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkslWrsbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=315-331&author=C.+Liuauthor=Q.+Zhouauthor=Y.+Liauthor=L.+V.+Garnerauthor=S.+P.+Watkinsauthor=L.+J.+Carterauthor=J.+Smootauthor=A.+C.+Greggauthor=A.+D.+Danielsauthor=S.+Jerveyauthor=D.+Albaiu&title=Research+and+Development+on+Therapeutic+Agents+and+Vaccines+for+COVID-19+and+Related+Human+Coronavirus+Diseases&doi=10.1021%2Facscentsci.0c00272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases</span></div><div class="casAuthors">Liu, Cynthia; Zhou, Qiongqiong; Li, Yingzhu; Garner, Linda V.; Watkins, Steve P.; Carter, Linda J.; Smoot, Jeffrey; Gregg, Anne C.; Daniels, Angela D.; Jervey, Susan; Albaiu, Dana</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">315-331</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe.  Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiol. of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines.  To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection.  It highlights antiviral strategies involving small mols. and biologics targeting complex mol. interactions involved in coronavirus infection and replication.  The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV.  The patent anal. of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines.  More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19.  The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAA030tIyfebVg90H21EOLACvtfcHk0lhg2F4H6MkAHg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkslWrsbo%253D&md5=fa29fb4cc3353a140e3a6a74059a99b1</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.0c00272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.0c00272%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DGarner%26aufirst%3DL.%2BV.%26aulast%3DWatkins%26aufirst%3DS.%2BP.%26aulast%3DCarter%26aufirst%3DL.%2BJ.%26aulast%3DSmoot%26aufirst%3DJ.%26aulast%3DGregg%26aufirst%3DA.%2BC.%26aulast%3DDaniels%26aufirst%3DA.%2BD.%26aulast%3DJervey%26aufirst%3DS.%26aulast%3DAlbaiu%26aufirst%3DD.%26atitle%3DResearch%2520and%2520Development%2520on%2520Therapeutic%2520Agents%2520and%2520Vaccines%2520for%2520COVID-19%2520and%2520Related%2520Human%2520Coronavirus%2520Diseases%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2020%26volume%3D6%26spage%3D315%26epage%3D331%26doi%3D10.1021%2Facscentsci.0c00272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginex, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maestro, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nozal, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrado-Gil, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuesta-Geijo, M. Ã.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urquiza, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RamÃ­rez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">COVID-19: Drug Targets and Potential Treatments</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00606</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00606" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Gilauthor=T.+Ginexauthor=I.+Maestroauthor=V.+Nozalauthor=L.+Barrado-Gilauthor=M.+%C3%81.+Cuesta-Geijoauthor=J.+Urquizaauthor=D.+Ram%C3%ADrezauthor=C.+Alonsoauthor=N.+E.+Campilloauthor=A.+Martinez&title=COVID-19%3A+Drug+Targets+and+Potential+Treatments&doi=10.1021%2Facs.jmedchem.0c00606"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00606%26sid%3Dliteratum%253Aachs%26aulast%3DGil%26aufirst%3DC.%26aulast%3DGinex%26aufirst%3DT.%26aulast%3DMaestro%26aufirst%3DI.%26aulast%3DNozal%26aufirst%3DV.%26aulast%3DBarrado-Gil%26aufirst%3DL.%26aulast%3DCuesta-Geijo%26aufirst%3DM.%2B%25C3%2581.%26aulast%3DUrquiza%26aufirst%3DJ.%26aulast%3DRam%25C3%25ADrez%26aufirst%3DD.%26aulast%3DAlonso%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DCOVID-19%253A%2520Drug%2520Targets%2520and%2520Potential%2520Treatments%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00606" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kok, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, K. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span> <span> </span><span class="NLM_article-title">Genomic Characterization of the 2019 Novel Human-Pathogenic Coronavirus Isolated from a Patient with Atypical Pneumonia after Visiting Wuhan</span>. <i>Emerging Microbes Infect.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">221</span>â <span class="NLM_lpage">236</span>, <span class="refDoi">Â DOI: 10.1080/22221751.2020.1719902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1080%2F22221751.2020.1719902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31987001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotFOktLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=221-236&author=J.+F.+W.+Chanauthor=K.+H.+Kokauthor=Z.+Zhuauthor=H.+Chuauthor=K.+K.+W.+Toauthor=S.+Yuanauthor=K.+Y.+Yuen&title=Genomic+Characterization+of+the+2019+Novel+Human-Pathogenic+Coronavirus+Isolated+from+a+Patient+with+Atypical+Pneumonia+after+Visiting+Wuhan&doi=10.1080%2F22221751.2020.1719902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</span></div><div class="casAuthors">Chan, Jasper Fuk-Woo; Kok, Kin-Hang; Zhu, Zheng; Chu, Hin; To, Kelvin Kai-Wang; Yuan, Shuofeng; Yuen, Kwok-Yung</div><div class="citationInfo"><span class="NLM_cas:title">Emerging Microbes & Infections</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">221-236</span>CODEN:
                <span class="NLM_cas:coden">EMIMC4</span>;
        ISSN:<span class="NLM_cas:issn">2222-1751</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A mysterious outbreak of atypical pneumonia in late 2019 was traced to a seafood wholesale market in Wuhan of China.  Within a few weeks, a novel coronavirus tentatively named as 2019 novel coronavirus (2019-nCoV) was announced by the World Health Organization.  We performed bioinformatics anal. on a virus genome from a patient with 2019-nCoV infection and compared it with other related coronavirus genomes.  Overall, the genome of 2019-nCoV has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV.  The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses.  However, the external subdomain of Spike's receptor binding domain of 2019-nCoV shares only 40% amino acid identity with other SARS-related coronaviruses.  Remarkably, its orf3b encodes a completely novel short protein.  Furthermore, its new orf8 likely encodes a secreted protein with an alpha-helix, following with a beta-sheet(s) contg. six strands.  Learning from the roles of civet in SARS and camel in MERS, hunting for the animal source of 2019-nCoV and its more ancestral virus would be important for understanding the origin and evolution of this novel lineage B betacoronavirus.  These findings provide the basis for starting further studies on the pathogenesis, and optimizing the design of diagnostic, antiviral and vaccination strategies for this emerging infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2BxE9eKNpaLVg90H21EOLACvtfcHk0lifUjZwGM6fiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotFOktLg%253D&md5=1ff0b451da73344406c7485aa5018a45</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1080%2F22221751.2020.1719902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F22221751.2020.1719902%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DJ.%2BF.%2BW.%26aulast%3DKok%26aufirst%3DK.%2BH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DChu%26aufirst%3DH.%26aulast%3DTo%26aufirst%3DK.%2BK.%2BW.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26atitle%3DGenomic%2520Characterization%2520of%2520the%25202019%2520Novel%2520Human-Pathogenic%2520Coronavirus%2520Isolated%2520from%2520a%2520Patient%2520with%2520Atypical%2520Pneumonia%2520after%2520Visiting%2520Wuhan%26jtitle%3DEmerging%2520Microbes%2520Infect.%26date%3D2020%26volume%3D9%26spage%3D221%26epage%3D236%26doi%3D10.1080%2F22221751.2020.1719902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z. L.</span></span> <span> </span><span class="NLM_article-title">Origin and Evolution of Pathogenic Coronaviruses</span>. <i>Nat. Rev. Microbiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">181</span>â <span class="NLM_lpage">192</span>, <span class="refDoi">Â DOI: 10.1038/s41579-018-0118-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41579-018-0118-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30531947" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVyhtbnL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2019&pages=181-192&author=J.+Cuiauthor=F.+Liauthor=Z.+L.+Shi&title=Origin+and+Evolution+of+Pathogenic+Coronaviruses&doi=10.1038%2Fs41579-018-0118-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Origin and evolution of pathogenic coronaviruses</span></div><div class="casAuthors">Cui, Jie; Li, Fang; Shi, Zheng-Li</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Microbiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">181-192</span>CODEN:
                <span class="NLM_cas:coden">NRMACK</span>;
        ISSN:<span class="NLM_cas:issn">1740-1526</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A review.  Severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) are two highly transmissible and pathogenic viruses that emerged in humans at the beginning of the 21st century.  Both viruses likely originated in bats, and genetically diverse coronaviruses that are related to SARS-CoV and MERS-CoV were discovered in bats worldwide.  In this Review, we summarize the current knowledge on the origin and evolution of these two pathogenic coronaviruses and discuss their receptor usage; we also highlight the diversity and potential of spillover of bat-borne coronaviruses, as evidenced by the recent spillover of swine acute diarrhoea syndrome coronavirus (SADS-CoV) to pigs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosxL8lhv4N5rVg90H21EOLACvtfcHk0lifUjZwGM6fiQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVyhtbnL&md5=b2b2c40c0cdf30107d8c70f482fc4f63</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41579-018-0118-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41579-018-0118-9%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DZ.%2BL.%26atitle%3DOrigin%2520and%2520Evolution%2520of%2520Pathogenic%2520Coronaviruses%26jtitle%3DNat.%2520Rev.%2520Microbiol.%26date%3D2019%26volume%3D17%26spage%3D181%26epage%3D192%26doi%3D10.1038%2Fs41579-018-0118-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sanche, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Severson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hengartner, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, R.</span></span> <span> </span><span class="NLM_article-title">RESEARCH High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2</span>. <i>Emerging Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1470</span>â <span class="NLM_lpage">1477</span>, <span class="refDoi">Â DOI: 10.3201/eid2607.200282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3201%2Feid2607.200282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32255761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB38zhslOrtA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2020&pages=1470-1477&author=S.+Sancheauthor=Y.+T.+Linauthor=C.+Xuauthor=E.+Romero-Seversonauthor=N.+Hengartnerauthor=R.+Ke&title=RESEARCH+High+Contagiousness+and+Rapid+Spread+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+2&doi=10.3201%2Feid2607.200282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2</span></div><div class="casAuthors">Sanche Steven; Lin Yen Ting; Xu Chonggang; Romero-Severson Ethan; Hengartner Nick; Ke Ruian</div><div class="citationInfo"><span class="NLM_cas:title">Emerging infectious diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1470-1477</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 is the causative agent of the ongoing coronavirus disease pandemic.  Initial estimates of the early dynamics of the outbreak in Wuhan, China, suggested a doubling time of the number of infected persons of 6-7 days and a basic reproductive number (R0) of 2.2-2.7.  We collected extensive individual case reports across China and estimated key epidemiologic parameters, including the incubation period (4.2 days).  We then designed 2 mathematical modeling approaches to infer the outbreak dynamics in Wuhan by using high-resolution domestic travel and infection data.  Results show that the doubling time early in the epidemic in Wuhan was 2.3-3.3 days.  Assuming a serial interval of 6-9 days, we calculated a median R0 value of 5.7 (95% CI 3.8-8.9).  We further show that active surveillance, contact tracing, quarantine, and early strong social distancing efforts are needed to stop transmission of the virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR1QLaeKXMGxHRxY89Cm6SyfW6udTcc2eZbXJ_KMbV8yrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB38zhslOrtA%253D%253D&md5=60d7c57b32b8a34c33362239e1d2c98e</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3201%2Feid2607.200282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3201%252Feid2607.200282%26sid%3Dliteratum%253Aachs%26aulast%3DSanche%26aufirst%3DS.%26aulast%3DLin%26aufirst%3DY.%2BT.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRomero-Severson%26aufirst%3DE.%26aulast%3DHengartner%26aufirst%3DN.%26aulast%3DKe%26aufirst%3DR.%26atitle%3DRESEARCH%2520High%2520Contagiousness%2520and%2520Rapid%2520Spread%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25202%26jtitle%3DEmerging%2520Infect.%2520Dis.%26date%3D2020%26volume%3D26%26spage%3D1470%26epage%3D1477%26doi%3D10.3201%2Feid2607.200282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shereen, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kazmi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bashir, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddique, R.</span></span> <span> </span><span class="NLM_article-title">COVID-19 Infection: Origin, Transmission, and Characteristics of Human Coronaviruses</span>. <i>J. Adv. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">91</span>â <span class="NLM_lpage">98</span>, <span class="refDoi">Â DOI: 10.1016/j.jare.2020.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jare.2020.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32257431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmsl2ktbk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2020&pages=91-98&author=M.+A.+Shereenauthor=S.+Khanauthor=A.+Kazmiauthor=N.+Bashirauthor=R.+Siddique&title=COVID-19+Infection%3A+Origin%2C+Transmission%2C+and+Characteristics+of+Human+Coronaviruses&doi=10.1016%2Fj.jare.2020.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses</span></div><div class="casAuthors">Shereen, Muhammad Adnan; Khan, Suliman; Kazmi, Abeer; Bashir, Nadia; Siddique, Rabeea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Advanced Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">91-98</span>CODEN:
                <span class="NLM_cas:coden">JAROES</span>;
        ISSN:<span class="NLM_cas:issn">2090-1224</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The coronavirus disease 19 (COVID-19) is a highly transmittable and pathogenic viral infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in Wuhan, China and spread around the world.  Genomic anal. revealed that SARS-CoV-2 is phylogenetically related to severe acute respiratory syndrome-like (SARS-like) bat viruses, therefore bats could be the possible primary reservoir.  The intermediate source of origin and transfer to humans is not known, however, the rapid human to human transfer has been confirmed widely.  There is no clin. approved antiviral drug or vaccine available to be used against COVID-19.  However, few broad-spectrum antiviral drugs have been evaluated against COVID-19 in clin. trials, resulted in clin. recovery.  In the current review, we summarize and comparatively analyze the emergence and pathogenicity of COVID-19 infection and previous human coronaviruses severe acute respiratory syndrome coronavirus (SARS-CoV) and middle east respiratory syndrome coronavirus (MERS-CoV).  We also discuss the approaches for developing effective vaccines and therapeutic combinations to cope with this viral outbreak.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGortH4RKXf6eLVg90H21EOLACvtfcHk0lhFGgrDy8zOCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmsl2ktbk%253D&md5=31106b4d9e5f3131fcd206caed6ebc80</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.jare.2020.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jare.2020.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DShereen%26aufirst%3DM.%2BA.%26aulast%3DKhan%26aufirst%3DS.%26aulast%3DKazmi%26aufirst%3DA.%26aulast%3DBashir%26aufirst%3DN.%26aulast%3DSiddique%26aufirst%3DR.%26atitle%3DCOVID-19%2520Infection%253A%2520Origin%252C%2520Transmission%252C%2520and%2520Characteristics%2520of%2520Human%2520Coronaviruses%26jtitle%3DJ.%2520Adv.%2520Res.%26date%3D2020%26volume%3D24%26spage%3D91%26epage%3D98%26doi%3D10.1016%2Fj.jare.2020.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fehr, A. R.</span>; <span class="NLM_string-name">Perlman, S.</span></span> <span> </span><span class="NLM_article-title">Coronaviruses: An Overview of Their Replication and Pathogenesis</span>. In  <i>Coronaviruses: Methods and Protocols</i>; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2015</span>; Vol.  <span class="NLM_volume">1282</span>, pp  <span class="NLM_fpage">1</span>â <span class="NLM_lpage">23</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2F978-1-4939-2438-7_1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=1-23&author=A.+R.+Fehr&author=S.+Perlman&title=Coronaviruses%3A+Methods+and+Protocols"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-2438-7_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-4939-2438-7_1%26sid%3Dliteratum%253Aachs%26aulast%3DFehr%26aufirst%3DA.%2BR.%26atitle%3DCoronaviruses%253A%2520An%2520Overview%2520of%2520Their%2520Replication%2520and%2520Pathogenesis%26btitle%3DCoronaviruses%253A%2520Methods%2520and%2520Protocols%26pub%3DSpringer%26date%3D2015%26volume%3D1282%26spage%3D1%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loganathan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleicher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quevedo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langille, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teng, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathod, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samavarchi-Tehrani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugh, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gingras, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramek, D.</span></span> <span> </span><span class="NLM_article-title">Rare Driver Mutations in Head and Neck Squamous Cell Carcinomas Converge on NOTCH Signaling</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1264</span>â <span class="NLM_lpage">1269</span>, <span class="refDoi">Â DOI: 10.1126/science.aax0902</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.aax0902" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32165588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFemt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1264-1269&author=S.+K.+Loganathanauthor=K.+Schleicherauthor=A.+Malikauthor=R.+Quevedoauthor=E.+Langilleauthor=K.+Tengauthor=R.+H.+Ohauthor=B.+Rathodauthor=R.+Tsaiauthor=P.+Samavarchi-Tehraniauthor=T.+J.+Pughauthor=A.+C.+Gingrasauthor=D.+Schramek&title=Rare+Driver+Mutations+in+Head+and+Neck+Squamous+Cell+Carcinomas+Converge+on+NOTCH+Signaling&doi=10.1126%2Fscience.aax0902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Rare driver mutations in head and neck squamous cell carcinomas converge on NOTCH signaling</span></div><div class="casAuthors">Loganathan, Sampath K.; Schleicher, Krista; Malik, Ahmad; Quevedo, Rene; Langille, Ellen; Teng, Katie; Oh, Robin H.; Rathod, Bhavisha; Tsai, Ricky; Samavarchi-Tehrani, Payman; Pugh, Trevor J.; Gingras, Anne-Claude; Schramek, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">1264-1269</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In most human cancers, only a few genes are mutated at high frequencies; most are mutated at low frequencies.  The functional consequences of these recurrent but infrequent "long tail" mutations are often unknown.  We focused on 484 long tail genes in head and neck squamous cell carcinoma (HNSCC) and used in vivo CRISPR to screen for genes that, upon mutation, trigger tumor development in mice.  Of the 15 tumor-suppressor genes identified, ADAM10 and AJUBA suppressed HNSCC in a haploinsufficient manner by promoting NOTCH receptor signaling.  ADAM10 and AJUBA mutations or monoallelic loss occur in 28% of human HNSCC cases and are mutually exclusive with NOTCH receptor mutations.  Our results show that oncogenic mutations in 67% of human HNSCC cases converge onto the NOTCH signaling pathway, making NOTCH inactivation a hallmark of HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTSwKJHSQZ2rVg90H21EOLACvtfcHk0lhFGgrDy8zOCg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFemt7c%253D&md5=7974c2cb4fc78ca29ec267cdb01aef2d</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1126%2Fscience.aax0902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aax0902%26sid%3Dliteratum%253Aachs%26aulast%3DLoganathan%26aufirst%3DS.%2BK.%26aulast%3DSchleicher%26aufirst%3DK.%26aulast%3DMalik%26aufirst%3DA.%26aulast%3DQuevedo%26aufirst%3DR.%26aulast%3DLangille%26aufirst%3DE.%26aulast%3DTeng%26aufirst%3DK.%26aulast%3DOh%26aufirst%3DR.%2BH.%26aulast%3DRathod%26aufirst%3DB.%26aulast%3DTsai%26aufirst%3DR.%26aulast%3DSamavarchi-Tehrani%26aufirst%3DP.%26aulast%3DPugh%26aufirst%3DT.%2BJ.%26aulast%3DGingras%26aufirst%3DA.%2BC.%26aulast%3DSchramek%26aufirst%3DD.%26atitle%3DRare%2520Driver%2520Mutations%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinomas%2520Converge%2520on%2520NOTCH%2520Signaling%26jtitle%3DScience%26date%3D2020%26volume%3D367%26spage%3D1264%26epage%3D1269%26doi%3D10.1126%2Fscience.aax0902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kleine-Weber, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¼ger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erichsen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiergens, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrler, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitsche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ¼ller, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ¶hlmann, S.</span></span> <span> </span><span class="NLM_article-title">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">271</span>â <span class="NLM_lpage">280</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.02.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.02.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32142651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=271-280&author=M.+Hoffmannauthor=H.+Kleine-Weberauthor=S.+Schroederauthor=N.+Kr%C3%BCgerauthor=T.+Herrlerauthor=S.+Erichsenauthor=T.+S.+Schiergensauthor=G.+Herrlerauthor=N.+H.+Wuauthor=A.+Nitscheauthor=M.+A.+M%C3%BCllerauthor=C.+Drostenauthor=S.+P%C3%B6hlmann&title=SARS-CoV-2+Cell+Entry+Depends+on+ACE2+and+TMPRSS2+and+Is+Blocked+by+a+Clinically+Proven+Protease+Inhibitor&doi=10.1016%2Fj.cell.2020.02.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor</span></div><div class="casAuthors">Hoffmann, Markus; Kleine-Weber, Hannah; Schroeder, Simon; Krueger, Nadine; Herrler, Tanja; Erichsen, Sandra; Schiergens, Tobias S.; Herrler, Georg; Wu, Nai-Huei; Nitsche, Andreas; Mueller, Marcel A.; Drosten, Christian; Poehlmann, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">271-280.e8</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency.  Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases.  Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets.  Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming.  A TMPRSS2 inhibitor approved for clin. use blocked entry and might constitute a treatment option.  Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry.  Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq92X1lVQaLirVg90H21EOLACvtfcHk0lgOw2JVw02RpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktl2qtb8%253D&md5=60aea5c939a2d4df034a91d6198fb3ef</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.02.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.02.052%26sid%3Dliteratum%253Aachs%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DKleine-Weber%26aufirst%3DH.%26aulast%3DSchroeder%26aufirst%3DS.%26aulast%3DKr%25C3%25BCger%26aufirst%3DN.%26aulast%3DHerrler%26aufirst%3DT.%26aulast%3DErichsen%26aufirst%3DS.%26aulast%3DSchiergens%26aufirst%3DT.%2BS.%26aulast%3DHerrler%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DN.%2BH.%26aulast%3DNitsche%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BA.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DP%25C3%25B6hlmann%26aufirst%3DS.%26atitle%3DSARS-CoV-2%2520Cell%2520Entry%2520Depends%2520on%2520ACE2%2520and%2520TMPRSS2%2520and%2520Is%2520Blocked%2520by%2520a%2520Clinically%2520Proven%2520Protease%2520Inhibitor%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D271%26epage%3D280%26doi%3D10.1016%2Fj.cell.2020.02.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e8.</p></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wrapp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbett, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsmith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abiona, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLellan, J. S.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>367</i></span>,  <span class="NLM_fpage">1260</span>â <span class="NLM_lpage">1263</span>, <span class="refDoi">Â DOI: 10.1126/science.abb2507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb2507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32075877" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvFemt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=367&publication_year=2020&pages=1260-1263&author=D.+Wrappauthor=N.+Wangauthor=K.+S.+Corbettauthor=J.+A.+Goldsmithauthor=C.+L.+Hsiehauthor=O.+Abionaauthor=B.+S.+Grahamauthor=J.+S.+McLellan&title=Cryo-EM+Structure+of+the+2019-NCoV+Spike+in+the+Prefusion+Conformation&doi=10.1126%2Fscience.abb2507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</span></div><div class="casAuthors">Wrapp, Daniel; Wang, Nianshuang; Corbett, Kizzmekia S.; Goldsmith, Jory A.; Hsieh, Ching-Lin; Abiona, Olubukola; Graham, Barney S.; McLellan, Jason S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">367</span>
        (<span class="NLM_cas:issue">6483</span>),
    <span class="NLM_cas:pages">1260-1263</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The outbreak of a novel coronavirus (2019-nCoV) represents a pandemic threat that has been declared a public health emergency of international concern.  The CoV spike (S) glycoprotein is a key target for vaccines, therapeutic antibodies, and diagnostics.  To facilitate medical countermeasure development, we detd. a 3.5-angstrom-resoln. cryo-electron microscopy structure of the 2019-nCoV S trimer in the prefusion conformation.  The predominant state of the trimer has one of the three receptor-binding domains (RBDs) rotated up in a receptor-accessible conformation.  We also provide biophys. and structural evidence that the 2019-nCoV S protein binds angiotensin-converting enzyme 2 (ACE2) with higher affinity than does severe acute respiratory syndrome (SARS)-CoV S.  Addnl., we tested several published SARS-CoV RBD-specific monoclonal antibodies and found that they do not have appreciable binding to 2019-nCoV S, suggesting that antibody cross-reactivity may be limited between the two RBDs.  The structure of 2019-nCoV S should enable the rapid development and evaluation of medical countermeasures to address the ongoing public health crisis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFmIhnTBqdt7Vg90H21EOLACvtfcHk0lgOw2JVw02RpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvFemt70%253D&md5=27d08cbb9a43d1da051a8a92a9f68aa5</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb2507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb2507%26sid%3Dliteratum%253Aachs%26aulast%3DWrapp%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DN.%26aulast%3DCorbett%26aufirst%3DK.%2BS.%26aulast%3DGoldsmith%26aufirst%3DJ.%2BA.%26aulast%3DHsieh%26aufirst%3DC.%2BL.%26aulast%3DAbiona%26aufirst%3DO.%26aulast%3DGraham%26aufirst%3DB.%2BS.%26aulast%3DMcLellan%26aufirst%3DJ.%2BS.%26atitle%3DCryo-EM%2520Structure%2520of%2520the%25202019-NCoV%2520Spike%2520in%2520the%2520Prefusion%2520Conformation%26jtitle%3DScience%26date%3D2020%26volume%3D367%26spage%3D1260%26epage%3D1263%26doi%3D10.1126%2Fscience.abb2507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>181</i></span>,  <span class="NLM_fpage">894</span>â <span class="NLM_lpage">904</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.03.045</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.03.045" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32275855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmvFGrur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=181&publication_year=2020&pages=894-904&author=Q.+Wangauthor=Y.+Zhangauthor=L.+Wuauthor=S.+Niuauthor=C.+Songauthor=Z.+Zhangauthor=G.+Luauthor=C.+Qiaoauthor=Y.+Huauthor=K.+Y.+Yuenauthor=Q.+Wangauthor=H.+Zhouauthor=J.+Yanauthor=J.+Qi&title=Structural+and+Functional+Basis+of+SARS-CoV-2+Entry+by+Using+Human+ACE2&doi=10.1016%2Fj.cell.2020.03.045"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</span></div><div class="casAuthors">Wang, Qihui; Zhang, Yanfang; Wu, Lili; Niu, Sheng; Song, Chunli; Zhang, Zengyuan; Lu, Guangwen; Qiao, Chengpeng; Hu, Yu; Yuen, Kwok-Yung; Wang, Qisheng; Zhou, Huan; Yan, Jinghua; Qi, Jianxun</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">181</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">894-904.e9</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns.  Recently, ACE2 was reported as an entry receptor for SARS-CoV-2.  In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that obsd. for SARS-CoV.  However, at. details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD.  Addnl., a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2.  These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaKfOekHApZrVg90H21EOLACvtfcHk0lgOw2JVw02RpA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmvFGrur4%253D&md5=188108e44f104860d4a2b83707ce7230</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.03.045&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.03.045%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DNiu%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DG.%26aulast%3DQiao%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DJ.%26atitle%3DStructural%2520and%2520Functional%2520Basis%2520of%2520SARS-CoV-2%2520Entry%2520by%2520Using%2520Human%2520ACE2%26jtitle%3DCell%26date%3D2020%26volume%3D181%26spage%3D894%26epage%3D904%26doi%3D10.1016%2Fj.cell.2020.03.045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e9.</p></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>581</i></span>,  <span class="NLM_fpage">215</span>â <span class="NLM_lpage">220</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2180-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2180-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32225176" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXoslOqtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=581&publication_year=2020&pages=215-220&author=J.+Lanauthor=J.+Geauthor=J.+Yuauthor=S.+Shanauthor=H.+Zhouauthor=S.+Fanauthor=Q.+Zhangauthor=X.+Shiauthor=Q.+Wangauthor=L.+Zhangauthor=X.+Wang&title=Structure+of+the+SARS-CoV-2+Spike+Receptor-Binding+Domain+Bound+to+the+ACE2+Receptor&doi=10.1038%2Fs41586-020-2180-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</span></div><div class="casAuthors">Lan, Jun; Ge, Jiwan; Yu, Jinfang; Shan, Sisi; Zhou, Huan; Fan, Shilong; Zhang, Qi; Shi, Xuanling; Wang, Qisheng; Zhang, Linqi; Wang, Xinquan</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">581</span>
        (<span class="NLM_cas:issue">7807</span>),
    <span class="NLM_cas:pages">215-220</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new and highly pathogenic coronavirus (severe acute respiratory syndrome coronavirus-2, SARS-CoV-2) caused an outbreak in Wuhan city, Hubei province, China, starting from Dec. 2019 that quickly spread nationwide and to other countries around the world1-3.  Here, to better understand the initial step of infection at an at. level, we detd. the crystal structure of the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2 bound to the cell receptor ACE2.  The overall ACE2-binding mode of the SARS-CoV-2 RBD is nearly identical to that of the SARS-CoV RBD, which also uses ACE2 as the cell receptor4.  Structural anal. identified residues in the SARS-CoV-2 RBD that are essential for ACE2 binding, the majority of which either are highly conserved or share similar side chain properties with those in the SARS-CoV RBD.  Such similarity in structure and sequence strongly indicate convergent evolution between the SARS-CoV-2 and SARS-CoV RBDs for improved binding to ACE2, although SARS-CoV-2 does not cluster within SARS and SARS-related coronaviruses1-3,5.  The epitopes of two SARS-CoV antibodies that target the RBD are also analyzed for binding to the SARS-CoV-2 RBD, providing insights into the future identification of cross-reactive antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXsiu14u7z5bVg90H21EOLACvtfcHk0lj-0LQyOjeB2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXoslOqtL8%253D&md5=279c60143e8e5eb505457e0778baa8ef</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2180-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2180-5%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DJ.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DShan%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DFan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DStructure%2520of%2520the%2520SARS-CoV-2%2520Spike%2520Receptor-Binding%2520Domain%2520Bound%2520to%2520the%2520ACE2%2520Receptor%26jtitle%3DNature%26date%3D2020%26volume%3D581%26spage%3D215%26epage%3D220%26doi%3D10.1038%2Fs41586-020-2180-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dick, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirzaie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cocklin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c00502</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00502" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=S.+Xiuauthor=A.+Dickauthor=H.+Juauthor=S.+Mirzaieauthor=F.+Abdiauthor=S.+Cocklinauthor=P.+Zhanauthor=X.+Liu&title=Inhibitors+of+SARS-CoV-2+Entry%3A+Current+and+Future+Opportunities&doi=10.1021%2Facs.jmedchem.0c00502"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00502%26sid%3Dliteratum%253Aachs%26aulast%3DXiu%26aufirst%3DS.%26aulast%3DDick%26aufirst%3DA.%26aulast%3DJu%26aufirst%3DH.%26aulast%3DMirzaie%26aufirst%3DS.%26aulast%3DAbdi%26aufirst%3DF.%26aulast%3DCocklin%26aufirst%3DS.%26aulast%3DZhan%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DX.%26atitle%3DInhibitors%2520of%2520SARS-CoV-2%2520Entry%253A%2520Current%2520and%2520Future%2520Opportunities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c00502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cannalire, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanelli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beccari, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelliccia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span> <span> </span><span class="NLM_article-title">Sars-Cov-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5707</span>, <span class="refDoi">Â DOI: 10.3390/ijms21165707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fijms21165707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVChs7rL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=5707&author=R.+Cannalireauthor=I.+Stefanelliauthor=C.+Cerchiaauthor=A.+R.+Beccariauthor=S.+Pellicciaauthor=V.+Summa&title=Sars-Cov-2+Entry+Inhibitors%3A+Small+Molecules+and+Peptides+Targeting+Virus+or+Host+Cells&doi=10.3390%2Fijms21165707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">SARS-CoV-2 entry inhibitors: small molecules and peptides targeting virus or host cells</span></div><div class="casAuthors">Cannalire, Rolando; Stefanelli, Irina; Cerchia, Carmen; Beccari, Andrea R.; Pelliccia, Sveva; Summa, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5707</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The pandemic evolution of SARS-CoV-2 infection is forcing the scientific community to unprecedented efforts to explore all possible approaches against COVID-19.  In this context, targeting virus entry is a promising antiviral strategy for controlling viral infections.  The main strategies pursued to inhibit the viral entry are considering both the virus and the host factors involved in the process.  Primarily, direct-acting antivirals rely on inhibition of the interaction between ACE2 and the receptor binding domain (RBD) of the Spike (S) protein or targeting the more conserved heptad repeats (HRs), involved in the membrane fusion process.  The inhibition of host TMPRSS2 and cathepsins B/L may represent a complementary strategy to be investigated.  In this review, we discuss the development entry inhibitors targeting the S protein, as well as the most promising host targeting strategies involving TMPRSS2 and CatB/L, which have been exploited so far against CoVs and other related viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMTb3-BDmGt7Vg90H21EOLACvtfcHk0lj-0LQyOjeB2A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVChs7rL&md5=7aafad1d4cdb83377df1734f81d2fa3b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3390%2Fijms21165707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21165707%26sid%3Dliteratum%253Aachs%26aulast%3DCannalire%26aufirst%3DR.%26aulast%3DStefanelli%26aufirst%3DI.%26aulast%3DCerchia%26aufirst%3DC.%26aulast%3DBeccari%26aufirst%3DA.%2BR.%26aulast%3DPelliccia%26aufirst%3DS.%26aulast%3DSumma%26aufirst%3DV.%26atitle%3DSars-Cov-2%2520Entry%2520Inhibitors%253A%2520Small%2520Molecules%2520and%2520Peptides%2520Targeting%2520Virus%2520or%2520Host%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D5707%26doi%3D10.3390%2Fijms21165707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, S. R.</span></span> <span> </span><span class="NLM_article-title">Antagonism of the Interferon-Induced OAS-RNase L Pathway by Murine Coronavirus Ns2 Protein Is Required for Virus Replication and Liver Pathology</span>. <i>Cell Host Microbe</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">607</span>â <span class="NLM_lpage">616</span>, <span class="refDoi">Â DOI: 10.1016/j.chom.2012.04.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.chom.2012.04.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22704621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XosFCjuro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=607-616&author=L.+Zhaoauthor=B.+K.+Jhaauthor=A.+Wuauthor=R.+Elliottauthor=J.+Ziebuhrauthor=A.+E.+Gorbalenyaauthor=R.+H.+Silvermanauthor=S.+R.+Weiss&title=Antagonism+of+the+Interferon-Induced+OAS-RNase+L+Pathway+by+Murine+Coronavirus+Ns2+Protein+Is+Required+for+Virus+Replication+and+Liver+Pathology&doi=10.1016%2Fj.chom.2012.04.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Antagonism of the Interferon-Induced OAS-RNase L Pathway by Murine Coronavirus ns2 Protein Is Required for Virus Replication and Liver Pathology</span></div><div class="casAuthors">Zhao, Ling; Jha, Babal K.; Wu, Ashley; Elliott, Ruth; Ziebuhr, John; Gorbalenya, Alexander E.; Silverman, Robert H.; Weiss, Susan R.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Host & Microbe</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">607-616</span>CODEN:
                <span class="NLM_cas:coden">CHMECB</span>;
        ISSN:<span class="NLM_cas:issn">1931-3128</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Many viruses induce hepatitis in humans, highlighting the need to understand the underlying mechanisms of virus-induced liver pathol.  The murine coronavirus known as mouse hepatitis virus (MHV) causes acute hepatitis in its natural host and provides a useful model for understanding virus interaction with liver cells.  The MHV accessory protein, ns2, antagonizes the type I interferon response and promotes hepatitis.  We show that ns2 has 2',5'-phosphodiesterase activity, which blocks the interferon inducible 2',5'-oligoadenylate synthetase (OAS)-RNase L pathway to facilitate hepatitis development.  Ns2 cleaves 2',5'-oligoadenylate, the product of OAS, to prevent activation of the cellular endoribonuclease RNase L and consequently block viral RNA degrdn.  An ns2 mutant virus was unable to replicate in the liver or induce hepatitis in wild-type mice, but was highly pathogenic in RNase L deficient mice.  Thus, RNase L is a crit. cellular factor for protection against viral infection of the liver and the resulting hepatitis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZE4VGIhUHLVg90H21EOLACvtfcHk0liJhScxBTsYWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XosFCjuro%253D&md5=7417b0b387719d0d3d0ada997e695abf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.chom.2012.04.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chom.2012.04.011%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DJha%26aufirst%3DB.%2BK.%26aulast%3DWu%26aufirst%3DA.%26aulast%3DElliott%26aufirst%3DR.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DSilverman%26aufirst%3DR.%2BH.%26aulast%3DWeiss%26aufirst%3DS.%2BR.%26atitle%3DAntagonism%2520of%2520the%2520Interferon-Induced%2520OAS-RNase%2520L%2520Pathway%2520by%2520Murine%2520Coronavirus%2520Ns2%2520Protein%2520Is%2520Required%2520for%2520Virus%2520Replication%2520and%2520Liver%2520Pathology%26jtitle%3DCell%2520Host%2520Microbe%26date%3D2012%26volume%3D11%26spage%3D607%26epage%3D616%26doi%3D10.1016%2Fj.chom.2012.04.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freitas, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Durie, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tripp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S. D.</span></span> <span> </span><span class="NLM_article-title">Characterization and Noncovalent Inhibition of the Deubiquitinase and DeISGylase Activity of SARS-CoV-2 Papain-Like Protease</span>. <i>ACS Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2099</span>â <span class="NLM_lpage">2109</span>, <span class="refDoi">Â DOI: 10.1021/acsinfecdis.0c00168</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsinfecdis.0c00168" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpslylsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2020&pages=2099-2109&author=B.+T.+Freitasauthor=I.+A.+Durieauthor=J.+Murrayauthor=J.+E.+Longoauthor=H.+C.+Millerauthor=D.+Crichauthor=R.+J.+Hoganauthor=R.+A.+Trippauthor=S.+D.+Pegan&title=Characterization+and+Noncovalent+Inhibition+of+the+Deubiquitinase+and+DeISGylase+Activity+of+SARS-CoV-2+Papain-Like+Protease&doi=10.1021%2Facsinfecdis.0c00168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease</span></div><div class="casAuthors">Freitas, Brendan T.; Durie, Ian A.; Murray, Jackelyn; Longo, Jaron E.; Miller, Holden C.; Crich, David; Hogan, Robert Jeff; Tripp, Ralph A.; Pegan, Scott D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Infectious Diseases</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2099-2109</span>CODEN:
                <span class="NLM_cas:coden">AIDCBC</span>;
        ISSN:<span class="NLM_cas:issn">2373-8227</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent for COVID-19, is a novel human betacoronavirus that is rapidly spreading worldwide.  The outbreak currently includes over 3.7 million cases and 260,000 fatalities.  As a betacoronavirus, SARS-CoV-2 encodes for a papain-like protease (PLpro) that is likely responsible for cleavage of the coronavirus (CoV) viral polypeptide.  The PLpro is also responsible for suppression of host innate immune responses by virtue of its ability to reverse host ubiquitination and ISGylation events.  Here, the biochem. activity of SARS-CoV-2 PLpro against ubiquitin (Ub) and interferon-stimulated gene product 15 (ISG15) substrates is evaluated, revealing that the protease has a marked redn. in its ability to process K48 linked Ub substrates compared to its counterpart in SARS-CoV.  Addnl., its substrate activity more closely mirrors that of the PLpro from the Middle East respiratory syndrome coronavirus and prefers ISG15s from certain species including humans.  Addnl., naphthalene based PLpro inhibitors are shown to be effective at halting SARS-CoV-2 PLpro activity as well as SARS-CoV-2 replication.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrtEvK1olMlrVg90H21EOLACvtfcHk0liJhScxBTsYWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpslylsbs%253D&md5=314ea59a92d60345f982e78e31e5b569</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facsinfecdis.0c00168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsinfecdis.0c00168%26sid%3Dliteratum%253Aachs%26aulast%3DFreitas%26aufirst%3DB.%2BT.%26aulast%3DDurie%26aufirst%3DI.%2BA.%26aulast%3DMurray%26aufirst%3DJ.%26aulast%3DLongo%26aufirst%3DJ.%2BE.%26aulast%3DMiller%26aufirst%3DH.%2BC.%26aulast%3DCrich%26aufirst%3DD.%26aulast%3DHogan%26aufirst%3DR.%2BJ.%26aulast%3DTripp%26aufirst%3DR.%2BA.%26aulast%3DPegan%26aufirst%3DS.%2BD.%26atitle%3DCharacterization%2520and%2520Noncovalent%2520Inhibition%2520of%2520the%2520Deubiquitinase%2520and%2520DeISGylase%2520Activity%2520of%2520SARS-CoV-2%2520Papain-Like%2520Protease%26jtitle%3DACS%2520Infect.%2520Dis.%26date%3D2020%26volume%3D6%26spage%3D2099%26epage%3D2109%26doi%3D10.1021%2Facsinfecdis.0c00168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span>; <span class="NLM_string-name">Lokugamage, K. G.</span>; <span class="NLM_string-name">Makino, S.</span></span> <span> </span><span class="NLM_article-title">Viral and Cellular MRNA Translation in Coronavirus-Infected Cells</span>. In  <i>Advances in Virus Research</i>; <span class="NLM_publisher-name">Academic Press</span>, <span class="NLM_year">2016</span>; Vol.  <span class="NLM_volume">96</span>, pp  <span class="NLM_fpage">165</span>â <span class="NLM_lpage">192</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=165-192&author=K.+Nakagawa&author=K.+G.+Lokugamage&author=S.+Makino&title=Advances+in+Virus+Research"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DNakagawa%26aufirst%3DK.%26atitle%3DViral%2520and%2520Cellular%2520MRNA%2520Translation%2520in%2520Coronavirus-Infected%2520Cells%26btitle%3DAdvances%2520in%2520Virus%2520Research%26pub%3DAcademic%2520Press%26date%3D2016%26volume%3D96%26spage%3D165%26epage%3D192" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curth, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drosten, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauerhering, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Becker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rox, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of SARS-CoV-2 Main Protease Provides a Basis for Design of Improved a-Ketoamide Inhibitors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">409</span>â <span class="NLM_lpage">412</span>, <span class="refDoi">Â DOI: 10.1126/science.abb3405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb3405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32198291" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnslKrtL8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=409-412&author=L.+Zhangauthor=D.+Linauthor=X.+Sunauthor=U.+Curthauthor=C.+Drostenauthor=L.+Sauerheringauthor=S.+Beckerauthor=K.+Roxauthor=R.+Hilgenfeld&title=Crystal+Structure+of+SARS-CoV-2+Main+Protease+Provides+a+Basis+for+Design+of+Improved+a-Ketoamide+Inhibitors&doi=10.1126%2Fscience.abb3405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved Î±-ketoamide inhibitors</span></div><div class="casAuthors">Zhang, Linlin; Lin, Daizong; Sun, Xinyuanyuan; Curth, Ute; Drosten, Christian; Sauerhering, Lucie; Becker, Stephan; Rox, Katharina; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6489</span>),
    <span class="NLM_cas:pages">409-412</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is a global health emergency.  An attractive drug target among coronaviruses is the main protease (Mpro, also called 3CLpro) because of its essential role in processing the polyproteins that are translated from the viral RNA.  We report the x-ray structures of the unliganded SARS-CoV-2 Mpro and its complex with an Î±-ketoamide inhibitor.  This was derived from a previously designed inhibitor but with the P3-P2 amide bond incorporated into a pyridone ring to enhance the half-life of the compd. in plasma.  On the basis of the unliganded structure, we developed the lead compd. into a potent inhibitor of the SARS-CoV-2 Mpro.  The pharmacokinetic characterization of the optimized inhibitor reveals a pronounced lung tropism and suitability for administration by the inhalative route.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrT531N47m4BbVg90H21EOLACvtfcHk0liJhScxBTsYWQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnslKrtL8%253D&md5=9ac417c20f54c3327f9de9088b512d52</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb3405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb3405%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DCurth%26aufirst%3DU.%26aulast%3DDrosten%26aufirst%3DC.%26aulast%3DSauerhering%26aufirst%3DL.%26aulast%3DBecker%26aufirst%3DS.%26aulast%3DRox%26aufirst%3DK.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DCrystal%2520Structure%2520of%2520SARS-CoV-2%2520Main%2520Protease%2520Provides%2520a%2520Basis%2520for%2520Design%2520of%2520Improved%2520a-Ketoamide%2520Inhibitors%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D409%26epage%3D412%26doi%3D10.1126%2Fscience.abb3405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschueren, K. H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigalke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heisen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesters, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">PH-Dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-Ray Structure Analyses</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">25</span>â <span class="NLM_lpage">40</span>, <span class="refDoi">Â DOI: 10.1016/j.jmb.2005.09.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jmb.2005.09.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16242152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsL7I" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2005&pages=25-40&author=J.+Tanauthor=K.+H.+G.+Verschuerenauthor=K.+Anandauthor=J.+Shenauthor=M.+Yangauthor=Y.+Xuauthor=Z.+Raoauthor=J.+Bigalkeauthor=B.+Heisenauthor=J.+R.+Mestersauthor=K.+Chenauthor=X.+Shenauthor=H.+Jiangauthor=R.+Hilgenfeld&title=PH-Dependent+Conformational+Flexibility+of+the+SARS-CoV+Main+Proteinase+%28Mpro%29+Dimer%3A+Molecular+Dynamics+Simulations+and+Multiple+X-Ray+Structure+Analyses&doi=10.1016%2Fj.jmb.2005.09.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">pH-dependent Conformational Flexibility of the SARS-CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and Multiple X-ray Structure Analyses</span></div><div class="casAuthors">Tan, Jinzhi; Verschueren, Koen H. G.; Anand, Kanchan; Shen, Jianhua; Yang, Maojun; Xu, Yechun; Rao, Zihe; Bigalke, Janna; Heisen, Burkhard; Mesters, Jeroen R.; Chen, Kaixian; Shen, Xu; Jiang, Hualiang; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-40</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The SARS coronavirus main proteinase (Mpro) is a key enzyme in the processing of the viral polyproteins and thus an attractive target for the discovery of drugs directed against SARS.  The enzyme has been shown by x-ray crystallog. to undergo significant pH-dependent conformational changes.  Here, we assess the conformational flexibility of the Mpro by anal. of multiple crystal structures (including two new crystal forms) and by mol. dynamics (MD) calcns.  The MD simulations take into account the different protonation states of two histidine residues in the substrate-binding site and explain the pH-activity profile of the enzyme.  The low enzymic activity of the Mpro monomer and the need for dimerization are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQ5RJ00EWJ7bVg90H21EOLACvtfcHk0lj82S6sN4CkwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFKmsL7I&md5=38db21c716511e9322d97efb85c52a0e</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2005.09.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2005.09.012%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DVerschueren%26aufirst%3DK.%2BH.%2BG.%26aulast%3DAnand%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DBigalke%26aufirst%3DJ.%26aulast%3DHeisen%26aufirst%3DB.%26aulast%3DMesters%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DShen%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DPH-Dependent%2520Conformational%2520Flexibility%2520of%2520the%2520SARS-CoV%2520Main%2520Proteinase%2520%2528Mpro%2529%2520Dimer%253A%2520Molecular%2520Dynamics%2520Simulations%2520and%2520Multiple%2520X-Ray%2520Structure%2520Analyses%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2005%26volume%3D354%26spage%3D25%26epage%3D40%26doi%3D10.1016%2Fj.jmb.2005.09.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">1637</span>â <span class="NLM_lpage">1642</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M310875200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.M310875200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14561748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisF2gsQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=1637-1642&author=K.+Fanauthor=P.+Weiauthor=Q.+Fengauthor=S.+Chenauthor=C.+Huangauthor=L.+Maauthor=B.+Laiauthor=J.+Peiauthor=Y.+Liuauthor=J.+Chenauthor=L.+Lai&title=Biosynthesis%2C+Purification%2C+and+Substrate+Specificity+of+Severe+Acute+Respiratory+Syndrome+Coronavirus+3C-like+Proteinase&doi=10.1074%2Fjbc.M310875200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Biosynthesis, Purification, and Substrate Specificity of Severe Acute Respiratory Syndrome Coronavirus 3C-like Proteinase</span></div><div class="casAuthors">Fan, Keqiang; Wei, Ping; Feng, Qian; Chen, Sidi; Huang, Changkang; Ma, Liang; Lai, Bing; Pei, Jianfeng; Liu, Ying; Chen, Jianguo; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1637-1642</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The 3C-like proteinase of severe acute respiratory syndrome (SARS) coronavirus has been proposed to be a key target for structural-based drug design against SARS.  In order to understand the active form and the substrate specificity of the enzyme, we have cloned, expressed, and purified SARS 3C-like proteinase.  Analytic gel filtration shows a mixt. of monomer and dimer at a protein concn. of 4 mg/mL and mostly monomer at 0.2 mg/mL, which correspond to the concn. used in the enzyme assays.  The linear decrease of the enzymic-specific activity with the decrease of enzyme concn. revealed that only the dimeric form is active and the dimeric interface could be targeted for structural-based drug design against SARS 3C-like proteinase.  By using a high pressure liq. chromatog. assay, SARS 3C-like proteinase was shown to cut the 11 peptides covering all of the 11 cleavage sites on the viral polyprotein with different efficiency.  The two peptides corresponding to the two self-cleavage sites are the two with highest cleavage efficiency, whereas peptides with non-canonical residues at P2 or P1' positions react slower.  The P2 position of the substrates seems to favor large hydrophobic residues.  Secondary structure studies for the peptide substrates revealed that substrates with more Î²-sheetlike structure tend to react fast.  This study provides a basic understanding of the enzyme catalysis and a full substrate specificity spectrum for SARS 3C-like proteinase, which are helpful for structural-based inhibitor design against SARS and other coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM1N-CzXh2trVg90H21EOLACvtfcHk0lj82S6sN4CkwQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisF2gsQ%253D%253D&md5=ead84667c200117a64213a6baac25214</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M310875200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M310875200%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DK.%26aulast%3DWei%26aufirst%3DP.%26aulast%3DFeng%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DMa%26aufirst%3DL.%26aulast%3DLai%26aufirst%3DB.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DBiosynthesis%252C%2520Purification%252C%2520and%2520Substrate%2520Specificity%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25203C-like%2520Proteinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D1637%26epage%3D1642%26doi%3D10.1074%2Fjbc.M310875200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span> <span> </span><span class="NLM_article-title">Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme. Defining the Extra Domain as a New Target for Design of Highly Specific Protease Inhibitors</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">24765</span>â <span class="NLM_lpage">24773</span>, <span class="refDoi">Â DOI: 10.1074/jbc.M311744200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.M311744200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=15037623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksV2iu7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=24765-24773&author=J.+Shiauthor=Z.+Weiauthor=J.+Song&title=Dissection+Study+on+the+Severe+Acute+Respiratory+Syndrome+3C-like+Protease+Reveals+the+Critical+Role+of+the+Extra+Domain+in+Dimerization+of+the+Enzyme.+Defining+the+Extra+Domain+as+a+New+Target+for+Design+of+Highly+Specific+Protease+Inhibitors&doi=10.1074%2Fjbc.M311744200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Dissection Study on the Severe Acute Respiratory Syndrome 3C-like Protease Reveals the Critical Role of the Extra Domain in Dimerization of the Enzyme: Defining the extra domain as a new target for design of highly specific protease inhibitors</span></div><div class="casAuthors">Shi, Jiahai; Wei, Zheng; Song, Jianxing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">24765-24773</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome (SARS) 3C-like protease consists of two distinct folds, namely the N-terminal chymotrypsin fold contg. the domains I and II hosting the complete catalytic machinery and the C-terminal extra helical domain III unique for the coronavirus 3CL proteases.  Previously the functional role of this extra domain has been completely unknown, and it was believed that the coronavirus 3CL proteases share the same enzymic mechanism with picornavirus 3C proteases, which contain the chymotrypsin fold but have no extra domain.  To understand the functional role of the extra domain and to characterize the enzyme-substrate interactions by use of the dynamic light scattering, CD, and NMR spectroscopy, we (1) dissected the full-length SARS 3CL protease into two distinct folds and subsequently investigated their structural and dimerization properties and (2) studied the structural and binding interactions of three substrate peptides with the entire enzyme and its two dissected folds.  The results lead to several findings; (1) although two dissected parts folded into the native-like structures, the chymotrypsin fold only had weak activity as compared with the entire enzyme, and (2) although the chymotrypsin fold remained a monomer within a wide range of protein concns., the extra domain existed as a stable dimer even at a very low concn.  This observation strongly indicates that the extra domain contributes to the dimerization of the SARS 3CL protease, thus, switching the enzyme from the inactive form (monomer) to the active form (dimer).  This discovery not only separates the coronavirus 3CL protease from the picornavirus 3C protease in terms of the enzymic mechanism but also defines the dimerization interface on the extra helical domain as a new target for design of the specific protease inhibitors.  Furthermore, the detn. of the preferred soln. conformation of the substrate peptide S1 together with the NMR differential line-broadening and transferred nuclear Overhauser enhancement study allows us to pinpoint the bound structure of the S1 peptide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUDKFqysiYzLVg90H21EOLACvtfcHk0lgC_Qxh2MRPTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksV2iu7o%253D&md5=84829ea4faca1439c26815246f22528b</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311744200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311744200%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DJ.%26atitle%3DDissection%2520Study%2520on%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%25203C-like%2520Protease%2520Reveals%2520the%2520Critical%2520Role%2520of%2520the%2520Extra%2520Domain%2520in%2520Dimerization%2520of%2520the%2520Enzyme.%2520Defining%2520the%2520Extra%2520Domain%2520as%2520a%2520New%2520Target%2520for%2520Design%2520of%2520Highly%2520Specific%2520Protease%2520Inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D24765%26epage%3D24773%26doi%3D10.1074%2Fjbc.M311744200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. T. A.</span></span> <span> </span><span class="NLM_article-title">Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3â²- Digallate (TF3)</span>. <i>Evidence-based Complement. Altern. Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">209</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1093/ecam/neh081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fecam%2Fneh081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=15937562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC2sbotVGjtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=209-215&author=C.+N.+Chenauthor=C.+P.+C.+Linauthor=K.+K.+Huangauthor=W.+C.+Chenauthor=H.+P.+Hsiehauthor=P.+H.+Liangauthor=J.+T.+A.+Hsu&title=Inhibition+of+SARS-CoV+3C-like+Protease+Activity+by+Theaflavin-3%2C3%E2%80%B2-+Digallate+%28TF3%29&doi=10.1093%2Fecam%2Fneh081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3'-digallate (TF3)</span></div><div class="casAuthors">Chen Chia-Nan; Lin Coney P C; Huang Kuo-Kuei; Chen Wei-Cheng; Hsieh Hsin-Pang; Liang Po-Huang; Hsu John T-A</div><div class="citationInfo"><span class="NLM_cas:title">Evidence-based complementary and alternative medicine : eCAM</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-215</span>
        ISSN:<span class="NLM_cas:issn">1741-427X</span>.
    </div><div class="casAbstract">SARS-CoV is the causative agent of severe acute respiratory syndrome (SARS).  The virally encoded 3C-like protease (3CL(Pro)) has been presumed critical for the viral replication of SARS-CoV in infected host cells.  In this study, we screened a natural product library consisting of 720 compounds for inhibitory activity against 3CL(Pro).  Two compounds in the library were found to be inhibitive: tannic acid (IC(50) = 3 microM) and 3-isotheaflavin-3-gallate (TF2B) (IC(50) = 7 microM).  These two compounds belong to a group of natural polyphenols found in tea.  We further investigated the 3CL(Pro)-inhibitory activity of extracts from several different types of teas, including green tea, oolong tea, Puer tea and black tea.  Our results indicated that extracts from Puer and black tea were more potent than that from green or oolong teas in their inhibitory activities against 3CL(Pro).  Several other known compositions in teas were also evaluated for their activities in inhibiting 3CL(Pro).  We found that caffeine, (-)-epigallocatechin gallte (EGCg), epicatechin (EC), theophylline (TP), catechin (C), epicatechin gallate (ECg) and epigallocatechin (EGC) did not inhibit 3CL(Pro) activity.  Only theaflavin-3,3'-digallate (TF3) was found to be a 3CL(Pro) inhibitor.  This study has resulted in the identification of new compounds that are effective 3CL(Pro) inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcReGZlkwH5z_Awxfk_AGB-EfW6udTcc2eaMVrdQygj_Abntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sbotVGjtg%253D%253D&md5=308c27b8dec804c91fde2ed84dd39478</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1093%2Fecam%2Fneh081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fecam%252Fneh081%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%2BN.%26aulast%3DLin%26aufirst%3DC.%2BP.%2BC.%26aulast%3DHuang%26aufirst%3DK.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DHsieh%26aufirst%3DH.%2BP.%26aulast%3DLiang%26aufirst%3DP.%2BH.%26aulast%3DHsu%26aufirst%3DJ.%2BT.%2BA.%26atitle%3DInhibition%2520of%2520SARS-CoV%25203C-like%2520Protease%2520Activity%2520by%2520Theaflavin-3%252C3%25E2%2580%25B2-%2520Digallate%2520%2528TF3%2529%26jtitle%3DEvidence-based%2520Complement.%2520Altern.%2520Med.%26date%3D2005%26volume%3D2%26spage%3D209%26epage%3D215%26doi%3D10.1093%2Fecam%2Fneh081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>582</i></span>,  <span class="NLM_fpage">289</span>â <span class="NLM_lpage">293</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2223-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2223-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32272481" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=582&publication_year=2020&pages=289-293&author=Z.+Jinauthor=X.+Duauthor=Y.+Xuauthor=Y.+Dengauthor=M.+Liuauthor=Y.+Zhaoauthor=B.+Zhangauthor=X.+Liauthor=L.+Zhangauthor=C.+Pengauthor=Y.+Duanauthor=J.+Yuauthor=L.+Wangauthor=K.+Yangauthor=F.+Liuauthor=R.+Jiangauthor=X.+Yangauthor=T.+Youauthor=X.+Liuauthor=X.+Yangauthor=F.+Baiauthor=H.+Liuauthor=X.+Liuauthor=L.+W.+Guddatauthor=W.+Xuauthor=G.+Xiaoauthor=C.+Qinauthor=Z.+Shiauthor=H.+Jiangauthor=Z.+Raoauthor=H.+Yang&title=Structure+of+Mpro+from+SARS-CoV-2+and+Discovery+of+Its+Inhibitors&doi=10.1038%2Fs41586-020-2223-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors</span></div><div class="casAuthors">Jin, Zhenming; Du, Xiaoyu; Xu, Yechun; Deng, Yongqiang; Liu, Meiqin; Zhao, Yao; Zhang, Bing; Li, Xiaofeng; Zhang, Leike; Peng, Chao; Duan, Yinkai; Yu, Jing; Wang, Lin; Yang, Kailin; Liu, Fengjiang; Jiang, Rendi; Yang, Xinglou; You, Tian; Liu, Xiaoce; Yang, Xiuna; Bai, Fang; Liu, Hong; Liu, Xiang; Guddat, Luke W.; Xu, Wenqing; Xiao, Gengfu; Qin, Chengfeng; Shi, Zhengli; Jiang, Hualiang; Rao, Zihe; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">582</span>
        (<span class="NLM_cas:issue">7811</span>),
    <span class="NLM_cas:pages">289-293</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the etiol. agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19).  Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited.  Here, we describe the results of a program that aimed to rapidly discover lead compds. for clin. use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening.  This program focused on identifying drug leads that target main protease (Mpro) of SARS-CoV-2: Mpro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-2.  We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then detd. the crystal structure of Mpro of SARS-CoV-2 in complex with this compd.  Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compds.-including approved drugs, drug candidates in clin. trials and other pharmacol. active compds.-as inhibitors of Mpro.  Six of these compds. inhibited Mpro, showing half-maximal inhibitory concn. values that ranged from 0.67 to 21.4Î¼M.  One of these compds. (ebselen) also exhibited promising antiviral activity in cell-based assays.  Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clin. potential in response to new infectious diseases for which no specific drugs or vaccines are available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFupuh6WIyW7Vg90H21EOLACvtfcHk0lgC_Qxh2MRPTA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtVyhsrrO&md5=b84f350fe9ce1109485df6caf814ba82</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2223-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2223-y%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDeng%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DJiang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DYou%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DQin%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520Mpro%2520from%2520SARS-CoV-2%2520and%2520Discovery%2520of%2520Its%2520Inhibitors%26jtitle%3DNature%26date%3D2020%26volume%3D582%26spage%3D289%26epage%3D293%26doi%3D10.1038%2Fs41586-020-2223-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rut, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groborz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmudzinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drag, M.</span></span> <span> </span><span class="NLM_article-title">Substrate Specificity Profiling of SARS-CoV-2 Mpro Protease Provides Basis for Anti-COVID-19 Drug Design</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.03.07.981928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.03.07.981928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32511411" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+Rutauthor=K.+Groborzauthor=L.+Zhangauthor=X.+Sunauthor=M.+Zmudzinskiauthor=R.+Hilgenfeldauthor=M.+Drag&title=Substrate+Specificity+Profiling+of+SARS-CoV-2+Mpro+Protease+Provides+Basis+for+Anti-COVID-19+Drug+Design&doi=10.1101%2F2020.03.07.981928"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1101%2F2020.03.07.981928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.03.07.981928%26sid%3Dliteratum%253Aachs%26aulast%3DRut%26aufirst%3DW.%26aulast%3DGroborz%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DZmudzinski%26aufirst%3DM.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DDrag%26aufirst%3DM.%26atitle%3DSubstrate%2520Specificity%2520Profiling%2520of%2520SARS-CoV-2%2520Mpro%2520Protease%2520Provides%2520Basis%2520for%2520Anti-COVID-19%2520Drug%2520Design%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.03.07.981928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusov, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nian, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von Brunn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanko, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wilde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4562</span>â <span class="NLM_lpage">4578</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.9b01828</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01828" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXivValt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4562-4578&author=L.+Zhangauthor=D.+Linauthor=Y.+Kusovauthor=Y.+Nianauthor=Q.+Maauthor=J.+Wangauthor=A.+Von+Brunnauthor=P.+Leyssenauthor=K.+Lankoauthor=J.+Neytsauthor=A.+De+Wildeauthor=E.+J.+Snijderauthor=H.+Liuauthor=R.+Hilgenfeld&title=%CE%B1-Ketoamides+as+Broad-Spectrum+Inhibitors+of+Coronavirus+and+Enterovirus+Replication%3A+Structure-Based+Design%2C+Synthesis%2C+and+Activity+Assessment&doi=10.1021%2Facs.jmedchem.9b01828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Î±-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment</span></div><div class="casAuthors">Zhang, Linlin; Lin, Daizong; Kusov, Yuri; Nian, Yong; Ma, Qingjun; Wang, Jiang; von Brunn, Albrecht; Leyssen, Pieter; Lanko, Kristina; Neyts, Johan; de Wilde, Adriaan; Snijder, Eric J.; Liu, Hong; Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4562-4578</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The main protease of coronaviruses and the 3C protease of enteroviruses share a similar active-site architecture and a unique requirement for glutamine in the P1 position of the substrate.  Because of their unique specificity and essential role in viral polyprotein processing, these proteases are suitable targets for the development of antiviral drugs.  In order to obtain near-equipotent, broad-spectrum antivirals against alphacoronaviruses, betacoronaviruses, and enteroviruses, we pursued structure-based design of peptidomimetic Î±-ketoamides as inhibitors of main and 3C proteases.  Six crystal structures of protease:inhibitor complexes were detd. as part of this study.  Compds. synthesized were tested against the recombinant proteases as well as in viral replicons and virus-infected cell cultures; most of them were not cell-toxic.  Optimization of the P2 substituent of the Î±-ketoamides proved crucial for achieving near-equipotency against the three virus genera.  The best near-equipotent inhibitors, (I) [R1 = cyclopentylmethyl (P2) and R1 = cyclohexylmethyl (P2)], display low-micromolar EC50 values against enteroviruses, alphacoronaviruses, and betacoronaviruses in cell cultures.  In Huh7 cells, I [R1 = cyclohexylmethyl (P2)] exhibits three-digit picomolar activity against Middle East Respiratory Syndrome coronavirus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWpcfl4wTRLLVg90H21EOLACvtfcHk0lgscj3HbbQK3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXivValt7o%253D&md5=60d91a8ecf916856a844d835ecf84d5f</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01828%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLin%26aufirst%3DD.%26aulast%3DKusov%26aufirst%3DY.%26aulast%3DNian%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DVon%2BBrunn%26aufirst%3DA.%26aulast%3DLeyssen%26aufirst%3DP.%26aulast%3DLanko%26aufirst%3DK.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3DDe%2BWilde%26aufirst%3DA.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3D%25CE%25B1-Ketoamides%2520as%2520Broad-Spectrum%2520Inhibitors%2520of%2520Coronavirus%2520and%2520Enterovirus%2520Replication%253A%2520Structure-Based%2520Design%252C%2520Synthesis%252C%2520and%2520Activity%2520Assessment%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4562%26epage%3D4578%26doi%3D10.1021%2Facs.jmedchem.9b01828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiew, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandadapu, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alliston, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-O.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antivirals against 3C or 3C-Like Proteases of Picornaviruses, Noroviruses, and Coronaviruses</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">11754</span>â <span class="NLM_lpage">11762</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01348-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01348-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22915796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFCmur3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2012&pages=11754-11762&author=Y.+Kimauthor=S.+Lovellauthor=K.-C.+Tiewauthor=S.+R.+Mandadapuauthor=K.+R.+Allistonauthor=K.+P.+Battaileauthor=W.+C.+Groutasauthor=K.-O.+Chang&title=Broad-Spectrum+Antivirals+against+3C+or+3C-Like+Proteases+of+Picornaviruses%2C+Noroviruses%2C+and+Coronaviruses&doi=10.1128%2FJVI.01348-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses</span></div><div class="casAuthors">Kim, Yunjeong; Lovell, Scott; Tiew, Kok-Chuan; Mandadapu, Sivakoteswara Rao; Alliston, Kevin R.; Battaile, Kevin P.; Groutas, William C.; Chang, Kyeong-Ok</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">86</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">11754-11762</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Phylogenetic anal. has demonstrated that some pos.-sense RNA viruses can be classified into the picornavirus-like super-cluster, which includes picornaviruses, caliciviruses, and coronaviruses.  These viruses possess 3C or 3C-like proteases (3Cpro or 3CLpro, resp.), which contain a typical chymotrypsin-like fold and a catalytic triad (or dyad) with a Cys residue as a nucleophile.  The conserved key sites of 3Cpro or 3CLpro may serve as attractive targets for the design of broad-spectrum antivirals for multiple viruses in the supercluster.  We previously reported the structure-based design and synthesis of potent protease inhibitors of Norwalk virus (NV), a member of the Caliciviridae family.  We report herein the broad-spectrum antiviral activities of three compds. possessing a common dipeptidyl residue with different warheads, i.e., an aldehyde (GC373), a bisulfite adduct (GC376), and an Î±-ketoamide (GC375), against viruses that belong to the supercluster.  All compds. were highly effective against the majority of tested viruses, with half-maximal inhibitory concns. in the high nanomolar or low micromolar range in enzyme- and/or cell-based assays and with high therapeutic indexes.  We also report the high-resoln. X-ray cocrystal structures of NV 3CLpro-, poliovirus 3Cpro-, and transmissible gastroenteritis virus 3CLpro- GC376 inhibitor complexes, which show the compd. covalently bound to a nucleophilic Cys residue in the catalytic site of the corresponding protease.  We conclude that these compds. have the potential to be developed as antiviral therapeutics aimed at a single virus or multiple viruses in the picornavirus-like supercluster by targeting 3Cpro or 3CLpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDn4MUH7bIlLVg90H21EOLACvtfcHk0lgscj3HbbQK3Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFCmur3M&md5=c7fe984b52490199a2c2ef333c22fb98</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1128%2FJVI.01348-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01348-12%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DTiew%26aufirst%3DK.-C.%26aulast%3DMandadapu%26aufirst%3DS.%2BR.%26aulast%3DAlliston%26aufirst%3DK.%2BR.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.-O.%26atitle%3DBroad-Spectrum%2520Antivirals%2520against%25203C%2520or%25203C-Like%2520Proteases%2520of%2520Picornaviruses%252C%2520Noroviruses%252C%2520and%2520Coronaviruses%26jtitle%3DJ.%2520Virol.%26date%3D2012%26volume%3D86%26spage%3D11754%26epage%3D11762%26doi%3D10.1128%2FJVI.01348-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gwaltney, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi-Burris, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gersten, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsyu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patick, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zalman, L. S.</span></span> <span> </span><span class="NLM_article-title">Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">3907</span>â <span class="NLM_lpage">3916</span>, <span class="refDoi">Â DOI: 10.1128/AAC.47.12.3907-3916.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.47.12.3907-3916.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14638501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpsV2nu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2003&pages=3907-3916&author=F.+G.+Haydenauthor=R.+B.+Turnerauthor=J.+M.+Gwaltneyauthor=K.+Chi-Burrisauthor=M.+Gerstenauthor=P.+Hsyuauthor=A.+K.+Patickauthor=G.+J.+Smithauthor=L.+S.+Zalman&title=Phase+II%2C+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Studies+of+Ruprintrivir+Nasal+Spray+2-Percent+Suspension+for+Prevention+and+Treatment+of+Experimentally+Induced+Rhinovirus+Colds+in+Healthy+Volunteers&doi=10.1128%2FAAC.47.12.3907-3916.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2% suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers</span></div><div class="casAuthors">Hayden, Frederick G.; Turner, Ronald B.; Gwaltney, Jack M.; Chi-burris, Kathy; Gersten, Merril; Hsyu, Poe; Patick, Amy K.; Smith, George J., III; Zalman, Leora S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3907-3916</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Human rhinovirus (HRV) infections are usually self-limited but may be assocd. with serious consequences, particularly in those with asthma and chronic respiratory disease.  Effective antiviral agents are needed for preventing and treating HRV illnesses.  Ruprintrivir (Agouron Pharmaceuticals, Inc., San Diego, Calif.) selectively inhibits HRV 3C protease and shows potent, broad-spectrum anti-HRV activity in vitro.  We conducted three double-blind, placebo-controlled clin. trials in 202 healthy volunteers to assess the activity of ruprintrivir in exptl. HRV infection.  Subjects were randomized to receive intranasal ruprintrivir (8 mg) or placebo sprays as prophylaxis (two or five times daily [2Ã/day or 5Ã/day] for 5 days) starting 6 h before infection or as treatment (5Ã/day for 4 days) starting 24 h after infection.  Ruprintrivir prophylaxis reduced the proportion of subjects with pos. viral cultures (for 5Ã/day dosing groups, 44% for ruprintrivir treatment group vs. 70% for placebo treatment group [P = 0.03]; for 2Ã/day dosing groups, 60% for ruprintrivir group vs. 92% for placebo group [P = 0.004]) and viral titers but did not decrease the frequency of colds.  Ruprintrivir treatment reduced the mean total daily symptom score (2.2 for ruprintrivir treatment group and 3.3 for the placebo treatment group [P = 0.014]) by 33%.  Secondary endpoints, including viral titers, individual symptom scores, and nasal discharge wts., were also reduced by ruprintrivir treatment.  Overall, ruprintrivir was well tolerated; blood-tinged mucus and nasal passage irritation were the most common adverse effects reported.  Pharmacokinetic anal. of plasma and nasal ruprintrivir concns. revealed intranasal drug residence with minimal systemic absorption.  Results from these studies in exptl. rhinoviral infection support continued investigation of intranasal ruprintrivir in the setting of natural HRV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoudaxRiBJLg7Vg90H21EOLACvtfcHk0lhl2XJgPM4vJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpsV2nu7w%253D&md5=6d6c33f56af0c4f45145b291ace2dba1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1128%2FAAC.47.12.3907-3916.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.47.12.3907-3916.2003%26sid%3Dliteratum%253Aachs%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DTurner%26aufirst%3DR.%2BB.%26aulast%3DGwaltney%26aufirst%3DJ.%2BM.%26aulast%3DChi-Burris%26aufirst%3DK.%26aulast%3DGersten%26aufirst%3DM.%26aulast%3DHsyu%26aufirst%3DP.%26aulast%3DPatick%26aufirst%3DA.%2BK.%26aulast%3DSmith%26aufirst%3DG.%2BJ.%26aulast%3DZalman%26aufirst%3DL.%2BS.%26atitle%3DPhase%2520II%252C%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Studies%2520of%2520Ruprintrivir%2520Nasal%2520Spray%25202-Percent%2520Suspension%2520for%2520Prevention%2520and%2520Treatment%2520of%2520Experimentally%2520Induced%2520Rhinovirus%2520Colds%2520in%2520Healthy%2520Volunteers%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2003%26volume%3D47%26spage%3D3907%26epage%3D3916%26doi%3D10.1128%2FAAC.47.12.3907-3916.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pillaiyar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manickam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Namasivayam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, S. H.</span></span> <span> </span><span class="NLM_article-title">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6595</span>â <span class="NLM_lpage">6628</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.5b01461</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01461" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=6595-6628&author=T.+Pillaiyarauthor=M.+Manickamauthor=V.+Namasivayamauthor=Y.+Hayashiauthor=S.+H.+Jung&title=An+Overview+of+Severe+Acute+Respiratory+Syndrome-Coronavirus+%28SARS-CoV%29+3CL+Protease+Inhibitors%3A+Peptidomimetics+and+Small+Molecule+Chemotherapy&doi=10.1021%2Facs.jmedchem.5b01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy</span></div><div class="casAuthors">Pillaiyar, Thanigaimalai; Manickam, Manoj; Namasivayam, Vigneshwaran; Hayashi, Yoshio; Jung, Sang-Hun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6595-6628</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10-15%) fatalities in 2003.  The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its viral protease, SARS-CoV 3CLpro, has been shown to be essential for replication and has hence been recognized as a potent drug target for SARS infection.  Currently, there is no effective treatment for this epidemic despite the intensive research that has been undertaken since 2003 (over 3500 publications).  This perspective focuses on the status of various efficacious anti-SARS-CoV 3CLpro chemotherapies discovered during the last 12 years (2003-2015) from all sources, including lab. synthetic methods, natural products, and virtual screening.  We describe here mainly peptidomimetic and small mol. inhibitors of SARS-CoV 3CLpro.  Attempts have been made to provide a complete description of the structural features and binding modes of these inhibitors under many conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoB_JCXe-m0RLVg90H21EOLACvtfcHk0lhl2XJgPM4vJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XisVyns7c%253D&md5=6ce37076204280f64a7f362633fcee1a</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01461%26sid%3Dliteratum%253Aachs%26aulast%3DPillaiyar%26aufirst%3DT.%26aulast%3DManickam%26aufirst%3DM.%26aulast%3DNamasivayam%26aufirst%3DV.%26aulast%3DHayashi%26aufirst%3DY.%26aulast%3DJung%26aufirst%3DS.%2BH.%26atitle%3DAn%2520Overview%2520of%2520Severe%2520Acute%2520Respiratory%2520Syndrome-Coronavirus%2520%2528SARS-CoV%2529%25203CL%2520Protease%2520Inhibitors%253A%2520Peptidomimetics%2520and%2520Small%2520Molecule%2520Chemotherapy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D6595%26epage%3D6628%26doi%3D10.1021%2Facs.jmedchem.5b01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwong, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauffman, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurter, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, P.</span></span> <span> </span><span class="NLM_article-title">Discovery and Development of Telaprevir: An NS3â4A Protease Inhibitor for Treating Genotype 1 Chronic Hepatitis C Virus</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">993</span>â <span class="NLM_lpage">1003</span>, <span class="refDoi">Â DOI: 10.1038/nbt.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnbt.2020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22068541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=993-1003&author=A.+D.+Kwongauthor=R.+S.+Kauffmanauthor=P.+Hurterauthor=P.+Mueller&title=Discovery+and+Development+of+Telaprevir%3A+An+NS3%E2%80%934A+Protease+Inhibitor+for+Treating+Genotype+1+Chronic+Hepatitis+C+Virus&doi=10.1038%2Fnbt.2020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus</span></div><div class="casAuthors">Kwong, Ann D.; Kauffman, Robert S.; Hurter, Patricia; Mueller, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">993-1003</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Infection with hepatitis C virus (HCV) is a major medical problem with over 170 million people infected worldwide.  Substantial morbidity and mortality are assocd. with hepatic manifestations (cirrhosis and hepatocellular carcinoma), which develop with increasing frequency in people infected with HCV for more than 20 years.  Less well known is the burden of HCV disease assocd. with extrahepatic manifestations (diabetes, B-cell proliferative disorders, depression, cognitive disorders, arthritis and Sjoegren's syndrome).  For patients infected with genotype 1 HCV, treatment with polyethylene glycol decorated interferon (peginterferon) Î± and ribavirin (PR) is assocd. with a low (40-50%) success rate, substantial treatment-limiting side effects and a long (48-wk) duration of treatment.  In the past 15 years, major scientific advances have enabled the development of new classes of HCV therapy, the direct-acting antiviral agents, also known as specifically targeted antiviral therapy for hepatitis C (STAT-C).  In combination with PR, the HCV NS3-4A protease inhibitor telaprevir has recently been approved for treatment of genotype 1 chronic HCV in the United States, Canada, European Union and Japan.  Compared with PR, telaprevir combination therapy offers significantly improved viral cure rates and the possibility of shortened treatment duration for diverse patient populations.  Developers of innovative drugs have to blaze a new path with few validated sign posts to guide the way.  Indeed, telaprevir's development was once put on hold because of its performance in a std. IC50 assay.  Data from new hypotheses and novel expts. were required to justify further investment and reduce risk that the drug might fail in the clinic.  In addn., the poor drug-like properties of telaprevir were a formidable hurdle, which the manufg. and formulation teams had to overcome to make the drug.  Finally, novel clin. trial designs were developed to improve efficacy and shorten treatment in parallel instead of sequentially.  Lessons learned from the development of telaprevir suggest that makers of innovative medicines cannot rely solely on traditional drug discovery metrics, but must develop innovative, scientifically guided pathways for success.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodUEHshXTAvbVg90H21EOLACvtfcHk0lhl2XJgPM4vJA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVCntLvJ&md5=952966419a2e72107550d0a63c337ae4</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.2020%26sid%3Dliteratum%253Aachs%26aulast%3DKwong%26aufirst%3DA.%2BD.%26aulast%3DKauffman%26aufirst%3DR.%2BS.%26aulast%3DHurter%26aufirst%3DP.%26aulast%3DMueller%26aufirst%3DP.%26atitle%3DDiscovery%2520and%2520Development%2520of%2520Telaprevir%253A%2520An%2520NS3%25E2%2580%25934A%2520Protease%2520Inhibitor%2520for%2520Treating%2520Genotype%25201%2520Chronic%2520Hepatitis%2520C%2520Virus%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D993%26epage%3D1003%26doi%3D10.1038%2Fnbt.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatraman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogen, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arasappan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jao, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parekh, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinto, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santhanam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vibulbhan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butkiewicz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agrawal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingravallo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pichardo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baroudy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malcolm, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prongay, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madison, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broske, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brisson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prelusky, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korfmacher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bogdanowich-Knipp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlovsky, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saksena, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwinski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Girijavallabhan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njoroge, F. G.</span></span> <span> </span><span class="NLM_article-title">Discovery of (1R,5S)-N-[3-Amino-1-(Cyclobutylmethyl)-2,3-Dioxopropyl]-3- [2(S)-[[[(1,1-Dimethylethyl)Amino]Carbonyl]Amino]-3,3-Dimethyl-1-Oxobutyl]-6, 6-Dimethyl-3-Azabicyclo[3.1.0]Hexan-2(S)-Carboxamide (SCH 503034), a Selective, Potent, Orally Bioavaila</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6074</span>â <span class="NLM_lpage">6086</span>, <span class="refDoi">Â DOI: 10.1021/jm060325b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060325b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6074-6086&author=S.+Venkatramanauthor=S.+L.+Bogenauthor=A.+Arasappanauthor=F.+Bennettauthor=K.+Chenauthor=E.+Jaoauthor=Y.+T.+Liuauthor=R.+Loveyauthor=S.+Hendrataauthor=Y.+Huangauthor=W.+Panauthor=T.+Parekhauthor=P.+Pintoauthor=V.+Popovauthor=R.+Pikeauthor=S.+Ruanauthor=B.+Santhanamauthor=B.+Vibulbhanauthor=W.+Wuauthor=W.+Yangauthor=J.+Kongauthor=X.+Liangauthor=J.+Wongauthor=R.+Liuauthor=N.+Butkiewiczauthor=R.+Chaseauthor=A.+Hartauthor=S.+Agrawalauthor=P.+Ingravalloauthor=J.+Pichardoauthor=R.+Kongauthor=B.+Baroudyauthor=B.+Malcolmauthor=Z.+Guoauthor=A.+Prongayauthor=V.+Madisonauthor=L.+Broskeauthor=X.+Cuiauthor=K.+C.+Chengauthor=Y.+Hsiehauthor=J.+M.+Brissonauthor=D.+Preluskyauthor=W.+Korfmacherauthor=R.+Whiteauthor=S.+Bogdanowich-Knippauthor=A.+Pavlovskyauthor=P.+Bradleyauthor=A.+K.+Saksenaauthor=A.+Gangulyauthor=J.+Piwinskiauthor=V.+Girijavallabhanauthor=F.+G.+Njoroge&title=Discovery+of+%281R%2C5S%29-N-%5B3-Amino-1-%28Cyclobutylmethyl%29-2%2C3-Dioxopropyl%5D-3-+%5B2%28S%29-%5B%5B%5B%281%2C1-Dimethylethyl%29Amino%5DCarbonyl%5DAmino%5D-3%2C3-Dimethyl-1-Oxobutyl%5D-6%2C+6-Dimethyl-3-Azabicyclo%5B3.1.0%5DHexan-2%28S%29-Carboxamide+%28SCH+503034%29%2C+a+Selective%2C+Potent%2C+Orally+Bioavaila&doi=10.1021%2Fjm060325b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection</span></div><div class="casAuthors">Venkatraman, Srikanth; Bogen, Stephane L.; Arasappan, Ashok; Bennett, Frank; Chen, Kevin; Jao, Edwin; Liu, Yi-Tsung; Lovey, Raymond; Hendrata, Siska; Huang, Yuhua; Pan, Weidong; Parekh, Tejal; Pinto, Patrick; Popov, Veljko; Pike, Russel; Ruan, Sumei; Santhanam, Bama; Vibulbhan, Bancha; Wu, Wanli; Yang, Weiying; Kong, Jianshe; Liang, Xiang; Wong, Jesse; Liu, Rong; Butkiewicz, Nancy; Chase, Robert; Hart, Andrea; Agrawal, Sony; Ingravallo, Paul; Pichardo, John; Kong, Rong; Baroudy, Bahige; Malcolm, Bruce; Guo, Zhuyan; Prongay, Andrew; Madison, Vincent; Broske, Lisa; Cui, Xiaoming; Cheng, Kuo-Chi; Hsieh, Tony Y.; Brisson, Jean-Marc; Prelusky, Danial; Korfmacher, Walter; White, Ronald; Bogdanowich-Knipp, Susan; Pavlovsky, Anastasia; Bradley, Prudence; Saksena, Anil K.; Ganguly, Ashit; Piwinski, John; Girijavallabhan, Viyyoor; Njoroge, F. George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6074-6086</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is the major cause of chronic liver disease, leading to cirrhosis and hepatocellular carcinoma, which affects more than 170 million people worldwide.  Currently the only therapeutic regimens are s.c. interferon-Î± or polyethylene glycol (PEG)-interferon-Î± alone or in combination with oral ribavirin.  Although combination therapy is reasonably successful with the majority of genotypes, its efficacy against the predominant genotype (genotype 1) is moderate at best, with only about 40% of the patients showing sustained virol. response.  Herein, the SAR leading to the discovery of SCH 503034 (I), a novel, potent, selective, orally bioavailable NS3 protease inhibitor that has been advanced to clin. trials in human beings for the treatment of hepatitis C viral infections is described.  X-ray structure of I complexed with the NS3 protease and biol. data are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjAR2KjtnJV7Vg90H21EOLACvtfcHk0lgrygCuBAMM1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlOlsLg%253D&md5=e48b2e2d3eb19f7f28aaa76f96d03414</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1021%2Fjm060325b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060325b%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatraman%26aufirst%3DS.%26aulast%3DBogen%26aufirst%3DS.%2BL.%26aulast%3DArasappan%26aufirst%3DA.%26aulast%3DBennett%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DJao%26aufirst%3DE.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DLovey%26aufirst%3DR.%26aulast%3DHendrata%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DPan%26aufirst%3DW.%26aulast%3DParekh%26aufirst%3DT.%26aulast%3DPinto%26aufirst%3DP.%26aulast%3DPopov%26aufirst%3DV.%26aulast%3DPike%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DSanthanam%26aufirst%3DB.%26aulast%3DVibulbhan%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DKong%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWong%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DButkiewicz%26aufirst%3DN.%26aulast%3DChase%26aufirst%3DR.%26aulast%3DHart%26aufirst%3DA.%26aulast%3DAgrawal%26aufirst%3DS.%26aulast%3DIngravallo%26aufirst%3DP.%26aulast%3DPichardo%26aufirst%3DJ.%26aulast%3DKong%26aufirst%3DR.%26aulast%3DBaroudy%26aufirst%3DB.%26aulast%3DMalcolm%26aufirst%3DB.%26aulast%3DGuo%26aufirst%3DZ.%26aulast%3DProngay%26aufirst%3DA.%26aulast%3DMadison%26aufirst%3DV.%26aulast%3DBroske%26aufirst%3DL.%26aulast%3DCui%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DK.%2BC.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DBrisson%26aufirst%3DJ.%2BM.%26aulast%3DPrelusky%26aufirst%3DD.%26aulast%3DKorfmacher%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%26aulast%3DBogdanowich-Knipp%26aufirst%3DS.%26aulast%3DPavlovsky%26aufirst%3DA.%26aulast%3DBradley%26aufirst%3DP.%26aulast%3DSaksena%26aufirst%3DA.%2BK.%26aulast%3DGanguly%26aufirst%3DA.%26aulast%3DPiwinski%26aufirst%3DJ.%26aulast%3DGirijavallabhan%26aufirst%3DV.%26aulast%3DNjoroge%26aufirst%3DF.%2BG.%26atitle%3DDiscovery%2520of%2520%25281R%252C5S%2529-N-%255B3-Amino-1-%2528Cyclobutylmethyl%2529-2%252C3-Dioxopropyl%255D-3-%2520%255B2%2528S%2529-%255B%255B%255B%25281%252C1-Dimethylethyl%2529Amino%255DCarbonyl%255DAmino%255D-3%252C3-Dimethyl-1-Oxobutyl%255D-6%252C%25206-Dimethyl-3-Azabicyclo%255B3.1.0%255DHexan-2%2528S%2529-Carboxamide%2520%2528SCH%2520503034%2529%252C%2520a%2520Selective%252C%2520Potent%252C%2520Orally%2520Bioavaila%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D6074%26epage%3D6086%26doi%3D10.1021%2Fjm060325b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boggild, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajic-Veljanoski, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald-Blumer, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridout, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tile, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Josse, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, A. M.</span></span> <span> </span><span class="NLM_article-title">Odanacatib for the Treatment of Osteoporosis</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">1717</span>â <span class="NLM_lpage">1726</span>, <span class="refDoi">Â DOI: 10.1517/14656566.2015.1064897</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1517%2F14656566.2015.1064897" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26149759" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyru7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=1717-1726&author=M.+K.+Boggildauthor=O.+Gajic-Veljanoskiauthor=H.+McDonald-Blumerauthor=R.+Ridoutauthor=L.+Tileauthor=R.+Josseauthor=A.+M.+Cheung&title=Odanacatib+for+the+Treatment+of+Osteoporosis&doi=10.1517%2F14656566.2015.1064897"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Odanacatib for the treatment of osteoporosis</span></div><div class="casAuthors">Boggild, Miranda K.; Gajic-Veljanoski, Olga; McDonald-Blumer, Heather; Ridout, Rowena; Tile, Lianne; Josse, Robert; Cheung, Angela M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1717-1726</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">Introduction: Osteoporosis and fragility fractures are important public health concerns.  Cathepsin K inhibitors, including odanacatib, are a novel class of medications for osteoporosis whose mechanism of action is to directly inhibit bone resorption without killing osteoclasts, thereby permitting the complex coupling between bone resorption and formation to continue.  Areas covered: The physiol. basis for the mechanism of action of cathepsin K inhibitors is covered in addn. to a review of the preclin., Phase I, Phase II and preliminary Phase III trial data of odanacatib.  Expert opinion: Evidence suggests that odanacatib has similar efficacy to bisphosphonates at increasing bone mineral d. and decreasing risk of fragility fractures.  Although odanacatib may preferentially inhibit bone resorption more than formation, the clin. significance of this difference in mechanism of action is not yet known.  A careful anal. of the Phase III trial data is needed with specific attention to adverse events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsg4VWIxbTXLVg90H21EOLACvtfcHk0lgrygCuBAMM1A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyru7jM&md5=44c4eda645f2550e5b62e42d9984e879</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1517%2F14656566.2015.1064897&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14656566.2015.1064897%26sid%3Dliteratum%253Aachs%26aulast%3DBoggild%26aufirst%3DM.%2BK.%26aulast%3DGajic-Veljanoski%26aufirst%3DO.%26aulast%3DMcDonald-Blumer%26aufirst%3DH.%26aulast%3DRidout%26aufirst%3DR.%26aulast%3DTile%26aufirst%3DL.%26aulast%3DJosse%26aufirst%3DR.%26aulast%3DCheung%26aufirst%3DA.%2BM.%26atitle%3DOdanacatib%2520for%2520the%2520Treatment%2520of%2520Osteoporosis%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2015%26volume%3D16%26spage%3D1717%26epage%3D1726%26doi%3D10.1517%2F14656566.2015.1064897" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span> <span> </span><span class="NLM_article-title">Development of Small-Molecule MERS-CoV Inhibitors</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">721</span>, <span class="refDoi">Â DOI: 10.3390/v10120721</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fv10120721" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=721&author=R.+Liangauthor=L.+Wangauthor=N.+Zhangauthor=X.+Dengauthor=M.+Suauthor=Y.+Suauthor=L.+Huauthor=C.+Heauthor=T.+Yingauthor=S.+Jiangauthor=F.+Yu&title=Development+of+Small-Molecule+MERS-CoV+Inhibitors&doi=10.3390%2Fv10120721"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Development of small-molecule MERS-CoV inhibitors</span></div><div class="casAuthors">Liang, Ruiying; Wang, Lili; Zhang, Naru; Deng, Xiaoqian; Su, Meng; Su, Yudan; Hu, Lanfang; He, Chen; Ying, Tianlei; Jiang, Shibo; Yu, Fei</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">721</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Middle East respiratory syndrome coronavirus (MERS-CoV) with potential to cause global pandemics remains a threat to the public health, security, and economy.  In this review, we focus on advances in the research and development of small-mol. MERS-CoV inhibitors targeting different stages of the MERS-CoV life cycle, aiming to prevent or treat MERS-CoV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqctTvasJSAE7Vg90H21EOLACvtfcHk0liYS-wEyKwx7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFehtrnK&md5=9250f51075255474d07a53bf2cf71bfb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.3390%2Fv10120721&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv10120721%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DL.%26aulast%3DHe%26aufirst%3DC.%26aulast%3DYing%26aufirst%3DT.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DF.%26atitle%3DDevelopment%2520of%2520Small-Molecule%2520MERS-CoV%2520Inhibitors%26jtitle%3DViruses%26date%3D2018%26volume%3D10%26spage%3D721%26doi%3D10.3390%2Fv10120721" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span> <span> </span><span class="NLM_article-title">From SARS to MERS: Crystallographic Studies on Coronaviral Proteases Enable Antiviral Drug Design</span>. <i>FEBS J.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>281</i></span>,  <span class="NLM_fpage">4085</span>â <span class="NLM_lpage">4096</span>, <span class="refDoi">Â DOI: 10.1111/febs.12936</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1111%2Ffebs.12936" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25039866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=2014&pages=4085-4096&author=R.+Hilgenfeld&title=From+SARS+to+MERS%3A+Crystallographic+Studies+on+Coronaviral+Proteases+Enable+Antiviral+Drug+Design&doi=10.1111%2Ffebs.12936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design</span></div><div class="casAuthors">Hilgenfeld, Rolf</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Journal</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4085-4096</span>CODEN:
                <span class="NLM_cas:coden">FJEOAC</span>;
        ISSN:<span class="NLM_cas:issn">1742-464X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Here, the author focuses on the important contributions that macromol. crystallog. has made over the past 12 yr to elucidating structures and mechanisms of the essential proteases of coronaviruses, the main protease (Mpro) and the papain-like protease (PLpro).  The role of x-ray crystallog. in structure-assisted drug discovery against these targets is discussed.  Aspects dealt with in this review include the emergence of the SARS coronavirus in 2002-2003 and of the MERS coronavirus 10 yr later and the origins of these viruses.  The crystal structure of the free SARS coronavirus Mpro and its dependence on pH is discussed, as are efforts to design inhibitors on the basis of these structures.  The mechanism of maturation of the enzyme from the viral polyprotein is still a matter of debate.  The crystal structure of the SARS coronavirus PLpro and its complex with ubiquitin is also discussed, as is its ortholog from MERS coronavirus.  Efforts at predictive structure-based inhibitor development for bat coronavirus Mpros to increase the preparedness against zoonotic transmission to man are described as well.  The paper closes with a brief discussion of structure-based discovery of antivirals in an academic setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoy_Y5ir6KZ8LVg90H21EOLACvtfcHk0liYS-wEyKwx7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFKnsbbI&md5=6a9330976a5c3a13dd4bf7bed14665ce</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1111%2Ffebs.12936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ffebs.12936%26sid%3Dliteratum%253Aachs%26aulast%3DHilgenfeld%26aufirst%3DR.%26atitle%3DFrom%2520SARS%2520to%2520MERS%253A%2520Crystallographic%2520Studies%2520on%2520Coronaviral%2520Proteases%2520Enable%2520Antiviral%2520Drug%2520Design%26jtitle%3DFEBS%2520J.%26date%3D2014%26volume%3D281%26spage%3D4085%26epage%3D4096%26doi%3D10.1111%2Ffebs.12936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span> <span> </span><span class="NLM_article-title">Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">22677</span>, <span class="refDoi">Â DOI: 10.1038/srep22677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsrep22677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26948040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XjslGrtLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=22677&author=F.+Wangauthor=C.+Chenauthor=W.+Tanauthor=K.+Yangauthor=H.+Yang&title=Structure+of+Main+Protease+from+Human+Coronavirus+NL63%3A+Insights+for+Wide+Spectrum+Anti-Coronavirus+Drug+Design&doi=10.1038%2Fsrep22677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design</span></div><div class="casAuthors">Wang, Fenghua; Chen, Cheng; Tan, Wenjie; Yang, Kailin; Yang, Haitao</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">22677</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">First identified in The Netherlands in 2004, human coronavirus NL63 (HCoV-NL63) was found to cause worldwide infections.  Patients infected by HCoV-NL63 are typically young children with upper and lower respiratory tract infection, presenting with symptoms including croup, bronchiolitis, and pneumonia.  Unfortunately, there are currently no effective antiviral therapy to contain HCoV-NL63 infection.  CoV genomes encode an integral viral component, main protease (Mpro), which is essential for viral replication through proteolytic processing of RNA replicase machinery.  Due to the sequence and structural conservation among all CoVs, Mpro has been recognized as an attractive mol. target for rational anti-CoV drug design.  Here we present the crystal structure of HCoV-NL63 Mpro in complex with a Michael acceptor inhibitor N3.  Structural anal., consistent with biochem. inhibition results, reveals the mol. mechanism of enzyme inhibition at the highly conservative substrate-recognition pocket.  We show such mol. target remains unchanged across 30 clin. isolates of HCoV-NL63 strains.  Through comparative study with Mpros from other human CoVs (including the deadly SARS-CoV and MERS-CoV) and their related zoonotic CoVs, our structure of HCoV-NL63 Mpro provides crit. insight into rational development of wide spectrum antiviral therapeutics to treat infections caused by human CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLT78CqKCbcLVg90H21EOLACvtfcHk0liYS-wEyKwx7Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjslGrtLg%253D&md5=b756a48075e0f5551871a9569a99c8c0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsrep22677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep22677%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DH.%26atitle%3DStructure%2520of%2520Main%2520Protease%2520from%2520Human%2520Coronavirus%2520NL63%253A%2520Insights%2520for%2520Wide%2520Spectrum%2520Anti-Coronavirus%2520Drug%2520Design%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D6%26spage%3D22677%26doi%3D10.1038%2Fsrep22677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">The Newly Emerged SARS-Like Coronavirus HCoV-EMC Also Has an âAchillesââ Heelâ³: Current Effective Inhibitor Targeting a 3C-like Protease.</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">248</span>â <span class="NLM_lpage">250</span>, <span class="refDoi">Â DOI: 10.1007/s13238-013-2841-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2Fs13238-013-2841-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23549610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC3srhslWqtg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=248-250&author=Z.+Renauthor=L.+Yanauthor=N.+Zhangauthor=Y.+Guoauthor=C.+Yangauthor=Z.+Louauthor=Z.+Rao&title=The+Newly+Emerged+SARS-Like+Coronavirus+HCoV-EMC+Also+Has+an+%E2%80%9CAchilles%E2%80%99%E2%80%99+Heel%E2%80%B3%3A+Current+Effective+Inhibitor+Targeting+a+3C-like+Protease.&doi=10.1007%2Fs13238-013-2841-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease</span></div><div class="casAuthors">Ren Zhilin; Yan Liming; Zhang Ning; Guo Yu; Yang Cheng; Lou Zhiyong; Rao Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Protein & cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">248-50</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR_LY3nQVW-IS-bLEOO4dYpfW6udTcc2ebT4Xi9kLvy47ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3srhslWqtg%253D%253D&md5=d785b3818d939e5ca1a9b7f6572291e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2Fs13238-013-2841-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-013-2841-3%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DThe%2520Newly%2520Emerged%2520SARS-Like%2520Coronavirus%2520HCoV-EMC%2520Also%2520Has%2520an%2520%25E2%2580%259CAchilles%25E2%2580%2599%25E2%2580%2599%2520Heel%25E2%2580%25B3%253A%2520Current%2520Effective%2520Inhibitor%2520Targeting%2520a%25203C-like%2520Protease.%26jtitle%3DProtein%2520Cell%26date%3D2013%26volume%3D4%26spage%3D248%26epage%3D250%26doi%3D10.1007%2Fs13238-013-2841-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">2515</span>â <span class="NLM_lpage">2527</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02114-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02114-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18094151" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitlyhu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=2515-2527&author=X.+Xueauthor=H.+Yuauthor=H.+Yangauthor=F.+Xueauthor=Z.+Wuauthor=W.+Shenauthor=J.+Liauthor=Z.+Zhouauthor=Y.+Dingauthor=Q.+Zhaoauthor=X.+C.+Zhangauthor=M.+Liaoauthor=M.+Bartlamauthor=Z.+Rao&title=Structures+of+Two+Coronavirus+Main+Proteases%3A+Implications+for+Substrate+Binding+and+Antiviral+Drug+Design&doi=10.1128%2FJVI.02114-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design</span></div><div class="casAuthors">Xue, Xiaoyu; Yu, Hongwei; Yang, Haitao; Xue, Fei; Wu, Zhixin; Shen, Wei; Li, Jun; Zhou, Zhe; Ding, Yi; Zhao, Qi; Zhang, Xuejun C.; Liao, Ming; Bartlam, Mark; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2515-2527</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Coronaviruses (CoVs) can infect humans and multiple species of animals, causing a wide spectrum of diseases.  The coronavirus main protease (Mpro), which plays a pivotal role in viral gene expression and replication through the proteolytic processing of replicase polyproteins, is an attractive target for anti-CoV drug design.  In this study, the crystal structures of infectious bronchitis virus (IBV) Mpro and a severe acute respiratory syndrome CoV (SARS-CoV) Mpro mutant (H41A), in complex with an N-terminal autocleavage substrate, were individually detd. to elucidate the structural flexibility and substrate binding of Mpro.  A monomeric form of IBV Mpro was identified for the first time in CoV Mpro structures.  A comparison of these two structures to other available Mpro structures provides new insights for the design of substrate-based inhibitors targeting CoV Mpros.  Furthermore, a Michael acceptor inhibitor (named N3) was cocrystd. with IBV Mpro and was found to demonstrate in vitro inactivation of IBV Mpro and potent antiviral activity against IBV in chicken embryos.  This provides a feasible animal model for designing wide-spectrum inhibitors against CoV-assocd. diseases.  The structure-based optimization of N3 has yielded two more efficacious lead compds., N27 and H16, with potent inhibition against SARS-CoV Mpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9WfRbvyd-w7Vg90H21EOLACvtfcHk0lhlREMpoeCvFQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitlyhu70%253D&md5=7407ae587531f95fe6372ffa88e6393d</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1128%2FJVI.02114-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02114-07%26sid%3Dliteratum%253Aachs%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DX.%2BC.%26aulast%3DLiao%26aufirst%3DM.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructures%2520of%2520Two%2520Coronavirus%2520Main%2520Proteases%253A%2520Implications%2520for%2520Substrate%2520Binding%2520and%2520Antiviral%2520Drug%2520Design%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D2515%26epage%3D2527%26doi%3D10.1128%2FJVI.02114-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilgenfeld, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuen, K. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlam, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases</span>. <i>PLoS Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">e324</span>, <span class="refDoi">Â DOI: 10.1371/journal.pbio.0030324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.pbio.0030324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16128623" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BD2MrjtlWksA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2005&pages=e324&author=H.+Yangauthor=W.+Xieauthor=X.+Xueauthor=K.+Yangauthor=J.+Maauthor=W.+Liangauthor=Q.+Zhaoauthor=Z.+Zhouauthor=D.+Peiauthor=J.+Ziebuhrauthor=R.+Hilgenfeldauthor=K.+Y.+Yuenauthor=L.+Wongauthor=G.+Gaoauthor=S.+Chenauthor=Z.+Chenauthor=D.+Maauthor=M.+Bartlamauthor=Z.+Rao&title=Design+of+Wide-Spectrum+Inhibitors+Targeting+Coronavirus+Main+Proteases&doi=10.1371%2Fjournal.pbio.0030324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Design of wide-spectrum inhibitors targeting coronavirus main proteases</span></div><div class="casAuthors">Yang Haitao; Xie Weiqing; Xue Xiaoyu; Yang Kailin; Ma Jing; Liang Wenxue; Zhao Qi; Zhou Zhe; Pei Duanqing; Ziebuhr John; Hilgenfeld Rolf; Yuen Kwok Yung; Wong Luet; Gao Guangxia; Chen Saijuan; Chen Zhu; Ma Dawei; Bartlam Mark; Rao Zihe</div><div class="citationInfo"><span class="NLM_cas:title">PLoS biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e324</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The genus Coronavirus contains about 25 species of coronaviruses (CoVs), which are important pathogens causing highly prevalent diseases and often severe or fatal in humans and animals.  No licensed specific drugs are available to prevent their infection.  Different host receptors for cellular entry, poorly conserved structural proteins (antigens), and the high mutation and recombination rates of CoVs pose a significant problem in the development of wide-spectrum anti-CoV drugs and vaccines.  CoV main proteases (M(pro)s), which are key enzymes in viral gene expression and replication, were revealed to share a highly conservative substrate-recognition pocket by comparison of four crystal structures and a homology model representing all three genetic clusters of the genus Coronavirus.  This conclusion was further supported by enzyme activity assays.  Mechanism-based irreversible inhibitors were designed, based on this conserved structural region, and a uniform inhibition mechanism was elucidated from the structures of Mpro-inhibitor complexes from severe acute respiratory syndrome-CoV and porcine transmissible gastroenteritis virus.  A structure-assisted optimization program has yielded compounds with fast in vitro inactivation of multiple CoV M(pro)s, potent antiviral activity, and extremely low cellular toxicity in cell-based assays.  Further modification could rapidly lead to the discovery of a single agent with clinical potential against existing and possible future emerging CoV-related diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTmeuy-d3hP7HHuJhbyicZfW6udTcc2ebT4Xi9kLvy47ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MrjtlWksA%253D%253D&md5=e71de1aa88f5c33517694e746325c6e8</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.0030324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.0030324%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DXue%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DK.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DHilgenfeld%26aufirst%3DR.%26aulast%3DYuen%26aufirst%3DK.%2BY.%26aulast%3DWong%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DD.%26aulast%3DBartlam%26aufirst%3DM.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DDesign%2520of%2520Wide-Spectrum%2520Inhibitors%2520Targeting%2520Coronavirus%2520Main%2520Proteases%26jtitle%3DPLoS%2520Biol.%26date%3D2005%26volume%3D3%26spage%3De324%26doi%3D10.1371%2Fjournal.pbio.0030324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dai, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1331</span>â <span class="NLM_lpage">1335</span>, <span class="refDoi">Â DOI: 10.1126/science.abb4489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb4489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32321856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1alsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1331-1335&author=W.+Daiauthor=B.+Zhangauthor=X.+M.+Jiangauthor=H.+Suauthor=J.+Liauthor=Y.+Zhaoauthor=X.+Xieauthor=Z.+Jinauthor=J.+Pengauthor=F.+Liuauthor=C.+Liauthor=Y.+Liauthor=F.+Baiauthor=H.+Wangauthor=X.+Chengauthor=X.+Cenauthor=S.+Huauthor=X.+Yangauthor=J.+Wangauthor=X.+Liuauthor=G.+Xiaoauthor=H.+Jiangauthor=Z.+Raoauthor=L.+K.+Zhangauthor=Y.+Xuauthor=H.+Yangauthor=H.+Liu&title=Structure-Based+Design+of+Antiviral+Drug+Candidates+Targeting+the+SARS-CoV-2+Main+Protease&doi=10.1126%2Fscience.abb4489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease</span></div><div class="casAuthors">Dai, Wenhao; Zhang, Bing; Jiang, Xia-Ming; Su, Haixia; Li, Jian; Zhao, Yao; Xie, Xiong; Jin, Zhenming; Peng, Jingjing; Liu, Fengjiang; Li, Chunpu; Li, You; Bai, Fang; Wang, Haofeng; Cheng, Xi; Cen, Xiaobo; Hu, Shulei; Yang, Xiuna; Wang, Jiang; Liu, Xiang; Xiao, Gengfu; Jiang, Hualiang; Rao, Zihe; Zhang, Lei-Ke; Xu, Yechun; Yang, Haitao; Liu, Hong</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6497</span>),
    <span class="NLM_cas:pages">1331-1335</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is the etiol. agent responsible for the global COVID-19 (coronavirus disease 2019) outbreak.  The main protease of SARS-CoV-2, Mpro, is a key enzyme that plays a pivotal role in mediating viral replication and transcription.  We designed and synthesized two lead compds. (11a and 11b) targeting Mpro.  Both exhibited excellent inhibitory activity and potent anti-SARS-CoV-2 infection activity.  The x-ray crystal structures of SARS-CoV-2 Mpro in complex with 11a or 11b, both detd. at a resoln. of 1.5 angstroms, showed that the aldehyde groups of 11a and 11b are covalently bound to cysteine 145 of Mpro.  Both compds. showed good pharmacokinetic properties in vivo, and 11a also exhibited low toxicity, which suggests that these compds. are promising drug candidates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFFvzOwCOpZrVg90H21EOLACvtfcHk0ljKFfrwLgXZGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1alsrzL&md5=ec87c340410edb919d2584a2b4d33e1a</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb4489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb4489%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DJiang%26aufirst%3DX.%2BM.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DPeng%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DX.%26aulast%3DCen%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DRao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%2BK.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DH.%26atitle%3DStructure-Based%2520Design%2520of%2520Antiviral%2520Drug%2520Candidates%2520Targeting%2520the%2520SARS-CoV-2%2520Main%2520Protease%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1331%26epage%3D1335%26doi%3D10.1126%2Fscience.abb4489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacco, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szeto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarbet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span> <span> </span><span class="NLM_article-title">Boceprevir, GC-376, and Calpain Inhibitors II, XII Inhibit SARS-CoV-2 Viral Replication by Targeting the Viral Main Protease</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">678</span>â <span class="NLM_lpage">692</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-0356-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41422-020-0356-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32541865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1WmsL%252FL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=678-692&author=C.+Maauthor=M.+D.+Saccoauthor=B.+Hurstauthor=J.+A.+Townsendauthor=Y.+Huauthor=T.+Szetoauthor=X.+Zhangauthor=B.+Tarbetauthor=M.+T.+Martyauthor=Y.+Chenauthor=J.+Wang&title=Boceprevir%2C+GC-376%2C+and+Calpain+Inhibitors+II%2C+XII+Inhibit+SARS-CoV-2+Viral+Replication+by+Targeting+the+Viral+Main+Protease&doi=10.1038%2Fs41422-020-0356-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease</span></div><div class="casAuthors">Ma, Chunlong; Sacco, Michael Dominic; Hurst, Brett; Townsend, Julia Alma; Hu, Yanmei; Szeto, Tommy; Zhang, Xiujun; Tarbet, Bart; Marty, Michael Thomas; Chen, Yu; Wang, Jun</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">678-692</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around Dec. 2019, and it is now widespread as a global pandemic.  The disease caused by SARS-CoV-2 virus is called COVID-19, which is highly contagious and has an overall mortality rate of 6.35% as of May 26, 2020.  There is no vaccine or antiviral available for SARS-CoV-2.  We report our discovery of inhibitors targeting the SARS-CoV-2 main protease (Mpro).  Using the FRET-based enzymic assay, several inhibitors including boceprevir, GC-376, and calpain inhibitors II and XII were identified to have potent activity with single-digit to submicromolar IC50 values in the enzymic assay.  The mechanism of action of the hits was further characterized using enzyme kinetic studies, thermal shift binding assays, and native mass spectrometry.  Significantly, 4 compds. (boceprevir, GC-376, and calpain inhibitors II and XII) inhibit SARS-CoV-2 viral replication in cell culture with EC50 values ranging 0.49-3.37Î¼M.  Notably, boceprevir and calpain inhibitors II and XII represent novel chemotypes that are distinct from known substrate-based peptidomimetic Mpro inhibitors.  A complex crystal structure of SARS-CoV-2 Mpro with GC-376, detd. at 2.15 Ã resoln. with 3 protomers per asym. unit, revealed 2 unique binding configurations, shedding light on the mol. interactions and protein conformational flexibility underlying substrate and inhibitor binding by Mpro.  Overall, the compds. identified provide promising starting points for the further development of SARS-CoV-2 therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVnFC-t0uFW7Vg90H21EOLACvtfcHk0ljKFfrwLgXZGQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1WmsL%252FL&md5=225d518c313474cdfbcfe678d35e26a4</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0356-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0356-z%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%26aulast%3DSacco%26aufirst%3DM.%2BD.%26aulast%3DHurst%26aufirst%3DB.%26aulast%3DTownsend%26aufirst%3DJ.%2BA.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DSzeto%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DTarbet%26aufirst%3DB.%26aulast%3DMarty%26aufirst%3DM.%2BT.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26atitle%3DBoceprevir%252C%2520GC-376%252C%2520and%2520Calpain%2520Inhibitors%2520II%252C%2520XII%2520Inhibit%2520SARS-CoV-2%2520Viral%2520Replication%2520by%2520Targeting%2520the%2520Viral%2520Main%2520Protease%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D678%26epage%3D692%26doi%3D10.1038%2Fs41422-020-0356-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasiti
Kankanamalage, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weerasekara, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, N. C.</span></span> <span> </span><span class="NLM_article-title">Reversal of the Progression of Fatal Coronavirus Infection in Cats by a Broad-Spectrum Coronavirus Protease Inhibitor</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1005531</span>, <span class="refDoi">Â DOI: 10.1371/journal.ppat.1005531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.ppat.1005531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27027316" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlGru7fN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=1005531&author=Y.+Kimauthor=H.+Liuauthor=A.+C.+Galasiti%0AKankanamalageauthor=S.+Weerasekaraauthor=D.+H.+Huaauthor=W.+C.+Groutasauthor=K.+O.+Changauthor=N.+C.+Pedersen&title=Reversal+of+the+Progression+of+Fatal+Coronavirus+Infection+in+Cats+by+a+Broad-Spectrum+Coronavirus+Protease+Inhibitor&doi=10.1371%2Fjournal.ppat.1005531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor</span></div><div class="casAuthors">Kim, Yunjeong; Liu, Hongwei; Kankanamalage, Anushka C. Galasiti; Weerasekara, Sahani; Hua, Duy H.; Groutas, William C.; Chang, Kyeong-Ok; Pedersen, Niels C.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e1005531/1-e1005531/18</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Coronaviruses infect animals and humans causing a wide range of diseases.  The diversity of coronaviruses in many mammalian species is contributed by relatively high mutation and recombination rates during replication.  This dynamic nature of coronaviruses may facilitate cross-species transmission and shifts in tissue or cell tropism in a host, resulting in substantial change in virulence.  Feline enteric coronavirus (FECV) causes inapparent or mild enteritis in cats, but a highly fatal disease, called feline infectious peritonitis (FIP), can arise through mutation of FECV to FIP virus (FIPV).  The pathogenesis of FIP is intimately assocd. with immune responses and involves depletion of T cells, features shared by some other coronaviruses like Severe Acute Respiratory Syndrome Coronavirus.  The increasing risks of highly virulent coronavirus infections in humans or animals call for effective antiviral drugs, but no such measures are yet available.  Previously, we have reported the inhibitors that target 3C-like protease (3CLpro) with broad-spectrum activity against important human and animal coronaviruses.  Here, we evaluated the therapeutic efficacy of our 3CLpro inhibitor in lab. cats with FIP.  Exptl. FIP is 100% fatal once certain clin. and lab. signs become apparent.We found that antiviral treatment led to full recovery of cats when treatment was started at a stage of disease that would be otherwise fatal if left untreated.  Antiviral treatment was assocd. with a rapid improvement in fever, ascites, lymphopenia and gross signs of illness and cats returned to normal health within 20 days or less of treatment.  Significant redn. in viral titers was also obsd. in cats.  These results indicate that continuous virus replication is required for progression of immune-mediated inflammatory disease of FIP.  These findings may provide important insights into devising therapeutic strategies and selection of antiviral compds. for further development for important coronaviruses in animals and humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprSH3BnhFwZLVg90H21EOLACvtfcHk0li9YBIGeYEoRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlGru7fN&md5=7900b2718caeaf528f10f553e0e8fa16</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1005531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1005531%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGalasiti%2BKankanamalage%26aufirst%3DA.%2BC.%26aulast%3DWeerasekara%26aufirst%3DS.%26aulast%3DHua%26aufirst%3DD.%2BH.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.%2BO.%26aulast%3DPedersen%26aufirst%3DN.%2BC.%26atitle%3DReversal%2520of%2520the%2520Progression%2520of%2520Fatal%2520Coronavirus%2520Infection%2520in%2520Cats%2520by%2520a%2520Broad-Spectrum%2520Coronavirus%2520Protease%2520Inhibitor%26jtitle%3DPLoS%2520Pathog.%26date%3D2016%26volume%3D12%26spage%3D1005531%26doi%3D10.1371%2Fjournal.ppat.1005531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galasiti Kankanamalage, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckstrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannasch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meadows, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. O.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a 3C-like Protease Inhibitor in Treating Various Forms of Acquired Feline Infectious Peritonitis</span>. <i>J. Feline Med. Surg.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">378</span>â <span class="NLM_lpage">392</span>, <span class="refDoi">Â DOI: 10.1177/1098612X17729626</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1177%2F1098612X17729626" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28901812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1cbns12gsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=378-392&author=N.+C.+Pedersenauthor=Y.+Kimauthor=H.+Liuauthor=A.+C.+Galasiti+Kankanamalageauthor=C.+Eckstrandauthor=W.+C.+Groutasauthor=M.+Bannaschauthor=J.+M.+Meadowsauthor=K.+O.+Chang&title=Efficacy+of+a+3C-like+Protease+Inhibitor+in+Treating+Various+Forms+of+Acquired+Feline+Infectious+Peritonitis&doi=10.1177%2F1098612X17729626"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis</span></div><div class="casAuthors">Pedersen Niels C; Liu Hongwei; Bannasch Michael; Kim Yunjeong; Chang Kyeong-Ok; Galasiti Kankanamalage Anushka C; Groutas William C; Eckstrand Chrissy; Meadows Juliana M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of feline medicine and surgery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">378-392</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Objectives The safety and efficacy of the 3C-like protease inhibitor GC376 was tested on a cohort of client-owned cats with various forms of feline infectious peritonitis (FIP).  Methods Twenty cats from 3.3-82 months of age (mean 10.4 months) with various forms of FIP were accepted into a field trial.  Fourteen cats presented with wet or dry-to-wet FIP and six cats presented with dry FIP.  GC376 was administered subcutaneously every 12 h at a dose of 15 mg/kg.  Cats with neurologic signs were excluded from the study.  Results Nineteen of 20 cats treated with GC376 regained outward health within 2 weeks of initial treatment.  However, disease signs recurred 1-7 weeks after primary treatment and relapses and new cases were ultimately treated for a minimum of 12 weeks.  Relapses no longer responsive to treatment occurred in 13 of these 19 cats within 1-7 weeks of initial or repeat treatment(s).  Severe neurologic disease occurred in 8/13 cats that failed treatment and five cats had recurrences of abdominal lesions.  At the time of writing, seven cats were in disease remission.  Five kittens aged 3.3-4.4 months with wet FIP were treated for 12 weeks and have been in disease remission after stopping treatment and at the time of writing for 5-14 months (mean 11.2 months).  A sixth kitten was in remission for 10 weeks after 12 weeks of treatment, relapsed and is responding to a second round of GC376.  The seventh was a 6.8-year-old cat with only mesenteric lymph node involvement that went into remission after three relapses that required progressively longer repeat treatments over a 10 month period.  Side effects of treatment included transient stinging upon injection and occasional foci of subcutaneous fibrosis and hair loss.  There was retarded development and abnormal eruption of permanent teeth in cats treated before 16-18 weeks of age.  Conclusions and relevance GC376 showed promise in treating cats with certain presentations of FIP and has opened the door to targeted antiviral drug therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTFFwhHX-Ibonqj_yg7twvpfW6udTcc2eaThe4KVr7-f7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbns12gsg%253D%253D&md5=69b4ebebb24b351bfb0f409e275b3153</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1177%2F1098612X17729626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1098612X17729626%26sid%3Dliteratum%253Aachs%26aulast%3DPedersen%26aufirst%3DN.%2BC.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DGalasiti%2BKankanamalage%26aufirst%3DA.%2BC.%26aulast%3DEckstrand%26aufirst%3DC.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DBannasch%26aufirst%3DM.%26aulast%3DMeadows%26aufirst%3DJ.%2BM.%26aulast%3DChang%26aufirst%3DK.%2BO.%26atitle%3DEfficacy%2520of%2520a%25203C-like%2520Protease%2520Inhibitor%2520in%2520Treating%2520Various%2520Forms%2520of%2520Acquired%2520Feline%2520Infectious%2520Peritonitis%26jtitle%3DJ.%2520Feline%2520Med.%2520Surg.%26date%3D2018%26volume%3D20%26spage%3D378%26epage%3D392%26doi%3D10.1177%2F1098612X17729626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span> <span> </span><span class="NLM_article-title">Both Boceprevir and GC376 Efficaciously Inhibit SARS-CoV-2 by Targeting Its Main Protease</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4417</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-18233-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-020-18233-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32887884" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsr3F" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4417&author=L.+Fuauthor=F.+Yeauthor=Y.+Fengauthor=F.+Yuauthor=Q.+Wangauthor=Y.+Wuauthor=C.+Zhaoauthor=H.+Sunauthor=B.+Huangauthor=P.+Niuauthor=H.+Songauthor=Y.+Shiauthor=X.+Liauthor=W.+Tanauthor=J.+Qiauthor=G.+F.+Gao&title=Both+Boceprevir+and+GC376+Efficaciously+Inhibit+SARS-CoV-2+by+Targeting+Its+Main+Protease&doi=10.1038%2Fs41467-020-18233-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease</span></div><div class="casAuthors">Fu, Lifeng; Ye, Fei; Feng, Yong; Yu, Feng; Wang, Qisheng; Wu, Yan; Zhao, Cheng; Sun, Huan; Huang, Baoying; Niu, Peihua; Song, Hao; Shi, Yi; Li, Xuebing; Tan, Wenjie; Qi, Jianxun; Gao, George Fu</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4417</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: COVID-19 was declared a pandemic on March 11 by WHO, due to its great threat to global public health.  The coronavirus main protease (Mpro, also called 3CLpro) is essential for processing and maturation of the viral polyprotein, therefore recognized as an attractive drug target.  Here we show that a clin. approved anti-HCV drug, Boceprevir, and a pre-clin. inhibitor against feline infectious peritonitis (corona) virus (FIPV), GC376, both efficaciously inhibit SARS-CoV-2 in Vero cells by targeting Mpro.  Moreover, combined application of GC376 with Remdesivir, a nucleotide analog that inhibits viral RNA dependent RNA polymerase (RdRp), results in sterilizing additive effect.  Further structural anal. reveals binding of both inhibitors to the catalytically active side of SARS-CoV-2 protease Mpro as main mechanism of inhibition.  Our findings may provide crit. information for the optimization and design of more potent inhibitors against the emerging SARS-CoV-2 virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt43KcNqLbkLVg90H21EOLACvtfcHk0li9YBIGeYEoRw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVSmsr3F&md5=273b11d16241499f15103885be398b23</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18233-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18233-x%26sid%3Dliteratum%253Aachs%26aulast%3DFu%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%2BF.%26atitle%3DBoth%2520Boceprevir%2520and%2520GC376%2520Efficaciously%2520Inhibit%2520SARS-CoV-2%2520by%2520Targeting%2520Its%2520Main%2520Protease%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4417%26doi%3D10.1038%2Fs41467-020-18233-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vuong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arutyunova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shields, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKay, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Belkum, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tyrrell, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vederas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemieux, M. J.</span></span> <span> </span><span class="NLM_article-title">Feline Coronavirus Drug Inhibits the Main Protease of SARS-CoV-2 and Blocks Virus Replication</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">4282</span>, <span class="refDoi">Â DOI: 10.1038/s41467-020-18096-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-020-18096-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32855413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslWqtbzN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=4282&author=W.+Vuongauthor=M.+B.+Khanauthor=C.+Fischerauthor=E.+Arutyunovaauthor=T.+Lamerauthor=J.+Shieldsauthor=H.+A.+Saffranauthor=R.+T.+McKayauthor=M.+J.+van+Belkumauthor=M.+A.+Joyceauthor=H.+S.+Youngauthor=D.+L.+Tyrrellauthor=J.+C.+Vederasauthor=M.+J.+Lemieux&title=Feline+Coronavirus+Drug+Inhibits+the+Main+Protease+of+SARS-CoV-2+and+Blocks+Virus+Replication&doi=10.1038%2Fs41467-020-18096-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication</span></div><div class="casAuthors">Vuong, Wayne; Khan, Muhammad Bashir; Fischer, Conrad; Arutyunova, Elena; Lamer, Tess; Shields, Justin; Saffran, Holly A.; McKay, Ryan T.; van Belkum, Marco J.; Joyce, Michael A.; Young, Howard S.; Tyrrell, D. Lorne; Vederas, John C.; Lemieux, M. Joanne</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4282</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The main protease, Mpro (or 3CLpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide.  Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor.  We show the prodrug and its parent GC373, are effective inhibitors of the Mpro from both SARS-CoV and SARS-CoV-2 with IC50 values in the nanomolar range.  Crystal structures of SARS-CoV-2 Mpro with these inhibitors have a covalent modification of the nucleophilic Cys145.  NMR anal. reveals that inhibition proceeds via reversible formation of a hemithioacetal.  GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture.  They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals.  The work here lays the framework for their use in human trials for the treatment of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMA7W4XtRQrbVg90H21EOLACvtfcHk0limFHlvUOPiJQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslWqtbzN&md5=c06d2dc9a65ae289505fe120d41d8885</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1038%2Fs41467-020-18096-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-020-18096-2%26sid%3Dliteratum%253Aachs%26aulast%3DVuong%26aufirst%3DW.%26aulast%3DKhan%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DC.%26aulast%3DArutyunova%26aufirst%3DE.%26aulast%3DLamer%26aufirst%3DT.%26aulast%3DShields%26aufirst%3DJ.%26aulast%3DSaffran%26aufirst%3DH.%2BA.%26aulast%3DMcKay%26aufirst%3DR.%2BT.%26aulast%3Dvan%2BBelkum%26aufirst%3DM.%2BJ.%26aulast%3DJoyce%26aufirst%3DM.%2BA.%26aulast%3DYoung%26aufirst%3DH.%2BS.%26aulast%3DTyrrell%26aufirst%3DD.%2BL.%26aulast%3DVederas%26aufirst%3DJ.%2BC.%26aulast%3DLemieux%26aufirst%3DM.%2BJ.%26atitle%3DFeline%2520Coronavirus%2520Drug%2520Inhibits%2520the%2520Main%2520Protease%2520of%2520SARS-CoV-2%2520and%2520Blocks%2520Virus%2520Replication%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D4282%26doi%3D10.1038%2Fs41467-020-18096-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rathnayake, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perera, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerholz, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kashipathy, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaile, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groutas, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K.-O.</span></span> <span> </span><span class="NLM_article-title">3C-like Protease Inhibitors Block Coronavirus Replication in Vitro and Improve Survival in MERS-CoVâInfected Mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eabc5332</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.abc5332</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.abc5332" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32747425" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabc5332&author=A.+D.+Rathnayakeauthor=J.+Zhengauthor=Y.+Kimauthor=K.+D.+Pereraauthor=S.+Mackinauthor=D.+K.+Meyerholzauthor=M.+M.+Kashipathyauthor=K.+P.+Battaileauthor=S.+Lovellauthor=S.+Perlmanauthor=W.+C.+Groutasauthor=K.-O.+Chang&title=3C-like+Protease+Inhibitors+Block+Coronavirus+Replication+in+Vitro+and+Improve+Survival+in+MERS-CoV%E2%80%93Infected+Mice&doi=10.1126%2Fscitranslmed.abc5332"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abc5332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abc5332%26sid%3Dliteratum%253Aachs%26aulast%3DRathnayake%26aufirst%3DA.%2BD.%26aulast%3DZheng%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DY.%26aulast%3DPerera%26aufirst%3DK.%2BD.%26aulast%3DMackin%26aufirst%3DS.%26aulast%3DMeyerholz%26aufirst%3DD.%2BK.%26aulast%3DKashipathy%26aufirst%3DM.%2BM.%26aulast%3DBattaile%26aufirst%3DK.%2BP.%26aulast%3DLovell%26aufirst%3DS.%26aulast%3DPerlman%26aufirst%3DS.%26aulast%3DGroutas%26aufirst%3DW.%2BC.%26aulast%3DChang%26aufirst%3DK.-O.%26atitle%3D3C-like%2520Protease%2520Inhibitors%2520Block%2520Coronavirus%2520Replication%2520in%2520Vitro%2520and%2520Improve%2520Survival%2520in%2520MERS-CoV%25E2%2580%2593Infected%2520Mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deabc5332%26doi%3D10.1126%2Fscitranslmed.abc5332" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">A Trial of LopinavirâRitonavir in Adults Hospitalized with Severe Covid-19</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>382</i></span>,  <span class="NLM_fpage">1787</span>â <span class="NLM_lpage">1799</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa2001282</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa2001282" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32187464" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB383kvFOjtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=382&publication_year=2020&pages=1787-1799&author=B.+Caoauthor=Y.+Wangauthor=D.+Wenauthor=W.+Liuauthor=J.+Wangauthor=G.+Fanauthor=L.+Ruanauthor=B.+Songauthor=Y.+Caiauthor=M.+Weiauthor=X.+Liauthor=J.+Xiaauthor=N.+Chenauthor=J.+Xiangauthor=T.+Yuauthor=T.+Baiauthor=X.+Xieauthor=L.+Zhangauthor=C.+Liauthor=Y.+Yuanauthor=H.+Chenauthor=H.+Liauthor=H.+Huangauthor=S.+Tuauthor=F.+Gongauthor=Y.+Liuauthor=Y.+Weiauthor=C.+Dongauthor=F.+Zhouauthor=X.+Guauthor=J.+Xuauthor=Z.+Liuauthor=Y.+Zhangauthor=H.+Liauthor=L.+Shangauthor=K.+Wangauthor=K.+Liauthor=X.+Zhouauthor=X.+Dongauthor=Z.+Quauthor=S.+Luauthor=X.+Huauthor=S.+Ruanauthor=S.+Luoauthor=J.+Wuauthor=L.+Pengauthor=F.+Chengauthor=L.+Panauthor=J.+Zouauthor=C.+Jiaauthor=J.+Wangauthor=X.+Liuauthor=S.+Wangauthor=X.+Wuauthor=Q.+Geauthor=J.+Heauthor=H.+Zhanauthor=F.+Qiuauthor=L.+Guoauthor=C.+Huangauthor=T.+Jakiauthor=F.+G.+Haydenauthor=P.+W.+Horbyauthor=D.+Zhangauthor=C.+Wang&title=A+Trial+of+Lopinavir%E2%80%93Ritonavir+in+Adults+Hospitalized+with+Severe+Covid-19&doi=10.1056%2FNEJMoa2001282"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</span></div><div class="casAuthors">Cao Bin; Wang Yeming; Wen Danning; Liu Wen; Wang Jingli; Fan Guohui; Ruan Lianguo; Song Bin; Cai Yanping; Wei Ming; Li Xingwang; Xia Jiaan; Chen Nanshan; Xiang Jie; Yu Ting; Bai Tao; Xie Xuelei; Zhang Li; Li Caihong; Yuan Ye; Chen Hua; Li Huadong; Huang Hanping; Tu Shengjing; Gong Fengyun; Liu Ying; Wei Yuan; Dong Chongya; Zhou Fei; Gu Xiaoying; Xu Jiuyang; Liu Zhibo; Zhang Yi; Li Hui; Shang Lianhan; Wang Ke; Li Kunxia; Zhou Xia; Dong Xuan; Qu Zhaohui; Lu Sixia; Hu Xujuan; Ruan Shunan; Luo Shanshan; Wu Jing; Peng Lu; Cheng Fang; Pan Lihong; Zou Jun; Jia Chunmin; Wang Juan; Liu Xia; Wang Shuzhen; Wu Xudong; Ge Qin; He Jing; Zhan Haiyan; Qiu Fang; Guo Li; Huang Chaolin; Jaki Thomas; Hayden Frederick G; Horby Peter W; Zhang Dingyu; Wang Chen</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">382</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1787-1799</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2.  METHODS:  We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or less while they were breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) of less than 300 mm Hg.  Patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or standard care alone.  The primary end point was the time to clinical improvement, defined as the time from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever came first.  RESULTS:  A total of 199 patients with laboratory-confirmed SARS-CoV-2 infection underwent randomization; 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group.  Treatment with lopinavir-ritonavir was not associated with a difference from standard care in the time to clinical improvement (hazard ratio for clinical improvement, 1.31; 95% confidence interval [CI], 0.95 to 1.80).  Mortality at 28 days was similar in the lopinavir-ritonavir group and the standard-care group (19.2% vs. 25.0%; difference, -5.8 percentage points; 95% CI, -17.3 to 5.7).  The percentages of patients with detectable viral RNA at various time points were similar.  In a modified intention-to-treat analysis, lopinavir-ritonavir led to a median time to clinical improvement that was shorter by 1 day than that observed with standard care (hazard ratio, 1.39; 95% CI, 1.00 to 1.91).  Gastrointestinal adverse events were more common in the lopinavir-ritonavir group, but serious adverse events were more common in the standard-care group.  Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events.  CONCLUSIONS:  In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care.  Future trials in patients with severe illness may help to confirm or exclude the possibility of a treatment benefit. (Funded by Major Projects of National Science and Technology on New Drug Creation and Development and others; Chinese Clinical Trial Register number, ChiCTR2000029308.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSLXU2_2H1oIv6BottYdIAWfW6udTcc2eYD6cQCcL7mLbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383kvFOjtQ%253D%253D&md5=affdbe91481a3ada1a2fed29e2ad17f9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa2001282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa2001282%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DRuan%26aufirst%3DL.%26aulast%3DSong%26aufirst%3DB.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DN.%26aulast%3DXiang%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DBai%26aufirst%3DT.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DYuan%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DTu%26aufirst%3DS.%26aulast%3DGong%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DShang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DQu%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DX.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DPan%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DGe%26aufirst%3DQ.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DZhan%26aufirst%3DH.%26aulast%3DQiu%26aufirst%3DF.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DC.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DHorby%26aufirst%3DP.%2BW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DA%2520Trial%2520of%2520Lopinavir%25E2%2580%2593Ritonavir%2520in%2520Adults%2520Hospitalized%2520with%2520Severe%2520Covid-19%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2020%26volume%3D382%26spage%3D1787%26epage%3D1799%26doi%3D10.1056%2FNEJMoa2001282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, C. Y.</span></span> <span> </span><span class="NLM_article-title">Mutation of Glu-166 Blocks the Substrate-Induced Dimerization of SARS Coronavirus Main Protease</span>. <i>Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>98</i></span>,  <span class="NLM_fpage">1327</span>â <span class="NLM_lpage">1336</span>, <span class="refDoi">Â DOI: 10.1016/j.bpj.2009.12.4272</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bpj.2009.12.4272" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=20371333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntlKnsLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=98&publication_year=2010&pages=1327-1336&author=S.+C.+Chengauthor=G.+G.+Changauthor=C.+Y.+Chou&title=Mutation+of+Glu-166+Blocks+the+Substrate-Induced+Dimerization+of+SARS+Coronavirus+Main+Protease&doi=10.1016%2Fj.bpj.2009.12.4272"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Mutation of Glu-166 blocks the substrate-induced dimerization of SARS coronavirus main protease</span></div><div class="casAuthors">Cheng, Shu-Chun; Chang, Gu-Gang; Chou, Chi-Yuan</div><div class="citationInfo"><span class="NLM_cas:title">Biophysical Journal</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">98</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1327-1336</span>CODEN:
                <span class="NLM_cas:coden">BIOJAU</span>;
        ISSN:<span class="NLM_cas:issn">0006-3495</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The maturation of SARS coronavirus involves the autocleavage of polyproteins 1a and 1ab by the main protease (Mpro) and a papain-like protease; these represent attractive targets for the development of anti-SARS drugs.  The functional unit of Mpro is a homodimer, and each subunit has a His-41Â·Â·Â·Cys-145 catalytic dyad.  Current thinking in this area is that Mpro dimerization is essential for catalysis; although, the influence of the substrate binding on the dimer formation has never been explored.  Here, we delineate the contributions of the peptide substrate to Mpro dimerization.  Enzyme kinetic assays indicate that the monomeric mutant R298A/L exhibits lower activity but in a cooperative manner.  Anal. ultracentrifugation analyses indicate that in the presence of substrates, the major species of R298A/L shows a significant size shift toward the dimeric form and the monomer-dimer dissocn. const. of R298A/L decreases by 12- to 17-fold, approaching that for wild-type.  Furthermore, this substrate-induced dimerization was found to be reversible after substrates were removed.  Based on the crystal structures, a key residue, Glu-166, which is responsible for recognizing the Gln-P1 of the substrate and binding to Ser-1 of another promoter, will interact with Asn-142 and block the S1 subsite entrance in the monomer.  Our studies indicate that mutation of Glu-166 in the R298A mutant indeed blocks the substrate-induced dimerization.  This demonstrates that Glu-166 plays a pivotal role in connecting the substrate binding site with the dimer interface.  We conclude that protein-ligand and protein-protein interactions are closely correlated in Mpro.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd9okYa5bCE7Vg90H21EOLACvtfcHk0ljwJkmIZoJUlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntlKnsLw%253D&md5=e553f8131ded8f8a5ef07181ad0819c8</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.bpj.2009.12.4272&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bpj.2009.12.4272%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DS.%2BC.%26aulast%3DChang%26aufirst%3DG.%2BG.%26aulast%3DChou%26aufirst%3DC.%2BY.%26atitle%3DMutation%2520of%2520Glu-166%2520Blocks%2520the%2520Substrate-Induced%2520Dimerization%2520of%2520SARS%2520Coronavirus%2520Main%2520Protease%26jtitle%3DBiophys.%2520J.%26date%3D2010%26volume%3D98%26spage%3D1327%26epage%3D1336%26doi%3D10.1016%2Fj.bpj.2009.12.4272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaulieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonneau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¶s, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cameron, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cartier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cordingley, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goudreau, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukolj, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LagacÃ©, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaPlante, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narjes, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupart, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rancourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sentjens, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St George, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoneau, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibeault, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weldon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LlinÃ s-Brunet, M.</span></span> <span> </span><span class="NLM_article-title">An NS3 Protease Inhibitor with Antiviral Effects in Humans Infected with Hepatitis C Virus</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>426</i></span>,  <span class="NLM_fpage">186</span>â <span class="NLM_lpage">189</span>, <span class="refDoi">Â DOI: 10.1038/nature02099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature02099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=14578911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=426&publication_year=2003&pages=186-189&author=D.+Lamarreauthor=P.+C.+Andersonauthor=M.+Baileyauthor=P.+Beaulieuauthor=G.+Bolgerauthor=P.+Bonneauauthor=M.+B%C3%B6sauthor=D.+R.+Cameronauthor=M.+Cartierauthor=M.+G.+Cordingleyauthor=A.+M.+Faucherauthor=N.+Goudreauauthor=S.+H.+Kawaiauthor=G.+Kukoljauthor=L.+Lagac%C3%A9author=S.+R.+LaPlanteauthor=H.+Narjesauthor=M.+A.+Poupartauthor=J.+Rancourtauthor=R.+E.+Sentjensauthor=R.+St+Georgeauthor=B.+Simoneauauthor=G.+Steinmannauthor=D.+Thibeaultauthor=Y.+S.+Tsantrizosauthor=S.+M.+Weldonauthor=C.+L.+Yongauthor=M.+Llin%C3%A0s-Brunet&title=An+NS3+Protease+Inhibitor+with+Antiviral+Effects+in+Humans+Infected+with+Hepatitis+C+Virus&doi=10.1038%2Fnature02099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus</span></div><div class="casAuthors">Lamarre, Daniel; Anderson, Paul C.; Bailey, Murray; Beaulieu, Pierre; Bolger, Gordon; Bonneau, Pierre; Boes, Michael; Cameron, Dale R.; Cartier, Mireille; Cordingley, Michael G.; Faucher, Anne-Marie; Goudreau, Nathalie; Kawai, Stephen H.; Kukolj, George; Lagace, Lisette; LaPlante, Steven R.; Narjes, Hans; Poupart, Marc-Andre; Rancourt, Jean; Sentjens, Roel E.; St. George, Roger; Simoneau, Bruno; Steinmann, Gerhard; Thibeault, Diane; Tsantrizos, Youla S.; Weldon, Steven M.; Yong, Chan-Loi; Llinas-Brunet, Montse</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">426</span>
        (<span class="NLM_cas:issue">6963</span>),
    <span class="NLM_cas:pages">186-189</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality.  Current interferon-based therapies are suboptimal esp. in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics.  The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients.  Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small mol. inhibitor biol. available through oral ingestion and the first of its class in human trials.  Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive redn. of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor.  Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPnVapDO21RLVg90H21EOLACvtfcHk0ljwJkmIZoJUlw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXovVKmtbw%253D&md5=36db818d5af257d3ebeef1a061ca68cb</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1038%2Fnature02099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature02099%26sid%3Dliteratum%253Aachs%26aulast%3DLamarre%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DP.%2BC.%26aulast%3DBailey%26aufirst%3DM.%26aulast%3DBeaulieu%26aufirst%3DP.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBonneau%26aufirst%3DP.%26aulast%3DB%25C3%25B6s%26aufirst%3DM.%26aulast%3DCameron%26aufirst%3DD.%2BR.%26aulast%3DCartier%26aufirst%3DM.%26aulast%3DCordingley%26aufirst%3DM.%2BG.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DGoudreau%26aufirst%3DN.%26aulast%3DKawai%26aufirst%3DS.%2BH.%26aulast%3DKukolj%26aufirst%3DG.%26aulast%3DLagac%25C3%25A9%26aufirst%3DL.%26aulast%3DLaPlante%26aufirst%3DS.%2BR.%26aulast%3DNarjes%26aufirst%3DH.%26aulast%3DPoupart%26aufirst%3DM.%2BA.%26aulast%3DRancourt%26aufirst%3DJ.%26aulast%3DSentjens%26aufirst%3DR.%2BE.%26aulast%3DSt%2BGeorge%26aufirst%3DR.%26aulast%3DSimoneau%26aufirst%3DB.%26aulast%3DSteinmann%26aufirst%3DG.%26aulast%3DThibeault%26aufirst%3DD.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DWeldon%26aufirst%3DS.%2BM.%26aulast%3DYong%26aufirst%3DC.%2BL.%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26atitle%3DAn%2520NS3%2520Protease%2520Inhibitor%2520with%2520Antiviral%2520Effects%2520in%2520Humans%2520Infected%2520with%2520Hepatitis%2520C%2520Virus%26jtitle%3DNature%26date%3D2003%26volume%3D426%26spage%3D186%26epage%3D189%26doi%3D10.1038%2Fnature02099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LlinÃ s-Brunet, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolger, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faucher, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferland, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garneau, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorys, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grand-MaÃ®tre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halmos, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lapeyre-Paquette, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poirier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RhÃ©aume, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsantrizos, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamarre, D.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">1605</span>â <span class="NLM_lpage">1608</span>, <span class="refDoi">Â DOI: 10.1021/jm0342414</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0342414" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1605-1608&author=M.+Llin%C3%A0s-Brunetauthor=M.+D.+Baileyauthor=G.+Bolgerauthor=C.+Brochuauthor=A.+M.+Faucherauthor=J.+M.+Ferlandauthor=M.+Garneauauthor=E.+Ghiroauthor=V.+Gorysauthor=C.+Grand-Ma%C3%AEtreauthor=T.+Halmosauthor=N.+Lapeyre-Paquetteauthor=F.+Liardauthor=M.+Poirierauthor=M.+Rh%C3%A9aumeauthor=Y.+S.+Tsantrizosauthor=D.+Lamarre&title=Structure-Activity+Study+on+a+Novel+Series+of+Macrocyclic+Inhibitors+of+the+Hepatitis+C+Virus+NS3+Protease+Leading+to+the+Discovery+of+BILN+2061&doi=10.1021%2Fjm0342414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061</span></div><div class="casAuthors">Llinas-Brunet, Montse; Bailey, Murray D.; Bolger, Gordon; Brochu, Christian; Faucher, Anne-Marie; Ferland, Jean Marie; Garneau, Michel; Ghiro, Elise; Gorys, Vida; Grand-Maitre, Chantal; Halmos, Ted; Lapeyre-Paquette, Nicole; Liard, Francine; Poirier, Martin; Rheaume, Manon; Tsantrizos, Youla S.; Lamarre, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1605-1608</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified.  Structure-activity relationship studies were performed focusing on optimizing the N-terminal carbamate and the arom. substituent on the (4R)-hydroxyproline moiety.  Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified.  BILN 2061 was selected as the best compd., the first NS3 protease inhibitor reported with antiviral activity in man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KmuWcS2jSrVg90H21EOLACvtfcHk0licAVUfAAAkZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhs1ylsLo%253D&md5=d4d8116d2a688e4088e94be617fc396b</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1021%2Fjm0342414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0342414%26sid%3Dliteratum%253Aachs%26aulast%3DLlin%25C3%25A0s-Brunet%26aufirst%3DM.%26aulast%3DBailey%26aufirst%3DM.%2BD.%26aulast%3DBolger%26aufirst%3DG.%26aulast%3DBrochu%26aufirst%3DC.%26aulast%3DFaucher%26aufirst%3DA.%2BM.%26aulast%3DFerland%26aufirst%3DJ.%2BM.%26aulast%3DGarneau%26aufirst%3DM.%26aulast%3DGhiro%26aufirst%3DE.%26aulast%3DGorys%26aufirst%3DV.%26aulast%3DGrand-Ma%25C3%25AEtre%26aufirst%3DC.%26aulast%3DHalmos%26aufirst%3DT.%26aulast%3DLapeyre-Paquette%26aufirst%3DN.%26aulast%3DLiard%26aufirst%3DF.%26aulast%3DPoirier%26aufirst%3DM.%26aulast%3DRh%25C3%25A9aume%26aufirst%3DM.%26aulast%3DTsantrizos%26aufirst%3DY.%2BS.%26aulast%3DLamarre%26aufirst%3DD.%26atitle%3DStructure-Activity%2520Study%2520on%2520a%2520Novel%2520Series%2520of%2520Macrocyclic%2520Inhibitors%2520of%2520the%2520Hepatitis%2520C%2520Virus%2520NS3%2520Protease%2520Leading%2520to%2520the%2520Discovery%2520of%2520BILN%25202061%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1605%26epage%3D1608%26doi%3D10.1021%2Fjm0342414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Claudio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiMuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Filippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gates, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazuda, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span> <span> </span><span class="NLM_article-title">MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">4161</span>â <span class="NLM_lpage">4167</span>, <span class="refDoi">Â DOI: 10.1128/AAC.00324-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.00324-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22615282" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2012&pages=4161-4167&author=V.+Summaauthor=S.+W.+Ludmererauthor=J.+A.+McCauleyauthor=C.+Fandozziauthor=C.+Burleinauthor=G.+Claudioauthor=P.+J.+Colemanauthor=J.+M.+DiMuzioauthor=M.+Ferraraauthor=M.+Di+Filippoauthor=A.+T.+Gatesauthor=D.+J.+Grahamauthor=S.+Harperauthor=D.+J.+Hazudaauthor=C.+McHaleauthor=E.+Monteagudoauthor=V.+Pucciauthor=M.+Rowleyauthor=M.+T.+Ruddauthor=A.+Sorianoauthor=M.+W.+Stahlhutauthor=J.+P.+Vaccaauthor=D.+B.+Olsenauthor=N.+J.+Livertonauthor=S.+S.+Carroll&title=MK-5172%2C+a+Selective+Inhibitor+of+Hepatitis+C+Virus+NS3%2F4a+Protease+with+Broad+Activity+across+Genotypes+and+Resistant+Variants&doi=10.1128%2FAAC.00324-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants</span></div><div class="casAuthors">Summa, Vincenzo; Ludmerer, Steven W.; McCauley, John A.; Fandozzi, Christine; Burlein, Christine; Claudio, Giuliano; Coleman, Paul J.; DiMuzio, Jillian M.; Ferrara, Marco; Di Filippo, Marcello; Gates, Adam T.; Graham, Donald J.; Harper, Steven; Hazuda, Daria J.; McHale, Carolyn; Monteagudo, Edith; Pucci, Vincenzo; Rowley, Michael; Rudd, Michael T.; Soriano, Aileen; Stahlhut, Mark W.; Vacca, Joseph P.; Olsen, David B.; Liverton, Nigel J.; Carroll, Steven S.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4161-4167</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">HCV NS3/4a protease inhibitors are proven therapeutic agents against chronic hepatitis C virus infection, with boceprevir and telaprevir having recently received regulatory approval as add-on therapy to pegylated interferon/ribavirin for patients harboring genotype 1 infections.  Overcoming antiviral resistance, broad genotype coverage, and a convenient dosing regimen are important attributes for future agents to be used in combinations without interferon.  In this communication, we report the preclin. profile of MK-5172, a novel P2-P4 quinoxaline macrocyclic NS3/4a protease inhibitor currently in clin. development.  The compd. demonstrates subnanomolar activity against a broad enzyme panel encompassing major hepatitis C virus (HCV) genotypes as well as variants resistant to earlier protease inhibitors.  In replicon selections, MK-5172 exerted high selective pressure, which yielded few resistant colonies.  In both rat and dog, MK-5172 demonstrates good plasma and liver exposures, with 24-h liver levels suggestive of once-daily dosing.  When administered to HCV-infected chimpanzees harboring chronic gt1a or gt1b infections, MK-5172 suppressed viral load between 4 to 5 logs at a dose of 1 mg/kg of body wt. twice daily (b.i.d.) for 7 days.  Based on its preclin. profile, MK-5172 is anticipated to be broadly active against multiple HCV genotypes and clin. important resistance variants and highly suited for incorporation into newer all-oral regimens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomXxLJMTmWqrVg90H21EOLACvtfcHk0licAVUfAAAkZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFajs7zF&md5=8874f9279917137113e429cda31c1bba</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1128%2FAAC.00324-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00324-12%26sid%3Dliteratum%253Aachs%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DFandozzi%26aufirst%3DC.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DClaudio%26aufirst%3DG.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DDiMuzio%26aufirst%3DJ.%2BM.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDi%2BFilippo%26aufirst%3DM.%26aulast%3DGates%26aufirst%3DA.%2BT.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DHazuda%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DSoriano%26aufirst%3DA.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26atitle%3DMK-5172%252C%2520a%2520Selective%2520Inhibitor%2520of%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520with%2520Broad%2520Activity%2520across%2520Genotypes%2520and%2520Resistant%2520Variants%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2012%26volume%3D56%26spage%3D4161%26epage%3D4167%26doi%3D10.1128%2FAAC.00324-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Harper, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCauley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudd, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiFilippo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrocchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butcher, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nizi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludmerer, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimuzio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McHale, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahlhut, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteagudo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cianetti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giuliano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pucci, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trainor, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fandozzi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coleman, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacca, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Summa, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liverton, N. J.</span></span> <span> </span><span class="NLM_article-title">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">332</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1021/ml300017p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300017p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=332-336&author=S.+Harperauthor=J.+A.+McCauleyauthor=M.+T.+Ruddauthor=M.+Ferraraauthor=M.+DiFilippoauthor=B.+Crescenziauthor=U.+Kochauthor=A.+Petrocchiauthor=M.+K.+Hollowayauthor=J.+W.+Butcherauthor=J.+J.+Romanoauthor=K.+J.+Bushauthor=K.+F.+Gilbertauthor=C.+J.+McIntyreauthor=K.+T.+Nguyenauthor=E.+Niziauthor=S.+S.+Carrollauthor=S.+W.+Ludmererauthor=C.+Burleinauthor=J.+M.+Dimuzioauthor=D.+J.+Grahamauthor=C.+M.+McHaleauthor=M.+W.+Stahlhutauthor=D.+B.+Olsenauthor=E.+Monteagudoauthor=S.+Cianettiauthor=C.+Giulianoauthor=V.+Pucciauthor=N.+Trainorauthor=C.+M.+Fandozziauthor=M.+Rowleyauthor=P.+J.+Colemanauthor=J.+P.+Vaccaauthor=V.+Summaauthor=N.+J.+Liverton&title=Discovery+of+MK-5172%2C+a+Macrocyclic+Hepatitis+C+Virus+NS3%2F4a+Protease+Inhibitor&doi=10.1021%2Fml300017p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor</span></div><div class="casAuthors">Harper, Steven; McCauley, John A.; Rudd, Michael T.; Ferrara, Marco; DiFilippo, Marcello; Crescenzi, Benedetta; Koch, Uwe; Petrocchi, Alessia; Holloway, M. Katharine; Butcher, John W.; Romano, Joseph J.; Bush, Kimberly J.; Gilbert, Kevin F.; McIntyre, Charles J.; Nguyen, Kevin T.; Nizi, Emanuela; Carroll, Steven S.; Ludmerer, Steven W.; Burlein, Christine; DiMuzio, Jillian M.; Graham, Donald J.; McHale, Carolyn M.; Stahlhut, Mark W.; Olsen, David B.; Monteagudo, Edith; Cianetti, Simona; Giuliano, Claudio; Pucci, Vincenzo; Trainor, Nicole; Fandozzi, Christine M.; Rowley, Michael; Coleman, Paul J.; Vacca, Joseph P.; Summa, Vincenzo; Liverton, Nigel J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">332-336</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new class of HCV NS3/4a protease inhibitors contg. a P2 to P4 macrocyclic constraint was designed using a mol. modeling-derived strategy.  Building on the profile of previous clin. compds. and exploring the P2 and linker regions of the series allowed for optimization of broad genotype and mutant enzyme potency, cellular activity, and rat liver exposure following oral dosing.  These studies led to the identification of clin. candidate 15 (MK-5172), which is active against genotype 1-3 NS3/4a and clin. relevant mutant enzymes and has good plasma exposure and excellent liver exposure in multiple species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAzCaAN9VqJrVg90H21EOLACvtfcHk0lguDhdWyq7hzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFyjurg%253D&md5=efc04ad0ad47aef13b367fc38d6bbf63</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Fml300017p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300017p%26sid%3Dliteratum%253Aachs%26aulast%3DHarper%26aufirst%3DS.%26aulast%3DMcCauley%26aufirst%3DJ.%2BA.%26aulast%3DRudd%26aufirst%3DM.%2BT.%26aulast%3DFerrara%26aufirst%3DM.%26aulast%3DDiFilippo%26aufirst%3DM.%26aulast%3DCrescenzi%26aufirst%3DB.%26aulast%3DKoch%26aufirst%3DU.%26aulast%3DPetrocchi%26aufirst%3DA.%26aulast%3DHolloway%26aufirst%3DM.%2BK.%26aulast%3DButcher%26aufirst%3DJ.%2BW.%26aulast%3DRomano%26aufirst%3DJ.%2BJ.%26aulast%3DBush%26aufirst%3DK.%2BJ.%26aulast%3DGilbert%26aufirst%3DK.%2BF.%26aulast%3DMcIntyre%26aufirst%3DC.%2BJ.%26aulast%3DNguyen%26aufirst%3DK.%2BT.%26aulast%3DNizi%26aufirst%3DE.%26aulast%3DCarroll%26aufirst%3DS.%2BS.%26aulast%3DLudmerer%26aufirst%3DS.%2BW.%26aulast%3DBurlein%26aufirst%3DC.%26aulast%3DDimuzio%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BJ.%26aulast%3DMcHale%26aufirst%3DC.%2BM.%26aulast%3DStahlhut%26aufirst%3DM.%2BW.%26aulast%3DOlsen%26aufirst%3DD.%2BB.%26aulast%3DMonteagudo%26aufirst%3DE.%26aulast%3DCianetti%26aufirst%3DS.%26aulast%3DGiuliano%26aufirst%3DC.%26aulast%3DPucci%26aufirst%3DV.%26aulast%3DTrainor%26aufirst%3DN.%26aulast%3DFandozzi%26aufirst%3DC.%2BM.%26aulast%3DRowley%26aufirst%3DM.%26aulast%3DColeman%26aufirst%3DP.%2BJ.%26aulast%3DVacca%26aufirst%3DJ.%2BP.%26aulast%3DSumma%26aufirst%3DV.%26aulast%3DLiverton%26aufirst%3DN.%2BJ.%26atitle%3DDiscovery%2520of%2520MK-5172%252C%2520a%2520Macrocyclic%2520Hepatitis%2520C%2520Virus%2520NS3%252F4a%2520Protease%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D332%26epage%3D336%26doi%3D10.1021%2Fml300017p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Mitchell, L. J.,  Jr.</span>; <span class="NLM_string-name">Nieman, J. A.</span></span> <span> </span><span class="NLM_article-title">Anticoronaviral Compounds and Compositions, Their Pharmaceutical Uses and Materials for Their Synthesis</span>. <span class="NLM_patent">WO2005113580A1</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+S.+Kania&author=L.+J.+Mitchell&author=J.+A.+Nieman&title=Anticoronaviral+Compounds+and+Compositions%2C+Their+Pharmaceutical+Uses+and+Materials+for+Their+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DAnticoronaviral%2520Compounds%2520and%2520Compositions%252C%2520Their%2520Pharmaceutical%2520Uses%2520and%2520Materials%2520for%2520Their%2520Synthesis%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span>; <span class="NLM_string-name">Mitchell, L. J.,  Jr.</span>; <span class="NLM_string-name">Nieman, J. A.</span></span> <span> </span><span class="NLM_article-title">Anticoronaviral Compounds and Compositions, Their Pharmaceutical Uses and Materials for Their Synthesis</span>. <span class="NLM_patent">WO2006061714A2</span>, <span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=R.+S.+Kania&author=L.+J.+Mitchell&author=J.+A.+Nieman&title=Anticoronaviral+Compounds+and+Compositions%2C+Their+Pharmaceutical+Uses+and+Materials+for+Their+Synthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DKania%26aufirst%3DR.%2BS.%26atitle%3DAnticoronaviral%2520Compounds%2520and%2520Compositions%252C%2520Their%2520Pharmaceutical%2520Uses%2520and%2520Materials%2520for%2520Their%2520Synthesis%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thanigaimalai, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konno, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koiwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yakushiji, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaji, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naser-Tavakolian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶n, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freire, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, Y.</span></span> <span> </span><span class="NLM_article-title">Development of Potent Dipeptide-Type SARS-CoV 3CL Protease Inhibitors with Novel P3 Scaffolds: Design, Synthesis, Biological Evaluation, and Docking Studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">372</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2013.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.ejmech.2013.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23994330" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2013&pages=372-384&author=P.+Thanigaimalaiauthor=S.+Konnoauthor=T.+Yamamotoauthor=Y.+Koiwaiauthor=A.+Taguchiauthor=K.+Takayamaauthor=F.+Yakushijiauthor=K.+Akajiauthor=S.+E.+Chenauthor=A.+Naser-Tavakolianauthor=A.+Sch%C3%B6nauthor=E.+Freireauthor=Y.+Hayashi&title=Development+of+Potent+Dipeptide-Type+SARS-CoV+3CL+Protease+Inhibitors+with+Novel+P3+Scaffolds%3A+Design%2C+Synthesis%2C+Biological+Evaluation%2C+and+Docking+Studies&doi=10.1016%2Fj.ejmech.2013.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies</span></div><div class="casAuthors">Thanigaimalai, Pillaiyar; Konno, Sho; Yamamoto, Takehito; Koiwai, Yuji; Taguchi, Akihiro; Takayama, Kentaro; Yakushiji, Fumika; Akaji, Kenichi; Chen, Shen-En; Naser-Tavakolian, Aurash; Schon, Arne; Freire, Ernesto; Hayashi, Yoshio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">372-384</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">We report the design and synthesis of a series of dipeptide-type inhibitors with novel P3 scaffolds that display potent inhibitory activity against SARS-CoV 3CLpro.  A docking study involving binding between the dipeptidic lead compd. (I) and 3CLpro suggested the modification of a structurally flexible P3 N-(3-methoxyphenyl)glycine with various rigid P3 moieties in I.  The modifications led to the identification of several potent derivs. with the inhibitory activities (Ki or IC50) in the submicromolar to nanomolar range.  Compd. (II) , in particular, displayed the most potent inhibitory activity, with a Ki value of 0.006 Î¼M.  This potency was 65-fold higher than the potency of the lead compd. I (Ki = 0.39 Î¼M).  In addn., the Ki value of II was in very good agreement with the binding affinity (16 nM) obsd. in isothermal titrn. calorimetry (ITC).  A SAR study around the P3 group in the lead 4 led to the identification of a rigid indole-2-carbonyl unit as one of the best P3 moieties (III).  Further optimization showed that a methoxy substitution at the 4-position on the indole unit was highly favorable for enhancing the inhibitory potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeJOG03zeobLVg90H21EOLACvtfcHk0lguDhdWyq7hzw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1ShsrzL&md5=28055f45719f5220358fac55d015d2ff</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DThanigaimalai%26aufirst%3DP.%26aulast%3DKonno%26aufirst%3DS.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DKoiwai%26aufirst%3DY.%26aulast%3DTaguchi%26aufirst%3DA.%26aulast%3DTakayama%26aufirst%3DK.%26aulast%3DYakushiji%26aufirst%3DF.%26aulast%3DAkaji%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DS.%2BE.%26aulast%3DNaser-Tavakolian%26aufirst%3DA.%26aulast%3DSch%25C3%25B6n%26aufirst%3DA.%26aulast%3DFreire%26aufirst%3DE.%26aulast%3DHayashi%26aufirst%3DY.%26atitle%3DDevelopment%2520of%2520Potent%2520Dipeptide-Type%2520SARS-CoV%25203CL%2520Protease%2520Inhibitors%2520with%2520Novel%2520P3%2520Scaffolds%253A%2520Design%252C%2520Synthesis%252C%2520Biological%2520Evaluation%252C%2520and%2520Docking%2520Studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D68%26spage%3D372%26epage%3D384%26doi%3D10.1016%2Fj.ejmech.2013.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brothers, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozminski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockner, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marra, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planken, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowe, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solowiej, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taggart, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.0c01063</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01063" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=R.+L.+Hoffmanauthor=R.+S.+Kaniaauthor=M.+A.+Brothersauthor=J.+F.+Daviesauthor=R.+A.+Ferreauthor=K.+S.+Gajiwalaauthor=M.+Heauthor=R.+J.+Hoganauthor=K.+Kozminskiauthor=L.+Y.+Liauthor=J.+W.+Locknerauthor=J.+Louauthor=M.+T.+Marraauthor=L.+J.+Mitchellauthor=B.+W.+Murrayauthor=J.+A.+Niemanauthor=S.+Noellauthor=S.+P.+Plankenauthor=T.+Roweauthor=K.+Ryanauthor=G.+J.+Smithauthor=J.+E.+Solowiejauthor=C.+M.+Steppanauthor=B.+Taggart&title=Discovery+of+Ketone-Based+Covalent+Inhibitors+of+Coronavirus+3CL+Proteases+for+the+Potential+Therapeutic+Treatment+of+COVID-19&doi=10.1021%2Facs.jmedchem.0c01063"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01063%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DR.%2BL.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DBrothers%26aufirst%3DM.%2BA.%26aulast%3DDavies%26aufirst%3DJ.%2BF.%26aulast%3DFerre%26aufirst%3DR.%2BA.%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DHe%26aufirst%3DM.%26aulast%3DHogan%26aufirst%3DR.%2BJ.%26aulast%3DKozminski%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DL.%2BY.%26aulast%3DLockner%26aufirst%3DJ.%2BW.%26aulast%3DLou%26aufirst%3DJ.%26aulast%3DMarra%26aufirst%3DM.%2BT.%26aulast%3DMitchell%26aufirst%3DL.%2BJ.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DNieman%26aufirst%3DJ.%2BA.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DPlanken%26aufirst%3DS.%2BP.%26aulast%3DRowe%26aufirst%3DT.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DSmith%26aufirst%3DG.%2BJ.%26aulast%3DSolowiej%26aufirst%3DJ.%2BE.%26aulast%3DSteppan%26aufirst%3DC.%2BM.%26aulast%3DTaggart%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520Ketone-Based%2520Covalent%2520Inhibitors%2520of%2520Coronavirus%25203CL%2520Proteases%2520for%2520the%2520Potential%2520Therapeutic%2520Treatment%2520of%2520COVID-19%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26doi%3D10.1021%2Facs.jmedchem.0c01063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boras, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anson, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arenson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aschenbrenner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bakowski, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beutler, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kadar, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kania, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimoto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkpatrick, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanyon, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lendy, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lillis, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthra, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oâ Brien, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâConnor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogilvie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pettersson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reese, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossulek, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sathish, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steppan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticehurst, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Updyke, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allerton, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.09.12.293498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.09.12.293498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32935104" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=B.+Borasauthor=R.+M.+Jonesauthor=B.+J.+Ansonauthor=D.+Arensonauthor=L.+Aschenbrennerauthor=M.+A.+Bakowskiauthor=N.+Beutlerauthor=J.+Binderauthor=E.+Chenauthor=H.+Engauthor=J.+Hammondauthor=R.+Hoffmanauthor=E.+P.+Kadarauthor=R.+Kaniaauthor=E.+Kimotoauthor=M.+G.+Kirkpatrickauthor=L.+Lanyonauthor=E.+K.+Lendyauthor=J.+R.+Lillisauthor=S.+A.+Luthraauthor=C.+Maauthor=S.+Noellauthor=R.+S.+Obachauthor=M.+N.+O%E2%80%99+Brienauthor=R.+O%E2%80%99Connorauthor=K.+Ogilvieauthor=D.+Owenauthor=M.+Petterssonauthor=M.+R.+Reeseauthor=T.+F.+Rogersauthor=M.+I.+Rossulekauthor=J.+G.+Sathishauthor=C.+Steppanauthor=M.+Ticehurstauthor=L.+W.+Updykeauthor=Y.+Zhuauthor=J.+Wangauthor=A.+K.+Chatterjeeauthor=A.+D.+Mesecarauthor=A.+S.+Andersonauthor=C.+Allerton&title=Discovery+of+a+Novel+Inhibitor+of+Coronavirus+3CL+Protease+as+a+Clinical+Candidate+for+the+Potential+Treatment+of+COVID-19&doi=10.1101%2F2020.09.12.293498"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1101%2F2020.09.12.293498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.09.12.293498%26sid%3Dliteratum%253Aachs%26aulast%3DBoras%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DR.%2BM.%26aulast%3DAnson%26aufirst%3DB.%2BJ.%26aulast%3DArenson%26aufirst%3DD.%26aulast%3DAschenbrenner%26aufirst%3DL.%26aulast%3DBakowski%26aufirst%3DM.%2BA.%26aulast%3DBeutler%26aufirst%3DN.%26aulast%3DBinder%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DEng%26aufirst%3DH.%26aulast%3DHammond%26aufirst%3DJ.%26aulast%3DHoffman%26aufirst%3DR.%26aulast%3DKadar%26aufirst%3DE.%2BP.%26aulast%3DKania%26aufirst%3DR.%26aulast%3DKimoto%26aufirst%3DE.%26aulast%3DKirkpatrick%26aufirst%3DM.%2BG.%26aulast%3DLanyon%26aufirst%3DL.%26aulast%3DLendy%26aufirst%3DE.%2BK.%26aulast%3DLillis%26aufirst%3DJ.%2BR.%26aulast%3DLuthra%26aufirst%3DS.%2BA.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DNoell%26aufirst%3DS.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599%2BBrien%26aufirst%3DM.%2BN.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DR.%26aulast%3DOgilvie%26aufirst%3DK.%26aulast%3DOwen%26aufirst%3DD.%26aulast%3DPettersson%26aufirst%3DM.%26aulast%3DReese%26aufirst%3DM.%2BR.%26aulast%3DRogers%26aufirst%3DT.%2BF.%26aulast%3DRossulek%26aufirst%3DM.%2BI.%26aulast%3DSathish%26aufirst%3DJ.%2BG.%26aulast%3DSteppan%26aufirst%3DC.%26aulast%3DTicehurst%26aufirst%3DM.%26aulast%3DUpdyke%26aufirst%3DL.%2BW.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DChatterjee%26aufirst%3DA.%2BK.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26aulast%3DAnderson%26aufirst%3DA.%2BS.%26aulast%3DAllerton%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Inhibitor%2520of%2520Coronavirus%25203CL%2520Protease%2520as%2520a%2520Clinical%2520Candidate%2520for%2520the%2520Potential%2520Treatment%2520of%2520COVID-19%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.09.12.293498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span> <i>Pfizer Investor
Day Features Significant Number of Pipeline Advances
for COVID-19 Programs and Across Numerous Therapeutic Areas</i>; <span class="NLM_publisher-name">Pfizer</span>, <span class="NLM_year">2020</span>;<a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline" class="extLink">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-investor-day-features-significant-number-pipeline</a> (accessed 2020-09-25).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Pfizer+Investor%0ADay+Features+Significant+Number+of+Pipeline+Advances%0Afor+COVID-19+Programs+and+Across+Numerous+Therapeutic+Areas%3B+Pfizer%2C+2020%3Bhttps%3A%2F%2Fwww.pfizer.com%2Fnews%2Fpress-release%2Fpress-release-detail%2Fpfizer-investor-day-features-significant-number-pipeline+%28accessed+2020-09-25%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DPfizer%2520Investor%250ADay%2520Features%2520Significant%2520Number%2520of%2520Pipeline%2520Advances%250Afor%2520COVID-19%2520Programs%2520and%2520Across%2520Numerous%2520Therapeutic%2520Areas%26pub%3DPfizer%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.-x.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, W.-j.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, H.-c.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.-n.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.-q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.-s.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.-f.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.-w.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.-p.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-l.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.-c.</span></span> <span> </span><span class="NLM_article-title">Anti-SARS-CoV-2 Activities in Vitro of Shuanghuanglian Preparations and Bioactive Ingredients</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1167</span>â <span class="NLM_lpage">1177</span>, <span class="refDoi">Â DOI: 10.1038/s41401-020-0483-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41401-020-0483-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32737471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFShu7vI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2020&pages=1167-1177&author=H.-x.+Suauthor=S.+Yaoauthor=W.-f.+Zhaoauthor=M.-j.+Liauthor=J.+Liuauthor=W.-j.+Shangauthor=H.+Xieauthor=C.-q.+Keauthor=H.-c.+Huauthor=M.-n.+Gaoauthor=K.-q.+Yuauthor=H.+Liuauthor=J.-s.+Shenauthor=W.+Tangauthor=L.-k.+Zhangauthor=G.-f.+Xiaoauthor=L.+Niauthor=D.-w.+Wangauthor=J.-p.+Zuoauthor=H.-l.+Jiangauthor=F.+Baiauthor=Y.+Wuauthor=Y.+Yeauthor=Y.-c.+Xu&title=Anti-SARS-CoV-2+Activities+in+Vitro+of+Shuanghuanglian+Preparations+and+Bioactive+Ingredients&doi=10.1038%2Fs41401-020-0483-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients</span></div><div class="casAuthors">Su, Hai-xia; Yao, Sheng; Zhao, Wen-feng; Li, Min-jun; Liu, Jia; Shang, Wei-juan; Xie, Hang; Ke, Chang-qiang; Hu, Hang-chen; Gao, Mei-na; Yu, Kun-qian; Liu, Hong; Shen, Jing-shan; Tang, Wei; Zhang, Lei-ke; Xiao, Geng-fu; Ni, Li; Wang, Dao-wen; Zuo, Jian-ping; Jiang, Hua-liang; Bai, Fang; Wu, Yan; Ye, Yang; Xu, Ye-chun</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1167-1177</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and there is no cure currently.  The 3CL protease (3CLpro) is a highly conserved protease which is indispensable for CoVs replication, and is a promising target for development of broad-spectrum antiviral drugs.  In this study we investigated the anti-SARS-CoV-2 potential of Shuanghuanglian prepn., a Chinese traditional patent medicine with a long history for treating respiratory tract infection in China.  We showed that either the oral liq. of Shuanghuanglian, the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-2 3CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.  Baicalin and baicalein, two ingredients of Shuanghuanglian, were characterized as the first noncovalent, nonpeptidomimetic inhibitors of SARS-CoV-2 3CLpro and exhibited potent antiviral activities in a cell-based system.  Remarkably, the binding mode of baicalein with SARS-CoV-2 3CLpro detd. by X-ray protein crystallog. was distinctly different from those of known 3CLpro inhibitors.  Baicalein was productively ensconced in the core of the substrate-binding pocket by interacting with two catalytic residues, the crucial S1/S2 subsites and the oxyanion loop, acting as a "shield" in front of the catalytic dyad to effectively prevent substrate access to the catalytic dyad within the active site.  Overall, this study provides an example for exploring the in vitro potency of Chinese traditional patent medicines and effectively identifying bioactive ingredients toward a specific target, and gains evidence supporting the in vivo studies of Shuanghuanglian oral liq. as well as two natural products for COVID-19 treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoE-aZrrHwqZrVg90H21EOLACvtfcHk0lianPjwEyVJYg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFShu7vI&md5=8560cc7a979d67e0fa0cf17eee71ef00</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fs41401-020-0483-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-020-0483-6%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.-x.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.-f.%26aulast%3DLi%26aufirst%3DM.-j.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DW.-j.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DC.-q.%26aulast%3DHu%26aufirst%3DH.-c.%26aulast%3DGao%26aufirst%3DM.-n.%26aulast%3DYu%26aufirst%3DK.-q.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.-s.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.-k.%26aulast%3DXiao%26aufirst%3DG.-f.%26aulast%3DNi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DD.-w.%26aulast%3DZuo%26aufirst%3DJ.-p.%26aulast%3DJiang%26aufirst%3DH.-l.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.-c.%26atitle%3DAnti-SARS-CoV-2%2520Activities%2520in%2520Vitro%2520of%2520Shuanghuanglian%2520Preparations%2520and%2520Bioactive%2520Ingredients%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2020%26volume%3D41%26spage%3D1167%26epage%3D1177%26doi%3D10.1038%2Fs41401-020-0483-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Scutellaria Baicalensis Extract and Baicalein Inhibit Replication of SARS-CoV-2 and Its 3C-like Protease in Vitro</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.10.035824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.10.035824" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Liuauthor=F.+Yeauthor=Q.+Sunauthor=H.+Liangauthor=C.+Liauthor=R.+Luauthor=B.+Huangauthor=W.+Tanauthor=L.+Lai&title=Scutellaria+Baicalensis+Extract+and+Baicalein+Inhibit+Replication+of+SARS-CoV-2+and+Its+3C-like+Protease+in+Vitro&doi=10.1101%2F2020.04.10.035824"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1101%2F2020.04.10.035824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.10.035824%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DLiang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DLu%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DScutellaria%2520Baicalensis%2520Extract%2520and%2520Baicalein%2520Inhibit%2520Replication%2520of%2520SARS-CoV-2%2520and%2520Its%25203C-like%2520Protease%2520in%2520Vitro%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.10.035824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of Baicalin and Baicalein as Novel, Natural Product Inhibitors of SARS-CoV-2 3CL Protease in Vitro</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.13.038687</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.13.038687" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=H.+Suauthor=S.+Yaoauthor=W.+Zhaoauthor=M.+Liauthor=J.+Liuauthor=W.+Shangauthor=H.+Xieauthor=C.+Keauthor=M.+Gaoauthor=K.+Yuauthor=H.+Liuauthor=J.+Shenauthor=W.+Tangauthor=L.+Zhangauthor=J.+Zuoauthor=H.+Jiangauthor=F.+Baiauthor=Y.+Wuauthor=Y.+Yeauthor=Y.+Xu&title=Discovery+of+Baicalin+and+Baicalein+as+Novel%2C+Natural+Product+Inhibitors+of+SARS-CoV-2+3CL+Protease+in+Vitro&doi=10.1101%2F2020.04.13.038687"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1101%2F2020.04.13.038687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.13.038687%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DW.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DKe%26aufirst%3DC.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZuo%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Baicalin%2520and%2520Baicalein%2520as%2520Novel%252C%2520Natural%2520Product%2520Inhibitors%2520of%2520SARS-CoV-2%25203CL%2520Protease%2520in%2520Vitro%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.13.038687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, X.</span></span> <span> </span><span class="NLM_article-title">Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of Baicalein Chewable Tablets in Healthy Subjects</span>. <i>J. Ethnopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">210</span>â <span class="NLM_lpage">215</span>, <span class="refDoi">Â DOI: 10.1016/j.jep.2014.08.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jep.2014.08.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25219601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFGlurrJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2014&pages=210-215&author=M.+Liauthor=A.+Shiauthor=H.+Pangauthor=W.+Xueauthor=Y.+Liauthor=G.+Caoauthor=B.+Yanauthor=F.+Dongauthor=K.+Liauthor=W.+Xiaoauthor=G.+Heauthor=G.+Duauthor=X.+Hu&title=Safety%2C+Tolerability%2C+and+Pharmacokinetics+of+a+Single+Ascending+Dose+of+Baicalein+Chewable+Tablets+in+Healthy+Subjects&doi=10.1016%2Fj.jep.2014.08.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects</span></div><div class="casAuthors">Li, Min; Shi, Aixin; Pang, Hongxian; Xue, Wei; Li, Yang; Cao, Guoying; Yan, Bei; Dong, Fan; Li, Kexin; Xiao, Wei; He, Guorong; Du, Guanhua; Hu, Xin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Ethnopharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">210-215</span>CODEN:
                <span class="NLM_cas:coden">JOETD7</span>;
        ISSN:<span class="NLM_cas:issn">0378-8741</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The root of Scutellaria baicalensis Georgi has been used extensively in traditional Chinese medicine for the treatment of inflammation, fever, cough, dysentery, and hypertension.  Baicalein is a flavonoid isolated from the root of Scutellaria baicalensis Georgi and is a novel neuroprotective agent under development for the treatment of Parkinson's disease.  We aimed to investigate the pharmacokinetic (PK) properties of baicalein and its main metabolite, bacalin, after single-dose administration in healthy Chinese subjects.  The safety and tolerability of baicalein were also assessed.This was a Phase I, randomized, double-blind, single-dose trial of baicalein (100-2800 mg) in 72 healthy adults.  Samples of blood, urine and feces were collected at regular intervals up to 48 h after administration of the study drug.  Baicalein and baicalin were then analyzed using liq. chromatog.-tandem mass spectrometry (LC/MS/MS).  The max. concn. that the drug achieved after dosing (Cmax), time to Cmax (Tmax), terminal half-life (t1/2), area under the curve from time zero to time of last quantifiable concn. (AUC(0, t)), area under the curve from time zero to infinity (AUC(0, â)), apparent total plasma clearance (CL/F), and apparent total vol. of distribution (V/F) were detd. using non-compartmental models.  Dose proportion was tested using a method combining the equivalence criterion and power model.  Phys. examns., vital signs, ECG findings, hematol., and urinalysis were monitored before and at regular intervals after administration of the study drug.  The PK profile of baicelein and baicelin was characterized by a median Tmax of 0.75-3.5 h and 0.5-3 h, resp., followed by a multiphasic profile with a t1/2 of 1.90-15.01 h and 4.22-10.80 h, resp.  The ests. of the proportionality coeff. (90% CI) for Cmax, AUC0-t and AUC0-â were 0.83 (0.70-0.96), 0.91 (0.81-1.00) and 0.92 (0.82-1.02), resp.  All values overlapped within the pre-specified range of (0.89-1.11), (0.93-1.07), and (0.93-1.07), resp.  Dose proportionality was inconclusive for a baicalein dose range of 100-2800 mg.  The total urinary clearance of baicalein and baicalin was <1%.  Approx. 27% of baicalein was eliminated as unchanged drug in feces.  Baicalein was well tolerated.  Eleven treatment-related adverse events were obsd., and all were rated as "mild" and resolved without further treatment.  No serious adverse events occurred.Single oral doses of 100-2800 mg of baicalein were safe and well tolerated by healthy subjects.  Clin. lab. assessments showed no signs of toxicity in the liver or kidney.  The favorable safety profile and PK properties warrant further clin. studies for baicalein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozaMGqrPx7VbVg90H21EOLACvtfcHk0lhWuc5CCQae6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFGlurrJ&md5=4904b8921908f1f6618188f132763d7f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.jep.2014.08.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jep.2014.08.031%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DA.%26aulast%3DPang%26aufirst%3DH.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DG.%26aulast%3DYan%26aufirst%3DB.%26aulast%3DDong%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DHe%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DHu%26aufirst%3DX.%26atitle%3DSafety%252C%2520Tolerability%252C%2520and%2520Pharmacokinetics%2520of%2520a%2520Single%2520Ascending%2520Dose%2520of%2520Baicalein%2520Chewable%2520Tablets%2520in%2520Healthy%2520Subjects%26jtitle%3DJ.%2520Ethnopharmacol.%26date%3D2014%26volume%3D156%26spage%3D210%26epage%3D215%26doi%3D10.1016%2Fj.jep.2014.08.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grum-Tokars, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turlington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saldanha, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chase, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eggler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielech, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindsley, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span> <span> </span><span class="NLM_article-title">Discovery, Synthesis, and Structure-Based Optimization of a Series of N -(Tert -Butyl)-2-(N -Arylamido)-2-(Pyridin-3-Yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">534</span>â <span class="NLM_lpage">546</span>, <span class="refDoi">Â DOI: 10.1021/jm301580n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301580n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=534-546&author=J.+Jacobsauthor=V.+Grum-Tokarsauthor=Y.+Zhouauthor=M.+Turlingtonauthor=S.+A.+Saldanhaauthor=P.+Chaseauthor=A.+Egglerauthor=E.+S.+Dawsonauthor=Y.+M.+Baez-Santosauthor=S.+Tomarauthor=A.+M.+Mielechauthor=S.+C.+Bakerauthor=C.+W.+Lindsleyauthor=P.+Hodderauthor=A.+Mesecarauthor=S.+R.+Stauffer&title=Discovery%2C+Synthesis%2C+and+Structure-Based+Optimization+of+a+Series+of+N+-%28Tert+-Butyl%29-2-%28N+-Arylamido%29-2-%28Pyridin-3-Yl%29+Acetamides+%28ML188%29+as+Potent+Noncovalent+Small+Molecule+Inhibitors+of+the+Severe+Acute+Respiratory+Syndrome+Coronavirus+%28SARS-CoV%29+3CL&doi=10.1021%2Fjm301580n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease</span></div><div class="casAuthors">Jacobs, Jon; Grum-Tokars, Valerie; Zhou, Ya; Turlington, Mark; Saldanha, S. Adrian; Chase, Peter; Eggler, Aimee; Dawson, Eric S.; Baez-Santos, Yahira M.; Tomar, Sakshi; Mielech, Anna M.; Baker, Susan C.; Lindsley, Craig W.; Hodder, Peter; Mesecar, Andrew; Stauffer, Shaun R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">534-546</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A high-throughput screen of the NIH mol. libraries sample collection and subsequent optimization of a lead dipeptide-like series of severe acute respiratory syndrome (SARS) main protease (3CLpro) inhibitors led to the identification of probe compd. ML188 (I), [(R)-N-(4-(tert-butyl)phenyl)-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-3-yl)ethyl)furan-2-carboxamide, Pubchem CID: 46897844].  Unlike the majority of reported coronavirus 3CLpro inhibitors that act via covalent modification of the enzyme, I is a noncovalent SARS-CoV 3CLpro inhibitor with moderate MW and good enzyme and antiviral inhibitory activity.  A multicomponent Ugi reaction was utilized to rapidly explore structure-activity relationships within S1', S1, and S2 enzyme binding pockets.  The X-ray structure of SARS-CoV 3CLpro bound with I was instrumental in guiding subsequent rounds of chem. optimization.  I provides an excellent starting point for the further design and refinement of 3CLpro inhibitors that act by a noncovalent mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ_0gMuIcLErVg90H21EOLACvtfcHk0lhWuc5CCQae6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVWqtL%252FE&md5=6f619d5642a8d29bdb9eee0b28a80247</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1021%2Fjm301580n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301580n%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DJ.%26aulast%3DGrum-Tokars%26aufirst%3DV.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DTurlington%26aufirst%3DM.%26aulast%3DSaldanha%26aufirst%3DS.%2BA.%26aulast%3DChase%26aufirst%3DP.%26aulast%3DEggler%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DE.%2BS.%26aulast%3DBaez-Santos%26aufirst%3DY.%2BM.%26aulast%3DTomar%26aufirst%3DS.%26aulast%3DMielech%26aufirst%3DA.%2BM.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DLindsley%26aufirst%3DC.%2BW.%26aulast%3DHodder%26aufirst%3DP.%26aulast%3DMesecar%26aufirst%3DA.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26atitle%3DDiscovery%252C%2520Synthesis%252C%2520and%2520Structure-Based%2520Optimization%2520of%2520a%2520Series%2520of%2520N%2520-%2528Tert%2520-Butyl%2529-2-%2528N%2520-Arylamido%2529-2-%2528Pyridin-3-Yl%2529%2520Acetamides%2520%2528ML188%2529%2520as%2520Potent%2520Noncovalent%2520Small%2520Molecule%2520Inhibitors%2520of%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520%2528SARS-CoV%2529%25203CL%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D534%26epage%3D546%26doi%3D10.1021%2Fjm301580n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span> <i>COVID-19, Main Protease
Structure and XChem Fragment Screen</i>; <span class="NLM_publisher-name">Diamond
Light Source</span>, <span class="NLM_year">2020</span>; <a href="https://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html" class="extLink">hhttps://www.diamond.ac.uk/covid-19/for-scientists/Main-protease-structure-and-XChem.html</a> (accessed 2020-06-).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+COVID-19%2C+Main+Protease%0AStructure+and+XChem+Fragment+Screen%3B+Diamond%0ALight+Source%2C+2020%3B+hhttps%3A%2F%2Fwww.diamond.ac.uk%2Fcovid-19%2Ffor-scientists%2FMain-protease-structure-and-XChem.html+%28accessed+2020-06-%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DCOVID-19%252C%2520Main%2520Protease%250AStructure%2520and%2520XChem%2520Fragment%2520Screen%26pub%3DDiamond%250ALight%2520Source%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parnham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sies, H.</span></span> <span> </span><span class="NLM_article-title">Ebselen: Prospective Therapy for Cerebral Ischaemia</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">607</span>â <span class="NLM_lpage">619</span>, <span class="refDoi">Â DOI: 10.1517/13543784.9.3.607</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1517%2F13543784.9.3.607" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=11060699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhslKnsbs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2000&pages=607-619&author=M.+Parnhamauthor=H.+Sies&title=Ebselen%3A+Prospective+Therapy+for+Cerebral+Ischaemia&doi=10.1517%2F13543784.9.3.607"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Ebselen: prospective therapy for cerebral ischaemia</span></div><div class="casAuthors">Parnham, Michael; Sies, Helmut</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">607-619</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 82 refs.  Stroke occurs due to hemorrhage or occlusive injury and results in ischemia and reperfusion injury.  A variety of destructive mechanisms are involved including oxygen radical generation, calcium overload, cytotoxicity and apoptosis as well as the generation of inflammatory mediators.  Ebselen, 2-phenyl-1,2-benzisoselenazol-3(2H)-one (PZ 51, DR3305), is a mimic of GSH peroxidase which also reacts with peroxynitrite and can inhibit enzymes such as lipoxygenases, NO synthases, NADPH oxidase, protein kinase C and H+/K+-ATPase.  Ebselen is in a late stage of development for the treatment of stroke.  The mol. actions of ebselen contribute to its anti-inflammatory and anti-oxidant properties, which have been demonstrated in a variety of in vivo models.  Numerous in vitro expts. using isolated LDL, liposomes, microsomes, isolated cells and organs have established that ebselen protects against oxidative challenge.  Unlike many inorg. and aliph. selenium compds., ebselen has low toxicity as metab. of the compd. does not liberate the selenium moiety, which remains within the ring structure.  Subsequent metab. involves methylation, glucuronidation and hydroxylation.  Exptl. studies in rats and dogs have revealed that ebselen is able to inhibit both vasospasm and tissue damage in stroke models, which correlates with its inhibitory effects on oxidative processes.  Results from randomized, placebo-controlled, double-blind clin. studies on the neurol. consequences of acute ischemic stroke, subarachnoid hemorrhage and acute middle cerebral artery occlusion, have revealed that ebselen significantly enhances outcome in patients who have experienced occlusive cerebral ischemia of limited duration.  The benefit achieved with ebselen is closely related to the rapidity with which the treatment is initiated, following the onset of the stroke attack.  Safety and tolerability are good and no adverse effects have become apparent.  Ebselen is currently at the pre-registration stage for subarachnoid hemorrhage and stroke in Japan.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGRNMF1u9z8rVg90H21EOLACvtfcHk0lhWuc5CCQae6Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhslKnsbs%253D&md5=4f5cd68b3073784362ce3b43ce474a7d</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1517%2F13543784.9.3.607&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543784.9.3.607%26sid%3Dliteratum%253Aachs%26aulast%3DParnham%26aufirst%3DM.%26aulast%3DSies%26aufirst%3DH.%26atitle%3DEbselen%253A%2520Prospective%2520Therapy%2520for%2520Cerebral%2520Ischaemia%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2000%26volume%3D9%26spage%3D607%26epage%3D619%26doi%3D10.1517%2F13543784.9.3.607" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bredenbeek, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thiel, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, L. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rozanov, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spaan, W. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span> <span> </span><span class="NLM_article-title">Unique and Conserved Features of Genome and Proteome of SARS-Coronavirus, an Early Split-off from the Coronavirus Group 2 Lineage</span>. <i>J. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>331</i></span>,  <span class="NLM_fpage">991</span>â <span class="NLM_lpage">1004</span>, <span class="refDoi">Â DOI: 10.1016/S0022-2836(03)00865-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0022-2836%2803%2900865-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=12927536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVCls7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=331&publication_year=2003&pages=991-1004&author=E.+J.+Snijderauthor=P.+J.+Bredenbeekauthor=J.+C.+Dobbeauthor=V.+Thielauthor=J.+Ziebuhrauthor=L.+L.+M.+Poonauthor=Y.+Guanauthor=M.+Rozanovauthor=W.+J.+M.+Spaanauthor=A.+E.+Gorbalenya&title=Unique+and+Conserved+Features+of+Genome+and+Proteome+of+SARS-Coronavirus%2C+an+Early+Split-off+from+the+Coronavirus+Group+2+Lineage&doi=10.1016%2FS0022-2836%2803%2900865-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage</span></div><div class="casAuthors">Snijder, Eric J.; Bredenbeek, Peter J.; Dobbe, Jessika C.; Thiel, Volker; Ziebuhr, John; Poon, Leo L. M.; Guan, Yi; Rozanov, Mikhail; Spaan, Willy J. M.; Gorbalenya, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">331</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">991-1004</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The genome organization and expression strategy of the newly identified severe acute respiratory syndrome coronavirus (SARS-CoV) were predicted using recently published genome sequences.  Fourteen putative open reading frames were identified, 12 of which were predicted to be expressed from a nested set of eight subgenomic mRNAs.  The synthesis of these mRNAs in SARS-CoV-infected cells was confirmed exptl.  The 4382- and 7073 amino acid residue SARS-CoV replicase polyproteins are predicted to be cleaved into 16 subunits by two viral proteinases (bringing the total no. of SARS-CoV proteins to 28).  A phylogenetic anal. of the replicase gene, using a distantly related torovirus as an outgroup, demonstrated that, despite a no. of unique features, SARS-CoV is most closely related to group 2 coronaviruses.  Distant homologs of cellular RNA processing enzymes were identified in group 2 coronaviruses, with four of them being conserved in SARS-CoV.  These newly recognized viral enzymes place the mechanism of coronavirus RNA synthesis in a completely new perspective.  Furthermore, together with previously described viral enzymes, they will be important targets for the design of antiviral strategies aimed at controlling the further spread of SARS-CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrm1drrDFEB-7Vg90H21EOLACvtfcHk0lib_SFsVtSaoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVCls7w%253D&md5=ae66a6495dfa0c753d589f91e3f9a23c</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2803%2900865-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252803%252900865-9%26sid%3Dliteratum%253Aachs%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DBredenbeek%26aufirst%3DP.%2BJ.%26aulast%3DDobbe%26aufirst%3DJ.%2BC.%26aulast%3DThiel%26aufirst%3DV.%26aulast%3DZiebuhr%26aufirst%3DJ.%26aulast%3DPoon%26aufirst%3DL.%2BL.%2BM.%26aulast%3DGuan%26aufirst%3DY.%26aulast%3DRozanov%26aufirst%3DM.%26aulast%3DSpaan%26aufirst%3DW.%2BJ.%2BM.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26atitle%3DUnique%2520and%2520Conserved%2520Features%2520of%2520Genome%2520and%2520Proteome%2520of%2520SARS-Coronavirus%252C%2520an%2520Early%2520Split-off%2520from%2520the%2520Coronavirus%2520Group%25202%2520Lineage%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D331%26spage%3D991%26epage%3D1004%26doi%3D10.1016%2FS0022-2836%2803%2900865-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©cine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">The SARS-Coronavirus PLnc Domain of Nsp3 as a Replication/Transcription Scaffolding Protein</span>. <i>Virus Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>133</i></span>,  <span class="NLM_fpage">136</span>â <span class="NLM_lpage">148</span>, <span class="refDoi">Â DOI: 10.1016/j.virusres.2007.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.virusres.2007.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18255185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktVKlu7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=133&publication_year=2008&pages=136-148&author=I.+Imbertauthor=E.+J.+Snijderauthor=M.+Dimitrovaauthor=J.+C.+Guillemotauthor=P.+L%C3%A9cineauthor=B.+Canard&title=The+SARS-Coronavirus+PLnc+Domain+of+Nsp3+as+a+Replication%2FTranscription+Scaffolding+Protein&doi=10.1016%2Fj.virusres.2007.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">The SARS-Coronavirus PLnc domain of nsp3 as a replication/transcription scaffolding protein</span></div><div class="casAuthors">Imbert, Isabelle; Snijder, Eric J.; Dimitrova, Maria; Guillemot, Jean-Claude; Lecine, Patrick; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Virus Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">133</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">136-148</span>CODEN:
                <span class="NLM_cas:coden">VIREDF</span>;
        ISSN:<span class="NLM_cas:issn">0168-1702</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Many genetic and mechanistic features distinguish the coronavirus replication machinery from that encoded by most other RNA viruses.  The coronavirus replication/transcription complex is an assembly of viral and, most probably, cellular proteins that mediate the synthesis of both the unusually large (â¼30 kb) RNA genome and an extensive set of subgenomic mRNAs.  The viral components of the complex are encoded by the giant replicase gene, which is expressed in the form of two polyproteins (pp1a and pp1ab) that are processed into 16 cleavage products (nonstructural proteins 1-16).  Using the combination of yeast two-hybrid screening and GST pull-down assays, the authors have now analyzed all potential interactions between SARS-Coronavirus nonstructural proteins, which may contribute to the structure and/or function of the viral replication/transcription complex.  The authors demonstrate the existence of a complex network of interactions involving all 16 nonstructural proteins.  These results both confirmed previously described assocns. and identified novel heterodimerizations.  The interaction map thus provides a sum of the interactions that may occur at some point during coronavirus RNA synthesis and provides a framework for future research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzhK3gRYNU_7Vg90H21EOLACvtfcHk0lib_SFsVtSaoQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktVKlu7c%253D&md5=e91af89368fcb6d9b1e0f5aca95b86c8</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.virusres.2007.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.virusres.2007.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DImbert%26aufirst%3DI.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DDimitrova%26aufirst%3DM.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DL%25C3%25A9cine%26aufirst%3DP.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DThe%2520SARS-Coronavirus%2520PLnc%2520Domain%2520of%2520Nsp3%2520as%2520a%2520Replication%252FTranscription%2520Scaffolding%2520Protein%26jtitle%3DVirus%2520Res.%26date%3D2008%26volume%3D133%26spage%3D136%26epage%3D148%26doi%3D10.1016%2Fj.virusres.2007.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neuman, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatterjee, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klaus, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">WÃ¼thrich, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchmeier, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuhn, P.</span></span> <span> </span><span class="NLM_article-title">Proteomics Analysis Unravels the Functional Repertoire of Coronavirus Nonstructural Protein 3</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>82</i></span>,  <span class="NLM_fpage">5279</span>â <span class="NLM_lpage">5294</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02631-07</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02631-07" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18367524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmt1Slsrw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2008&pages=5279-5294&author=B.+W.+Neumanauthor=J.+S.+Josephauthor=K.+S.+Saikatenduauthor=P.+Serranoauthor=A.+Chatterjeeauthor=M.+A.+Johnsonauthor=L.+Liaoauthor=J.+P.+Klausauthor=J.+R.+Yatesauthor=K.+W%C3%BCthrichauthor=R.+C.+Stevensauthor=M.+J.+Buchmeierauthor=P.+Kuhn&title=Proteomics+Analysis+Unravels+the+Functional+Repertoire+of+Coronavirus+Nonstructural+Protein+3&doi=10.1128%2FJVI.02631-07"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3</span></div><div class="casAuthors">Neuman, Benjamin W.; Joseph, Jeremiah S.; Saikatendu, Kumar S.; Serrano, Pedro; Chatterjee, Amarnath; Johnson, Margaret A.; Liao, Lujian; Klaus, Joseph P.; Yates, John R., III; Wuthrich, Kurt; Stevens, Raymond C.; Buchmeier, Michael J.; Kuhn, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5279-5294</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome (SARS) coronavirus infection and growth are dependent on initiating signaling and enzyme actions upon viral entry into the host cell.  Proteins packaged during virus assembly may subsequently form the first line of attack and host manipulation upon infection.  A complete characterization of virion components is therefore important to understanding the dynamics of early stages of infection.  Mass spectrometry and kinase profiling techniques identified nearly 200 incorporated host and viral proteins.  We used published interaction data to identify hubs of connectivity with potential significance for virion formation.  Surprisingly, the hub with the most potential connections was not the viral M protein but the nonstructural protein 3 (nsp3), which is one of the novel virion components identified by mass spectrometry.  Based on new exptl. data and a bioinformatics anal. across the Coronaviridae, we propose a higher-resoln. functional domain architecture for nsp3 that dets. the interaction capacity of this protein.  Using recombinant protein domains expressed in Escherichia coli, we identified two addnl. RNA-binding domains of nsp3.  One of these domains is located within the previously described SARS-unique domain, and there is a nucleic acid chaperone-like domain located immediately downstream of the papain-like proteinase domain.  We also identified a novel cysteine-coordinated metal ion-binding domain.  Analyses of interdomain interactions and provisional functional annotation of the remaining, so-far-uncharacterized domains are presented.  Overall, the ensemble of data surveyed here paint a more complete picture of nsp3 as a conserved component of the viral protein processing machinery, which is intimately assocd. with viral RNA in its role as a virion component.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIKSoeNFXMf7Vg90H21EOLACvtfcHk0lhzDc74eoNPyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmt1Slsrw%253D&md5=a82c5530f2f91b00f90989e240a40597</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1128%2FJVI.02631-07&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02631-07%26sid%3Dliteratum%253Aachs%26aulast%3DNeuman%26aufirst%3DB.%2BW.%26aulast%3DJoseph%26aufirst%3DJ.%2BS.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DSerrano%26aufirst%3DP.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BA.%26aulast%3DLiao%26aufirst%3DL.%26aulast%3DKlaus%26aufirst%3DJ.%2BP.%26aulast%3DYates%26aufirst%3DJ.%2BR.%26aulast%3DW%25C3%25BCthrich%26aufirst%3DK.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DBuchmeier%26aufirst%3DM.%2BJ.%26aulast%3DKuhn%26aufirst%3DP.%26atitle%3DProteomics%2520Analysis%2520Unravels%2520the%2520Functional%2520Repertoire%2520of%2520Coronavirus%2520Nonstructural%2520Protein%25203%26jtitle%3DJ.%2520Virol.%26date%3D2008%26volume%3D82%26spage%3D5279%26epage%3D5294%26doi%3D10.1128%2FJVI.02631-07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lindner, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fotouhi-Ardakani, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lytvyn, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lachance, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sulea, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MÃ©nard, R.</span></span> <span> </span><span class="NLM_article-title">The Papain-Like Protease from the Severe Acute Respiratory Syndrome Coronavirus Is a Deubiquitinating Enzyme</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">15199</span>â <span class="NLM_lpage">15208</span>, <span class="refDoi">Â DOI: 10.1128/JVI.79.24.15199-15208.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.79.24.15199-15208.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16306591" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslOitw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2005&pages=15199-15208&author=H.+A.+Lindnerauthor=N.+Fotouhi-Ardakaniauthor=V.+Lytvynauthor=P.+Lachanceauthor=T.+Suleaauthor=R.+M%C3%A9nard&title=The+Papain-Like+Protease+from+the+Severe+Acute+Respiratory+Syndrome+Coronavirus+Is+a+Deubiquitinating+Enzyme&doi=10.1128%2FJVI.79.24.15199-15208.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme</span></div><div class="casAuthors">Lindner, Holger A.; Fotouhi-Ardakani, Nasser; Lytvyn, Viktoria; Lachance, Paule; Sulea, Traian; Menard, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">15199-15208</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The severe acute respiratory syndrome coronavirus papain-like protease (SARS-CoV PLpro) is involved in the processing of the viral polyprotein and, thereby, contributes to the biogenesis of the virus replication complex.  Structural bioinformatics has revealed a relationship for the SARS-CoV PLpro to herpesvirus-assocd. ubiquitin-specific protease (HAUSP), a ubiquitin-specific protease, indicating potential deubiquitinating activity in addn. to its function in polyprotein processing.  In order to confirm this prediction, we overexpressed and purified SARS-CoV PLpro (amino acids [aa]1507 to 1858) from Escherichia coli.  The purified enzyme hydrolyzed ubiquitin-7-amino-4-methylcoumarin (Ub-AMC), a general deubiquitinating enzyme substrate, with a catalytic efficiency of 13,100 M-1 s-1, 220-fold more efficiently than the small synthetic peptide substrate Z-LRGG-AMC, which incorporates the C-terminal four residues of ubiquitin.  In addn., SARS-CoV PLpro was inhibited by the specific deubiquitinating enzyme inhibitor ubiquitin aldehyde, with an inhibition const. of 210 nM.  The purified SARS-CoV PLpro disassembles branched polyubiquitin chains with lengths of two to seven (Ub2-7) or four (Ub4) units, which involves isopeptide bond cleavage.  SARS-CoV PLpro processing activity was also detected against a protein fused to the C terminus of the ubiquitin-like modifier ISG15, both in vitro using the purified enzyme and in HeLa cells by coexpression with SARS-CoV PLpro (aa 1198 to 2009).  These results clearly establish that SARS-CoV PLpro is a deubiquitinating enzyme, thereby confirming our earlier prediction.  This unexpected activity for a coronavirus papain-like protease suggests a novel viral strategy to modulate the host cell ubiquitination machinery to its advantage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1m1bqW9GpybVg90H21EOLACvtfcHk0lhzDc74eoNPyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslOitw%253D%253D&md5=dff5e5e3d3b2fc8838413a8551480383</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1128%2FJVI.79.24.15199-15208.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.79.24.15199-15208.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLindner%26aufirst%3DH.%2BA.%26aulast%3DFotouhi-Ardakani%26aufirst%3DN.%26aulast%3DLytvyn%26aufirst%3DV.%26aulast%3DLachance%26aufirst%3DP.%26aulast%3DSulea%26aufirst%3DT.%26aulast%3DM%25C3%25A9nard%26aufirst%3DR.%26atitle%3DThe%2520Papain-Like%2520Protease%2520from%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Is%2520a%2520Deubiquitinating%2520Enzyme%26jtitle%3DJ.%2520Virol.%26date%3D2005%26volume%3D79%26spage%3D15199%26epage%3D15208%26doi%3D10.1128%2FJVI.79.24.15199-15208.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡ez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St John, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">The SARS-Coronavirus Papain-like Protease: Structure, Function and Inhibition by Designed Antiviral Compounds</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">21</span>â <span class="NLM_lpage">38</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2014.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2014.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25554382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVOnsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2015&pages=21-38&author=Y.+M.+B%C3%A1ez-Santosauthor=S.+E.+St+Johnauthor=A.+D.+Mesecar&title=The+SARS-Coronavirus+Papain-like+Protease%3A+Structure%2C+Function+and+Inhibition+by+Designed+Antiviral+Compounds&doi=10.1016%2Fj.antiviral.2014.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds</span></div><div class="casAuthors">Baez-Santos, Yahira M.; St. John, Sarah E.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-38</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Over 10 years have passed since the deadly human coronavirus that causes severe acute respiratory syndrome (SARS-CoV) emerged from the Guangdong Province of China.  Despite the fact that the SARS-CoV pandemic infected over 8500 individuals, claimed over 800 lives and cost billions of dollars in economic loss worldwide, there still are no clin. approved antiviral drugs, vaccines or monoclonal antibody therapies to treat SARS-CoV infections.  The recent emergence of the deadly human coronavirus that causes Middle East respiratory syndrome (MERS-CoV) is a sobering reminder that new and deadly coronaviruses can emerge at any time with the potential to become pandemics.  Therefore, the continued development of therapeutic and prophylactic countermeasures to potentially deadly coronaviruses is warranted.  The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication.  Although the primary function of PLpro and 3CLpro are to process the viral polyprotein in a coordinated manner, PLpro has the addnl. function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses.  Therefore, targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells.  This review provides an up-to-date discussion on the SARS-CoV papain-like protease including a brief overview of the SARS-CoV genome and replication followed by a more in-depth discussion on the structure and catalytic mechanism of SARS-CoV PLpro, the multiple cellular functions of SARS-CoV PLpro, the inhibition of SARS-CoV PLpro by small mol. inhibitors, and the prospect of inhibiting papain-like protease from other coronaviruses.  This paper forms part of a series of invited articles in Antiviral Research on "From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses.".</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqkf_6BE2QqbVg90H21EOLACvtfcHk0lhzDc74eoNPyg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVOnsw%253D%253D&md5=fcdde62e05b499546c73f3014ea521ad</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2014.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2014.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1ez-Santos%26aufirst%3DY.%2BM.%26aulast%3DSt%2BJohn%26aufirst%3DS.%2BE.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DThe%2520SARS-Coronavirus%2520Papain-like%2520Protease%253A%2520Structure%252C%2520Function%2520and%2520Inhibition%2520by%2520Designed%2520Antiviral%2520Compounds%26jtitle%3DAntiviral%2520Res.%26date%3D2015%26volume%3D115%26spage%3D21%26epage%3D38%26doi%3D10.1016%2Fj.antiviral.2014.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saikatendu, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santarsiero, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barretto, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">Severe Acute Respiratory Syndrome Coronavirus Papain-like-Protease: Structure of a Viral Deubiquitinating Enzyme</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">5717</span>â <span class="NLM_lpage">5722</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0510851103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.0510851103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=16581910" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XktFaisLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5717-5722&author=K.+Ratiaauthor=K.+S.+Saikatenduauthor=B.+D.+Santarsieroauthor=N.+Barrettoauthor=S.+C.+Bakerauthor=R.+C.+Stevensauthor=A.+D.+Mesecar&title=Severe+Acute+Respiratory+Syndrome+Coronavirus+Papain-like-Protease%3A+Structure+of+a+Viral+Deubiquitinating+Enzyme&doi=10.1073%2Fpnas.0510851103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme</span></div><div class="casAuthors">Ratia, Kiira; Saikatendu, Kumar Singh; Santarsiero, Bernard D.; Barretto, Naina; Baker, Susan C.; Stevens, Raymond C.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5717-5722</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro).  These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality assocd. with outbreaks of SARS-CoV.  In this work, we describe the 1.85-Ã crystal structure of the catalytic core of SARS-CoV PLpro and show that the overall architecture adopts a fold closely resembling that of known deubiquitinating enzymes (DUBs).  Key features, however, distinguish PLpro from characterized deubiquitinating enzymes, including an intact zinc-binding motif, an unobstructed catalytically competent active site, and the presence of an intriguing, ubiquitin-like (Ubl) N-terminal domain.  To gain insight into the active-site recognition of the C-terminal tail of ubiquitin and the related LXGG motif, we propose a model of PLpro in complex with ubiquitin-aldehyde that reveals well defined sites within the catalytic cleft that help to account for strict substrate-recognition motifs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob2x9rmNLlYbVg90H21EOLACvtfcHk0lhCSQmO3PrqbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XktFaisLc%253D&md5=a8531cf47993390ebeb194f71acf0ae4</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510851103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510851103%26sid%3Dliteratum%253Aachs%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DSaikatendu%26aufirst%3DK.%2BS.%26aulast%3DSantarsiero%26aufirst%3DB.%2BD.%26aulast%3DBarretto%26aufirst%3DN.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DSevere%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Papain-like-Protease%253A%2520Structure%2520of%2520a%2520Viral%2520Deubiquitinating%2520Enzyme%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D5717%26epage%3D5722%26doi%3D10.1073%2Fpnas.0510851103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rut, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zmudzinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patchett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snipas, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El Oualid, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bekes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drag, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, S. K.</span></span> <span> </span><span class="NLM_article-title">Activity Profiling and Structures of Inhibitor-Bound SARS-CoV-2-PLpro Protease Provides a Framework for Anti-COVID-19 Drug Design</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.04.29.068890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.04.29.068890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32511411" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=W.+Rutauthor=Z.+Lvauthor=M.+Zmudzinskiauthor=S.+Patchettauthor=D.+Nayakauthor=S.+J.+Snipasauthor=F.+El+Oualidauthor=T.+T.+Huangauthor=M.+Bekesauthor=M.+Dragauthor=S.+K.+Olsen&title=Activity+Profiling+and+Structures+of+Inhibitor-Bound+SARS-CoV-2-PLpro+Protease+Provides+a+Framework+for+Anti-COVID-19+Drug+Design&doi=10.1101%2F2020.04.29.068890"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1101%2F2020.04.29.068890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.04.29.068890%26sid%3Dliteratum%253Aachs%26aulast%3DRut%26aufirst%3DW.%26aulast%3DLv%26aufirst%3DZ.%26aulast%3DZmudzinski%26aufirst%3DM.%26aulast%3DPatchett%26aufirst%3DS.%26aulast%3DNayak%26aufirst%3DD.%26aulast%3DSnipas%26aufirst%3DS.%2BJ.%26aulast%3DEl%2BOualid%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DT.%2BT.%26aulast%3DBekes%26aufirst%3DM.%26aulast%3DDrag%26aufirst%3DM.%26aulast%3DOlsen%26aufirst%3DS.%2BK.%26atitle%3DActivity%2520Profiling%2520and%2520Structures%2520of%2520Inhibitor-Bound%2520SARS-CoV-2-PLpro%2520Protease%2520Provides%2520a%2520Framework%2520for%2520Anti-COVID-19%2520Drug%2520Design%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.04.29.068890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÄglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brul, S.</span></span> <span> </span><span class="NLM_article-title">Ebselen as a Highly Active Inhibitor of PLProCoV2</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.05.17.100768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.05.17.100768" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+W%C4%99glarz-Tomczakauthor=J.+M.+Tomczakauthor=M.+Talmaauthor=S.+Brul&title=Ebselen+as+a+Highly+Active+Inhibitor+of+PLProCoV2&doi=10.1101%2F2020.05.17.100768"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1101%2F2020.05.17.100768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.17.100768%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C4%2599glarz-Tomczak%26aufirst%3DE.%26aulast%3DTomczak%26aufirst%3DJ.%2BM.%26aulast%3DTalma%26aufirst%3DM.%26aulast%3DBrul%26aufirst%3DS.%26atitle%3DEbselen%2520as%2520a%2520Highly%2520Active%2520Inhibitor%2520of%2520PLProCoV2%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.17.100768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomczak, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burda-Grabowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brul, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Potent Inhibitors of PLproCoV2 by Screening Libraries of Selenium-Containing Compounds</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.05.20.107052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.05.20.107052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=E.+Weglarz-Tomczakauthor=J.+M.+Tomczakauthor=M.+Giurgauthor=M.+Burda-Grabowskaauthor=S.+Brul&title=Discovery+of+Potent+Inhibitors+of+PLproCoV2+by+Screening+Libraries+of+Selenium-Containing+Compounds&doi=10.1101%2F2020.05.20.107052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1101%2F2020.05.20.107052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.05.20.107052%26sid%3Dliteratum%253Aachs%26aulast%3DWeglarz-Tomczak%26aufirst%3DE.%26aulast%3DTomczak%26aufirst%3DJ.%2BM.%26aulast%3DGiurg%26aufirst%3DM.%26aulast%3DBurda-Grabowska%26aufirst%3DM.%26aulast%3DBrul%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Potent%2520Inhibitors%2520of%2520PLproCoV2%2520by%2520Screening%2520Libraries%2520of%2520Selenium-Containing%2520Compounds%26jtitle%3DbioRxiv%26date%3D2020%26doi%3D10.1101%2F2020.05.20.107052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">WÄglarz-Tomczak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burda-Grabowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giurg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucha, A.</span></span> <span> </span><span class="NLM_article-title">Identification of Methionine Aminopeptidase 2 as a Molecular Target of the Organoselenium Drug Ebselen and Its Derivatives/Analogues: Synthesis, Inhibitory Activity and Molecular Modeling Study</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5254</span>â <span class="NLM_lpage">5259</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2016.09.050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bmcl.2016.09.050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27692546" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFymtrbN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2016&pages=5254-5259&author=E.+W%C4%99glarz-Tomczakauthor=M.+Burda-Grabowskaauthor=M.+Giurgauthor=A.+Mucha&title=Identification+of+Methionine+Aminopeptidase+2+as+a+Molecular+Target+of+the+Organoselenium+Drug+Ebselen+and+Its+Derivatives%2FAnalogues%3A+Synthesis%2C+Inhibitory+Activity+and+Molecular+Modeling+Study&doi=10.1016%2Fj.bmcl.2016.09.050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study</span></div><div class="casAuthors">Weglarz-Tomczak, Ewelina; Burda-Grabowska, Malgorzata; Giurg, Miroslaw; Mucha, Artur</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5254-5259</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A collection of twenty-six organoselenium compds., ebselen and its structural analogs, provided a novel approach for inhibiting the activity of human methionine aminopeptidase 2 (MetAP2).  This metalloprotease, being responsible for the removal of the amino-terminal methionine from newly synthesized proteins, plays a key role in angiogenesis, which is essential for the progression of diseases, including solid tumor cancers.  In this work, we discovered that ebselen, a synthetic organoselenium drug mol. with anti-inflammatory, anti-oxidant and cytoprotective activity, inhibits one of the main enzymes in the tumor progression pathway.  Using three-step synthesis, we obtained twenty-five ebselen derivs./analogs, e.g. I, ten of which are new, and tested their inhibitory activity toward three neutral aminopeptidases (MetAP2, alanine and leucine aminopeptidases).  All of the tested compds. proved to be selective, slow-binding inhibitors of MetAP2.  Similarly to ebselen, most of its analogs exhibited a moderate potency (IC50 = 1-12 Î¼M).  Moreover, we identified three strong inhibitors that bind favorably to the enzyme with the half maximal inhibitory concn. in the submicromolar range.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBrtF35eyEPbVg90H21EOLACvtfcHk0lhCSQmO3PrqbA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFymtrbN&md5=060229972f89968d856375356318d19f</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2016.09.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2016.09.050%26sid%3Dliteratum%253Aachs%26aulast%3DW%25C4%2599glarz-Tomczak%26aufirst%3DE.%26aulast%3DBurda-Grabowska%26aufirst%3DM.%26aulast%3DGiurg%26aufirst%3DM.%26aulast%3DMucha%26aufirst%3DA.%26atitle%3DIdentification%2520of%2520Methionine%2520Aminopeptidase%25202%2520as%2520a%2520Molecular%2520Target%2520of%2520the%2520Organoselenium%2520Drug%2520Ebselen%2520and%2520Its%2520Derivatives%252FAnalogues%253A%2520Synthesis%252C%2520Inhibitory%2520Activity%2520and%2520Molecular%2520Modeling%2520Study%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D26%26spage%3D5254%26epage%3D5259%26doi%3D10.1016%2Fj.bmcl.2016.09.050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baliji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">A Noncovalent Class of Papain-like Protease/Deubiquitinase Inhibitors Blocks SARS Virus Replication</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">16119</span>â <span class="NLM_lpage">16124</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0805240105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.0805240105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=18852458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlSju7rN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=16119-16124&author=K.+Ratiaauthor=S.+Peganauthor=J.+Takayamaauthor=K.+Sleemanauthor=M.+Coughlinauthor=S.+Balijiauthor=R.+Chaudhuriauthor=W.+Fuauthor=B.+S.+Prabhakarauthor=M.+E.+Johnsonauthor=S.+C.+Bakerauthor=A.+K.+Ghoshauthor=A.+D.+Mesecar&title=A+Noncovalent+Class+of+Papain-like+Protease%2FDeubiquitinase+Inhibitors+Blocks+SARS+Virus+Replication&doi=10.1073%2Fpnas.0805240105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication</span></div><div class="casAuthors">Ratia, Kiira; Pegan, Scott; Takayama, Jun; Sleeman, Katrina; Coughlin, Melissa; Baliji, Surendranath; Chaudhuri, Rima; Fu, Wentao; Prabhakar, Bellur S.; Johnson, Michael E.; Baker, Susan C.; Ghosh, Arun K.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">16119-16124</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We report the discovery and optimization of a potent inhibitor against the papain-like protease (PLpro) from the coronavirus that causes severe acute respiratory syndrome (SARS-CoV).  This unique protease is not only responsible for processing the viral polyprotein into its functional units but is also capable of cleaving ubiquitin and ISG15 conjugates and plays a significant role in helping SARS-CoV evade the human immune system.  We screened a structurally diverse library of 50,080 compds. for inhibitors of PLpro and discovered a noncovalent lead inhibitor with an IC50 value of 20 Î¼M, which was improved to 600 nM via synthetic optimization.  The resulting compd., GRL0617, inhibited SARS-CoV viral replication in Vero E6 cells with an EC50 of 15 Î¼M and had no assocd. cytotoxicity.  The X-ray structure of PLpro in complex with GRL0617 indicates that the compd. has a unique mode of inhibition whereby it binds within the 54-53 subsites of the enzyme and induces a loop closure that shuts down catalysis at the active site.  These findings provide proof-of-principle that PLpro is a viable target for development of antivirals directed against SARS-CoV, and that potent noncovalent cysteine protease inhibitors can be developed with specificity directed toward pathogenic deubiquitinating enzymes without inhibiting host DUBs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHkOorXemIEbVg90H21EOLACvtfcHk0lj_Zr7rOLFrJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlSju7rN&md5=c842f5d8458e7c091cbdef1fd94a8c87</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0805240105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0805240105%26sid%3Dliteratum%253Aachs%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DPegan%26aufirst%3DS.%26aulast%3DTakayama%26aufirst%3DJ.%26aulast%3DSleeman%26aufirst%3DK.%26aulast%3DCoughlin%26aufirst%3DM.%26aulast%3DBaliji%26aufirst%3DS.%26aulast%3DChaudhuri%26aufirst%3DR.%26aulast%3DFu%26aufirst%3DW.%26aulast%3DPrabhakar%26aufirst%3DB.%2BS.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DA%2520Noncovalent%2520Class%2520of%2520Papain-like%2520Protease%252FDeubiquitinase%2520Inhibitors%2520Blocks%2520SARS%2520Virus%2520Replication%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D16119%26epage%3D16124%26doi%3D10.1073%2Fpnas.0805240105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takayama, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ratia, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhuri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sleeman, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coughlin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulhearn, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhakar, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome - Coronavirus Papain-like Protease</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5228</span>â <span class="NLM_lpage">5240</span>, <span class="refDoi">Â DOI: 10.1021/jm900611t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900611t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlSnt7o%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5228-5240&author=A.+K.+Ghoshauthor=J.+Takayamaauthor=Y.+Aubinauthor=K.+Ratiaauthor=R.+Chaudhuriauthor=Y.+Baezauthor=K.+Sleemanauthor=M.+Coughlinauthor=D.+B.+Nicholsauthor=D.+C.+Mulhearnauthor=B.+S.+Prabhakarauthor=S.+C.+Bakerauthor=M.+E.+Johnsonauthor=A.+D.+Mesecar&title=Structure-Based+Design%2C+Synthesis%2C+and+Biological+Evaluation+of+a+Series+of+Novel+and+Reversible+Inhibitors+for+the+Severe+Acute+Respiratory+Syndrome+-+Coronavirus+Papain-like+Protease&doi=10.1021%2Fjm900611t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Design, Synthesis, and Biological Evaluation of a Series of Novel and Reversible Inhibitors for the Severe Acute Respiratory Syndrome-Coronavirus Papain-Like Protease</span></div><div class="casAuthors">Ghosh, Arun K.; Takayama, Jun; Aubin, Yoann; Ratia, Kiira; Chaudhuri, Rima; Baez, Yahira; Sleeman, Katrina; Coughlin, Melissa; Nichols, Daniel B.; Mulhearn, Debbie C.; Prabhakar, Bellur S.; Baker, Susan C.; Johnson, Michael E.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5228-5240</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe here the design, synthesis, mol. modeling, and biol. evaluation of a series of small mol., nonpeptide inhibitors of SARS-CoV PLpro.  Our initial lead compd. was identified via high-throughput screening of a diverse chem. library.  We subsequently carried out structure-activity relationship studies and optimized the lead structure to potent inhibitors that have shown antiviral activity against SARS-CoV infected Vero E6 cells.  Upon the basis of the X-ray crystal structure of inhibitor (III)-bound to SARS-CoV PLpro, a drug design template was created.  Our structure-based modification led to the design of a more potent inhibitor, (I) (enzyme IC50 = 0.46 Î¼M; antiviral EC50 = 6 Î¼M).  Interestingly, its methylamine deriv., (II), displayed good enzyme inhibitory potency (IC50 = 1.3 Î¼M) and the most potent SARS antiviral activity (EC50 = 5.2 Î¼M) in the series.  We have carried out computational docking studies and generated a predictive 3D-QSAR model for SARS-CoV PLpro inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJF7Pn_WVnyrVg90H21EOLACvtfcHk0lj_Zr7rOLFrJg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlSnt7o%253D&md5=6de7ca3e3417238331a8901ddaf84da9</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1021%2Fjm900611t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900611t%26sid%3Dliteratum%253Aachs%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26aulast%3DTakayama%26aufirst%3DJ.%26aulast%3DAubin%26aufirst%3DY.%26aulast%3DRatia%26aufirst%3DK.%26aulast%3DChaudhuri%26aufirst%3DR.%26aulast%3DBaez%26aufirst%3DY.%26aulast%3DSleeman%26aufirst%3DK.%26aulast%3DCoughlin%26aufirst%3DM.%26aulast%3DNichols%26aufirst%3DD.%2BB.%26aulast%3DMulhearn%26aufirst%3DD.%2BC.%26aulast%3DPrabhakar%26aufirst%3DB.%2BS.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BE.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DStructure-Based%2520Design%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Series%2520of%2520Novel%2520and%2520Reversible%2520Inhibitors%2520for%2520the%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520-%2520Coronavirus%2520Papain-like%2520Protease%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5228%26epage%3D5240%26doi%3D10.1021%2Fjm900611t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">BÃ¡ez-Santos, Y. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barraza, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agius, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mielech, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsen, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesecar, A. D.</span></span> <span> </span><span class="NLM_article-title">X-Ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2393</span>â <span class="NLM_lpage">2412</span>, <span class="refDoi">Â DOI: 10.1021/jm401712t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401712t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtVeqtLk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=2393-2412&author=Y.+M.+B%C3%A1ez-Santosauthor=S.+J.+Barrazaauthor=M.+W.+Wilsonauthor=M.+P.+Agiusauthor=A.+M.+Mielechauthor=N.+M.+Davisauthor=S.+C.+Bakerauthor=S.+D.+Larsenauthor=A.+D.+Mesecar&title=X-Ray+Structural+and+Biological+Evaluation+of+a+Series+of+Potent+and+Highly+Selective+Inhibitors+of+Human+Coronavirus+Papain-like+Proteases&doi=10.1021%2Fjm401712t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">X-ray Structural and Biological Evaluation of a Series of Potent and Highly Selective Inhibitors of Human Coronavirus Papain-like Proteases</span></div><div class="casAuthors">Baez-Santos, Yahira M.; Barraza, Scott J.; Wilson, Michael W.; Agius, Michael P.; Mielech, Anna M.; Davis, Nicole M.; Baker, Susan C.; Larsen, Scott D.; Mesecar, Andrew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2393-2412</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-guided design was used to generate a series of noncovalent inhibitors with nanomolar potency against the papain-like protease (PLpro) from the SARS coronavirus (CoV).  A no. of inhibitors exhibit antiviral activity against SARS-CoV infected Vero E6 cells and broadened specificity toward the homologous PLP2 enzyme from the human coronavirus NL63.  Selectivity and cytotoxicity studies established a more than 100-fold preference for the coronaviral enzyme over homologous human deubiquitinating enzymes (DUBs), and no significant cytotoxicity in Vero E6 and HEK293 cell lines is obsd.  X-ray structural analyses of inhibitor-bound crystal structures revealed subtle differences between binding modes of the initial benzodioxolane lead I and the most potent analogs II [X = 3-F, 4-F], featuring a monofluoro substitution at para and meta positions of the benzyl ring, resp.  Finally, the less lipophilic bis(amide) and methoxypyridine exhibit significantly improved metabolic stability and are viable candidates for advancing to in vivo studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokcS8tGH7OabVg90H21EOLACvtfcHk0lhHNKaJ0eVMug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtVeqtLk%253D&md5=1c478c6345bc13e67d233f1815e867a4</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1021%2Fjm401712t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401712t%26sid%3Dliteratum%253Aachs%26aulast%3DB%25C3%25A1ez-Santos%26aufirst%3DY.%2BM.%26aulast%3DBarraza%26aufirst%3DS.%2BJ.%26aulast%3DWilson%26aufirst%3DM.%2BW.%26aulast%3DAgius%26aufirst%3DM.%2BP.%26aulast%3DMielech%26aufirst%3DA.%2BM.%26aulast%3DDavis%26aufirst%3DN.%2BM.%26aulast%3DBaker%26aufirst%3DS.%2BC.%26aulast%3DLarsen%26aufirst%3DS.%2BD.%26aulast%3DMesecar%26aufirst%3DA.%2BD.%26atitle%3DX-Ray%2520Structural%2520and%2520Biological%2520Evaluation%2520of%2520a%2520Series%2520of%2520Potent%2520and%2520Highly%2520Selective%2520Inhibitors%2520of%2520Human%2520Coronavirus%2520Papain-like%2520Proteases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D2393%26epage%3D2412%26doi%3D10.1021%2Fjm401712t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ziebuhr, J.</span></span> <span> </span><span class="NLM_article-title">The Coronavirus Replicase</span>. In  <i>Current Topics in Microbiology and Immunology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enjuanes, L.</span></span>, Ed.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2005</span>; Vol.  <span class="NLM_volume">287</span>, pp  <span class="NLM_fpage">57</span>â <span class="NLM_lpage">94</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=57-94&author=J.+Ziebuhrauthor=L.+Enjuanes&title=Current+Topics+in+Microbiology+and+Immunology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DZiebuhr%26aufirst%3DJ.%26atitle%3DThe%2520Coronavirus%2520Replicase%26btitle%3DCurrent%2520Topics%2520in%2520Microbiology%2520and%2520Immunology%26aulast%3DEnjuanes%26aufirst%3DL.%26pub%3DSpringer%26date%3D2005%26volume%3D287%26spage%3D57%26epage%3D94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Te
Velthuis, A. J. W.</span></span> <span> </span><span class="NLM_article-title">Common and Unique Features of Viral RNA-Dependent Polymerases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">4403</span>â <span class="NLM_lpage">4420</span>, <span class="refDoi">Â DOI: 10.1007/s00018-014-1695-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1007%2Fs00018-014-1695-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25080879" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1GntbrN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2014&pages=4403-4420&author=A.+J.+W.+Te%0AVelthuis&title=Common+and+Unique+Features+of+Viral+RNA-Dependent+Polymerases&doi=10.1007%2Fs00018-014-1695-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Common and unique features of viral RNA-dependent polymerases</span></div><div class="casAuthors">te Velthuis, Aartjan J. W.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">4403-4420</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Eukaryotes and bacteria can be infected with a wide variety of RNA viruses.  On av., these pathogens share little sequence similarity and use different replication and transcription strategies.  Nevertheless, the members of nearly all RNA virus families depend on the activity of a virally encoded RNA-dependent polymerase for the condensation of nucleotide triphosphates.  This review provides an overview of our current understanding of the viral RNA-dependent polymerase structure and the biochem. and biophysics that is involved in replicating and transcribing the genetic material of RNA viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxoxM9xeapFrVg90H21EOLACvtfcHk0lhHNKaJ0eVMug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1GntbrN&md5=4ebf3c7985543f3069cfdc94485a2c7b</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs00018-014-1695-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-014-1695-z%26sid%3Dliteratum%253Aachs%26aulast%3DTe%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26atitle%3DCommon%2520and%2520Unique%2520Features%2520of%2520Viral%2520RNA-Dependent%2520Polymerases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2014%26volume%3D71%26spage%3D4403%26epage%3D4420%26doi%3D10.1007%2Fs00018-014-1695-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Subissi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posthuma, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven-Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span> <span> </span><span class="NLM_article-title">One Severe Acute Respiratory Syndrome Coronavirus Protein Complex Integrates Processive RNA Polymerase and Exonuclease Activities</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">E3900</span>â <span class="NLM_lpage">E3909</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1323705111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.1323705111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=25197083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVGntb3M" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=E3900-E3909&author=L.+Subissiauthor=C.+C.+Posthumaauthor=A.+Colletauthor=J.+C.+Zevenhoven-Dobbeauthor=A.+E.+Gorbalenyaauthor=E.+Decrolyauthor=E.+J.+Snijderauthor=B.+Canardauthor=I.+Imbert&title=One+Severe+Acute+Respiratory+Syndrome+Coronavirus+Protein+Complex+Integrates+Processive+RNA+Polymerase+and+Exonuclease+Activities&doi=10.1073%2Fpnas.1323705111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities</span></div><div class="casAuthors">Subissi, Lorenzo; Posthuma, Clara C.; Collet, Axelle; Zevenhoven-Dobbe, Jessika C.; Gorbalenya, Alexander E.; Decroly, Etienne; Snijder, Eric J.; Canard, Bruno; Imbert, Isabelle</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">E3900-E3909</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">In addn. to members causing milder human infections, the Coronaviridae family includes potentially lethal zoonotic agents causing severe acute respiratory syndrome (SARS) and the recently emerged Middle East respiratory syndrome.  The â¼30-kb pos.-stranded RNA genome of coronaviruses encodes a replication/transcription machinery that is unusually complex and composed of 16 nonstructural proteins (nsps).  SARS-CoV nsp12, the canonical RNA-dependent RNA polymerase (RdRp), exhibits poorly processive RNA synthesis in vitro, at odds with the efficient replication of a very large RNA genome in vivo.  Here, we report that SARS-CoV nsp7 and nsp8 activate and confer processivity to the RNA-synthesizing activity of nsp12.  Using biochem. assays and reverse genetics, the importance of conserved nsp7 and nsp8 residues was probed.  Whereas several nsp7 mutations affected virus replication to a limited extent, the replacement of two nsp8 residues (P183 and R190) essential for interaction with nsp12 and a third (K58) crit. for the interaction of the polymerase complex with RNA were all lethal to the virus.  Without a loss of processivity, the nsp7/nsp8/nsp12 complex can assoc. with nsp14, a bifunctional enzyme bearing 3'-5' exoribonuclease and RNA cap N7-guanine methyltransferase activities involved in replication fidelity and 5'-RNA capping, resp.  The identification of this tripartite polymerase complex that in turn assocs. with the nsp14 proofreading enzyme sheds light on how coronaviruses assemble an RNA-synthesizing machinery to replicate the largest known RNA genomes.  This protein complex is a fascinating example of the functional integration of RNA polymerase, capping, and proofreading activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodG7yPmFowK7Vg90H21EOLACvtfcHk0lhHNKaJ0eVMug"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVGntb3M&md5=ed2d7e8787ddd0d8a5e4565932cc54ef</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1323705111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1323705111%26sid%3Dliteratum%253Aachs%26aulast%3DSubissi%26aufirst%3DL.%26aulast%3DPosthuma%26aufirst%3DC.%2BC.%26aulast%3DCollet%26aufirst%3DA.%26aulast%3DZevenhoven-Dobbe%26aufirst%3DJ.%2BC.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DDecroly%26aufirst%3DE.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DCanard%26aufirst%3DB.%26aulast%3DImbert%26aufirst%3DI.%26atitle%3DOne%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%2520Protein%2520Complex%2520Integrates%2520Processive%2520RNA%2520Polymerase%2520and%2520Exonuclease%2520Activities%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26spage%3DE3900%26epage%3DE3909%26doi%3D10.1073%2Fpnas.1323705111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Imbert, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourhis, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussetta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coutard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egloff, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">A Second, Non-Canonical RNA-Dependent RNA Polymerase in SARS Coronavirus</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4933</span>â <span class="NLM_lpage">4942</span>, <span class="refDoi">Â DOI: 10.1038/sj.emboj.7601368</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsj.emboj.7601368" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=17024178" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVyktb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2006&pages=4933-4942&author=I.+Imbertauthor=J.+C.+Guillemotauthor=J.+M.+Bourhisauthor=C.+Bussettaauthor=B.+Coutardauthor=M.+P.+Egloffauthor=F.+Ferronauthor=A.+E.+Gorbalenyaauthor=B.+Canard&title=A+Second%2C+Non-Canonical+RNA-Dependent+RNA+Polymerase+in+SARS+Coronavirus&doi=10.1038%2Fsj.emboj.7601368"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">A second, non-canonical RNA-dependent RNA polymerase in SARS Coronavirus</span></div><div class="casAuthors">Imbert, Isabelle; Guillemot, Jean-Claude; Bourhis, Jean-Marie; Bussetta, Cecile; Coutard, Bruno; Egloff, Marie-Pierre; Ferron, Francois; Gorbalenya, Alexander E.; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">4933-4942</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In (+) RNA coronaviruses, replication and transcription of the giant â¼30 kb genome to produce genome- and subgenome-size RNAs of both polarities are mediated by a cognate membrane-bound enzymic complex.  Its RNA-dependent RNA polymerase (RdRp) activity appears to be supplied by non-structural protein 12 (nsp12) that includes an RdRp domain conserved in all RNA viruses.  Using SARS coronavirus, we now show that coronaviruses uniquely encode a second RdRp residing in nsp8.  This protein strongly prefers the internal 5'-(G/U)CC-3' trinucleotides on RNA templates to initiate the synthesis of complementary oligonucleotides of <6 residues in a reaction whose fidelity is relatively low.  Distant structural homol. between the C-terminal domain of nsp8 and the catalytic palm subdomain of RdRps of RNA viruses suggests a common origin of the two coronavirus RdRps, which however may have evolved different sets of catalytic residues.  A parallel between the nsp8 RdRp and cellular DNA-dependent RNA primases is drawn to propose that the nsp8 RdRp produces primers utilized by the primer-dependent nsp12 RdRp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY5dpY0uvoWbVg90H21EOLACvtfcHk0lhKCZvz1m5aQQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVyktb%252FJ&md5=d41d31d46aeed39c3a2fe105f7b1ee8c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1038%2Fsj.emboj.7601368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.emboj.7601368%26sid%3Dliteratum%253Aachs%26aulast%3DImbert%26aufirst%3DI.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DBourhis%26aufirst%3DJ.%2BM.%26aulast%3DBussetta%26aufirst%3DC.%26aulast%3DCoutard%26aufirst%3DB.%26aulast%3DEgloff%26aufirst%3DM.%2BP.%26aulast%3DFerron%26aufirst%3DF.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DA%2520Second%252C%2520Non-Canonical%2520RNA-Dependent%2520RNA%2520Polymerase%2520in%2520SARS%2520Coronavirus%26jtitle%3DEMBO%2520J.%26date%3D2006%26volume%3D25%26spage%3D4933%26epage%3D4942%26doi%3D10.1038%2Fsj.emboj.7601368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saindane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harcourt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thornburg, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanstrom, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">An Orally Bioavailable Broad-Spectrum Antiviral Inhibits SARS-CoV-2 in Human Airway Epithelial Cell Cultures and Multiple Coronaviruses in Mice</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">eabb5883</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.abb5883</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.abb5883" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32253226" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=eabb5883&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=S.+Zhouauthor=R.+L.+Grahamauthor=A.+J.+Pruijssersauthor=M.+L.+Agostiniauthor=S.+R.+Leistauthor=A.+Sch%C3%A4ferauthor=K.+H.+Dinnonauthor=L.+J.+Stevensauthor=J.+D.+Chappellauthor=X.+Luauthor=T.+M.+Hughesauthor=A.+S.+Georgeauthor=C.+S.+Hillauthor=S.+A.+Montgomeryauthor=A.+J.+Brownauthor=G.+R.+Bluemlingauthor=M.+G.+Natchusauthor=M.+Saindaneauthor=A.+A.+Kolykhalovauthor=G.+Painterauthor=J.+Harcourtauthor=A.+Taminauthor=N.+J.+Thornburgauthor=R.+Swanstromauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=An+Orally+Bioavailable+Broad-Spectrum+Antiviral+Inhibits+SARS-CoV-2+in+Human+Airway+Epithelial+Cell+Cultures+and+Multiple+Coronaviruses+in+Mice&doi=10.1126%2Fscitranslmed.abb5883"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.abb5883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.abb5883%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DStevens%26aufirst%3DL.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHughes%26aufirst%3DT.%2BM.%26aulast%3DGeorge%26aufirst%3DA.%2BS.%26aulast%3DHill%26aufirst%3DC.%2BS.%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DSaindane%26aufirst%3DM.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DPainter%26aufirst%3DG.%26aulast%3DHarcourt%26aufirst%3DJ.%26aulast%3DTamin%26aufirst%3DA.%26aulast%3DThornburg%26aufirst%3DN.%2BJ.%26aulast%3DSwanstrom%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DAn%2520Orally%2520Bioavailable%2520Broad-Spectrum%2520Antiviral%2520Inhibits%2520SARS-CoV-2%2520in%2520Human%2520Airway%2520Epithelial%2520Cell%2520Cultures%2520and%2520Multiple%2520Coronaviruses%2520in%2520Mice%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2020%26volume%3D12%26spage%3Deabb5883%26doi%3D10.1126%2Fscitranslmed.abb5883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchdoerfer, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, A. B.</span></span> <span> </span><span class="NLM_article-title">Structure of the SARS-CoV Nsp12 Polymerase Bound to Nsp7 and Nsp8 Co-Factors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2342</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-10280-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-019-10280-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31138817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BB3M3gslGnsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=2342&author=R.+N.+Kirchdoerferauthor=A.+B.+Ward&title=Structure+of+the+SARS-CoV+Nsp12+Polymerase+Bound+to+Nsp7+and+Nsp8+Co-Factors&doi=10.1038%2Fs41467-019-10280-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors</span></div><div class="casAuthors">Kirchdoerfer Robert N; Ward Andrew B</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2342</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent history is punctuated by the emergence of highly pathogenic coronaviruses such as SARS- and MERS-CoV into human circulation.  Upon infecting host cells, coronaviruses assemble a multi-subunit RNA-synthesis complex of viral non-structural proteins (nsp) responsible for the replication and transcription of the viral genome.  Here, we present the 3.1 ÃA resolution structure of the SARS-CoV nsp12 polymerase bound to its essential co-factors, nsp7 and nsp8, using single particle cryo-electron microscopy. nsp12 possesses an architecture common to all viral polymerases as well as a large N-terminal extension containing a kinase-like fold and is bound by two nsp8 co-factors.  This structure illuminates the assembly of the coronavirus core RNA-synthesis machinery, provides key insights into nsp12 polymerase catalysis and fidelity and acts as a template for the design of novel antiviral therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTHhQTFTUGoc7HHuJhbyicZfW6udTcc2eZIT2j_1xWnQbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3gslGnsg%253D%253D&md5=71c144c86c8cef5df8bd02905d93d6dc</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-10280-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-10280-3%26sid%3Dliteratum%253Aachs%26aulast%3DKirchdoerfer%26aufirst%3DR.%2BN.%26aulast%3DWard%26aufirst%3DA.%2BB.%26atitle%3DStructure%2520of%2520the%2520SARS-CoV%2520Nsp12%2520Polymerase%2520Bound%2520to%2520Nsp7%2520and%2520Nsp8%2520Co-Factors%26jtitle%3DNat.%2520Commun.%26date%3D2019%26volume%3D10%26spage%3D2342%26doi%3D10.1038%2Fs41467-019-10280-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ming, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structure of the RNA-Dependent RNA Polymerase from COVID-19 Virus</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">779</span>â <span class="NLM_lpage">782</span>, <span class="refDoi">Â DOI: 10.1126/science.abb7498</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abb7498" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32277040" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpsVyrsr4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=779-782&author=Y.+Gaoauthor=L.+Yanauthor=Y.+Huangauthor=F.+Liuauthor=Y.+Zhaoauthor=L.+Caoauthor=T.+Wangauthor=Q.+Sunauthor=Z.+Mingauthor=L.+Zhangauthor=J.+Geauthor=L.+Zhengauthor=Y.+Zhangauthor=H.+Wangauthor=Y.+Zhuauthor=C.+Zhuauthor=T.+Huauthor=T.+Huaauthor=B.+Zhangauthor=X.+Yangauthor=J.+Liauthor=H.+Yangauthor=Z.+Liuauthor=W.+Xuauthor=L.+W.+Guddatauthor=Q.+Wangauthor=Z.+Louauthor=Z.+Rao&title=Structure+of+the+RNA-Dependent+RNA+Polymerase+from+COVID-19+Virus&doi=10.1126%2Fscience.abb7498"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the RNA-dependent RNA polymerase from COVID-19 virus</span></div><div class="casAuthors">Gao, Yan; Yan, Liming; Huang, Yucen; Liu, Fengjiang; Zhao, Yao; Cao, Lin; Wang, Tao; Sun, Qianqian; Ming, Zhenhua; Zhang, Lianqi; Ge, Ji; Zheng, Litao; Zhang, Ying; Wang, Haofeng; Zhu, Yan; Zhu, Chen; Hu, Tianyu; Hua, Tian; Zhang, Bing; Yang, Xiuna; Li, Jun; Yang, Haitao; Liu, Zhijie; Xu, Wenqing; Guddat, Luke W.; Wang, Quan; Lou, Zhiyong; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6492</span>),
    <span class="NLM_cas:pages">779-782</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A novel coronavirus [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)] outbreak has caused a global coronavirus disease 2019 (COVID-19) pandemic, resulting in tens of thousands of infections and thousands of deaths worldwide.  The RNA-dependent RNA polymerase [(RdRp), also named nsp12] is the central component of coronaviral replication and transcription machinery, and it appears to be a primary target for the antiviral drug remdesivir.  We report the cryoelectron microscopy structure of COVID-19 virus full-length nsp12 in complex with cofactors nsp7 and nsp8 at 2.9-angstrom resoln.  In addn. to the conserved architecture of the polymerase core of the viral polymerase family, nsp12 possesses a newly identified Î²-hairpin domain at its N terminus.  A comparative anal. model shows how remdesivir binds to this polymerase.  The structure provides a basis for the design of new antiviral therapeutics that target viral RdRp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbDgKUj7ZIg7Vg90H21EOLACvtfcHk0liW5MFkbJk3IA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpsVyrsr4%253D&md5=07c9ca12ca757e52c2db2e4b4dcbf55b</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1126%2Fscience.abb7498&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abb7498%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DMing%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructure%2520of%2520the%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520COVID-19%2520Virus%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D779%26epage%3D782%26doi%3D10.1126%2Fscience.abb7498" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mcdonald, S. M.</span></span> <span> </span><span class="NLM_article-title">RNA Synthetic Mechanisms Employed by Diverse Families of RNA Viruses</span>. <i>Wiley Interdiscip. Rev. RNA</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">351</span>â <span class="NLM_lpage">367</span>, <span class="refDoi">Â DOI: 10.1002/wrna.1164</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fwrna.1164" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23606593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpslCgurw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=351-367&author=S.+M.+Mcdonald&title=RNA+Synthetic+Mechanisms+Employed+by+Diverse+Families+of+RNA+Viruses&doi=10.1002%2Fwrna.1164"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">RNA synthetic mechanisms employed by diverse families of RNA viruses</span></div><div class="casAuthors">McDonald, Sarah M.</div><div class="citationInfo"><span class="NLM_cas:title">Wiley Interdisciplinary Reviews: RNA</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">351-367</span>CODEN:
                <span class="NLM_cas:coden">WIRRCU</span>;
        ISSN:<span class="NLM_cas:issn">1757-7012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  RNA viruses are ubiquitous in nature, infecting every known organism on the planet.  These viruses can also be notorious human pathogens with significant medical and economic burdens.  Central to the lifecycle of an RNA virus is the synthesis of new RNA mols., a process that is mediated by specialized virally encoded enzymes called RNA-dependent RNA polymerases (RdRps).  RdRps directly catalyze phosphodiester bond formation between nucleoside triphosphates in an RNA-templated manner.  These enzymes are strikingly conserved in their structural and functional features, even among diverse RNA viruses belonging to different families.  During host cell infection, the activities of viral RdRps are often regulated by viral cofactor proteins.  Cofactors can modulate the type and timing of RNA synthesis by directly engaging the RdRp and/or by indirectly affecting its capacity to recognize template RNA.  High-resoln. structures of RdRps as apoenzymes, bound to RNA templates, in the midst of catalysis, and/or interacting with regulatory cofactor proteins, have dramatically increased our understanding of viral RNA synthetic mechanisms.  Combined with elegant biochem. studies, such structures are providing a scientific platform for the rational design of antiviral agents aimed at preventing and treating RNA virus-induced diseases.  WIREs RNA 2013, 4:351-367. doi: 10.1002/wrna.1164 Conflict of interest: The author has declared no conflicts of interest for this article.  For further resources related to this article, please visit the WIREs website.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6St7RlbCxJ7Vg90H21EOLACvtfcHk0liW5MFkbJk3IA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpslCgurw%253D&md5=d376dde615f98162f3cb480b68782b38</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1002%2Fwrna.1164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fwrna.1164%26sid%3Dliteratum%253Aachs%26aulast%3DMcdonald%26aufirst%3DS.%2BM.%26atitle%3DRNA%2520Synthetic%2520Mechanisms%2520Employed%2520by%2520Diverse%2520Families%2520of%2520RNA%2520Viruses%26jtitle%3DWiley%2520Interdiscip.%2520Rev.%2520RNA%26date%3D2013%26volume%3D4%26spage%3D351%26epage%3D367%26doi%3D10.1002%2Fwrna.1164" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lehmann, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulyaeva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zevenhoven-Dobbe, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janssen, G. M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruben, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overkleeft, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Veelen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samborskiy, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kravchenko, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leontovich, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sidorov, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posthuma, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorbalenya, A. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of an Essential Nucleotidylating Activity Associated with a Newly Delineated Conserved Domain in the RNA Polymerase-Containing Protein of All Nidoviruses</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">8416</span>â <span class="NLM_lpage">8434</span>, <span class="refDoi">Â DOI: 10.1093/nar/gkv838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fnar%2Fgkv838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26304538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslGqs7jK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=8416-8434&author=K.+C.+Lehmannauthor=A.+Gulyaevaauthor=J.+C.+Zevenhoven-Dobbeauthor=G.+M.+C.+Janssenauthor=M.+Rubenauthor=H.+S.+Overkleeftauthor=P.+A.+Van+Veelenauthor=D.+V.+Samborskiyauthor=A.+A.+Kravchenkoauthor=A.+M.+Leontovichauthor=I.+A.+Sidorovauthor=E.+J.+Snijderauthor=C.+C.+Posthumaauthor=A.+E.+Gorbalenya&title=Discovery+of+an+Essential+Nucleotidylating+Activity+Associated+with+a+Newly+Delineated+Conserved+Domain+in+the+RNA+Polymerase-Containing+Protein+of+All+Nidoviruses&doi=10.1093%2Fnar%2Fgkv838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses</span></div><div class="casAuthors">Lehmann, Kathleen C.; Gulyaeva, Anastasia; Zevenhoven-Dobbe, Jessika C.; Janssen, George M. C.; Ruben, Mark; Overkleeft, Hermen S.; van Veelen, Peter A.; Samborskiy, Dmitry V.; Kravchenko, Alexander A.; Leontovich, Andrey M.; Sidorov, Igor A.; Snijder, Eric J.; Posthuma, Clara C.; Gorbalenya, Alexander E.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8416-8434</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">RNA viruses encode an RNA-dependent RNA polymerase (RdRp) that catalyzes the synthesis of their RNA(s).  In the case of pos.-stranded RNA viruses belonging to the order Nidovirales, the RdRp resides in a replicase subunit that is unusually large.  Bioinformatics anal. of this non-structural protein has now revealed a nidoviral signature domain (genetic marker) that is N-terminally adjacent to the RdRp and has no apparent homologs elsewhere.  Based on its conservation profile, this domain is proposed to have nucleotidylation activity.  We used recombinant non-structural protein 9 of the arterivirus equine arteritis virus (EAV) and different biochem. assays, including irreversible labeling with a GTP analog followed by a proteomics anal., to demonstrate the manganese-dependent covalent binding of guanosine and uridine phosphates to a lysine/histidine residue.  Most likely this was the invariant lysine of the newly identified domain, named nidovirus RdRp-assocd. nucleotidyltransferase (NiRAN), whose substitution with alanine severely diminished the described binding.  Furthermore, this mutation crippled EAV and prevented the replication of severe acute respiratory syndrome coronavirus (SARS-CoV) in cell culture, indicating that NiRAN is essential for nidoviruses.  Potential functions supported by NiRAN may include nucleic acid ligation, mRNA capping and protein-primed RNA synthesis, possibilities that remain to be explored in future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptC0dNyfEUh7Vg90H21EOLACvtfcHk0ljdPK7i9SbRpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslGqs7jK&md5=007b4fc844862dca2e4bb01f09ff88fc</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkv838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkv838%26sid%3Dliteratum%253Aachs%26aulast%3DLehmann%26aufirst%3DK.%2BC.%26aulast%3DGulyaeva%26aufirst%3DA.%26aulast%3DZevenhoven-Dobbe%26aufirst%3DJ.%2BC.%26aulast%3DJanssen%26aufirst%3DG.%2BM.%2BC.%26aulast%3DRuben%26aufirst%3DM.%26aulast%3DOverkleeft%26aufirst%3DH.%2BS.%26aulast%3DVan%2BVeelen%26aufirst%3DP.%2BA.%26aulast%3DSamborskiy%26aufirst%3DD.%2BV.%26aulast%3DKravchenko%26aufirst%3DA.%2BA.%26aulast%3DLeontovich%26aufirst%3DA.%2BM.%26aulast%3DSidorov%26aufirst%3DI.%2BA.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3DPosthuma%26aufirst%3DC.%2BC.%26aulast%3DGorbalenya%26aufirst%3DA.%2BE.%26atitle%3DDiscovery%2520of%2520an%2520Essential%2520Nucleotidylating%2520Activity%2520Associated%2520with%2520a%2520Newly%2520Delineated%2520Conserved%2520Domain%2520in%2520the%2520RNA%2520Polymerase-Containing%2520Protein%2520of%2520All%2520Nidoviruses%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2015%26volume%3D43%26spage%3D8416%26epage%3D8434%26doi%3D10.1093%2Fnar%2Fgkv838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H. E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">1499</span>â <span class="NLM_lpage">1504</span>, <span class="refDoi">Â DOI: 10.1126/science.abc1560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscience.abc1560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32358203" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CltLfK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2020&pages=1499-1504&author=W.+Yinauthor=C.+Maoauthor=X.+Luanauthor=D.-D.+Shenauthor=Q.+Shenauthor=H.+Suauthor=X.+Wangauthor=F.+Zhouauthor=W.+Zhaoauthor=M.+Gaoauthor=S.+Changauthor=Y.-C.+Xieauthor=G.+Tianauthor=H.-W.+Jiangauthor=S.-C.+Taoauthor=J.+Shenauthor=Y.+Jiangauthor=H.+Jiangauthor=Y.+Xuauthor=S.+Zhangauthor=Y.+Zhangauthor=H.+E.+Xu&title=Structural+Basis+for+the+Inhibition+of+the+RNA-Dependent+RNA+Polymerase+from+SARS-CoV-2+by+Remdesivir&doi=10.1126%2Fscience.abc1560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir</span></div><div class="casAuthors">Yin, Wanchao; Mao, Chunyou; Luan, Xiaodong; Shen, Dan-Dan; Shen, Qingya; Su, Haixia; Wang, Xiaoxi; Zhou, Fulai; Zhao, Wenfeng; Gao, Minqi; Chang, Shenghai; Xie, Yuan-Chao; Tian, Guanghui; Jiang, He-Wei; Tao, Sheng-Ce; Shen, Jingshan; Jiang, Yi; Jiang, Hualiang; Xu, Yechun; Zhang, Shuyang; Zhang, Yan; Xu, H. Eric</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">6498</span>),
    <span class="NLM_cas:pages">1499-1504</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">1095-9203</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global crisis.  Replication of SARS-CoV-2 requires the viral RNA-dependent RNA polymerase (RdRp) enzyme, a target of the antiviral drug remdesivir.  Here, we report the cryo-electron microscopy structure of the SARS-CoV-2 RdRp, both in the apo form at 2.8-angstrom resoln. and in complex with a 50-base template-primer RNA and remdesivir at 2.5-angstrom resoln.  The complex structure reveals that the partial double-stranded RNA template is inserted into the central channel of the RdRp, where remdesivir is covalently incorporated into the primer strand at the first replicated base pair, and terminates chain elongation.  Our structures provide insights into the mechanism of viral RNA replication and a rational template for drug design to combat the viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlizem_f4e1LVg90H21EOLACvtfcHk0ljdPK7i9SbRpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CltLfK&md5=e5d7c8a1c27a02fdbfa9381482a0c3e8</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1126%2Fscience.abc1560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.abc1560%26sid%3Dliteratum%253Aachs%26aulast%3DYin%26aufirst%3DW.%26aulast%3DMao%26aufirst%3DC.%26aulast%3DLuan%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DD.-D.%26aulast%3DShen%26aufirst%3DQ.%26aulast%3DSu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DW.%26aulast%3DGao%26aufirst%3DM.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DY.-C.%26aulast%3DTian%26aufirst%3DG.%26aulast%3DJiang%26aufirst%3DH.-W.%26aulast%3DTao%26aufirst%3DS.-C.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DH.%2BE.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Inhibition%2520of%2520the%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520SARS-CoV-2%2520by%2520Remdesivir%26jtitle%3DScience%26date%3D2020%26volume%3D368%26spage%3D1499%26epage%3D1504%26doi%3D10.1126%2Fscience.abc1560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span> <span> </span><span class="NLM_article-title">Structural and Biochemical Characterization of the Nsp12-Nsp7-Nsp8 Core Polymerase Complex from SARS-CoV-2</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">107774</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.107774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.celrep.2020.107774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32531208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGhs7jJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2020&pages=107774&author=Q.+Pengauthor=R.+Pengauthor=B.+Yuanauthor=J.+Zhaoauthor=M.+Wangauthor=X.+Wangauthor=Q.+Wangauthor=Y.+Sunauthor=Z.+Fanauthor=J.+Qiauthor=G.+F.+Gaoauthor=Y.+Shi&title=Structural+and+Biochemical+Characterization+of+the+Nsp12-Nsp7-Nsp8+Core+Polymerase+Complex+from+SARS-CoV-2&doi=10.1016%2Fj.celrep.2020.107774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and biochemical characterization of the nsp12-nsp7-nsp8 core polymerase complex from SARS-CoV-2</span></div><div class="casAuthors">Peng, Qi; Peng, Ruchao; Yuan, Bin; Zhao, Jingru; Wang, Min; Wang, Xixi; Wang, Qian; Sun, Yan; Fan, Zheng; Qi, Jianxun; Gao, George F.; Shi, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">107774</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has caused a huge no. of human deaths.  Currently, there are no specific drugs or vaccines available for this virus (SARS-CoV-2).  The viral polymerase is a promising antiviral target.  Here, the authors describe the near-at.-resoln. structure of the SARS-CoV-2 polymerase complex consisting of the nsp12 catalytic subunit and nsp7-nsp8 cofactors.  This structure highly resembles the counterpart of SARS-CoV with conserved motifs for all viral RNA-dependent RNA polymerases and suggests a mechanism of activation by cofactors.  Biochem. studies reveal reduced activity of the core polymerase complex and lower thermostability of individual subunits of SARS-CoV-2 compared with SARS-CoV.  These findings provide important insights into RNA synthesis by coronavirus polymerase and indicate adaptation of SARS-CoV-2 toward humans with a relatively lower body temp. than the natural bat hosts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiKzBMRKFv-7Vg90H21EOLACvtfcHk0ljdPK7i9SbRpg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGhs7jJ&md5=ffd9ec806cb1735c829f49cb2f34bdbe</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.107774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.107774%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DQ.%26aulast%3DPeng%26aufirst%3DR.%26aulast%3DYuan%26aufirst%3DB.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DShi%26aufirst%3DY.%26atitle%3DStructural%2520and%2520Biochemical%2520Characterization%2520of%2520the%2520Nsp12-Nsp7-Nsp8%2520Core%2520Polymerase%2520Complex%2520from%2520SARS-CoV-2%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D31%26spage%3D107774%26doi%3D10.1016%2Fj.celrep.2020.107774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hillen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farnung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dienemann, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tegunov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span> <span> </span><span class="NLM_article-title">Structure of Replicating SARS-CoV-2 Polymerase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>584</i></span>,  <span class="NLM_fpage">154</span>â <span class="NLM_lpage">156</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2368-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2368-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32438371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=584&publication_year=2020&pages=154-156&author=H.+S.+Hillenauthor=G.+Kokicauthor=L.+Farnungauthor=C.+Dienemannauthor=D.+Tegunovauthor=P.+Cramer&title=Structure+of+Replicating+SARS-CoV-2+Polymerase&doi=10.1038%2Fs41586-020-2368-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of replicating SARS-CoV-2 polymerase</span></div><div class="casAuthors">Hillen, Hauke S.; Kokic, Goran; Farnung, Lucas; Dienemann, Christian; Tegunov, Dimitry; Cramer, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">584</span>
        (<span class="NLM_cas:issue">7819</span>),
    <span class="NLM_cas:pages">154-156</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: The new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses an RNA-dependent RNA polymerase (RdRp) for the replication of its genome and the transcription of its genes1-3.  Here we present a cryo-electron microscopy structure of the SARS-CoV-2 RdRp in an active form that mimics the replicating enzyme.  The structure comprises the viral proteins non-structural protein 12 (nsp12), nsp8 and nsp7, and more than two turns of RNA template-product duplex.  The active-site cleft of nsp12 binds to the first turn of RNA and mediates RdRp activity with conserved residues.  Two copies of nsp8 bind to opposite sides of the cleft and position the second turn of RNA.  Long helical extensions in nsp8 protrude along exiting RNA, forming pos. charged 'sliding poles'.  These sliding poles can account for the known processivity of RdRp that is required for replicating the long genome of coronaviruses3.  Our results enable a detailed anal. of the inhibitory mechanisms that underlie the antiviral activity of substances such as remdesivir, a drug for the treatment of coronavirus disease 2019 (COVID-19)4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvvV9anYxFpbVg90H21EOLACvtfcHk0ljWoW6xaiapJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVygtLjN&md5=a6c1595799a31219d6a54228f5df82c9</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2368-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2368-8%26sid%3Dliteratum%253Aachs%26aulast%3DHillen%26aufirst%3DH.%2BS.%26aulast%3DKokic%26aufirst%3DG.%26aulast%3DFarnung%26aufirst%3DL.%26aulast%3DDienemann%26aufirst%3DC.%26aulast%3DTegunov%26aufirst%3DD.%26aulast%3DCramer%26aufirst%3DP.%26atitle%3DStructure%2520of%2520Replicating%2520SARS-CoV-2%2520Polymerase%26jtitle%3DNature%26date%3D2020%26volume%3D584%26spage%3D154%26epage%3D156%26doi%3D10.1038%2Fs41586-020-2368-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mehellou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rattan, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balzarini, J.</span></span> <span> </span><span class="NLM_article-title">The ProTide Prodrug Technology: From the Concept to the Clinic</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2211</span>â <span class="NLM_lpage">2226</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.7b00734</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00734" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2211-2226&author=Y.+Mehellouauthor=H.+S.+Rattanauthor=J.+Balzarini&title=The+ProTide+Prodrug+Technology%3A+From+the+Concept+to+the+Clinic&doi=10.1021%2Facs.jmedchem.7b00734"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">The ProTide Prodrug Technology: From the Concept to the Clinic</span></div><div class="casAuthors">Mehellou, Youcef; Rattan, Hardeep S.; Balzarini, Jan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2211-2226</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ProTide technol. is a prodrug approach developed for the efficient intracellular delivery of nucleoside analog monophosphates and monophosphonates.  In this approach, the hydroxyls of the monophosphate or monophosphonate groups are masked by an arom. group and an amino acid ester moiety, which are enzymically cleaved-off inside cells to release the free nucleoside monophosphate and monophosphonate species.  Structurally, this represents the current end-point of an extensive medicinal chem. endeavor that spans almost three decades.  It started from the masking of nucleoside monophosphate and monophosphonate groups by simple alkyl groups and evolved into the sophisticated ProTide system as known today.  This technol. has been extensively employed in drug discovery, and it has already led to the discovery of two FDA-approved (antiviral) ProTides.  In this work, we will review the development of the ProTide technol., its application in drug discovery, and its role in the improvement of drug delivery and efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeaJFaQn4HwrVg90H21EOLACvtfcHk0ljWoW6xaiapJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlSitL3P&md5=ab9f5805c3c9d2d80fbdd82a3ad86c73</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00734%26sid%3Dliteratum%253Aachs%26aulast%3DMehellou%26aufirst%3DY.%26aulast%3DRattan%26aufirst%3DH.%2BS.%26aulast%3DBalzarini%26aufirst%3DJ.%26atitle%3DThe%2520ProTide%2520Prodrug%2520Technology%253A%2520From%2520the%2520Concept%2520to%2520the%2520Clinic%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2211%26epage%3D2226%26doi%3D10.1021%2Facs.jmedchem.7b00734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span>; <span class="NLM_string-name">Neyts, J.</span></span> <span> </span><span class="NLM_article-title">Antiviral Agents Acting as DNA or RNA Chain Terminators</span>. In  <i>Handbook of Experimental Pharmacology</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">KrÃ¤usslich, H.-G.</span>, <span class="NLM_string-name">Bartenschlager, R.</span></span>, Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">2009</span>; Vol.  <span class="NLM_volume">189</span>, pp  <span class="NLM_fpage">53</span>â <span class="NLM_lpage">84</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=53-84&author=E.+De+Clercq&author=J.+Neytsauthor=H.-G.+Kr%C3%A4usslich&author=R.+Bartenschlager&title=Handbook+of+Experimental+Pharmacology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DAntiviral%2520Agents%2520Acting%2520as%2520DNA%2520or%2520RNA%2520Chain%2520Terminators%26btitle%3DHandbook%2520of%2520Experimental%2520Pharmacology%26aulast%3DKr%25C3%25A4usslich%26aufirst%3DH.-G.%26pub%3DSpringer%26date%3D2009%26volume%3D189%26spage%3D53%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunders, O. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butler, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, C. U.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Antiviral Activity of a Series of 1â²-Substituted 4-Aza-7,9-Dideazaadenosine C-Nucleosides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2705</span>â <span class="NLM_lpage">2707</span>, <span class="refDoi">Â DOI: 10.1016/j.bmcl.2012.02.105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.bmcl.2012.02.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=22446091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVGqt7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2705-2707&author=A.+Choauthor=O.+L.+Saundersauthor=T.+Butlerauthor=L.+Zhangauthor=J.+Xuauthor=J.+E.+Velaauthor=J.+Y.+Fengauthor=A.+S.+Rayauthor=C.+U.+Kim&title=Synthesis+and+Antiviral+Activity+of+a+Series+of+1%E2%80%B2-Substituted+4-Aza-7%2C9-Dideazaadenosine+C-Nucleosides&doi=10.1016%2Fj.bmcl.2012.02.105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides</span></div><div class="casAuthors">Cho, Aesop; Saunders, Oliver L.; Butler, Thomas; Zhang, Lijun; Xu, Jie; Vela, Jennifer E.; Feng, Joy Y.; Ray, Adrian S.; Kim, Choung U.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2705-2707</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 1'-substituted analogs of 4-aza-7,9-dideazaadenosine C-nucleoside, e.g. I, were prepd. and evaluated for the potential as antiviral agents.  These compds. showed a broad range of inhibitory activity against various RNA viruses.  In particular, the whole cell potency against HCV when R = CN was attributed to inhibition of HCV NS5B polymerase and intracellular concn. of the corresponding nucleoside triphosphate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAj_ComFGJ9LVg90H21EOLACvtfcHk0ljWoW6xaiapJw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVGqt7Y%253D&md5=b7576da7b34ae7b3862d80b52645465a</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.105%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DA.%26aulast%3DSaunders%26aufirst%3DO.%2BL.%26aulast%3DButler%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DVela%26aufirst%3DJ.%2BE.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DKim%26aufirst%3DC.%2BU.%26atitle%3DSynthesis%2520and%2520Antiviral%2520Activity%2520of%2520a%2520Series%2520of%25201%25E2%2580%25B2-Substituted%25204-Aza-7%252C9-Dideazaadenosine%2520C-Nucleosides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2705%26epage%3D2707%26doi%3D10.1016%2Fj.bmcl.2012.02.105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuthman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tongeren, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garza, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donnelly, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shurtleff, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retterer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gharaibeh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamani, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenny, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimes, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomba, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilhelmsen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichols, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagle, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugelman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palacios, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerffler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trancheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braun, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayers, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>531</i></span>,  <span class="NLM_fpage">381</span>â <span class="NLM_lpage">385</span>, <span class="refDoi">Â DOI: 10.1038/nature17180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature17180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=26934220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC28XjvVGnu70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=531&publication_year=2016&pages=381-385&author=T.+K.+Warrenauthor=R.+Jordanauthor=M.+K.+Loauthor=A.+S.+Rayauthor=R.+L.+Mackmanauthor=V.+Solovevaauthor=D.+Siegelauthor=M.+Perronauthor=R.+Bannisterauthor=H.+C.+Huiauthor=N.+Larsonauthor=R.+Strickleyauthor=J.+Wellsauthor=K.+S.+Stuthmanauthor=S.+A.+Van+Tongerenauthor=N.+L.+Garzaauthor=G.+Donnellyauthor=A.+C.+Shurtleffauthor=C.+J.+Rettererauthor=D.+Gharaibehauthor=R.+Zamaniauthor=T.+Kennyauthor=B.+P.+Eatonauthor=E.+Grimesauthor=L.+S.+Welchauthor=L.+Gombaauthor=C.+L.+Wilhelmsenauthor=D.+K.+Nicholsauthor=J.+E.+Nussauthor=E.+R.+Nagleauthor=J.+R.+Kugelmanauthor=G.+Palaciosauthor=E.+Doerfflerauthor=S.+Nevilleauthor=E.+Carraauthor=M.+O.+Clarkeauthor=L.+Zhangauthor=W.+Lewauthor=B.+Rossauthor=Q.+Wangauthor=K.+Chunauthor=L.+Wolfeauthor=D.+Babusisauthor=Y.+Parkauthor=K.+M.+Strayauthor=I.+Tranchevaauthor=J.+Y.+Fengauthor=O.+Barauskasauthor=Y.+Xuauthor=P.+Wongauthor=M.+R.+Braunauthor=M.+Flintauthor=L.+K.+McMullanauthor=S.+S.+Chenauthor=R.+Fearnsauthor=S.+Swaminathanauthor=D.+L.+Mayersauthor=C.+F.+Spiropoulouauthor=W.+A.+Leeauthor=S.+T.+Nicholauthor=T.+Cihlarauthor=S.+Bavari&title=Therapeutic+Efficacy+of+the+Small+Molecule+GS-5734+against+Ebola+Virus+in+Rhesus+Monkeys&doi=10.1038%2Fnature17180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys</span></div><div class="casAuthors">Warren, Travis K.; Jordan, Robert; Lo, Michael K.; Ray, Adrian S.; Mackman, Richard L.; Soloveva, Veronica; Siegel, Dustin; Perron, Michel; Bannister, Roy; Hui, Hon C.; Larson, Nate; Strickley, Robert; Wells, Jay; Stuthman, Kelly S.; Van Tongeren, Sean A.; Garza, Nicole L.; Donnelly, Ginger; Shurtleff, Amy C.; Retterer, Cary J.; Gharaibeh, Dima; Zamani, Rouzbeh; Kenny, Tara; Eaton, Brett P.; Grimes, Elizabeth; Welch, Lisa S.; Gomba, Laura; Wilhelmsen, Catherine L.; Nichols, Donald K.; Nuss, Jonathan E.; Nagle, Elyse R.; Kugelman, Jeffrey R.; Palacios, Gustavo; Doerffler, Edward; Neville, Sean; Carra, Ernest; Clarke, Michael O.; Zhang, Lijun; Lew, Willard; Ross, Bruce; Wang, Queenie; Chun, Kwon; Wolfe, Lydia; Babusis, Darius; Park, Yeojin; Stray, Kirsten M.; Trancheva, Iva; Feng, Joy Y.; Barauskas, Ona; Xu, Yili; Wong, Pamela; Braun, Molly R.; Flint, Mike; McMullan, Laura K.; Chen, Shan-Shan; Fearns, Rachel; Swaminathan, Swami; Mayers, Douglas L.; Spiropoulou, Christina F.; Lee, William A.; Nichol, Stuart T.; Cihlar, Tomas; Bavari, Sina</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">531</span>
        (<span class="NLM_cas:issue">7594</span>),
    <span class="NLM_cas:pages">381-385</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The most recent Ebola virus outbreak in West Africa, which was unprecedented in the no. of cases and fatalities, geog. distribution, and no. of nations affected, highlights the need for safe, effective, and readily available antiviral agents for treatment and prevention of acute Ebola virus (EBOV) disease (EVD) or sequelae.  No antiviral therapeutics have yet received regulatory approval or demonstrated clin. efficacy.  Here we report the discovery of a novel small mol. GS-5734, a monophosphoramidate prodrug of an adenosine analog, with antiviral activity against EBOV.  GS-5734 exhibits antiviral activity against multiple variants of EBOV and other filoviruses in cell-based assays.  The pharmacol. active nucleoside triphosphate (NTP) is efficiently formed in multiple human cell types incubated with GS-5734 in vitro, and the NTP acts as an alternative substrate and RNA-chain terminator in primer-extension assays using a surrogate respiratory syncytial virus RNA polymerase.  I.v. administration of GS-5734 to nonhuman primates resulted in persistent NTP levels in peripheral blood mononuclear cells (half-life, 14 h) and distribution to sanctuary sites for viral replication including testes, eyes, and brain.  In a rhesus monkey model of EVD, once-daily i.v. administration of 10 mg kg-1 GS-5734 for 12 days resulted in profound suppression of EBOV replication and protected 100% of EBOV-infected animals against lethal disease, ameliorating clin. disease signs and pathophysiol. markers, even when treatments were initiated three days after virus exposure when systemic viral RNA was detected in two out of six treated animals.  These results show the first substantive post-exposure protection by a small-mol. antiviral compd. against EBOV in nonhuman primates.  The broad-spectrum antiviral activity of GS-5734 in vitro against other pathogenic RNA viruses, including filoviruses, arenaviruses, and coronaviruses, suggests the potential for wider medical use.  GS-5734 is amenable to large-scale manufg., and clin. studies investigating the drug safety and pharmacokinetics are ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqX4QsyLVjgHLVg90H21EOLACvtfcHk0lhYFhpz6P5ytw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XjvVGnu70%253D&md5=ab121d827ac0a40cc1fed3dd1df905b6</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1038%2Fnature17180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17180%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DLarson%26aufirst%3DN.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DStuthman%26aufirst%3DK.%2BS.%26aulast%3DVan%2BTongeren%26aufirst%3DS.%2BA.%26aulast%3DGarza%26aufirst%3DN.%2BL.%26aulast%3DDonnelly%26aufirst%3DG.%26aulast%3DShurtleff%26aufirst%3DA.%2BC.%26aulast%3DRetterer%26aufirst%3DC.%2BJ.%26aulast%3DGharaibeh%26aufirst%3DD.%26aulast%3DZamani%26aufirst%3DR.%26aulast%3DKenny%26aufirst%3DT.%26aulast%3DEaton%26aufirst%3DB.%2BP.%26aulast%3DGrimes%26aufirst%3DE.%26aulast%3DWelch%26aufirst%3DL.%2BS.%26aulast%3DGomba%26aufirst%3DL.%26aulast%3DWilhelmsen%26aufirst%3DC.%2BL.%26aulast%3DNichols%26aufirst%3DD.%2BK.%26aulast%3DNuss%26aufirst%3DJ.%2BE.%26aulast%3DNagle%26aufirst%3DE.%2BR.%26aulast%3DKugelman%26aufirst%3DJ.%2BR.%26aulast%3DPalacios%26aufirst%3DG.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DNeville%26aufirst%3DS.%26aulast%3DCarra%26aufirst%3DE.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLew%26aufirst%3DW.%26aulast%3DRoss%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DWolfe%26aufirst%3DL.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DTrancheva%26aufirst%3DI.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DWong%26aufirst%3DP.%26aulast%3DBraun%26aufirst%3DM.%2BR.%26aulast%3DFlint%26aufirst%3DM.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DMayers%26aufirst%3DD.%2BL.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBavari%26aufirst%3DS.%26atitle%3DTherapeutic%2520Efficacy%2520of%2520the%2520Small%2520Molecule%2520GS-5734%2520against%2520Ebola%2520Virus%2520in%2520Rhesus%2520Monkeys%26jtitle%3DNature%26date%3D2016%26volume%3D531%26spage%3D381%26epage%3D385%26doi%3D10.1038%2Fnature17180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doerffler, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chun, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neville, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carra, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lew, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soloveva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stray, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barauskas, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rheingold, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strickley, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaminathan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span> <span> </span><span class="NLM_article-title">Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][Triazin-4-Amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">1648</span>â <span class="NLM_lpage">1661</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b01594</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01594" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Gjsb4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=1648-1661&author=D.+Siegelauthor=H.+C.+Huiauthor=E.+Doerfflerauthor=M.+O.+Clarkeauthor=K.+Chunauthor=L.+Zhangauthor=S.+Nevilleauthor=E.+Carraauthor=W.+Lewauthor=B.+Rossauthor=Q.+Wangauthor=L.+Wolfeauthor=R.+Jordanauthor=V.+Solovevaauthor=J.+Knoxauthor=J.+Perryauthor=M.+Perronauthor=K.+M.+Strayauthor=O.+Barauskasauthor=J.+Y.+Fengauthor=Y.+Xuauthor=G.+Leeauthor=A.+L.+Rheingoldauthor=A.+S.+Rayauthor=R.+Bannisterauthor=R.+Strickleyauthor=S.+Swaminathanauthor=W.+A.+Leeauthor=S.+Bavariauthor=T.+Cihlarauthor=M.+K.+Loauthor=T.+K.+Warrenauthor=R.+L.+Mackman&title=Discovery+and+Synthesis+of+a+Phosphoramidate+Prodrug+of+a+Pyrrolo%5B2%2C1-f%5D%5BTriazin-4-Amino%5D+Adenine+C-Nucleoside+%28GS-5734%29+for+the+Treatment+of+Ebola+and+Emerging+Viruses&doi=10.1021%2Facs.jmedchem.6b01594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses</span></div><div class="casAuthors">Siegel, Dustin; Hui, Hon C.; Doerffler, Edward; Clarke, Michael O.; Chun, Kwon; Zhang, Lijun; Neville, Sean; Carra, Ernest; Lew, Willard; Ross, Bruce; Wang, Queenie; Wolfe, Lydia; Jordan, Robert; Soloveva, Veronica; Knox, John; Perry, Jason; Perron, Michel; Stray, Kirsten M.; Barauskas, Ona; Feng, Joy Y.; Xu, Yili; Lee, Gary; Rheingold, Arnold L.; Ray, Adrian S.; Bannister, Roy; Strickley, Robert; Swaminathan, Swami; Lee, William A.; Bavari, Sina; Cihlar, Tomas; Lo, Michael K.; Warren, Travis K.; Mackman, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1648-1661</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The recent Ebola virus (EBOV) outbreak in West Africa was the largest recorded in history with over 28,000 cases, resulting in >11,000 deaths including >500 healthcare workers.  A focused screening and lead optimization effort identified 4b (GS-5734) with anti-EBOV EC50 = 86 nM in macrophages as the clin. candidate.  Structure activity relationships established that the 1'-CN group and C-linked nucleobase were crit. for optimal anti-EBOV potency and selectivity against host polymerases.  A robust diastereoselective synthesis provided sufficient quantities of 4b to enable preclin. efficacy in a non-human-primate EBOV challenge model.  Once-daily 10 mg/kg iv treatment on days 3-14 postinfection had a significant effect on viremia and mortality, resulting in 100% survival of infected treated animals [ Nature 2016, 531, 381-385].  A phase 2 study (PREVAIL IV) is currently enrolling and will evaluate the effect of 4b on viral shedding from sanctuary sites in EBOV survivors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWkPjn__gILVg90H21EOLACvtfcHk0lg_RZzT1T87Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Gjsb4%253D&md5=b2a05cfeb4fd30fbca0d1d584ddcc220</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01594%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DDoerffler%26aufirst%3DE.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DChun%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DNeville%26aufirst%3DS.%26aulast%3DCarra%26aufirst%3DE.%26aulast%3DLew%26aufirst%3DW.%26aulast%3DRoss%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWolfe%26aufirst%3DL.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DSoloveva%26aufirst%3DV.%26aulast%3DKnox%26aufirst%3DJ.%26aulast%3DPerry%26aufirst%3DJ.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DStray%26aufirst%3DK.%2BM.%26aulast%3DBarauskas%26aufirst%3DO.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DG.%26aulast%3DRheingold%26aufirst%3DA.%2BL.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DStrickley%26aufirst%3DR.%26aulast%3DSwaminathan%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DW.%2BA.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26atitle%3DDiscovery%2520and%2520Synthesis%2520of%2520a%2520Phosphoramidate%2520Prodrug%2520of%2520a%2520Pyrrolo%255B2%252C1-f%255D%255BTriazin-4-Amino%255D%2520Adenine%2520C-Nucleoside%2520%2528GS-5734%2529%2520for%2520the%2520Treatment%2520of%2520Ebola%2520and%2520Emerging%2520Viruses%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D1648%26epage%3D1661%26doi%3D10.1021%2Facs.jmedchem.6b01594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">Remdesivir Is a Direct-Acting Antiviral That Inhibits RNA-Dependent RNA Polymerase from Severe Acute Respiratory Syndrome Coronavirus 2 with High Potency</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">6785</span>â <span class="NLM_lpage">6797</span>, <span class="refDoi">Â DOI: 10.1074/jbc.RA120.013679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.RA120.013679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32284326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=6785-6797&author=C.+J.+Gordonauthor=E.+P.+Tchesnokovauthor=E.+Woolnerauthor=J.+K.+Perryauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=Remdesivir+Is+a+Direct-Acting+Antiviral+That+Inhibits+RNA-Dependent+RNA+Polymerase+from+Severe+Acute+Respiratory+Syndrome+Coronavirus+2+with+High+Potency&doi=10.1074%2Fjbc.RA120.013679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</span></div><div class="casAuthors">Gordon, Calvin J.; Tchesnokov, Egor P.; Woolner, Emma; Perry, Jason K.; Feng, Joy Y.; Porter, Danielle P.; Gotte, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6785-6797</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Effective treatments for coronavirus disease 2019 (COVID-19) are urgently needed to control this current pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  Replication of SARS-CoV-2 depends on the viral RNA-dependent RNA polymerase (RdRp), which is the likely target of the investigational nucleotide analog remdesivir (RDV).  RDV shows broad-spectrum antiviral activity against RNA viruses, and previous studies with RdRps from Ebola virus and Middle East respiratory syndrome coronavirus (MERS-CoV) have revealed that delayed chain termination is RDV's plausible mechanism of action.  Here, we expressed and purified active SARS-CoV-2 RdRp composed of the nonstructural proteins nsp8 and nsp12.  Enzyme kinetics indicated that this RdRp efficiently incorporates the active triphosphate form of RDV (RDV-TP) into RNA.  Incorporation of RDV-TP at position i caused termination of RNA synthesis at position i + 3.  We obtained almost identical results with SARS-CoV, MERS-CoV, and SARS-CoV-2 RdRps.  A unique property of RDV-TP is its high selectivity over incorporation of its natural nucleotide counterpart ATP.  In this regard, the triphosphate forms of 2'-C-methylated compds., including sofosbuvir, approved for the management of hepatitis C virus infection, and the broad-acting antivirals favipiravir and ribavirin, exhibited significant deficits.  Furthermore, we provide evidence for the target specificity of RDV, as RDV-TP was less efficiently incorporated by the distantly related Lassa virus RdRp, and termination of RNA synthesis was not obsd.  These results collectively provide a unifying, refined mechanism of RDV-mediated RNA synthesis inhibition in coronaviruses and define this nucleotide analog as a direct-acting antiviral.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgHbFv_ESm2rVg90H21EOLACvtfcHk0lg_RZzT1T87Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Wqt7bN&md5=10cbcacce46953727591712e0edebed8</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1074%2Fjbc.RA120.013679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.RA120.013679%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DC.%2BJ.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DWoolner%26aufirst%3DE.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DRemdesivir%2520Is%2520a%2520Direct-Acting%2520Antiviral%2520That%2520Inhibits%2520RNA-Dependent%2520RNA%2520Polymerase%2520from%2520Severe%2520Acute%2520Respiratory%2520Syndrome%2520Coronavirus%25202%2520with%2520High%2520Potency%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D6785%26epage%3D6797%26doi%3D10.1074%2Fjbc.RA120.013679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shannon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, N. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selisko, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eydoux, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alvarez, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemot, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decroly, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peersen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferron, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canard, B.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and SARS-CoV-2: Structural Requirements at Both Nsp12 RdRp and Nsp14 Exonuclease Active-Sites</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104793</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2020.104793" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32283108" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntFSrt70%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104793&author=A.+Shannonauthor=N.+T.+T.+Leauthor=B.+Seliskoauthor=C.+Eydouxauthor=K.+Alvarezauthor=J.+C.+Guillemotauthor=E.+Decrolyauthor=O.+Peersenauthor=F.+Ferronauthor=B.+Canard&title=Remdesivir+and+SARS-CoV-2%3A+Structural+Requirements+at+Both+Nsp12+RdRp+and+Nsp14+Exonuclease+Active-Sites&doi=10.1016%2Fj.antiviral.2020.104793"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites</span></div><div class="casAuthors">Shannon, Ashleigh; Le, Nhung Thi-Tuyet; Selisko, Barbara; Eydoux, Cecilia; Alvarez, Karine; Guillemot, Jean-Claude; Decroly, Etienne; Peersen, Olve; Ferron, Francois; Canard, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104793</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The rapid global emergence of SARS-CoV-2 has been the cause of significant health concern, highlighting the immediate need for antivirals.  Viral RNA-dependent RNA polymerases (RdRp) play essential roles in viral RNA synthesis, and thus remains the target of choice for the prophylactic or curative treatment of several viral diseases, due to high sequence and structural conservation.  To date, the most promising broad-spectrum class of viral RdRp inhibitors are nucleoside analogs (NAs), with over 25 approved for the treatment of several medically important viral diseases.  However, Coronaviruses stand out as a particularly challenging case for NA drug design due to the presence of an exonuclease (ExoN) domain capable of excising incorporated NAs and thus providing resistance to many of these available antivirals.  Here we use the available structures of the SARS-CoV RdRp and ExoN proteins, as well as Lassa virus N exonuclease to derive models of catalytically competent SARS-CoV-2 enzymes.  We then map a promising NA candidate, GS-441524 (the active metabolite of Remdesivir) to the nucleoside active site of both proteins, identifying the residues important for nucleotide recognition, discrimination, and excision.  Interestingly, GS-441524 addresses both enzyme active sites in a manner consistent with significant incorporation, delayed chain termination, and altered excision due to the ribose 1'-CN group, which may account for the increased antiviral effect compared to other available analogs.  Addnl., we propose structural and function implications of two previously identified RdRp resistance mutations in relation to resistance against Remdesivir.  This study highlights the importance of considering the balance between incorporation and excision properties of NAs between the RdRp and ExoN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotbZG0obWWsrVg90H21EOLACvtfcHk0lg_RZzT1T87Dw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntFSrt70%253D&md5=e7eb04df547768ddd50c875c11f7ccb5</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104793%26sid%3Dliteratum%253Aachs%26aulast%3DShannon%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DN.%2BT.%2BT.%26aulast%3DSelisko%26aufirst%3DB.%26aulast%3DEydoux%26aufirst%3DC.%26aulast%3DAlvarez%26aufirst%3DK.%26aulast%3DGuillemot%26aufirst%3DJ.%2BC.%26aulast%3DDecroly%26aufirst%3DE.%26aulast%3DPeersen%26aufirst%3DO.%26aulast%3DFerron%26aufirst%3DF.%26aulast%3DCanard%26aufirst%3DB.%26atitle%3DRemdesivir%2520and%2520SARS-CoV-2%253A%2520Structural%2520Requirements%2520at%2520Both%2520Nsp12%2520RdRp%2520and%2520Nsp14%2520Exonuclease%2520Active-Sites%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104793%26doi%3D10.1016%2Fj.antiviral.2020.104793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir</span>. <i>Viruses</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">326</span>, <span class="refDoi">Â DOI: 10.3390/v11040326</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.3390%2Fv11040326" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslymt7fJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=326&author=E.+P.+Tchesnokovauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=Mechanism+of+Inhibition+of+Ebola+Virus+RNA-Dependent+RNA+Polymerase+by+Remdesivir&doi=10.3390%2Fv11040326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir</span></div><div class="casAuthors">Tchesnokov, Egor P.; Feng, Joy Y.; Porter, Danielle P.; Goette, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Viruses</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">326</span>CODEN:
                <span class="NLM_cas:coden">VIRUBR</span>;
        ISSN:<span class="NLM_cas:issn">1999-4915</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Remdesivir (GS-5734) is a 1'-cyano-substituted adenosine nucleotide analog prodrug that shows broad-spectrum antiviral activity against several RNA viruses.  This compd. is currently under clin. development for the treatment of Ebola virus disease (EVD).  While antiviral effects have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola virus (EBOV) inhibition for remdesivir remains to be fully elucidated.  The EBOV RNA-dependent RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochem. studies with the relevant triphosphate (TP) form of remdesivir and its presumptive target.  In this study, we confirmed that remdesivir-TP is able to compete for incorporation with ATP (ATP).  Enzyme kinetics revealed that EBOV RdRp and Respiratory syncytial virus (RSV) RdRp incorporate ATP and remdesivir-TP with similar efficiencies.  The selectivity of ATP against remdesivir-TP is â¼4 for EBOV RdRp and â¼3 for RSV RdRp.  In contrast, purified human mitochondrial RNA polymerase (h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of â¼500-fold.  For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide incorporation event at position i+1.  For RSV RdRp, we measured a â¼6-fold inhibition at position i+1 although RNA synthesis was not terminated.  Chain termination was in both cases delayed and was seen predominantly at position i+5.  This pattern is specific to remdesivir-TP and its 1'-cyano modification.  Compds. with modifications at the 2'-position show different patterns of inhibition.  While 2'-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and prevents nucleotide incorporation at position i+1.  Taken together, our biochem. data indicate that the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed chain termination.  The long distance of five residues between the incorporated nucleotide analog and its inhibitory effect warrant further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc37XlGxWUUbVg90H21EOLACvtfcHk0lipelXEtq6rVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslymt7fJ&md5=1193e2fa405b0298678db0a005aa292e</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.3390%2Fv11040326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fv11040326%26sid%3Dliteratum%253Aachs%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DMechanism%2520of%2520Inhibition%2520of%2520Ebola%2520Virus%2520RNA-Dependent%2520RNA%2520Polymerase%2520by%2520Remdesivir%26jtitle%3DViruses%26date%3D2019%26volume%3D11%26spage%3D326%26doi%3D10.3390%2Fv11040326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Symons, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beigelman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deval, J.</span></span> <span> </span><span class="NLM_article-title">Initiation, Extension, and Termination of RNA Synthesis by a Paramyxovirus Polymerase</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">e1006889</span>, <span class="refDoi">Â DOI: 10.1371/journal.ppat.1006889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1371%2Fjournal.ppat.1006889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29425244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsleltrvM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&pages=e1006889&author=P.+C.+Jordanauthor=C.+Liuauthor=P.+Raynaudauthor=M.+K.+Loauthor=C.+F.+Spiropoulouauthor=J.+A.+Symonsauthor=L.+Beigelmanauthor=J.+Deval&title=Initiation%2C+Extension%2C+and+Termination+of+RNA+Synthesis+by+a+Paramyxovirus+Polymerase&doi=10.1371%2Fjournal.ppat.1006889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase</span></div><div class="casAuthors">Jordan, Paul C.; Liu, Cheng; Raynaud, Pauline; Lo, Michael K.; Spiropoulou, Christina F.; Symons, Julian A.; Beigelman, Leo; Deval, Jerome</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e1006889/1-e1006889/23</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Paramyxoviruses represent a family of RNA viruses causing significant human diseases.  These include measles virus, the most infectious virus ever reported, in addn. to parainfluenza virus, and other emerging viruses.  Paramyxoviruses likely share common replication machinery but their mechanisms of RNA biosynthesis activities and details of their complex polymerase structures are unknown.  Mechanistic and functional details of a paramyxovirus polymerase would have sweeping implications for understanding RNA virus replication and for the development of new antiviral medicines.  To study paramyxovirus polymerase structure and function, we expressed an active recombinant Nipah virus (NiV) polymerase complex assembled from the multifunctional NiV L protein bound to its phosphoprotein cofactor.  NiV is an emerging highly pathogenic virus that causes severe encephalitis and has been declared a global public health concern due to its high mortality rate.  Using neg.-stain electron microscopy, we demonstrated NiV polymerase forms ring-like particles resembling related RNA polymerases.  We identified conserved sequence elements driving recognition of the 3'- terminal genomic promoter by NiV polymerase, and leading to initiation of RNA synthesis, primer extension, and transition to elongation mode.  Polyadenylation resulting from NiV polymerase stuttering provides a mechanistic basis for transcription termination.  It also suggests a divergent adaptation in promoter recognition between pneumo- and paramyxoviruses.  The lack of available antiviral therapy for NiV prompted us to identify the triphosphate forms of R1479 and GS-5734, two clin. relevant nucleotide analogs, as substrates and inhibitors of NiV polymerase activity by delayed chain termination.  Overall, these findings provide low-resoln. structural details and the mechanism of an RNA polymerase from a previously uncharacterized virus family.  This work illustrates important functional differences yet remarkable similarities between the polymerases of nonsegmented neg.-strand RNA viruses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_SobNcmdy9rVg90H21EOLACvtfcHk0lipelXEtq6rVA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsleltrvM&md5=c4e11dad7faf0fb43d2dfff9f3dc202a</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1006889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1006889%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DP.%2BC.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DRaynaud%26aufirst%3DP.%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3DSymons%26aufirst%3DJ.%2BA.%26aulast%3DBeigelman%26aufirst%3DL.%26aulast%3DDeval%26aufirst%3DJ.%26atitle%3DInitiation%252C%2520Extension%252C%2520and%2520Termination%2520of%2520RNA%2520Synthesis%2520by%2520a%2520Paramyxovirus%2520Polymerase%26jtitle%3DPLoS%2520Pathog.%26date%3D2018%26volume%3D14%26spage%3De1006889%26doi%3D10.1371%2Fjournal.ppat.1006889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchesnokov, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GÃ¶tte, M.</span></span> <span> </span><span class="NLM_article-title">The Antiviral Compound Remdesivir Potently Inhibits RNAdependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>295</i></span>,  <span class="NLM_fpage">4773</span>â <span class="NLM_lpage">4779</span>, <span class="refDoi">Â DOI: 10.1074/jbc.AC120.013056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1074%2Fjbc.AC120.013056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32094225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVelsrg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=295&publication_year=2020&pages=4773-4779&author=C.+J.+Gordonauthor=E.+P.+Tchesnokovauthor=J.+Y.+Fengauthor=D.+P.+Porterauthor=M.+G%C3%B6tte&title=The+Antiviral+Compound+Remdesivir+Potently+Inhibits+RNAdependent+RNA+Polymerase+from+Middle+East+Respiratory+Syndrome+Coronavirus&doi=10.1074%2Fjbc.AC120.013056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus</span></div><div class="casAuthors">Gordon, Calvin J.; Tchesnokov, Egor P.; Feng, Joy Y.; Porter, Danielle P.; Gotte, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">295</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4773-4779</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">1083-351X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at contg. the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2).  Remdesivir (RDV) is an investigational compd. with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV).  RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps).  Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV.  We initially demonstrated that nsp8 and nsp12 form an active complex.  The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP.  Of note, the selectivity value for RDV-TP obtained with a steady-state approach suggests that it is more efficiently incorporated than ATP and 2 other nucleotide analogs.  Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3.  Hence, the likely mechanism of action is delayed RNA chain termination.  The addnl. 3 nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity.  Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbDEbqkrS27Vg90H21EOLACvtfcHk0lil_qws8RyCoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVelsrg%253D&md5=e47890519ac94b27e3185224db05c225</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1074%2Fjbc.AC120.013056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.AC120.013056%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DC.%2BJ.%26aulast%3DTchesnokov%26aufirst%3DE.%2BP.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DG%25C3%25B6tte%26aufirst%3DM.%26atitle%3DThe%2520Antiviral%2520Compound%2520Remdesivir%2520Potently%2520Inhibits%2520RNAdependent%2520RNA%2520Polymerase%2520from%2520Middle%2520East%2520Respiratory%2520Syndrome%2520Coronavirus%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2020%26volume%3D295%26spage%3D4773%26epage%3D4779%26doi%3D10.1074%2Fjbc.AC120.013056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guddat, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Z.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>182</i></span>,  <span class="NLM_fpage">417</span>â <span class="NLM_lpage">428</span>, <span class="refDoi">Â DOI: 10.1016/j.cell.2020.05.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.cell.2020.05.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32526208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFGhtrjN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=182&publication_year=2020&pages=417-428&author=Q.+Wangauthor=J.+Wuauthor=H.+Wangauthor=Y.+Gaoauthor=Q.+Liuauthor=A.+Muauthor=W.+Jiauthor=L.+Yanauthor=Y.+Zhuauthor=C.+Zhuauthor=X.+Fangauthor=X.+Yangauthor=Y.+Huangauthor=H.+Gaoauthor=F.+Liuauthor=J.+Geauthor=Q.+Sunauthor=X.+Yangauthor=W.+Xuauthor=Z.+Liuauthor=H.+Yangauthor=Z.+Louauthor=B.+Jiangauthor=L.+W.+Guddatauthor=P.+Gongauthor=Z.+Rao&title=Structural+Basis+for+RNA+Replication+by+the+SARS-CoV-2+Polymerase&doi=10.1016%2Fj.cell.2020.05.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase</span></div><div class="casAuthors">Wang, Quan; Wu, Jiqin; Wang, Haofeng; Gao, Yan; Liu, Qiaojie; Mu, An; Ji, Wenxin; Yan, Liming; Zhu, Yan; Zhu, Chen; Fang, Xiang; Yang, Xiaobao; Huang, Yucen; Gao, Hailong; Liu, Fengjiang; Ge, Ji; Sun, Qianqian; Yang, Xiuna; Xu, Wenqing; Liu, Zhijie; Yang, Haitao; Lou, Zhiyong; Jiang, Biao; Guddat, Luke W.; Gong, Peng; Rao, Zihe</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">182</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417-428.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Nucleotide analog inhibitors, including broad-spectrum remdesivir and favipiravir, have shown promise in in vitro assays and some clin. studies for COVID-19 treatment, this despite an incomplete mechanistic understanding of the viral RNA-dependent RNA polymerase nsp12 drug interactions.  We examine the mol. basis of SARS-CoV-2 RNA replication by detg. the cryo-EM structures of the stalled pre- and post- translocated polymerase complexes.  Compared with the apo complex, the structures show notable structural rearrangements happening to nsp12 and its co-factors nsp7 and nsp8 to accommodate the nucleic acid, whereas there are highly conserved residues in nsp12, positioning the template and primer for an in-line attack on the incoming nucleotide.  Furthermore, we investigate the inhibition mechanism of the triphosphate metabolite of remdesivir through structural and kinetic analyses.  A transition model from the nsp7-nsp8 hexadecameric primase complex to the nsp12-nsp7-nsp8 polymerase complex is also proposed to provide clues for the understanding of the coronavirus transcription and replication machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr24LizT9ajcbVg90H21EOLACvtfcHk0lil_qws8RyCoA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFGhtrjN&md5=ae9117fd346b577d85d37088b1999fb9</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.05.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.05.034%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DMu%26aufirst%3DA.%26aulast%3DJi%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DC.%26aulast%3DFang%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DGao%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DLou%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DGuddat%26aufirst%3DL.%2BW.%26aulast%3DGong%26aufirst%3DP.%26aulast%3DRao%26aufirst%3DZ.%26atitle%3DStructural%2520Basis%2520for%2520RNA%2520Replication%2520by%2520the%2520SARS-CoV-2%2520Polymerase%26jtitle%3DCell%26date%3D2020%26volume%3D182%26spage%3D417%26epage%3D428%26doi%3D10.1016%2Fj.cell.2020.05.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">e13.</p></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudhamsu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrivastava-Ranjan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotard, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flint, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMullan, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span> <span> </span><span class="NLM_article-title">GS-5734 and Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">43395</span>, <span class="refDoi">Â DOI: 10.1038/srep43395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fsrep43395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28262699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1czjtFaltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=43395&author=M.+K.+Loauthor=R.+Jordanauthor=A.+Arveyauthor=J.+Sudhamsuauthor=P.+Shrivastava-Ranjanauthor=A.+L.+Hotardauthor=M.+Flintauthor=L.+K.+McMullanauthor=D.+Siegelauthor=M.+O.+Clarkeauthor=R.+L.+Mackmanauthor=H.+C.+Huiauthor=M.+Perronauthor=A.+S.+Rayauthor=T.+Cihlarauthor=S.+T.+Nicholauthor=C.+F.+Spiropoulou&title=GS-5734+and+Its+Parent+Nucleoside+Analog+Inhibit+Filo-%2C+Pneumo-%2C+and+Paramyxoviruses&doi=10.1038%2Fsrep43395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses</span></div><div class="casAuthors">Lo Michael K; Shrivastava-Ranjan Punya; Hotard Anne L; Flint Mike; McMullan Laura K; Nichol Stuart T; Spiropoulou Christina F; Jordan Robert; Arvey Aaron; Sudhamsu Jawahar; Siegel Dustin; Clarke Michael O; Mackman Richard L; Hui Hon C; Perron Michel; Ray Adrian S; Cihlar Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">43395</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">GS-5734 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a non-human primate model of Ebola virus infection.  It has been administered under compassionate use to two Ebola patients, both of whom survived, and is currently in Phase 2 clinical development for treatment of Ebola virus disease.  Here we report the antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, providing evidence to support new indications for this compound against human viruses of significant public health concern.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTe-gGPhesmNRpyrDyM_m9cfW6udTcc2ebkc9oLgcjQBLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czjtFaltg%253D%253D&md5=23a17a6f59bbe3e7b3f2f8770858a0c1</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fsrep43395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep43395%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DArvey%26aufirst%3DA.%26aulast%3DSudhamsu%26aufirst%3DJ.%26aulast%3DShrivastava-Ranjan%26aufirst%3DP.%26aulast%3DHotard%26aufirst%3DA.%2BL.%26aulast%3DFlint%26aufirst%3DM.%26aulast%3DMcMullan%26aufirst%3DL.%2BK.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DHui%26aufirst%3DH.%2BC.%26aulast%3DPerron%26aufirst%3DM.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26atitle%3DGS-5734%2520and%2520Its%2520Parent%2520Nucleoside%2520Analog%2520Inhibit%2520Filo-%252C%2520Pneumo-%252C%2520and%2520Paramyxoviruses%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D43395%26doi%3D10.1038%2Fsrep43395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lo, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gary, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klena, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nichol, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaki, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiropoulou, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, E.</span></span> <span> </span><span class="NLM_article-title">Remdesivir (GS-5734) Protects African Green Monkeys from Nipah Virus Challenge</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaau9242</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aau9242</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aau9242" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31142680" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaau9242&author=M.+K.+Loauthor=F.+Feldmannauthor=J.+M.+Garyauthor=R.+Jordanauthor=R.+Bannisterauthor=J.+Croninauthor=N.+R.+Patelauthor=J.+D.+Klenaauthor=S.+T.+Nicholauthor=T.+Cihlarauthor=S.+R.+Zakiauthor=H.+Feldmannauthor=C.+F.+Spiropoulouauthor=E.+de+Wit&title=Remdesivir+%28GS-5734%29+Protects+African+Green+Monkeys+from+Nipah+Virus+Challenge&doi=10.1126%2Fscitranslmed.aau9242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau9242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau9242%26sid%3Dliteratum%253Aachs%26aulast%3DLo%26aufirst%3DM.%2BK.%26aulast%3DFeldmann%26aufirst%3DF.%26aulast%3DGary%26aufirst%3DJ.%2BM.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DCronin%26aufirst%3DJ.%26aulast%3DPatel%26aufirst%3DN.%2BR.%26aulast%3DKlena%26aufirst%3DJ.%2BD.%26aulast%3DNichol%26aufirst%3DS.%2BT.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DZaki%26aufirst%3DS.%2BR.%26aulast%3DFeldmann%26aufirst%3DH.%26aulast%3DSpiropoulou%26aufirst%3DC.%2BF.%26aulast%3Dde%2BWit%26aufirst%3DE.%26atitle%3DRemdesivir%2520%2528GS-5734%2529%2520Protects%2520African%2520Green%2520Monkeys%2520from%2520Nipah%2520Virus%2520Challenge%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaau9242%26doi%3D10.1126%2Fscitranslmed.aau9242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DÃ¶rnemann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burzio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsse, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprecher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Clerck, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Herp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">KoliÃ©, M.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yosifiva, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caluwaerts, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antierens, A.</span></span> <span> </span><span class="NLM_article-title">First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease</span>. <i>J. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>215</i></span>,  <span class="NLM_fpage">171</span>â <span class="NLM_lpage">174</span>, <span class="refDoi">Â DOI: 10.1093/infdis/jiw493</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Finfdis%2Fjiw493" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28073857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC1c7ktlyltA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=215&publication_year=2017&pages=171-174&author=J.+D%C3%B6rnemannauthor=C.+Burzioauthor=A.+Ronsseauthor=A.+Sprecherauthor=H.+De+Clerckauthor=M.+Van+Herpauthor=M.-C.+Koli%C3%A9author=V.+Yosifivaauthor=S.+Caluwaertsauthor=A.+K.+McElroyauthor=A.+Antierens&title=First+Newborn+Baby+to+Receive+Experimental+Therapies+Survives+Ebola+Virus+Disease&doi=10.1093%2Finfdis%2Fjiw493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease</span></div><div class="casAuthors">Dornemann Jenny; Burzio Chiara; Ronsse Axelle; Sprecher Armand; De Clerck Hilde; Van Herp Michel; Yosifiva Vesselina; Caluwaerts Severine; Antierens Annick; Kolie Marie-Claire; Caluwaerts Severine; McElroy Anita K; McElroy Anita K</div><div class="citationInfo"><span class="NLM_cas:title">The Journal of infectious diseases</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">215</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">171-174</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A neonate born to an Ebola virus-positive woman was diagnosed with Ebola virus infection on her first day of life.  The patient was treated with monoclonal antibodies (ZMapp), a buffy coat transfusion from an Ebola survivor, and the broad-spectrum antiviral GS-5734.  On day 20, a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polymerase chain reaction.  The patient was discharged in good health on day 33 of life.  Further follow-up consultations showed age-appropriate weight gain and neurodevelopment at the age of 12 months.  This patient is the first neonate documented to have survived congenital infection with Ebola virus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRVSdx4lvJNFrZpSb_XWfMrfW6udTcc2ea968MUeB60-rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c7ktlyltA%253D%253D&md5=6bd13c191096d2273beb5cc05306ccc7</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1093%2Finfdis%2Fjiw493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Finfdis%252Fjiw493%26sid%3Dliteratum%253Aachs%26aulast%3DD%25C3%25B6rnemann%26aufirst%3DJ.%26aulast%3DBurzio%26aufirst%3DC.%26aulast%3DRonsse%26aufirst%3DA.%26aulast%3DSprecher%26aufirst%3DA.%26aulast%3DDe%2BClerck%26aufirst%3DH.%26aulast%3DVan%2BHerp%26aufirst%3DM.%26aulast%3DKoli%25C3%25A9%26aufirst%3DM.-C.%26aulast%3DYosifiva%26aufirst%3DV.%26aulast%3DCaluwaerts%26aufirst%3DS.%26aulast%3DMcElroy%26aufirst%3DA.%2BK.%26aulast%3DAntierens%26aufirst%3DA.%26atitle%3DFirst%2520Newborn%2520Baby%2520to%2520Receive%2520Experimental%2520Therapies%2520Survives%2520Ebola%2520Virus%2520Disease%26jtitle%3DJ.%2520Infect.%2520Dis.%26date%3D2017%26volume%3D215%26spage%3D171%26epage%3D174%26doi%3D10.1093%2Finfdis%2Fjiw493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cropley, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filipe, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gifford, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jabeen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karageorgopoulos, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackenby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R. S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacConnachie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahungu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mepham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seaton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenu, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gopal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, E. C.</span></span> <span> </span><span class="NLM_article-title">Late Ebola Virus Relapse Causing Meningoencephalitis: A Case Report</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">498</span>â <span class="NLM_lpage">503</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(16)30386-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2816%2930386-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27209148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC2s%252FitV2ksg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=498-503&author=M.+Jacobsauthor=A.+Rodgerauthor=D.+J.+Bellauthor=S.+Bhaganiauthor=I.+Cropleyauthor=A.+Filipeauthor=R.+J.+Giffordauthor=S.+Hopkinsauthor=J.+Hughesauthor=F.+Jabeenauthor=I.+Johannessenauthor=D.+Karageorgopoulosauthor=A.+Lackenbyauthor=R.+Lesterauthor=R.+S.+N.+Liuauthor=A.+MacConnachieauthor=T.+Mahunguauthor=D.+Martinauthor=N.+Marshallauthor=S.+Mephamauthor=R.+Ortonauthor=M.+Palmariniauthor=M.+Patelauthor=C.+Perryauthor=S.+E.+Petersauthor=D.+Porterauthor=D.+Ritchieauthor=N.+D.+Ritchieauthor=R.+A.+Seatonauthor=V.+B.+Sreenuauthor=K.+Templetonauthor=S.+Warrenauthor=G.+S.+Wilkieauthor=M.+Zambonauthor=R.+Gopalauthor=E.+C.+Thomson&title=Late+Ebola+Virus+Relapse+Causing+Meningoencephalitis%3A+A+Case+Report&doi=10.1016%2FS0140-6736%2816%2930386-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Late Ebola virus relapse causing meningoencephalitis: a case report</span></div><div class="casAuthors">Jacobs Michael; Rodger Alison; Bell David J; MacConnachie Alisdair; Perry Colin; Peters S Erica; Porter Duncan; Ritchie David; Ritchie Neil D; Seaton R Andrew; Bhagani Sanjay; Cropley Ian; Hopkins Susan; Karageorgopoulos Drosos; Lester Rebecca; Mahungu Tabitha; Mepham Stephen; Warren Simon; Filipe Ana; Gifford Robert J; Hughes Joseph; Orton Richard; Palmarini Massimo; Sreenu Vattipally B; Wilkie Gavin S; Jabeen Farrah; Johannessen Ingolfur; Templeton Kate; Lackenby Angie; Zambon Maria; Liu Rebecca S N; Martin Daniel; Marshall Neal; Patel Monika; Gopal Robin; Thomson Emma C</div><div class="citationInfo"><span class="NLM_cas:title">Lancet (London, England)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10043</span>),
    <span class="NLM_cas:pages">498-503</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There are thousands of survivors of the 2014 Ebola outbreak in west Africa.  Ebola virus can persist in survivors for months in immune-privileged sites; however, viral relapse causing life-threatening and potentially transmissible disease has not been described.  We report a case of late relapse in a patient who had been treated for severe Ebola virus disease with high viral load (peak cycle threshold value 13.2).  METHODS:  A 39-year-old female nurse from Scotland, who had assisted the humanitarian effort in Sierra Leone, had received intensive supportive treatment and experimental antiviral therapies, and had been discharged with undetectable Ebola virus RNA in peripheral blood.  The patient was readmitted to hospital 9 months after discharge with symptoms of acute meningitis, and was found to have Ebola virus in cerebrospinal fluid (CSF).  She was treated with supportive therapy and experimental antiviral drug GS-5734 (Gilead Sciences, San Francisco, Foster City, CA, USA).  We monitored Ebola virus RNA in CSF and plasma, and sequenced the viral genome using an unbiased metagenomic approach.  FINDINGS:  On admission, reverse transcriptase PCR identified Ebola virus RNA at a higher level in CSF (cycle threshold value 23.7) than plasma (31.3); infectious virus was only recovered from CSF.  The patient developed progressive meningoencephalitis with cranial neuropathies and radiculopathy.  Clinical recovery was associated with addition of high-dose corticosteroids during GS-5734 treatment.  CSF Ebola virus RNA slowly declined and was undetectable following 14 days of treatment with GS-5734.  Sequencing of plasma and CSF viral genome revealed only two non-coding changes compared with the original infecting virus.  INTERPRETATION:  Our report shows that previously unanticipated, late, severe relapses of Ebola virus can occur, in this case in the CNS.  This finding fundamentally redefines what is known about the natural history of Ebola virus infection.  Vigilance should be maintained in the thousands of Ebola survivors for cases of relapsed infection.  The potential for these cases to initiate new transmission chains is a serious public health concern.  FUNDING:  Royal Free London NHS Foundation Trust.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRYRsrOSKHcwJQHPYJuLg8TfW6udTcc2ea968MUeB60-rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s%252FitV2ksg%253D%253D&md5=c2cb4099c19a6603874e120d53a7c8b4</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2930386-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252930386-5%26sid%3Dliteratum%253Aachs%26aulast%3DJacobs%26aufirst%3DM.%26aulast%3DRodger%26aufirst%3DA.%26aulast%3DBell%26aufirst%3DD.%2BJ.%26aulast%3DBhagani%26aufirst%3DS.%26aulast%3DCropley%26aufirst%3DI.%26aulast%3DFilipe%26aufirst%3DA.%26aulast%3DGifford%26aufirst%3DR.%2BJ.%26aulast%3DHopkins%26aufirst%3DS.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DJabeen%26aufirst%3DF.%26aulast%3DJohannessen%26aufirst%3DI.%26aulast%3DKarageorgopoulos%26aufirst%3DD.%26aulast%3DLackenby%26aufirst%3DA.%26aulast%3DLester%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DR.%2BS.%2BN.%26aulast%3DMacConnachie%26aufirst%3DA.%26aulast%3DMahungu%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DD.%26aulast%3DMarshall%26aufirst%3DN.%26aulast%3DMepham%26aufirst%3DS.%26aulast%3DOrton%26aufirst%3DR.%26aulast%3DPalmarini%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DC.%26aulast%3DPeters%26aufirst%3DS.%2BE.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DD.%26aulast%3DRitchie%26aufirst%3DN.%2BD.%26aulast%3DSeaton%26aufirst%3DR.%2BA.%26aulast%3DSreenu%26aufirst%3DV.%2BB.%26aulast%3DTempleton%26aufirst%3DK.%26aulast%3DWarren%26aufirst%3DS.%26aulast%3DWilkie%26aufirst%3DG.%2BS.%26aulast%3DZambon%26aufirst%3DM.%26aulast%3DGopal%26aufirst%3DR.%26aulast%3DThomson%26aufirst%3DE.%2BC.%26atitle%3DLate%2520Ebola%2520Virus%2520Relapse%2520Causing%2520Meningoencephalitis%253A%2520A%2520Case%2520Report%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D498%26epage%3D503%26doi%3D10.1016%2FS0140-6736%2816%2930386-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mulangu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodd, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davey, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshiani
Mbaya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Proschan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukadi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lusakibanza
Manzo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nzolo, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tshomba Oloma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibanda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coulibaly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levine, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muyembe-Tamfum, J.-J.</span></span> <span> </span><span class="NLM_article-title">A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>381</i></span>,  <span class="NLM_fpage">2293</span>â <span class="NLM_lpage">2303</span>, <span class="refDoi">Â DOI: 10.1056/NEJMoa1910993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1056%2FNEJMoa1910993" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31774950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVylsLzP" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=381&publication_year=2019&pages=2293-2303&author=S.+Mulanguauthor=L.+E.+Doddauthor=R.+T.+Daveyauthor=O.+Tshiani%0AMbayaauthor=M.+Proschanauthor=D.+Mukadiauthor=M.+Lusakibanza%0AManzoauthor=D.+Nzoloauthor=A.+Tshomba+Olomaauthor=A.+Ibandaauthor=R.+Aliauthor=S.+Coulibalyauthor=A.+C.+Levineauthor=R.+Graisauthor=J.+Diazauthor=H.+C.+Laneauthor=J.-J.+Muyembe-Tamfum&title=A+Randomized%2C+Controlled+Trial+of+Ebola+Virus+Disease+Therapeutics&doi=10.1056%2FNEJMoa1910993"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">A randomized, controlled trial of ebola virus disease therapeutics</span></div><div class="casAuthors">Mulangu, Sabue; Dodd, Lori E.; Davey, Richard T., Jr.; Mbaya, Olivier Tshiani; Proschan, Michael; Mukadi, Daniel; Manzo, Mariano Lusakibanza; Nzolo, Didier; Oloma, Antoine Tshomba; Ibanda, Augustin; Ali, Rosine; Coulibaly, Sinare; Levine, Adam C.; Grais, Rebecca; Diaz, Janet; Lane, H. Clifford; Muyembe-Tamfum, Jean-Jacques</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">381</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2293-2303</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Although several exptl. therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial. methods We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018.  Patients of any age who had a pos. result for Ebola virus RNA on reverse-transcriptase-polymerase-chain-reaction assay were enrolled.  All patients received std. care and were randomly assigned in a 1:1:1:1 ratio to i.v. administration of the triple monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3.  The REGN-EB3 group was added in a later version of the protocol, so data from these patients were compared with those of patients in the ZMapp group who were enrolled at or after the time the REGN-EB3 group was added (the ZMapp subgroup).  The primary end point was death at 28 days. results A total of 681 patients were enrolled from Nov. 20, 2018, to August 9, 2019, at which time the data and safety monitoring board recommended that patients be assigned only to the MAb114 and REGN-EB3 groups for the remainder of the trial; the recommendation was based on the results of an interim anal. that showed superiority of these groups to ZMapp and remdesivir with respect to mortality.  At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P = 0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P = 0.002).  A shorter duration of symptoms before admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated with improved survival.  Four serious adverse events were judged to be potentially related to the trial drugs. conclusions Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD.  Scientifically and ethically sound clin. research can be conducted during disease outbreaks and can help inform the outbreak response.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsF31fomvTPrVg90H21EOLACvtfcHk0lgBAWq4gXz7sg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVylsLzP&md5=ace616255b8372f99aef8dee4864d38f</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1910993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1910993%26sid%3Dliteratum%253Aachs%26aulast%3DMulangu%26aufirst%3DS.%26aulast%3DDodd%26aufirst%3DL.%2BE.%26aulast%3DDavey%26aufirst%3DR.%2BT.%26aulast%3DTshiani%2BMbaya%26aufirst%3DO.%26aulast%3DProschan%26aufirst%3DM.%26aulast%3DMukadi%26aufirst%3DD.%26aulast%3DLusakibanza%2BManzo%26aufirst%3DM.%26aulast%3DNzolo%26aufirst%3DD.%26aulast%3DTshomba%2BOloma%26aufirst%3DA.%26aulast%3DIbanda%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DR.%26aulast%3DCoulibaly%26aufirst%3DS.%26aulast%3DLevine%26aufirst%3DA.%2BC.%26aulast%3DGrais%26aufirst%3DR.%26aulast%3DDiaz%26aufirst%3DJ.%26aulast%3DLane%26aufirst%3DH.%2BC.%26aulast%3DMuyembe-Tamfum%26aufirst%3DJ.-J.%26atitle%3DA%2520Randomized%252C%2520Controlled%2520Trial%2520of%2520Ebola%2520Virus%2520Disease%2520Therapeutics%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D381%26spage%3D2293%26epage%3D2303%26doi%3D10.1056%2FNEJMoa1910993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menachery, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralinski, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trantcheva, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bannister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmiotti, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">eaal3653</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aal3653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aal3653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=28659436" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=eaal3653&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=R.+L.+Grahamauthor=V.+D.+Menacheryauthor=L.+E.+Gralinskiauthor=J.+B.+Caseauthor=S.+R.+Leistauthor=K.+Pyrcauthor=J.+Y.+Fengauthor=I.+Trantchevaauthor=R.+Bannisterauthor=Y.+Parkauthor=D.+Babusisauthor=M.+O.+Clarkeauthor=R.+L.+MacKmanauthor=J.+E.+Spahnauthor=C.+A.+Palmiottiauthor=D.+Siegelauthor=A.+S.+Rayauthor=T.+Cihlarauthor=R.+Jordanauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=Broad-Spectrum+Antiviral+GS-5734+Inhibits+Both+Epidemic+and+Zoonotic+Coronaviruses&doi=10.1126%2Fscitranslmed.aal3653"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aal3653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aal3653%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DMenachery%26aufirst%3DV.%2BD.%26aulast%3DGralinski%26aufirst%3DL.%2BE.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DPyrc%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DTrantcheva%26aufirst%3DI.%26aulast%3DBannister%26aufirst%3DR.%26aulast%3DPark%26aufirst%3DY.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DMacKman%26aufirst%3DR.%2BL.%26aulast%3DSpahn%26aufirst%3DJ.%2BE.%26aulast%3DPalmiotti%26aufirst%3DC.%2BA.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DBroad-Spectrum%2520Antiviral%2520GS-5734%2520Inhibits%2520Both%2520Epidemic%2520and%2520Zoonotic%2520Coronaviruses%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2017%26volume%3D9%26spage%3Deaal3653%26doi%3D10.1126%2Fscitranslmed.aal3653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span> <span> </span><span class="NLM_article-title">Broad Spectrum Antiviral Remdesivir Inhibits Human Endemic and Zoonotic Deltacoronaviruses with a Highly Divergent RNA Dependent RNA Polymerase</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>169</i></span>,  <span class="NLM_fpage">104541</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2019.104541</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2019.104541" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31233808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Git7zI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=169&publication_year=2019&pages=104541&author=A.+J.+Brownauthor=J.+J.+Wonauthor=R.+L.+Grahamauthor=K.+H.+Dinnonauthor=A.+C.+Simsauthor=J.+Y.+Fengauthor=T.+Cihlarauthor=M.+R.+Denisonauthor=R.+S.+Baricauthor=T.+P.+Sheahan&title=Broad+Spectrum+Antiviral+Remdesivir+Inhibits+Human+Endemic+and+Zoonotic+Deltacoronaviruses+with+a+Highly+Divergent+RNA+Dependent+RNA+Polymerase&doi=10.1016%2Fj.antiviral.2019.104541"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase</span></div><div class="casAuthors">Brown, Ariane J.; Won, John J.; Graham, Rachel L.; Dinnon, Kenneth H., III; Sims, Amy C.; Feng, Joy Y.; Cihlar, Tomas; Denison, Mark R.; Baric, Ralph S.; Sheahan, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">169</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104541</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The genetically diverse Orthocoronavirinae (CoV) family is prone to cross species transmission and disease emergence in both humans and livestock.  Viruses similar to known epidemic strains circulating in wild and domestic animals further increase the probability of emergence in the future.  Currently, there are no approved therapeutics for any human CoV presenting a clear unmet medical need.  Remdesivir (RDV, GS-5734) is a monophosphoramidate prodrug of an adenosine analog with potent activity against an array of RNA virus families including Filoviridae, Paramyxoviridae, Pneumoviridae, and Orthocoronavirinae, through the targeting of the viral RNA dependent RNA polymerase (RdRp).  We developed multiple assays to further define the breadth of RDV antiviral activity against the CoV family.  Here, we show potent antiviral activity of RDV against endemic human CoVs OC43 (HCoV-OC43) and 229E (HCoV-229E) with submicromolar EC50 values.  Of known CoVs, the members of the deltacoronavirus genus have the most divergent RdRp as compared to SARS- and MERS-CoV and both avian and porcine members harbor a native residue in the RdRp that confers resistance in beta-CoVs.  Nevertheless, RDV is highly efficacious against porcine deltacoronavirus (PDCoV).  These data further extend the known breadth and antiviral activity of RDV to include both contemporary human and highly divergent zoonotic CoV and potentially enhance our ability to fight future emerging CoV.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtZuP2J4qyxbVg90H21EOLACvtfcHk0lieIMq9oimjpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Git7zI&md5=83a831806f8e8520713283d35de2bd7e</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2019.104541&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2019.104541%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DWon%26aufirst%3DJ.%2BJ.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26atitle%3DBroad%2520Spectrum%2520Antiviral%2520Remdesivir%2520Inhibits%2520Human%2520Endemic%2520and%2520Zoonotic%2520Deltacoronaviruses%2520with%2520a%2520Highly%2520Divergent%2520RNA%2520Dependent%2520RNA%2520Polymerase%26jtitle%3DAntiviral%2520Res.%26date%3D2019%26volume%3D169%26spage%3D104541%26doi%3D10.1016%2Fj.antiviral.2019.104541" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Case, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackman, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span> <span> </span><span class="NLM_article-title">Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease</span>. <i>mBio</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">e00221</span>, <span class="refDoi">Â DOI: 10.1128/mBio.00221-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FmBio.00221-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29511076" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Cktbo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=e00221&author=M.+L.+Agostiniauthor=E.+L.+Andresauthor=A.+C.+Simsauthor=R.+L.+Grahamauthor=T.+P.+Sheahanauthor=X.+Luauthor=E.+C.+Smithauthor=J.+B.+Caseauthor=J.+Y.+Fengauthor=R.+Jordanauthor=A.+S.+Rayauthor=T.+Cihlarauthor=D.+Siegelauthor=R.+L.+Mackmanauthor=M.+O.+Clarkeauthor=R.+S.+Baricauthor=M.+R.+Denison&title=Coronavirus+Susceptibility+to+the+Antiviral+Remdesivir+%28GS-5734%29+Is+Mediated+by+the+Viral+Polymerase+and+the+Proofreading+Exoribonuclease&doi=10.1128%2FmBio.00221-18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease</span></div><div class="casAuthors">Agostini, Maria L.; Andres, Erica L.; Sims, Amy C.; Graham, Rachel L.; Sheahan, Timothy P.; Lu, Xiaotao; Smith, Everett Clinton; Case, James Brett; Feng, Joy Y.; Jordan, Robert; Ray, Adrian S.; Cihlar, Tomas; Siege, Dustin; Mackman, Richard L.; Clarke, Michael O.; Baric, Ralph S.; Denison, Mark R.</div><div class="citationInfo"><span class="NLM_cas:title">mBio</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">e00221-18/1-e00221-18/15</span>CODEN:
                <span class="NLM_cas:coden">MBIOCL</span>;
        ISSN:<span class="NLM_cas:issn">2150-7511</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Emerging coronaviruses (CoVs) cause severe disease in humans, but no approved therapeutics are available.  The CoV nsp14 exoribonuclease (ExoN) has complicated development of antiviral nucleosides due to its proofreading activity.  We recently reported that the nucleoside analog GS-5734 (remdesivir) potently inhibits human and zoonotic CoVs in vitro and in a severe acute respiratory syndrome coronavirus (SARS-CoV) mouse model.  However, studies with GS-5734 have not reported resistance assocd. with GS-5734, nor do we understand the action of GS-5734 in wild-type (WT) proofreading CoVs.  Here, we show that GS-5734 inhibits murine hepatitis virus (MHV) with similar 50% effective concn. values (EC50) as SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV).  Passage of WT MHV in the presence of the GS-5734 parent nucleoside selected two mutations in the nsp12 polymerase at residues conserved across all CoVs that conferred up to 5.6-fold resistance to GS-5734, as detd. by EC50.  The resistant viruses were unable to compete with WT in direct coinfection passage in the absence of GS-5734.  Introduction of the MHV resistance mutations into SARS-CoV resulted in the same in vitro resistance phenotype and attenuated SARS-CoV pathogenesis in a mouse model.  Finally, we demonstrate that an MHV mutant lacking ExoN proofreading was significantly more sensitive to GS-5734.  Combined, the results indicate that GS-5734 interferes with the nsp12 polymerase even in the setting of intact ExoN proofreading activity and that resistance can be overcome with increased, nontoxic concns. of GS-5734, further supporting the development of GS-5734 as a broad-spectrum therapeutic to protect against contemporary and emerging CoVs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMg1wWYLfeubVg90H21EOLACvtfcHk0lieIMq9oimjpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Cktbo%253D&md5=5b2ce6ee0d21ac1143bf3e2837a21167</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1128%2FmBio.00221-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FmBio.00221-18%26sid%3Dliteratum%253Aachs%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DAndres%26aufirst%3DE.%2BL.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DSmith%26aufirst%3DE.%2BC.%26aulast%3DCase%26aufirst%3DJ.%2BB.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DRay%26aufirst%3DA.%2BS.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DSiegel%26aufirst%3DD.%26aulast%3DMackman%26aufirst%3DR.%2BL.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26atitle%3DCoronavirus%2520Susceptibility%2520to%2520the%2520Antiviral%2520Remdesivir%2520%2528GS-5734%2529%2520Is%2520Mediated%2520by%2520the%2520Viral%2520Polymerase%2520and%2520the%2520Proofreading%2520Exoribonuclease%26jtitle%3DmBio%26date%3D2018%26volume%3D9%26spage%3De00221%26doi%3D10.1128%2FmBio.00221-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, G.</span></span> <span> </span><span class="NLM_article-title">Remdesivir and Chloroquine Effectively Inhibit the Recently Emerged Novel Coronavirus (2019-NCoV) in Vitro</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">269</span>â <span class="NLM_lpage">271</span>, <span class="refDoi">Â DOI: 10.1038/s41422-020-0282-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41422-020-0282-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32020029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=269-271&author=M.+Wangauthor=R.+Caoauthor=L.+Zhangauthor=X.+Yangauthor=J.+Liuauthor=M.+Xuauthor=Z.+Shiauthor=Z.+Huauthor=W.+Zhongauthor=G.+Xiao&title=Remdesivir+and+Chloroquine+Effectively+Inhibit+the+Recently+Emerged+Novel+Coronavirus+%282019-NCoV%29+in+Vitro&doi=10.1038%2Fs41422-020-0282-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</span></div><div class="casAuthors">Wang, Manli; Cao, Ruiyuan; Zhang, Leike; Yang, Xinglou; Liu, Jia; Xu, Mingyue; Shi, Zhengli; Hu, Zhihong; Zhong, Wu; Xiao, Gengfu</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">269-271</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">In Dec. 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million people in central China.  The initial cases were linked to exposures in a seafood market in Wuhan.  The pathogen was soon identified as a novel coronavirus (2019-nCoV), which is closely related to severe acute respiratory syndrome CoV (SARS-CoV).  Currently, there is no specific treatment against the new virus.  Therefore, identifying effective antiviral agents to combat the disease is urgently needed.  In this study, we evaluated the antiviral efficiency of FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir (GS-5734) and favipiravir (T-705) against a clin. isolate of 2019-nCoV in vitro.  Our findings reveal that remdesivir and chloroquine are highly effective in the control of 2019-nCoV infection in vitro.  Since these compds. have been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCnj2tW4TeD7Vg90H21EOLACvtfcHk0lieIMq9oimjpQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt1Ciu7k%253D&md5=bdf16b352ebc06bc148ed5c513b7d414</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1038%2Fs41422-020-0282-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-020-0282-0%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DR.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DXiao%26aufirst%3DG.%26atitle%3DRemdesivir%2520and%2520Chloroquine%2520Effectively%2520Inhibit%2520the%2520Recently%2520Emerged%2520Novel%2520Coronavirus%2520%25282019-NCoV%2529%2520in%2520Vitro%26jtitle%3DCell%2520Res.%26date%3D2020%26volume%3D30%26spage%3D269%26epage%3D271%26doi%3D10.1038%2Fs41422-020-0282-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choy, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, A. Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaewpreedee, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sia, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hui, K. P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, D. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, M. C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, P. P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peiris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, H. L.</span></span> <span> </span><span class="NLM_article-title">Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro</span>. <i>Antiviral Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">104786</span>, <span class="refDoi">Â DOI: 10.1016/j.antiviral.2020.104786</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.antiviral.2020.104786" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32251767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXntVOhtLw%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2020&pages=104786&author=K.+T.+Choyauthor=A.+Y.+L.+Wongauthor=P.+Kaewpreedeeauthor=S.+F.+Siaauthor=D.+Chenauthor=K.+P.+Y.+Huiauthor=D.+K.+W.+Chuauthor=M.+C.+W.+Chanauthor=P.+P.+H.+Cheungauthor=X.+Huangauthor=M.+Peirisauthor=H.+L.+Yen&title=Remdesivir%2C+Lopinavir%2C+Emetine%2C+and+Homoharringtonine+Inhibit+SARS-CoV-2+Replication+in+Vitro&doi=10.1016%2Fj.antiviral.2020.104786"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</span></div><div class="casAuthors">Choy, Ka-Tim; Wong, Alvina Yin-Lam; Kaewpreedee, Prathanporn; Sia, Sin Fun; Chen, Dongdong; Hui, Kenrie Pui Yan; Chu, Daniel Ka Wing; Chan, Michael Chi Wai; Cheung, Peter Pak-Hang; Huang, Xuhui; Peiris, Malik; Yen, Hui-Ling</div><div class="citationInfo"><span class="NLM_cas:title">Antiviral Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104786</span>CODEN:
                <span class="NLM_cas:coden">ARSRDR</span>;
        ISSN:<span class="NLM_cas:issn">0166-3542</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">An escalating pandemic by the novel SARS-CoV-2 virus is impacting global health and effective therapeutic options are urgently needed.  We evaluated the in vitro antiviral effect of compds. that were previously reported to inhibit coronavirus replication and compds. that are currently under evaluation in clin. trials for SARS-CoV-2 patients.  We report the antiviral effect of remdesivir, lopinavir, homorringtonine, and emetine against SARS-CoV-2 virus in Vero E6 cells with the estd. 50% effective concn. at 23.15Î¼M, 26.63Î¼M, 2.55Î¼M and 0.46Î¼M, resp.  Ribavirin or favipiravir that are currently evaluated under clin. trials showed no inhibition at 100Î¼M.  Synergy between remdesivir and emetine was obsd., and remdesivir at 6.25Î¼M in combination with emetine at 0.195Î¼M may achieve 64.9% inhibition in viral yield.  Combinational therapy may help to reduce the effective concn. of compds. below the therapeutic plasma concns. and provide better clin. benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3CI4nCzzgaLVg90H21EOLACvtfcHk0ljK_TwCXQXwtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXntVOhtLw%253D&md5=d7907993ced412826670970df3fabd5a</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.antiviral.2020.104786&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.antiviral.2020.104786%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DK.%2BT.%26aulast%3DWong%26aufirst%3DA.%2BY.%2BL.%26aulast%3DKaewpreedee%26aufirst%3DP.%26aulast%3DSia%26aufirst%3DS.%2BF.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DHui%26aufirst%3DK.%2BP.%2BY.%26aulast%3DChu%26aufirst%3DD.%2BK.%2BW.%26aulast%3DChan%26aufirst%3DM.%2BC.%2BW.%26aulast%3DCheung%26aufirst%3DP.%2BP.%2BH.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DPeiris%26aufirst%3DM.%26aulast%3DYen%26aufirst%3DH.%2BL.%26atitle%3DRemdesivir%252C%2520Lopinavir%252C%2520Emetine%252C%2520and%2520Homoharringtonine%2520Inhibit%2520SARS-CoV-2%2520Replication%2520in%2520Vitro%26jtitle%3DAntiviral%2520Res.%26date%3D2020%26volume%3D178%26spage%3D104786%26doi%3D10.1016%2Fj.antiviral.2020.104786" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Runfeng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yunlong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jicheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiqi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qinhai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yongxia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chufang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhenhua, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haiming, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kui, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuxiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaobo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiaotao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanshan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zifeng, Y.</span></span> <span> </span><span class="NLM_article-title">Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity against Novel Coronavirus (SARS-CoV-2)</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">104761</span>, <span class="refDoi">Â DOI: 10.1016/j.phrs.2020.104761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.phrs.2020.104761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32205232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFartrs%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2020&pages=104761&author=L.+Runfengauthor=H.+Yunlongauthor=H.+Jichengauthor=P.+Weiqiauthor=M.+Qinhaiauthor=S.+Yongxiaauthor=L.+Chufangauthor=Z.+Jinauthor=J.+Zhenhuaauthor=J.+Haimingauthor=Z.+Kuiauthor=H.+Shuxiangauthor=D.+Junauthor=L.+Xiaoboauthor=H.+Xiaotaoauthor=W.+Linauthor=Z.+Nanshanauthor=Y.+Zifeng&title=Lianhuaqingwen+Exerts+Anti-Viral+and+Anti-Inflammatory+Activity+against+Novel+Coronavirus+%28SARS-CoV-2%29&doi=10.1016%2Fj.phrs.2020.104761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)</span></div><div class="casAuthors">Runfeng, Li; Yunlong, Hou; Jicheng, Huang; Weiqi, Pan; Qinhai, Ma; Yongxia, Shi; Chufang, Li; Jin, Zhao; Zhenhua, Jia; Haiming, Jiang; Kui, Zheng; Shuxiang, Huang; Jun, Dai; Xiaobo, Li; Xiaotao, Hou; Lin, Wang; Nanshan, Zhong; Zifeng, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104761</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017).  The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response.  The antiviral activity of LH against SARS-CoV-2 was assessed in Vero E6 cells using CPE and plaque redn. assay.  The effect of LH on virion morphol. was visualized under transmission electron microscope.  Pro-inflammatory cytokine expression levels upon SARS-CoV-2 infection in Huh-7 cells were measured by real-time quant. PCR assays.  LH significantly inhibited SARS-CoV-2 replication in Vero E6 cells and markedly reduced pro-inflammatory cytokines (TNF-Î±, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10) prodn. at the mRNA levels.  Furthermore, LH treatment resulted in abnormal particle morphol. of virion in cells.  LH significantly inhibits the SARS-COV-2 replication, affects virus morphol. and exerts anti-inflammatory activity in vitro.  These findings indicate that LH protects against the virus attack, making its use a novel strategy for controlling the COVID-19 disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqXIWE0RcS6LVg90H21EOLACvtfcHk0ljK_TwCXQXwtg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFartrs%253D&md5=e1fddba011a2e62fd7ed0c3c557b410f</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.104761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.104761%26sid%3Dliteratum%253Aachs%26aulast%3DRunfeng%26aufirst%3DL.%26aulast%3DYunlong%26aufirst%3DH.%26aulast%3DJicheng%26aufirst%3DH.%26aulast%3DWeiqi%26aufirst%3DP.%26aulast%3DQinhai%26aufirst%3DM.%26aulast%3DYongxia%26aufirst%3DS.%26aulast%3DChufang%26aufirst%3DL.%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DZhenhua%26aufirst%3DJ.%26aulast%3DHaiming%26aufirst%3DJ.%26aulast%3DKui%26aufirst%3DZ.%26aulast%3DShuxiang%26aufirst%3DH.%26aulast%3DJun%26aufirst%3DD.%26aulast%3DXiaobo%26aufirst%3DL.%26aulast%3DXiaotao%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DW.%26aulast%3DNanshan%26aufirst%3DZ.%26aulast%3DZifeng%26aufirst%3DY.%26atitle%3DLianhuaqingwen%2520Exerts%2520Anti-Viral%2520and%2520Anti-Inflammatory%2520Activity%2520against%2520Novel%2520Coronavirus%2520%2528SARS-CoV-2%2529%26jtitle%3DPharmacol.%2520Res.%26date%3D2020%26volume%3D156%26spage%3D104761%26doi%3D10.1016%2Fj.phrs.2020.104761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gralinksi, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinnon, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yount, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gully, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graham, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du Pont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murakami, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilello, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span> <span> </span><span class="NLM_article-title">Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">107940</span>, <span class="refDoi">Â DOI: 10.1016/j.celrep.2020.107940</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.celrep.2020.107940" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32668216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtl2isrzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2020&pages=107940&author=A.+J.+Pruijssersauthor=A.+S.+Georgeauthor=A.+Sch%C3%A4ferauthor=S.+R.+Leistauthor=L.+E.+Gralinksiauthor=K.+H.+Dinnonauthor=B.+L.+Yountauthor=M.+L.+Agostiniauthor=L.+J.+Stevensauthor=J.+D.+Chappellauthor=X.+Luauthor=T.+M.+Hughesauthor=K.+Gullyauthor=D.+R.+Martinezauthor=A.+J.+Brownauthor=R.+L.+Grahamauthor=J.+K.+Perryauthor=V.+Du+Pontauthor=J.+Pittsauthor=B.+Maauthor=D.+Babusisauthor=E.+Murakamiauthor=J.+Y.+Fengauthor=J.+P.+Bilelloauthor=D.+P.+Porterauthor=T.+Cihlarauthor=R.+S.+Baricauthor=M.+R.+Denisonauthor=T.+P.+Sheahan&title=Remdesivir+Inhibits+SARS-CoV-2+in+Human+Lung+Cells+and+Chimeric+SARS-CoV+Expressing+the+SARS-CoV-2+RNA+Polymerase+in+Mice&doi=10.1016%2Fj.celrep.2020.107940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice</span></div><div class="casAuthors">Pruijssers, Andrea J.; George, Amelia S.; Schafer, Alexandra; Leist, Sarah R.; Gralinksi, Lisa E.; Dinnon, Kenneth H.; Yount, Boyd L.; Agostini, Maria L.; Stevens, Laura J.; Chappell, James D.; Lu, Xiaotao; Hughes, Tia M.; Gully, Kendra; Martinez, David R.; Brown, Ariane J.; Graham, Rachel L.; Perry, Jason K.; Du Pont, Venice; Pitts, Jared; Ma, Bin; Babusis, Darius; Murakami, Eisuke; Feng, Joy Y.; Bilello, John P.; Porter, Danielle P.; Cihlar, Tomas; Baric, Ralph S.; Denison, Mark R.; Sheahan, Timothy P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">107940</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19.  With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs.  We report that remdesivir (RDV) potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 Î¼M).  Weaker activity is obsd. in Vero E6 cells (EC50 = 1.65 Î¼M) because of their low capacity to metabolize RDV.  To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase of SARS-CoV-2.  In mice infected with the chimeric virus, therapeutic RDV administration diminishes lung viral load and improves pulmonary function compared with vehicle-treated animals.  These data demonstrate that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clin. testing for treatment of COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUzmxM5ARME7Vg90H21EOLACvtfcHk0ljJC8WkVTwsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtl2isrzL&md5=d869e7d9f406848283f0a92d14e8f9ed</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2020.107940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2020.107940%26sid%3Dliteratum%253Aachs%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DGeorge%26aufirst%3DA.%2BS.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DGralinksi%26aufirst%3DL.%2BE.%26aulast%3DDinnon%26aufirst%3DK.%2BH.%26aulast%3DYount%26aufirst%3DB.%2BL.%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DStevens%26aufirst%3DL.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DHughes%26aufirst%3DT.%2BM.%26aulast%3DGully%26aufirst%3DK.%26aulast%3DMartinez%26aufirst%3DD.%2BR.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DGraham%26aufirst%3DR.%2BL.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DDu%2BPont%26aufirst%3DV.%26aulast%3DPitts%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DB.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DMurakami%26aufirst%3DE.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DBilello%26aufirst%3DJ.%2BP.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26atitle%3DRemdesivir%2520Inhibits%2520SARS-CoV-2%2520in%2520Human%2520Lung%2520Cells%2520and%2520Chimeric%2520SARS-CoV%2520Expressing%2520the%2520SARS-CoV-2%2520RNA%2520Polymerase%2520in%2520Mice%26jtitle%3DCell%2520Rep.%26date%3D2020%26volume%3D32%26spage%3D107940%26doi%3D10.1016%2Fj.celrep.2020.107940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leist, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¤fer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montgomery, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babusis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spahn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span> <span> </span><span class="NLM_article-title">Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta against MERS-CoV</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">222</span>, <span class="refDoi">Â DOI: 10.1038/s41467-019-13940-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41467-019-13940-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31924756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFeisr0%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=222&author=T.+P.+Sheahanauthor=A.+C.+Simsauthor=S.+R.+Leistauthor=A.+Sch%C3%A4ferauthor=J.+Wonauthor=A.+J.+Brownauthor=S.+A.+Montgomeryauthor=A.+Hoggauthor=D.+Babusisauthor=M.+O.+Clarkeauthor=J.+E.+Spahnauthor=L.+Bauerauthor=S.+Sellersauthor=D.+Porterauthor=J.+Y.+Fengauthor=T.+Cihlarauthor=R.+Jordanauthor=M.+R.+Denisonauthor=R.+S.+Baric&title=Comparative+Therapeutic+Efficacy+of+Remdesivir+and+Combination+Lopinavir%2C+Ritonavir%2C+and+Interferon+Beta+against+MERS-CoV&doi=10.1038%2Fs41467-019-13940-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</span></div><div class="casAuthors">Sheahan, Timothy P.; Sims, Amy C.; Leist, Sarah R.; Schafer, Alexandra; Won, John; Brown, Ariane J.; Montgomery, Stephanie A.; Hogg, Alison; Babusis, Darius; Clarke, Michael O.; Spahn, Jamie E.; Bauer, Laura; Sellers, Scott; Porter, Danielle; Feng, Joy Y.; Cihlar, Tomas; Jordan, Robert; Denison, Mark R.; Baric, Ralph S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Middle East respiratory syndrome coronavirus (MERS-CoV) is the causative agent of a severe respiratory disease assocd. with more than 2468 human infections and over 851 deaths in 27 countries since 2012.  There are no approved treatments for MERS-CoV infection although a combination of lopinavir, ritonavir and interferon beta (LPV/RTV-IFNb) is currently being evaluated in humans in the Kingdom of Saudi Arabia.  Here, we show that remdesivir (RDV) and IFNb have superior antiviral activity to LPV and RTV in vitro.  In mice, both prophylactic and therapeutic RDV improve pulmonary function and reduce lung viral loads and severe lung pathol.  In contrast, prophylactic LPV/RTV-IFNb slightly reduces viral loads without impacting other disease parameters.  Therapeutic LPV/RTV-IFNb improves pulmonary function but does not reduce virus replication or severe lung pathol.  Thus, we provide in vivo evidence of the potential for RDV to treat MERS-CoV infections.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf9TF1JefverVg90H21EOLACvtfcHk0ljJC8WkVTwsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFeisr0%253D&md5=6c0c2f8833068cf1c9bdef9847c31054</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fs41467-019-13940-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-019-13940-6%26sid%3Dliteratum%253Aachs%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DLeist%26aufirst%3DS.%2BR.%26aulast%3DSch%25C3%25A4fer%26aufirst%3DA.%26aulast%3DWon%26aufirst%3DJ.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DMontgomery%26aufirst%3DS.%2BA.%26aulast%3DHogg%26aufirst%3DA.%26aulast%3DBabusis%26aufirst%3DD.%26aulast%3DClarke%26aufirst%3DM.%2BO.%26aulast%3DSpahn%26aufirst%3DJ.%2BE.%26aulast%3DBauer%26aufirst%3DL.%26aulast%3DSellers%26aufirst%3DS.%26aulast%3DPorter%26aufirst%3DD.%26aulast%3DFeng%26aufirst%3DJ.%2BY.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DJordan%26aufirst%3DR.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26atitle%3DComparative%2520Therapeutic%2520Efficacy%2520of%2520Remdesivir%2520and%2520Combination%2520Lopinavir%252C%2520Ritonavir%252C%2520and%2520Interferon%2520Beta%2520against%2520MERS-CoV%26jtitle%3DNat.%2520Commun.%26date%3D2020%26volume%3D11%26spage%3D222%26doi%3D10.1038%2Fs41467-019-13940-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williamson, B. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldmann, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meade-White, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schulz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Doremalen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leighton, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yinda, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">PÃ©rez-PÃ©rez, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okumura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovaglio, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saturday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosio, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anzick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cihlar, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martens, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munster, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Wit, E.</span></span> <span> </span><span class="NLM_article-title">Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>585</i></span>,  <span class="NLM_fpage">273</span>â <span class="NLM_lpage">276</span>, <span class="refDoi">Â DOI: 10.1038/s41586-020-2423-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fs41586-020-2423-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32516797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslelu7rJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=585&publication_year=2020&pages=273-276&author=B.+N.+Williamsonauthor=F.+Feldmannauthor=B.+Schwarzauthor=K.+Meade-Whiteauthor=D.+P.+Porterauthor=J.+Schulzauthor=N.+van+Doremalenauthor=I.+Leightonauthor=C.+K.+Yindaauthor=L.+P%C3%A9rez-P%C3%A9rezauthor=A.+Okumuraauthor=J.+Lovaglioauthor=P.+W.+Hanleyauthor=G.+Saturdayauthor=C.+M.+Bosioauthor=S.+Anzickauthor=K.+Barbianauthor=T.+Cihlarauthor=C.+Martensauthor=D.+P.+Scottauthor=V.+J.+Munsterauthor=E.+de+Wit&title=Clinical+Benefit+of+Remdesivir+in+Rhesus+Macaques+Infected+with+SARS-CoV-2&doi=10.1038%2Fs41586-020-2423-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2</span></div><div class="casAuthors">Williamson, Brandi N.; Feldmann, Friederike; Schwarz, Benjamin; Meade-White, Kimberly; Porter, Danielle P.; Schulz, Jonathan; van Doremalen, Neeltje; Leighton, Ian; Yinda, Claude Kwe; Perez-Perez, Lizzette; Okumura, Atsushi; Lovaglio, Jamie; Hanley, Patrick W.; Saturday, Greg; Bosio, Catharine M.; Anzick, Sarah; Barbian, Kent; Cihlar, Tomas; Martens, Craig; Scott, Dana P.; Munster, Vincent J.; de Wit, Emmie</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">585</span>
        (<span class="NLM_cas:issue">7824</span>),
    <span class="NLM_cas:pages">273-276</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Effective therapies to treat coronavirus disease 2019 (COVID-19) are urgently needed.  While many investigational, approved, and repurposed drugs have been suggested as potential treatments, preclin. data from animal models can guide the search for effective treatments by ruling out those that lack efficacy in vivo.  Remdesivir (GS-5734) is a nucleotide analog prodrug with broad antiviral activity1,2 that is currently being investigated in COVID-19 clin. trials and recently received Emergency Use Authorization from the US Food and Drug Administration3,4.  In animal models, remdesivir was effective against infection with Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV)2,5,6.  In vitro, remdesivir inhibited replication of SARS-CoV-27,8.  Here we investigate the efficacy of remdesivir in a rhesus macaque model of SARS-CoV-2 infection9.  Unlike vehicle-treated animals, macaques treated with remdesivir did not show signs of respiratory disease; they also showed reduced pulmonary infiltrates on radiographs and reduced virus titers in bronchoalveolar lavages twelve hours after the first dose.  Virus shedding from the upper respiratory tract was not reduced by remdesivir treatment.  At necropsy, remdesivir-treated animals had lower lung viral loads and reduced lung damage.  Thus, treatment with remdesivir initiated early during infection had a clin. benefit in rhesus macaques infected with SARS-CoV-2.  Although the rhesus macaque model does not represent the severe disease obsd. in some patients with COVID-19, our data support the early initiation of remdesivir treatment in patients with COVID-19 to prevent progression to pneumonia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6fZodXTdabLVg90H21EOLACvtfcHk0ljJC8WkVTwsIg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslelu7rJ&md5=68d6cbbababc8d7b3d005285528b896e</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2423-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2423-5%26sid%3Dliteratum%253Aachs%26aulast%3DWilliamson%26aufirst%3DB.%2BN.%26aulast%3DFeldmann%26aufirst%3DF.%26aulast%3DSchwarz%26aufirst%3DB.%26aulast%3DMeade-White%26aufirst%3DK.%26aulast%3DPorter%26aufirst%3DD.%2BP.%26aulast%3DSchulz%26aufirst%3DJ.%26aulast%3Dvan%2BDoremalen%26aufirst%3DN.%26aulast%3DLeighton%26aufirst%3DI.%26aulast%3DYinda%26aufirst%3DC.%2BK.%26aulast%3DP%25C3%25A9rez-P%25C3%25A9rez%26aufirst%3DL.%26aulast%3DOkumura%26aufirst%3DA.%26aulast%3DLovaglio%26aufirst%3DJ.%26aulast%3DHanley%26aufirst%3DP.%2BW.%26aulast%3DSaturday%26aufirst%3DG.%26aulast%3DBosio%26aufirst%3DC.%2BM.%26aulast%3DAnzick%26aufirst%3DS.%26aulast%3DBarbian%26aufirst%3DK.%26aulast%3DCihlar%26aufirst%3DT.%26aulast%3DMartens%26aufirst%3DC.%26aulast%3DScott%26aufirst%3DD.%2BP.%26aulast%3DMunster%26aufirst%3DV.%2BJ.%26aulast%3Dde%2BWit%26aufirst%3DE.%26atitle%3DClinical%2520Benefit%2520of%2520Remdesivir%2520in%2520Rhesus%2520Macaques%2520Infected%2520with%2520SARS-CoV-2%26jtitle%3DNature%26date%3D2020%26volume%3D585%26spage%3D273%26epage%3D276%26doi%3D10.1038%2Fs41586-020-2423-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinner, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Criner, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas
LÃ³pez, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattelan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriano Viladomiu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogbuagu, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malhotra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullane, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castagna, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chai, L. Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roestenberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsang, O. T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Turnier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sengupta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyland, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osinusi, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brainard, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhagani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanyal, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huhn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marty, F. M.</span></span> <span> </span><span class="NLM_article-title">Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial</span>. <i>JAMA - J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1048</span>â <span class="NLM_lpage">1057</span>, <span class="refDoi">Â DOI: 10.1001/jama.2020.16349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1001%2Fjama.2020.16349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32821939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrnN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2020&pages=1048-1057&author=C.+D.+Spinnerauthor=R.+L.+Gottliebauthor=G.+J.+Crinerauthor=J.+R.+Arribas%0AL%C3%B3pezauthor=A.+M.+Cattelanauthor=A.+Soriano+Viladomiuauthor=O.+Ogbuaguauthor=P.+Malhotraauthor=K.+M.+Mullaneauthor=A.+Castagnaauthor=L.+Y.+A.+Chaiauthor=M.+Roestenbergauthor=O.+T.+Y.+Tsangauthor=E.+Bernasconiauthor=P.+Le+Turnierauthor=S.+C.+Changauthor=D.+Senguptaauthor=R.+H.+Hylandauthor=A.+O.+Osinusiauthor=H.+Caoauthor=C.+Blairauthor=H.+Wangauthor=A.+Gaggarauthor=D.+M.+Brainardauthor=M.+J.+McPhailauthor=S.+Bhaganiauthor=M.+Y.+Ahnauthor=A.+J.+Sanyalauthor=G.+Huhnauthor=F.+M.+Marty&title=Effect+of+Remdesivir+vs+Standard+Care+on+Clinical+Status+at+11+Days+in+Patients+with+Moderate+COVID-19%3A+A+Randomized+Clinical+Trial&doi=10.1001%2Fjama.2020.16349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial</span></div><div class="casAuthors">Spinner, Christoph D.; Gottlieb, Robert L.; Criner, Gerard J.; Lopez, Jose Ramon Arribas; Cattelan, Anna Maria; Viladomiu, Alex Soriano; Ogbuagu, Onyema; Malhotra, Prashant; Mullane, Kathleen M.; Castagna, Antonella; Chai, Louis Yi Ann; Roestenberg, Meta; Tsang, Owen Tak Yin; Bernasconi, Enos; Le Turnier, Paul; Chang, Shan-Chwen; SenGupta, Devi; Hyland, Robert H.; Osinusi, Anu O.; Cao, Huyen; Blair, Christiana; Wang, Hongyuan; Gaggar, Anuj; Brainard, Diana M.; McPhail, Mark J.; Bhagani, Sanjay; Ahn, Mi Young; Sanyal, Arun J.; Huhn, Gregory; Marty, Francisco M.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1048-1057</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Importance Remdesivir demonstrated clin. benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.  To det. the efficacy of 5 or 10 days of remdesivir treatment compared with std. care on clin. status on day 11 after initiation of treatment.  Randomized, open-label trial of hospitalized patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and moderate COVID-19 pneumonia (pulmonary infiltrates and room-air oxygen satn. >94%) enrolled from March 15 through Apr. 18, 2020, at 105 hospitals in the United States, Europe, and Asia.  The date of final follow-up was May 20, 2020.  Patients were randomized in a 1:1:1 ratio to receive a 10-day course of remdesivir (n = 197), a 5-day course of remdesivir (n = 199), or std. care (n = 200).  Remdesivir was dosed i.v. at 200 mg on day 1 followed by 100 mg/d. main outcomes and measures The primary end point was clin. status on day 11 on a 7-point ordinal scale ranging from death (category 1) to discharged (category 7).  Differences between remdesivir treatment groups and std. care were calcd. using proportional odds models and expressed as odds ratios.  An odds ratio greater than 1 indicates difference in clin. status distribution toward category 7 for the remdesivir group vs the std. care group. results Among 596 patients who were randomized, 584 began the study and received remdesivir or continued std. care (median age, 57 [interquartile range, 46-66] years; 227 [39%] women; 56% had cardiovascular disease, 42% hypertension, and 40% diabetes), and 533 (91%) completed the trial.  Median length of treatment was 5 days for patients in the 5-day remdesivir group and 6 days for patients in the 10-day remdesivir group.  On day 11, patients in the 5-day remdesivir group had statistically significantly higher odds of a better clin. status distribution than those receiving std. care (odds ratio, 1.65; 95% CI, 1.09-2.48; P = .02).  The clin. status distribution on day 11 between the 10-day remdesivir and std. care groups was not significantly different (P = .18 by Wilcoxon rank sum test).  By day 28, 9 patients had died: 2 (1%) in the 5-day remdesivir group, 3 (2%) in the 10-day remdesivir group, and 4 (2%) in the std. care group.  Nausea (10% vs 3%), hypokalemia (6% vs 2%), and headache (5% vs 3%) were more frequent among remdesivir-treated patients compared with std. care.  Among patients with moderate COVID-19, those randomized to a 10-day course of remdesivir did not have a statistically significant difference in clin. status compared with std. care at 11 days after initiation of treatment.  Patients randomized to a 5-day course of remdesivir had a statistically significant difference in clin. status compared with std. care, but the difference was of uncertain clin. importance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgn63W-yBN1bVg90H21EOLACvtfcHk0ljmzJeTZsHxZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrnN&md5=d4a70d73dd4e543ba457938cd017bd16</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1001%2Fjama.2020.16349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2020.16349%26sid%3Dliteratum%253Aachs%26aulast%3DSpinner%26aufirst%3DC.%2BD.%26aulast%3DGottlieb%26aufirst%3DR.%2BL.%26aulast%3DCriner%26aufirst%3DG.%2BJ.%26aulast%3DArribas%2BL%25C3%25B3pez%26aufirst%3DJ.%2BR.%26aulast%3DCattelan%26aufirst%3DA.%2BM.%26aulast%3DSoriano%2BViladomiu%26aufirst%3DA.%26aulast%3DOgbuagu%26aufirst%3DO.%26aulast%3DMalhotra%26aufirst%3DP.%26aulast%3DMullane%26aufirst%3DK.%2BM.%26aulast%3DCastagna%26aufirst%3DA.%26aulast%3DChai%26aufirst%3DL.%2BY.%2BA.%26aulast%3DRoestenberg%26aufirst%3DM.%26aulast%3DTsang%26aufirst%3DO.%2BT.%2BY.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DLe%2BTurnier%26aufirst%3DP.%26aulast%3DChang%26aufirst%3DS.%2BC.%26aulast%3DSengupta%26aufirst%3DD.%26aulast%3DHyland%26aufirst%3DR.%2BH.%26aulast%3DOsinusi%26aufirst%3DA.%2BO.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DBlair%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DGaggar%26aufirst%3DA.%26aulast%3DBrainard%26aufirst%3DD.%2BM.%26aulast%3DMcPhail%26aufirst%3DM.%2BJ.%26aulast%3DBhagani%26aufirst%3DS.%26aulast%3DAhn%26aufirst%3DM.%2BY.%26aulast%3DSanyal%26aufirst%3DA.%2BJ.%26aulast%3DHuhn%26aufirst%3DG.%26aulast%3DMarty%26aufirst%3DF.%2BM.%26atitle%3DEffect%2520of%2520Remdesivir%2520vs%2520Standard%2520Care%2520on%2520Clinical%2520Status%2520at%252011%2520Days%2520in%2520Patients%2520with%2520Moderate%2520COVID-19%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DJAMA%2520-%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2020%26volume%3D324%26spage%3D1048%26epage%3D1057%26doi%3D10.1001%2Fjama.2020.16349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, F. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horby, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span> <span> </span><span class="NLM_article-title">Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1569</span>â <span class="NLM_lpage">1578</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)31022-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2931022-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32423584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1569-1578&author=Y.+Wangauthor=D.+Zhangauthor=G.+Duauthor=R.+Duauthor=J.+Zhaoauthor=Y.+Jinauthor=S.+Fuauthor=L.+Gaoauthor=Z.+Chengauthor=Q.+Luauthor=Y.+Huauthor=G.+Luoauthor=K.+Wangauthor=Y.+Luauthor=H.+Liauthor=S.+Wangauthor=S.+Ruanauthor=C.+Yangauthor=C.+Meiauthor=Y.+Wangauthor=D.+Dingauthor=F.+Wuauthor=X.+Tangauthor=X.+Yeauthor=Y.+Yeauthor=B.+Liuauthor=J.+Yangauthor=W.+Yinauthor=A.+Wangauthor=G.+Fanauthor=F.+Zhouauthor=Z.+Liuauthor=X.+Guauthor=J.+Xuauthor=L.+Shangauthor=Y.+Zhangauthor=L.+Caoauthor=T.+Guoauthor=Y.+Wanauthor=H.+Qinauthor=Y.+Jiangauthor=T.+Jakiauthor=F.+G.+Haydenauthor=P.+W.+Horbyauthor=B.+Caoauthor=C.+Wang&title=Remdesivir+in+Adults+with+Severe+COVID-19%3A+A+Randomised%2C+Double-Blind%2C+Placebo-Controlled%2C+Multicentre+Trial&doi=10.1016%2FS0140-6736%2820%2931022-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</span></div><div class="casAuthors">Wang, Yeming; Zhang, Dingyu; Du, Guanhua; Du, Ronghui; Zhao, Jianping; Jin, Yang; Fu, Shouzhi; Gao, Ling; Cheng, Zhenshun; Lu, Qiaofa; Hu, Yi; Luo, Guangwei; Wang, Ke; Lu, Yang; Li, Huadong; Wang, Shuzhen; Ruan, Shunan; Yang, Chengqing; Mei, Chunlin; Wang, Yi; Ding, Dan; Wu, Feng; Tang, Xin; Ye, Xianzhi; Ye, Yingchun; Liu, Bing; Yang, Jie; Yin, Wen; Wang, Aili; Fan, Guohui; Zhou, Fei; Liu, Zhibo; Gu, Xiaoying; Xu, Jiuyang; Shang, Lianhan; Zhang, Yi; Cao, Lianjun; Guo, Tingting; Wan, Yan; Qin, Hong; Jiang, Yushen; Jaki, Thomas; Hayden, Frederick G.; Horby, Peter W.; Cao, Bin; Wang, Chen</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10236</span>),
    <span class="NLM_cas:pages">1569-1578</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19).  Remdesivir (GS-5734), a nucleoside analog prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vitro, and inhibits Middle East respiratory syndrome coronavirus, SARS-CoV-1, and SARS-CoV-2 replication in animal models.  We did a randomized, double-blind, placebo-controlled, multicenter trial at ten hospitals in Hubei, China.  Eligible patients were adults (aged â¥18 years) admitted to hospital with lab.-confirmed SARS-CoV-2 infection, with an interval from symptom onset to enrollment of 12 days or less, oxygen satn. of 94% or less on room air or a ratio of arterial oxygen partial pressure to fractional inspired oxygen of 300 mm Hg or less, and radiol. confirmed pneumonia.  Patients were randomly assigned in a 2:1 ratio to i.v. remdesivir (200 mg on day 1 followed by 100 mg on days 2-10 in single daily infusions) or the same vol. of placebo infusions for 10 days.  Patients were permitted concomitant use of lopinavir-ritonavir, interferons, and corticosteroids.  The primary endpoint was time to clin. improvement up to day 28, defined as the time (in days) from randomization to the point of a decline of two levels on a six-point ordinal scale of clin. status (from 1=discharged to 6=death) or discharged alive from hospital, whichever came first.  Primary anal. was done in the intention-to-treat (ITT) population and safety anal. was done in all patients who started their assigned treatment.  This trial is registered with ClinicalTrials.gov, NCT04257656.  Between Feb 6, 2020, and March 12, 2020, 237 patients were enrolled and randomly assigned to a treatment group (158 to remdesivir and 79 to placebo); one patient in the placebo group who withdrew after randomization was not included in the ITT population.  Remdesivir use was not assocd. with a difference in time to clin. improvement (hazard ratio 1Â·23 [95% CI 0Â·87-1Â·75]).  Although not statistically significant, patients receiving remdesivir had a numerically faster time to clin. improvement than those receiving placebo among patients with symptom duration of 10 days or less (hazard ratio 1Â·52 [0Â·95-2Â·43]).  Adverse events were reported in 102 (66%) of 155 remdesivir recipients vs. 50 (64%) of 78 placebo recipients.  Remdesivir was stopped early because of adverse events in 18 (12%) patients vs. four (5%) patients who stopped placebo early.  In this study of adult patients admitted to hospital for severe COVID-19, remdesivir was not assocd. with statistically significant clin. benefits.  However, the numerical redn. in time to clin. improvement in those treated earlier requires confirmation in larger studies.  Chinese Academy of Medical Sciences Emergency Project of COVID-19, National Key Research and Development Program of China, the Beijing Science and Technol. Project.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmNUsjDSS-z7Vg90H21EOLACvtfcHk0lg9eoj3xhvQ5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurc%253D&md5=160af7f665ed7fe089e9c07b3bec1acd</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2931022-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252931022-9%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DDu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DY.%26aulast%3DFu%26aufirst%3DS.%26aulast%3DGao%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DLu%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DRuan%26aufirst%3DS.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DMei%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DYe%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DFan%26aufirst%3DG.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DShang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DCao%26aufirst%3DL.%26aulast%3DGuo%26aufirst%3DT.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DJaki%26aufirst%3DT.%26aulast%3DHayden%26aufirst%3DF.%2BG.%26aulast%3DHorby%26aufirst%3DP.%2BW.%26aulast%3DCao%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DC.%26atitle%3DRemdesivir%2520in%2520Adults%2520with%2520Severe%2520COVID-19%253A%2520A%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%252C%2520Multicentre%2520Trial%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1569%26epage%3D1578%26doi%3D10.1016%2FS0140-6736%2820%2931022-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Norrie, J. D.</span></span> <span> </span><span class="NLM_article-title">Remdesivir for COVID-19: Challenges of Underpowered Studies</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">1525</span>â <span class="NLM_lpage">1527</span>, <span class="refDoi">Â DOI: 10.1016/S0140-6736(20)31023-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2FS0140-6736%2820%2931023-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32423580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVWlurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=1525-1527&author=J.+D.+Norrie&title=Remdesivir+for+COVID-19%3A+Challenges+of+Underpowered+Studies&doi=10.1016%2FS0140-6736%2820%2931023-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Remdesivir for COVID-19: challenges of underpowered studies</span></div><div class="casAuthors">Norrie, John David</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10236</span>),
    <span class="NLM_cas:pages">1525-1527</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review of a study reported by Wang Y. et al. (Lancet 2020; published online Apr. 29. https://doi.org/10.1016/S0140-6736(20)31022-9.) with commentary.  Wang et al. reported on a randomized, double-blind, placebo-controlled, multicenter trial of remdesivir in adults with severe COVID-19.  This trial posited 453 patients but was stopped after 237 because there were no further patients meeting the eligibility criteria.  Because the study was stopped early, it is underpowered and as such, no statistically significant conclusions could been drawn.  The authors conclude that during a pandemic, each individual study is at heightened risk of being incomplete.  They suggest that pooling data across possibly several underpowered but high-quality studies looks like our best way to obtain robust insights into what works, safely, and on whom.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCz4NS5z3PcrVg90H21EOLACvtfcHk0lg9eoj3xhvQ5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVWlurg%253D&md5=77c0e20b4f96d86e7df2764bb9c66402</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2931023-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252931023-0%26sid%3Dliteratum%253Aachs%26aulast%3DNorrie%26aufirst%3DJ.%2BD.%26atitle%3DRemdesivir%2520for%2520COVID-19%253A%2520Challenges%2520of%2520Underpowered%2520Studies%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D1525%26epage%3D1527%26doi%3D10.1016%2FS0140-6736%2820%2931023-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angus, D. C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of Remdesivir in COVID-19</span>. <i>JAMA - J. Am. Med. Assoc.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>324</i></span>,  <span class="NLM_fpage">1041</span>â <span class="NLM_lpage">1042</span>, <span class="refDoi">Â DOI: 10.1001/jama.2020.16337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1001%2Fjama.2020.16337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32821934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrbE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=324&publication_year=2020&pages=1041-1042&author=E.+K.+McCrearyauthor=D.+C.+Angus&title=Efficacy+of+Remdesivir+in+COVID-19&doi=10.1001%2Fjama.2020.16337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of remdesivir in COVID-19</span></div><div class="casAuthors">McCreary, Erin K.; Angus, Derek C.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">324</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1041-1042</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">1538-3598</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">This article discusses the remdesivir in COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-PwtDbtNXDLVg90H21EOLACvtfcHk0lg9eoj3xhvQ5g"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtrbE&md5=5179ba768ea574dacb1c6f21275395a6</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1001%2Fjama.2020.16337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.2020.16337%26sid%3Dliteratum%253Aachs%26aulast%3DMcCreary%26aufirst%3DE.%2BK.%26aulast%3DAngus%26aufirst%3DD.%2BC.%26atitle%3DEfficacy%2520of%2520Remdesivir%2520in%2520COVID-19%26jtitle%3DJAMA%2520-%2520J.%2520Am.%2520Med.%2520Assoc.%26date%3D2020%26volume%3D324%26spage%3D1041%26epage%3D1042%26doi%3D10.1001%2Fjama.2020.16337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shiraki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daikoku, T.</span></span> <span> </span><span class="NLM_article-title">Favipiravir, an Anti-Influenza Drug against Life-Threatening RNA Virus Infections</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">107512</span>, <span class="refDoi">Â DOI: 10.1016/j.pharmthera.2020.107512</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.pharmthera.2020.107512" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32097670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlt1WmsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2020&pages=107512&author=K.+Shirakiauthor=T.+Daikoku&title=Favipiravir%2C+an+Anti-Influenza+Drug+against+Life-Threatening+RNA+Virus+Infections&doi=10.1016%2Fj.pharmthera.2020.107512"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Favipiravir, an anti-influenza drug against life-threatening RNA virus infections</span></div><div class="casAuthors">Shiraki, Kimiyasu; Daikoku, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107512</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan.  Addnl., favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains.  This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduces the viral load.  Favipiravir cures all mice in a lethal influenza infection model, while oseltamivir fails to cure the animals.  Thus, favipiravir contributes to curing animals with lethal infection.  In addn. to influenza, favipiravir has a broad spectrum of anti-RNA virus activities in vitro and efficacies in animal models with lethal RNA viruses and has been used for treatment of human infection with life-threatening Ebola virus, Lassa virus, rabies, and severe fever with thrombocytopenia syndrome.  The best feature of favipiravir as an antiviral agent is the apparent lack of generation of favipiravir-resistant viruses.  Favipiravir alone maintains its therapeutic efficacy from the first to the last patient in an influenza pandemic or an epidemic lethal RNA virus infection.  Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which std. treatments are not available.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEwOO4h_byl7Vg90H21EOLACvtfcHk0liZWQ-belkTbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlt1WmsLc%253D&md5=8bec285689767cfdb14ee5b4735dc25c</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2020.107512&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2020.107512%26sid%3Dliteratum%253Aachs%26aulast%3DShiraki%26aufirst%3DK.%26aulast%3DDaikoku%26aufirst%3DT.%26atitle%3DFavipiravir%252C%2520an%2520Anti-Influenza%2520Drug%2520against%2520Life-Threatening%2520RNA%2520Virus%2520Infections%26jtitle%3DPharmacol.%2520Ther.%26date%3D2020%26volume%3D209%26spage%3D107512%26doi%3D10.1016%2Fj.pharmthera.2020.107512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">De Clercq, E.</span></span> <span> </span><span class="NLM_article-title">New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections</span>. <i>Chem. - Asian J.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3962</span>â <span class="NLM_lpage">3968</span>, <span class="refDoi">Â DOI: 10.1002/asia.201900841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1002%2Fasia.201900841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31389664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFChsLnJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=3962-3968&author=E.+De+Clercq&title=New+Nucleoside+Analogues+for+the+Treatment+of+Hemorrhagic+Fever+Virus+Infections&doi=10.1002%2Fasia.201900841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections</span></div><div class="casAuthors">De Clercq, Erik</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry - An Asian Journal</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3962-3968</span>CODEN:
                <span class="NLM_cas:coden">CAAJBI</span>;
        ISSN:<span class="NLM_cas:issn">1861-4728</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Eight different compds., all nucleoside analogs, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections.  They can be considered as either (i) adenine analogs (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogs contg. the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir).  All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine.  Four out of the eight compds. (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part.  The C-nucleoside and phosphoramidate (and for the adenine analogs the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSRhK_m16Ho7Vg90H21EOLACvtfcHk0liZWQ-belkTbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFChsLnJ&md5=d28d163157c152c7fe1bb83ac7ffb928</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1002%2Fasia.201900841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fasia.201900841%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BClercq%26aufirst%3DE.%26atitle%3DNew%2520Nucleoside%2520Analogues%2520for%2520the%2520Treatment%2520of%2520Hemorrhagic%2520Fever%2520Virus%2520Infections%26jtitle%3DChem.%2520-%2520Asian%2520J.%26date%3D2019%26volume%3D14%26spage%3D3962%26epage%3D3968%26doi%3D10.1002%2Fasia.201900841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Baranovich, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Armstrong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marjuki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webby, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Govorkova, E. A.</span></span> <span> </span><span class="NLM_article-title">T-705 (Favipiravir) Induces Lethal Mutagenesis in Influenza A H1N1 Viruses In Vitro</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">3741</span>â <span class="NLM_lpage">3751</span>, <span class="refDoi">Â DOI: 10.1128/JVI.02346-12</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.02346-12" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=23325689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktlymsLc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2013&pages=3741-3751&author=T.+Baranovichauthor=S.-S.+Wongauthor=J.+Armstrongauthor=H.+Marjukiauthor=R.+J.+Webbyauthor=R.+G.+Websterauthor=E.+A.+Govorkova&title=T-705+%28Favipiravir%29+Induces+Lethal+Mutagenesis+in+Influenza+A+H1N1+Viruses+In+Vitro&doi=10.1128%2FJVI.02346-12"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro</span></div><div class="casAuthors">Baranovich, Tatiana; Wong, Sook-San; Armstrong, Jianling; Marjuki, Henju; Webby, Richard J.; Webster, Robert G.; Govorkova, Elena A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Virology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3741-3751</span>CODEN:
                <span class="NLM_cas:coden">JOVIAM</span>;
        ISSN:<span class="NLM_cas:issn">0022-538X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Several novel anti-influenza compds. are in various phases of clin. development.  One of these, T-705 (favipiravir), has a mechanism of action that is not fully understood but is suggested to target influenza virus RNA-dependent RNA polymerase.  We investigated the mechanism of T-705 activity against influenza A (H1N1) viruses by applying selective drug pressure over multiple sequential passage in MDCK cells.  We found that T-705 treatment did not select specific mutations in potential target proteins, including PB1, PB2, PA, and NP.  Phenotypic assays based on cell viability confirmed that no T-705-resistant variants were selected.  In the presence of T-705, titers of infectious virus decreased significantly (P < 0.0001) during serial passage in MDCK cells inoculated with seasonal influenza A (H1N1) viruses at a low multiplicity of infection (MOI; 0.0001 PFU/cell) or with 2009 pandemic H1N1 viruses at a high MOI (10 PFU/cell).  There was no corresponding decrease in the no. of viral RNA copies; therefore, specific virus infectivity (the ratio of infectious virus yield to viral RNA copy no.) was reduced.  Sequence anal. showed enrichment of GâA and CâT transversion mutations, increased mutation frequency, and a shift of the nucleotide profiles of individual NP gene clones under drug selection pressure.  Our results demonstrate that T-705 induces a high rate of mutation that generates a nonviable viral phenotype and that lethal mutagenesis is a key antiviral mechanism of T-705.  Our findings also explain the broad spectrum of activity of T-705 against viruses of multiple families.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfot-qo_X4gLVg90H21EOLACvtfcHk0liZWQ-belkTbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktlymsLc%253D&md5=330bcd116c6e434828555ea4d57d208d</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1128%2FJVI.02346-12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.02346-12%26sid%3Dliteratum%253Aachs%26aulast%3DBaranovich%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DS.-S.%26aulast%3DArmstrong%26aufirst%3DJ.%26aulast%3DMarjuki%26aufirst%3DH.%26aulast%3DWebby%26aufirst%3DR.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%2BG.%26aulast%3DGovorkova%26aufirst%3DE.%2BA.%26atitle%3DT-705%2520%2528Favipiravir%2529%2520Induces%2520Lethal%2520Mutagenesis%2520in%2520Influenza%2520A%2520H1N1%2520Viruses%2520In%2520Vitro%26jtitle%3DJ.%2520Virol.%26date%3D2013%26volume%3D87%26spage%3D3741%26epage%3D3751%26doi%3D10.1128%2FJVI.02346-12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldhill, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Te Velthuis, A. J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langat, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambon, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackenby, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barclay, W. S.</span></span> <span> </span><span class="NLM_article-title">The Mechanism of Resistance to Favipiravir in Influenza</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">11613</span>â <span class="NLM_lpage">11618</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1811345115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1073%2Fpnas.1811345115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=30352857" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFSjs77O" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2018&pages=11613-11618&author=D.+H.+Goldhillauthor=A.+J.+W.+Te+Velthuisauthor=R.+A.+Fletcherauthor=P.+Langatauthor=M.+Zambonauthor=A.+Lackenbyauthor=W.+S.+Barclay&title=The+Mechanism+of+Resistance+to+Favipiravir+in+Influenza&doi=10.1073%2Fpnas.1811345115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of resistance to favipiravir in influenza</span></div><div class="casAuthors">Goldhill, Daniel H.; te Velthuis, Aartjan J. W.; Fletcher, Robert A.; Langat, Pinky; Zambon, Maria; Lackenby, Angie; Barclay, Wendy S.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">45</span>),
    <span class="NLM_cas:pages">11613-11618</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Favipiravir is a broad-spectrum antiviral that has shown promise in treatment of influenza virus infections.  While emergence of resistance has been obsd. for many antiinfluenza drugs, to date, clin. trials and lab. studies of favipiravir have not yielded resistant viruses.  Here we show evolution of resistance to favipiravir in the pandemic H1N1 influenza A virus in a lab. setting.  We found that two mutations were required for robust resistance to favipiravir.  We demonstrate that a K229R mutation in motif F of the PB1 subunit of the influenza virus RNA-dependent RNA polymerase (RdRP) confers resistance to favipiravir in vitro and in cell culture.  This mutation has a cost to viral fitness, but fitness can be restored by a P653L mutation in the PA subunit of the polymerase.  K229R also conferred favipiravir resistance to RNA polymerases of other influenza A virus strains, and its location within a highly conserved structural feature of the RdRP suggests that other RNA viruses might also acquire resistance through mutations in motif F.  The mutations identified here could be used to screen influenza virus-infected patients treated with favipiravir for the emergence of resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6syCwojqRlrVg90H21EOLACvtfcHk0liZWQ-belkTbQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFSjs77O&md5=c0f0e26951bf79cf2ccca5bc67facaed</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1811345115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1811345115%26sid%3Dliteratum%253Aachs%26aulast%3DGoldhill%26aufirst%3DD.%2BH.%26aulast%3DTe%2BVelthuis%26aufirst%3DA.%2BJ.%2BW.%26aulast%3DFletcher%26aufirst%3DR.%2BA.%26aulast%3DLangat%26aufirst%3DP.%26aulast%3DZambon%26aufirst%3DM.%26aulast%3DLackenby%26aufirst%3DA.%26aulast%3DBarclay%26aufirst%3DW.%2BS.%26atitle%3DThe%2520Mechanism%2520of%2520Resistance%2520to%2520Favipiravir%2520in%2520Influenza%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2018%26volume%3D115%26spage%3D11613%26epage%3D11618%26doi%3D10.1073%2Fpnas.1811345115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Delang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segura Guerrero, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">QuÃ©rat, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pastorino, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallmeier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jochmans, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snijder, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Lamballerie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martina, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neyts, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hemert, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyssen, P.</span></span> <span> </span><span class="NLM_article-title">Mutations in the Chikungunya Virus Non-Structural Proteins Cause Resistance to Favipiravir (T-705), a Broad-Spectrum Antiviral</span>. <i>J. Antimicrob. Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">2770</span>â <span class="NLM_lpage">2784</span>, <span class="refDoi">Â DOI: 10.1093/jac/dku209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1093%2Fjac%2Fdku209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=24951535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2MXis1Chsro%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2014&pages=2770-2784&author=L.+Delangauthor=N.+Segura+Guerreroauthor=A.+Tasauthor=G.+Qu%C3%A9ratauthor=B.+Pastorinoauthor=M.+Froeyenauthor=K.+Dallmeierauthor=D.+Jochmansauthor=P.+Herdewijnauthor=F.+Belloauthor=E.+J.+Snijderauthor=X.+de+Lamballerieauthor=B.+Martinaauthor=J.+Neytsauthor=M.+J.+van+Hemertauthor=P.+Leyssen&title=Mutations+in+the+Chikungunya+Virus+Non-Structural+Proteins+Cause+Resistance+to+Favipiravir+%28T-705%29%2C+a+Broad-Spectrum+Antiviral&doi=10.1093%2Fjac%2Fdku209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations in the Chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral</span></div><div class="casAuthors">Delang, Leen; Guerrero, Nidya Segura; Tas, Ali; Querat, Gilles; Pastorino, Boris; Froeyen, Mathy; Dallmeier, Kai; Jochmans, Dirk; Herdewijn, Piet; Bello, Felio; Snijder, Eric J.; de Lamballerie, Xavier; Martina, Byron; Neyts, Johan; van Hemert, Martijn J.; Leyssen, Pieter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antimicrobial Chemotherapy</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2770-2784</span>CODEN:
                <span class="NLM_cas:coden">JACHDX</span>;
        ISSN:<span class="NLM_cas:issn">0305-7453</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Objectives: T-705, also known as favipiravir, is a small-mol. inhibitor that is currently in clin. development for the treatment of influenza virus infections.  This mol. also inhibits the replication of a broad spectrum of other RNA viruses.  The objective of this study was to investigate the antiviral effect of favipiravir on Cchikungunya virus (CHIKV) replication and to contribute to unravelling the mol. mechanism of action against this virus.  Methods: The anti-CHIKV effect of favipiravir was examd. in cell culture and in a mouse model of lethal infection.  A five-step protocol was used to select for CHIKV variants with reduced susceptibility to favipiravir.  The resistant phenotype was confirmed in cell culture and the whole genome was sequenced.  The identified mutations were reverse-engineered into an infectious clone to confirm their impact on the antiviral efficacy of favipiravir.  Results: Favipiravir inhibits the replication of lab. strains and clin. isolates of CHIKV, as well as of a panel of other alphaviruses.  Several favipiravir-resistant CHIKV variants were independently selected and all of them in particular acquired the unique K291R mutation in the RNA-dependent RNA polymerase (RdRp).  Reverse-engineering of this K291R mutation into an infectious clone of CHIKV confirmed the link between the mutant genotype and the resistant phenotype.  Interestingly, this particular lysine is also highly conserved in the RdRp of pos.-stranded RNA viruses in general.  Conclusions: This study provides an important insight into the precise mol. mechanism by which favipiravir exerts its antiviral activity against (alpha)viruses, which may be of help in designing other potent broad-spectrum antivirals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLD2hrwuw29bVg90H21EOLACvtfcHk0lgiA2B_M7GavA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXis1Chsro%253D&md5=4b6a403c5bbd440308f0e35b0b9a722a</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1093%2Fjac%2Fdku209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjac%252Fdku209%26sid%3Dliteratum%253Aachs%26aulast%3DDelang%26aufirst%3DL.%26aulast%3DSegura%2BGuerrero%26aufirst%3DN.%26aulast%3DTas%26aufirst%3DA.%26aulast%3DQu%25C3%25A9rat%26aufirst%3DG.%26aulast%3DPastorino%26aufirst%3DB.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DDallmeier%26aufirst%3DK.%26aulast%3DJochmans%26aufirst%3DD.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DBello%26aufirst%3DF.%26aulast%3DSnijder%26aufirst%3DE.%2BJ.%26aulast%3Dde%2BLamballerie%26aufirst%3DX.%26aulast%3DMartina%26aufirst%3DB.%26aulast%3DNeyts%26aufirst%3DJ.%26aulast%3Dvan%2BHemert%26aufirst%3DM.%2BJ.%26aulast%3DLeyssen%26aufirst%3DP.%26atitle%3DMutations%2520in%2520the%2520Chikungunya%2520Virus%2520Non-Structural%2520Proteins%2520Cause%2520Resistance%2520to%2520Favipiravir%2520%2528T-705%2529%252C%2520a%2520Broad-Spectrum%2520Antiviral%26jtitle%3DJ.%2520Antimicrob.%2520Chemother.%26date%3D2014%26volume%3D69%26spage%3D2770%26epage%3D2784%26doi%3D10.1093%2Fjac%2Fdku209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ju, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial</span>. <i>medRxiv</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi">Â DOI: 10.1101/2020.03.17.20037432</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1101%2F2020.03.17.20037432" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=C.+Chenauthor=Y.+Zhangauthor=J.+Huangauthor=P.+Yinauthor=Z.+Chengauthor=J.+Wuauthor=S.+Chenauthor=Y.+Zhangauthor=B.+Chenauthor=M.+Luauthor=Y.+Luoauthor=L.+Juauthor=J.+Zhangauthor=X.+Wang&title=Favipiravir+versus+Arbidol+for+COVID-19%3A+A+Randomized+Clinical+Trial&doi=10.1101%2F2020.03.17.20037432"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1101%2F2020.03.17.20037432&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F2020.03.17.20037432%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DYin%26aufirst%3DP.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DB.%26aulast%3DLu%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DY.%26aulast%3DJu%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DFavipiravir%2520versus%2520Arbidol%2520for%2520COVID-19%253A%2520A%2520Randomized%2520Clinical%2520Trial%26jtitle%3DmedRxiv%26date%3D2020%26doi%3D10.1101%2F2020.03.17.20037432" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuthman, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garza, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Tongeren, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Retterer, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eaton, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pegoraro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honnold, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bantia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taubenheim, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minning, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span> <span> </span><span class="NLM_article-title">Protection against Filovirus Diseases by a Novel Broad-Spectrum Nucleoside Analogue BCX4430</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>508</i></span>,  <span class="NLM_fpage">402</span>â <span class="NLM_lpage">405</span>, <span class="refDoi">Â DOI: 10.1038/nature13027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1038%2Fnature13027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=24590073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtlWhu7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=508&publication_year=2014&pages=402-405&author=T.+K.+Warrenauthor=J.+Wellsauthor=R.+G.+Panchalauthor=K.+S.+Stuthmanauthor=N.+L.+Garzaauthor=S.+A.+Van+Tongerenauthor=L.+Dongauthor=C.+J.+Rettererauthor=B.+P.+Eatonauthor=G.+Pegoraroauthor=S.+Honnoldauthor=S.+Bantiaauthor=P.+Kotianauthor=X.+Chenauthor=B.+R.+Taubenheimauthor=L.+S.+Welchauthor=D.+M.+Minningauthor=Y.+S.+Babuauthor=W.+P.+Sheridanauthor=S.+Bavari&title=Protection+against+Filovirus+Diseases+by+a+Novel+Broad-Spectrum+Nucleoside+Analogue+BCX4430&doi=10.1038%2Fnature13027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430</span></div><div class="casAuthors">Warren, Travis K.; Wells, Jay; Panchal, Rekha G.; Stuthman, Kelly S.; Garza, Nicole L.; Van Tongeren, Sean A.; Dong, Lian; Retterer, Cary J.; Eaton, Brett P.; Pegoraro, Gianluca; Honnold, Shelley; Bantia, Shanta; Kotian, Pravin; Chen, Xilin; Taubenheim, Brian R.; Welch, Lisa S.; Minning, Dena M.; Babu, Yarlagadda S.; Sheridan, William P.; Bavari, Sina</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">508</span>
        (<span class="NLM_cas:issue">7496</span>),
    <span class="NLM_cas:pages">402-405</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Filoviruses are emerging pathogens and causative agents of viral haemorrhagic fever.  Case fatality rates of filovirus disease outbreaks are among the highest reported for any human pathogen, exceeding 90% (ref. 1).  Licensed therapeutic or vaccine products are not available to treat filovirus diseases.  Candidate therapeutics previously shown to be efficacious in non-human primate disease models are based on virus-specific designs and have limited broad-spectrum antiviral potential.  Here we show that BCX4430, a novel synthetic adenosine analog, inhibits infection of distinct filoviruses in human cells.  Biochem., reporter-based and primer-extension assays indicate that BCX4430 inhibits viral RNA polymerase function, acting as a non-obligate RNA chain terminator.  Post-exposure i.m. administration of BCX4430 protects against Ebola virus and Marburg virus disease in rodent models.  Most importantly, BCX4430 completely protects cynomolgus macaques from Marburg virus infection when administered as late as 48 h after infection.  In addn., BCX4430 exhibits broad-spectrum antiviral activity against numerous viruses, including bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses and flaviviruses.  This is the first report, to our knowledge, of non-human primate protection from filovirus disease by a synthetic drug-like small mol.  We provide addnl. pharmacol. characterizations supporting the potential development of BCX4430 as a countermeasure against human filovirus diseases and other viral diseases representing major public health threats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpev8c7g-X43rVg90H21EOLACvtfcHk0lgiA2B_M7GavA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtlWhu7w%253D&md5=dc7d390055ecf253e4b21c95b4e9e1a2</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1038%2Fnature13027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13027%26sid%3Dliteratum%253Aachs%26aulast%3DWarren%26aufirst%3DT.%2BK.%26aulast%3DWells%26aufirst%3DJ.%26aulast%3DPanchal%26aufirst%3DR.%2BG.%26aulast%3DStuthman%26aufirst%3DK.%2BS.%26aulast%3DGarza%26aufirst%3DN.%2BL.%26aulast%3DVan%2BTongeren%26aufirst%3DS.%2BA.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DRetterer%26aufirst%3DC.%2BJ.%26aulast%3DEaton%26aufirst%3DB.%2BP.%26aulast%3DPegoraro%26aufirst%3DG.%26aulast%3DHonnold%26aufirst%3DS.%26aulast%3DBantia%26aufirst%3DS.%26aulast%3DKotian%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DTaubenheim%26aufirst%3DB.%2BR.%26aulast%3DWelch%26aufirst%3DL.%2BS.%26aulast%3DMinning%26aufirst%3DD.%2BM.%26aulast%3DBabu%26aufirst%3DY.%2BS.%26aulast%3DSheridan%26aufirst%3DW.%2BP.%26aulast%3DBavari%26aufirst%3DS.%26atitle%3DProtection%2520against%2520Filovirus%2520Diseases%2520by%2520a%2520Novel%2520Broad-Spectrum%2520Nucleoside%2520Analogue%2520BCX4430%26jtitle%3DNature%26date%3D2014%26volume%3D508%26spage%3D402%26epage%3D405%26doi%3D10.1038%2Fnature13027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kotian, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panchal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bavari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julander, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rose, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kattan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taubenheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Babu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheridan, W. P.</span></span> <span> </span><span class="NLM_article-title">BCX4430 - A Broad-Spectrum Antiviral Adenosine Nucleoside Analog under Development for the Treatment of Ebola Virus Disease</span>. <i>J. Infect. Public Health</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">220</span>â <span class="NLM_lpage">226</span>, <span class="refDoi">Â DOI: 10.1016/j.jiph.2016.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.jiph.2016.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=27095300" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A280%3ADC%252BC28bhsFamsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=220-226&author=R.+Taylorauthor=P.+Kotianauthor=T.+Warrenauthor=R.+Panchalauthor=S.+Bavariauthor=J.+Julanderauthor=S.+Doboauthor=A.+Roseauthor=Y.+El-Kattanauthor=B.+Taubenheimauthor=Y.+Babuauthor=W.+P.+Sheridan&title=BCX4430+-+A+Broad-Spectrum+Antiviral+Adenosine+Nucleoside+Analog+under+Development+for+the+Treatment+of+Ebola+Virus+Disease&doi=10.1016%2Fj.jiph.2016.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease</span></div><div class="casAuthors">Taylor Raymond; Sheridan William P; Kotian Pravin; Dobo Sylvia; Rose Angela; El-Kattan Yahya; Babu Yarlagadda; Warren Travis; Panchal Rekha; Bavari Sina; Julander Justin; Taubenheim Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of infection and public health</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">220-6</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The adenosine nucleoside analog BCX4430 is a direct-acting antiviral drug under investigation for the treatment of serious and life-threatening infections from highly pathogenic viruses, such as the Ebola virus.  Cellular kinases phosphorylate BCX4430 to a triphosphate that mimics ATP; viral RNA polymerases incorporate the drug's monophosphate nucleotide into the growing RNA chain, causing premature chain termination.  BCX4430 is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV and SARS-CoV.  In vivo, BCX4430 is active after intramuscular, intraperitoneal, and oral administration in a variety of experimental infections.  In nonclinical studies involving lethal infections with Ebola virus, Marburg virus, Rift Valley fever virus, and Yellow Fever virus, BCX4430 has demonstrated pronounced efficacy.  In experiments conducted in several models, both a reduction in the viral load and an improvement in survival were found to be related to the dose of BCX4430.  A Phase 1 clinical trial of intramuscular administration of BCX4430 in healthy subjects is currently ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSL6Iq5eC6xuq__Jf7-eMvJfW6udTcc2ebYIgnzfbt687ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28bhsFamsg%253D%253D&md5=acafc4b0a98b418c3ce361faf012a229</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.jiph.2016.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jiph.2016.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DKotian%26aufirst%3DP.%26aulast%3DWarren%26aufirst%3DT.%26aulast%3DPanchal%26aufirst%3DR.%26aulast%3DBavari%26aufirst%3DS.%26aulast%3DJulander%26aufirst%3DJ.%26aulast%3DDobo%26aufirst%3DS.%26aulast%3DRose%26aufirst%3DA.%26aulast%3DEl-Kattan%26aufirst%3DY.%26aulast%3DTaubenheim%26aufirst%3DB.%26aulast%3DBabu%26aufirst%3DY.%26aulast%3DSheridan%26aufirst%3DW.%2BP.%26atitle%3DBCX4430%2520-%2520A%2520Broad-Spectrum%2520Antiviral%2520Adenosine%2520Nucleoside%2520Analog%2520under%2520Development%2520for%2520the%2520Treatment%2520of%2520Ebola%2520Virus%2520Disease%26jtitle%3DJ.%2520Infect.%2520Public%2520Health%26date%3D2016%26volume%3D9%26spage%3D220%26epage%3D226%26doi%3D10.1016%2Fj.jiph.2016.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urakova, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuznetsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crossman, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokratian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guthrie, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crowley, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolova, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frolov, I.</span></span> <span> </span><span class="NLM_article-title">Î²-D-N-4-Hydroxycytidine Is a Potent Anti-Alphavirus Compound That Induces a High Level of Mutations in the Viral Genome</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">e019650-17</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01965-17</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01965-17" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2017&pages=e019650-17&author=N.+Urakovaauthor=V.+Kuznetsovaauthor=D.+K.+Crossmanauthor=A.+Sokratianauthor=D.+B.+Guthrieauthor=A.+A.+Kolykhalovauthor=M.+A.+Lockwoodauthor=M.+G.+Natchusauthor=M.+R.+Crowleyauthor=G.+R.+Painterauthor=E.+I.+Frolovaauthor=I.+Frolov&title=%CE%B2-D-N-4-Hydroxycytidine+Is+a+Potent+Anti-Alphavirus+Compound+That+Induces+a+High+Level+of+Mutations+in+the+Viral+Genome&doi=10.1128%2FJVI.01965-17"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1128%2FJVI.01965-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01965-17%26sid%3Dliteratum%253Aachs%26aulast%3DUrakova%26aufirst%3DN.%26aulast%3DKuznetsova%26aufirst%3DV.%26aulast%3DCrossman%26aufirst%3DD.%2BK.%26aulast%3DSokratian%26aufirst%3DA.%26aulast%3DGuthrie%26aufirst%3DD.%2BB.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DCrowley%26aufirst%3DM.%2BR.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DFrolova%26aufirst%3DE.%2BI.%26aulast%3DFrolov%26aufirst%3DI.%26atitle%3D%25CE%25B2-D-N-4-Hydroxycytidine%2520Is%2520a%2520Potent%2520Anti-Alphavirus%2520Compound%2520That%2520Induces%2520a%2520High%2520Level%2520of%2520Mutations%2520in%2520the%2520Viral%2520Genome%26jtitle%3DJ.%2520Virol.%26date%3D2017%26volume%3D92%26spage%3De019650-17%26doi%3D10.1128%2FJVI.01965-17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhsous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrena, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shean, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Orally Efficacious Influenza Drug with High Resistance Barrier in Ferrets and Human Airway Epithelia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaax5866</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aax5866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aax5866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31645453" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaax5866&author=M.+Tootsauthor=J.+J.+Yoonauthor=R.+M.+Coxauthor=M.+Hartauthor=Z.+M.+Sticherauthor=N.+Makhsousauthor=R.+Pleskerauthor=A.+H.+Barrenaauthor=P.+G.+Reddyauthor=D.+G.+Mitchellauthor=R.+C.+Sheanauthor=G.+R.+Bluemlingauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+G.+Natchusauthor=G.+R.+Painterauthor=R.+K.+Plemper&title=Characterization+of+Orally+Efficacious+Influenza+Drug+with+High+Resistance+Barrier+in+Ferrets+and+Human+Airway+Epithelia&doi=10.1126%2Fscitranslmed.aax5866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5866%26sid%3Dliteratum%253Aachs%26aulast%3DToots%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DJ.%2BJ.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DHart%26aufirst%3DM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DMakhsous%26aufirst%3DN.%26aulast%3DPlesker%26aufirst%3DR.%26aulast%3DBarrena%26aufirst%3DA.%2BH.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DShean%26aufirst%3DR.%2BC.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DCharacterization%2520of%2520Orally%2520Efficacious%2520Influenza%2520Drug%2520with%2520High%2520Resistance%2520Barrier%2520in%2520Ferrets%2520and%2520Human%2520Airway%2520Epithelia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaax5866%26doi%3D10.1126%2Fscitranslmed.aax5866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agostini, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruijssers, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chappell, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheahan, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sims, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saindane, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baric, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denison, M. R.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Antiviral Î²-D-N-4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance</span>. <i>J. Virol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">e01348-19</span>, <span class="refDoi">Â DOI: 10.1128/JVI.01348-19</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FJVI.01348-19" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31578288" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2019&pages=e01348-19&author=M.+L.+Agostiniauthor=A.+J.+Pruijssersauthor=J.+D.+Chappellauthor=J.+Gribbleauthor=X.+Luauthor=E.+L.+Andresauthor=G.+R.+Bluemlingauthor=M.+A.+Lockwoodauthor=T.+P.+Sheahanauthor=A.+C.+Simsauthor=M.+G.+Natchusauthor=M.+Saindaneauthor=A.+A.+Kolykhalovauthor=G.+R.+Painterauthor=R.+S.+Baricauthor=M.+R.+Denison&title=Small-Molecule+Antiviral+%CE%B2-D-N-4-Hydroxycytidine+Inhibits+a+Proofreading-Intact+Coronavirus+with+a+High+Genetic+Barrier+to+Resistance&doi=10.1128%2FJVI.01348-19"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1128%2FJVI.01348-19&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FJVI.01348-19%26sid%3Dliteratum%253Aachs%26aulast%3DAgostini%26aufirst%3DM.%2BL.%26aulast%3DPruijssers%26aufirst%3DA.%2BJ.%26aulast%3DChappell%26aufirst%3DJ.%2BD.%26aulast%3DGribble%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DAndres%26aufirst%3DE.%2BL.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DSheahan%26aufirst%3DT.%2BP.%26aulast%3DSims%26aufirst%3DA.%2BC.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DSaindane%26aufirst%3DM.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DBaric%26aufirst%3DR.%2BS.%26aulast%3DDenison%26aufirst%3DM.%2BR.%26atitle%3DSmall-Molecule%2520Antiviral%2520%25CE%25B2-D-N-4-Hydroxycytidine%2520Inhibits%2520a%2520Proofreading-Intact%2520Coronavirus%2520with%2520a%2520High%2520Genetic%2520Barrier%2520to%2520Resistance%26jtitle%3DJ.%2520Virol.%26date%3D2019%26volume%3D93%26spage%3De01348-19%26doi%3D10.1128%2FJVI.01348-19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehteshami, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zandi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amblard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, O. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merits, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schinazi, R. F.</span></span> <span> </span><span class="NLM_article-title">Characterization of Î²-D-N4-Hydroxycytidine as a Novel Inhibitor of Chikungunya Virus</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">e023950-16</span>, <span class="refDoi">Â DOI: 10.1128/AAC.02395-16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.02395-16" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2017&pages=e023950-16&author=M.+Ehteshamiauthor=S.+Taoauthor=K.+Zandiauthor=H.+M.+Hsiaoauthor=Y.+Jiangauthor=E.+Hammondauthor=F.+Amblardauthor=O.+O.+Russellauthor=A.+Meritsauthor=R.+F.+Schinazi&title=Characterization+of+%CE%B2-D-N4-Hydroxycytidine+as+a+Novel+Inhibitor+of+Chikungunya+Virus&doi=10.1128%2FAAC.02395-16"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1128%2FAAC.02395-16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.02395-16%26sid%3Dliteratum%253Aachs%26aulast%3DEhteshami%26aufirst%3DM.%26aulast%3DTao%26aufirst%3DS.%26aulast%3DZandi%26aufirst%3DK.%26aulast%3DHsiao%26aufirst%3DH.%2BM.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHammond%26aufirst%3DE.%26aulast%3DAmblard%26aufirst%3DF.%26aulast%3DRussell%26aufirst%3DO.%2BO.%26aulast%3DMerits%26aufirst%3DA.%26aulast%3DSchinazi%26aufirst%3DR.%2BF.%26atitle%3DCharacterization%2520of%2520%25CE%25B2-D-N4-Hydroxycytidine%2520as%2520a%2520Novel%2520Inhibitor%2520of%2520Chikungunya%2520Virus%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2017%26volume%3D61%26spage%3De023950-16%26doi%3D10.1128%2FAAC.02395-16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludeke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luczo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edupuganti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockwood, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowen, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tompkins, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fearns, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">e00766-18</span>, <span class="refDoi">Â DOI: 10.1128/AAC.00766-18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1128%2FAAC.00766-18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=29891600" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2018&pages=e00766-18&author=J.-J.+Yoonauthor=M.+Tootsauthor=S.+Leeauthor=M.-E.+Leeauthor=B.+Ludekeauthor=J.+M.+Luczoauthor=K.+Gantiauthor=R.+M.+Coxauthor=Z.+M.+Sticherauthor=V.+Edupugantiauthor=D.+G.+Mitchellauthor=M.+A.+Lockwoodauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+L.+Mooreauthor=G.+R.+Painterauthor=A.+C.+Lowenauthor=S.+M.+Tompkinsauthor=R.+Fearnsauthor=M.+G.+Natchusauthor=R.+K.+Plemper&title=Orally+Efficacious+Broad-Spectrum+Ribonucleoside+Analog+Inhibitor+of+Influenza+and+Respiratory+Syncytial+Viruses&doi=10.1128%2FAAC.00766-18"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1128%2FAAC.00766-18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00766-18%26sid%3Dliteratum%253Aachs%26aulast%3DYoon%26aufirst%3DJ.-J.%26aulast%3DToots%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DM.-E.%26aulast%3DLudeke%26aufirst%3DB.%26aulast%3DLuczo%26aufirst%3DJ.%2BM.%26aulast%3DGanti%26aufirst%3DK.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DEdupuganti%26aufirst%3DV.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DLockwood%26aufirst%3DM.%2BA.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DMoore%26aufirst%3DM.%2BL.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DLowen%26aufirst%3DA.%2BC.%26aulast%3DTompkins%26aufirst%3DS.%2BM.%26aulast%3DFearns%26aufirst%3DR.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DOrally%2520Efficacious%2520Broad-Spectrum%2520Ribonucleoside%2520Analog%2520Inhibitor%2520of%2520Influenza%2520and%2520Respiratory%2520Syncytial%2520Viruses%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2018%26volume%3D62%26spage%3De00766-18%26doi%3D10.1128%2FAAC.00766-18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Toots, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, J.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cox, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sticher, Z. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makhsous, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plesker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrena, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shean, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bluemling, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolykhalov, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greninger, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Painter, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plemper, R. K.</span></span> <span> </span><span class="NLM_article-title">Characterization of Orally Efficacious Influenza Drug with High Resistance Barrier in Ferrets and Human Airway Epithelia</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">eaax5866</span>, <span class="refDoi">Â DOI: 10.1126/scitranslmed.aax5866</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1126%2Fscitranslmed.aax5866" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=31645453" title="">PubMed</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=eaax5866&author=M.+Tootsauthor=J.-J.+Yoonauthor=R.+M.+Coxauthor=M.+Hartauthor=Z.+M.+Sticherauthor=N.+Makhsousauthor=R.+Pleskerauthor=A.+H.+Barrenaauthor=P.+G.+Reddyauthor=D.+G.+Mitchellauthor=R.+C.+Sheanauthor=G.+R.+Bluemlingauthor=A.+A.+Kolykhalovauthor=A.+L.+Greningerauthor=M.+G.+Natchusauthor=G.+R.+Painterauthor=R.+K.+Plemper&title=Characterization+of+Orally+Efficacious+Influenza+Drug+with+High+Resistance+Barrier+in+Ferrets+and+Human+Airway+Epithelia&doi=10.1126%2Fscitranslmed.aax5866"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aax5866&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aax5866%26sid%3Dliteratum%253Aachs%26aulast%3DToots%26aufirst%3DM.%26aulast%3DYoon%26aufirst%3DJ.-J.%26aulast%3DCox%26aufirst%3DR.%2BM.%26aulast%3DHart%26aufirst%3DM.%26aulast%3DSticher%26aufirst%3DZ.%2BM.%26aulast%3DMakhsous%26aufirst%3DN.%26aulast%3DPlesker%26aufirst%3DR.%26aulast%3DBarrena%26aufirst%3DA.%2BH.%26aulast%3DReddy%26aufirst%3DP.%2BG.%26aulast%3DMitchell%26aufirst%3DD.%2BG.%26aulast%3DShean%26aufirst%3DR.%2BC.%26aulast%3DBluemling%26aufirst%3DG.%2BR.%26aulast%3DKolykhalov%26aufirst%3DA.%2BA.%26aulast%3DGreninger%26aufirst%3DA.%2BL.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DPainter%26aufirst%3DG.%2BR.%26aulast%3DPlemper%26aufirst%3DR.%2BK.%26atitle%3DCharacterization%2520of%2520Orally%2520Efficacious%2520Influenza%2520Drug%2520with%2520High%2520Resistance%2520Barrier%2520in%2520Ferrets%2520and%2520Human%2520Airway%2520Epithelia%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26spage%3Deaax5866%26doi%3D10.1126%2Fscitranslmed.aax5866" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Analysis of Therapeutic Targets for SARS-CoV-2 and Discovery of Potential Drugs by Computational Methods</span>. <i>Acta Pharm. Sin. B</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">766</span>â <span class="NLM_lpage">788</span>, <span class="refDoi">Â DOI: 10.1016/j.apsb.2020.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.apsb.2020.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32292689" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3MXnslWnug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=766-788&author=C.+Wuauthor=Y.+Liuauthor=Y.+Yangauthor=P.+Zhangauthor=W.+Zhongauthor=Y.+Wangauthor=Q.+Wangauthor=Y.+Xuauthor=M.+Liauthor=X.+Liauthor=M.+Zhengauthor=L.+Chenauthor=H.+Li&title=Analysis+of+Therapeutic+Targets+for+SARS-CoV-2+and+Discovery+of+Potential+Drugs+by+Computational+Methods&doi=10.1016%2Fj.apsb.2020.02.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="#"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=&md5=9874b665cc7a056b8e2f928dd3112440</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2Fj.apsb.2020.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.apsb.2020.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DP.%26aulast%3DZhong%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DAnalysis%2520of%2520Therapeutic%2520Targets%2520for%2520SARS-CoV-2%2520and%2520Discovery%2520of%2520Potential%2520Drugs%2520by%2520Computational%2520Methods%26jtitle%3DActa%2520Pharm.%2520Sin.%2520B%26date%3D2020%26volume%3D10%26spage%3D766%26epage%3D788%26doi%3D10.1016%2Fj.apsb.2020.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Elfiky, A. A.</span></span> <span> </span><span class="NLM_article-title">Anti-HCV, Nucleotide Inhibitors, Repurposing against COVID-19</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>248</i></span>,  <span class="NLM_fpage">117477</span>, <span class="refDoi">Â DOI: 10.1016/j.lfs.2020.117477</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=10.1016%2Fj.lfs.2020.117477" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=32119961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFeisLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=248&publication_year=2020&pages=117477&author=A.+A.+Elfiky&title=Anti-HCV%2C+Nucleotide+Inhibitors%2C+Repurposing+against+COVID-19&doi=10.1016%2Fj.lfs.2020.117477"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-HCV, nucleotide inhibitors, repurposing against COVID-19</span></div><div class="casAuthors">Elfiky, Abdo A.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">248</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">117477</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A newly emerged Human Coronavirus (HCoV) is reported two months ago in Wuhan, China (COVID-19).  Until today >2700 deaths from the 80,000 confirmed cases reported mainly in China and 40 other countries.  Human to human transmission is confirmed for COVID-19 by China a month ago.  Based on the World Health Organization (WHO) reports, SARS HCoV is responsible for >8000 cases with confirmed 774 deaths.  Addnl., MERS HCoV is responsible for 858 deaths out of about 2500 reported cases.  The current study aims to test anti-HCV drugs against COVID-19 RNA dependent RNA polymerase (RdRp).  In this study, sequence anal., modeling, and docking are used to build a model for Wuhan COVID-19 RdRp.  Addnl., the newly emerged Wuhan HCoV RdRp model is targeted by anti-polymerase drugs, including the approved drugs Sofosbuvir and Ribavirin.  The results suggest the effectiveness of Sofosbuvir, IDX-184, Ribavirin, and Remidisvir as potent drugs against the newly emerged HCoV disease.  The present study presents a perfect model for COVID-19 RdRp enabling its testing in silico against anti-polymerase drugs.  Besides, the study presents some drugs that previously proved its efficiency against the newly emerged viral infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosW2yKnGd-SrVg90H21EOLACvtfcHk0lhGgHz78l-rqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFeisLo%253D&md5=39ac1e1c2df2a282c1240267850ba35b</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2020.117477&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2020.117477%26sid%3Dliteratum%253Aachs%26aulast%3DElfiky%26aufirst%3DA.%2BA.%26atitle%3DAnti-HCV%252C%2520Nucleotide%2520Inhibitors%252C%2520Repurposing%2520against%2520COVID-19%26jtitle%3DLife%2520Sci.%26date%3D2020%26volume%3D248%26spage%3D117477%26doi%3D10.1016%2Fj.lfs.2020.117477" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sofia, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furman, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosley, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, B. S.</span></span> <span> </span><span class="NLM_article-title">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2481</span>â <span class="NLM_lpage">2531</span>, <span class="refDoi">Â DOI: 10.1021/jm201384j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201384j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2481-2531&author=M.+J.+Sofiaauthor=W.+Changauthor=P.+A.+Furmanauthor=R.+T.+Mosleyauthor=B.+S.+Ross&title=Nucleoside%2C+Nucleotide%2C+and+Non-Nucleoside+Inhibitors+of+Hepatitis+C+Virus+NS5B+RNA-Dependent+RNA-Polymerase&doi=10.1021%2Fjm201384j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase</span></div><div class="casAuthors">Sofia, Michael J.; Chang, Wonsuk; Furman, Phillip A.; Mosley, Ralph T.; Ross, Bruce S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2481-2531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This is a Perspectives review and does not require an abstr.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWh0maPUC6grVg90H21EOLACvtfcHk0lhGgHz78l-rqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1aqu7rF&md5=3236ff10d16104b1a39d77f04774ac77</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1021%2Fjm201384j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201384j%26sid%3Dliteratum%253Aachs%26aulast%3DSofia%26aufirst%3DM.%2BJ.%26aulast%3DChang%26aufirst%3DW.%26aulast%3DFurman%26aufirst%3DP.%2BA.%26aulast%3DMosley%26aufirst%3DR.%2BT.%26aulast%3DRoss%26aufirst%3DB.%2BS.%26atitle%3DNucleoside%252C%2520Nucleotide%252C%2520and%2520Non-Nucleoside%2520Inhibitors%2520of%2520Hepatitis%2520C%2520Virus%2520NS5B%2520RNA-Dependent%2520RNA-Polymerase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2481%26epage%3D2531%26doi%3D10.1021%2Fjm201384j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2E','PDB','6Y2E'); return false;">PDB: 6Y2E</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BX4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2BX4','PDB','2BX4'); return false;">PDB: 2BX4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2G" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2G','PDB','6Y2G'); return false;">PDB: 6Y2G</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SNE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3SNE','PDB','3SNE'); return false;">PDB: 3SNE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LU7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LU7','PDB','6LU7'); return false;">PDB: 6LU7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BQY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BQY','PDB','7BQY'); return false;">PDB: 7BQY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2F" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Y2F','PDB','6Y2F'); return false;">PDB: 6Y2F</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LZE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6LZE','PDB','6LZE'); return false;">PDB: 6LZE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M0K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M0K','PDB','6M0K'); return false;">PDB: 6M0K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRR','PDB','7BRR'); return false;">PDB: 7BRR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTJ','PDB','6WTJ'); return false;">PDB: 6WTJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WTT','PDB','6WTT'); return false;">PDB: 6WTT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C8U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C8U','PDB','7C8U'); return false;">PDB: 7C8U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6U" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6U','PDB','7C6U'); return false;">PDB: 7C6U</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7CBT','PDB','7CBT'); return false;">PDB: 7CBT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BRP','PDB','7BRP'); return false;">PDB: 7BRP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WNP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WNP','PDB','6WNP'); return false;">PDB: 6WNP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C6S','PDB','7C6S'); return false;">PDB: 7C6S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZRU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6ZRU','PDB','6ZRU'); return false;">PDB: 6ZRU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHL','PDB','6XHL'); return false;">PDB: 6XHL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6XHM','PDB','6XHM'); return false;">PDB: 6XHM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M2N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M2N','PDB','6M2N'); return false;">PDB: 6M2N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W63" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W63','PDB','6W63'); return false;">PDB: 6W63</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W79" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W79','PDB','6W79'); return false;">PDB: 6W79</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YB7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YB7','PDB','6YB7'); return false;">PDB: 6YB7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WUU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WUU','PDB','6WUU'); return false;">PDB: 6WUU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WX4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WX4','PDB','6WX4'); return false;">PDB: 6WX4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E9S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3E9S','PDB','3E9S'); return false;">PDB: 3E9S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M71" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6M71','PDB','6M71'); return false;">PDB: 6M71</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV1','PDB','7BV1'); return false;">PDB: 7BV1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BV2','PDB','7BV2'); return false;">PDB: 7BV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BW4" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BW4','PDB','7BW4'); return false;">PDB: 7BW4</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6YYT','PDB','6YYT'); return false;">PDB: 6YYT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C2K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7C2K','PDB','7C2K'); return false;">PDB: 7C2K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BZF" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7BZF','PDB','7BZF'); return false;">PDB: 7BZF</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i12"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01140">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_56376"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01140?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01140</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical structure of Rupintrivir; additional repurposed 3CL<sup>pro</sup> inhibitors reported in ref <a class="ref ref40" href="javascript:void(0);">(40)</a> of main text (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c01140/suppl_file/jm0c01140_si_001.pdf">jm0c01140_si_001.pdf (101.47 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01140&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01140%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01140" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                20MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a08866d7f3dca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
